Study List:

Study 1:
  NCT Number:                   NCT03195491
  Title:                        A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia
  Acronym:                      CheckMate870
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Lung Cancer|Non-Small Cell Lung Cancer
  Interventions:                Biological: Nivolumab
  Outcome Measures:             Incidence of high grade treatment-related select adverse events in non-hepatitis B virus (HBV) infected participants|Severity of high grade treatment-related select adverse events in non-HBV infected participants|Incidence of high grade treatment-related select adverse events in HBV infected participants|Severity of high grade treatment-related select adverse events in HBV infected participants|Laboratory test abnormalities|Incidence of adverse events in all treated patients|Severity of adverse events in all treated patients
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   400
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-870
  Start Date:                   December 19, 2017
  Primary Completion Date:      January 15, 2019
  Completion Date:              July 29, 2022
  First Posted:                 June 22, 2017
  Results First Posted:         null
  Last Update Posted:           September 26, 2018
  Locations:                    Local Institution, Dallas, Texas, United States|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Fuzhou, Fujian, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Beijing, Hebei, China|Local Institution, Harbin, Heilongjiang, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Wuhan, Hubei, China|Local Institution, Changsha, Hunan, China|Local Institution, Zhengzhou, Hunan, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Changchun, Jilin, China|Local Institution, Changchun, Jilin, China|Local Institution, Shenyang, Liaoning, China|Local Institution, Xi'an, Shan3xi, China|Local Institution, Jinan City, Shandong, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Tianjin, Tianjin, China|Local Institution, Tianjin, Tianjin, China|Local Institution, Urumqi, Xinjiang, China|Local Institution, Wulumuqi, Xinjiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Guangzhou, China|Local Institution, Shanghai, China|Local Institution, Shanghai, China|Local Institution, Shenyang, China|Local Institution, Bangkok, Thailand|Local Institution, Khon Kaen, Thailand
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03195491

Study 2:
  NCT Number:                   NCT02869789
  Title:                        An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Lung Cancer
  Interventions:                Drug: Nivolumab in combination with Ipilimumab
  Outcome Measures:             Number of participants who experience high grade AEs (Adverse Events)|Percentage of participants who experience high grade AEs|Progression-free survival (PFS)|ORR|Duration of Response (DOR)|Functional Assessment of Cancer Therapy-Lung (FACT-L)|Overall Survival (OS)
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 4
  Enrollment:                   1100
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-817|2016-002621-10
  Start Date:                   September 14, 2016
  Primary Completion Date:      June 16, 2020
  Completion Date:              November 17, 2021
  First Posted:                 August 17, 2016
  Results First Posted:         null
  Last Update Posted:           November 29, 2018
  Locations:                    Alabama Oncology, Birmingham, Alabama, United States|Local Institution, Chandler, Arizona, United States|Arizona Oncology Assoc, Pc-Hal, Phoenix, Arizona, United States|Arizona Oncol Assoc Dba (Hem Onc Physicians&Extenders) Hope, Tucson, Arizona, United States|Local Institution, Hot Springs, Arkansas, United States|University Of Arkansas For Medical Sciences, Little Rock, Arkansas, United States|CBCC Global Research, Inc., Bakersfield, California, United States|Local Institution, Berkeley, California, United States|Marin Cancer Care, Inc, Greenbrae, California, United States|Local Institution, La Jolla, California, United States|Los Angeles Hematology/Oncology Medical Group, Los Angeles, California, United States|Ucla, Los Angeles, California, United States|Torrance Health Association, Redondo Beach, California, United States|Local Institution, San Diego, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, United States|Gene Upshaw Memorial Tahoe Forest Cancer Center, Truckee, California, United States|Innovative Clinical Research Institute, Whittier, California, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|St. Mary's Hospital Regional Cancer Center, Grand Junction, Colorado, United States|Memorial Cancer Institute, Hollywood, Florida, United States|Cancer Specialists of North FL, Jacksonville, Florida, United States|Florida Cancer Affiliates - Ocala, Ocala, Florida, United States|University Cancer Blood Ctr, Athens, Georgia, United States|Winship Cancer Institute., Atlanta, Georgia, United States|Northside Hospital, Inc, Atlanta, Georgia, United States|Local Institution, Macon, Georgia, United States|Local Institution, Boise, Idaho, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Local Institution, Skokie, Illinois, United States|Local Institution, Indianapolis, Indiana, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|Kentucky One Health St. Joseph East Cancer Center, Lexington, Kentucky, United States|Maryland Oncology Hematology, P.A., Columbia, Maryland, United States|Minnesota Oncology Hematology, Pa, Edina, Minnesota, United States|Jackson Oncology Associates, Pllc, Jackson, Mississippi, United States|St. Francis Cancer Treatment Center, Grand Island, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Cancer Care Specialists, Reno, Nevada, United States|Essex Oncology Of North Jersey P.A., Belleville, New Jersey, United States|Saint Barnabas Medical Cancer Center, Livingston, New Jersey, United States|Local Institution, Morristown, New Jersey, United States|Local Institution, Bronx, New York, United States|Dumc, Durham, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Local Institution, Oklahoma City, Oklahoma, United States|Local Institution, Corvallis, Oregon, United States|Local Institution, Portland, Oregon, United States|Willamette Valley Cancer Center, Springfield, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Local Institution, Langhorne, Pennsylvania, United States|Allegheny Health Network, Pittsburgh, Pennsylvania, United States|Local Institution, Pittsburgh, Pennsylvania, United States|Guthrie Medical Group, Pc, Sayre, Pennsylvania, United States|Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina, United States|Tennessee Oncology, PLLC, Chattanooga, Tennessee, United States|Tennessee Oncology, Pc, Nashville, Tennessee, United States|Texas Oncology, PA - South Austin Cancer Center, Austin, Texas, United States|Texas Oncology, P.A., Dallas, Texas, United States|Texas Oncology, Dallas, Texas, United States|Texas Oncology-Fort Worth 12th Ave, Fort Worth, Texas, United States|Texas Oncology-Longview, Longview, Texas, United States|Texas Oncology-Plano East, Plano, Texas, United States|Texas Oncology Cancer Care And Research Center, Waco, Texas, United States|Virginia Cancer Specialists, Pc, Fairfax, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Local Institution, Renton, Washington, United States|Local Institution, Spokane, Washington, United States|Instituto Medico Especializado Alexander Fleming, Capital Federal, Buenos Aires, Argentina|Clinica Viedma S.A., Viedma, RIO Negro, Argentina|Hospital Italiano De Buenos Aires, Caba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Centro Medico San Roque, Tucuman, Argentina|Local Institution, Gent, Belgium|Local Institution, Liege, Belgium|Local Institution, Sint-Niklaas, Belgium|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Newmarket, Ontario, Canada|Local Institution, Greenfield Park, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Hopital Du Sacre-Coeur De Montreal, Montreal, Quebec, Canada|CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski, Rimouski, Quebec, Canada|Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-Centre-du-Quebec, Trois-Rivieres, Quebec, Canada|Centro Internacional de Estudios Clinicos, Recoleta, Santiago DE Chile, Chile|Fundacion Arturo Lopez Perez, Santiago, Chile|Komplexni onkologicke centrum, Novy Jicin, Czechia|Onkologicka klinika VFN a 1. LF UK, Praha 2, Czechia|Local Institution, Bordeaux, France|Local Institution, Dijon Cedex, France|Local Institution, Marseille Cedex 20, France|Local Institution, Nice, France|Local Institution, Paris, France|Local Institution, Pessac cedex, France|Local Institution, Rennes Cedex 9, France|Local Institution, Saint Herblain, France|Local Institution, Strasbourg Cedex, France|Local Institution, Toulon Cedex, France|Krankenhaus Nordwest Gmbh, Frankfurt, Frankfurt, Germany|SRH WALD KLINIKUM GERA gGmbH, Gera, Germany|Klinikum Kassel, Kassel, Germany|Klinik Loewenstein, Loewenstein, Germany|Hsk Dr.-Horst-Schmidt-Kliniken Wiesbaden, Wiesbaden, Germany|Sotiria General Hospital, Athens, Greece|Metropolitan Hospital, Neo Faliro, Greece|Papageorgiou General Hospital, Thessaloniki, Greece|Local Institution, Budapest, Hungary|Local Institution, Matrahaza, Hungary|Local Institution, Genova, Italy|Istituto Romagnolo Per Lo Studio E La Cura Dei Tumori, Meldola, Italy|Local Institution, Milan, Italy|Local Institution, Napoli, Italy|Ospedale Degli Infermi, Rimini, Italy|Local Institution, Siena, Italy|Azienda Ospedaliera S. Maria, Terni, Italy|Local Institution, Df, Distrito Federal, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Cuernavaca, Morelos, Mexico|Local Institution, Mazatlan, Sinaloa, Mexico|Local Institution, Monterrey, NL, Mexico|Local Institution, Queretaro, Mexico|Local Institution, Groningen, Netherlands|Local Institution, Rotterdam, Netherlands|Ambulatorium Chemioterapii, Bydgoszcz, Poland|Oddzial Wewnetrzny, Sucha Beskidzka, Poland|Klinika Nowotworow Pluca i Klatki Piersiowej, Warszawa, Poland|Focus Lab Plus SRL, Bucuresti, Romania|Sf. Nectarie Oncology Center, Craiova, Romania|Prof. Dr. Ion Chiricuta Institute Of Oncology Day Care Dep, Romania, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, A Coru?a, Spain|Local Institution, Barcelona, Spain|Local Institution, Jaen, Spain|Local Institution, Madrid, Spain|Local Institution, Majadahonda - Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Local Institution, Zaragoza, Spain|University Hospital Basel, Basel, Switzerland|University Hospital Zurich, Zuerich, Switzerland|Local Institution, Adana, Turkey|Local Institution, Antalya, Turkey|Local Institution, Istanbul, Turkey|Local Institution, London, Greater London, United Kingdom|Local Institution, Leicester, Leicestershire, United Kingdom|Local Institution, Edinburgh, Midlothian, United Kingdom|Local Institution, Newcastle Upon Tyne, United Kingdom|Local Institution, Wirral, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02869789

Study 3:
  NCT Number:                   NCT03098550
  Title:                        A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Advanced Cancer
  Interventions:                Biological: Nivolumab|Biological: Daratumumab
  Outcome Measures:             Incidence of adverse events (AE)|Incidence of serious adverse events (SAE)|Grade of laboratory abnormalities.|Objective Response rate (ORR)|Progression Free Survival (PFS)|Anti-Drug Antibodies (ADA) positivity|Area under the concentration-time curve (AUC)|Minimum observed concentration (Cmin)
  Sponsor/Collaborators:        Bristol-Myers Squibb|Janssen Biotech, Inc.
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   120
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-9GW|2017-000367-33
  Start Date:                   June 7, 2017
  Primary Completion Date:      August 30, 2020
  Completion Date:              August 30, 2020
  First Posted:                 March 31, 2017
  Results First Posted:         null
  Last Update Posted:           November 6, 2018
  Locations:                    Pacific Shores Medical Group, Huntington Beach, California, United States|University Of Colorado, Aurora, Colorado, United States|Moffitt Cancer Center, Tampa, Florida, United States|University Of Michigan, Ann Arbor, Michigan, United States|Providence Portland Medical Center, Portland, Oregon, United States|Local Institution, St Leonards, New South Wales, Australia|Local Institution, Edmonton, Canada|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 9, France|Local Institution, Strasbourg Cedex, France|Universitaetsklinikum Carl Gustav Carus, Dresden, Germany|Medizinische Universitaetsklinik Freiburg, Freiburg, Germany|Universitaetsklinik Heidelberg, Heidelberg, Germany|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Fundacion De Investigacion, San Juan, Puerto Rico|Hospital Gral. Univ. Gregorio Maranon, Madrid, Spain|Local Institution, Majadahonda - Madrid, Spain|Klinik Fur Onkologie, Basel, Switzerland|University Hospital of Lausanne, Lausanne, Switzerland
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03098550

Study 4:
  NCT Number:                   NCT02985957
  Title:                        A Study to Evaluate Preliminary Safety and Efficacy of Nivolumab Plus Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer
  Acronym:                      CheckMate 650
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Prostate Cancer
  Interventions:                Biological: Nivolumab|Biological: Ipilimumab
  Outcome Measures:             Objective Response Rate (ORR)|Radiographic Progression-Free Survival (rPFS)|Radiographic/Clinical Progression-Free Survival (rcPFS)|Overall Survival (OS)|Number of patients with adverse events|Number of patients with serious adverse events|Number of patients with adverse events leading to discontinuation|Number of patients with immune-mediated adverse events|Number of patients with deaths|Number of patients with laboratory abnormalities|Number of patients with changes in pain as measured by Brief Pain Inventory-Short Form (BPI-SF)|European Quality of Life- Five Dimensions (EQ-5D-3L) scores
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       Male
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   90
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-650|2016-001928-54
  Start Date:                   March 17, 2017
  Primary Completion Date:      December 16, 2018
  Completion Date:              March 24, 2022
  First Posted:                 December 7, 2016
  Results First Posted:         null
  Last Update Posted:           June 19, 2018
  Locations:                    University of Chicago, Chicago, Illinois, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Icahn School Of Medicine At Mount Sinai, New York, New York, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States|Local Institution, Clermont-ferrand, France|Local Institution, Lyon, France|Local Institution, Marseille Cedex 9, France|Local Institution, Villejuif, France
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02985957

Study 5:
  NCT Number:                   NCT02713867
  Title:                        A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks
  Acronym:                      CheckMate 384
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Lung Cancer
  Interventions:                Biological: Nivolumab
  Outcome Measures:             Progression Free Survival (PFS) rate at 6 months after randomization|Progression Free Survival (PFS) rate at 12 months after randomization|Progression Free Survival (PFS) rate by tumor histology and by response criteria|Progression Free Survival (PFS) rate|Overall Survival Rate (OSR)|Safety and Tolerability assessed by the incidence and severity of adverse events (AEs)
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   350
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-384
  Start Date:                   April 21, 2016
  Primary Completion Date:      June 30, 2022
  Completion Date:              June 30, 2022
  First Posted:                 March 21, 2016
  Results First Posted:         null
  Last Update Posted:           September 17, 2018
  Locations:                    Alabama Oncology, Birmingham, Alabama, United States|Arizona Oncology Assoc, Pc-Hal, Phoenix, Arizona, United States|Arizona Oncology Associates PC - NAHOA, Phoenix, Arizona, United States|CBCC Global Research, Inc., Bakersfield, California, United States|Southern California Permanente Medical Group, Bellflower, California, United States|St Jude Hospital Yorba Linda, Fullerton, California, United States|UCLA Hematology/Oncology Clinic, Los Angeles, California, United States|Torrance Health Association, Redondo Beach, California, United States|Sharp Memorial Hospital, San Diego, California, United States|Sansum Clinic, Santa Barbara, California, United States|Central Coast Med Oncology, Santa Maria, California, United States|Kaiser Permanente Medical Center, Vallejo, California, United States|Poudre Valley Health Care, Fort Collins, Colorado, United States|Rocky Mountain Cancer Centers Llp, Lone Tree, Colorado, United States|Florida Cancer Specialists S., Fort Myers, Florida, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, United States|Ocala Oncology Center, Pl, Ocala, Florida, United States|Sacred Heart Medical Oncology Group, Pensacola, Florida, United States|University Cancer Blood Ctr, Athens, Georgia, United States|John B. Amos Cancer Center, Columbus, Georgia, United States|Northwest Georgia Oncology Ctr, Marietta, Georgia, United States|Ingalls Health System, Harvey, Illinois, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Illinois Cancercare, Pc, Peoria, Illinois, United States|Ft. Wayne Med Onco-Hema Inc, Fort Wayne, Indiana, United States|Innova Schar Cancer Institute, Indianapolis, Indiana, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|Oncology Associated Of Western Kentucky, Paducah, Kentucky, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States|Cancer Care Of Maine, Brewer, Maine, United States|Center For Cancer And Blood Disorders, Bethesda, Maryland, United States|Providence Cancer Center, Southfield, Michigan, United States|Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota, United States|North Mississippi Med Center, Tupelo, Mississippi, United States|Mercy Medical Research Institute, Springfield, Missouri, United States|Oncology Hematology West PC, Omaha, Nebraska, United States|New York Oncology Hematology, P.C., Clifton Park, New York, United States|Broome Oncology, Johnson City, New York, United States|First Health Of The Carolinas, Pinehurst, North Carolina, United States|Hematology And Oncology Associates, Canton, Ohio, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|MetroHealth Cancer Care Center, Cleveland, Ohio, United States|Tri-County Hematology & Oncology Associates, Inc, Massillon, Ohio, United States|Hematology Oncology Consultants, Pc, Medford, Oregon, United States|Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Jones Clinic PC, Germantown, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Texas Oncology, P.A., Abilene, Texas, United States|Texas Oncology - Amarillo, Amarillo, Texas, United States|Texas Oncology, P.A., Dallas, Texas, United States|Texas Oncology, P.A., Dallas, Texas, United States|Texas Oncology, P.A., Denton, Texas, United States|Texas Oncology, P.A., El Paso, Texas, United States|Texas Oncology, P.A., Flower Mound, Texas, United States|Texas Oncology, P.A., Houston, Texas, United States|Texas Oncology, P.A., Longview, Texas, United States|Texas Oncology-Midland Allison Cancer Center, Midland, Texas, United States|Texas Oncology, P.A., Plano, Texas, United States|Texas Oncology, P.A., San Antonio, Texas, United States|Texas Oncology, P.A., Sherman, Texas, United States|Texas Oncology, P.A., Sugar Land, Texas, United States|Texas Oncology, Wichita Falls, Texas, United States|Innova Schar Cancer Institute, Falls Church, Virginia, United States|Shenandoah Oncology, Winchester, Virginia, United States|Cancer Care Northwest, Spokane Valley, Washington, United States|Northwest Cancer Specialists, P.C., Vancouver, Washington, United States|Yakima Valley Memorial Hospital/North Star Lodge, Yakima, Washington, United States|Local Institution, St. Leonards, New South Wales, Australia|Local Institution, Waratah, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Woolloongabba, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Bedford Park, South Australia, Australia|Local Institution, Hobart, Tasmania, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Murdoch, Western Australia, Australia|Local Institution, Elizabeth Vale, Australia|Local Institution, Wien, Austria|Local Institution, Newmarket, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, St. Jerome, Quebec, Canada|Local Institution, Quebec, Canada|Local Institution, Angers, France|Local Institution, Bayonne, France|Local Institution, Clermont-Ferrand, France|Local Institution, Le Mans, France|Local Institution, Mulhouse, France|Local Institution, Nimes, France|Local Institution, Paris, France|Local Institution, Paris, France|Local Institution, Pontoise, France|Local Institution, Suresnes, France|Local Institution, Tours, France|Local Institution, Vandoeuvre-les-Nancy, France|Local Institution, Villefranche-sur-Saone, France|Local Institution, Bad Berka, Germany|Local Institution, Berlin, Germany|Local Institution, Dresden, Germany|Local Institution, Freiburg, Germany|Local Institution, Gauting, Germany|Local Institution, Greifenstein, Germany|Local Institution, Hamburg, Germany|Local Institution, Hannover, Germany|Local Institution, Kassel, Germany|Local Institution, Kiel, Germany|Local Institution, Leipzig, Germany|Local Institution, Lostau, Germany|Local Institution, Moers, Germany|Local Institution, Nurnberg, Germany|Local Institution, Lucca, Italy|Local Institution, Monza, Italy|Local Institution, Napoli, Italy|Local Institution, Roma, Italy|Local Institution, El Palmar, Spain|Local Institution, Las Palmas de Gran Canaria, Spain|Local Institution, Sabadell-Barcelona, Spain|Local Institution, Seville, Spain
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02713867

Study 6:
  NCT Number:                   NCT03090737
  Title:                        Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer
  Acronym:                      CheckMate 907
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Non-Small Cell Lung Cancer
  Interventions:                Biological: Nivolumab
  Outcome Measures:             Incidence of high grade (Grades 3-4 and Grade 5) treatment-related adverse events|Progression-free Survival (PFS) as determined by investigator per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)|Objective Response Rate (ORR) as determined by investigator per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)|Overall Survival (OS)|Duration of Response (DOR) as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
  Sponsor/Collaborators:        Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   120
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-907|2016-003731-37
  Start Date:                   May 26, 2017
  Primary Completion Date:      August 11, 2020
  Completion Date:              December 7, 2020
  First Posted:                 March 27, 2017
  Results First Posted:         null
  Last Update Posted:           June 19, 2018
  Locations:                    Alabama Oncology, Birmingham, Alabama, United States|Los Angeles Hematology Oncology Medical Group, Los Angeles, California, United States|Local Institution, West Covina, California, United States|Cancer Specialists, Llc, Jacksonville, Florida, United States|St Vincent Frontier Cancer Center, Billings, Montana, United States|Broome Oncology, Johnson City, New York, United States|Guthrie Medical Group, Pc, Sayre, Pennsylvania, United States|Cancer Centre Of Southeastern Ontario At Kgh, Kingston, Ontario, Canada|Lakeridge Health, Oshawa, Ontario, Canada|University Health Network - Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Local Institution, Debrecen, Hungary|Local Institution, Farkasgyepu, Hungary|Local Institution, Torokbalint, Hungary|Local Institution, Nagoya, Aichi, Japan|Local Institution, Chuo-ku, Osaka, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Koto, Tokyo, Japan|Local Institution, Bucharest, Romania|Local Institution, Craiova, Romania|Local Institution, Port Elizabeth, Eastern CAPE, South Africa|Local Institution, Parktown, Johannesburg, Gauteng, South Africa|Local Institution, George, Western CAPE, South Africa
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03090737

Study 7:
  NCT Number:                   NCT02066636
  Title:                        A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen
  Acronym:                      CheckMate153
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Non Small Cell Lung Cancer (NSCLC)
  Interventions:                Drug: Nivolumab
  Outcome Measures:             Incidence for high grade (Grade 3-4 and Grade 5) treatment related select adverse events (AEs)|Incidence for high grade (Grade 3-4 and Grade 5) select AEs|Median time to onset and median time to resolution (Grade 3-4)|Percentage of subjects who received immune modulating medication or hormonal replacement therapy, percentage of subjects who received ≥40 mg Prednisone equivalents, total duration of all immune modulating medications given for select event
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   1380
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-153
  Start Date:                   February 28, 2014
  Primary Completion Date:      January 31, 2022
  Completion Date:              January 31, 2022
  First Posted:                 February 19, 2014
  Results First Posted:         null
  Last Update Posted:           August 14, 2018
  Locations:                    Southern Cancer Center Pc, Mobile, Alabama, United States|Cancer Center Treatment Center of America, Goodyear, Arizona, United States|Arizona Oncology Associates, Phoenix, Arizona, United States|Arizona Oncology Associates, Sedona, Arizona, United States|Arizona Oncol Assoc Dba (Hem Onc Physicians&Extenders) Hope, Tucson, Arizona, United States|Comprehensive Blood And Cancer Center, Bakersfield, California, United States|Diablo Valley Oncology, Concord, California, United States|Saint Jude Heritage Medical Group Virginia K Crosson Cancer Center, Fullerton, California, United States|Ucla Hema/Onc-Santa Monica, Los Angeles, California, United States|Torrance Memorial Medical Center, Redondo Beach, California, United States|Sutter Cancer Center, Sacramento, California, United States|Pacific Cancer Care, Salinas, California, United States|Local Institution, San Francisco, California, United States|Central Coast Med Oncology, San Luis Obispo, California, United States|Sansum Santa Barbara Medical Foundation Clinic, Santa Barbara, California, United States|Central Coast Med Oncology, Santa Maria, California, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Mountain Blue Cancer Care Center, Golden, Colorado, United States|St. Mary's Hospital Regional Cancer Center, Grand Junction, Colorado, United States|Eastern Ct Hem Onc Assoc, Norwich, Connecticut, United States|Holy Cross Hospital Inc., Fort Lauderdale, Florida, United States|Florida Cancer Specialists S., Fort Myers, Florida, United States|Baptist Cancer Institute, Jacksonville, Florida, United States|Watson Clinic Center For Research,Inc, Lakeland, Florida, United States|Baptist Health Medical Group Oncology, Miami, Florida, United States|Ocala Oncology Center, Ocala, Florida, United States|Cancer Institute Of Florida, Orlando, Florida, United States|Sacred Heart Medical Oncology Group, Pensacola, Florida, United States|Hematology/Oncology Associates Of The Treasure Coast, Port Saint Lucie, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Space Coast Cancer Center, Titusville, Florida, United States|University Cancer Blood Ctr, Athens, Georgia, United States|Piedmont Hospital, Atlanta, Georgia, United States|Central Georgia Cancer Care, Pc, Macon, Georgia, United States|Cancer Treatment Centers Of America, Newnan, Georgia, United States|Summit Cancer Care, Savannah, Georgia, United States|Lewis Hall Singletary Oncology Center, Thomasville, Georgia, United States|Pearlman Cancer Center, Valdosta, Georgia, United States|University Of Illinois Cancer Center, Chicago, Illinois, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Oncology Specialists, Park Ridge, Illinois, United States|Quincy Medical Group, Quincy, Illinois, United States|Orchard Healthcare Research Inc., Skokie, Illinois, United States|Southern Illinois University School Of Medicine, Springfield, Illinois, United States|Ft. Wayne Med Onco-Hema Inc, Fort Wayne, Indiana, United States|Indiana University Health Melvin And Bren Simon Cancer Center, Indianapolis, Indiana, United States|University Of Kansas Cancer Center, Kansas City, Kansas, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|Norton Cancer Center, Louisville, Kentucky, United States|University Medical Center, Inc, Louisville, Kentucky, United States|West KY Hematology Oncology Group PSC, Paducah, Kentucky, United States|Christus Schumpert Health, Shreveport, Louisiana, United States|Local Institution, Brewer, Maine, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Walter Reed National Mltry Medical Center, Bethesda, Maryland, United States|Maryland Oncology Hematology, P.A., Columbia, Maryland, United States|Bay Hematology Oncology, Easton, Maryland, United States|Michigan Cancer Research Consortinum, Ann Arbor, Michigan, United States|Cancer & Hematology Centers Of Western Michigan, Grand Rapids, Michigan, United States|Providence Cancer Center, Southfield, Michigan, United States|Forrest General Cancer Center, Hattiesburg, Mississippi, United States|Jackson Oncology Associates, Pllc, Jackson, Mississippi, United States|North Mississippi Hematology And Oncology Associates, Ltd, Tupelo, Mississippi, United States|Mercy Medical Research Institute, Springfield, Missouri, United States|Southeast Nebraska Hematology & Oncology Consultants, P.C., Lincoln, Nebraska, United States|Nebraska Cancer Specialists, Omaha, Nebraska, United States|Comprehensive Cancer Center Of Nevada, Las Vegas, Nevada, United States|VA Sierra Nevada Health Care System, Reno, Nevada, United States|Hunterdon Medical Center, Flemington, New Jersey, United States|Atlantic Health System, Summit, New Jersey, United States|Presbyterian Medical Group, Albuquerque, New Mexico, United States|St. Peters Hospital, Albany, New York, United States|Maimonides Medical Center, Brooklyn, New York, United States|Queens Medical Associates, Fresh Meadows, New York, United States|Broome Oncology, Johnson City, New York, United States|Winthrop University Hospital, Mineola, New York, United States|Mount Kisco Medical Group, Mount Kisco, New York, United States|Columbia University Medical Center (Cumc), New York, New York, United States|Hematology-Oncology Associates Of Rockland, Nyack, New York, United States|Randolph Cancer Center, Asheboro, North Carolina, United States|Cancer Care Of Wnc, Asheville, North Carolina, United States|Southeastern Medical Oncology Center, Goldsboro, North Carolina, United States|Moses Cone Regional Cancer Center, Greensboro, North Carolina, United States|East Carolina University Leo W. Jenkins Cancer Center, Greenville, North Carolina, United States|W.G. Bill Hefner VA Medical Center, Salisbury, North Carolina, United States|Mid Dakota Clinic, Pc, Bismarck, North Dakota, United States|Oncology Hematology Care, Incorporated, Cincinnati, Ohio, United States|Local Institution, Cleveland, Ohio, United States|Zangmeister Cancer Center, Columbus, Ohio, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|St. Luke's University Hospital Bethlehem, Bethlehem, Pennsylvania, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|St. Mary Medical Center, Langhorne, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina, United States|South Carolina Oncology Associates, Columbia, South Carolina, United States|Greenville Health System, Greenville, South Carolina, United States|Tennessee Oncology, PLLC, Chattanooga, Tennessee, United States|The Jones Clinic, Pc, Germantown, Tennessee, United States|The West Clinic, P.C., Germantown, Tennessee, United States|Tennessee Oncology, Pllc, Nashville, Tennessee, United States|Henry-Joyce Cancer Center, Nashville, Tennessee, United States|Texas Oncology-Abilene, Abilene, Texas, United States|Texas Oncology - Amarillo, Amarillo, Texas, United States|Texas Oncology, Arlington, Texas, United States|Texas Oncology-Beaumont, Beaumont, Texas, United States|Texas Oncology, Dallas, Texas, United States|Texas Oncology, Dallas, Texas, United States|Charles A. Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology, Denton, Texas, United States|The Center For Cancer And Blood Disorders, Fort Worth, Texas, United States|Texas Oncology, Grapevine, Texas, United States|Northwest Cancer Center, Houston, Texas, United States|Texas Oncology, McAllen, Texas, United States|Texas Oncology, Mesquite, Texas, United States|Texas Oncology - Odessa, Midland, Texas, United States|Texas Oncology-Plano East, Plano, Texas, United States|Cancer Care Centers Of South Texas, San Antonio, Texas, United States|Texas Cancer Center - Sherman, Sherman, Texas, United States|Texas Oncology Cancer Care And Research Center, Waco, Texas, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|University Of Virginia Health System., Charlottesville, Virginia, United States|Shenandoah Oncology, Winchester, Virginia, United States|Local Institution, Calgary, Alberta, Canada|Local Institution, Halifax, Nova Scotia, Canada|Kingston General Hospital, Kingston, Ontario, Canada|Local Institution, Ottawa, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Levis, Quebec, Canada|Local Institution, Montreal, Quebec, Canada
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02066636

Study 8:
  NCT Number:                   NCT01721759
  Title:                        Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                Has Results
  Conditions:                   Squamous Cell Non-small Cell Lung Cancer
  Interventions:                Drug: Nivolumab
  Outcome Measures:             Objective Response Rate (ORR) as Assessed by Independent Radiology Review Committee (IRC)|Objective Response Rate (ORR) as Assessed by Investigator
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   140
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-063|2012-003965-16
  Start Date:                   November 14, 2012
  Primary Completion Date:      January 22, 2014
  Completion Date:              December 30, 2018
  First Posted:                 November 6, 2012
  Results First Posted:         October 22, 2015
  Last Update Posted:           September 8, 2017
  Locations:                    University Of California, Davis Medical Center, Sacramento, California, United States|Va San Diego Healthcare System, San Diego, California, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Local Institution, Metairie, Louisiana, United States|Tufts Medical Center, Boston, Massachusetts, United States|Providence Cancer Institute, Southfield, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Beth Israel Comprehensive Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University Of North Carolina At Chapel Hill, Chapel Hill, North Carolina, United States|University Hospitals Of Cleveland, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Providence Oncology And Hematology, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|Network Office Of Research And Innovation, Allentown, Pennsylvania, United States|University Of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Oncology Consultants, Pa, Houston, Texas, United States|Local Institution, Caen, France|Local Institution, Creteil, France|Local Institution, Pierre Benite, France|Local Institution, Rennes, France|Local Institution, Strasbourg, France|Local Institution, Toulouse, France|Local Institution, Villejuif, France|Local Institution, Berlin, Germany|Local Institution, Koeln, Germany|Local Institution, Muenchen, Germany|Local Institution, Livorno, Italy|Local Institution, Lucca, Italy|Local Institution, Terni, Italy
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01721759

Study 9:
  NCT Number:                   NCT02538666
  Title:                        An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy
  Acronym:                      CheckMate 451
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Lung Cancer
  Interventions:                Biological: Nivolumab|Biological: Ipilimumab|Other: Placebo
  Outcome Measures:             Overall Survival (OS)|Progression Free Survival (PFS)|An OS descriptive analysis will be performed to evaluate nivolumab monotherapy versus nivolumab with Ipilimumab treatment regimen|A PFS descriptive analysis will be performed to evaluate nivolumab monotherapy versus nivolumab with Ipilimumab treatment regimen|Tumor mutation burden (TMB)
  Sponsor/Collaborators:        Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   1327
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  Other IDs:                    CA209-451|2015-002441-61
  Start Date:                   September 30, 2015
  Primary Completion Date:      October 1, 2018
  Completion Date:              November 20, 2019
  First Posted:                 September 2, 2015
  Results First Posted:         null
  Last Update Posted:           November 6, 2018
  Locations:                    Sutter Cancer Center, Sacramento, California, United States|Yale University, New Haven, Connecticut, United States|Florida Cancer Specialists S., Fort Myers, Florida, United States|Cancer Specialists of North FL, Jacksonville, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Winship Cancer Institute., Atlanta, Georgia, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States|University of Kansas Cancer Center - Clinical Research Center, Fairway, Kansas, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|Baptist Health Lexington, Lexington, Kentucky, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University, Durham, North Carolina, United States|Novant Health Oncology Specialists, Winston-Salem, North Carolina, United States|Sanford Health, Fargo, North Dakota, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Donald Guthrie Foundation, Sayre, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|Sanford Health, Sioux Falls, South Dakota, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Local Institution, Berazategui, Buenos Aires, Argentina|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Tucuman, Argentina|Local Institution, Kogarah, New South Wales, Australia|Local Institution, Wollongong, New South Wales, Australia|Local Institution, Birtinya, Queensland, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, East Melbourne, Victoria, Australia|Local Institution, Innsbruck, Austria|Local Institution, Salzburg, Austria|Local Institution, Wien, Austria|Local Institution, Brussels, Belgium|Local Institution, Charleroi, Belgium|Local Institution, Roeselare, Belgium|Local Institution, Fortaleza, Ceara, Brazil|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Itajai, Santa Catarina, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Salvador, Brazil|Local Institution, Edmonton, Alberta, Canada|Local Institution, Moncton, New Brunswick, Canada|Local Institution, Oshawa, Ontario, Canada|Health Sciences North, Sudbury, Ontario, Canada|Local Institution, Windsor, Ontario, Canada|Local Institution, Hefei, Anhui, China|Local Institution, Hefei, Anhui, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Harbin, Heilongjiang, China|Local Institution, Wuhang, Hubei, China|Local Institution, Changsha, Hunan, China|Local Institution, Nantong, Jiangsu, China|Local Institution, Nanchang, Jiangxi, China|Local Institution, Changchun, Jilin, China|Local Institution, Shenyang, Liaoning, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Kunming, Yunnan, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Wenzhou, Zhejiang, China|Local Institution, Guangzhou, China|Local Institution, Monteria, Cordoba, Colombia|Local Institution, Bogota, Colombia|Local Institution, Medellin, Colombia|Local Institution, Oulu, Finland|Local Institution, Tampere, Finland|Local Institution, Turku, Finland|Local Institution, Vaasa, Finland|Local Institution, Avignon Cedes 9, France|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 20, France|Local Institution, Paris Cedex 20, France|Local Institution, Pierre Benite, France|Local Institution, Rennes Cedex 9, France|Local Institution, Saint Herblain, France|Local Institution, Strasbourg, France|Local Institution, Toulouse, France|Local Institution, Augsburg, Germany|Local Institution, Bad Berka, Germany|Local Institution, Berlin, Germany|Local Institution, Bochum, Germany|Local Institution, Gauting, Germany|Local Institution, Grosshansdorf, Germany|Local Institution, Immenhausen, Germany|Local Institution, Tuebingen, Germany|Agioi Anargyroi Cancer Center, Nea Kifissia, Greece|Interbalkan European Medical Center, Thessaloniki, Greece|Local Institution, Hong Kong, Hong Kong|Local Institution, Wilton, Cork, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Limerick, Ireland|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Petach Tikva, Israel|Local Institution, Tel Aviv, Israel|Local Institution, Zerifin, Israel|Local Institution, Avellino, Italy|Local Institution, Bologna, Italy|Local Institution, Messina, Italy|Local Institution, Milan, Italy|Local Institution, Perugia, Italy|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Kurume-shi, Fukuoka, Japan|Local Institution, Gifu-shi, Gifu, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Kanazawa-shi, Ishikawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Kurashiki-shi, Okayama, Japan|Local Institution, Hirakata-shi, Osaka, Japan|Local Institution, Osaka-sayama-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Takatsuki-shi, Osaka, Japan|Local Institution, Hidaka-shi, Saitama, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Koto-ku, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Wakayama-shi, Wakayama, Japan|Local Institution, Seongnam-si, Gyeonggi-do, Korea, Republic of|Local Institution, Suwon-si, Gyeonggi-do, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Leon de los Aldama, Guanajuato, Mexico|Local Institution, Monterrey, Nuevo LEON, Mexico|Local Institution, Santiago de Queretaro, Queretaro, Mexico|Local Institution, 's-Hertogenbosch, Netherlands|Local Institution, Eindhoven, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Miraflores, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Gdansk, Poland|Local Institution, Gdynia, Poland|Local Institution, Olsztyn, Poland|Local Institution, Warszawa, Poland|Local Institution, Bucharest, Romania|Local Institution, Bucharest, Romania|Local Institution, Craiova, Romania|Local Institution, Lasi, Romania|Local Institution, Romania, Romania|Local Institution, Timisoara, Timis, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Johannesburg, Gauteng, South Africa|Local Institution, Cape Town, Western CAPE, South Africa|Local Institution, Cape Town, Western CAPE, South Africa|Local Institution, George, Western CAPE, South Africa|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Malaga, Spain|Local Institution, Sevilla, Spain|Local Institution, Lund, Sweden|Local Institution, Uppsala, Sweden|Local Institution, Aarau, Switzerland|Local Institution, Geneve, Switzerland|Local Institution, St. Gallen, Switzerland|Local Institution, Tainan, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, Truro, Cornwall, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Oxford, Oxfordshire, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom|Local Institution, Sheffield, United Kingdom|Local Institution, Wirral, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02538666

Study 10:
  NCT Number:                   NCT02409368
  Title:                        An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC
  Acronym:                      Checkmate 171
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Non-Small Cell Lung Cancer
  Interventions:                Drug: Nivolumab
  Outcome Measures:             Incidence of high-grade (CTCAE v4.0 Grades 3-4), treatment-related, select adverse events in subjects with advanced or metastatic SqNSCLC|Incidence and to characterize the outcome of all high-grade (CTCAE v4.0 Grades 3-4), select adverse events|Overall survival (OS) in all treated subject|Investigator-assessed objective response rate (ORR)|Median time to onset (Grades 3-4) of select adverse events|Median time to resolution (Grades 3-4) of select adverse events
  Sponsor/Collaborators:        Bristol-Myers Squibb|PPD
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   800
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other
  Other IDs:                    CA209-171|2014-001285-10
  Start Date:                   April 23, 2015
  Primary Completion Date:      September 15, 2019
  Completion Date:              December 24, 2019
  First Posted:                 April 6, 2015
  Results First Posted:         null
  Last Update Posted:           October 3, 2018
  Locations:                    Southampton University Hospitals NHS Trust, Raleigh, North Carolina, United States|Local Institution, Salzburg, Austria|Local Institution, Wels, Austria|Local Institution, Wien, Austria|Local Institution, Aalborg, Denmark|Local Institution, Herlev, Denmark|Local Institution, Odense C, Denmark|Local Institution, Oulu, Finland|Local Institution, Pori, Finland|Local Institution, Athens, Greece|Local Institution, Athens, Greece|Local Institution, Heraklion, Greece|Local Institution, Rio, Greece|Local Institution, Thessaloniki, Greece|Local Institution, Budapest, Hungary|Local Institution, Debrecen, Hungary|Local Institution, Pecs, Hungary|Local Institution, Dublin 8, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Gdansk, Poland|Local Institution, Gliwice, Poland|Instytut Medyczny Santa Familia Sp. z o.o., Lodz, Poland|Local Institution, Poznan, Poland|Local Institution, Warszawa, Poland|Local Institution, Zabrze, Poland|Local Institution, Coimbra, Portugal|Local Institution, Lisboa, Portugal|Local Institution, Lisboa, Portugal|Local Institution, Porto, Portugal|Local Institution, Porto, Portugal|Local Institution, Porto, Portugal|Local Institution, Bucharest, Romania|Local Institution, Bucharest, Romania|Local Institution, Cluj Napoca, Romania|Local Institution, Cluj-Napoca, Romania|Local Institution, Oradea, Romania|Local Institution, Timisoara, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Saint Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, A Coruna, Spain|Local Institution, Alicante, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Burgos, Spain|Local Institution, Granada, Spain|Local Institution, La Laguna, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Malaga, Spain|Local Institution, Palma de Mallorca, Spain|Local Institution, Santander, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Local Institution, Valencia, Spain|Local Institution, Zaragoza, Spain|Local Institution, Solna, Sweden|Local Institution, Stockholm, Sweden|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom|Local Institution, Bristol, United Kingdom|Local Institution, Cardiff, United Kingdom|Local Institution, Cottingham, United Kingdom|Local Institution, Glasgow, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|North Middlesex Hospital, London, United Kingdom|Local Institution, London, United Kingdom|Local Institution, London, United Kingdom|Local Institution, London, United Kingdom|Maidstone Hospital, Maidstone, United Kingdom|Local Institution, Northwood, United Kingdom|Local Institution, Plymouth, United Kingdom|Royal Preston Hospital, Preston, United Kingdom|Local Institution, Sheffield, United Kingdom|Local Institution, Wirral, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02409368

Study 11:
  NCT Number:                   NCT03417037
  Title:                        An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
  Acronym:                      
  Status:                       Withdrawn
  Study Results:                No Results Available
  Conditions:                   Lung Cancer|Non-Small Cell Lung Cancer
  Interventions:                Drug: BMS-986205|Biological: Nivolumab|Drug: Chemotherapy
  Outcome Measures:             Objective response rate (ORR) measured by number of participants with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) divided by the number of randomized participants for each treatment group|Progression free survival (PFS) measured by the time between the date of randomization and the first date of documented progression, as determined by the Blinded Independent Central Review, or death, due to any cause, whichever occurs first|Overall survival (OS) measured by the time between the date of randomization and the date of death due to any cause|Number of treatment-related adverse events (AE)|Number of treatment-related serious adverse events
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   0
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA017-062|2017-003058-18
  Start Date:                   May 24, 2018
  Primary Completion Date:      April 25, 2021
  Completion Date:              August 20, 2025
  First Posted:                 January 31, 2018
  Results First Posted:         null
  Last Update Posted:           April 30, 2018
  Locations:                    Local Institution, San Diego, California, United States|Local Institution, Fort Myers, Florida, United States|Local Institution, Jacksonville, Florida, United States|Local Institution, Saint Petersburg, Florida, United States|Local Institution, Tallahassee, Florida, United States|Local Institution, West Palm Beach, Florida, United States|Local Institution, Decatur, Georgia, United States|Local Institution, Marietta, Georgia, United States|Local Institution, Wichita, Kansas, United States|Local Institution, Louisville, Kentucky, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Bridgeton, Missouri, United States|Local Institution, Lincoln, Nebraska, United States|Local Institution, Cleveland, Ohio, United States|Local Institution, Gettysburg, Pennsylvania, United States|Local Institution, Greenville, South Carolina, United States|Local Institution, Lebanon, Tennessee, United States|Local Institution, Fort Worth, Texas, United States|Local Institution, Lubbock, Texas, United States|Local Institution, Darlinghurst, New South Wales, Australia|Local Institution, Brisbane, Queensland, Australia|Local Institution, Melbourne, Victoria, Australia|Local Institution, Murdoch, Western Australia, Australia|Local Institution, North Tamworth, Australia|Local Institution, Vienna, Austria|Local Institution, Wels, Austria|Local Institution, Ipatinga, Minas Gerais, Brazil|Local Institution, Jd. Petropolis-Londrina, Parana, Brazil|Local Institution, Centro-porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Morumbi, SAO Paulo, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Quebec, Canada|Local Institution, Praha 2, Czechia|Local Institution, Besancon, France|Local Institution, La Tronche, France|Local Institution, Paris Cedex 5, France|Local Institution, Pessac cedex, France|Local Institution, Pringy Cedex, France|Local Institution, Rennes Cedex 9, France|Local Institution, Saint Herblain, France|Local Institution, Toulon, France|Local Institution, Berlin, Germany|Local Institution, Gauting, Germany|Local Institution, Gera, Germany|Local Institution, Gottingen, Germany|Local Institution, Grosshansdorf, Germany|Local Institution, Hamburg, Germany|Local Institution, Heidelberg, Germany|Local Institution, Oldenburg, Germany|Local Institution, Paderborn, Germany|Local Institution, Wiesbaden, Germany|Local Institution, Athens, Greece|Local Institution, Athens, Greece|Local Institution, Thessaloniki, Greece|Local Institution, Modena, Italy|Local Institution, Monza (MB), Italy|Local Institution, Napoli, Italy|Local Institution, Perugia, Italy|Local Institution, Ravenna, Italy|Local Institution, Reggio Emilia, Italy|Local Institution, Fukushima-shi, Fukushima, Japan|Local Institution, Morioka-shi, Iwate, Japan|Local Institution, Osaka-sayama-shi, Osaka, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Merida, Yucatan, Mexico|Local Institution, A Coruna, Galicia, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Majadahonda - Madrid, Spain|Local Institution, Malaga, Spain|Local Institution, Valencia, Spain|Local Institution, Basel, Switzerland|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, ?stanbul, Turkey|Local Institution, Adana, Turkey|Local Institution, Antalya, Turkey|Local Institution, Istanbul, Turkey
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03417037

Study 12:
  NCT Number:                   NCT03001882
  Title:                        An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
  Acronym:                      CheckMate 592
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Non-Small Cell Lung Cancer
  Interventions:                Biological: Nivolumab|Biological: Ipilimumab
  Outcome Measures:             Objective Response Rate (ORR)|Objective Response Rate (ORR) of patient subgroups defined by baseline biomarkers|Disease Control Rate (DCR) of patient subgroups defined by baseline biomarkers|Duration of Response (DOR) of patient subgroups defined by baseline biomarkers|Time to Response (TTR) of patient subgroups defined by baseline biomarkers|Progression Free Survival (PFS) of patient subgroups defined by baseline biomarkers|Overall Survival (OS) of patient subgroups defined by baseline biomarkers|Incidence of Adverse Events (AEs)|Incidence of Serious Adverse Events (SAEs)
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   250
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-592|2018-000462-11
  Start Date:                   March 14, 2017
  Primary Completion Date:      September 28, 2021
  Completion Date:              December 14, 2021
  First Posted:                 December 23, 2016
  Results First Posted:         null
  Last Update Posted:           November 20, 2018
  Locations:                    Highland Oncology Group, Fayetteville, Arkansas, United States|Yale University, New Haven, Connecticut, United States|Cancer Specialists of North FL, Jacksonville, Florida, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Local Institution, Bronx, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Bon Secours-St Francis Hosp, Greenville, South Carolina, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Local Institution, Gent, Belgium|Local Institution, Gent, Belgium|Local Institution, Haine Saint Paul, Belgium|Local Institution, Liege, Belgium|Local Institution, Sint-Niklaas, Belgium|Local Institution, Pierre Benite, France|Local Institution, Strasbourg Cedex, France|Local Institution, Toulon, France|Klinik Essen-Mitte, Essen, Germany|Klinikverbund Kempten-Oberallgau, Immenstadt, Germany|Local Institution, Lowenstein, Germany|Klinikum Stuttgart, Stuttgart, Germany|ASST Papa Giovanni XXIII, Bergamo, Italy|Aou Policlinico V. Emanuele Di Catania, Catania, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|Azienda Ospedaliera Di Perugia, Perugia, Italy|Local Institution, Amsterdam, Netherlands|Local Institution, Nijmegen, Netherlands|Local Institution, Cluj-Napoca, Romania|Local Institution, Craiova, Romania|Instituto Catalan De Oncologia, Barcelona, Spain|Hosp Univer 12 De Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hosp Univ Virgen Macarena, Sevilla, Spain
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03001882

Study 13:
  NCT Number:                   NCT03048136
  Title:                        A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer
  Acronym:                      CheckMate 955
  Status:                       Withdrawn
  Study Results:                No Results Available
  Conditions:                   Non-Small Cell Lung Cancer
  Interventions:                Drug: Nivolumab|Drug: Ipilimumab
  Outcome Measures:             Incidence of high grade (Grade 3-4 and Grade 5) treatment-related select adverse events|Incidence of high grade (Grade 3-4 and Grade 5) immune-mediated adverse events|Progression-free survival (PFS) as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST v1.1)|Objective Response Rate (ORR) as assessed by the Investigator using tumor progression per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)|Overall survival (OS) as defined as the time from first dosing to the date of death|Duration of Response (DOR) as assessed by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   0
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-955
  Start Date:                   March 9, 2018
  Primary Completion Date:      September 29, 2019
  Completion Date:              September 29, 2019
  First Posted:                 February 9, 2017
  Results First Posted:         null
  Last Update Posted:           April 17, 2018
  Locations:                    Local Institution, San Francisco, California, United States|Local Institution, Lincoln, Nebraska, United States|Local Institution, Hackensack, New Jersey, United States|Local Institution, Columbus, Ohio, United States|Local Institution, Lancaster, Pennsylvania, United States|Local Institution, Langhorne, Pennsylvania, United States|Local Institution, Sayre, Pennsylvania, United States|Local Institution, Charleston, South Carolina, United States|Local Institution, Saint George, Utah, United States|Local Institution, Viedma, RIO Negro, Argentina|Local Institution, Montreal, Quebec, Canada|Local Institution, Dresden, Germany|Local Institution, Gauting, Germany|Local Institution, Gerlingen, Germany|Local Institution, Grosshansdorf, Germany|Local Institution, Lima, Peru|Local Institution, Lima, Peru
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03048136

Study 14:
  NCT Number:                   NCT01642004
  Title:                        Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                Has Results
  Conditions:                   Squamous Cell Non-small Cell Lung Cancer
  Interventions:                Biological: Nivolumab|Drug: Docetaxel
  Outcome Measures:             Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint|Overall Survival (OS) Rate in All Randomized Participants|Number of Deaths From Any Cause in All Randomized Participants at Primary Endpoint|Objective Response Rate (ORR) in All Randomized Participants at Primary Endpoint|Time To Response (TTR) in Months for All Confirmed Responders at Primary Endpoint|Duration of Objective Response (DOR) in Months for All Confirmed Responders at Primary Endpoint|Progression-Free Survival (PFS) at Primary Endpoint|Progression-Free Survival (PFS) Time in Months for All Randomized Participants at Primary Endpoint|Percentage of Participants Experiencing Disease-related Symptom Improvement by Week 12|Overall Survival (OS) Time in Months by Baseline PD-L1 Expression for All Randomized Participants at Primary Endpoint|Objective Response Rate (ORR) by Baseline PD-L1 Expression for All Randomized Participants at Primary Endpoint|Progression Free Survival (PFS) Time in Months by Baseline PD-L1 Expression for All Randomized Participants at Primary Endpoint
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   352
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-017|2011-004792-36
  Start Date:                   September 26, 2012
  Primary Completion Date:      November 17, 2014
  Completion Date:              December 29, 2018
  First Posted:                 July 17, 2012
  Results First Posted:         March 17, 2016
  Last Update Posted:           April 10, 2018
  Locations:                    Mayo Clinic Arizona, Scottsdale, Arizona, United States|City Of Hope, Duarte, California, United States|Yale University, New Haven, Connecticut, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Northwest Georgia Oncology Ctr, Marietta, Georgia, United States|University Of Chicago Medical Center, Chicago, Illinois, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Winthrop University Hospital, Mineola, New York, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|St Mary Medical Center, Langhorne, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Guthrie Medical Group, P.C., Sayre, Pennsylvania, United States|South Carolina Oncology Associates, Columbia, South Carolina, United States|Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|University Of Texas Southwestern Medical Center, Dallas, Texas, United States|The University Of Texas Md Anderson Cancer Center, Houston, Texas, United States|Swedish Cancer Institute, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|West Virginia University-Mbrcc, Morgantown, West Virginia, United States|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina|Local Institution, San Miguel De Tucuman, Tucuman, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Wollongong, New South Wales, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Elizabeth Vale, South Australia, Australia|Local Institution, Kurralta Park, South Australia, Australia|Local Institution, East Bentleigh, Victoria, Australia|Local Institution, Linz, Austria|Local Institution, Salzburg, Austria|Local Institution, Vienna, Austria|Local Institution, Wels, Austria|Cancercare Manitoba, Winnipeg, Manitoba, Canada|Jewish General Hospital, Montreal, Quebec, Canada|CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski, Rimouski, Quebec, Canada|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Recoleta, Santiago DE Chile, Chile|Local Institution, Vi?a Del Mar, Valparaiso, Chile|Local Institution, Antofagasta, Chile|Local Institution, Santiago, Chile|Local Institution, Praha 8, Czechia|Local Institution, Avignon Cedes 9, France|Local Institution, Caen, France|Local Institution, Dijon, France|Local Institution, La Roche Sur Yon Cedex 9, France|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 20, France|Local Institution, Pierre Benite, France|Local Institution, Rennes Cedex 9, France|Local Institution, Strasbourg, France|Local Institution, Toulouse, France|Local Institution, Bad Berka, Germany|Local Institution, Essen, Germany|Local Institution, Gerlingen, Germany|Local Institution, Grosshansdorf, Germany|Local Institution, Heidelberg, Germany|Local Institution, Koeln, Germany|Local Institution, Krefeld, Germany|Local Institution, Budapest, Hungary|Local Institution, Dublin 8, Dublin, Ireland|Local Institution, Dublin 9, Dublin, Ireland|Local Institution, Bologna, Italy|Local Institution, Meldola (fc), Italy|Local Institution, Milano, Italy|Local Institution, Padova, Italy|Local Institution, Perugia, Italy|Local Institution, Ravenna, Italy|Local Institution, Siena, Italy|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Leon, Guanajato, Guanajuato, Mexico|Local Institution, Hermosillo, Sonora, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Arequipa, Peru|Local Institution, Lima, Peru|Local Institution, Gdansk, Poland|Local Institution, Krakow, Poland|Local Institution, Olsztyn, Poland|Local Institution, Szczecin, Poland|Local Institution, Warszawa, Poland|Local Institution, Bucuresti, Romania|Local Institution, Cluj-Napoca, Romania|Local Institution, Constanta, Romania|Local Institution, Craiova, Romania|Local Institution, Iasi, Romania|Local Institution, Timisoara, Romania|Local Institution, Moscow, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Barakaldo, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, Cottingham, EAST Yorkshire, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Withington, Manchester, United Kingdom|Local Institution, Sheffield, Yorkshire, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01642004

Study 15:
  NCT Number:                   NCT02659059
  Title:                        Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer
  Acronym:                      CheckMate 568
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Non-Small-Cell Lung Cancer
  Interventions:                Biological: Nivolumab|Biological: Ipilimumab|Drug: Platinum Doublet Chemotherapy
  Outcome Measures:             Objective response rate (ORR)|ORR|Number of Patients with dose Limiting Toxicities (DLTs)|Number of Adverse Events (AEs)|Number of Serious Adverse Events (SAEs)|Number of Deaths|Number of Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE)|Progression free survival (PFS)|Overall Response Rate (ORR)|Overall Survival (OS)|PFS|OS
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   507
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-568
  Start Date:                   February 10, 2016
  Primary Completion Date:      November 6, 2018
  Completion Date:              April 20, 2022
  First Posted:                 January 20, 2016
  Results First Posted:         null
  Last Update Posted:           September 19, 2018
  Locations:                    Sharp Memorial Hospital, San Diego, California, United States|Cancer Center Of Central Connecticut, Plainville, Connecticut, United States|Cleveland Clinic Florida, Weston, Florida, United States|Winship Cancer Institute., Atlanta, Georgia, United States|Summit Cancer Care, Savannah, Georgia, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|University Of Louisville Medical Center, Inc., Dba, Louisville, Kentucky, United States|Johns Hopkins Cancer Center, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center., Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Nebraska Hematology Oncology Pc, Lincoln, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|New Mexico Hematology Oncology Consultants, Albuquerque, New Mexico, United States|Lovelace Cancer Care, Albuquerque, New Mexico, United States|New Mexico Cancer Care Alliance, Albuquerque, New Mexico, United States|Presbyterian Rust Medical Center, Albuquerque, New Mexico, United States|The Cancer Center at Presbyterian, Albuquerque, New Mexico, United States|Winthrop University Hospital, Mineola, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University, Durham, North Carolina, United States|Novant Health Oncology Specialists, Winston-Salem, North Carolina, United States|The Ohio State University, Columbus, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Allegheny Health Network, Pittsburgh, Pennsylvania, United States|Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Kingston Regional Cancer Centre, Kingston, Ontario, Canada|Sault Area Hospital, Sault Ste Marie, Ontario, Canada|Csss De St-Jerome, St.Jerome, Quebec, Canada
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02659059

Study 16:
  NCT Number:                   NCT02613507
  Title:                        Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer
  Acronym:                      CheckMate 078
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Non-Small Cell Lung Cancer
  Interventions:                Drug: Nivolumab|Drug: Docetaxel
  Outcome Measures:             Overall survival|Objective Response Rate (ORR)|Progression Free Survival (PFS),|Rate of Disease-related Symptom Improvement:
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   644
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-078|2015-001893-16
  Start Date:                   December 10, 2015
  Primary Completion Date:      September 15, 2017
  Completion Date:              January 15, 2019
  First Posted:                 November 24, 2015
  Results First Posted:         null
  Last Update Posted:           May 1, 2018
  Locations:                    Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Chongqing, Chongqing, China|Local Institution, Fuzhou, Fujian, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Changsha, Hunan, China|Local Institution, Changsha, Hunan, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Chang Chun, Jilin, China|Local Institution, Changchun, Jilin, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Beijing, China|Local Institution, Beijing, China|Local Institution, Beijing, China|Local Institution, Shanghai, China|Local Institution, Hong Kong, Hong Kong|Local Institution, Chelyabinsk, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St.petersburg, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02613507

Study 17:
  NCT Number:                   NCT02872116
  Title:                        Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer
  Acronym:                      CheckMate649
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Gastric Cancer|Gastroesophageal Junction Cancer
  Interventions:                Drug: Nivolumab|Drug: Ipilimumab|Drug: Oxaliplatin|Drug: Capecitabine|Drug: Leucovorin|Drug: Fluorouracil
  Outcome Measures:             Overall survival (OS) of nivolumab in combination with oxaliplatin + fluoropyrimidine versus oxaliplatin + fluoropyrimidine in programmed cell death ligand 1 (PD-L1) positive participants|Progression-free survival (PFS), as assessed by Blinded Independent Central Review (BICR), of nivolumab in combination with oxaliplatin plus fluoropyrimidine versus oxaliplatin plus fluoropyrimidine in PD-L1 positive participants|OS in all randomized participants|PFS, as assessed by BICR, in all randomized participants|Objective Response Rate (ORR), as assessed by BICR, in all randomized participants|Time to symptom deterioration (TTSD) of nivolumab + ipilimumab vs oxaliplatin + fluoropyrimidine in all randomized participants
  Sponsor/Collaborators:        Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   1649
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-649|2016-001018-76
  Start Date:                   October 4, 2016
  Primary Completion Date:      March 28, 2021
  Completion Date:              October 6, 2022
  First Posted:                 August 19, 2016
  Results First Posted:         null
  Last Update Posted:           November 6, 2018
  Locations:                    Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States|California Pacific Medical Center Research Institute, San Francisco, California, United States|University Of Colorado, Aurora, Colorado, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Georgetown University Med Ctr, Washington, District of Columbia, United States|Florida Cancer Specialists S., Fort Myers, Florida, United States|Baptist Health Medical Group Oncology LLC, Miami, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Northwest Georgia Oncology Center, P.C., Marietta, Georgia, United States|Illinois Cancer Specialists, Arlington Heights, Illinois, United States|Northwestern University, Chicago, Illinois, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute., Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Willamette Valley Cancer Center, Eugene, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Allegheny Health Network, Pittsburgh, Pennsylvania, United States|Tennessee Oncology, Pc, Nashville, Tennessee, United States|Texas Oncology, Bedford, Texas, United States|Texas Oncology, Texas Cancer Center At Medical City, Dallas, Texas, United States|Baylor Sammons Cancer Center, Dallas, Texas, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|Texas Oncology-Plano East, Plano, Texas, United States|Virginia Oncology Associates, Newport News, Virginia, United States|Hospital Municipal De Gastroenterologia Dr.Udaondo, Capital Federal, Buenos Aires, Argentina|Hospital Britanico, Capital Federal, Buenos Aires, Argentina|Clinica Viedma S.A., Viedma, RIO Negro, Argentina|Centro Para La Atencion Integral Del Paciente Oncologico, San Miguel De Tucuman, Tucuman, Argentina|Instituto Alexander Fleming, Caba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Local Institution, La Rioja, Argentina|Blacktown Hospital, Blacktown, New South Wales, Australia|Gosford Hospital, Gosford, New South Wales, Australia|Tasman Oncology Research Pty Ltd, Southport, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Ballarat Base Hospital, Ballarat, Victoria, Australia|Goulburn Valley Health, Shepparton, Victoria, Australia|Sunshine Hospital, St Albans, Victoria, Australia|St John of God Murdoch Hospital, Perth, Western Australia, Australia|Local Institution, Subiaco, Western Australia, Australia|Local Institution, Salvador, Bahia, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Edmonton, Alberta, Canada|Local Institution, London, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Centre Hospitalier De L'Universite De Montreal, Montreal, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Centre integre universitaire de sante et de service sociaux de l'estrie - CHUS, Sherbrooke, Quebec, Canada|Local Institution, Trois-Rivieres, Quebec, Canada|CHU de Quebec - Universite Laval, Quebec, Canada|Pontificia Universidad Catolica de Chile, Santiago, Metropolitana, Chile|Fundacion Arturo Lopez Perez, Santiago, Metropolitana, Chile|Hospital Clinico de la Universidad De Chile, Independencia, Santiago, Chile|Instituto Oncologico Clinica Renaca, Vina Del Mar, Valparaiso, Chile|ICOS - Inmunomedica, Temuco, Chile|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Chongqing, Chongqing, China|Local Institution, Fuzhou, Fujian, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Ha Erbin, Heilongjiang, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Changsha, Hunan, China|Local Institution, Changzhou, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Changchun, Jilin, China|Local Institution, Changchun, Jilin, China|Local Institution, Shenyang, Liaoning, China|Local Institution, Qingdao, Shandong, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Urumqi, Xinjiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Beijing, China|Local Institution, Hangzhou, China|Local Institution, Tianjin, China|Local Institution, Bogota, Cundinamarca, Colombia|Administradora Del Country S.A. - Clinica Del Country, Bogota, Colombia|Local Institution, Pasto, Colombia|Interni hematologicka a onkologicka klinika, Brno, Czechia|Klinika komplexni onkologicke pece, Brno, Czechia|Local Institution, Caen, France|Local Institution, Dijon, France|Local Institution, Lille, France|Local Institution, Montpellier, France|Local Institution, Nantes, France|Local Institution, Nice Cedex 2, France|Local Institution, Paris, France|Local Institution, Plerin, France|Charite Campus Virchow Klinikum, Berlin, Germany|University Hospital Of Cologne, Cologne, Germany|Universitaetsklinikum Carl Gustav Carus, Dresden, Germany|Universitatsklinikum Dusseldorf, Dusseldorf, Germany|Universitaetsklinikum Essen, Essen, Germany|Medizinische Universitaetsklinik Freiburg, Freiburg, Germany|Universitaets-Krankenhaus Eppendorf, Hamburg, Germany|Johannes -Gutenberg Universitat, Mainz, Germany|Klinikum Rechts Der Isar, Muenchen, Germany|Laiko General Hospital Of Athens, Athens, Greece|Ioannina University Hospital, Ioannina, Greece|Agioi Anargyroi Cancer Center, Nea Kifissia, Greece|University General Hospital of Patras, Patras, Greece|Local Institution, Hong Kong, Hong Kong|Local Institution, Hong Kong, Hong Kong|Semmelweis Egyetem Onkologiai Kozpont, Budapest, Hungary|Orszagos Onkologiai Intezet, Budapest, Hungary|DE KK Onkologiai Intezet, Debrecen, Hungary|Local Institution, Gyula, Hungary|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Petach Tikva, Israel|Local Institution, Ramat-gan, Israel|Local Institution, Tel Aviv, Israel|ASST Papa Giovanni XXIII, Bergamo, Italy|Local Institution, Firenze, Italy|Azienda Ospedaliera Universitaria Di Modena, Modena, Italy|Aorn Dei Colli, Napoli, Italy|Azienda Ospedaliera Universitaria Pisana, Pisa, Italy|Fondazione Policlinico Universitario A. Gemelli, Roma, Italy|Osp. Casa Sollievo Della Sofferenza, San Giovanni Rotondo, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Kashiwa, Chiba, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Minato-ku, Tokyo, Japan|Local Institution, Kita-gun, Japan|Local Institution, Tokyo, Japan|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Mexico City, Distrito Federal, Mexico|Local Institution, Tlalpan, Distrito Federal, Mexico|Local Institution, Toluca, Estado DE Mexico, Mexico|Local Institution, Queretaro, Mexico|Clinica Anglo Americana, Lima, Peru|Instituto Nacional De Enfermedades Neoplasicas, Lima, Peru|Hospital Nacional Cayetano Heredia, Lima, Peru|Clinica Internacional sede San Borja, Lima, Peru|II Klinika Chirurgii Ogolnej, Gastroenterologicznej i Nowotworow Ukladu Pokarmowego, Lublin, Poland|Local Institution, Nowy Sacz, Poland|Centrum Onkologiczne: Oddzial Onkologii Klinicznej oraz Poradnia Onkologiczna, Tarnobrzeg, Poland|Klinika Gastroenterologii Onkologicznej, Warszawa, Poland|Local Institution, Lisboa, Portugal|Local Institution, Porto, Portugal|Local Institution, Baia Mare, JUD Maramures, Romania|Local Institution, Bucharest, Romania|Local Institution, Cluj-Napoca, Romania|Local Institution, Craiova, Romania|Local Institution, Suceava, Romania|Local Institution, Chelyabinsk, Russian Federation|Local Institution, Kazan, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Badajoz, Spain|Local Institution, Badalona-barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Pozuelo De Alarcon, Madrid, Spain|Local Institution, Valencia, Spain|Local Institution, Zaragoza, Spain|Local Institution, Tainan, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, Ankara, Turkey|Local Institution, Ankara, Turkey|Local Institution, Antalya, Turkey|Local Institution, Diyarbak?r, Turkey|Local Institution, Edrine, Turkey|Local Institution, Istanbul, Turkey|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Nottingham, Nottinghamshire, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom|Local Institution, Southampton, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02872116

Study 18:
  NCT Number:                   NCT03338790
  Title:                        An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer
  Acronym:                      CheckMate 9KD
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Prostate Cancer
  Interventions:                Biological: Nivolumab|Drug: Docetaxel|Drug: Enzalutamide|Drug: Rucaparib|Drug: Prednisone
  Outcome Measures:             Objective Response Rate (ORR)|Prostate-specific antigen response rate (RR-PSA)|Radiographic progression-free survival (rPFS)|Time to response (TTR)|Duration of response (DOR)|Time to prostate-specific antigen progression (TTP-PSA)|Overall Survival (OS)|Incidence of adverse events (AEs)|Incidence of serious adverse events (SAEs)
  Sponsor/Collaborators:        Bristol-Myers Squibb|Clovis Oncology|Astellas Pharma Inc
  Gender:                       Male
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   330
  Funded Bys:                   Industry|Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-9KD
  Start Date:                   December 15, 2017
  Primary Completion Date:      February 18, 2020
  Completion Date:              November 18, 2020
  First Posted:                 November 9, 2017
  Results First Posted:         null
  Last Update Posted:           November 12, 2018
  Locations:                    Southern Cancer Center Pc, Daphne, Alabama, United States|Desert Hematology Oncology Medical Group, Rancho Mirage, California, United States|Local Institution, San Francisco, California, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Baptist Health Medical Group Oncology, Miami, Florida, United States|Northwest Georgia Oncology Centers, P.C., Marietta, Georgia, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Tulane University, New Orleans, Louisiana, United States|Maryland Oncology Hematology, P.A., Rockville, Maryland, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Detroit, Michigan, United States|Local Institution, Minneapolis, Minnesota, United States|Jackson Oncology Associates, Pllc, Jackson, Mississippi, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha, Nebraska, United States|New York Oncology Hematology, P.C., Amsterdam, New York, United States|Local Institution, New York, New York, United States|Duke University, Durham, North Carolina, United States|Providence Portland Medical Center, Portland, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Virginia Cancer Care Specialist, PC, Fairfax, Virginia, United States|Local Institution, Caba, Buenos Aires, Argentina|Instituto Medico Especializado Alexander Fleming, Capital Federal, Buenos Aires, Argentina|Hospital Britanico De Buenos Aires, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Hospital Italiano De Buenos Aires, Caba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Local Institution, Camperdown, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Local Institution, South Brisbane, Queensland, Australia|Monash Medical Centre Clayton, Clayton, Victoria, Australia|Austin Hospital, Heidelberg, Victoria, Australia|Local Institution, Elizabeth Vale, Australia|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Curitiba, Parana, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Campinas, SAO Paulo, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Santa Catarina, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Edmonton, Alberta, Canada|BC Cancer - Kelowna, Kelowna, British Columbia, Canada|Local Institution, Vancouver, British Columbia, Canada|The Moncton Hospital, Moncton, New Brunswick, Canada|Local Institution, Saint John, New Brunswick, Canada|Juravinski Cancer Center, Hamilton, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Centre Hospitalier De L'Universite De Montreal, Montreal, Quebec, Canada|CHU de Quebec - Universite Laval, Quebec, Canada|Bradford Hill Centro de Investigaciones Clinicas, Santiago de Chile, Metropolitana, Chile|Instituto Oncologico, Vina Del Mar, Valparaiso, Chile|Local Institution, Monteria, Cordoba, Colombia|Local Institution, Bogota, Colombia|Local Institution, Medellin, Colombia|Local Institution, Besancon, France|Local Institution, Clermont-ferrand, France|Local Institution, Lyon, France|Local Institution, Marseille, France|Local Institution, Villejuif, France|Universitaetsklinikum Essen, Essen, Germany|Universitaetsmedizin Goettingen, Goettingen, Germany|Uniklinik Heidelberg, Heidelberg, Germany|Universitaetsklinikum Jena, Jena, Germany|Praxisklinik Fuer Haematologie Und Onkologie, Koblenz, Germany|Klinikum rechts der Isar der Technischen Universitat Munchen, Munich, Germany|Local Institution, Leon, Guanajuato, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Culiacan, Sinaloa, Mexico|Local Institution, Madrid, Spain|Local Institution, Pamplona, Spain|Local Institution, Sevilla, Spain
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03338790

Study 19:
  NCT Number:                   NCT03519256
  Title:                        A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder
  Acronym:                      CheckMate 9UT
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Bladder Cancer|Bladder Tumors|Neoplasms, Bladder
  Interventions:                Biological: Nivolumab|Biological: BCG|Drug: BMS-986205
  Outcome Measures:             Proportion of carcinoma in situ (CIS) participants with complete response (CR), per Pathology Review Committee (PRC)|Duration of complete response (DOCR), per PRC, in CIS participants with CR|Event Free Survival (EFS), per PRC, for all non-CIS participants|Progression-free Survival (PFS)|Incidence of Adverse Events (AEs)|Incidence of Serious Adverse Events (SAEs)|Incidence of AEs leading to discontinuation|Incidence of deaths|Incidence of laboratory abnormalities
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   436
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-9UT|2017-003581-27
  Start Date:                   May 25, 2018
  Primary Completion Date:      January 4, 2022
  Completion Date:              April 16, 2023
  First Posted:                 May 8, 2018
  Results First Posted:         null
  Last Update Posted:           November 20, 2018
  Locations:                    Local Institution, Phoenix, Arizona, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Local Institution, Riverside, California, United States|Local Institution, San Francisco, California, United States|Emory University, Atlanta, Georgia, United States|The University Of Chicago, Chicago, Illinois, United States|Local Institution, Westwood, Kansas, United States|Local Institution, Wichita, Kansas, United States|Local Institution, Shreveport, Louisiana, United States|Local Institution, Baltimore, Maryland, United States|Local Institution, Ann Arbor, Michigan, United States|Local Institution, Minneapolis, Minnesota, United States|Adult & Pediatric Urology, Omaha, Nebraska, United States|Local Institution, Voorhees, New Jersey, United States|Local Institution, New York, New York, United States|Local Institution, New York, New York, United States|Local Institution, New York, New York, United States|Local Institution, Columbus, Ohio, United States|Local Institution, Springfield, Oregon, United States|Local Institution, Bala-Cynwyd, Pennsylvania, United States|Local Institution, Hershey, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States|Erlanger Health System, Chattanooga, Tennessee, United States|Local Institution, Nashville, Tennessee, United States|Local Institution, Dallas, Texas, United States|Local Institution, Houston, Texas, United States|Local Institution, Lubbock, Texas, United States|Local Institution, San Antonio, Texas, United States|Local Institution, Virginia Beach, Virginia, United States|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Ciudad Autonoma Buenos Aires, Buenos Aires, Argentina|Local Institution, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Local Institution, Viedma, RIO Negro, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Fortaleza, Ceara, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Campinas, SAN Paulo, Brazil|Local Institution, Itacorubi, Florianopolis, Santa Catarina, Brazil|Local Institution, Jau, SAO Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, St. John's, Newfoundland and Labrador, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Sherbrooke, Quebec, Canada|Local Institution, Quebec, Canada|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Angers, France|Local Institution, Bordeaux, France|Local Institution, LILLE Cedex, France|Local Institution, Strasbourg Cedex, France|Local Institution, Suresnes, France|Local Institution, Hong Kong, Hong Kong|IRCCS Istituto Nazionale Tumori Milano, Milano, Italy|Local Institution, Modena, Italy|Local Institution, Napoli, Italy|Local Institution, Pisa, Italy|Local Institution, Tuxtla Gutierrez, Chiapas, Mexico|Local Institution, Ciudad de Mexico, Distrito Federal, Mexico|Local Institution, Df, Distrito Federal, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Nijmegen, Netherlands|Local Institution, Utrecht, Netherlands|Local Institution, Omsk, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Local Institution, Barcelona, Spain|Hosp Univer 12 De Octubre, Madrid, Spain|Hospital Universitario Virgen De La Victoria, Malaga, Spain|Local Institution, Istanbul, Turkey|Local Institution, Istanbul, Turkey|Local Institution, Istanbul, Turkey|Local Institution, Chelmsford, Essex, United Kingdom|Local Institution, Lancaster, United Kingdom|Local Institution, London, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Southampton, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03519256

Study 20:
  NCT Number:                   NCT03400332
  Title:                        An Investigational Immuno-Therapy Study of Experimental Medication BMS-986253 Given in Combination With Nivolumab in Patients With Advanced Cancers
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Cancer
  Interventions:                Drug: BMS-986253|Biological: Nivolumab
  Outcome Measures:             Incidence of adverse events (AE)|Incidence of serious adverse events (SAE)|Incidence of AEs meeting protocol-defined dose limiting toxicities (DLT) criteria|Incidence of AEs leading to discontinuation|Incidence of deaths|Incidence of labornatory abnormalities|Overall response rate (ORR)|Median duration of response (mDOR)|Incidence of anti-drug antibody (ADA) to BMS-986253|Serum biomarker concentration|Maximum observed serum concentration (Cmax)|Time of maximum observed serum concentration (Tmax)|Area under the serum concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)]|Area under the serum concentration-time curve in 1 dosing interval [AUC(TAU)]|Observed serum concentration at the end of a dosing interval (Ctau)|Trough observed serum concentration at the end of the dosing interval (Ctrough)
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   260
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA027-002
  Start Date:                   January 31, 2018
  Primary Completion Date:      February 28, 2023
  Completion Date:              March 1, 2023
  First Posted:                 January 17, 2018
  Results First Posted:         null
  Last Update Posted:           October 4, 2018
  Locations:                    Rocky Mountain Cancer Centers, Denver, Colorado, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Lutherville, Maryland, United States|Maryland Oncology Hematology P.A., Rockville, Maryland, United States|Local Institution, Ann Arbor, Michigan, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Local Institution, New Brunswick, New Jersey, United States|Local Institution, New York, New York, United States|Columbia University Medical Center (Cumc), New York, New York, United States|Local Institution, Oklahoma City, Oklahoma, United States|Willamette Valley Cancer Institute And Research Center, Eugene, Oregon, United States|Local Institution, Philadelphia, Pennsylvania, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|Greenville Health System, Greenville, South Carolina, United States|Texas Oncology, Austin, Texas, United States|Texas Oncology - Baylor Charles A. Simmons Cancer Center, Dallas, Texas, United States|Texas Oncology-Fort Worth 12th Ave, Fort Worth, Texas, United States|Local Institution, Houston, Texas, United States|Texas Oncology-San Antonio Medical Center, San Antonio, Texas, United States|Texas Oncology, P.A., Tyler, Texas, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Local Institution, Edmonton, Alberta, Canada|Local Institution, Vancouver, British Columbia, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Pamplona, Spain|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Birmingham, WEST Midlands, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03400332

Study 21:
  NCT Number:                   NCT02832167
  Title:                        An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread
  Acronym:                      CheckMate 627
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Cancer
  Interventions:                Biological: Nivolumab
  Outcome Measures:             Objective Response Rate (ORR) as determined by investigator|Overall Survival (OS) is defined as the time from the first dosing date to the date of death|Duration of clinical response|Incidence of adverse events (AEs)|Incidence of serious adverse events (SAEs)|Clinical Benefit Rate (CBR) defined as the number of participants with a best overall response of confirmed complete response (CR) or partial response (PR), or stable disease divided by the number of all treated participants|Time to Response (TTR) defined as the time from first dosing date to the date of the first confirmed response, as assessed by investigator|Programmed death-ligand 1 (PD-L1) expression as determined by biomarker analysis|MisMatch Repair (MMR) alterations as determined by biomarker analysis
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   250
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-627|2016-000461-23
  Start Date:                   September 13, 2016
  Primary Completion Date:      June 16, 2019
  Completion Date:              December 20, 2019
  First Posted:                 July 14, 2016
  Results First Posted:         null
  Last Update Posted:           May 22, 2018
  Locations:                    Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States|CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center, Bakersfield, California, United States|St. Jude Hospital Yorba Linda, Fullerton, California, United States|LACN, Los Angeles, California, United States|UCLA Main Campus - University California Los Angeles, Los Angeles, California, United States|Torrence Health Association, DBA Torrance Memorial;Physician Network/Cancer Care Associates, Redondo Beach, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|Cancer Center of Santa Barbara with Sansum Clinic, Santa Barbara, California, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, United States|St. Mary's Hospital And Regional Medical Center, Grand Junction, Colorado, United States|Rocky Mountain Cancer Centers, Lakewood, Colorado, United States|Memorial Healthcare System, Hollywood, Florida, United States|Florida Cancer Affiliates, Ocala, Florida, United States|UF Health Cancer Center - Orlando Health, Orlando, Florida, United States|Florida Cancer Specialists & Research Institute, Saint Petersburg, Florida, United States|Florida Cancer Specialists, West Palm Beach, Florida, United States|Florida Cancer Specialists, West Palm Beach, Florida, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States|Local Institution, Wichita, Kansas, United States|Maryland Oncology Hematology P.A., Columbia, Maryland, United States|Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota, United States|Research Medical Center, Kansas City, Missouri, United States|Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha, Nebraska, United States|Comprehensive Cancer Centers Of Nevada, Las Vegas, Nevada, United States|Saint Barnabas Medical Cancer Center, Livingston, New Jersey, United States|New York Oncology Hematology, P.C., Albany, New York, United States|Hematology Oncology Associates, PC, Medford, Oregon, United States|Willamette Valley Cancer Institute and Research Center, Springfield, Oregon, United States|Northwest Cancer Specialists, P.C., Tualatin, Oregon, United States|Greenville Health System, Greenville, South Carolina, United States|West Cancer Center, Germantown, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Texas Oncology - Baylor Charles A. Simmons Cancer Center, Dallas, Texas, United States|Texas Oncology, P.A., Fort Worth, Texas, United States|Texas Oncology, P.A., Fort Worth, Texas, United States|Texas Oncology, P.A., Fort Worth, Texas, United States|Texas Oncology, P.A., Fort Worth, Texas, United States|Texas Oncology, P.A., Fort Worth, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Texas Oncology, P.A., San Antonio, Texas, United States|Texas Oncology The Woodlands, The Woodlands, Texas, United States|Texas Oncology - Waco, Waco, Texas, United States|Virginia Cancer Care Specialist, PC, Fairfax, Virginia, United States|Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Wytheville, Virginia, United States|Local Institution, Berlin, Germany|Local Institution, Bonn, Germany|Local Institution, Dresden, Germany|Local Institution, Essen, Germany|Local Institution, Freiburg, Germany|Local Institution, Hamburg, Germany|Local Institution, Heidelberg, Germany|Local Institution, Munchen, Germany
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02832167

Study 22:
  NCT Number:                   NCT02481830
  Title:                        Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer
  Acronym:                      CheckMate331
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Lung Cancer
  Interventions:                Drug: Nivolumab|Drug: Topotecan|Drug: Amrubicin
  Outcome Measures:             Overall survival (OS) in subjects with relapsed SCLC|Progression free survival (PFS)|Objective response rate (ORR)
  Sponsor/Collaborators:        Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   803
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-331|2015-001097-18
  Start Date:                   August 28, 2015
  Primary Completion Date:      August 17, 2018
  Completion Date:              November 30, 2019
  First Posted:                 June 25, 2015
  Results First Posted:         null
  Last Update Posted:           November 20, 2018
  Locations:                    Univ Of Ark For Med Sci, Little Rock, Arkansas, United States|Smilow Cancer Hospital. At Yale New Haven, New Haven, Connecticut, United States|Emory University, Atlanta, Georgia, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Nebraska Hematology Oncology Pc, Lincoln, Nebraska, United States|Broome Oncology, Johnson City, New York, United States|Duke University, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|St. Luke's University Health Network, Bethlehem, Pennsylvania, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Tennessee Oncology, Pllc, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Local Institution, Waratah, New South Wales, Australia|Local Institution, Brisbane, Queensland, Australia|Local Institution, Kurralta Park, South Australia, Australia|Local Institution, Perth, Western Australia, Australia|Local Institution, Elizabeth Vale, Australia|Local Institution, Murdoch, Australia|Local Institution, Graz, Austria|Local Institution, Wels, Austria|Akh Wien, Wien, Austria|Local Institution, Bruxelles, Belgium|Local Institution, Edegem, Belgium|Local Institution, Leuven, Belgium|Local Institution, Yvoir, Belgium|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Recoleta, Santiago DE Chile, Chile|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Guanzhou, Guangdong, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Changchun, Jilin, China|Local Institution, Xian, Shaanxi, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Urumqi, Xinjiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Beijing, China|Local Institution, Guangzhou, China|Local Institution, Hangzhou, China|Local Institution, Shanghai, China|Local Institution, Brno, Czechia|Klinika komplexni onkologicke pece, Brno, Czechia|Klinika plicnich nemoci a tuberkulozy, Olomouc, Czechia|Pneumologicka klinika 1. LF a TN, Praha 4, Czechia|Local Institution, Copenhagen, Denmark|Local Institution, Herlev, Denmark|Local Institution, Odense, Denmark|Local Institution, Brest, France|Local Institution, Lille Cedex, France|Local Institution, Paris Cedex 14, France|Local Institution, Pringy Cedex, France|Local Institution, Reims, France|Local Institution, Toulon Cedex, France|Local Institution, Bamberg, Germany|Local Institution, Berlin, Germany|Local Institution, Essen, Germany|Local Institution, Frankfurt am Main, Germany|Local Institution, Gera, Germany|Local Institution, Gerlingen, Germany|Local Institution, Grosshansdorf, Germany|Local Institution, Halle (saale), Germany|Local Institution, Hamburg, Germany|Local Institution, Heidelberg, Germany|Local Institution, Immenstadt, Germany|Local Institution, Koeln, Germany|Local Institution, Muenchen, Germany|Local Institution, Oberhausen, Germany|Local Institution, Regensburg, Germany|University Hospital Of Heraklion, Heraklion, Creta, Greece|Sotiria General Hospital, Athens, Greece|Papageorgiou General Hospital, Thessaloniki, Greece|Orsz.Koranyi Tbc es Pulm.Int., Budapest, Hungary|Pulmonologiai Klinika, Budapest, Hungary|Local Institution, Beer Sheva, Israel|Local Institution, Kfar Saba, Israel|Local Institution, Ramat -Gan, Israel|Ospedale Bellaria-Maggiore, Bologna, Italy|Ospedale Civile Di Livorno, Livorno, Italy|Ospedale San Luca, Lucca, Italy|Istituto Romagnolo Per Lo Studio E La Cura Dei Tumori, Meldola, Italy|IRCCS Istituto Nazionale Tumori Milano, Milano, Italy|Azienda Ospedaliera - Nuovo Ospedale San Gerardo, Monza, Italy|Ospedale Degli Infermi, Rimini, Italy|Azienda Ospedaliera S. Andrea, Roma, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Nagoya, Aichi, Japan|Local Institution, Kashiwa, Chiba, Japan|Local Institution, Matsuyama, Ehime, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Akashi-shi, Hyogo, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Natori-shi, Miyagi, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Habikino-shi, Osaka, Japan|Local Institution, Hirakata-shi, Osaka, Japan|Local Institution, Osaka-sayama, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Sakai, Osaka, Japan|Local Institution, Kitaadachigun, Saitama, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Koto-ku, Tokyo, Japan|Local Institution, Wakayama, Japan|Local Institution, Cheongju-si, Chungcheonbuk-do, Korea, Republic of|Local Institution, Suwon, Gyeonggi-do, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Bergen, Norway|Local Institution, Oslo, Norway|Wojewodzki Szpital Zespolony W Elblagu, Elblag, Poland|Klinika Onkologii I Radioterapii Am, Gdansk, Poland|Oddzial Onkologiczny, Krakow, Poland|Regionalny Osrodek Onkologiczny, Lodz, Poland|Oddzial Onkologii Klinicznej, Poznan, Poland|Klinika Nowotworow Pluca i Klatki Piersiowej, Warszawa, Poland|Local Institution, Bucharest, Romania|Local Institution, Craiova, Romania|Local Institution, Romania, Romania|Local Institution, Timisoara, Timis, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Ryazan, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Local Institution, Basel, Switzerland|Centre hospitalier universitaire Vaudois (CHUV), Lausanne, Switzerland|Local Institution, Winterthur, Switzerland|Local Institution, Zurich, Switzerland|Local Institution, Taichung, Taiwan|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Maidstone, Kent, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02481830

Study 23:
  NCT Number:                   NCT02387996
  Title:                        A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                Has Results
  Conditions:                   Various Advanced Cancer
  Interventions:                Drug: Nivolumab
  Outcome Measures:             Objective Response Rate Per BIRC Assessment|ORR Per BIRC Assessment by PD-L1 Expression Level|Progression-Free Survival (PFS) Per BIRC Assessment|PFS Per BIRC Assessment by PD-L1 Expression Level|Overall Survival|OS by PD-L1 Expression Level|Objective Response Rate (ORR) Per Investigator|ORR Per Investigator by PD-L1 Expression Level
  Sponsor/Collaborators:        Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   386
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-275
  Start Date:                   March 4, 2015
  Primary Completion Date:      April 15, 2016
  Completion Date:              October 2, 2019
  First Posted:                 March 13, 2015
  Results First Posted:         May 24, 2017
  Last Update Posted:           February 15, 2018
  Locations:                    Mayo Clinic, Scottsdale, Arizona, United States|City Of Hope, Duarte, California, United States|Pacific Hematology Oncology Associates, San Francisco, California, United States|University Of Colorado, Aurora, Colorado, United States|University Cancer Blood Ctr, Athens, Georgia, United States|Ft. Wayne Med Onco-Hema Inc, Fort Wayne, Indiana, United States|Indiana University Health - University Hospital, Indianapolis, Indiana, United States|University Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States|Crescent City Research Consortium, LLC, Marrero, Louisiana, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|GU Research Network, LLC, Omaha, Nebraska, United States|Mount Sinai Medical Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Providence Portland Medical Center, Portland, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Erlanger Oncology & Hematology - Univ. of TN, Chattanooga, Tennessee, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Local Institution, Waratah, New South Wales, Australia|Local Institution, Elizabeth Vale, South Australia, Australia|Local Institution, Brussels, Belgium|Local Institution, Edegem, Belgium|Local Institution, Hasselt, Belgium|Local Institution, Brno, Czechia|Local Institution, Olomouc, Czechia|Local Institution, Praha 5, Czechia|Local Institution, Helsinki, Finland|Local Institution, Tampere, Finland|Local Institution, Erfurt, Germany|Local Institution, Erlangen, Germany|Local Institution, Hamburg, Germany|Local Institution, Heidelberg, Germany|Local Institution, Jena, Germany|Local Institution, Muenchen, Germany|Local Institution, Rostock, Germany|Local Institution, Tuebingen, Germany|Local Institution, Arezzo, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Pavia, Italy|U.O. Oncologia Medica Azienda, Roma, Italy|Local Institution, Akita-shi, Akita, Japan|Local Institution, Hirosaki-shi, Aomori, Japan|Local Institution, Tsukuba-shi, Ibaraki, Japan|Local Institution, Morioka-shi, Iwate, Japan|Local Institution, Yokohama, Kanagawa, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Osaka-Sayama-Shi, Osaka, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Gdansk, Poland|Local Institution, Krakow, Poland|Local Institution, Lodz, Poland|Local Institution, Szczecin, Poland|Local Institution, Wroclaw, Poland|Local Institution, Badalona-barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Hospitalet de Llobregat - Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, Lund, Sweden
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02387996

Study 24:
  NCT Number:                   NCT03158272
  Title:                        A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Advanced Malignancies
  Interventions:                Biological: Cabiralizumab|Biological: Nivolumab
  Outcome Measures:             Incidenence of Adverse Events (AEs)|Incidence of serious adverse events (SAEs)|Incidence of laboratory abnormalities|Incidence of death|Incidence of AEs|Trough observed concentration (Ctrough) Accumulation Index; ratio of Ctrough at steady-state (AI_Ctrough)|Area under the serum concentration-time curve from time zero to [AUC(0-T)|Maximum observed serum concentration (Cmax)|Trough observed serum concentration (Ctrough)|Effective elimination half-life that explains the degree of Ctrough (T-HALFeff_Ctrough)|Time of maximum observed serum concentration (Tmax)|Volume of distribution at steady state (Vss)|Incidence of Antidrug Antibodies (ADA)|Best overall response (BOR)|Duration of response
  Sponsor/Collaborators:        Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd
  Gender:                       All
  Age:                          20 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   36
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA025-001
  Start Date:                   May 25, 2017
  Primary Completion Date:      November 29, 2020
  Completion Date:              November 30, 2020
  First Posted:                 May 18, 2017
  Results First Posted:         null
  Last Update Posted:           October 3, 2018
  Locations:                    Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Chuo-ku, Tokyo, Japan
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03158272

Study 25:
  NCT Number:                   NCT02617589
  Title:                        An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)
  Acronym:                      CheckMate 498
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Brain Cancer
  Interventions:                Drug: Nivolumab|Drug: Temozolomide|Radiation: Radiotherapy
  Outcome Measures:             Overall survival (OS)|Progression free survival (PFS)|Overall survival
  Sponsor/Collaborators:        Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   550
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-498|2015-003739-37
  Start Date:                   February 29, 2016
  Primary Completion Date:      March 10, 2019
  Completion Date:              October 1, 2019
  First Posted:                 December 1, 2015
  Results First Posted:         null
  Last Update Posted:           November 20, 2018
  Locations:                    University of Alabama at Birmingham, Birmingham, Alabama, United States|St. Joseph Hospital And Medical Center, Phoenix, Arizona, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|UCLA Neuro-Oncology Program, Los Angeles, California, United States|Sutter Institute For Medical Research, Sacramento, California, United States|Sharp Memorial Hospital, San Diego, California, United States|The Regents of the University of California, San Francisco, San Francisco, California, United States|Yale Cancer Center, New Haven, Connecticut, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|University Of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University - Winship Cancer Institute, Atlanta, Georgia, United States|The University Of Chicago, Chicago, Illinois, United States|University Of Kansas Medical Center, Westwood, Kansas, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Johns Hopkins University School Of Medicine, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|JFK Medical Center, Edison, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Columbia University Medical Center (Cumc), New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Preston Robert Tisch Brain Tumor Center at Duke University, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Local Institution, Oklahoma City, Oklahoma, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|Erlanger Oncology & Hematology - Univ. of TN, Chattanooga, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University Of Texas Southwestern Medical Center, Dallas, Texas, United States|University Of Texas Md Anderson Cancer Ctr, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Swedish Neuroscience Institute, Seattle, Washington, United States|Local Institution, Liverpool, New South Wales, Australia|Royal North Shore Hospital, St. Leonards, New South Wales, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Prahran, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Kepler Universitaetsklinikum, Linz, Austria|Medical University Of Vienna, Vienna, Austria|Universitair Ziekenhuis Brussel, Brussels, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|Uz Leuven, Leuven, Belgium|BC Cancer - Vancouver, Vancouver, British Columbia, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada|Local Institution, Copenhagen, Denmark|Local Institution, Odense, Denmark|Local Institution, Bron Cedex, France|Local Institution, Lille Cedex, France|Local Institution, Marseille, France|Local Institution, Paris cedex 13, France|Local Institution, Paris, France|Local Institution, Rennes Cedex, France|Local Institution, Toulouse, France|Local Institution, Vandoeuvre Les Nancy, France|Universitaetsklinikum Bonn, Bonn, Germany|Uniklinik Erlangen, Erlangen, Germany|Klinikum Der J. W. Goethe-Universitaet Frankfurt/Main, Frankfurt am Main, Germany|Medizinische Universitaetsklinik Freiburg, Freiburg, Germany|Universitaetsklinikum Hamburg, Hamburg, Germany|Universitaetsklinik Heidelberg, Heidelberg, Germany|Universitaetsklinik Koeln, Koeln, Germany|Universitaetsklinikum Muenster, Muenster, Germany|Klinikum rechts der Isar der Technischen Universitat Munchen, Munich, Germany|Bezirksklinikum Regensburg, Regensburg, Germany|Universitasklinikum Tubingen, Tuebingen, Germany|Local Institution, Petach Tikva, Israel|Local Institution, Tel Aviv, Israel|Local Institution, Bologna, Italy|Local Institution, Milano, Italy|Local Institution, Padova, Italy|Local Institution, Rozzano (milano), Italy|Local Institution, Siena, Italy|Azienda Ospedaliera Citta della Salute e della Scienza, Torino, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Onsen-gun, Ehime, Japan|Local Institution, Hiroshima-Shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kobe, Hyogo, Japan|Local Institution, Tsukuba-shi, Ibaraki, Japan|Local Institution, Kanazawa-shi, Ishikawa, Japan|Local Institution, Kagoshima-shi, Kagoshima, Japan|Local Institution, Sagamihara-shi, Kanagawa, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Hirakata-shi, Osaka, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Hidaka-shi, Saitama, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Mitaka-shi, Tokyo, Japan|Local Institution, Yamagata-shi, Yamagata, Japan|Local Institution, Tokyo, Japan|NKI AVL, Amsterdam, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Erasmus Mc, Rotterdam, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Local Institution, Oslo, Norway|Uniwersyteckie Centrum Kliniczne Klinika Onkologii I Radiote, Gdansk, Poland|Local Institution, Warszawa, Poland|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Badalona-Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Santiago De Compostela, Spain|Local Institution, Valencia, Spain|Local Institution, Lund, Sweden|Local Institution, Solna, Sweden|University Hospital Geneva, Geneve, Switzerland|Centre hospitalier universitaire Vaudois (CHUV), Lausanne, Switzerland|Universitaetsspital Zuerich, Zuerich, Switzerland|University College Hospital, London, Greater London, United Kingdom|Christie Hospital Nhs Found. Trust, Manchester, Greater Manchester, United Kingdom|Royal Marsden Hospital, Sutton, Surrey, United Kingdom|Beaston West of Scotland Cancer Centre, Glasgow, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02617589

Study 26:
  NCT Number:                   NCT03351231
  Title:                        An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer
  Acronym:                      
  Status:                       Terminated
  Study Results:                No Results Available
  Conditions:                   Cancer
  Interventions:                Drug: BMS-986242|Biological: Nivolumab
  Outcome Measures:             Incidence of adverse events (AE)|Incidence of serious adverse events (SAE)|Incidence of dose limiting toxicities (DLT)|Incidence of AE's leading to discontinuation|Incidence of death|Incidence of laboratory abnormalities|Maximum observed plasma concentration (Cmax)|Time of maximum observed plasma concentration (Tmax)|Area under the concentration-time curve in 1 dosing interval [AUC(TAU)]|Area under the concentration-time curve from time zero to infinity [AUC(INF)]|Trough observed plasma concentration at the end of the dosing interval (Ctrough)|Apparent elimination half-life (T-HALF)|Apparent total body clearance (CLT/F)|Apparent volume of distribution at steady state (Vss/F)|Accumulation index (AI)|Percent urinary recovery over 24 hours (%UR24)|Percent urinary recovery over 72 hours (%UR72)|Incidence of anti-drug antibody (ADA) to nivolumab in combination with BMS-986242|Overall response rate (ORR)
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   7
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA024-001|2017-003603-21
  Start Date:                   November 27, 2017
  Primary Completion Date:      August 28, 2018
  Completion Date:              August 28, 2018
  First Posted:                 November 22, 2017
  Results First Posted:         null
  Last Update Posted:           September 28, 2018
  Locations:                    University Of Alabama At Birmingham, Birmingham, Alabama, United States|Hoag Memorial Hospital Presbyterian, Los Angeles, California, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Local Institution, Baltimore, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03351231

Study 27:
  NCT Number:                   NCT03363776
  Title:                        An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Cancer
  Interventions:                Biological: BMS-986277|Biological: Nivolumab
  Outcome Measures:             Number of adverse events (AE)|Number of serious adverse events (SAE)|Number of AEs meeting dose limiting toxities criteria|Number of AEs leading to discontinuation|Number of AEs resulting in death|Incidence of clinical laboratory test abnormalities|Incidence of vital sign abnormalities|Objective response rate (ORR)|Disease control rate (DCR)|Median duration of response (mDOR)|Median progression-free survival (mPFS)|Progression-free survival (PFS)|Maximum observed blood concentration (Cmax)|Time of maximum observed blood concentration (Tmax)|Area under the blood concentration-time curve from time zero to time of last quanitifiable concentration [AUC(0-T)]|Area under the blood concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]|Apparent terminal half-life (T-HALF)|Total body clearance (CLT)|Volume of distribution at steady-state (Vss)|Volume of distribution of the elimination phase (Vz)|Average plasma concentration over a dosing interval (AUC[0-48]/48) (Css-avg)
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   200
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA034-001|2017-002199-24
  Start Date:                   November 24, 2017
  Primary Completion Date:      September 28, 2022
  Completion Date:              December 29, 2022
  First Posted:                 December 6, 2017
  Results First Posted:         null
  Last Update Posted:           October 4, 2018
  Locations:                    Local Institution, New York, New York, United States|Local Institution, Hamilton, Ontario, Canada|Local Institution, Ottawa, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Pamplona, Spain
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03363776

Study 28:
  NCT Number:                   NCT01968109
  Title:                        An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Neoplasms by Site
  Interventions:                Biological: Relatlimab|Biological: Nivolumab|Biological: BMS-986213
  Outcome Measures:             Proportion of subjects with Adverse Events (AEs)|Proportion of subjects with Serious Adverse Events (SAEs)|Proportion of Deaths|Proportion of subjects with laboratory abnormalities|Objective response rate (ORR)|Disease control rate (DCR)|Duration of response (DOR)|Proportion of participants with AEs meeting acute safety criteria|Maximum observed serum concentration (Cmax) of BMS-986016 administered both alone and in combination with nivolumab|Time of maximum observed serum concentration (Tmax) of BMS-986016 administered both alone and in combination with nivolumab|Trough observed serum concentration (Ctrough) of BMS-986016 administered both alone and in combination with nivolumab|Concentration at the end of a dosing interval (Ctau) [Eg: concentration at 336 hours] of BMS-986016 administered both alone and in combination with nivolumab|Area under the concentration-time curve in one dosing interval [AUC(TAU)] of BMS-986016 administered both alone and in combination with nivolumab|Total body clearance (CLT) of BMS-986016 administered both alone and in combination with nivolumab|Volume of distribution at steady state (Vss) of BMS-986016 administered both alone and in combination with nivolumab|Effective elimination half-life that explains the degree of area under the concentration-time curve (AUC) accumulation observed (T-HALFeff AUC) of BMS-986016 administered both alone and in combination with nivolumab|Effective elimination half-life that explains the degree of Cmax accumulation observed (T-HALFeff Cmax) of BMS-986016 administered both alone and in combination with nivolumab|Accumulation index; ratio of AUC(TAU) at steady state to AUC(TAU) after the first dose (AI_AUC) of BMS-986016 administered both alone and in combination with nivolumab|Cmax accumulation index; ratio of Cmax at steady state to Cmax after the first dose (AI_Cmax) of BMS-986016 administered both alone and in combination with nivolumab|Ctau accumulation index; ratio of Ctau at steady state to Ctau after the first dose (AI_Ctau) of BMS-986016 administered both alone and in combination with nivolumab|Degree of fluctuation (DF) or fluctuation index ([Cmax - Ctau]/Css,avg]) of BMS-986016 administered both alone and in combination with nivolumab|Immunogenicity measured by anti-drug antibody (ADA) for BMS-986016 (all subjects) and nivolumab|QTc interval from centrally read electrocardiograms (ECGs)|Best overall response (BOR)|ORR|DCR|Progression-free survival (PFS)|Overall survival (OS)
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          12 Years and older   (Child, Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   1000
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA224-020|2014-002605-38
  Start Date:                   October 14, 2013
  Primary Completion Date:      August 28, 2020
  Completion Date:              December 18, 2020
  First Posted:                 October 23, 2013
  Results First Posted:         null
  Last Update Posted:           November 6, 2018
  Locations:                    UCSD Moores Cancer Center, La Jolla, California, United States|University Of Colorado, Aurora, Colorado, United States|H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|University Of Chicago Medical Center, Chicago, Illinois, United States|Advocate Health and Hospitals Corporation, Niles, Illinois, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Mayo Clinic - PPDS, Rochester, Minnesota, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Providence Portland Med Ctr, Portland, Oregon, United States|Lehigh Valley Hospital and Health Network, Allentown, Pennsylvania, United States|UPMC Eye and Ear Institute, Pittsburgh, Pennsylvania, United States|Baylor Sammons Cancer Center, Dallas, Texas, United States|Md Anderson Can Cnt, Houston, Texas, United States|University Of Washington Cancer Care Alliance, Seattle, Washington, United States|Local Institution, North Sydney, New South Wales, Australia|Local Institution, Greenslopes, Queensland, Australia|Local Institution, Southport, Queensland, Australia|Local Institution, Melbourne, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Wien, Austria|Local Institution, Wien, Austria|Local Institution, Toronto, Ontario, Canada|CHU de Quebec - Universite Laval, Quebec, Canada|Local Institution, Copenhagen, Denmark|Local Institution, Herlev, Denmark|Local Institution, Helsinki, Finland|Local Institution, Marseille Cedex 5, France|Local Institution, Nantes Cedex 01, France|Local Institution, Pierre Benite Cedex, France|Local Institution, Toulouse Cedex 9, France|Local Institution, Vlllejuif, France|Local Institution, Essen, Germany|Local Institution, Heilbronn, Germany|Local Institution, Wuerzburg, Germany|Istituto Europeo Di Oncologia, Milano, Italy|Istituto Nazionale Tumori Fondazione Pascale, Napoli, Italy|Istituto Oncologico Veneto - I.R.C.C.S., Padova, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands|Local Institution, Oslo, Norway|H. Univ. Vall dHebron, Barcelona, Spain|Hospital Universitario Virgen De La Victoria, Malaga, Spain|Clinica Universitaria De Navarra, Pamplona, Spain|Local Institution, Lausanne, Switzerland|Local Institution, Zurich, Switzerland|University College Hospital, London, Greater London, United Kingdom|The Royal Marsden Hospital, London, United Kingdom|Christie Hospital, Manchester, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01968109

Study 29:
  NCT Number:                   NCT02477826
  Title:                        An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
  Acronym:                      CheckMate 227
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Non-Small Cell Lung Cancer
  Interventions:                Drug: Nivolumab|Drug: Ipilimumab|Drug: Carboplatin|Drug: Cisplatin|Drug: Gemcitabine|Drug: Pemetrexed|Drug: Paclitaxel
  Outcome Measures:             Overall survival (OS)|Progression-free Survival (PFS) as determined by blinded independent central review (BICR)|Objective response rate (ORR)|Disease related symptom improvement as measured by the Lung Cancer Symptom Score (LCSS) in all subjects
  Sponsor/Collaborators:        Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   2220
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-227|2014-003630-23
  Start Date:                   August 5, 2015
  Primary Completion Date:      January 31, 2019
  Completion Date:              December 31, 2020
  First Posted:                 June 23, 2015
  Results First Posted:         null
  Last Update Posted:           November 29, 2018
  Locations:                    Southern Cancer Center, Inc., Mobile, Alabama, United States|Local Institution, La Jolla, California, United States|California Pacific Medical Center, San Francisco, California, United States|Yale University, New Haven, Connecticut, United States|Emory University Hospital, Atlanta, Georgia, United States|Northwest Georgia Oncology Centers, P.C., Marietta, Georgia, United States|Baptist Health Lexington, Lexington, Kentucky, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Southfield, Michigan, United States|Local Institution, Rochester, Minnesota, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|St. Mary Medical Center, Langhorne, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Guthrie Medical Group, Pc, Sayre, Pennsylvania, United States|Hollings Cancer Center, Charleston, South Carolina, United States|Greenville Health System, Greenville, South Carolina, United States|St Francis Hospital, Greenville, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|The University Of Texas, Dallas, Texas, United States|University Of Texas Southwestern Medical Center, Dallas, Texas, United States|University Of Texas Md Anderson Cancer Ctr, Houston, Texas, United States|Huntsman Cancer Institute At The Univ. Of Utah, Salt Lake City, Utah, United States|Kadlec Clinical Hematology and Oncology, Kennewick, Washington, United States|COIBA, Berazategui, Buenos Aires, Argentina|Instituto Alexander Fleming, Capital Federal, Buenos Aires, Argentina|Hospital Italiano De Buenos Aires, Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina|Fundacion Investigar, Ciudad de Buenos Aires, Buenos Aires, Argentina|Hospital Privado De Comunidad, Mar Del Plata, Buenos Aires, Argentina|Hospital Privado Centro Medico De Cordoba, Córdoba, Cordoba, Argentina|Clinica Viedma S.A., Viedma, RIO Negro, Argentina|Centro Medico San Roque, San Miguel de Tucuman, Tucuman, Argentina|Local Institution, Caba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Clinica Privada Universitaria Reina Fabiola, Cordoba, Argentina|Local Institution, Garran, Australian Capital Territory, Australia|Blacktown Hospital, Blacktown, New South Wales, Australia|Local Institution, Gosford, New South Wales, Australia|Tamworth Hospital, Tamworth, New South Wales, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Local Institution, Elizabeth Vale, South Australia, Australia|Local Institution, Clayton, Victoria, Australia|St Vincent's Hospital, Fitzroy, Victoria, Australia|Local Institution, Perth, Western Australia, Australia|Local Institution, Murdoch, Australia|Medizinische Universitatsklinik, Graz, Austria|Akh Wien, Vienna, Austria|Klinikum Wels-Grieskirchen Gmbh, Wels, Austria|Local Institution, Charleroi, Belgium|Local Institution, Edegem, Belgium|Local Institution, Gent, Belgium|Local Institution, Hasselt, Belgium|Local Institution, Roeselare, Belgium|Local Institution, Sint Niklaas, Belgium|Local Institution, Salvador, Bahia, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Rio De Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Cross Cancer Institute, Edmonton, Alberta, Canada|Dr. H.Bliss Murphy Cancer Centre, St. John's, Newfoundland and Labrador, Canada|London Regional Cancer Program, London, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski, Rimouski, Quebec, Canada|Centre integre universitaire de sante et de service sociaux de l'estrie - CHUS, Sherbrooke, Quebec, Canada|Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-Centre-du-Quebec, Trois-Rivieres, Quebec, Canada|CHU de Quebec - Universite Laval, Quebec, Canada|Institut Universitaire de Cardiologie et de Pneumologie de Quebec - Universite Laval, Quebec, Canada|Fundacion Arturo Lopez Perez, Santiago, Metropolitana, Chile|Centro Internacional de Estudios Clinicos, Recoleta, Santiago DE Chile, Chile|Instituto Oncologico, Vina Del Mar, Valparaiso, Chile|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Chongqing, Chongqing, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guanzhou, Guangdong, China|Local Institution, Haikou, Hainan, China|Local Institution, Haerbin, Heilongjiang, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Changsha, Hunan, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanchang, Jiangxi, China|Local Institution, Changchun, Jilin, China|Local Institution, Changchun, Jilin, China|Local Institution, Shenyang, Liaoning, China|Local Institution, Xi'an, Shaanxi, China|Local Institution, Xi'an, Shan3xi, China|Local Institution, Qingdao, Shandong, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Urumqi, Xinjiang, China|Local Institution, Hanghzou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Beijing, China|Local Institution, Beijing, China|Local Institution, Changsha, China|Local Institution, Chongqing, China|Local Institution, Chongqing, China|Local Institution, Hangzhou, China|Local Institution, Hangzhou, China|Local Institution, Kunming, China|Local Institution, Shanghai, China|Oncologos Del Occidente Sa, Pereira, Risaralda, Colombia|Administradora Del Country S.A. - Clinica Del Country, Bogota, Colombia|Hospital Universitario San Ignacio, Bogota, Colombia|Hospital Pablo Tobon Uribe, Medellin, Colombia|Plicni klinika, Hradec Kralove, Czechia|Klinika plicnich nemoci a tuberkulozy, Olomouc, Czechia|Pneumologicka klinika 1. LF a TN, Praha 4, Czechia|Oddeleni Onkologie, Pribram, Czechia|Local Institution, Oulu, Finland|Local Institution, Turku, Finland|Local Institution, ANGERS Cedex 2, France|Local Institution, Besançon Cedex, France|Local Institution, Bron Cedex, France|Local Institution, Caen, France|Local Institution, Creteil, France|Local Institution, Limoges cedex, France|Local Institution, Marseille Cedex 20, France|Local Institution, Paris, France|Local Institution, Pessac, France|Local Institution, Rennes Cedex 9, France|Local Institution, Rouen, France|Local Institution, Saint Herblain, France|Local Institution, Saint Priest En Jarez, France|Local Institution, Strasbourg, France|Local Institution, Toulon, France|Zentralklinik Bad Berka Gmbh, Bad Berka, Thuringen, Germany|Local Institution, Berlin, Germany|Universitaetsklinikum Essen, Essen, Germany|Universitatsklinikum Frankfurt, Frankfurt, Germany|SRH WALD KLINIKUM GERA gGmbH, Gera, Germany|Klinik Schillerhoehe, Gerlingen, Germany|Krankenhaus Grosshansdorf, Grosshansdorf, Germany|Stadtisches Krankenhaus Martha Maria Halle-Dolau, Halle, Germany|Thoraxklinik-Heidelberg Ggmbh, Heidelberg, Germany|Lungenklinik Hemer, Hemer, Germany|Klinikverbund Kempten-Oberallgau, Immenstadt, Germany|Universitaetsklinikum Magdeburg A. o. R., Magdeburg, Germany|Klinikum Bogenhausen, Muenchen, Germany|Hsk Dr.-Horst-Schmidt-Kliniken Wiesbaden, Wiesbaden, Germany|Local Institution, Athens, Greece|Local Institution, Heraklio, Greece|Local Institution, Neo Faliro, Greece|Local Institution, Thessaloniki, Greece|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Matrahaza, Hungary|Local Institution, Dublin 8, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Limerick, Ireland|Local Institution, Jerusalem, Israel|Local Institution, Kfar-saba, Israel|Local Institution, Petach Tikva, Israel|Local Institution, Tel-hashomer, Israel|Local Institution, Zerifin, Israel|Local Institution, Avellino, Italy|Local Institution, Bergamo, Italy|Local Institution, Bologna, Italy|Local Institution, Livorno, Italy|Local Institution, Messina, Italy|Local Institution, Milano, Italy|Local Institution, Milan, Italy|Local Institution, Napoli, Italy|Local Institution, Ravenna, Italy|Local Institution, Roma, Italy|Local Institution, Roma, Italy|Local Institution, S.Andrea Fratte PG, Italy|Local Institution, Terni, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Kurume-shi, Fukuoka, Japan|Local Institution, Ota-shi, Gunma, Japan|Local Institution, Hiroshima-shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Akashi-shi, Hyogo, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Kanazawa-shi, Ishikawa, Japan|Local Institution, Yokohama-Shi, Kanagawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Natori-shi, Miyagi, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Kurashiki-shi, Okayama, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Hirakata-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Osakasayama-shi, Osaka, Japan|Local Institution, Takatsuki-shi, Osaka, Japan|Local Institution, Hidaka-shi, Saitama, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Koto-ku, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Wakayama-shi, Wakayama, Japan|Local Institution, Ube-shi, Yamaguchi, Japan|Local Institution, Cheongju-si, Chungcheonbuk-do, Korea, Republic of|Local Institution, Seongnam-si, Gyeonggi-do, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Beirut, Lebanon|Local Institution, Beirut, Lebanon|Local Institution, Df, Distrito Federal, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Phylasis Clinicas Research S de R. L. de C. V., Cuautitlan, Estado DE Mexico, Mexico|Local Institution, Toluca, Estado DE Mexico, Mexico|Instituto Jalisciense De Cancerologia, Guadalajara, Jalisco, Mexico|Local Institution, Morelia, Michoacan, Mexico|Axis Heilsa S de Rl de Cv, Monterrey, Nuevo LEON, Mexico|Medical Care & Research, Merida, Yucatan, Mexico|Local Institution, Chihuahua, Mexico|Local Institution, San Luis Potosi, Mexico|Centro de Alta Especialidad en Reumatologia e Investigacion del Potosi S.C., San Luis Potosi, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Amsterdam, Netherlands|Local Institution, Breda, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Veldhoven, Netherlands|Clinica Ricardo Palma, Lima, Peru|Instituto Nacional De Enfermedades Neoplasicas, Lima, Peru|Clinica San Felipe- Unidad de Oncologia Medica, Lima, Peru|Instituto Oncologico Miraflores, Lima, Peru|Oncocenter Peru SAC - Oncosalud, Lima, Peru|Ambulatorium Chemioterapii, Bydgoszcz, Poland|Wojewodzkie Centrum Onkologii, Gdansk, Poland|Oddzial Onkologii I Radioterapii Szpital Morski Im. Pck, Gdynia, Poland|Centrum Onkologii-Inst.Im.M.Sklodowskiej-Curie O.W Gliwicach, Gliwice, Poland|Regionalny Osrodek Onkologiczny, Lodz, Poland|Klinika Nowotworow Pluca i Klatki Piersiowej, Warszawa, Poland|ORTHOS Szpital Wielospecjalistyczny Sp. z o.o., Wroclaw, Poland|Institute Of Oncology "Prof.Dr.Alexandru Trestioreanu" Bucha, Bucharest, Romania|Sf. Nectarie Oncology Center, Craiova, Romania|S.C. Radiotherapy Center Cluj S.R.L., Floresti, Romania|Prof. Dr. Ion Chiricuta Institute Of Oncology Day Care Dep, Romania, Romania|Local Institution, Chelyabinsk, Russian Federation|Local Institution, Kazan, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Ufa, Russian Federation|Local Institution, Riyadh 11426, Saudi Arabia|Local Institution, Riyadh-11211, Saudi Arabia|Local Institution, Johannesburg, Gauteng, South Africa|Local Institution, Pretoria, Gauteng, South Africa|Local Institution, Saxonwold, Johannesburg, Gauteng, South Africa|Local Institution, Vereeniging, South Africa|Local Institution, Majadahonda, Madrid, Spain|Local Institution, Badalona (Barcelona), Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Klinik Fur Onkologie, Basel, Switzerland|Kantonsspital Graubuenden, Chur, Switzerland|Centre hospitalier universitaire Vaudois (CHUV), Lausanne, Switzerland|Local Institution, Winterthur, Switzerland|Local Institution, Taichung, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Tao-Yuan County, Taiwan|Local Institution, Ankara, Turkey|Local Institution, Antalya, Turkey|Local Institution, Kayseri, Turkey|Local Institution, Al Ain, United Arab Emirates|Local Institution, Middlesborough, Cleveland, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Leicester, Leicestershire, United Kingdom|Local Institution, Birmingham, WEST Midlands, United Kingdom|Local Institution, Cambridgeshire, United Kingdom|Local Institution, Edinburgh, United Kingdom|Local Institution, Surrey, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02477826

Study 30:
  NCT Number:                   NCT03369223
  Title:                        An Investigational Immunotherapy Study of BMS-986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Advanced Cancer
  Interventions:                Biological: BMS-986249|Biological: Nivolumab
  Outcome Measures:             Incidence of Adverse Events (AE)|Incidence of Serious Adverse Events (SAE)|Incidence of AEs meeting protocol-defined dose-limiting toxicity (DLT) criteria|Incidence of AEs leading to discontinuation|Incidence of death|Incidence of Laboratory abnormalities|Cmax (Maximum observed serum concentration)|Tmax (Time of maximum observed concentration)|AUC(0-T) (Area under the serum concentration-time curve from time zero to time of last quantifiable concentration)|AUC(TAU) (Area under the concentration-time curve in 1 dosing interval)|Ctau (Observed concentration at the end of a dosing interval)|Ctrough (Trough observed concentrations)|Best overall response (BOR)|Duration of response (DOR)|Progression-Free survival (PFS)|Time to response (TTR)|Total body clearance (CLT)|Average serum concentration over a dosing interval (AUC[TAU]/tau) at steady state (Css-avg)|Terminal serum half-life if data permit (T-HALF)|Ratio of an exposure measure at steady state to that after the first dose [exposure measure includes AUC[TAU] and Cmax (AI)]
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   300
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA030-001|2018-000416-21
  Start Date:                   December 5, 2017
  Primary Completion Date:      July 30, 2020
  Completion Date:              July 30, 2020
  First Posted:                 December 11, 2017
  Results First Posted:         null
  Last Update Posted:           October 4, 2018
  Locations:                    University of Colorado Cancer Center, Aurora, Colorado, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Baptist Health Medical Group Oncology LLC, Miami, Florida, United States|Local Institution, Baltimore, Maryland, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Columbia University Medical Center (Cumc), New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Willamette Valley Cancer Institute And Research Center, Eugene, Oregon, United States|Northwest Cancer Specialists, Portland, Oregon, United States|Local Institution, Philadelphia, Pennsylvania, United States|Greenville Health System, Greenville, South Carolina, United States|Texas Oncology-Austin Midtown, Austin, Texas, United States|Texas Oncology - Baylor Charles A. Simmons Cancer Center, Dallas, Texas, United States|Local Institution, Houston, Texas, United States|Texas Oncology-San Antonio Medical Center, San Antonio, Texas, United States|Texas Oncology, P.A., Tyler, Texas, United States|Virginia Cancer Specialists (Leesburg) - USOR, Leesburg, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Local Institution, North Sydney, New South Wales, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Frankston, Victoria, Australia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03369223

Study 31:
  NCT Number:                   NCT03444753
  Title:                        An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Advanced Cancer
  Interventions:                Biological: BMS-986299|Biological: Nivolumab|Biological: Ipilimumab
  Outcome Measures:             Incidence of dose-limiting toxicities (DLTs)|Incidence of adverse events (AEs)|Incidence of serious adverse events (SAEs)|Incidence of AEs leading to discontinuation and deaths|Incidence of clinical laboratory abnormalities|Maximum observed plasma concentration (Cmax)|Time of maximum observed plasma concentration (Tmax)|Area under the serum concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)]|Area under the plasma concentration-time curve from time zero to 24 hours postdose [AUC(0-24)]
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   90
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA039-001
  Start Date:                   March 20, 2018
  Primary Completion Date:      November 14, 2021
  Completion Date:              December 19, 2021
  First Posted:                 February 23, 2018
  Results First Posted:         null
  Last Update Posted:           October 4, 2018
  Locations:                    University Of California San Diego Moores Cancer Center, La Jolla, California, United States|Washington University, Saint Louis, Missouri, United States|MD Anderson Cancer Center, Houston, Texas, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03444753

Study 32:
  NCT Number:                   NCT02743494
  Title:                        An Investigational Immuno-therapy Study of Nivolumab or Placebo in Patients With Resected Esophageal or Gastroesophageal Junction Cancer
  Acronym:                      CheckMate 577
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Advanced Cancer
  Interventions:                Drug: Nivolumab|Other: Placebo
  Outcome Measures:             Disease-Free Survival of adjuvant nivolumab in subjects with resected esophageal cancer or gastroesophageal junction cancer who have received chemoradiotherapy followed by surgery|Overall Survival of adjuvant nivolumab in subjects with resected esophageal cancer or gastroesophageal junction cancer who have received chemoradiotherapy followed by surgery|Overall survival rate
  Sponsor/Collaborators:        Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   760
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  Other IDs:                    CA209-577|2015-005556-10
  Start Date:                   May 23, 2016
  Primary Completion Date:      September 14, 2020
  Completion Date:              October 11, 2024
  First Posted:                 April 19, 2016
  Results First Posted:         null
  Last Update Posted:           November 20, 2018
  Locations:                    Univ. Of Southern Calif. /Norris Comprehensive Cancer Center, Los Angeles, California, United States|Pacific Hematology Oncology Associates, San Francisco, California, United States|Ucsf Cancer Center, San Francisco, California, United States|University Of Colorado, Aurora, Colorado, United States|Georgetown University Med Ctr, Washington, District of Columbia, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Cancer Specialists of North FL, Jacksonville, Florida, United States|University Of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Sacred Heart Medical Group, Pensacola, Florida, United States|SCRI Florida Cancer Specialists North, Saint Petersburg, Florida, United States|University Of Chicago, Chicago, Illinois, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute., Boston, Massachusetts, United States|Mass General/North Shore Cancer Center for Outpatient Care, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Jersey Shore University Medical Center, Neptune, New Jersey, United States|Albert Einstein Cancer Center At The Montefiore Medical Park, Bronx, New York, United States|NYU Langone Medical Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Duke Cancer Center, Durham, North Carolina, United States|Local Institution, Fargo, North Dakota, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Local Institution, Oklahoma City, Oklahoma, United States|Oregon Health & Sci Univ, Portland, Oregon, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Allegheny Health Network, Pittsburgh, Pennsylvania, United States|Local Institution, Sioux Falls, South Dakota, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Vanderbilt University Med Ctr, Nashville, Tennessee, United States|Dallas VA Medical Center, Dallas, Texas, United States|Local Institution, Dallas, Texas, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|Scott & White Memorial Hospital And Clinic, Temple, Texas, United States|Local Institution, Seattle, Washington, United States|University of Washington, Seattle, Washington, United States|University Of Wisconsin, Madison, Wisconsin, United States|Hospital Municipal De Gastroenterologia Dr.Udaondo, Capital Federal, Buenos Aires, Argentina|Hospital Aleman, Ciudad Autonoma Buenos Aires, Buenos Aires, Argentina|Clinica Viedma S.A., Viedma, RIO Negro, Argentina|Hospital Provincial Del Centenario, Rosario, Santa FE, Argentina|Centro Para La Atencion Integral Del Paciente Oncologico, San Miguel De Tucuman, Tucuman, Argentina|Fundacion Favaloro, Buenos Aires, Argentina|Hospital Britanico, Buenos Aires, Argentina|Instituto Medico Especialazado Alexander Fleming, Caba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Local Institution, Blacktown, New South Wales, Australia|Local Institution, Gosford, New South Wales, Australia|Royal North Shore Hospital, St Leonards, New South Wales, Australia|Local Institution, Tamworth, New South Wales, Australia|Local Institution, Brisbane, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Local Institution, Hobart, Tasmania, Australia|Moorabbin Hospital, Clayton, Victoria, Australia|Local Institution, Perth, Western Australia, Australia|Local Institution, Bruxelles, Belgium|Local Institution, Edegem, Belgium|Local Institution, Gent, Belgium|Local Institution, Leuven, Belgium|Local Institution, Liege, Belgium|Local Institution, Namur, Belgium|Local Institution, Brasilia, Distrito Federal, Brazil|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Curitiba, Parana, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Itacorubi, Florianopolis, Santa Catarina, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Jose De Rio Preto, SAO Paulo, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Salvador, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency-Vancouver Ctr, Vancouver, British Columbia, Canada|Nova Scotia Health Authority QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|London Regional Cancer Program, London, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Montreal General Hospital, Montreal, Quebec, Canada|Local Institution, Ottawa, Quebec, Canada|Local Institution, Trois-Rivieres, Quebec, Canada|Hotel Dieu De Quebec, Quebec, Canada|Local Institution, Beijing, Beijing, China|Local Institution, Fuzhou, Fujian, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Linhai, Zhejiang, China|Local Institution, Changsha, China|Local Institution, Shanghai, China|Local Institution, Tianjin, China|Klinika komplexni onkologicke pece, Brno, Czechia|Klinika onkologie a radioterapie, Hradec Kralove, Czechia|Onkologicka klinika, Olomouc, Czechia|Aarhus University Hospital, Aarhus C, Denmark|Local Institution, Avignon Cedes 9, France|Local Institution, Dijon Cedex, France|Local Institution, LILLE Cedex, France|Local Institution, Paris, France|Local Institution, Pessac, France|Local Institution, Pierre Benite Cedex, France|Local Institution, Rennes Cedex 9, France|Local Institution, Rouen, France|Local Institution, Toulouse, France|Charite Campus Virchow Klinikum, Berlin, Germany|Kliniken Essen-Mitte/Huyssens-Stift, Essen, Germany|Local Institution, Hamburg, Germany|University Hospital Of Cologne, Koeln, Germany|Johannes -Gutenberg Universitat, Mainz, Germany|Universitaets-Klinikum Marburg, Marburg, Germany|Klinikum Rechts Der Isar, Munich, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Germany|Local Institution, Hong Kong, Hong Kong|Local Institution, Budapest, Hungary|Orszagos Onkologiai Intezet, Budapest, Hungary|DE KK Onkologiai Intezet, Debrecen, Hungary|Local Institution, Kaposvar, Hungary|Local Institution, Wilton, Cork, Ireland|Local Institution, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Petach Tikva, Israel|Local Institution, Ramat-gan, Israel|Local Institution, Tel Aviv, Israel|Local Institution, Bergamo, Italy|Local Institution, Milano, Italy|Local Institution, Milano, Italy|Local Institution, Reggio Emilia, Italy|Local Institution, Roma, Italy|Local Institution, Akita-Shi, Akita, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Gifu-shi, Gifu, Japan|Local Institution, Hiroshima-Shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kagoshima-shi, Kagoshima, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Osaka-sayama-shi, Osaka, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Koto-ku, Tokyo, Japan|Local Institution, Minato-ku, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Shinjuuku-ku, Tokyo, Japan|Local Institution, Fukuoka, Japan|Local Institution, Kita-gun, Japan|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Centro de Estudios y Prevencion Del Cancer, AC, Tuxtla Gutierrez, Chiapas, Mexico|Instituto Nacional De Cancerologia, Tlalpan, Distrito Federal C.P., Mexico|Fundacion Rodolfo Padilla Padilla A.C., Leon de los Aldama, Guanajuato, Mexico|Hospital Cardiologica De Aguascalientes, Aguascalientes, Mexico|Supere Centro de Infusion S.A de C.V., Ciudad de Mexico, Mexico|Instituto Nacional De Ciencias Medicas Y Nutricion S.Z., Distrito Federal, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Maastrict, Netherlands|Hospital Nacional Daniel Alcides Carrion, Callao, Peru|Instituto Nacional De Enfermedades Neoplasicas, Lima, Peru|Hospital Nacional Cayetano Heredia, Lima, Peru|Oncosalud Sac, Lima, Peru|Local Institution, Lima, Peru|II Klinika Radioterapii i Chemioterapii, Gliwice, Poland|Oddzial Kliniczny Chirurgii Klatki Piersiowej, Krakow, Poland|II Klinika Chirurgii Ogolnej, Gastroenterologicznej i Nowotworow Ukladu Pokarmowego, Lublin, Poland|Oddzial Onkologii Klinicznej i Doswiadczalnej, Poznan, Poland|Klinika Gastroenterologii Onkologicznej, Warszawa, Poland|Local Institution, San Juan, Puerto Rico|SC Oncopremium Team SRL, Baia Mare, Romania|Fundeni Clinical Institute Gastroenterology; Hepatology Clin, Bucharest, Romania|Focus Lab Plus SRL, Bucuresti, Romania|Bendis Clinic Srl, Cluj-napoca, Romania|Sf. Nectarie Oncology Center, Craiova, Romania|S.C. Radiotherapy Center Cluj S.R.L., Floresti, Romania|Local Institution, Cheboksary, Russian Federation|Local Institution, Moscow, Russian Federation|N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Saint-Petersburg Medical University Named After I.P.Pavlov, Saint-Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Barcelona, Spain|Local Institution, Cordoba, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Universitaetsspital Basel, Basel, Switzerland|Kantonsspital St Gallen, St Gallen, Switzerland|Local Institution, Taichung, Taiwan|Local Institution, Tainan, Taiwan|Local Institution, Taipei, Taiwan|Baskent University Adana Hospital, Adana, Turkey|Local Institution, Ankara, Turkey|Ataturk University, Erzurum, Turkey|Istanbul Universitesi Cerrahpasa Tip Fakultesi Onkoloji, Istanbul, Turkey|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Withington, Manchester, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom|Local Institution, Cardiff, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02743494

Study 33:
  NCT Number:                   NCT02667587
  Title:                        An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)
  Acronym:                      CheckMate548
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Brain Neoplasms
  Interventions:                Drug: Nivolumab|Drug: Temozolomide|Radiation: Radiotherapy|Other: Nivolumab Placebo
  Outcome Measures:             Overall survival (OS) defined as time from the date of randomization to the date of death.|Progression free survival (PFS), defined as the time from randomization to the date of the first documented tumor progression or death to any cause.|Correlation of PFS and OS
  Sponsor/Collaborators:        Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   693
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  Other IDs:                    CA209-548|2015-004722-34
  Start Date:                   May 5, 2016
  Primary Completion Date:      February 11, 2022
  Completion Date:              August 1, 2023
  First Posted:                 January 29, 2016
  Results First Posted:         null
  Last Update Posted:           October 23, 2018
  Locations:                    University of Alabama at Birmingham, Birmingham, Alabama, United States|St. Joseph Hospital And Medical Center, Phoenix, Arizona, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|UCLA Neuro-Oncology Program, Los Angeles, California, United States|Sutter Institute For Medical Research, Sacramento, California, United States|Sharp Memorial Hospital, San Diego, California, United States|The Regents of the University of California, San Francisco, San Francisco, California, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|University Of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Local Institution, Chicago, Illinois, United States|University Of Kansas Medical Center, Westwood, Kansas, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Johns Hopkins University School Of Medicine, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|JFK Medical Center, Edison, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Columbia University, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Preston Robert Tisch Brain Tumor Center at Duke University, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|Erlanger Oncology & Hematology - Univ. of TN, Chattanooga, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University Of Texas Southwestern Medical Center, Dallas, Texas, United States|Local Institution, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Swedish Neuroscience Institute, Seattle, Washington, United States|Local Institution, Liverpool, New South Wales, Australia|Royal North Shore Hospital, St. Leonards, New South Wales, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Prahran, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Kepler Universitaetsklinikum, Linz, Austria|Medical University Of Vienna, Vienna, Austria|Universitair Ziekenhuis Brussel, Brussels, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|Uz Leuven, Leuven, Belgium|BC Cancer - Vancouver, Vancouver, British Columbia, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada|Local Institution, Copenhagen, Denmark|Local Institution, Odense, Denmark|Local Institution, Lille Cedex, France|Local Institution, Lyon Cedex 03, France|Local Institution, Marseille, France|Local Institution, Nancy, France|Local Institution, Paris cedex 13, France|Local Institution, Paris, France|Local Institution, Rennes Cedex, France|Local Institution, Toulouse, France|Universitaetsklinikum Bonn, Bonn, Germany|Uniklinik Erlangen, Erlangen, Germany|Klinikum Der J. W. Goethe-Universitaet Frankfurt/Main, Frankfurt Am Main, Germany|Universitaetsklinikum Freiburg, Freiburg, Germany|Universitaetsklinikum Hamburg, Hamburg, Germany|Universitaetsklinik Heidelberg, Heidelberg, Germany|Universitaetsklinik Koeln, Koeln, Germany|Universitaetsklinikum Muenster, Muenster, Germany|Klinikum rechts der Isar der Technischen Universitat Munchen, Munich, Germany|Bezirksklinikum Regensburg, Regensburg, Germany|Universitasklinikum Tubingen, Tuebingen, Germany|Local Institution, Petach Tikva, Israel|Local Institution, Tel Aviv, Israel|Local Institution, Bologna, Italy|Local Institution, Milano, Italy|Local Institution, Padova, Italy|Local Institution, Rozzano (milano), Italy|Local Institution, Siena, Italy|Local Institution, Torino, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Hiroshima-Shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Tsukuba-shi, Ibaraki, Japan|Local Institution, Kanazawa-shi, Ishikawa, Japan|Local Institution, Kagoshima-shi, Kagoshima, Japan|Local Institution, Sagamihara-shi, Kanagawa, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Hirakata-shi, Osaka, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Hidaka-shi, Saitama, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Mitaka-shi, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Yamagata-shi, Yamagata, Japan|Local Institution, Kyoto, Japan|NKI AVL, Amsterdam, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Erasmus Mc, Rotterdam, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Local Institution, Oslo, Norway|Uniwersyteckie Centrum Kliniczne Klinika Onkologii I Radiote, Gdansk, Poland|Klinika Nowotworow Glowy i Szyi, Warszawa, Poland|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Badalona-barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Santiago Compostela, Spain|Local Institution, Valencia, Spain|Local Institution, Lund, Sweden|Local Institution, Solna, Sweden|University Hospital Geneva, Geneve, Switzerland|Centre hospitalier universitaire Vaudois (CHUV), Lausanne, Switzerland|UniversitaetsSpital Zurich, Zuerich, Switzerland|University College Hospital, London, Greater London, United Kingdom|Christie Hospital Nhs Found. Trust, Manchester, Greater Manchester, United Kingdom|Royal Marsden Hospital, Sutton, Surrey, United Kingdom|Beaston West of Scotland Cancer Centre, Glasgow, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02667587

Study 34:
  NCT Number:                   NCT01714739
  Title:                        A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   CANCER,NOS
  Interventions:                Drug: Lirilumab|Drug: Nivolumab|Drug: Ipilimumab
  Outcome Measures:             Safety and tolerability of BMS-986015 given in combination with BMS-936558 or BMS-936558 plus BMS-734016 as measured by incidence of adverse events|Safety and tolerability of BMS-986015 given in combination with BMS-936558 or BMS-936558 plus BMS-734016 as measured by incidence of clinical laboratory test abnormalities including hematology, serum chemistry, and thyroid panel abnormalities|Objective response rate (ORR)|Maximum observed serum concentration (Cmax) of BMS-986015 derived from serum concentration versus time|Time of maximum observed serum concentration (Tmax) of BMS-986015 derived from serum concentration versus time|Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)] of BMS-986015 derived from serum concentration versus time|Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of BMS-986015 derived from serum concentration versus time|Trough observed serum concentration (Ctrough) of BMS-986015 derived from serum concentration versus time|Area under the concentration-time curve in one dosing interval [AUC(TAU)] of BMS-986015 derived from serum concentration versus time|Clearance (CL) of BMS-986015 derived from serum concentration versus time|Volume of distribution at steady state (Vss) of BMS-986015 derived from serum concentration versus time|Half-life (t1/2) of BMS-986015 derived from serum concentration versus time|Anti-drug antibody (ADA) response to BMS-986015 in combination with BMS-936558 or BMS-734016|Overall survival (OS)|Progression-Free Survival (PFS)|Duration of response (DOR)
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   337
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  Other IDs:                    CA223-001
  Start Date:                   October 7, 2012
  Primary Completion Date:      October 15, 2019
  Completion Date:              October 16, 2019
  First Posted:                 October 26, 2012
  Results First Posted:         null
  Last Update Posted:           September 5, 2018
  Locations:                    Ucsf, San Francisco, California, United States|Florida Cancer Affiliates - Ocala, Ocala, Florida, United States|University Of Chicago Medical Center, Chicago, Illinois, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Lutherville, Maryland, United States|Beth Israel Deaconess Med Ctr, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Providence Portland Med Ctr, Portland, Oregon, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|UPMC Eye and Ear Institute, Pittsburgh, Pennsylvania, United States|West Cancer Center, Germantown, Tennessee, United States|Texas Oncology-Central Austin Cancer Center, Austin, Texas, United States|University Of Texas Medical Branch Of Galveston, Galveston, Texas, United States|University Of Washington, Seattle, Washington, United States|Juravinski Cancer Center, Hamilton, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Local Institution, Bordeaux, France|Local Institution, Lyon Cedex 08, France|Local Institution, Nice Cedex 2, France|Local Institution, Paris, France|Local Institution, Villejuif Cedex, France|Local Institution, Milano, MI, Italy|Local Institution, Siena, Italy|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Kantonsspital Graubuenden, Chur, Switzerland|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01714739

Study 35:
  NCT Number:                   NCT01629758
  Title:                        Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Neoplasms by Site
  Interventions:                Biological: Denenicokin|Biological: Nivolumab
  Outcome Measures:             Safety, as measured by the rate of adverse events and serious adverse events|Efficacy as measured by tumor assessment (RECIST)|Immunogenicity as measured by incidence of specific antidrug antibodies (ADA) to BMS-98470 and BMS-936558
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   33
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA220-008
  Start Date:                   June 2012
  Primary Completion Date:      December 2014
  Completion Date:              December 2014
  First Posted:                 June 28, 2012
  Results First Posted:         null
  Last Update Posted:           March 6, 2015
  Locations:                    Oncology Research Associates, Pllc D/B/A, Scottsdale, Arizona, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Moffitt Cancer Center, Tampa, Florida, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01629758

Study 36:
  NCT Number:                   NCT02041533
  Title:                        An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                Has Results
  Conditions:                   Stage IV or Recurrent Non-Small Cell Lung Cancer
  Interventions:                Biological: Nivolumab|Drug: Gemcitabine|Drug: Cisplatin|Drug: Carboplatin|Drug: Paclitaxel|Drug: Pemetrexed
  Outcome Measures:             Progression-Free Survival in Participants With PD-L1 Expression >= 5%|Progression-Free Survival in All Randomized Participants|Overall Survival in Participants With PD-L1 Expression >= 5%|Overall Survival in All Randomized Participants|Objective Response Rate (ORR) in Participants With PD-L1 Expression >= 5%|Duration of Response in Participants With PD-L1 Expression>= 5%|Time to Response in Participants With PD-L1 Expression >= 5%|Disease-related Symptom Improvement Rate by Week 12
  Sponsor/Collaborators:        Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   1325
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-026|2012-004502-93
  Start Date:                   March 25, 2014
  Primary Completion Date:      July 1, 2016
  Completion Date:              October 1, 2018
  First Posted:                 January 22, 2014
  Results First Posted:         July 26, 2017
  Last Update Posted:           February 14, 2018
  Locations:                    Southern Cancer Center, Inc., Mobile, Alabama, United States|Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Arizona Oncol Assoc Dba (Hem Onc Physicians&Extenders) Hope, Tucson, Arizona, United States|Stanford Cancer Institute, Stanford, California, United States|University Of Colorado Hosp, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|Baptist Health Medical Group Oncology, Miami, Florida, United States|Ocala Oncology Center, Ocala, Florida, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Emory University - Winship Cancer Institute, Atlanta, Georgia, United States|Northwest Georgia Oncology Center, P.C., Marietta, Georgia, United States|Rush University Med Ctr, Chicago, Illinois, United States|Baptist Health Lexington, Lexington, Kentucky, United States|Crescent City Research Consortium, LLC, Marrero, Louisiana, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center., Boston, Massachusetts, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|New York University Clinical Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University Of North Carolina At Chapel Hill, Chapel Hill, North Carolina, United States|Duke University, Durham, North Carolina, United States|University Hospitals, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|Hollings Cancer Center, Charleston, South Carolina, United States|St Francis Hospital, Greenville, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University Of Texas Southwestern Medical Center, Dallas, Texas, United States|Univ Of Tx. Md Anderson, Houston, Texas, United States|Cancer Centers of South Texas, San Antonio, Texas, United States|Yakima Valley Memorial Hospital/North Star Lodge, Yakima, Washington, United States|COIBA, Berazategui, Buenos Aires, Argentina|Instituto Medico Especializado Alexander Fleming, Capital Federal, Buenos Aires, Argentina|Hospital Italiano De Buenos Aires, Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina|Clinica Colombo, Cordoba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Local Institution, Camperdown, New South Wales, Australia|Local Institution, Brisbane, Queensland, Australia|Local Institution, Elizabeth Vale, South Australia, Australia|Local Institution, Fitzroy, Victoria, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Wels, Austria|Local Institution, Wien, Austria|Universitair Ziekenhuis Brussel, Brussels, Belgium|Antwerp University Hospital, Edegem, Belgium|Uz Gent, Gent, Belgium|Uz Leuven, Leuven, Belgium|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Centre Hospitalier De L'Universite De Montreal, Montreal, Quebec, Canada|CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski, Rimouski, Quebec, Canada|Local Institution, Olomouc, Czechia|Local Institution, Ostrava - Poruba, Czechia|Local Institution, Praha 8, Czechia|Local Institution, Usti nad Labem, Czechia|Local Institution, Helsinki, Finland|Local Institution, Tampere, Finland|Local Institution, Vaasa, Finland|Local Institution, Caen, France|Local Institution, Lille, France|Local Institution, Marseille Cedex 20, France|Local Institution, Pontoise Cedex, France|Local Institution, Rennes Cedex 9, France|Local Institution, Strasbourg, France|Sozialstiftung Bamberg, Bamberg, Germany|Klinik Schillerhoehe, Gerlingen, Germany|Krankenhaus Grosshansdorf, Grosshansdorf, Germany|Thoraxklinik-Heidelberg Ggmbh, Heidelberg, Germany|Local Institution, Koeln, Germany|Local Institution, Wiesbaden, Germany|Local Institution, Heraklion, Creta, Greece|Local Institution, Athens, Greece|Local Institution, Budapest, Hungary|Local Institution, Debrecen, Hungary|Local Institution, Matrahaza, Hungary|Azienda Ospedaliera Moscati, Avellino, Italy|Local Institution, Livorno, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Perugia, Italy|Local Institution, Terni, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Nagoya, Aichi, Japan|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Natori-shi, Miyagi, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Osaka-sayama, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Sakai-shi, Osaka, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Akashi, Hyogo, Japan|Local Institution, Habikino City, Osaka, Japan|Local Institution, Kobe, Hyogo, Japan|Local Institution, Ota, Gunma, Japan|Local Institution, Sapporo, Hokkaido, Japan|Local Institution, Tokyo, Japan|Local Institution, Wakayama, Japan|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Mexico City, Distrito Federal, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Merida, Yucatan, Mexico|Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands|Umcg, Universitair Medisch Centrum Groningen, Groningen, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Bydgoszcz, Poland|Local Institution, Krakow, Poland|Local Institution, Lodz, Poland|Local Institution, Warszawa, Poland|Local Institution, Wodzislaw Slaski, Poland|Local Institution, Cluj Napoca, Romania|Local Institution, Cluj-napoca, Romania|Local Institution, Ploiesti, Romania|Local Institution, Barcelona, Spain|Local Institution, Las Palmas De Gran Canaria, Spain|Local Institution, Madrid, Spain|Local Institution, Malaga, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Local Institution, Stockholm, Sweden|Local Institution, Uppsala, Sweden|Local Institution, Chur, Switzerland|Local Institution, Lausanne, Switzerland|Local Institution, Zuerich, Switzerland|Local Institution, Taipei, Taiwan|Local Institution, Kayseri, Turkey|North Middlesex University Hospital, London, Greater London, United Kingdom|Christie Hospital Nhs Trust, Manchester, Greater Manchester, United Kingdom|St James'S University Hospital, Leeds, Yorkshire, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02041533

Study 37:
  NCT Number:                   NCT03184870
  Title:                        A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Colorectal Cancer|Pancreatic Cancer
  Interventions:                Drug: BMS-813160|Biological: Nivolumab|Drug: Nab-paclitaxel|Drug: Gemcitabine|Drug: 5-fluorouracil (5-FU)|Drug: Leucovorin|Drug: Irinotecan
  Outcome Measures:             Adverse events (AEs)|Serious adverse events (SAEs)|AEs meeting protocol-defined dose limiting toxicity criteria|AEs leading to discontinuation|Death|Incidence of laboratory abnormalities|Electrocardiogram (ECG)|Summary measures of vital signs|Overall response rate (ORR)|Median duration of response (DOR)|Progression free survival (PFS) rate|Decrease in regulatory T cells (Treg) & tumor-associated macrophages (TAM) in tumor samples|Maximum observed plasma concentration (Cmax)|Time of maximum observed plasma concentration (Tmax)|Trough observed plasma concentration (Ctrough)|Observed plasma concentration at 24 hours post dose (C24)|Area under the concentration-time curve from time 0 to 8 hours postdose [AUC(0-8)]|Area under the concentration-time curve from time 0 to 24 hours post dose [AUC(0-24)]|Apparent total body clearance (CLT/F)|Accumulation index, calculated based on ratio of AUC(0-24) and Cmax at steady state to after the first dose (AI)|Renal clearance (CLR)|Percent urinary recovery over 24 hours corrected for molecular weight (%UR)|Ratio of metabolite Cmax to parent Cmax, corrected for molecular (MR_Cmax)|Ratio of metabolite AUC(0-24) to parent AUC(0-24), corrected for molecular weight [MR_AUC(0-24)]|Frequency of positive anti-drug antibody (ADA) to nivolumab during combination therapy
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   348
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CV202-103|2017-001725-40
  Start Date:                   August 4, 2017
  Primary Completion Date:      December 10, 2020
  Completion Date:              December 20, 2021
  First Posted:                 June 14, 2017
  Results First Posted:         null
  Last Update Posted:           October 4, 2018
  Locations:                    University Of Alabama At Birmingham, Birmingham, Alabama, United States|Local Institution, Scottsdale, Arizona, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States|University Of Colorado, Aurora, Colorado, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Johns Hopkins University, Baltimore, Maryland, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Local Institution, Rochester, New York, United States|Local Institution, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Local Institution, Nashville, Tennessee, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Local Institution, Malvern, Victoria, Australia|Cross Cancer Institute, Edmonton, Alberta, Canada|Local Institution, Vancouver, British Columbia, Canada|Local Institution, Ottawa, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Local Institution, Besancon Cedex, France|Local Institution, Lyon Cedex 08, France|Local Institution, Montpellier, France|Local Institution, Paris, France|Local Institution, Dresden, Germany|Local Institution, Heidelberg, Germany|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Majadahonda - Madrid, Spain
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03184870

Study 38:
  NCT Number:                   NCT01454102
  Title:                        Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Non-small Cell Lung Cancer
  Interventions:                Biological: Nivolumab|Drug: Gemcitabine|Drug: Cisplatin|Drug: Pemetrexed|Drug: Paclitaxel|Drug: Carboplatin|Drug: Bevacizumab|Drug: Erlotinib|Biological: Ipilimumab
  Outcome Measures:             Safety and tolerability of Nivolumab in combination with chemotherapy measured by frequency of drug related adverse events|Safety and tolerability of Nivolumab in combination with chemotherapy measured by frequency of serious adverse events|Safety and tolerability of Nivolumab in combination with chemotherapy measured by frequency of clinical laboratory test by worst toxicity grade|ORR based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 of subjects treated in arms A, B, C and D|PFSR based on RECIST 1.1 of subjects treated in arms A, B, C and D|ORR based on RECIST 1.1 of subjects treated in arms E, F, K, L, M, O, P, Q, R, S|PFSR based on RECIST 1.1 of subjects treated in arms E, F, K, L, M, O, P, Q, R, S|ORR based on RECIST 1.1 of subjects treated in arms G, H, I, J and N|PFSR based on RECIST 1.1 of subjects treated in arms G, H, I, J and N
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   472
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-012
  Start Date:                   December 9, 2011
  Primary Completion Date:      July 20, 2016
  Completion Date:              December 29, 2018
  First Posted:                 October 18, 2011
  Results First Posted:         null
  Last Update Posted:           November 7, 2017
  Locations:                    Ucla, Santa Monica, California, United States|Yale University, New Haven, Connecticut, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Ut Southwestern Medical Center At Dallas, Dallas, Texas, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Local Institution, Hamilton, Ontario, Canada|Local Institution, Ottawa, Ontario, Canada|Local Institution, Toronto, Ontario, Canada
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01454102

Study 39:
  NCT Number:                   NCT03446040
  Title:                        An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Advanced Cancer
  Interventions:                Biological: BMS-986258|Biological: Nivolumab|Drug: rHuPH20
  Outcome Measures:             Incidence of adverse events (AEs)|Incidence of serious adverse events (SAEs)|Incidence of AEs leading to discontinuation and deaths|Incidence of AEs meeting protocol defined dose-limiting toxicities (DLTs) criteria|Objective response rate (ORR)|Median duration of response (mDOR)|Progression free survival rate (PFSR)|Maximum observed serum concentration (Cmax)|Time of maximum observed concentration (Tmax)|Area under the serum concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)]|Observed concentration at the end of a dosing interval (Ctau)|Area under the serum concentration-time curve in 1 dosing interval [AUC(TAU)]|Trough observed serum concentration at the end of the dosing interval (Ctrough)|Concentration at the end of infusion (Ceoi)|Incidence of anti-drug antibody (ADA) to BMS-986258
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   308
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA031-002
  Start Date:                   March 1, 2018
  Primary Completion Date:      July 4, 2023
  Completion Date:              July 5, 2023
  First Posted:                 February 26, 2018
  Results First Posted:         null
  Last Update Posted:           October 4, 2018
  Locations:                    Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Local Institution, Aurora, Colorado, United States|Local Institution, Pittsburgh, Pennsylvania, United States|The West Clinic, P.C., Germantown, Tennessee, United States|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Chuo-ku, Tokyo, Japan
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03446040

Study 40:
  NCT Number:                   NCT03661632
  Title:                        An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Advanced Cancer
  Interventions:                Drug: BMS-986310|Biological: Nivolumab
  Outcome Measures:             Incidence of Adverse Events (AE)|Incidence of Serious Adverse Events (SAE)|Incidence of AEs meeting protocol-defined dose-limiting toxicity (DLT) criteria|Incidence of AEs leading to discontinuation|Incidence of Laboratory abnormalities|Incidence of death|Objective response rate (ORR)|Median duration of response (mDOR)|Progression free survival rate (PFSR)|Maximum observed serum concentration (Cmax)|Observed serum concentration at the end of a dosing interval (Ctau)|Area under the serum concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)]|Apparent total body clearance (CLT/F)|Area under the serum concentration-time curve in 1 dosing interval [AUC(TAU)]|AUC accumulation index (AI_AUC)|Cmax accumulation index (AI_Cmax)|Summary changes of prostaglandin E metabolite (PGEM) in urine|Summary changes of tumor necrosis factor (TNFa) in blood
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   280
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA044-001|2018-002108-15
  Start Date:                   August 30, 2018
  Primary Completion Date:      March 31, 2023
  Completion Date:              March 31, 2023
  First Posted:                 September 7, 2018
  Results First Posted:         null
  Last Update Posted:           November 9, 2018
  Locations:                    Local Institution, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Local Institution, Pittsburgh, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States|Local Institution, Bruxelles, Belgium|Local Institution, Gent, Belgium|Local Institution, Edmonton, Alberta, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Haifa, Israel|Local Institution, Tel Aviv, Israel
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03661632

Study 41:
  NCT Number:                   NCT02061761
  Title:                        Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Hematologic Neoplasms
  Interventions:                Biological: BMS-986016|Biological: BMS-936558
  Outcome Measures:             Proportion of subjects with Adverse Events (AEs)|Proportion of subjects with Serious Adverse Events (SAEs)|Proportion of Deaths|Proportion of subjects with clinical laboratory test abnormalities|Objective response rate (ORR)|Duration of Response (DOR)|Maximum observed serum concentration (Cmax) of BMS-986016 administered alone and in combination with Nivolumab|Time of maximum observed serum concentration (Tmax) of BMS-986016 administered both alone and in combination with Nivolumab|Trough observed serum concentration (Ctrough) of BMS-986016 administered both alone and in combination with Nivolumab|Concentration at the end of a dosing interval (Ctau) of BMS-986016 administered both alone and in combination with Nivolumab|Average concentration over a dosing interval [AUC(TAU)/tau] (Css,avg) of BMS-986016 administered both alone and in combination with Nivolumab|Area under the concentration-time curve in one dosing interval (AUC(TAU)) of BMS-986016 administered both alone and in combination with Nivolumab|Total body clearance (CLT) of BMS-986016 administered both alone alone and in combination with Nivolumab|Volume of distribution at steady state (Vss) of BMS-986016 administered both alone and in combination with Nivolumab|Effective elimination half-life that explains the degree of AUC administered alone accumulation observed (T-HALFeff AUC) of BMS-986016 administered both alone and in combination with Nivolumab|Effective elimination half-life that explains the degree of Cmax administered alone accumulation observed (T-HALFeff Cmax) of BMS-986016 administered both alone and in combination with Nivolumab|Accumulation index; ration of AUC(TAU) at steady state to AUC(TAU) after the first dose (AI_AUC) of BMS-986016 administered both alone and in combination with Nivolumab|Cmax accumulation index; ratio of Cmax at steady state to Cmax after the first dose (AI_Cmax) of BMS-986016 administered both alone and in combination with Nivolumab|Ctau accumulation index; ratio of Ctau at steady state to Ctau after the first dose (AI_Ctau) of BMS-986016 administered both alone and in combination with Nivolumab|Degree of fluctuation or fluctuation index ([Cmax - Ctau]/Css,avg) (DF) of BMS-986016 administered both alone and in combination with Nivolumab|Incidence of ADA to nivolumab and BMS-986016|Summary of AEs of special interest by
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   132
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA224-022
  Start Date:                   February 25, 2014
  Primary Completion Date:      March 29, 2019
  Completion Date:              January 15, 2020
  First Posted:                 February 13, 2014
  Results First Posted:         null
  Last Update Posted:           November 15, 2018
  Locations:                    The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Weill Cornell Medical College, New York, New York, United States|Oregon Health & Science University, Portland, Oregon, United States|MD Anderson Cancer Center, Houston, Texas, United States|University of Washington, Seattle, Washington, United States|BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|University Health Network - Princess Margaret Cancer Centre, Toronto, Ontario, Canada
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02061761

Study 42:
  NCT Number:                   NCT02966548
  Title:                        Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Cancer
  Interventions:                Drug: Relatlimab|Drug: Nivolumab
  Outcome Measures:             Number of adverse events (AE)|Number of serious adverse events (SAE)|Number of deaths|Number of laboratory abnormalities|Maximum observed serum concentration (Cmax) of BMS-986016|Time of maximum observed serum concentration (Tmax) of BMS-986016|Trough observed serum concentration (Ctrough) of BMS-986016|Concentration at the end of a dosing interval (Ctau) of BMS-986016|Average concentration over a dosing interval [AUC(TAU)/tau] (Css,avg) of BMS-986016|Area under the serum concentration-time curve in 1 dosing interval [AUC(TAU)] of BMS-986016|Total body clearance (CLT) of BMS-986016|Volume of distribution at steady state (Vss) of BMS-986016|Effective elimination half-life (T-HALFeff) that explains the degree of AUC accumulation observed (T-HALFeff AUC) of BMS-986016|Effective elimination half-life that explains the degree of Cmax accumulation observed (T-HALFeff Cmax) of BMS-986016|Accumulation index; ration of AUC(TAU) at steady state to AUC(TAU) after the first dose (AI_AUC) of BMS-986016|Cmax accumulation index; ratio of Cmax at steady state to Cmax after the first dose (AI_Cmax) of BMS-986016|Ctau accumulation index; ratio of Ctau at steady state to Ctau after the first dose (AI_Ctau) of BMS-986016|Degree of fluctuation or fluctuation index ([Cmax - Ctau]/Css,avg) (DF) of BMS-986016|Best overall response (BOR)|Duration of response (DOR)|Frequency of positive anti-drug antibody (ADA) to BMS-986016|Frequency of positive anti-drug antibody (ADA) to Nivolumab
  Sponsor/Collaborators:        Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd
  Gender:                       All
  Age:                          20 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   45
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA224-034
  Start Date:                   November 28, 2016
  Primary Completion Date:      June 30, 2020
  Completion Date:              July 1, 2020
  First Posted:                 November 17, 2016
  Results First Posted:         null
  Last Update Posted:           August 14, 2018
  Locations:                    Local Institution, Kashiwa-shi, Chiba, Japan
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02966548

Study 43:
  NCT Number:                   NCT02935634
  Title:                        A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer
  Acronym:                      FRACTION-GC
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Advanced Gastric Cancer
  Interventions:                Biological: Nivolumab|Biological: Ipilimumab|Biological: Relatlimab|Biological: BMS-986205
  Outcome Measures:             Objective Response Rate (ORR)|Duration of Response (DOR)|Progression-free Survival Rate (PFSR)|Incidence of Adverse Events (AEs)|Incidence of Serious Adverse Events (SAEs)|AEs leading to discontinuation|AEs leading to death
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years to 110 Years   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   300
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA018-003|2016-002807-24
  Start Date:                   November 23, 2016
  Primary Completion Date:      November 17, 2021
  Completion Date:              November 18, 2021
  First Posted:                 October 17, 2016
  Results First Posted:         null
  Last Update Posted:           November 28, 2018
  Locations:                    Local Institution, Phoenix, Arizona, United States|City Of Hope National Medical Center, Duarte, California, United States|University Of Colorado, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|Georgetown University Med Ctr, Washington, District of Columbia, United States|UF Health Medical Oncology - Davis Cancer Pavilion, Gainesville, Florida, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|John Hopkins, Baltimore, Maryland, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Providence Portland Medical Center, Portland, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|UPMC, Pittsburgh, Pennsylvania, United States|Seattle Cancer Care Assoc. Univ of Washington, Seattle, Washington, United States|Westmead Hospital, Westmead, New South Wales, Australia|Austin Health, Heidelberg, Victoria, Australia|Local Institution, Randwick, Australia|Cross Cancer Institute, Edmonton, Alberta, Canada|Local Institution, Vancouver, British Columbia, Canada|Local Institution, Halifax, Nova Scotia, Canada|Local Institution, Ottawa, Ontario, Canada|Local Institution, Toronto,, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 9, France|Local Institution, Montpellier Cedex 5, France|Local Institution, Villejuif, France|Nationales Centrum Fur Tumorerkrankungen (Nct), Heidelberg, Germany|Universitaetsklinikum Leipzig, Leipzig, Germany|Local Institution, Ramat Gan, Israel|Local Institution, Tel Aviv, Israel|IRCCS Istituto Nazionale Tumori Milano, Milano, Italy|Istituto Europeo Di Oncologia, Milan, Italy|Amsterdam UMC ? locatie AMC, Amsterdam, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Local Institution, Singapore, Singapore|Local Institution, Badalona-barcelona, Spain|Local Institution, Madrid, Spain|Kantonsspital Graubunden, Chur, Switzerland|Local Institution, Zuerich, Switzerland
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02935634

Study 44:
  NCT Number:                   NCT03745807
  Title:                        An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Advanced Cancer
  Interventions:                Biological: NKTR-214|Biological: Nivolumab
  Outcome Measures:             Incidence of adverse events (AEs)|Incidence of serious adverse events (SAEs)|Incidence of AEs leading to discontinuation|Incidence of deaths|Incidence of AEs meeting protocol-defined dose limiting toxicity (DLT) criteria|Incidence of laboratory abnormalities|Maximum observed concentration (Cmax)|Time of maximum observed concentration (Tmax)|Area under the concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)]|Area under the concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]|Total body clearance (CLT)|Volume of distribution (Vz)|Apparent terminal phase half-life (T-HALF)|Trough observed serum concentration at the end of the dosing interval (Ctrough)|Incidence of anti-drug antibodies (ADA) to NKTR-214|Incidence of anti-drug antibodies (ADA) to nivolumab|Best overall response (BOR)|Duration of response (DOR)
  Sponsor/Collaborators:        Bristol-Myers Squibb|Nektar Therapeutics|Ono Pharmaceutical Co. Ltd
  Gender:                       All
  Age:                          20 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   6
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA045-010|18-214-14
  Start Date:                   December 25, 2018
  Primary Completion Date:      June 1, 2021
  Completion Date:              June 2, 2021
  First Posted:                 November 19, 2018
  Results First Posted:         null
  Last Update Posted:           November 19, 2018
  Locations:                    Local Institution, Chuo-ku, Tokyo, Japan
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03745807

Study 45:
  NCT Number:                   NCT03192943
  Title:                        A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Advanced Cancer
  Interventions:                Drug: BMS-986205|Biological: Nivolumab
  Outcome Measures:             Incidence of Adverse Events (AEs)|Incidence of Serious Adverse Events (SAEs)|Incidence of Death|Incidence of Laboratory Abnormalities|AEs leading to discontinuation|Maximum observed plasma concentration (Cmax)|Time of maximum observed plasma concentration (Tmax)|Area under the plasma concentration-time curve in one dosing interval [AUC(TAU)]|Trough observed plasma concentration at the end of the dosing interval (Ctrough)|Apparent total body clearance (CLT/F)|Apparent volume of distribution at steady-state (Vss/F)|Percent urinary recovery over 24 hours (%UR24)|Biomarker Availability|Incidence of anti-drug antibody (ADA)|Best Overall Response (BOR)|Duration of Response (DOR)
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          20 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   18
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA017-048
  Start Date:                   June 23, 2017
  Primary Completion Date:      July 21, 2019
  Completion Date:              July 21, 2019
  First Posted:                 June 20, 2017
  Results First Posted:         null
  Last Update Posted:           October 4, 2018
  Locations:                    Local Institution, Chuo-ku, Tokyo, Japan
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03192943

Study 46:
  NCT Number:                   NCT03377361
  Title:                        An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Patients With Previously Treated Cancer of the Colon or Rectum That Has Spread
  Acronym:                      CheckMate9N9
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Colorectal Cancer|Colorectal Tumors|Colorectal Carcinoma|Colorectal Neoplasm
  Interventions:                Biological: Nivolumab|Drug: Trametinib|Biological: Ipilimumab
  Outcome Measures:             Number of Adverse Events (AEs)|Number of Serious Adverse Events (SAEs)|Objective response rate (ORR)|Disease control rate (DCR)|Duration of response (DoR)|Time to response (TTR)|Progression free survival (PFS)|Overall survival (OS)
  Sponsor/Collaborators:        Bristol-Myers Squibb|Novartis
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   345
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-9N9|2017-001830-24
  Start Date:                   January 22, 2018
  Primary Completion Date:      September 21, 2021
  Completion Date:              November 24, 2022
  First Posted:                 December 19, 2017
  Results First Posted:         null
  Last Update Posted:           October 9, 2018
  Locations:                    University Of Alabama At Birmingham, Birmingham, Alabama, United States|Local Institution, Phoenix, Arizona, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Usc, Los Angeles, California, United States|University of California San Francisco (UCSF), San Francisco, California, United States|Local Institution, Fort Collins, Colorado, United States|Local Institution, New Haven, Connecticut, United States|Local Institution, Indianapolis, Indiana, United States|Local Institution, Baltimore, Maryland, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Rochester, Minnesota, United States|Local Institution, New York, New York, United States|Local Institution, New York, New York, United States|Local Institution, Charlotte, North Carolina, United States|Local Institution, Durham, North Carolina, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Local Institution, Houston, Texas, United States|University Of Wisconsin, Madison, Wisconsin, United States|Local Institution, Blacktown, New South Wales, Australia|Local Institution, Herston, Queensland, Australia|Local Institution, Southport, Queensland, Australia|Local Institution, Clayton, Victoria, Australia|Local Institution, Brussels, Belgium|Local Institution, Brussel, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Leuven, Belgium|Local Institution, Ottawa, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Quebec, Canada|Local Institution, Cologne, Germany|Local Institution, Hamburg, Germany|Local Institution, Hannover, Germany|Local Institution, Heilbronn, Germany|Local Institution, Mannheim, Germany|Local Institution, Munich, Germany|Local Institution, Ulm, Germany|Local Institution, Wuerzburg, Germany|Local Institution, Milano, Italy|Local Institution, Modena, Italy|Local Institution, Padova, Italy|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Aberdeen, Aberdeenshire, United Kingdom|Local Institution, Bristol, Avon, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Coventry, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Surrey, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03377361

Study 47:
  NCT Number:                   NCT01673867
  Title:                        Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC
  Acronym:                      CheckMate057
  Status:                       Active, not recruiting
  Study Results:                Has Results
  Conditions:                   Non-Squamous Cell Non-small Cell Lung Cancer
  Interventions:                Biological: Nivolumab|Drug: Docetaxel
  Outcome Measures:             Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint|One-year Overall Survival (OS) Rate in All Randomized Participants|Number of Deaths From Any Cause in All Randomized Participants at Primary Endpoint|Objective Response Rate (ORR) in All Randomized Participants at Primary Endpoint|Duration of Objective Response (DOR) in Months for All Confirmed Responders at Primary Endpoint|Time To Response (TTR) in Months for All Confirmed Responders at Primary Endpoint|Progression-Free Survival (PFS) Rate at 12 Months|Progression-Free Survival (PFS) Time in Months for All Randomized Participants at Primary Endpoint|Percentage of Participants Experiencing Disease-related Symptom Improvement by Week 12|Overall Survival (OS) Time in Months by Baseline PD-L1 Expression for All Randomized Participants at Primary Endpoint|Objective Response Rate (ORR) by Baseline PD-L1 Expression for All Randomized Participants at Primary Endpoint
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   792
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-057|2012-002472-14
  Start Date:                   October 10, 2012
  Primary Completion Date:      February 5, 2015
  Completion Date:              December 21, 2018
  First Posted:                 August 28, 2012
  Results First Posted:         February 26, 2016
  Last Update Posted:           April 10, 2018
  Locations:                    Mayo Clinic Arizona, Scottsdale, Arizona, United States|City Of Hope National Medical Center, Duarte, California, United States|City Of Hope, Duarte, California, United States|Sharp Clinical Oncology Research, San Diego, California, United States|San Francisco Oncology Associates, San Francisco, California, United States|Yale University, New Haven, Connecticut, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Northwest Georgia Oncology Center, P.C., Marietta, Georgia, United States|University Of Chicago Medical Center, Chicago, Illinois, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|The Johns Hopkins University, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Winthrop University Hospital Oncology/Hematology, Mineola, New York, United States|Winthrop University Hospital, Mineola, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|St. Mary Medical Center, Langhorne, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Guthrie Clinic, Ltd, Sayre, Pennsylvania, United States|Guthrie Medical Group, P.C., Sayre, Pennsylvania, United States|South Carolina Oncology Associates, Columbia, South Carolina, United States|Tennessee Oncology, PLLC, Chattanooga, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Henry-Joyce Cancer Center, Nashville, Tennessee, United States|University Of Texas Southwestern Medical Center, Dallas, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Univ Of Tx. Md Anderson, Houston, Texas, United States|Columbia Basin Hematology And Oncology, Kennewick, Washington, United States|Kadlec Clinical Hematology and Oncology, Kennewick, Washington, United States|Swedish Cancer Institute, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|West Virginia University-Mbrcc, Morgantown, West Virginia, United States|West Virginia University-Mbrcc, Morgantown, West Virginia, United States|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Ciudad De Buenos Aires, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, La Rioja, Argentina|Local Institution, Tweed Heads, New South Wales, Australia|Local Institution, Woolloongabba, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Kurralta Park, South Australia, Australia|Local Institution, Frankston, Victoria, Australia|Local Institution, Melbourne, Victoria, Australia|Local Institution, Linz, Austria|Local Institution, Salzburg, Austria|Local Institution, Vienna, Austria|Local Institution, Wels, Austria|Local Institution, Salvador, Bahia, Brazil|Local Institution, Salvador, Bahia, Brazil|Local Institution, Fortaleza, Ceara, Brazil|Local Institution, Fortaleza, Ceara, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Barretos, Sao Paulo, Brazil|Local Institution, Rio De Janeiro, Brazil|Local Institution, Rio De Janeiro, Brazil|Cross Cancer Institute, Edmonton, Alberta, Canada|Local Institution, London, Ontario, Canada|Centre De Sante Et De Services Sociaux Rimouski Neigette, Rimouski, Quebec, Canada|CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski, Rimouski, Quebec, Canada|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Recoleta, Santiago DE Chile, Chile|Local Institution, Vi?a Del Mar, Valparaiso, Chile|Local Institution, Praha 8, Czechia|Local Institution, Creteil, France|Local Institution, Dijon Cedex, France|Local Institution, La Roche Sur Yon Cedex 9, France|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 20, France|Local Institution, Poitiers, France|Local Institution, Rennes Cedex 9, France|Local Institution, Toulouse, France|Local Institution, Bad Berka, Germany|Local Institution, Gerlingen, Germany|Local Institution, Grosshansdorf, Germany|Local Institution, Heidelberg, Germany|Local Institution, Koeln, Germany|Local Institution, Mainz, Germany|Local Institution, Recklinghausen, Germany|Local Institution, Ulm, Germany|Local Institution, Hong Kong, Hong Kong|Local Institution, Budapest, Hungary|Local Institution, Bergamo, Italy|Local Institution, Bologna, Italy|Local Institution, Meldola (fc), Italy|Local Institution, Milano, Italy|Local Institution, Padova, Italy|Local Institution, Parma, Italy|Local Institution, Perugia, Italy|Local Institution, Ravenna, Italy|Local Institution, Siena, Italy|Local Institution, Mexico City, Distrito Federal, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Monterrey, Nuevo LEON, Mexico|Local Institution, Hermosillo, Sonora, Mexico|Local Institution, Oslo, Norway|Local Institution, Miraflores, Lima, Peru|Local Institution, Arequipa, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Gdansk, Poland|Local Institution, Krakow, Poland|Local Institution, Olsztyn, Poland|Local Institution, Szczecin, Poland|Local Institution, Warszawa, Poland|Local Institution, Bucuresti, Romania|Local Institution, Cluj-Napoca, Romania|Local Institution, Craiova, Romania|Local Institution, Iasi, Romania|Local Institution, Timisoara, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, Vizcaya, Spain|Local Institution, Chur, Graubuenden, Switzerland|Local Institution, Basel, Switzerland|Local Institution, Chur, Switzerland
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01673867

Study 48:
  NCT Number:                   NCT03656718
  Title:                        A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Neoplasms by Site
  Interventions:                Biological: Nivolumab|Drug: rHuPH20
  Outcome Measures:             Maximum observed serum concentration (Cmax)|Time of maximum observed serum concentration (Tmax)|Area under the serum concentration-time curve in 1 dosing interval [AUC(TAU)]|Observed serum concentration at the end of a dosing interval (Ctau)|Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), AEs leading to discontinuation|Incidence of death|Incidence of clinical laboratory test abnormalities|Incidence of AEs in the MedDRA Anaphylactic Reaction broad scope SMQ|Incidence of events within the hypersensitivity/infusion reaction select AE category|Incidence of anti-drug antibodies (ADAs) and neutralizing antibodies to nivolumab
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   60
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-8KX|2018-001585-42
  Start Date:                   September 24, 2018
  Primary Completion Date:      September 26, 2021
  Completion Date:              October 25, 2024
  First Posted:                 September 3, 2018
  Results First Posted:         null
  Last Update Posted:           October 12, 2018
  Locations:                    Local Institution, Atlanta, Georgia, United States|Local Institution, Detroit, Michigan, United States|Local Institution, Charlotte, North Carolina, United States|Willamette Valley Cancer Institute And Research Center, Eugene, Oregon, United States|Local Institution, Greenville, South Carolina, United States|Texas Oncology- Austin Midtown, Austin, Texas, United States|Texas Oncology-Beaumont, Beaumont, Texas, United States|Local Institution, Dallas, Texas, United States|Us Oncology, Tyler, Texas, United States|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Dunedin, New Zealand|Local Institution, Tauranga, New Zealand|Local Institution, Wellington, New Zealand|Local Institution, Madrid, Spain|Local Institution, Malaga, Spain
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03656718

Study 49:
  NCT Number:                   NCT02737475
  Title:                        An Investigational Immuno-therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Patients With Solid Cancers That Are Advanced or Have Spread
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Advanced Cancer
  Interventions:                Drug: BMS-986178|Drug: Nivolumab|Drug: Ipilimumab
  Outcome Measures:             Incidence of AE's (adverse events) and SAE's (serious adverse events), AE's leading to discontinuation, deaths and clinical laboratory test abnormalities|Cmax (maximum observed serum concentration) for BMS-986178 alone and in combination with nivolumab and/or ipilimumab, if data permits|Tmax (time of maximum observed concentration) for BMS-986178 alone and in combination with nivolumab and/or ipilimumab, if data permits|AUC(0-t) (area under the concentration-time curve from time zero to the time) for BMS-986178 alone and in combination with nivolumab and/or ipilimumab, if data permits|AUC(TAU) (area under the concentration-time curve in 1 dosing interval) for BMS-986178 alone and in combination with nivolumab and/or ipilimumab, if data permits|Ctau (the observed concentration at the end of a dosing interval) for BMS- 986178 alone and in combination with nivolumab and/or ipilimumab, if data permits|CLT (total body clearance) for BMS-986178 alone and in combination with nivolumab and/or ipilimumab, if data permits|Css-avg [average concentration over a dosing interval (AUC(TAU)/tau)] for BMS-986178 alone and in combination with nivolumab and/or ipilimumab, if data permits|AI [ratio of an exposure measure at steady state to that after the first dose (exposure measure includes AUC(TAU), Cmax and Ctau)] for BMS- 986178 alone and in combination with nivolumab and/or ipilimumab, if data permits|T-HALFeff [effective elimination half-life to explain degree of accumulation for a specific exposure measure (exposure measure includes AUC(TAU), Cmax and Ctau)] for BMS-986178 alone and in combination with nivolumab and/or ipilimumab, if data permits|Ctrough [trough observed plasma concentrations (this includes pre-dose concentrations (C0) and Ctau)] for BMS-986178 alone and in combination with nivolumab and/or ipilimumab, if data permits|Immunoassay of anti-nivolumab antibody in combination with anti-BMS- 986178 antibody|Immunoassay of anti-ipilimumab antibody in combination with anti-BMS-986178 antibody|Objective Response Rate (ORR)|Progression Free Survival Rate (PFSR)|Immunoassay of anti-BMS-986178 antibody alone|Number of participants showing a change in one of the pharmacodynamic biomarkers of BMS-986178 administered in combination with nivolumab
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   435
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA012-004|2015-004816-39
  Start Date:                   June 16, 2016
  Primary Completion Date:      May 12, 2021
  Completion Date:              October 15, 2021
  First Posted:                 April 14, 2016
  Results First Posted:         null
  Last Update Posted:           October 3, 2018
  Locations:                    University Of Colorado, Aurora, Colorado, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Columbia University Medical Center (Cumc), New York, New York, United States|Providence Portland Medical Center, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Cross Cancer Institute, Edmonton, Alberta, Canada|Local Institution, Ottawa, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Toulouse, France|Local Institution, Villejuif, France|Local Institution, Ramat Gan, Israel|Local Institution, Tel Aviv, Israel|Local Institution, Milano, Italy|Local Institution, Rozzano, Italy|Local Institution, Amsterdam, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|H. Univ. Vall dHebron, Barcelona, Spain|Fundacion Jimenez Diaz, Madrid, Spain|Hosp. Univ. Puerta De Hierro, Majadahonda - Madrid, Spain|Hospital Universitario Virgen De La Victoria, Malaga, Spain|Clinica Universitaria De Navarra, Pamplona, Spain
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02737475

Study 50:
  NCT Number:                   NCT03130959
  Title:                        An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies
  Acronym:                      CheckMate 908
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Various Advanced Cancer
  Interventions:                Biological: Nivolumab|Biological: Ipilimumab
  Outcome Measures:             Incidence of dose limiting toxicity (DLT)|Incidence of serious adverse events (SAEs)|Incidence of adverse events (AEs)|Overall Survival (OS)|Progression Free Survival (PFS)|Incidence of AEs|Incidence of SAEs|Incidence of laboratory abnormalities|Overall Survival|Progression Free Survival
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          6 Months to 21 Years   (Child, Adult)
  Phases:                       Phase 2
  Enrollment:                   170
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-908|2016-004441-82
  Start Date:                   June 6, 2017
  Primary Completion Date:      June 14, 2021
  Completion Date:              June 15, 2021
  First Posted:                 April 27, 2017
  Results First Posted:         null
  Last Update Posted:           September 11, 2018
  Locations:                    Children's Hospital Of Los Angeles, Los Angeles, California, United States|Local Institution, San Francisco, California, United States|Children'S Hospital, Aurora, Colorado, United States|Local Institution, New Haven, Connecticut, United States|Mcknight Brain Institute, Gainesville, Florida, United States|Children'S Memorial Hospital, Chicago, Illinois, United States|The Johns Hopkins Hospital, Baltimore, Maryland, United States|Dana-Farber Cancer Inst, Boston, Massachusetts, United States|Washington University, Saint Louis, Missouri, United States|The Herbert Irving Pavilion, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Local Institution, Rochester, New York, United States|Cincinnati Children'S Hospital Medical Center, Cincinnati, Ohio, United States|Children'S Hospital Of Philadelphia, Philadelphia, Pennsylvania, United States|Local Institution, Pittsburgh, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|St Jude Children'S Research Hospital, Memphis, Tennessee, United States|Baylor College Of Medicine, Houston, Texas, United States|Local Institution, Randwick, New South Wales, Australia|Local Institution, Sth Brisbane, Queensland, Australia|Local Institution, Clayton, Victoria, Australia|Local Institution, Parkville, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Curitiba, Parana, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Ribeirao Preto, SAO Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Edmonton, Alberta, Canada|Local Institution, Toronto, Ontario, Canada|The Montreal Children's Hospital of the MUHC, Montreal, Quebec, Canada|CHU de Quebec, Quebec, Canada|Local Institution, Angers, France|Local Institution, Bordeaux Cedex, France|Local Institution, Lille, France|Local Institution, Lyon, France|Local Institution, Marseille, France|Local Institution, Paris, France|Local Institution, Vandoeuvre les Nancy, France|Local Institution, VIillejuif, France|Universitaetsklinik Essen, Essen, Germany|Universitaetsklinikum Hamburg, Hamburg, Germany|Hopp Children?s Cancer Center at NCT Heidelberg, Heidelberg, Germany|Univ. Klinikum Wuerzburg, Wuerzburg, Germany|Local Institution, Hong Kong, Hong Kong|Local Institution, Haifa, Israel|Local Institution, Ramat Gan, Israel|Erasmus Mc , Locatie Sophia, Rotterdam, Netherlands|Prinses Maxima Centrum voor Kinderoncologie, Utrecht, Netherlands|Local Institution, Oslo, Norway|Local Institution, Warszawa, Poland|Local Institution, Moscow, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Esplugues de Llobregat, Spain|Local Institution, Madrid, Spain|Local Institution, Valencia, Spain|Local Institution, Solna, Sweden|Great Ormond Street Hospital For Children, London, Greater London, United Kingdom|Alder Hey Children'S Hospital, Liverpool, Merseyside, United Kingdom|Royal Victoria Infirmary, Newcastle Upon Tyne, Tyne and Wear, United Kingdom|Local Institution, Birmingham, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03130959

Study 51:
  NCT Number:                   NCT03203876
  Title:                        A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Advanced Cancer
  Interventions:                Biological: Lirilumab|Biological: Nivolumab|Biological: Ipilimumab
  Outcome Measures:             Incidence of dose-limiting toxicity (DLT)|Incidence of adverse events (AEs)|Incidence of serious adverse events (SAEs)|Incidence of death|Frequency of laboratory test toxicity grade shifting from baseline|Incidence of AEs leading to discontinuation|Maximum serum observed concentration (Cmax)|Time of maximum observed serum concentration (Tmax)|Area under the serum concentration-time curve from time zero to the time of last quantifiable concentration [AUC(0-T)]|Area under the serum concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]|Trough observed serum concentration (Ctrough)|Area under the serum concentration-time curve in one dosing interval [AUC(TAU)]|Clearance (CL)|Volume of distribution at steady state (Vss)|Ratio of an exposure measure at steady-state to that after the first dose (AI)|Half-life (T-HALF)|Effective elimination half-life that explains the degree of accumulation observed for a specific exposure measure (T-HALF eff)|Best overall response (BOR)|Duration of response (DOR)|Incidence of anti-drug antibody (ADA)
  Sponsor/Collaborators:        Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd
  Gender:                       All
  Age:                          20 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   21
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA223-030
  Start Date:                   July 5, 2017
  Primary Completion Date:      December 9, 2018
  Completion Date:              December 10, 2018
  First Posted:                 June 29, 2017
  Results First Posted:         null
  Last Update Posted:           August 29, 2018
  Locations:                    Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Kobe-shi, Hyogo, Japan
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03203876

Study 52:
  NCT Number:                   NCT03110107
  Title:                        First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Patients With Advanced Solid Tumors
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Advanced Cancer
  Interventions:                Biological: Ipilimumab|Biological: BMS-986218|Biological: Nivolumab
  Outcome Measures:             Incidence of Adverse Events (AEs)|Incidence of Serious Adverse Events (SAEs)|Objective Response Rate (ORR) of BMS-986218 monotherapy relative to Ipilimumab in immuno-oncology (IO) progressed melanoma cohort|Median Duration of Response (mDOR) of BMS-986218 monotherapy relative to Ipilimumab in IO progressed melanoma cohort|Progression Free Survival (PFS) of BMS-986218 monotherapy relative to Ipilimumab in IO progressed melanoma cohort|ORR of BMS-986218 alone or in combination with Nivolumab|mDOR of BMS-986218 alone or in combination with Nivolumab|PFS of BMS-986218 alone or in combination with Nivolumab|Incidence of anti-drug antibody (ADA) to BMS-986218|Percentage of change from baseline in T-regulatory cells (Tregs)|Maximum observed serum concentration (Cmax)|Time of maximum observed concentration (Tmax)|Area under the concentration-time curve from time zero to the time of the|Area under the concentration-time curve in 1 dosing interval [AUC(TAU)]|Trough observed serum concentration (Ctrough)|Total body clearance (CLT)|Average serum concentration over a dosing interval (AUC[TAU]/tau) at steady state (Css-avg)|Ratio of an exposure measure at steady state to that after the first dose [exposure measure includes AUC[TAU] and Cmax (AI)]|Terminal serum half-life if data permit (T-HALF)|Observed concentration at the end of a dosing interval (Ctau)
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   452
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA022-001|2017-000597-11
  Start Date:                   April 28, 2017
  Primary Completion Date:      April 6, 2020
  Completion Date:              March 20, 2021
  First Posted:                 April 12, 2017
  Results First Posted:         null
  Last Update Posted:           October 3, 2018
  Locations:                    Local Institution, Aurora, Colorado, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Las Vegas, Nevada, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Columbia University Medical Center (Cumc), New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|Local Institution, North Sydney, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Lyon Cedex 08, France|Local Institution, Toulouse Cedex 9, France|Local Institution, Villejuif, France|Local Institution, Ramat Gan, Israel|Local Institution, Napoli, Italy|Local Institution, Siena, Italy|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Pamplona, Spain
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03110107

Study 53:
  NCT Number:                   NCT03036098
  Title:                        Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer
  Acronym:                      CheckMate901
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Urothelial Cancer
  Interventions:                Biological: nivolumab|Biological: ipilimumab|Drug: gemcitabine|Drug: cisplatin|Drug: carboplatin
  Outcome Measures:             Progression free survival (PFS) in cisplatin-ineligible participants using Response Evaluation Criteria in Solid Tumors (RECIST 1.1)|Overall survival (OS) of cisplatin-ineligible participants|PFS based on BICR assessment of nivolumab combined with standard of care (SOC) chemotherapy to SOC chemotherapy in cisplatin-ineligible participants with previously untreated, unresectable or metastatic Urothelial Cancer (UC)|Progression free survival (PFS) in all participants using Response Evaluation Criteria in Solid Tumors (RECIST 1.1)|Overall survival (OS) in all participants|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire- Core 30 (EORTC QLQ-C30) Global Health Status score|OS in cisplatin-eligible participants with previously untreated, unresectable or metastatic UC.
  Sponsor/Collaborators:        Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   897
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-901|2016-003881-14
  Start Date:                   March 24, 2017
  Primary Completion Date:      April 26, 2020
  Completion Date:              December 23, 2022
  First Posted:                 January 30, 2017
  Results First Posted:         null
  Last Update Posted:           November 6, 2018
  Locations:                    Local Institution, Birmingham, Alabama, United States|Local Institution, Birmingham, Alabama, United States|Alaska Urological Institute dba Alaska Clinical Research Center, Anchorage, Alaska, United States|Local Institution, Little Rock, Arkansas, United States|VA of Central California Health Care System, Fresno, California, United States|St Joseph Heritage Healthcare, Santa Rosa, California, United States|Boca Raton Regional Hospital, Boca Raton, Florida, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|Cancer Specialists of North FL, Jacksonville, Florida, United States|University Cancer Blood Ctr, Athens, Georgia, United States|Lewis Hall Singletary Oncology Center, Thomasville, Georgia, United States|University Of Illinois At Chicago, Chicago, Illinois, United States|Local Institution, Iowa City, Iowa, United States|Ochsner Clinic, New Orleans, Louisiana, United States|Beth Israel Deaconess Med Ctr, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Milford Regional Medical Center, Boston, Massachusetts, United States|South Shore Hospital Cancer Center, Boston, Massachusetts, United States|St. Joseph Mercy Hospital, Ypsilanti, Michigan, United States|Ridges Cancer Clinic, Burnsville, Minnesota, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|St Lukes Hospital, Kansas City, Missouri, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|GU Research Network, LLC, Omaha, Nebraska, United States|Nh Hematology - Oncology, Hooksett, New Hampshire, United States|University Of New Mexico, Albuquerque, New Mexico, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Winthrop University Hospital, Mineola, New York, United States|Icahn School Of Medicine At Mount Sinai, New York, New York, United States|Local Institution, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|The Ohio State University, Columbus, Ohio, United States|Providence Portland Med Ctr, Portland, Oregon, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Local Institution, Houston, Texas, United States|Local Institution, Salt Lake City, Utah, United States|Seattle Cancer Care Alliance, Kirkland, Washington, United States|Local Institution, Milwaukee, Wisconsin, United States|Instituto Medico Especializado Alexander Fleming, Capital Federal, Buenos Aires, Argentina|Hospital Privado De Comunidad, Mar Del Plata, Buenos Aires, Argentina|Clinica Viedma S.A., Viedma, RIO Negro, Argentina|Centro De Diagnostico Urologico S.R.L., Buenos Aires, Argentina|Local Institution, Cordoba, Argentina|Clinica Privada Universitaria Reina Fabiola, Cordoba, Argentina|Local Institution, Darlinghurst, New South Wales, Australia|Local Institution, Waratah, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Chermside, Queensland, Australia|Local Institution, Tugun, Queensland, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Doubleview, Western Australia, Australia|Local Institution, Brasilia, Distrito Federal, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Passo Fundo, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Florianopolis, Santa Catarina, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Jose do Rio Preto, SAO Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Nova Scotia Health Authority QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|London Regional Cancer Program, London Health Sciences Centre, London, Ontario, Canada|Centre integre universitaire de sante et de service sociaux de l'estrie - CHUS, Sherbrooke, Quebec, Canada|CHU de Quebec - L'Hotel-Dieu de Quebec, Quebec, Canada|Local Institution, Santiago, Metropolitana, Chile|Centro Internacional de Estudios Clinicos, Recoleta, Santiago DE Chile, Chile|Hospital Clinico Vina Del Mar, Vina Del Mar, Valparaiso, Chile|Local Institution, Vitacura, Chile|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Chongqing, Chongqing, China|Local Institution, Wuhan, Hubei, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Changchun, Jilin, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, China|Local Institution, Shanghai, China|Klinika komplexni onkologicke pece, Brno, Czechia|Klinika onkologie a radioterapie, Hradec Kralove, Czechia|Local Institution, Aalborg, Denmark|Local Institution, Herlev, Denmark|Local Institution, Helsinki, Finland|Local Institution, Lille, France|Local Institution, Marseille Cedex 9, France|Local Institution, Nimes Cedex 09, France|Local Institution, Saint Priest En Jarez, France|Local Institution, Suresnes, France|Local Institution, Tours Cedex, France|Local Institution, Villejuif, France|Universitat Dresden, Dresden, Germany|Universitaetsklinikum Essen, Essen, Germany|Medizinische Universitaetsklinik Freiburg, Freiburg, Germany|Asklepios Klinik Altona, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitaetsklinikum Jena, Jena, Germany|Local Institution, Muenchen, Germany|Klinikum Nuernberg Nord, Urologische Klinik, Nuernberg, Germany|Uniklinik Tuebingen, Tuebingen, Germany|Kliniken Nordoberpfalz AG, Weiden, Germany|Univ. Klinikum Wuerzburg, Wuerzburg, Germany|Alexandra General Hospital, Athens, Greece|Ioannina University Hospital, Ioannina, Greece|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Debrecen, Hungary|Local Institution, Miskolc, Hungary|Local Institution, Kfar Saba, Israel|Local Institution, Ramat Gan, Israel|Ospedale S. Donato - Usl 8, Arezzo, Italy|Ospedale Per Gli Infermi, Faenza, Italy|Istituto Romagnolo Per Lo Studio E La Cura Dei Tumori, Forli, Italy|Ospedale Della Misericordia Grosseto, Grosseto, Italy|IRCCS Istituto Nazionale Tumori Milano, Milano, Italy|Azienda Ospedaliera Di Rilievo Nazionale A. Cardarelli, Napoli, Italy|Local Institution, Hirosaki-shi, Aomori, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Sapporo-city, Hokkaido, Japan|Local Institution, Tsukuba-shi, Ibaraki, Japan|Local Institution, Kita-Gun, Kagawa, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Osakasayama, Osaka, Japan|Local Institution, Takatsuki-shi, Osaka, Japan|Local Institution, Hamamatsu-shi, Shizuoka, Japan|Local Institution, Arakawa-ku,tokyo, Tokyo, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Shinjuku-Ku, Tokyo, Japan|Local Institution, Ube City, Yamaguchi, Japan|Local Institution, Goyang-si, Korea, Republic of|Local Institution, Seongnam-si, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Comite Mexicano para la Prevenion de la Osteoporosis A.C., Ciudad de Mexico, Distrito Federal, Mexico|Local Institution, Mexico City, Distrito Federal, Mexico|Local Institution, Tlalpan, Distrito Federal, Mexico|Centro Universitario Contra el Cancer UANL, Monterrey, Nuevo LEON, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Enschede, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Leeuwarden, Netherlands|Local Institution, Bergen, Norway|Local Institution, Lorenskog, Norway|Instituto Nacional De Enfermedades Neoplasicas, Lima, Peru|Clinica El Golf, Lima, Peru|Ambulatorium Chemioterapii, Bydgoszcz, Poland|Local Institution, Koszalin, Poland|Klinika Nowotworow Ukladu Moczowego Centrum Onkologii - Inst, Warszawa, Poland|Local Institution, Cluj-Napoca, Romania|Local Institution, Craiova, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Novosibirsk, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, Singapore, Singapore|Comp. Hosp. Univ. A Coruna, A Coruna, Spain|Hospital Santa Creu I Sant Pau, Barcelona, Spain|Hospital Universitario Ramon Y Cajal, Madrid, Spain|Hosp Univer 12 De Octubre, Madrid, Spain|H. U. Marques de Valdecilla, Santander, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain|Instituto Valenciano De Oncologia, Valencia, Spain|Local Institution, Jonkoping, Sweden|Local Institution, Linkoping, Sweden|Local Institution, Lund, Sweden|Kantonsspital Baden, Baden, Switzerland|Kantonsspital Graubuenden, Chur, Switzerland|Local Institution, Kaohsiung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, Ankara, Turkey|Local Institution, Istanbul, Turkey|Local Institution, Izmir, Turkey
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03036098

Study 54:
  NCT Number:                   NCT02060188
  Title:                        An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread
  Acronym:                      CheckMate142
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Microsatellite Unstable Colorectal Cancer|Microsatellite Stable Colorectal Cancer|Mismatch Repair Proficient Colorectal Cancer|Mismatch Repair Deficient Colorectal Cancer
  Interventions:                Drug: Ipilimumab|Drug: Nivolumab|Drug: Cobimetinib|Drug: Daratumumab|Drug: anti-LAG-3 antibody
  Outcome Measures:             Objective response rate (ORR) in all MSI-High and non-MSI-High subjects as determined by Investigators|ORR in all MSI-H and non-MSI-H subjects based on IRRC determination
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   340
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-142|2013-003939-30
  Start Date:                   March 7, 2014
  Primary Completion Date:      December 3, 2019
  Completion Date:              December 30, 2020
  First Posted:                 February 11, 2014
  Results First Posted:         null
  Last Update Posted:           November 20, 2018
  Locations:                    Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Pacific Hematology Oncology Associates, San Francisco, California, United States|Emory University, Atlanta, Georgia, United States|Dana Farber Cancer Institute., Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Allina Health System, Minneapolis, Minnesota, United States|Duke University Office of Research Administration, Durham, North Carolina, United States|Novant Health Oncology Specialists, Winston-Salem, North Carolina, United States|Providence Cancer Center Oncology and Hematology Care- Eastside, Portland, Oregon, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|University Of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|Vanderbilt University Med Ctr, Nashville, Tennessee, United States|Md Anderson Can Cnt, Houston, Texas, United States|Local Institution, Camperdown, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Tasman Oncology Research Pty Ltd, Southport, Queensland, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Local Institution, Brussels, Belgium|Local Institution, Brussels, Belgium|Local Institution, Leuven, Belgium|Local Institution, Edmonton, Alberta, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Paris, France|Local Institution, Dublin 4, Ireland|Local Institution, Dublin 9, Ireland|Local Institution, Galway, Ireland|Local Institution, Candiolo, TO, Italy|Local Institution, Modena, Italy|Local Institution, Padova, Italy|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02060188

Study 55:
  NCT Number:                   NCT03662659
  Title:                        An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Gastric Cancer|Cancer of the Stomach|Esophagogastric Junction
  Interventions:                Biological: BMS-986213|Biological: Nivolumab|Drug: XELOX|Drug: FOLFOX|Drug: SOX
  Outcome Measures:             Objective Response Rate (ORR)|Incidence of Adverse Events (AEs)|Incidence of Serious Adverse Events (SAEs)|Incidence of AEs leading to discontinuation|Incidence of death|Incidence of laboratory abnormalities|Duration of Response (DOR)|Overall survival (OS)|Progression Free Survival (PFS)
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   250
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA224-060|2018-001069-18
  Start Date:                   October 4, 2018
  Primary Completion Date:      December 27, 2020
  Completion Date:              July 1, 2023
  First Posted:                 September 7, 2018
  Results First Posted:         null
  Last Update Posted:           November 6, 2018
  Locations:                    Local Institution, Duarte, California, United States|Local Institution, Fresno, California, United States|Local Institution, La Jolla, California, United States|Local Institution, Los Angeles, California, United States|Local Institution, Los Angeles, California, United States|Local Institution, Newport Beach, California, United States|Local Institution, Orange, California, United States|Local Institution, Aurora, Colorado, United States|Local Institution, New Haven, Connecticut, United States|Local Institution, Hackensack, New Jersey, United States|Local Institution, New York, New York, United States|Local Institution, Bismarck, North Dakota, United States|Local Institution, Fargo, North Dakota, United States|Local Institution, Sioux Falls, South Dakota, United States|Local Institution, Dallas, Texas, United States|Local Institution, Seattle, Washington, United States|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Local Institution, Caba, Argentina|Local Institution, Tucuman, Argentina|Local Institution, Westmead, New South Wales, Australia|Local Institution, Herston, Queensland, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Malvern, Victoria, Australia|St John of God Murdoch Hospital, Murdoch, Western Australia, Australia|Local Institution, Bedford Park, Australia|Local Institution, Bruxelles, Belgium|Local Institution, Leuven, Belgium|Local Institution, Edmonton, Alberta, Canada|Local Institution, Kelowna, British Columbia, Canada|Local Institution, Halifax, Nova Scotia, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Sherbrooke, Quebec, Canada|Local Institution, Trois-Rivieres, Quebec, Canada|Local Institution, Quebec, Canada|Local Institution, Rancagua, L.g.bernardoohiggins, Chile|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Vina Del Mar, Valparaiso, Chile|Local Institution, Brno, Czechia|Local Institution, Olomouc, Czechia|Local Institution, Avignon cedex 9, France|Local Institution, Dijon, France|Local Institution, Paris, France|Local Institution, Rouen Cedex, France|Local Institution, Essen, Germany|Local Institution, Frankfurt, Germany|Local Institution, Hamburg, Germany|Local Institution, Hannover, Germany|Local Institution, Heidelberg, Germany|Local Institution, Mannheim, Germany|Local Institution, Marburg, Germany|Local Institution, San Juan, Puerto Rico|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Nottingham, Nottinghamshire, United Kingdom|Local Institution, Coventry, WEST Midlands, United Kingdom|Local Institution, Lancaster, United Kingdom|Local Institution, Northwood, United Kingdom|Local Institution, Southampton, United Kingdom|Local Institution, Surrey, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03662659

Study 56:
  NCT Number:                   NCT02534506
  Title:                        Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Malignant Tumors
  Interventions:                Drug: Urelumab|Drug: Nivolumab
  Outcome Measures:             Safety of urelumab monotherapy as measured by the dose limiting toxicity (DLT) in subjects with advanced and/or metastatic malignant tumors|Safety of urelumab monotherapy as measured by adverse events (AEs) and serious adverse events (SAEs) in subjects with advanced and/or metastatic malignant tumors|Tolerability of urelumab monotherapy as measured by the DLT in subjects with advanced and/or metastatic malignant tumors|Tolerability of urelumab monotherapy as measured by AEs and SAEs in subjects with advanced and/or metastatic malignant tumors|Safety of urelumab-nivolumab combination therapy as measured by AEs and SAEs in subjects with advanced and/or metastatic malignant tumors|Tolerability of urelumab-nivolumab combination therapy as measured by AEs and SAEs in subjects with advanced and/or metastatic malignant tumors|Cmax (Maximum observed serum concentration) of urelumab when administered alone|Ctrough (Trough observed serum concentration) of urelumab when administered alone|Tmax (Time of maximum observed serum concentration) of urelumab when administered alone|AUC(0-T) [Area under the concentration-time curve from time zero to the last quantifiable concentration] of urelumab when administered alone|AUC(TAU) [Area under the concentration-time curve in one dosing interval] of urelumab when administered alone|AUC(INF) [Area under the concentration-time curve from time zero to infinity and the extrapolated area] of urelumab when administered alone|T-HALF (Elimination half life) of urelumab when administered alone|CLT (Total body clearance) of urelumab when administered alone|Vss (Volume of distribution at steady state) of urelumab when administered alone|AI (Accumulation Index: ratio of AUC(TAU) and Cmax in cycle at steady state to those after the first cycle) of urelumab when administered alone|Cmax of urelumab when co-administered|Coeff of urelumab when co-administered|Ctrough of urelumab and nivolumab when co-administered|Tmax of urelumab and nivolumab when co-administered|AUC(0-T) of urelumab and nivolumab when co-administered|AUC(TAU) of urelumab and nivolumab when co-administered|AUC(INF) of urelumab and nivolumab when co-administered|T-HALF of urelumab when co-administered|CLT of urelumab when co-administered|Vss of urelumab when co-administered|Anti-drug Antibody (ADA) status of the subject in response to Urelumab when administered alone|ADA status of the subject in response to Urelumab and Nivolumab when co-administered|Best overall response (BOR) of urelumab monotherapy|BOR of urelumab and nivolumab combination therapy
  Sponsor/Collaborators:        Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd
  Gender:                       All
  Age:                          20 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   18
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA186-110
  Start Date:                   November 6, 2015
  Primary Completion Date:      June 17, 2019
  Completion Date:              June 18, 2019
  First Posted:                 August 27, 2015
  Results First Posted:         null
  Last Update Posted:           October 3, 2018
  Locations:                    Local Institution, Kobe-shi, Hyogo, Japan
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02534506

Study 57:
  NCT Number:                   NCT02658890
  Title:                        An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Advanced Cancer|Melanoma|Non-Small Cell Lung Cancer
  Interventions:                Drug: BMS-986205|Drug: Nivolumab|Drug: Ipilimumab
  Outcome Measures:             Safety and tolerability of BMS-986205 as measured by a composite of the incidence of adverse events (AEs), serious adverse events (SAEs), AEs leading to discontinuation, deaths, and clinical laboratory test abnormalities.|Safety of BMS-986205 plus nivolumab as measured by a composite of the incidence of adverse events (AEs), serious adverse events (SAEs), AEs leading to discontinuation, deaths, and clinical laboratory test abnormalities.|Safety of BMS-986205 plus both nivolumab and ipilimumab as measured by incidence of adverse events (AEs), serious adverse events (SAEs), AEs leading to discontinuation, deaths, and clinical laboratory test abnormalities.|Anti-tumor activity of BMS 986205 administered in combination with nivolumab as measured by the best overall response (BOR)|Anti-tumor activity of BMS 986205 administered in combination with nivolumab as measured by the duration of response (DOR)|Anti-tumor activity of BMS 986205 administered in combination with nivolumab as measured by progression-free survival rates (PFSRs)|Anti-tumor activity of BMS 986205 administered in combination with both nivolumab and ipilimumab as measured by the best overall response (BOR)|Anti-tumor activity of BMS 986205 administered in combination with both nivolumab and ipilimumab as measured by the duration of response (DOR)|Anti-tumor activity of BMS 986205 administered in combination with both nivolumab and ipilimumab as measured by progression-free survival rates (PFSRs)|Maximum observed plasma concentration (Cmax) of BMS-986205|Time of maximum observed plasma concentration (Tmax) of BMS-986205|Area under the concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of BMS-986205|Area under the concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-T)] of BMS-986205|Area under the concentration-time curve in 1 dosing interval [AUC(TAU)] of BMS-986205|Trough observed plasma concentration at the end of the dosing interval (Ctrough) of BMS-986205|Observed plasma concentration at 24 hours (C24) of BMS-986205|Apparent terminal phase half-life (T-HALF) of BMS-986205|Apparent total body clearance (CLT/F) of BMS-986205|Apparent renal clearance (CLR/F) of BMS-986205|Volume of distribution of terminal phase (Vz/F) of BMS-986205|Apparent volume of distribution at steady state (Vss/F) of BMS-986205|Accumulation index (AI) of BMS-986205|Percent urinary recovery (%UR) of BMS-986205|Percent urinary recovery over 24 hours(%UR24) of BMS-986205|Ratio of metabolite Cmax to parent Cmax, corrected for molecular weight (MR_Cmax) of BMS-986205|Ratio of metabolite AUC(0-T) to parent AUC(0-T), corrected for molecular weight (single dose in clinical pharmacology substudy only) [MR_AUC(0-T)] of BMS-986205|Ratio of metabolite AUC(TAU) to parent AUC(TAU), corrected for molecular weight [MR_AUC(TAU)] of BMS-986205|Ratio of metabolite AUC(INF) to parent AUC(INF), corrected for molecular weight (single dose in clinical pharmacology substudy only) [MR_AUC(INF)] of BMS-986205|Anti-drug antibody (ADA) response to Nivolumab in combination with BMS-986205|Anti-drug antibody (ADA) response to Ipilimumab in combination with BMS-986205
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years to 100 Years   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   907
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA017-003|2015-004914-79
  Start Date:                   February 18, 2016
  Primary Completion Date:      April 29, 2019
  Completion Date:              February 28, 2020
  First Posted:                 January 20, 2016
  Results First Posted:         null
  Last Update Posted:           October 4, 2018
  Locations:                    Local Institution, Phoenix, Arizona, United States|University of Arizona Cancer Center, Tucson, Arizona, United States|UCSD Moores Cancer Center, La Jolla, California, United States|Local Institution, Jacksonville, Florida, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Emory Winship Cancer Institute, Atlanta, Georgia, United States|Northside Hospital, Inc, Atlanta, Georgia, United States|University Of Chicago, Chicago, Illinois, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Lutherville, Maryland, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Local Institution, Rochester, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|New York University, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia|Melanoma Institute Australia, North Sydney, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Local Institution, Clayton, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|Linear Clinical Research Ltd, Nedlands, Western Australia, Australia|Cross Cancer Institute, Edmonton, Alberta, Canada|Local Institution, Vancouver, British Columbia, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Greenfield Park, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Local Institution, Helsinki, Finland|Local Institution, Helsinki, Finland|Local Institution, Lille CEDEX, France|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 5, France|Local Institution, Nantes Cedex 01, France|Local Institution, Paris, France|Local Institution, Toulouse, France|Local Institution, Villejuif, France|Local Institution, Essen, Germany|Local Institution, Heilbronn, Germany|Local Institution, Milano, Italy|Local Institution, Milano, Italy|Local Institution, Milano, Italy|Local Institution, Rozzano MI, Italy|Local Institution, Oslo, Norway|Oddzial Badan Wczesnych Faz, Warszawa, Mazowieckie, Poland|Local Institution, Gdansk, Poland|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Solna, Sweden
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02658890

Study 58:
  NCT Number:                   NCT02913313
  Title:                        An Investigational Immuno-therapy Study to Evaluate the Safety and Effectiveness of Experimental Medication BMS-986207 by Itself and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Broad Solid Tumor
  Interventions:                Drug: BMS-986207|Biological: Nivolumab
  Outcome Measures:             Incidence of adverse events of BMS-986207|Incidence of adverse events of nivolumab (BMS-936558) and BMS-986207 when given in combination|Incidence of clinically significant abnormalities in general laboratory tests of BMS-986207|Incidence of clinically significant abnormalities in general laboratory tests of nivolumab(BMS-936558) and BMS-986207 when given in combination|Best Overall Response (BOR)|Objective Response Rate (ORR)|median Duration of Response (mDOR)|Progression Free Survival Rate (PFSR)|Maximum observed plasma concentration (Cmax) of BMS-986207|Time of maximum observed plasma concentration (Tmax) of BMS-986207|Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-t)] of BMS-986207|Trough observed plasma concentration (Ctrough) of BMS-986207|Area under the concentration-time curve in one dosing interval [AUC(tau)] of BMS-986207|Total body clearance (CLT) of BMS-986207|Observed concentration at the end of a dosing interval (Ctau) of BMS-986207|Effective elimination half-life (T-HALFeff) of BMS-986207|Accumulation Index (AI) of BMS-986207|Average concentration of BMS-986207 over a dosing interval|Immunogenicity measured by the occurrence of anti-drug antibody after the administration of BMS-986207|Immunogenicity measured by the occurrence of anti-drug antibody after the administration of BMS-986207 in combination with nivolumab (BMS-936558)|Tumor infiltrating lymphocyte (TIL) evaluations for BMS-986207|Serum cytokines profiling for BMS-986207|Serum proteome analysis for BMS-986207|Flow-cytometry evaluation of circulating immune cell subsets for BMS-986207|Tumor-specific immune cells for BMS-986207|Tumor infiltrating lymphocyte (TIL) evaluations for BMS-986207 in combination with nivolumab (BMS-936558)|Serum cytokines profiling for BMS-986207 in combination with nivolumab (BMS-936558)|Serum proteome analysis for BMS-986207 in combination with nivolumab(BMS-936558)|Flow-cytometry evaluation of circulating immune cell subsets for BMS-986207 in combination with nivolumab (BMS-936558)|Tumor-specific immune cells for BMS-986207 in combination with nivolumab(BMS-936558)
  Sponsor/Collaborators:        Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   170
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA020-002|2016-002263-34
  Start Date:                   November 29, 2016
  Primary Completion Date:      December 15, 2022
  Completion Date:              December 16, 2022
  First Posted:                 September 23, 2016
  Results First Posted:         null
  Last Update Posted:           October 3, 2018
  Locations:                    John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Columbia University Medical Center (Cumc), New York, New York, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Ottawa, Ontario, Canada|University Health Network - Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Chuo-ku, Tokyo, Japan
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02913313

Study 59:
  NCT Number:                   NCT03444766
  Title:                        Study of Nivolumab for Advanced Cancers in India
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Non-Small Cell Lung Cancer (NSCLC)|Non-Small-Cell Lung Carcinoma|Nonsmall Cell Lung Cancer|Kidney Cancer|Kidney Neoplasms|Renal Cancer|Renal Neoplasms
  Interventions:                Drug: Nivolumab
  Outcome Measures:             Number of Adverse Events (AE)|Number of treatment-related Serious Adverse Events (SAE)|Number of AE that lead to discontinuation from treatment with nivolumab
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 4
  Enrollment:                   100
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-887
  Start Date:                   March 6, 2018
  Primary Completion Date:      December 30, 2018
  Completion Date:              April 29, 2020
  First Posted:                 February 23, 2018
  Results First Posted:         null
  Last Update Posted:           October 10, 2018
  Locations:                    Local Institution, Bangalore, India|Local Institution, Bangalore, India|Local Institution, Bangalore, India|Local Institution, Bengaluru, India|Local Institution, Hyderabad, India|Local Institution, Jaipur, India|Local Institution, Kolkata, India|Local Institution, Kolkata, India|Local Institution, Mumbai, India|Local Institution, New Delhi, India|Local Institution, Vellore, India
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03444766

Study 60:
  NCT Number:                   NCT02574078
  Title:                        A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
  Acronym:                      CheckMate370
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Non-Small Cell Lung Cancer
  Interventions:                Drug: Nivolumab|Drug: Bevacizumab|Drug: Pemetrexed|Other: Best Supportive Care|Drug: nab-Paclitaxel|Drug: Paclitaxel|Drug: Docetaxel|Drug: Gemcitabine|Drug: Erlotinib|Drug: Crizotinib|Drug: Carboplatin
  Outcome Measures:             Group A: Progression-free survival (PFS)|Group A: Overall survival (OS)|Group B: Progression-free survival (PFS)|Group B: Overall survival (OS)|Group C: Progression-free survival (PFS)|Group C: Overall survival (OS)|Group D: Progression-free survival (PFS)|Group E: Number of Incidence of treatment-related Adverse events (AEs) leading to both study drugs discontinuation|Group A: Duration of response (DOR)|Group A: Objective Response rate (ORR)|Group B: Duration of response (DOR)|Group B: Objective Response rate (ORR)|Group C: Duration of response (DOR)|Group C: Objective Response rate (ORR)|Group D: Overall survival(OS)|Group D: Duration of response (DOR)|Group D: Objective Response rate (ORR)|Group E: PFS|Group E: ORR
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   342
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-370
  Start Date:                   November 13, 2015
  Primary Completion Date:      April 15, 2019
  Completion Date:              April 15, 2019
  First Posted:                 October 12, 2015
  Results First Posted:         null
  Last Update Posted:           May 2, 2018
  Locations:                    Alabama Oncology, Birmingham, Alabama, United States|Southern Cancer Center Pc, Mobile, Alabama, United States|Arizona Oncology Assoc, Pc-Hal, Phoenix, Arizona, United States|Northern Arizona Hematology & Oncology Associates, Sedona, Arizona, United States|Arizona Oncol Assoc Dba (Hem Onc Physicians&Extenders) Hope, Tucson, Arizona, United States|Arizona Clinical Research Center, Inc., Tucson, Arizona, United States|Comprehensive Blood And Cancer Center, Bakersfield, California, United States|St. Joseph Heritage Medical Group, Fullerton, California, United States|Scripps Cancer Center, La Jolla, California, United States|UCLA Hematology/Oncology Clinic, Los Angeles, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|Central Coast Med Oncology, Santa Maria, California, United States|Sansum Santa Barbara Medical Foundation Clinic, Solvang, California, United States|St. Mary's Hospital Regional Cancer Center, Grand Junction, Colorado, United States|Rocky Mountain Cancer Centers, Lakewood, Colorado, United States|Eastern Ct Hem Onc Assoc, Norwich, Connecticut, United States|Stamford Hospital, Stamford, Connecticut, United States|Va Ct Healthcare System, West Haven, Connecticut, United States|Florida Cancer Specialists S., Fort Myers, Florida, United States|University of Florida at Shands, Gainesville, Florida, United States|Memorial Cancer Institute, Hollywood, Florida, United States|Baptist Health Medical Group Oncology, Miami, Florida, United States|Ocala Oncology Center, Ocala, Florida, United States|Hematology Oncology Associates Of The Treasure Coast, Port Saint Lucie, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Tallahassee Memorial Cancer Center, Tallahassee, Florida, United States|Florida Cancer Affiliates, Trinity, Florida, United States|University Cancer Blood Ctr, Athens, Georgia, United States|Cancer Treatment Centers Of America, Newnan, Georgia, United States|Summit Cancer Care, Savannah, Georgia, United States|Lewis Hall Singletary Oncology Center, Thomasville, Georgia, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Community Clinical Research Center, Anderson, Indiana, United States|Ft. Wayne Med Onco-Hema Inc, Fort Wayne, Indiana, United States|Cotton-O-Neil Clinical Research Center, Topeka, Kansas, United States|West KY Hematology Oncology Group PSC, Paducah, Kentucky, United States|Christus St. Francis Cabrini Cancer Center, Alexandria, Louisiana, United States|East Jefferson General Hospital, Metairie, Louisiana, United States|New England Cancer Specialists, Scarborough, Maine, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|University Of Maryland, Baltimore, Maryland, United States|Sinai Hospital Of Baltimore, Baltimore, Maryland, United States|Center For Cancer And Blood Disorders, Bethesda, Maryland, United States|Maryland Oncology Hematology, P.A., Columbia, Maryland, United States|Bay Hematology Oncology, Easton, Maryland, United States|Cancer & Hematology Centers Of Western Michigan, Grand Rapids, Michigan, United States|Minnesota Oncology Hematology, P.A., Edina, Minnesota, United States|Forrest General Cancer Center, Hattiesburg, Mississippi, United States|Jackson Oncology Associates, Pllc, Jackson, Mississippi, United States|St. Louis Cancer Care, Llp, Bridgeton, Missouri, United States|Saint Vincent Frontier Cancer Center, Billings, Montana, United States|Southeast Nebraska Cancer Center, Lincoln, Nebraska, United States|Nebraska Cancer Specialists, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Hunterdon Medical Center, Flemington, New Jersey, United States|Summit Medical Group, Morristown, New Jersey, United States|Atlantic Health System, Summit, New Jersey, United States|Morristown Medical Center, Summit, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|New York Oncology Hematology, Pc, Albany, New York, United States|Glens Falls Hospital, Glens Falls, New York, United States|Broome Oncology, Johnson City, New York, United States|Northern Westchester Hospital, Mount Kisco, New York, United States|Columbia University Medical Center (Cumc), New York, New York, United States|Hematology-Oncology Associates Of Rockland, Nyack, New York, United States|White Plains Hospital, White Plains, New York, United States|Cone Health Cancer Center, Greensboro, North Carolina, United States|Moses Cone Health System, Greensboro, North Carolina, United States|Randolph Cancer Center, Greensboro, North Carolina, United States|First Health Of The Carolinas, Pinehurst, North Carolina, United States|W.G. Bill Hefner VA Medical Center, Salisbury, North Carolina, United States|Cancer Care Center, Bismarck, North Dakota, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Mid Ohio Oncology Hematology, Columbus, Ohio, United States|Oklahoma Cancer Specialists and Research Institute, LLC, Tulsa, Oklahoma, United States|Oncology Associates Of Oregon, Pc, Eugene, Oregon, United States|Hematology Oncology Associates, Medford, Oregon, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|St. Luke's University Hospital Bethlehem, Bethlehem, Pennsylvania, United States|Erie Regional Cancer Center, Erie, Pennsylvania, United States|Abington Hematology Oncology Associates, Inc, Willow Grove, Pennsylvania, United States|Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina, United States|Greenville Health System, Greenville, South Carolina, United States|Sanford Research, Sioux Falls, South Dakota, United States|Sanford Health, Sioux Falls, South Dakota, United States|Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States|The Jones Clinic, Pc, Germantown, Tennessee, United States|West Cancer Center, Germantown, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Texas Oncology-Abilene, Abilene, Texas, United States|Texas Oncology - Amarillo, Amarillo, Texas, United States|Texas Oncology-Arlington North, Arlington, Texas, United States|Texas Oncology-Beaumont, Beaumont, Texas, United States|Texas Oncology, Bedford, Texas, United States|Texas Oncology/Methodist Charlton Cancer Ctr, Dallas, Texas, United States|Texas Oncology, Dallas, Texas, United States|Texas Oncology, Dallas, Texas, United States|Texas Oncology, P.A., Dallas, Texas, United States|Texas Oncology, Denton, Texas, United States|Texas Oncology, El Paso, Texas, United States|Texas Oncology, Flower Mound, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|Texas Oncology, Fort Worth, Texas, United States|The Center For Cancer And Blood Disorders, Fort Worth, Texas, United States|Texas Oncology, Houston, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Investigational Products Ctr, Irving, Texas, United States|Texas Cancer Center Of Mesquite, Mesquite, Texas, United States|Texas Oncology, Pa, Midland, Texas, United States|Texas Oncology, New Braunfels, Texas, United States|Texas Oncology, Paris, Texas, United States|Texas Oncology-Plano East, Plano, Texas, United States|Texas Oncology Plano West Cancer Center, Plano, Texas, United States|Cancer Centers of South Texas, San Antonio, Texas, United States|Texas Cancer Center - Sherman, Sherman, Texas, United States|Texas Oncology Cancer Center - Sugar Land, Sugar Land, Texas, United States|Texas Oncology-Tyler, Tyler, Texas, United States|Texas Oncology Cancer Care And Research Center, Waco, Texas, United States|Texas Oncology, P.A., Webster, Texas, United States|Texas Oncology, Weslaco, Texas, United States|Texas Oncology-Wichita Falls, Wichita Falls, Texas, United States|Oncology & Hematology Associates Of Southwest Virginia, Inc., Blacksburg, Virginia, United States|Virginia Cancer Specialists, Pc, Fairfax, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Shenandoah Oncology, Winchester, Virginia, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Cancer Care Northwest, Spokane Valley, Washington, United States|Northwest Cancer Specialists, Pc, Vancouver, Washington, United States|Yakima Valley Memorial Hospital/North Star Lodge, Yakima, Washington, United States|Edwards Comprehensive Cancer Center, Huntington, West Virginia, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02574078

Study 61:
  NCT Number:                   NCT03195478
  Title:                        Study of Nivolumab in Combination With Ipilimumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Solid Tumor
  Interventions:                Drug: Nivolumab|Drug: Ipilimumab
  Outcome Measures:             Composite of Number and percent of all treated subjects that experience Adverse Events (AEs)|Composite of Number and percent of all treated subjects that experience serious adverse events (SAEs)|Composite of Number and percent of all treated subjects that experience AEs leading to discontinuation|Composite of Number and percent of all treated subjects that experience AEs leading to death|Composite of Number and percent of subjects with clinical laboratory abnormalities|Maximum observed serum concentration (Cmax)|Time of maximum observed serum concentration (Tmax)|Area under the plasma concentration-time curve from time zero to the last time of the last quantifiable concentration (AUC[0-T])|Area under the concentration-time curve in one dosing interval (AUC[TAU])|Serum concentration achieved at the end of study drug infusion (Ceoinf)|Trough observed serum concentration at the end of dosing interval (Ctrough)|Concentration at the end of dosing interval (Ctau)|Anti-drug Antibody (ADA)|Best overall response (BOR) by investigator using Response Evaluation Criteria in Solid Tumor (RECIST v1.1)|Objective response rate (ORR)|Progression Free Survival Rate (PFSR) at 6 months
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   27
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-672
  Start Date:                   July 27, 2017
  Primary Completion Date:      November 26, 2019
  Completion Date:              June 25, 2020
  First Posted:                 June 22, 2017
  Results First Posted:         null
  Last Update Posted:           July 25, 2018
  Locations:                    Local Institution, Beijing, China
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03195478

Study 62:
  NCT Number:                   NCT02998528
  Title:                        A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)
  Acronym:                      CheckMate 816
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Non Small Cell Lung Cancer
  Interventions:                Biological: Nivolumab|Biological: ipilimumab|Drug: cisplatin|Drug: vinorelbine|Drug: gemcitabine|Drug: docetaxel|Drug: pemetrexed|Drug: carboplatin
  Outcome Measures:             Event-Free Survival|Pathological Complete Response|Overall survival (OS)|Major pathological response (MPR)
  Sponsor/Collaborators:        Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   642
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-816|2016-003536-21
  Start Date:                   January 13, 2017
  Primary Completion Date:      May 8, 2023
  Completion Date:              November 8, 2028
  First Posted:                 December 20, 2016
  Results First Posted:         null
  Last Update Posted:           October 3, 2018
  Locations:                    Arizona Oncology Assoc, Pc-Hal, Phoenix, Arizona, United States|HOPE Cancer Center of East Texas, Phoenix, Arizona, United States|Local Institution, Phoenix, Arizona, United States|Los Angeles Hematology/Oncology Medical Group, Los Angeles, California, United States|Local Institution, Los Angeles, California, United States|Local Institution, Sacramento, California, United States|Local Institution, Santa Barbara, California, United States|Local Institution, Santa Rosa, California, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|Cancer Center Of Central Connecticut, Plainville, Connecticut, United States|University of Miami, Deerfield Beach, Florida, United States|Local Institution, Hollywood, Florida, United States|Local Institution, Jacksonville, Florida, United States|Cancer Institute Of Florida, Orlando, Florida, United States|Local Institution, Orlando, Florida, United States|Indian River Medical Center, Vero Beach, Florida, United States|Local Institution, Athens, Georgia, United States|Local Institution, Fort Gordon, Georgia, United States|Northwest Georgia Oncology Center, P.C., Marietta, Georgia, United States|Northwestern Medicine, Chicago, Illinois, United States|University Of Chicago Medical Center, Chicago, Illinois, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Local Institution, Tinley Park, Illinois, United States|Local Institution, Fort Wayne, Indiana, United States|Local Institution, Wichita, Kansas, United States|Local Institution, Elizabethtown, Kentucky, United States|Local Institution, Lexington, Kentucky, United States|Local Institution, Louisville, Kentucky, United States|University Medical Center New Orleans, New Orleans, Louisiana, United States|Medstar Franklin Sqaure Medical Center, Baltimore, Maryland, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Local Institution, Fairhaven, Massachusetts, United States|Local Institution, Worcester, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Local Institution, Columbia, Missouri, United States|St Vincent Frontier Cancer Center, Billings, Montana, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|The Cancer Center At Hackensack University Medical Center, Hackensack, New Jersey, United States|Valley Hospital Luckow Pavili, Westwood, New Jersey, United States|New York Oncology Hematology, Pc, Albany, New York, United States|Laura & Isaac Perlmutter Cancer Center, New York, New York, United States|Local Institution, New York, New York, United States|Local Institution, High Point, North Carolina, United States|Christ Hospital, Cincinnati, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Genesis Health Care System, Zanesville, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Local Institution, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Local Institution, Pittsburgh, Pennsylvania, United States|Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|Bon Secours-St Francis Hosp, Greenville, South Carolina, United States|Tennessee Oncology, Pc, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Oncology, PA - South Austin Cancer Center, Austin, Texas, United States|Texas Oncology, Bedford, Texas, United States|WBAMC Oncology Department, El Paso, Texas, United States|Local Institution, Fort Worth, Texas, United States|Local Institution, Houston, Texas, United States|Millenium Oncology, Houston, Texas, United States|Local Institution, Lubbock, Texas, United States|Texas Cancer Center - Sherman, Sherman, Texas, United States|Texas Oncology, Waco, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|Local Institution, Saint George, Utah, United States|Southwest Regional Cancer Clinic, Saint George, Utah, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|University of Vermont Cancer Center, Burlington, Vermont, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Local Institution, Fredericksburg, Virginia, United States|Instituto Medico Especializado Alexander Fleming, Capital Federal, Buenos Aires, Argentina|Hospital Italiano De Buenos Aires, Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina|Local Institution, Brasilia, Distrito Federal, Brazil|Local Institution, Belo Horizonte, MG, Brazil|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Ijui, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|CISSS de l'Outaouais, Gatineau, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Mcgill University Health Center, Montreal, Quebec, Canada|Local Institution, St. Jerome, Quebec, Canada|Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-Centre-du-Quebec, Trois-Rivieres, Quebec, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada|Local Institution, Beijing, Beijing, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Nanchang, Jiangxi, China|Local Institution, Xi'an, Shan3xi, China|Local Institution, Tianjin, Tianjin, China|Local Institution, Shanghai, China|Local Institution, Marseille Cedex 20, France|Local Institution, Paris, France|Local Institution, Paris, France|Local Institution, Pierre Benite, France|Local Institution, Rennes Cedex 9, France|Local Institution, Strasbourg Cedex, France|Local Institution, Toulouse, France|Local Institution, Tours Cedex, France|Sotiria General Hospital, Athens, Greece|Interbalkan European Medical Center, Thessaloniki, Greece|Local Institution, Budapest, Hungary|Local Institution, Szekesfehervar, Hungary|Local Institution, Bari, Italy|Local Institution, Genova, Italy|Local Institution, Perugia, Italy|Local Institution, Ravenna, Italy|Local Institution, Roma, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Nagoya, Aichi, Japan|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Kitakyushu-shi, Fukuoka, Japan|Local Institution, Fukushima-shi, Fukushima, Japan|Local Institution, Hiroshima-Shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Osaka-sayama, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Sakai-shi, Osaka, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Tokyo, Japan|Local Institution, Hwasun-gun, Jeonnam, Korea, Republic of|Local Institution, Busan, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Institute Of Oncology "Prof.Dr.Alexandru Trestioreanu" Bucha, Bucharest, Romania|Sf. Nectarie Oncology Center, Craiova, Romania|Prof. Dr. Ion Chiricuta Institute Of Oncology Day Care Dep, Romania, Romania|Local Institution, Parktown, Johannesburg, Gauteng, South Africa|Local Institution, Cape Town, Western CAPE, South Africa|H. Univ. Vall dHebron, Barcelona, Spain|Hosp Univer 12 De Octubre, Madrid, Spain|Hosp. Univ. Puerta De Hierro, Majadahonda - Madrid, Spain|Local Institution, Taichung, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, ?stanbul, Turkey|Local Institution, Adana, Turkey|Local Institution, Ankara, Turkey|Local Institution, Ankara, Turkey|Local Institution, Istanbul, Turkey
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02998528

Study 63:
  NCT Number:                   NCT02593786
  Title:                        A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors
  Acronym:                      CheckMate 077
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Solid Tumors
  Interventions:                Drug: Nivolumab
  Outcome Measures:             Safety measured by number of subjects who experience AEs, SAEs, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs, laboratory tests and physical examinations|Tolerability measured by number of subjects who experience AEs, SAEs, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs, laboratory tests and physical examinations|Objective response rate (ORR)
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   56
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-077
  Start Date:                   December 25, 2015
  Primary Completion Date:      October 8, 2019
  Completion Date:              October 8, 2019
  First Posted:                 November 2, 2015
  Results First Posted:         null
  Last Update Posted:           October 4, 2018
  Locations:                    Local Institution, Guangzhou, Guangdong, China
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02593786

Study 64:
  NCT Number:                   NCT03668119
  Title:                        A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
  Acronym:                      CheckMate 848
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Pan Tumor
  Interventions:                Biological: Nivolumab|Biological: Ipilimumab
  Outcome Measures:             Objective Response Rate (ORR)|Duration of response (DOR)|ORR|TTR|Clinical benefit rate (CBR)|Overall survival (OS)|PFS|Incidence of Adverse Events (AEs)|Incidence of Serious Adverse Events (SAEs)|Incidence of laboratory abnormalities|Incidence of anti-drug antibody (ADA)
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          12 Years and older   (Child, Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   159
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-848|2016-002898-35
  Start Date:                   October 29, 2018
  Primary Completion Date:      March 14, 2021
  Completion Date:              September 8, 2023
  First Posted:                 September 12, 2018
  Results First Posted:         null
  Last Update Posted:           November 20, 2018
  Locations:                    Local Institution, Birmingham, Alabama, United States|Local Institution, Bakersfield, California, United States|Local Institution, Los Angeles, California, United States|Local Institution, Orange, California, United States|Local Institution, Santa Monica, California, United States|Local Institution, Truckee, California, United States|Local Institution, Lakewood, Colorado, United States|Local Institution, Hollywood, Florida, United States|Local Institution, Atlanta, Georgia, United States|Local Institution, Chicago, Illinois, United States|Local Institution, Niles, Illinois, United States|Local Institution, Fort Wayne, Indiana, United States|Local Institution, Minneapolis, Minnesota, United States|Local Institution, Rochester, Minnesota, United States|Local Institution, Saint Louis, Missouri, United States|Local Institution, Livingston, New Jersey, United States|Local Institution, Johnson City, New York, United States|Local Institution, Durham, North Carolina, United States|Local Institution, Columbus, Ohio, United States|Local Institution, Portland, Oregon, United States|Local Institution, Philadelphia, Pennsylvania, United States|Local Institution, Germantown, Tennessee, United States|Local Institution, Austin, Texas, United States|Local Institution, Dallas, Texas, United States|Local Institution, Houston, Texas, United States|Local Institution, Houston, Texas, United States|Local Institution, Tyler, Texas, United States|Local Institution, Charlottesville, Virginia, United States|Local Institution, Madison, Wisconsin, United States|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Ciudad Autonoma Beunos Aires, Buenos Aires, Argentina|Local Institution, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Local Institution, Viedma, RIO Negro, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Caba, Argentina|Local Institution, Caba, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Darlinghurst, New South Wales, Australia|Local Institution, St Leonards, New South Wales, Australia|Local Institution, Sydney, New South Wales, Australia|Local Institution, Woolloongabba, Queensland, Australia|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Leuven, Belgium|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Passo Fundo, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Jose Do Rio Preto, SAO Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Edmonton, Alberta, Canada|Local Institution, Hamilton, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Santiago de Chile, Metropolitana, Chile|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Vina Del Mar, Valparaiso, Chile|Local Institution, Copenhagen, Denmark|Local Institution, Herlev, Denmark|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 9, France|Local Institution, Paris Cedex 5, France|Local Institution, Toulouse Cedex 9, France|Local Institution, Villejuif, France|Local Institution, Berlin, Germany|Local Institution, Bonn, Germany|Local Institution, Dresden, Germany|Local Institution, Essen, Germany|Local Institution, Heidelberg, Germany|Local Institution, Wuerzburg, Germany|Local Institution, Amsterdam, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Surquillo, Lima, Peru|Local Institution, Arequipa, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Warszawa, Mazowieckie, Poland|Local Institution, Gdansk, Poland|Local Institution, San Juan, Puerto Rico|Local Institution, Bucuresti, Romania|Local Institution, Cluj-Napoca, Romania|Local Institution, Craiova, Romania|Local Institution, Floresti, Romania|Local Institution, Timisoara, Timis, Romania|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Pamplona, Spain|Local Institution, London, Greater London, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Preston, United Kingdom|Local Institution, Surrey, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03668119

Study 65:
  NCT Number:                   NCT02598960
  Title:                        An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Solid Tumors
  Interventions:                Drug: BMS-986156|Drug: Nivolumab
  Outcome Measures:             Safety of BMS-986156 based on number of incidence of adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation and deaths in addition to clinical laboratory test abnormalities|Objective response rate (ORR)|Progression free survival rate (PFSR)|Duration of response|Maximum observed concentration (Cmax) of BMS-986156|Time of maximum observed concentration (Tmax) of BMS-986156|Area under the concentration-time curve in one dosing interval (AUC [TAU]) of BMS-986156|Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T) of BMS-986156|Anti-drug antibody (ADA) response to BMS-986156|Anti-drug antibody response to BMS-986156 and Nivolumab
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   310
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA009-002|2015-002505-11
  Start Date:                   October 9, 2015
  Primary Completion Date:      January 30, 2020
  Completion Date:              May 28, 2020
  First Posted:                 November 6, 2015
  Results First Posted:         null
  Last Update Posted:           November 12, 2018
  Locations:                    University Of Alabama At Birmingham, Birmingham, Alabama, United States|UCSD Moores Cancer Center, La Jolla, California, United States|Emory University, Atlanta, Georgia, United States|The Ohio State University, Columbus, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|The West Clinic, P.C., Germantown, Tennessee, United States|Local Institution, Liverpool, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Brisbane, Queensland, Australia|Local Institution, Nedlands, Western Australia, Australia|Universitair Ziekenhuis Gent, Gent, Belgium|Local Institution, Edmonton, Alberta, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Paris Cedex 5, France|Centre Claudius Regaud, Toulouse Cedex 9, France|Institut Gustave Roussy, Vlllejuif, France|Local Institution, Bonn, Germany|Local Institution, Freiburg, Germany|Local Institution, Wuerzburg, Germany|IRCCS Istituto Nazionale Tumori Milano, Milano, Italy|Istituto Europeo Di Oncologia, Milan, Italy|Local Institution, Amsterdam, Netherlands|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Cantonal Hospital St. Gallen, St. Gallen, Switzerland|Local Institution, Zurich, Switzerland
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02598960

Study 66:
  NCT Number:                   NCT00441337
  Title:                        A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
  Acronym:                      MDX1106-01
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Carcinoma, Non-Small-Cell Lung|Colorectal Cancer|Malignant Melanoma|Renal Cancer|Prostate Cancer
  Interventions:                Biological: MDX-1106
  Outcome Measures:             Number of Participants With Severe Adverse Events (AEs), Serious Adverse Events (SAEs), Drug-Related AEs, Deaths, Discontinuation of Study Drug Due to AE, Dose-Limiting Toxicity (DLT) AE and Immune-related AEs (irAEs) in Safety Population|Geometric Mean Maximum Serum Concentration (Cmax) Observed Post-Single Dose|Median Time at Which the Maximum Serum Concentration Occurred (Tmax) Post-Single Dose|Geometric Mean Area Under the Curve (AUC) From Time of Dosing to Time of Last Observation (0-T) and Extrapolated to Infinity (INF) Observed Post-Single Dose|Mean Elimination Half-life (T-HALF) Post-Single Dose|Geometric Mean Total Body Clearance of Drug From Serum (CLT) Post-Single Dose|Mean Volume of Distribution (Vz) Post-Single Dose|Percent of Participants With Best Overall Response Rate in Safety Population and in Tumor Evaluable Population|Percent of Participants With Prostate-Specific Antigen (PSA) Response After the First Dose by Day 85 In Participants With Hormone-Refractory Prostate Adenocarcinoma (HRPC)|Number of Participants With Best Overall Response (BOR) by Category in Safety Population|Percentage of Participants With Disease Control and Major Durable Disease Control|Median Time to Tumor Response and Duration of Tumor Response|Time to Tumor Progression and Tumor Progression Free Survival|Median Time to PSA Progression in Days and Median PSA Progression Free Survival in Days in PSA Evaluable Population|Mean Change From Baseline in PSA Relative Velocity at Days 29, 57, and 85 With Cycle 1 in PSA Evaluable Population|Mean Change From Baseline in Electrocardiogram Parameters PR, QRS and QT in Safety Population|Mean Diastolic Blood Pressure at Baseline and Post-Infusion Day 1 (Cycle 1) in 0.3 mg Cohort - Safety Population|Mean Systolic Blood Pressure at Baseline and Post-Infusion Day 1 (Cycle 1) in 0.3 mg Cohort - Safety Population|Mean Diastolic Blood Pressure at Baseline and Post-Infusion Day 1 (Cycle 1) in 1mg, 3mg, and 10 mg Cohorts - Safety Population|Mean Systolic Blood Pressure at Baseline and Post-Infusion Day 1 (Cycle 1) in in 1mg, 3mg, and 10 mg Cohorts - Safety Population
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   39
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-001 ST|MDX1106-01
  Start Date:                   August 2006
  Primary Completion Date:      November 2009
  Completion Date:              November 2009
  First Posted:                 February 28, 2007
  Results First Posted:         February 20, 2015
  Last Update Posted:           February 20, 2015
  Locations:                    Johns Hopkins Unv., School of Medicine, Baltimore, Maryland, United States|Henry Ford Health System, Detroit, Michigan, United States|Washington University School of Medicine - Barnes Jewish Hospital, St. Louis, Missouri, United States|Carolina BioOncology Institute, PLLC, Huntersville, North Carolina, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00441337

Study 67:
  NCT Number:                   NCT03459222
  Title:                        An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Advanced Cancer
  Interventions:                Biological: Relatlimab|Biological: Nivolumab|Drug: BMS-986205|Biological: Ipilimumab
  Outcome Measures:             Number of clinical laboratory test abnormalities|Number of Adverse Events (AEs)|Number of Serious Adverse Events (SAEs)|Number of AEs meeting protocol defined dose-limiting toxicity (DLT) criteria|Number of AEs leading to discontinuation and deaths|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Median Duration of Response (mDOR)|Progression Free Survival (PFS)
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   230
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA224-048|2018-000058-22
  Start Date:                   May 25, 2018
  Primary Completion Date:      April 4, 2022
  Completion Date:              May 16, 2022
  First Posted:                 March 8, 2018
  Results First Posted:         null
  Last Update Posted:           November 20, 2018
  Locations:                    City of Hope National Medical Center, Duarte, California, United States|University Of Colorado, Aurora, Colorado, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|The West Clinic, P.C., Germantown, Tennessee, United States|Local Institution, Seattle, Washington, United States|Local Institution, North Sydney, New South Wales, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Marseille Cedex 5, France|Local Institution, Toulouse, France|Local Institution, Villejuif, France|Local Institution, Lausanne, Switzerland|Local Institution, Zurich, Switzerland|Local Institution, Newcastle Upon Tyne, United Kingdom|Local Institution, Oxford, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03459222

Study 68:
  NCT Number:                   NCT02341625
  Title:                        A Study of BMS-986148 in Patients With Select Advanced Solid Tumors
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Advanced Cancer
  Interventions:                Drug: BMS-986148|Biological: Nivolumab
  Outcome Measures:             Safety is measured by incidence of adverse events (AEs) at its worst grade, serious adverse events (SAEs) at its worst grade, adverse events leading to discontinuations, deaths, frequency of laboratory test toxicity grade shifting from baseline|Maximum observed serum or plasma concentration (Cmax) of BMS-986148|Time of maximum observed serum or plasma concentration (Tmax) of BMS-986148|Concentration at the end of a dosing interval (Ctau) of BMS-986148|Trough observed serum or plasma concentration (this includes pre-dose concentrations and Ctau concentrations) (Ctrough) of BMS-986148|Area under the concentration-time curve from time 0 to time t (AUC(0-t)) of BMS-986148 (t= t last)|Area under the concentration-time curve in one dosing interval (AUC(TAU)) of BMS-986148|Terminal serum or plasma half-life (T-Half) of BMS-986148|Total body clearance calculated as Dose divided by AUC(TAU) (CLT) of BMS-986148|Volume of distribution at steady-state (Vss) of BMS-986148|Volume of distribution of terminal phase (Vz) of BMS-986148|Accumulation index; ratio of Cmax at steady-state to Cmax after the first dose (AI_Cmax) of BMS-986148|Accumulation index; ratio of Ctau at steady-state to Ctau after the first dose (AI_Ctau) of BMS-986148|Average concentration over a dosing interval calculated by dividing AUC(TAU) by tau (Cavg) of BMS-986148|Best overall response (BOR) of BMS-986148|Objective Response rate (ORR)|Duration of response|Progression free survival|Progression free survival rate|Overall survival|Overall survival rate|Changes in QTcF of BMS-986148|Immunogenicity of BMS-986148
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   407
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA008-002|2014-002485-70
  Start Date:                   June 17, 2015
  Primary Completion Date:      June 14, 2021
  Completion Date:              August 29, 2022
  First Posted:                 January 19, 2015
  Results First Posted:         null
  Last Update Posted:           October 3, 2018
  Locations:                    UC San Diego Moores Cancer Ctr, La Jolla, California, United States|Duke University Medical Center, Durham, North Carolina, United States|Local Institution, Liverpool, New South Wales, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Clayton, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Gent, EAST Flanders, Belgium|Local Institution, Bruxelles, Belgium|Cross Cancer Institute, Edmonton, Alberta, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Local Institution, Milano, Italy|Istituto Europeo Di Oncologia, Milan, Italy|Istituto Clinico Humanitas, Rozzano (milano), Italy|Local Institution, Amsterdam, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Southampton, Hampshire, United Kingdom|The Beatson West Of Scotland Cancer Centre, Glasgow, Lanarkshire, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02341625

Study 69:
  NCT Number:                   NCT02632409
  Title:                        An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer
  Acronym:                      CheckMate 274
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Various Advanced Cancer
  Interventions:                Biological: Nivolumab|Other: Placebo
  Outcome Measures:             Disease free survival (DFS)|Non-Urothelial track recurrence free survival (NUTRFS)|Disease specific survival (DSS)|Overall survival (OS)
  Sponsor/Collaborators:        Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   640
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  Other IDs:                    CA209-274|2014-003626-40
  Start Date:                   February 11, 2016
  Primary Completion Date:      April 30, 2020
  Completion Date:              May 1, 2020
  First Posted:                 December 16, 2015
  Results First Posted:         null
  Last Update Posted:           November 6, 2018
  Locations:                    Alaska Urological Institute dba Alaska Clinical Research Center, Anchorage, Alaska, United States|Arizona Oncology Associates, Tucson, Arizona, United States|University Of California San Francisco-Fresno, Fresno, California, United States|University Of California - Davis, Sacramento, California, United States|California Pacific Medical Center, San Francisco, California, United States|Rocky Mountain Cancer Centers, Lakewood, Colorado, United States|University Of Florida, Gainesville, Florida, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Loyola University Medical Center, Maywood, Illinois, United States|Ft. Wayne Med Onco-Hema Inc, Fort Wayne, Indiana, United States|Tulane University, New Orleans, Louisiana, United States|Cancer & Hematology Centers Of Western Michigan, Grand Rapids, Michigan, United States|Fairview Health Services, Burnsville, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|GU Research Network, LLC, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|New York Oncology Hematology, P.C., Albany, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Winthrop University Hospital, Mineola, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University Of North Carolina, Chapel Hill, North Carolina, United States|Providence Portland Medical Center, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|Northwest Cancer Specialists, Pc, Tualatin, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Cancer Institute Cancer Services, Pittsburgh, Pennsylvania, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States|Erlanger Oncology & Hematology - Univ. of TN, Chattanooga, Tennessee, United States|Local Institution, Virginia Beach, Virginia, United States|COIBA, Berazategui, Buenos Aires, Argentina|Instituto Medico Especializado Alexander Fleming, Capital Federal, Buenos Aires, Argentina|Hospital Italiano De Buenos Aires, Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina|Hospital Britanico De Buenos Aires, Ciudad Autonoma de BuenosAires, Buenos Aires, Argentina|Clinica Viedma S.A., Viedma, RIO Negro, Argentina|Centro Para La Atencion Integral Del Paciente Oncologico, San Miguel De Tucuman, Tucuman, Argentina|Liverpool Hospital, Liverpool, New South Wales, Australia|Royal North Shore Hospital, St. Leonards, New South Wales, Australia|Calvary Mater Newcastle, Waratah, New South Wales, Australia|Local Institution, Frankston, Victoria, Australia|St John of God Murdoch Hospital, Perth, Western Australia, Australia|Lyell McEwin Hospital, Elizabeth Vale, Australia|Krankenhaus Der Barmherzigen Schwestern, Linz, Austria|Salzburger Landeskliniken Lkh, Salzburg, Austria|Akh Wien, Vienna, Austria|AKH Allgemeines Krankenhaus Wien, Wien, Austria|Local Institution, Hasselt, Belgium|Chu De Liege, Liege, Belgium|Local Institution, Roeselare, Belgium|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, S?o Paulo, SAO Paulo, Brazil|Local Institution, Rio De Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Edmonton, Alberta, Canada|Mcgill University Health Center - Royal Victoria Hospital, Montreal, Quebec, Canada|Local Institution, Sherbrooke, Quebec, Canada|Centre Hospitalier De L'Universite De Montreal, Montreal, Canada|Fundacion Arturo Lopez Perez, Santiago, Metropolitana, Chile|Instituto Oncologico Clinica Renaca, Vina Del Mar, Valparaiso, Chile|Clinica Alemana de Temuco S.A., Temuco, Chile|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Chongqing, Chongqing, China|Local Institution, Fuzhou, Fujian, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Nanning, Guangxi, China|Local Institution, Wuhan, Hubei, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanchang, Jiangxi, China|Local Institution, Xi'an, Shan3xi, China|Local Institution, Yantai, Shandong, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Wenzhou, Zhejiang, China|Local Institution, Shanghai, China|Administradora Del Country S.A. - Clinica Del Country, Bogota, Colombia|Fundacion Oftalmologica De Santander - Foscal, Floridablanca, Colombia|Hospital Pablo Tobon Uribe, Medellin, Colombia|Local Institution, Aalborg, Denmark|Local Institution, Aarhus C, Denmark|Local Institution, Copenhagen, Denmark|Local Institution, La Roche sur Yon, France|Local Institution, Marseille Cedex 9, France|Local Institution, Paris, France|Local Institution, Strasbourg, France|Local Institution, Suresnes, France|Local Institution, Villejuif, France|Zeisigwaldkliniken Bethanien, Chemnitz, Germany|Klinik Essen-Mitte, Essen, Germany|Univ Klinikum Der Ernst-Moritz-Arndt-Univ Greifswald, Greifswald, Germany|Uni Hamburg-Eppendorf, Hamburg, Germany|Local Institution, Heidelberg, Germany|Universitaetsklinikum Jena, Jena, Germany|Universitatsklinikum Giessen Und Marburg, Marburg, Germany|Universitaetsklinikum Muenster, Muenster, Germany|Klinikum rechts der Isar der Technischen Universitat Munchen, Munich, Germany|Local Institution, Nuernberg, Germany|Klinikum Der Universitaet Regensburg, Regensburg, Germany|Klinikum Stuttgart, Stuttgart, Germany|Alexandra General Hospital, Athens, Greece|Theagenio Hospital, Thessaloniki, Greece|Local Institution, Wilton, Cork, Ireland|Adelaide And Meath Hospital, Dublin, Ireland|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Ramat Gan, Israel|Local Institution, Zerifin, Israel|Ospedale S. Donato - Usl 8, Arezzo, Italy|ASST Papa Giovanni XXIII, Bergamo, Italy|IRCCS Istituto Nazionale Tumori Milano, Milano, Italy|Local Institution, Pavia, Italy|Azienda Ospedaliera Universitaria Pisana, Pisa, Italy|Arcispedale S. Maria Nuova - A.O. Reggio Emilia, Reggio Emilia, Italy|Istituto Regina Elena, Roma, Italy|Azienda Ospedaliera S. Camillo Forlanini, Roma, Italy|AOUS - Policlinico S.Maria Alle Scotte, Siena, Italy|Local Institution, Akita-shi, Akita, Japan|Local Institution, Hirosaki-shi, Aomori, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Sapporo-shi, Hokai-do, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Tsukuba-shi, Ibaraki, Japan|Local Institution, Nagasaki-shi, Nagasaki, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Higashinari-ku, Osaka, Japan|Local Institution, Osaka-Sayama-Shi, Osaka, Japan|Local Institution, Hamamatsu-shi, Shizuoka, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Shinjuku-Ku, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Seongnam-si, Gyeonggi-do, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Df, Distrito Federal, Mexico|Instituto Nacional De Cancerologia, Mexico City, Distrito Federal, Mexico|Arke Estudios Clinicos Sa De Cv, Mexico, Distrito Federal, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, Nuevo LEON, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Maastrict, Netherlands|Local Institution, Nijmegen, Netherlands|Local Institution, Arequipa, Peru|Clinica Internacional sede San Borja, Lima, Peru|Klinika Onkologii i Radioterapii, Gdansk, Poland|Regionalny Osrodek Onkologiczny, Lodz, Poland|Mazovia Szpital, Warsaw, Poland|Local Institution, Wroclaw, Poland|Oddzial Onkologii Klinicznej, Wroclaw, Poland|Local Institution, Bucuresti, Romania|Local Institution, Craiova, Romania|Local Institution, Floresti, Romania|Local Institution, Timisoara, Timis, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Hospital Universitari Germans Trias I Pujol, Badalona-barcelona, Spain|Hospital General Universitari Vall D'Hebron, Barcelona, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Ramon Y Cajal, Madrid, Spain|Hosp Univer 12 De Octubre, Madrid, Spain|H. U. Marques de Valdecilla, Santander, Spain|Hospital General Universitario Virgen Del Rocio, Sevilla, Spain|Local Institution, Lund, Sweden|Kantonsspital Basel, Basel, Switzerland|OnkoZentrum Zurich, Zuerich, Switzerland|Local Institution, Kaohsiung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Cardiff, Cardiganshire, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Edinburgh, Midlothian, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom|Cancer Research Centre, Sheffield, Yorkshire, United Kingdom|Local Institution, London, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02632409

Study 70:
  NCT Number:                   NCT02419417
  Title:                        Study of BMS-986158 in Subjects With Select Advanced Cancers
  Acronym:                      BET
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Advanced Tumors
  Interventions:                Drug: BMS-986158|Biological: Nivolumab
  Outcome Measures:             Number of Adverse Events (AEs)|Number of Serious Adverse Events (SAEs)|Number of AEs leading to discontinuation|Number of laboratory test toxicity grade shifting from baseline|Best Overall Response|Objective Response Rate (ORR)|Duration of Response|Maximum observed plasma concentration (Cmax)|Time of maximum observed plasma concentration (Tmax)|Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))|Area under the concentration-time curve in one dosing interval (AUC(TAU))|Apparent terminal phase half-life (T-HALF)|Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF))|Apparent total body clearance, reported only for parent, not for metabolite (CLT/F)|Apparent volume of distribution of terminal phase, reported only for parent, not for metabolite (Vz/F)|Minimum observed concentration within a dosing interval (Cmin)|Concentration at the end of a dosing interval (Ctau)|Trough observed plasma concentration (this includes predose concentrations (C0) and concentrations at the end of dosing interval (Ctau)) (Ctrough)|Degree of Fluctuation or Fluctuation Index ([Cmax-Cmin)/Css-avg])|[Cmax - Cmin] / Cmin; to be calculated at steady-state (Swing)|Accumulation Index (AI)|Effective elimination half-life that explains the degree of accumulation observed for a specific exposure measure (T-HALFeff)|Ratio of metabolite Cmax to parent Cmax, corrected for molecular weight (MR_Cmax)|Ratio of metabolite AUC(0-T) to parent AUC(0-T), corrected for molecular weight (MR_AUC(0-T))|Ratio of metabolite AUC(INF) to parent AUC(INF), corrected for molecular weight (following single dose only) (MR_AUC(INF))|Ratio of metabolite AUC(TAU) to parent AUC(TAU), corrected for molecular weight (MR_AUC(TAU))|Electrocardiogram (ECG) QT (time of ventricular activity including both depolarization and repolarization) Interval
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          12 Years and older   (Child, Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   150
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA011-001|2015-000324-29
  Start Date:                   June 5, 2015
  Primary Completion Date:      December 2, 2021
  Completion Date:              December 3, 2021
  First Posted:                 April 17, 2015
  Results First Posted:         null
  Last Update Posted:           August 29, 2018
  Locations:                    City Of Hope National Medical Center, Duarte, California, United States|University Of Colorado, Aurora, Colorado, United States|Local Institution, Portland, Oregon, United States|Institute for Translational Oncology Research-ITOR, Greenville, South Carolina, United States|Local Institution, Melbourne, Victoria, Australia|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Gent, Belgium|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Lyon Cedex 08, France|Local Institution, Villejuif, France|Local Institution, Maastrict, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Pamplona, Spain|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Newcastle Upon Tyne, United Kingdom|Local Institution, Whitchurch, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02419417

Study 71:
  NCT Number:                   NCT02472977
  Title:                        Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors
  Acronym:                      CXCessoR4
  Status:                       Terminated
  Study Results:                Has Results
  Conditions:                   Solid Tumor
  Interventions:                Drug: Ulocuplumab|Drug: Nivolumab
  Outcome Measures:             Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Immune-mediated AEs|Objective Response Rate (ORR) Per RECIST 1.1 Criteria|Overall Survival (OS)|Number of Participants With Laboratory Abnormalities|Number of Participants With Electrocardiogram Abnormalities|Progression-Free Survival (PFS)
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   61
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other
  Other IDs:                    CA212-115|2015-000136-15
  Start Date:                   July 13, 2015
  Primary Completion Date:      January 27, 2017
  Completion Date:              January 27, 2017
  First Posted:                 June 16, 2015
  Results First Posted:         March 29, 2018
  Last Update Posted:           November 1, 2018
  Locations:                    University Of Colorado Hosp, Aurora, Colorado, United States|Indiana University Health, Indianapolis, Indiana, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Columbia University Medical Center (Cumc), New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Local Institution, Helsinki, Finland
  Study Documents:              "Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/77/NCT02472977/SAP_000.pdf|"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/77/NCT02472977/Prot_001.pdf
  URL:                          https://ClinicalTrials.gov/show/NCT02472977

Study 72:
  NCT Number:                   NCT02488759
  Title:                        An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors
  Acronym:                      CheckMate358
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Various Advanced Cancer
  Interventions:                Drug: Nivolumab|Drug: Ipilimumab|Drug: Relatlimab|Drug: Daratumumab
  Outcome Measures:             The safety and tolerability will be measured by the incidence of drug-related adverse events (AEs) and serious adverse events (SAEs)|Objective response rate|Rate of surgery delay|Progression-free survival|Overall survival|Duration of response
  Sponsor/Collaborators:        Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   600
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-358|2015-000230-29
  Start Date:                   October 8, 2015
  Primary Completion Date:      May 13, 2019
  Completion Date:              December 31, 2019
  First Posted:                 July 2, 2015
  Results First Posted:         null
  Last Update Posted:           October 19, 2018
  Locations:                    H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Local Institution, New Orleans, Louisiana, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Lutherville, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Desc. Med Ctr, Boston, Massachusetts, United States|University Of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Memorial Sloan-Kettering Cancer Center-Breast Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Providence Portland Medical Center, Portland, Oregon, United States|UPMC Eye and Ear Institute, Pittsburgh, Pennsylvania, United States|Sanford Clinic Clinical Research, Sioux Falls, South Dakota, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Brussels, Belgium|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Marseille Cedex 9, France|Local Institution, Paris, France|Centre Claudius Regaud, Toulouse Cedex 9, France|Institut Gustave Roussy, Vlllejuif, France|Local Institution, Essen, Germany|Local Institution, Heidelberg, Germany|Local Institution, Heilbronn, Germany|Local Institution, Wuerzburg, Germany|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Koto-ku, Tokyo, Japan|Local Institution, Ciudad de Mexico, Distrito Federal, Mexico|Local Institution, Oaxaca de Juarez, Oaxaca, Mexico|Local Institution, Merida, Yucatan, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Utrecht, Netherlands|Local Institution, Craiova, Romania|H. Univ. Vall dHebron, Barcelona, Spain|Hospital Madrid Norte Sanchinarro, Madrid, Spain|Clinica Universitaria De Navarra, Navarra, Spain|Local Institution, Tainan, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Birmingham, WEST Midlands, United Kingdom|Local Institution, Glasgow, United Kingdom|Local Institution, London, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02488759

Study 73:
  NCT Number:                   NCT02253992
  Title:                        An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Advanced Solid Tumors|Advanced B-cell NHL
  Interventions:                Biological: Urelumab|Biological: Nivolumab
  Outcome Measures:             Safety as measured by the rate of adverse events (AEs) and Serious Adverse Events (SAEs)|Best Overall Response (BOR)|Objective response rate (ORR)|Duration of Response (DOR)|Progression-free survival rate (PFSR)|Maximum observed serum concentration (Cmax) of Urelumab,(µg/mL)|Time of maximum observed serum concentration (Tmax) of Urelumab, (hr)|Area under the concentration-time curve in one dosing interval (AUCTAU) of Urelumab (µg.hr/mL)|Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUCinf) of Urelumab (µg.hr/mL)|Total body clearance (CLT) of Urelumab (L/day)|Volume of distribution at steady state (Vss) of Urelumab|Half life (t1/2) of Urelumab|Trough concentration (Cmin) of Urelumab (µg/mL)|Occurrence of specific anti-drug antibodies (ADA) to Urelumab and Nivolumab|Anti-drug Antibody (ADA) status of the subject in response to Urelumab and Nivolumab|Nivolumab end of Infusion concentration (EOI)|Trough concentration (Cmin) of Nivolumab (µg/mL)
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   232
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA186-107|2014-002241-22
  Start Date:                   September 29, 2014
  Primary Completion Date:      June 27, 2019
  Completion Date:              September 27, 2019
  First Posted:                 October 1, 2014
  Results First Posted:         null
  Last Update Posted:           October 25, 2018
  Locations:                    Stanford University School Of Medicine, Palo Alto, California, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|University Of Chicago, Chicago, Illinois, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Lutherville, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|NYU Langone Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Providence Portland Medical Center, Portland, Oregon, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|Md Anderson, Houston, Texas, United States|Local Institution, Besancon, France|Local Institution, Marseille, France|Local Institution, Rennes Cedex 9, France|Local Institution, Villejuif, France|Universitaetsklinikum Essen, Essen, Germany|Clinica Universitaria De Navarra, Pamplona, Spain
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02253992

Study 74:
  NCT Number:                   NCT03704077
  Title:                        An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Gastric Cancer|Cancer of the Stomach|Stomach Cancer|Gastroesophageal Junction
  Interventions:                Biological: Relatlimab + Nivolumab|Biological: Nivolumab|Drug: Paclitaxel|Drug: Ramucirumab
  Outcome Measures:             Overall response rate (ORR)|Incidence of adverse events (AEs)|Incidence of serious adverse events (SAEs)|Incidence of AEs leading to discontinuation|Incidence of deaths|Incidence of laboratory abnormalities|ORR|Duration of response (DOR)|Progression free survival (PFS)|Overall survival (OS)
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   610
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA224-061|2018-001070-20
  Start Date:                   May 15, 2019
  Primary Completion Date:      January 3, 2021
  Completion Date:              July 11, 2023
  First Posted:                 October 12, 2018
  Results First Posted:         null
  Last Update Posted:           November 14, 2018
  Locations:                    Local Institution, Daphne, Alabama, United States|Local Institution, Bakersfield, California, United States|Local Institution, Fullerton, California, United States|Local Institution, Los Angeles, California, United States|Local Institution, Redondo Beach, California, United States|Local Institution, Santa Barbara, California, United States|Local Institution, Aurora, Colorado, United States|Local Institution, Lakewood, Colorado, United States|Local Institution, Miami, Florida, United States|Local Institution, Tampa, Florida, United States|Local Institution, Marietta, Georgia, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Saint Louis, Missouri, United States|Local Institution, New Brunswick, New Jersey, United States|Local Institution, Chapel Hill, North Carolina, United States|Local Institution, Charlotte, North Carolina, United States|Local Institution, Fargo, North Dakota, United States|Local Institution, Allentown, Pennsylvania, United States|Local Institution, Sioux Falls, South Dakota, United States|Local Institution, Vancouver, Washington, United States|Local Institution, Viedma, RIO Negro, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Caba, Argentina|Local Institution, Ciudad Autonoma de Buenos Aires, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Northmead, New South Wales, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Malvern, Victoria, Australia|Local Institution, Melbourne, Victoria, Australia|Local Institution, Murdoch, Western Australia, Australia|Local Institution, Bedford Park, Australia|Local Institution, Fortaleza, Ceara, Brazil|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Jau, SAO Paulo, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Halifax, Nova Scotia, Canada|Local Institution, Hamilton, Ontario, Canada|Local Institution, Ottawa, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Sherbrooke, Quebec, Canada|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Medellin, Colombia|Local Institution, Berlin, Germany|Local Institution, Cologne, Germany|Local Institution, Erlangen, Germany|Local Institution, Essen, Germany|Local Institution, Frankfurt am Main, Germany|Local Institution, Freiburg, Germany|Local Institution, Hamburg, Germany|Local Institution, Hannover, Germany|Local Institution, Jena, Germany|Local Institution, Mainz, Germany|Local Institution, Mannheim, Germany|Local Institution, Marburg, Germany|Local Institution, Paderborn, Germany|Local Institution, Reutlingen, Germany|Local Institution, Wiesbaden, Germany|Local Institution, Bergamo, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Napoli, Italy|Local Institution, Reggio Emilia, Italy|Local Institution, Tuxtla Gutierrez, Chiapas, Mexico|Local Institution, Mexico City, Distrito Federal, Mexico|Local Institution, ZONA Centro. LEON, Guanajuato, Mexico|Local Institution, Merida, Yucatan, Mexico|Local Institution, Aguascalientes, Mexico|Local Institution, Lisboa, Portugal|Local Institution, Porto, Portugal|Local Institution, Rio Piedras, Puerto Rico|Local Institution, Bucuresti, Romania|Local Institution, Cluj-Napoca, Romania|Local Institution, Craiova, Romania|Local Institution, Floresti, Romania|Local Institution, Badajoz, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Valencia, Spain
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03704077

Study 75:
  NCT Number:                   NCT03143153
  Title:                        A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin
  Acronym:                      CheckMate 648
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Various Advanced Cancer
  Interventions:                Biological: Nivolumab|Biological: Ipilimumab|Drug: Cisplatin|Drug: Fluorouracil
  Outcome Measures:             Overall survival (OS)|Progression-free Survival (PFS)|Objective Response Rate (ORR)
  Sponsor/Collaborators:        Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   939
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-648|2016-001514-20
  Start Date:                   June 19, 2017
  Primary Completion Date:      May 25, 2020
  Completion Date:              December 30, 2021
  First Posted:                 May 8, 2017
  Results First Posted:         null
  Last Update Posted:           November 20, 2018
  Locations:                    Southern Cancer Center, Inc., Mobile, Alabama, United States|Local Institution, Tucson, Arizona, United States|Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|University Of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Baptist Health Medical Group Oncology LLC, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Northwest Georgia Oncology Center, P.C., Marietta, Georgia, United States|Local Institution, Chicago, Illinois, United States|Jersey Shore University Medical Center, Neptune, New Jersey, United States|Local Institution, Durham, North Carolina, United States|Oncology Associates Of Oregon, Pc, Eugene, Oregon, United States|Northwest Cancer Specialists, P.C., Portland, Oregon, United States|Local Institution, Austin, Texas, United States|Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|Oncology & Hematology Associates Of Southwest Virginia, Inc., Roanoke, Virginia, United States|West Virginia University-Mbrcc, Morgantown, West Virginia, United States|Hospital Municipal De Gastroenterologia Dr.Udaondo, Capital Federal, Buenos Aires, Argentina|Hospital Provincial Del Centenario, Rosario, Santa FE, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Cordoba, Argentina|Centro Oncologico Riojano Integral, La Rioja, Argentina|Local Institution, Randwick, New South Wales, Australia|Local Institution, Tamworth, New South Wales, Australia|Local Institution, Douglas, Queensland, Australia|Local Institution, Murdoch, Western Australia, Australia|Local Institution, Salzburg, Austria|Local Institution, Salvador, Bahia, Brazil|Local Institution, Ipatinga, Minas Gerais, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Jau, SAO Paulo, Brazil|Local Institution, Sao Jose Do Rio Preto, SAO Paulo, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Moncton, New Brunswick, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Trois-Rivieres, Quebec, Canada|Fundacion Arturo Lopez Perez, Santiago, Metropolitana, Chile|Local Institution, Independencia, Santiago, Chile|Local Institution, Santiago, Chile|Local Institution, Hefei, Anhui, China|Local Institution, Hefei, Anhui, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Fuzhou, Fujian, China|Local Institution, Fuzhou, Fujian, China|Local Institution, Shantou, Guangdong, China|Local Institution, Harbin, Heilongjiang, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Changsha, Hunan, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Changchun, Jilin, China|Local Institution, Shenyang, Liaoning, China|Local Institution, Xian, Shaanxi, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Shanghai, China|Oncologos Del Occidente Sa, Pereira, Risaralda, Colombia|Instituto Nac. de Cancerologia, Bogota, Colombia|Hospital Pablo Tobon Uribe, Medellin, Colombia|Interni hematologicka a onkologicka klinika, Brno, Czechia|Klinika komplexni onkologicke pece, Brno, Czechia|Komplexni onkologicke centrum, Novy Jicin, Czechia|Local Institution, Odense, Denmark|Local Institution, Caen, France|Local Institution, Lille, France|Local Institution, Montpellier, France|Local Institution, Rennes Cedex, France|Local Institution, Toulouse, France|Local Institution, Villejuif, France|Local Institution, Hong Kong, Hong Kong|Local Institution, Kowloon, Hong Kong|ASST Papa Giovanni XXIII, Bergamo, Italy|IRCCS Istituto Nazionale Tumori Milano, Milano, Italy|I.O.V. Istituto Oncologico Veneto Ircss, Padova, Italy|Local Institution, Akita-shi, Akita, Japan|Local Institution, Hirosaki-shi, Aomori, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Fukushima-shi, Fukushima, Japan|Local Institution, Gifu City, Gifu, Japan|Local Institution, Ota, Gunma, Japan|Local Institution, Hiroshima-Shi, Hiroshima, Japan|Local Institution, Sapporo, Hokkaido, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Kobe, Hyogo, Japan|Local Institution, Kanazawa, Ishikawa, Japan|Local Institution, Kagoshima-shi, Kagoshima, Japan|Local Institution, Isehara, Kanagawa, Japan|Local Institution, Kawasaki-shi, Kanagawa, Japan|Local Institution, Sagamihara-shi, Kanagawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Sendai, Miyagi, Japan|Local Institution, Niigata-City, Niigata, Japan|Local Institution, Kurashiki-shi, Okayama, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Chuo-ku, Osaka, Japan|Local Institution, Hirakata-shi, Osaka, Japan|Local Institution, Osaka Sayama-shi, Osaka, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Takatsuki City, Osaka, Japan|Local Institution, Hidaka, Saitama, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Shimotsuga-gun, Tochigi, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Koto-ku, Tokyo, Japan|Local Institution, Minato-ku, Tokyo, Japan|Local Institution, Shinagawa-ku, Tokyo, Japan|Local Institution, Shinjuku-Ku, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Toyama-shi, Toyama, Japan|Local Institution, Wakayama-shi, Wakayama, Japan|Local Institution, Ube-shi, Yamaguchi, Japan|Local Institution, Akashi, Japan|Local Institution, Chiba, Japan|Local Institution, Kyoto, Japan|Local Institution, Shizuoka, Japan|Local Institution, Yokohama, Japan|Local Institution, Busan, Korea, Republic of|Local Institution, Daegu, Korea, Republic of|Local Institution, Daejeon, Korea, Republic of|Local Institution, Jeonju-si, Korea, Republic of|Local Institution, Seongnam-si, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Ulsan, Korea, Republic of|Local Institution, Tuxtla Gutierrez, Chiapas, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Merida, Yucatan, Mexico|Hospital Nacional Daniel Alcides Carrion, Callao, Peru|Local Institution, Lima, Peru|Instituto Nacional De Enfermedades Neoplasicas, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|II Klinika Chirurgii Ogolnej, Gastroenterologicznej i Nowotworow Ukladu Pokarmowego, Lublin, Poland|Klinika Gastroenterologii Onkologicznej, Warszawa, Poland|Local Institution, Lisboa, Portugal|Local Institution, Porto, Portugal|Focus Lab Plus SRL, Bucuresti, Romania|CF Clinical Hospital Cluj-Napoca, Cluj-Napoca, Romania|Sf. Nectarie Oncology Center, Craiova, Romania|County Emergency Hospital Suceava, Suceava, Romania|Local Institution, Moscow, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Changhua, Taiwan|Local Institution, Kaohsiung City, Taiwan|Local Institution, Kaohsiung, Taiwan|Local Institution, Kaohsiung, Taiwan|Local Institution, Keelung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Tainan City, Taiwan|Local Institution, Tainan, Taiwan|Local Institution, Taipei City, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, Ankara, Turkey|Local Institution, Diyarbak?r, Turkey|Local Institution, Edrine, Turkey|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Surrey, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03143153

Study 76:
  NCT Number:                   NCT03414983
  Title:                        An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread
  Acronym:                      CheckMate 9X8
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Colorectal Cancer
  Interventions:                Biological: Nivolumab|Drug: Oxaliplatin|Drug: Leucovorin|Drug: Fluorouracil|Drug: Bevacizumab
  Outcome Measures:             Progression Free Survival (PFS)|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Duration of Response (DoR)|Time to Response (TTR)|Overall Survival (OS)|Number of Adverse Events ( AEs)|Number of Serious Adverse Events ( SAEs)|Number of deaths|Number of clinical abnormalities
  Sponsor/Collaborators:        Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2|Phase 3
  Enrollment:                   180
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-9X8|2017-003662-27
  Start Date:                   February 14, 2018
  Primary Completion Date:      August 16, 2021
  Completion Date:              August 18, 2022
  First Posted:                 January 30, 2018
  Results First Posted:         null
  Last Update Posted:           November 20, 2018
  Locations:                    Uab Comprehensive Cancer Center, Birmingham, Alabama, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Local Institution, San Diego, California, United States|Local Institution, Santa Barbara, California, United States|University of Colorado, Aurora, Colorado, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Yale Cancer Center, New Haven, Connecticut, United States|Local Institution, Jacksonville, Florida, United States|Baptist Health Medical Group, Miami, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Illinois Cancer Specialists, Arlington Heights, Illinois, United States|Local Institution, Indianapolis, Indiana, United States|Investigative Clinical Research Of Indiana, Llc, Indianapolis, Indiana, United States|Regional Cancer Care Associates, LLC, Bethesda, Maryland, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Papillion, Nebraska, United States|Comprehensive Cancer Centers Of Nevada, Henderson, Nevada, United States|Broome Oncology, Johnson City, New York, United States|Laura & Isaac Perlmutter Cancer Ctr at NYU Langone, New York, New York, United States|Local Institution, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Northwest Cancer Specialists, P.C., Tualatin, Oregon, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegheny Health Network, Pittsburgh, Pennsylvania, United States|Sanford Research, Sioux Falls, South Dakota, United States|Local Institution, Chattanooga, Tennessee, United States|Local Institution, Chattanooga, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Texas Oncology, P.A., Bedford, Texas, United States|Texas Oncology-Baylor Charles A Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology-Fort Worth 12th Ave, Fort Worth, Texas, United States|Texas Oncology-Tyler, Longview, Texas, United States|Cancer Centers of South Texas, San Antonio, Texas, United States|Virginia Cancer Center, Richmond, Virginia, United States|Oncology & Hematology Associates Of Southwest Virginia, Inc., Roanoke, Virginia, United States|University Of Wisconsin, Madison, Wisconsin, United States|Local Institution, Edmonton, Alberta, Canada|Local Institution, Ottawa, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Centre Hospitalier De L'Universite De Montreal, Montreal, Quebec, Canada|Centre integre universitaire de sante et de service sociaux de l'estrie - CHUS, Sherbrooke, Quebec, Canada|Local Institution, Trois-Rivieres, Quebec, Canada|Local Institution, Quebec, Canada|Local Institution, Nagoya, Aichi, Japan|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Fundacion De Investigacion De Diego, San Juan, Puerto Rico|H. Univ. Vall dHebron, Barcelona, Spain|Hospital Universitario Ramon Y Cajal, Madrid, Spain|Hosp. Univ. Puerta De Hierro, Majadahonda - Madrid, Spain
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03414983

Study 77:
  NCT Number:                   NCT02823574
  Title:                        Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
  Acronym:                      CheckMate 714
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Head and Neck Cancer
  Interventions:                Biological: Nivolumab|Biological: Ipilimumab|Other: Placebo
  Outcome Measures:             Overall response rate (ORR) in platinum refractory subgroup|Duration of Response (DOR) in platinum refractory subgroup|ORR in platinum eligible subgroup|Progression Free Survival (PFS) in platinum eligible and refractory subgroups|Overall Survival (OS) in platinum eligible and refractory subgroups|DOR in platinum eligible subgroup|Tumor mutation burden (TMB) in platinum eligible and refractory subgroups
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   400
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  Other IDs:                    CA209-714|2016-001645-64
  Start Date:                   September 22, 2016
  Primary Completion Date:      January 30, 2019
  Completion Date:              January 30, 2024
  First Posted:                 July 6, 2016
  Results First Posted:         null
  Last Update Posted:           November 6, 2018
  Locations:                    University of Arizona Cancer Center, Tucson, Arizona, United States|City Of Hope, Duarte, California, United States|Los Angeles Cancer Network, Los Angeles, California, United States|Ucla Department Of Medicine, Los Angeles, California, United States|Torrance Health Association, Redondo Beach, California, United States|Sutter Cancer Center, Sacramento, California, United States|Ucsf, San Francisco, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|Central Coast Med Oncology, Santa Maria, California, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Dekalb Medical Center, Decatur, Georgia, United States|University Of Chicago, Chicago, Illinois, United States|Ft. Wayne Med Onco-Hema Inc, Fort Wayne, Indiana, United States|University Of Louisville, Louisville, Kentucky, United States|Oncology Associated Of Western Kentucky, Paducah, Kentucky, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Mass General Hospital, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Mission Hospital, Inc, Asheville, North Carolina, United States|University Of Cincinnati Medical School, Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|UPMC, Pittsburgh, Pennsylvania, United States|Donald Guthrie Foundation, Sayre, Pennsylvania, United States|UT Southwestern Medical Center, Dallas, Texas, United States|University Of Washington, Seattle, Washington, United States|Centro de Investigacion Pergamino SA- Clinica Pergamino, Pergamino, Buenos Aires, Argentina|Hospital Italiano De Buenos Aires, Buenos Aires, Argentina|Universitair Ziekenhuis Gent, Gent, Belgium|Az Nikolaas, Sint-Niklaas, Belgium|Ucl Mont-Godinne, Yvoir, Belgium|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Ipatinga, Minas Gerais, Brazil|Local Institution, Curitiba, Parana, Brazil|Local Institution, Caxias do Sul, RIO Grande DO SUL, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Santo Andre, SAO Paulo, Brazil|Local Institution, Sao Jose do Rio Preto, SAO Paulo, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Cross Cancer Institute., Edmonton, Alberta, Canada|The Ottawa General Hospital, Ottawa, Ontario, Canada|University Health Network - Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Centre Hospitalier De L'Universite De Montreal, Montreal, Quebec, Canada|CHU de Quebec - Universite Laval - Hopital de l'Enfant Jesus, Quebec, Canada|Fundacion Arturo Lopez Perez, Santiago, Metropolitana, Chile|Klinika komplexni onkologicke pece, Brno, Czechia|Klinika onkologie a radioterapie, Hradec Kralove, Czechia|Onkologicka klinika, Olomouc, Czechia|Helsinki University Hospital, Helsinki, Finland|Chu Amiens - Groupe Hospitalier Sud, Amiens Cedex 1, France|Local Institution, Bordeaux, France|Centre Jean Perrin, Clermont Ferrand cedex 01, France|Local Institution, Clichy, France|Centre Leon Berard, Lyon Cedex 08, France|Hopital De La Timone, Marseille Cedex 5, France|Local Institution, Nice, France|Local Institution, Rennes Cedex, France|Local Institution, Villejuif, France|St. James'S Hospital, Dublin 8, Dublin, Ireland|IRCCS Istituto Nazionale Tumori Milano, Milano, Italy|Istituto Nazionale Tumori Fondazione Pascale, Napoli, Italy|Local Institution, Merida, Yucatan, Mexico|Local Institution, Merida, Yucatan, Mexico|Local Institution, Oaxaca, Mexico|NKI AVL, Amsterdam, Netherlands|Vu Medical Centre, Amsterdam, Netherlands|Umcg, Universitair Medisch Centrum Groningen, Groningen, Netherlands|Haukeland University Hospital, Bergen, Norway|The Norwegian Radium Hospital, Oslo, Norway|Centrul Medical Sanador, Bucharest, Romania|CF Clinical Hospital Cluj-Napoca, Cluj-Napoca, Romania|Sf. Nectarie Oncology Center, Craiova, Romania|Institutul Regional de Oncologie Iasi, Iasi, Romania|County Emergency Hospital Suceava, Suceava, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Ryazan, Russian Federation|Local Institution, Port Elizabeth, Eastern CAPE, South Africa|Local Institution, Johannesburg, Gauteng, South Africa|Local Institution, Pretoria, Gauteng, South Africa|Local Institution, Cape Town, Western CAPE, South Africa|Local Institution, A Coruna, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Marbella, Spain|Local Institution, San Sabastian Gipuzkoa, Spain|Sahlgrenska University Hospital, Goteborg, Sweden|Local Institution, Lund, Sweden|Local Institution, Stockholm, Sweden|Local Institution, Adana, Turkey|Local Institution, Antalya, Turkey|Local Institution, Izmir, Turkey|Aberdeen Royal Infirmary, Aberdeen, Aberdeenshire, United Kingdom|Royal Marsden Nhs Foundation Trust, London, Greater London, United Kingdom|The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, Merseyside, United Kingdom|Royal Marsden Hospital, Sutton, Surrey, United Kingdom|Freeman Hospital, Newcastle Upon Tyne, Tyne and Wear, United Kingdom|Local Institution, Cardiff, United Kingdom|Beatson Oncology Centre, Glasgow, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02823574

Study 78:
  NCT Number:                   NCT02750514
  Title:                        An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer
  Acronym:                      FRACTION-Lung
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Advanced Cancer
  Interventions:                Biological: Nivolumab|Drug: Dasatinib|Biological: Relatlimab|Biological: Ipilimumab|Drug: BMS-986205
  Outcome Measures:             Objective Response Rate (ORR)|Duration of Response (DOR)|Progression-free Survival Rate (PFSR)|Safety and tolerability of Nivolumab based on incidence of adverse events, serious adverse events, adverse events leading to discontinuation and deaths|Safety and tolerability of Nivolumab & Dasatinib combination based on incidence of adverse events, serious adverse events, adverse events leading to discontinuation and deaths|Safety and tolerability of Nivolumab & BMS-986016 combination based on incidence of adverse events, serious adverse events, adverse events leading to discontinuation and deaths|Safety and tolerability of Nivolumab & Ipilimumab combination based on incidence of adverse events, serious adverse events, adverse events leading to discontinuation and deaths|Safety and tolerability of Nivolumab & BMS-966205 combination based on incidence of adverse events, serious adverse events, adverse events leading to discontinuation and deaths
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   504
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA018-001
  Start Date:                   May 6, 2016
  Primary Completion Date:      April 28, 2021
  Completion Date:              April 29, 2021
  First Posted:                 April 25, 2016
  Results First Posted:         null
  Last Update Posted:           October 4, 2018
  Locations:                    City of Hope National Medical Center, Duarte, California, United States|University of California San Diego (UCSD), La Jolla, California, United States|University of Southern California (USC), Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|University of Californa, Los Angeles (UCLA), Los Angeles, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|University of Colorado Denver, Aurora, Colorado, United States|Yale Cancer Center, New Haven, Connecticut, United States|Local Institution, Washington, District of Columbia, United States|Local Institution, Atlanta, Georgia, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|University of Maryland - Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland, United States|Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute (DFCI), Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Washington University, The Center for Advanced Medicine, Saint Louis, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Univ of NC Shool of Medicine, Chapel Hill, North Carolina, United States|The Ohio State University, Columbus, Ohio, United States|Northwest Cancer Specialists, Portland, Oregon, United States|Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|The West Clinic, P.C. d/b/a West Cancer Center, Germantown, Tennessee, United States|Sarah Cannon Cancer Center, Nashville, Tennessee, United States|Sammons Cancer Center (Uso), Dallas, Texas, United States|Texas Oncology, P.A., Fort Sam Houston, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Us Oncology, Tyler, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Virginia Cancer Care Specialist, PC, Fairfax, Virginia, United States|University of Washington-Seattle Cancer Care Alliance, Seattle, Washington, United States|Local Institution, Clayton, Australia|Local Institution, Salzburg, Austria|Juravinski Cancer Centre, Hamilton Health Sciences-Mcmaster Univeristy's Faculty Of Health Sciences, Hamilton, Ontario, Canada|University Of Ottawa - The Ottawa Hospital Cancer centre, Ottawa, Ontario, Canada|Local Institution, Edmonton, Canada|Local Institution, Copenhagen, Denmark|Local Institution, Paris, France|Local Institution, Toulouse, France|Local Institution, Villejuif Cedex, France|Local Institution, Milano, Italy|Local Institution, Milan, Italy|Local Institution, Rozzano, Italy|Local Institution, Amsterdam, Netherlands|Local Institution, Oslo, Norway|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Pamplona, Spain|Local Institution, Stockholm, Sweden|Local Institution, Lausanne, Switzerland|Local Institution, London, Greater London, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02750514

Study 79:
  NCT Number:                   NCT01928394
  Title:                        A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Advanced or Metastatic Solid Tumors
  Interventions:                Biological: Nivolumab|Biological: Ipilimumab|Drug: Cobimetinib
  Outcome Measures:             Objective response rate (ORR)|Number of treatment-related adverse events (AEs) leading to drug discontinuations|Progression Free Survival (PFS)|Overall Survival (OS)
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   1620
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-032|2013-002844-10
  Start Date:                   October 7, 2013
  Primary Completion Date:      May 31, 2019
  Completion Date:              December 22, 2020
  First Posted:                 August 23, 2013
  Results First Posted:         null
  Last Update Posted:           November 19, 2018
  Locations:                    Northwest Alabama Cancer Center, Pc, Muscle Shoals, Alabama, United States|University Of Colorado, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|University Of Florida, Gainesville, Florida, United States|H. Lee Moffitt Cancer Center & Research Inst, Inc, Tampa, Florida, United States|Winship Cancer Institute., Atlanta, Georgia, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Dana Farber/Partners Cancercare, Inc., Boston, Massachusetts, United States|Dana-Farber/ Partners Cancer Care, Inc., Boston, Massachusetts, United States|Nebraska Cancer Specialists, Omaha, Nebraska, United States|Winthrop University Hospital, Mineola, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Duke Cancer Institute, Durham, North Carolina, United States|Oregon Health & Science University, Portland, Oregon, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Ctr, Nashville, Tennessee, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|Swedish Cancer Institute, Seattle, Washington, United States|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Local Institution, Copenhagen, Denmark|Local Institution, Helsinki, Finland|Local Institution, Tampere, Finland|Local Institution, Bonn, Germany|Local Institution, Frankfurt, Germany|Local Institution, Heidelberg, Germany|Local Institution, Kassel, Germany|Azienda Ospedaliera S.Orsola-Malpighi, Bologna, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Istituto Oncologico Veneto IOV, Padova, Italy|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, London, Greater London, United Kingdom|Local Institution, Glasgow, Lanarkshire, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01928394

Study 80:
  NCT Number:                   NCT03215706
  Title:                        A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC
  Acronym:                      CheckMate 9LA
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Non-Small Cell Lung Cancer
  Interventions:                Biological: Ipilimumab|Biological: Nivolumab|Drug: Carboplatin|Drug: Paclitaxel|Drug: Pemetrexed|Drug: Cisplatin
  Outcome Measures:             Overall Survival (OS)|Progression Free Survival (PFS)|Overall Response Rate (ORR)|ORR|PFS|OS
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   700
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-9LA|2017-001195-35
  Start Date:                   July 20, 2017
  Primary Completion Date:      August 25, 2019
  Completion Date:              May 20, 2020
  First Posted:                 July 12, 2017
  Results First Posted:         null
  Last Update Posted:           November 29, 2018
  Locations:                    Memorial Health Systems, Colorado Springs, Colorado, United States|Cancer Center Of Central Connecticut, Plainville, Connecticut, United States|Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States|Local Institution, Atlanta, Georgia, United States|Local Institution, LaGrange, Georgia, United States|Northwest Georgia Oncology Center, P.C., Marietta, Georgia, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|Baptist Health Lexington, Lexington, Kentucky, United States|Henry Ford Health System, Detroit, Michigan, United States|Broome Oncology, Johnson City, New York, United States|Winthrop University Hospital, Mineola, New York, United States|The Ohio State University, Columbus, Ohio, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|West Penn Hospital, Pittsburgh, Pennsylvania, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina, United States|Southwest Regional Cancer Clinic, Saint George, Utah, United States|University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States|Local Institution, Milwaukee, Wisconsin, United States|Instituto Alexander Fleming, Caba, Buenos Aires, Argentina|Instituto Medico Rio Cuarto S.A., Rio Cuarto, Cordoba, Argentina|Clinica Viedma S.A., Viedma, RIO Negro, Argentina|Sanatorio Parque, Rosario, Santa FE, Argentina|Local Institution, Caba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Local Institution, Gosford, New South Wales, Australia|Local Institution, Bedford Park, South Australia, Australia|Local Institution, Elizabeth Vale, South Australia, Australia|Local Institution, Box Hill, Victoria, Australia|Local Institution, Heidelberg, Victoria, Australia|St John of God Murdoch Hospital, Murdoch, Western Australia, Australia|Local Institution, Charleroi, Belgium|Local Institution, Leuven, Belgium|Local Institution, Roeselare, Belgium|Local Institution, Natal, RIO Grande DO Norte, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Blumenau, Santa Catarina, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Jose De Rio Preto, SAO Paulo, Brazil|Local Institution, Rio De Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Montreal, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Mcgill University Health Center - Royal Victoria Hospital, Montreal, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski, Rimouski, Quebec, Canada|Bradford Hill Centro de Investigaciones Clinicas, Santiago de Chile, Metropolitana, Chile|Fundacion Arturo Lopez Perez, Santiago, Metropolitana, Chile|Hospital Clinico Vina Del Mar, Vina Del Mar, Valparaiso, Chile|Local Institution, Changchun, Jilin, China|Local Institution, Xi'an, Shan3xi, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Beijing, China|Local Institution, Amiens Cedex 1, France|Local Institution, Caen, France|Local Institution, Lille Cedex, France|Local Institution, Lyon Cedex 08, France|Local Institution, Montpellier Cedex, France|Local Institution, Nantes, France|Local Institution, Paris, France|Local Institution, Pierre Benite, France|Local Institution, Saint-Brieuc, France|Local Institution, Berlin, Germany|Asklepios Fachkliniken Munchen-Gauting Thorakale Onkologie, Gauting, Germany|Klinik Schillerhoehe, Gerlingen, Germany|Krankenhaus Grosshansdorf, Grosshansdorf, Germany|Lungenklinik Hemer, Hemer, Germany|Fachklinik Fuer Lungenkrankheiten, Immenhausen, Germany|Universitaetsklinikum Magdeburg A. o. R., Magdeburg, Germany|Klinikum Bogenhausen, Muenchen, Germany|Local Institution, Dublin, Ireland|Local Institution, Limerick, Ireland|Ospedale San Luca, Lucca, Italy|Ospedale San Raffaele, Milano, Italy|Azienda Ospedaliera Monaldi, Napoli, Italy|Local Institution, Fukushima-shi, Fukushima, Japan|Local Institution, Maebashi-shi, Gunma, Japan|Local Institution, Ota-shi, Gunma, Japan|Local Institution, Hiroshima-shi, Hiroshima, Japan|Local Institution, Hiroshima-shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Akashi-shi, Hyogo, Japan|Local Institution, Himeji-shi, Hyogo, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Kanazawa-shi, Ishikawa, Japan|Local Institution, Morioka-shi, Iwate, Japan|Local Institution, Yokohama-Shi, Kanagawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Habikino-shi, Osaka, Japan|Local Institution, Osaka-sayama-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Hidaka-shi, Saitama, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Ube-shi, Yamaguchi, Japan|Oncotech, La Paz, BAJA Californa SUR, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Faicic S. de Rl. de Cv, Veracruz, Veracruz, Mexico|Ambulatorium Chemioterapii, Bydgoszcz, Poland|Oddzial Onkologii, Bytom, Poland|Local Institution, Elblag, Poland|Local Institution, Gdansk, Poland|Local Institution, Bucharest, Romania|Local Institution, Cluj-Napoca, Romania|Local Institution, Craiova, Romania|Local Institution, Moscow, Russian Federation|Local Institution, St.petersburg, Russian Federation|Comp. Hosp. Univ. A Coruna, A Coru?a, Spain|H. Univ. Vall dHebron, Barcelona, Spain|Hosp Univer 12 De Octubre, Madrid, Spain|Hospital Carlos Haya De Malaga, Malaga, Spain|Hospital Universitario La Fe, Valencia, Spain|Local Institution, London, Greater London, United Kingdom|Local Institution, Maidstone, Kent, United Kingdom|Local Institution, Guildford, Surrey, United Kingdom|Local Institution, Tauton, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03215706

Study 81:
  NCT Number:                   NCT03251924
  Title:                        A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Cancer|Tumors|Neoplasm|Malignancy
  Interventions:                Drug: BMS-986226|Biological: Nivolumab|Biological: Ipilimumab
  Outcome Measures:             Incidence of adverse events (AE)|Incidence of serious adverse events (SAE)|Incidence of AE due to discontinuation|Incidence of AE resulting in death|Incidence of AEs meeting protocol defined dose-limiting toxicity (DLT) criteria|Incidence of clinical laboratory test abnormalities graded according to common terminology criteria for adverse events (CTCAE)|Objective response rate (ORR) measure by Clopper-Pearson method|Median Duration of Response (mDOR) measured by Kaplan-Meier method|Progression Free Survival (PFS) measured by Kaplan-Meier method|Maximum observed plasma concentration (Cmax)|Time of maximum observed plasma concentration (Tmax)|Area under the concentration-time curve from time 0 to the time of the last [AUC (0-T)]|Area under the concentration-time curve in 1 dosing interval [AUC(TAU)]|Incidence of anti-drug antibodies to BMS-986226 assessed by immunoassay|Change from baseline in immunoassay for BMS-986226
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   277
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA021-002|2017-000238-73
  Start Date:                   August 31, 2017
  Primary Completion Date:      April 6, 2020
  Completion Date:              December 5, 2020
  First Posted:                 August 16, 2017
  Results First Posted:         null
  Last Update Posted:           October 4, 2018
  Locations:                    Local Institution, Boston, Massachusetts, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Local Institution, Hamilton, Ontario, Canada|Local Institution, Toronto, Ontario, Canada
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03251924

Study 82:
  NCT Number:                   NCT03386838
  Title:                        An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck
  Acronym:                      
  Status:                       Terminated
  Study Results:                No Results Available
  Conditions:                   Head and Neck Cancer
  Interventions:                Biological: Nivolumab|Drug: BMS-986205|Biological: Cetuximab|Drug: Cisplatin|Drug: Carboplatin|Drug: Fluorouracil
  Outcome Measures:             Progression-free survival (PFS) as determined by Blinded Independent Central Review (BICR) using RECIST 1.1|Overall survival (OS)|Objective response rate (ORR) determined by BICR using RECIST 1.1|Number of adverse events (AE)|Number of serious adverse events (SAE)|Time to meaningful symptomatic deterioration (TTSD)
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   1
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA017-063|2017-003059-46
  Start Date:                   March 28, 2018
  Primary Completion Date:      April 19, 2018
  Completion Date:              April 19, 2018
  First Posted:                 December 29, 2017
  Results First Posted:         null
  Last Update Posted:           April 30, 2018
  Locations:                    Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03386838

Study 83:
  NCT Number:                   NCT03661320
  Title:                        A Study of Chemo Only Versus Chemo Plus Nivo With or Without BMS-986205, Followed by Post- Surgery Therapy With Nivo or Nivo and BMS-986205 in Patients With MIBC
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Bladder Cancer|Muscle-Invasive Bladder Cancer|BMS-986205
  Interventions:                Biological: Nivolumab|Drug: BMS-986205|Drug: Gemcitabine|Drug: Cisplatin|Drug: BMS-986205 Placebo
  Outcome Measures:             Pathological Complete Response (pCR) rate of neoadjuvant Nivo/BMS-986205 +Chemo|Event-Free Survival (EFS) of neoadjuvant Nivo/BMS-986205 + Chemo followed by continued Nivo/BMS-986205 after RC|Pathological Complete Response (pCR) rate of neoadjuvent Chemo Alone|Pathological Complete Response (pCR) rate of neoadjuvant Nivo + Chemo|Event-Free Survival (EFS) of SOC Chemo after RC|Event-Free Survival (EFS) of neoadjuvant Nivo + Chemo followed by continued Nivo after RC|Overall Survival (OS)|Incidence of Adverse Events (AE)|Incidence of Serious Adverse Events (SAE)|Incidence of Laboratory abnormalities
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   1200
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  Other IDs:                    CA017-078|2017-004692-31
  Start Date:                   October 12, 2018
  Primary Completion Date:      November 28, 2023
  Completion Date:              December 30, 2026
  First Posted:                 September 7, 2018
  Results First Posted:         null
  Last Update Posted:           November 29, 2018
  Locations:                    Local Institution, Mobile, Alabama, United States|Arizona Oncology Associates, Tucson, Arizona, United States|Local Institution, Irvine, California, United States|Local Institution, La Jolla, California, United States|Local Institution, Sacramento, California, United States|Local Institution, Littleton, Colorado, United States|Local Institution, New Haven, Connecticut, United States|Local Institution, Newark, Delaware, United States|Local Institution, Pensacola, Florida, United States|Local Institution, Tampa, Florida, United States|Local Institution, Atlanta, Georgia, United States|Local Institution, Chicago, Illinois, United States|Local Institution, Peoria, Illinois, United States|Local Institution, Boston, Massachusetts, United States|Minnesota Oncology Hematology, Minneapolis, Minnesota, United States|Local Institution, Minneapolis, Minnesota, United States|Local Institution, Omaha, Nebraska, United States|Comprehensive Cancer Centers Of Nevada, Las Vegas, Nevada, United States|New York Oncology Hematology, Pc, Albany, New York, United States|Local Institution, Lake Success, New York, United States|Local Institution, New York, New York, United States|Local Institution, Tualatin, Oregon, United States|Local Institution, Nashville, Tennessee, United States|Local Institution, Austin, Texas, United States|Local Institution, Dallas, Texas, United States|Local Institution, Fort Sam Houston, Texas, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Local Institution, Woden, Australian Capital Territory, Australia|Local Institution, Kingswood, New South Wales, Australia|Local Institution, St Leonards, New South Wales, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Murdoch, Western Australia, Australia|Local Institution, Klagenfurt Am Woerthersee, Austria|Local Institution, Krems, Austria|Local Institution, Linz, Austria|Local Institution, Wien, Austria|Local Institution, Antwerpen, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Gent, Belgium|Local Institution, Leuven, Belgium|Local Institution, Fortaleza, Ceara, Brazil|Local Institution, Ipatinga, Minas Gerais, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Jau, SAO Paulo, Brazil|Local Institution, Sao Jose Do Rio Preto, SAO Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, ?lborg, Denmark|Local Institution, Arhus, Denmark|Local Institution, Herlev, Denmark|Local Institution, Besancon, France|Local Institution, Bordeaux, France|Local Institution, Marseille, France|Local Institution, Nice, France|Local Institution, Strasbourg Cedex, France|Local Institution, TOULOUSE Cedex 9, France|Local Institution, Aachen, Germany|Local Institution, Erfurt, Germany|Local Institution, Essen, Germany|Local Institution, Goettingen, Germany|Local Institution, Heidelberg, Germany|Local Institution, Herne, Germany|Local Institution, Jena, Germany|Local Institution, Luebeck, Germany|Local Institution, Magdeburg, Germany|Local Institution, Mainz, Germany|Local Institution, Mainz, Germany|Local Institution, Muenchen, Germany|Local Institution, Nuernberg, Germany|Local Institution, Trier, Germany|Local Institution, Athens, Greece|Local Institution, Larissa, Greece|Local Institution, Beer Sheva, Israel|Local Institution, Haifa, Israel|Local Institution, Ramat Gan, Israel|Local Institution, Zapopan, Jalisco, Mexico|Local Institution, Monterrey, Nuevo LEON, Mexico|Local Institution, Colima, Mexico|Local Institution, Auckland, New Zealand|Local Institution, Christchurch, New Zealand|Local Institution, Lorenskog, Norway|Local Institution, Oslo, Norway|Local Institution, Bucharest, Romania|Local Institution, Craiova, Romania|Local Institution, Saint-Petersburg, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Local Institution, Lugo, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, London, Greater London, United Kingdom|Local Institution, Glasgow, United Kingdom|Local Institution, Oxford, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03661320

Study 84:
  NCT Number:                   NCT02247349
  Title:                        BMS-986012 in Relapsed/Refractory SCLC
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Small Cell Lung Cancer
  Interventions:                Biological: BMS-986012 (anti-fucosyl-GM1)|Biological: Nivolumab
  Outcome Measures:             Safety as measured by frequency of worst grade of adverse events (AEs), worst grade of serious adverse events (SAEs), incidence of adverse events leading to discontinuations, and deaths|Maximum observed serum concentration (Cmax) for BMS-986012 (anti-fucosyl-GM1)|Maximum observed serum concentration (Cmax) for BMS-986012 (anti-fucosyl-GM1) in combination with Nivolumab|Time of maximum observed serum concentration (Tmax) for BMS-986012 (anti-fucosyl-GM1)|Time of maximum observed serum concentration (Tmax) for BMS-986012 (anti-fucosyl-GM1) in combination with Nivolumab|Observed serum concentration at the end of a dosing interval (Ctau) for BMS-986012 (anti-fucosyl-GM1)|Observed serum concentration at the end of a dosing interval (Ctau) for BMS-986012 (anti-fucosyl-GM1) in combination with Nivolumab|Area under the serum concentration-time curve from time zero to time t (AUC(0-t)) for BMS-986012 (anti-fucosyl-GM1) in combination with Nivolumab|Area under the serum concentration-time curve from time zero to time t (AUC(0-t)) for BMS-986012 (anti-fucosyl-GM1)|Area under the serum concentration-time curve in one dosing interval (AUC(TAU)) for BMS-986012 (anti-fucosyl-GM1)|Area under the serum concentration-time curve in one dosing interval (AUC(TAU)) for BMS-986012 (anti-fucosyl-GM1) in combination with Nivolumab|Best overall response (BOR) for BMS-986012 (anti-fucosyl-GM1)|Objective Response Rate (ORR) for BMS-986012 (anti-fucosyl-GM1)|Duration of Response for BMS-986012 (anti-fucosyl-GM1)|Progression Free Survival (PFS) for BMS-986012 (anti-fucosyl-GM1)|Progression Free Survival Rate (PFSR) at week "t"; for BMS-986012 (anti-fucosyl-GM1)|Overall Survival (OS) for BMS-986012 (anti-fucosyl-GM1)|Overall Survival Rate (OSR) at month "t" for BMS-986012 (anti-fucosyl-GM1)|Occurrence of specific anti-drug antibodies (ADA) to BMS-986012 every 3 weeks for first 3 cycles then every 4 cycles, at end of treatment and during clinical follow-up|Occurrence of specific anti-drug antibodies (ADA) to BMS-986012 in combination with Nivolumab every 3 weeks for first 3 cycles then every 4 cycles, at end of treatment and during clinical follow-up|Changes in the QTcF following administration of BMS-986012 at multiple timepoints during first cycle, then Day 1 of subsequent cycles and at end of treatment|Changes in the QTcF following administration of BMS-986012 in combination with Nivolumab at multiple timepoints during first cycle, then Day 1 of subsequent cycles and at end of treatment
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   172
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA001-030|2014-002372-89
  Start Date:                   October 30, 2014
  Primary Completion Date:      October 16, 2018
  Completion Date:              October 17, 2018
  First Posted:                 September 25, 2014
  Results First Posted:         null
  Last Update Posted:           October 3, 2018
  Locations:                    Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Local Institution, St. Leonards, New South Wales, Australia|Local Institution, Brisbane, Queensland, Australia|Local Institution, Clayton, Victoria, Australia|Uz Gent, Gent, Belgium|Local Institution, Liege, Belgium|Cross Cancer Institute, Edmonton, Alberta, Canada|Nova Scotia Health Authority QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|London Regional Cancer Program, London, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Local Institution, Seoul, Korea, Republic of|Radboud Universitair Medisch Centrum, Nijmegen, Netherlands|Local Institution, San Juan, Puerto Rico
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02247349

Study 85:
  NCT Number:                   NCT03329846
  Title:                        An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Melanoma|Skin Cancer
  Interventions:                Drug: BMS-986205|Biological: Nivolumab|Drug: Placebo
  Outcome Measures:             Incidence of Adverse Events (AEs)|Incidence of Serious Adverse Events (SAEs)
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          12 Years and older   (Child, Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   72
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA017-055|2017-002499-14
  Start Date:                   November 21, 2017
  Primary Completion Date:      July 31, 2020
  Completion Date:              July 31, 2020
  First Posted:                 November 6, 2017
  Results First Posted:         null
  Last Update Posted:           October 9, 2018
  Locations:                    Angeles Clinic and Research Institute, Los Angeles, California, United States|University Of Colorado, Aurora, Colorado, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|The University of Chicago Medicine, Chicago, Illinois, United States|Oregon Health & Science University, Portland, Oregon, United States|Local Institution, Seattle, Washington, United States|Local Institution, Blacktown, New South Wales, Australia|Melanoma Institute Australia, North Sydney, New South Wales, Australia|Local Institution, Greenslopes, Queensland, Australia|Local Institution, Woolloongabba, Queensland, Australia|Local Institution, Box Hill, Victoria, Australia|Local Institution, Melbourne, Victoria, Australia|Local Institution, Melbourne, Victoria, Australia|Local Institution, Montreal, Quebec, Canada|Local Institution, Quebec, Canada|Klinika onkologie a radioterapie, Hradec Kralove, Czechia|Dermatovenerologicka klinika 3. LF UK a FNKV, Praha 10, Czechia|Dermatovenerologicka klinika VFN a 1. LF UK, Praha 2, Czechia|Local Institution, Boulogne-billancourt, France|Local Institution, Saint Etienne Cedex 2, France|Local Institution, Villejuif Cedex, France|Elbe Klinikum Buxtehude, Buxtehude, Germany|Universitaetsklinikum Carl Gustav Carus, Dresden, Germany|Universitaetsklinikum Essen, Essen, Germany|SRH Wald-Kliniken Gera GmbH, Gera, Germany|Georg August Universitaet Goettingen, Goettingen, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Nationales Centrum Fuer Tumorerkrakungen (Nct) Heidelberg, Heidelberg, Germany|Ludwig-Maximilians-Universitaet, Muenchen, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Germany|Local Institution, Thessaloniki, Greece|Local Institution, Dooradoyle, Limerick, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Meldola, Italy|Local Institution, Milano, Italy|Istituto Nazionale Tumori Fondazione Pascale, Napoli, Italy|Local Institution, Siena, Italy|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Amsterdam, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Nijmegen, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Christchurch, New Zealand|Local Institution, Wellington, New Zealand|Klinika Nowotworow Tkanek Miekkich, Kosci i Czerniakow, Warszawa, Poland|Hospital Clinic I Provincial, Barcelona, Spain|Complejo Hospitalario de Jaen, Jaen, Spain|Local Institution, Madrid, Spain|Local Institution, Malaga, Spain|Comp. H. U. De Santiago, Santiago Compostela, Spain|Local Institution, Valencia, Spain|Universitaetsspital Zuerich, Zurich, Switzerland|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Belfast, United Kingdom|Local Institution, Cambridge, United Kingdom|Local Institution, Cottingham, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Tauton, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03329846

Study 86:
  NCT Number:                   NCT02741570
  Title:                        Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
  Acronym:                      CheckMate 651
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Head and Neck Cancer
  Interventions:                Biological: Nivolumab|Biological: Ipilimumab|Drug: Cetuximab/Erbitux|Drug: Cisplatin/Platinol|Drug: Carboplatin/Paraplatin|Drug: Fluorouracil/Adrucil
  Outcome Measures:             Overall Survival (OS) in participants with PD-L1 expressing tumors|Progression Free Survival (PFS) in pariticipants with PD-L1 expressing tumors|OS in all participants|PFS in all pariticipants|Objective Response Rate (ORR) in all participants|Duration of Response (DOR) in all participants
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   930
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-651|2016-000725-39
  Start Date:                   August 4, 2016
  Primary Completion Date:      August 14, 2020
  Completion Date:              August 15, 2025
  First Posted:                 April 18, 2016
  Results First Posted:         null
  Last Update Posted:           July 6, 2018
  Locations:                    University of Arizona Cancer Center, Tucson, Arizona, United States|City Of Hope, Duarte, California, United States|Local Institution, San Francisco, California, United States|Board of Trustees of the Leland Stanford Junior University, Stanford, California, United States|21st Century Oncology Of Jacksonville, Llc, Jacksonville, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Univ Of Chicago, Chicago, Illinois, United States|Mass General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University Of Michigan, Ann Arbor, Michigan, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|James Cancer Hospital, Columbus, Ohio, United States|St. Mary Medical Center, Langhorne, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Houston Methodist Medical Center, Houston, Texas, United States|Univ Of Tx. Md Anderson, Houston, Texas, United States|University Of Virginia Health System, Charlottesville, Virginia, United States|Local Institution, Fairfax, Virginia, United States|West Virginia University, Morgantown, West Virginia, United States|Blacktown Hospital, Blacktown, New South Wales, Australia|St Vincent'S Hospital (Nsw), Darlinghurst, New South Wales, Australia|Local Institution, Gosford, New South Wales, Australia|Royal North Shore Hospital, St. Leonards, New South Wales, Australia|Local Institution, Brisbane, Queensland, Australia|Local Institution, Douglas, Queensland, Australia|Lyell McEwin Hospital, Elizabeth Vale, South Australia, Australia|Monash Medical Center, Clayton, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Melbourne, Australia|Krankenhaus Der Barmherzigen Schwestern, Linz, Austria|Medical University Of Vienna, Wien, Austria|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RS, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Jose De Rio Preto, SAO Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Amiens, France|Local Institution, Bordeaux, France|Local Institution, La Tronche, France|Local Institution, Lille, France|Local Institution, Lyon, France|Local Institution, Lyon, France|Local Institution, Marseille, France|Local Institution, Nice Cedex 2, France|Local Institution, Paris, France|Local Institution, Paris, France|Local Institution, Paris, France|Local Institution, Strasbourg, France|Local Institution, Villejuif Cedex, France|Universitaetsklinikum Bonn, Bonn, Germany|Klinikum Der Albrecht-Ludwigs-Universitat, Freiburg, Germany|Uniklinikum Hamburg-Eppendorf, Hamburg, Germany|Klinikum Der Universitaet, Hannover, Germany|Universitaetsklinik Heidelberg, Heidelberg, Germany|Universitaetsklinikum Leipzig, Leipzig, Germany|Universitaetsmedizin Der Johannes Gutenberg-Universitaet, Mainz, Germany|Klinikum rechts der Isar der Technischen Universitat Munchen, Muenchen, Germany|Universitaetsklinikum Ulm, Ulm, Germany|Universitat Wurzburg, Wuerzburg, Germany|Local Institution, Athens, Greece|Local Institution, Nea Kifissia, Greece|Local Institution, Thessaloniki, Greece|Local Institution, Dublin 8, Dublin, Ireland|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Petah-tikva, Israel|Local Institution, Ramat-gan, Israel|Local Institution, Tel Aviv, Israel|Istituto Romagnolo Per Lo Studio E La Cura Dei Tumori, Meldola, FC, Italy|IRCCS Istituto Nazionale Tumori Milano, Milano, MI, Italy|Azienda Ospedaliera Citta della Salute e della Scienza, Torino, TO, Italy|Local Institution, Mestre, VE, Italy|A.O. Santa Croce E Carle, Cuneo, Italy|Azienda Ospedaliera Universitaria Di Modena, Modena, Italy|Aorn Dei Colli, Napoli, Italy|Istituto Nazionale Tumori Fondazione Pascale, Napoli, Italy|Local Institution, Perugia, Italy|Fondazione Policlinico Universitario A. Gemelli, Roma, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Kashiwa, Chiba, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Akashi-shi, Hyogo, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Isehara, Kanagawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Natori, Miyagi, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Osakasayaha, Osaka, Japan|Local Institution, Takatsuki-shi, Osaka, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Shimotsuke-shi, Tochigi, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Koto-ku, Tokyo, Japan|Local Institution, Kita-gun, Japan|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Df, Distrito Federal, Mexico|Local Institution, Mexico City, Distrito Federal, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Leon de los Aldama, Guanajuato, Mexico|Local Institution, Morelia, Michoacan, Mexico|Joaquin Gabriel Reinoso Toledo, Monterrey, Nuevo LEON, Mexico|Local Institution, Oaxaca, Mexico|Ambulatorium Chemioterapii, Bydgoszcz, Poland|Klinika Onkologii i Radioterapii, Gdansk, Poland|Centrum Onkologii-Inst.Im.M.Sklodowskiej-Curie O.W Gliwicach, Gliwice, Poland|Osrodek Badan Klinicznych, Krakow, Poland|Klinika Nowotworow Glowy i Szyi, Warszawa, Poland|Local Institution, Barcelona, Spain|Local Institution, L?Hospitalet De Llobregat, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Klinik Fur Onkologie, Basel, Switzerland|Universitatsspital Zurich, Zuerich, Switzerland|Local Institution, Taichung, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Newcastle Upon Tyne, Durham, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom|Local Institution, Birmingham, WEST Midlands, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Sheffield, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02741570

Study 87:
  NCT Number:                   NCT02996110
  Title:                        A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma
  Acronym:                      FRACTION-RCC
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Advanced Cancer
  Interventions:                Biological: Nivolumab|Biological: Ipilimumab|Biological: Relatlimab|Drug: BMS-986205
  Outcome Measures:             Objective Response Rate (ORR)|Duration of Response (DOR)|Progression-free Survival Rate (PFSR)|Safety as measured by incidence of AEs (Adverse Events)|Safety as measured by incidence of SAEs (Serious Adverse Events)|Tolerability as measured by incidence of AEs|Tolerability as measured by SAEs
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   200
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA018-005|2016-003082-26
  Start Date:                   January 17, 2017
  Primary Completion Date:      January 17, 2022
  Completion Date:              January 18, 2022
  First Posted:                 December 19, 2016
  Results First Posted:         null
  Last Update Posted:           November 28, 2018
  Locations:                    Local Institution, San Francisco, California, United States|Yale Cancer Center, New Haven, Connecticut, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Augusta University, Augusta, Georgia, United States|Rush University Med Ctr, Chicago, Illinois, United States|Sidney Kimmel Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Karmanos Cancer Center, Detroit, Michigan, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Columbia University Medical Center (Cumc), New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|The Ohio State University, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Hollings Cancer Center, Charleston, South Carolina, United States|Tennessee Oncology, Pc, Nashville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Westmead Hospital, Westmead, New South Wales, Australia|Monash Medical Centre Clayton, Bentleigh, Victoria, Australia|Krankenhaus Der Barmherzigen Schwestern, Linz, Austria|Local Institution, Halifax, Nova Scotia, Canada|Local Institution, Hamilton, Ontario, Canada|Local Institution, Oshawa, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Local Institution, Quebec, Canada|Local Institution, Haifa, Israel|Local Institution, Ramat Gan, Israel|IRCCS Istituto Nazionale Tumori Milano, Milano, Italy|Istituto Nazionale Tumori Fondazione Pascale, Napoli, Italy
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02996110

Study 88:
  NCT Number:                   NCT00730639
  Title:                        A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies
  Acronym:                      MDX1106-03
  Status:                       Active, not recruiting
  Study Results:                Has Results
  Conditions:                   Metastatic Castration-resistant Prostrate Cancer|Renal Cell Carcinoma|Metastatic Melanoma|Non-small Cell Lung Cancer
  Interventions:                Biological: BMS-936558 (MDX-1106)
  Outcome Measures:             Number of Participants With Severe Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment-Related AEs, Deaths, Discontinuation of Study Drug Due to AEs|Number of Participants With Abnormal Serum Chemistry Laboratory Values|Number of Participants With Abnormal Hematology Laboratory Values|Immunogenicity Assessment|Objective Response Rate|Duration of Tumor Response|Geometric Mean Maximum Serum Concentration (Cmax)|Median Time of Maximum Serum Concentration (Tmax)|Geometric Mean Area Under the Curve (AUC[TAU]) in One Dosing Interval Observed Post-Single Dose|Geometric Mean Total Body Clearance of Drug From Serum (CLT)|Mean Effective Half-life (T-HALFeff)
  Sponsor/Collaborators:        Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   395
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-003|MDX1106-03
  Start Date:                   January 22, 2009
  Primary Completion Date:      February 4, 2013
  Completion Date:              May 14, 2019
  First Posted:                 August 8, 2008
  Results First Posted:         April 15, 2016
  Last Update Posted:           August 2, 2018
  Locations:                    Pinnacle Oncology Hematology, Scottsdale, Arizona, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University Of Michigan Cancer Center, Ann Arbor, Michigan, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Carolina Biooncology Institute, Huntersville, North Carolina, United States|Christ Hospital, Cincinnati, Ohio, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Ctr, Nashville, Tennessee, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00730639

Study 89:
  NCT Number:                   NCT03348904
  Title:                        Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer
  Acronym:                      
  Status:                       Terminated
  Study Results:                No Results Available
  Conditions:                   Lung Cancer
  Interventions:                Drug: Nivolumab|Drug: Epacadostat|Drug: Placebo|Drug: Carboplatin|Drug: Cisplatin|Drug: Gemcitabine|Drug: Paclitaxel|Drug: Pemetrexed
  Outcome Measures:             Overall survival (OS) of nivolumab plus epacadostat in combination with chemotherapy (Arm A) compared to chemotherapy (Arm B)|Progression-free survival (PFS) of nivolumab plus epacadostat in combination with chemotherapy (Arm A) compared to chemotherapy (Arm B)|Objective response rate (ORR) of nivolumab plus epacadostat in combination with chemotherapy (Arm A) compared to chemotherapy (Arm B)|Duration of response (DOR) of nivolumab plus epacadostat in combination with chemotherapy (Arm A) compared to chemotherapy (Arm B)|Estimate of OS of nivolumab and placebo in combination with chemotherapy (Arm C)|Estimate of PFS of nivolumab and placebo in combination with chemotherapy (Arm C)|Estimate of ORR of nivolumab and placebo in combination with chemotherapy (Arm C)|Estimate of DOR of nivolumab and placebo in combination with chemotherapy (Arm C)
  Sponsor/Collaborators:        Incyte Corporation|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   2
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  Other IDs:                    CA2099NC/ECHO-309
  Start Date:                   December 27, 2017
  Primary Completion Date:      May 22, 2018
  Completion Date:              May 22, 2018
  First Posted:                 November 21, 2017
  Results First Posted:         null
  Last Update Posted:           July 20, 2018
  Locations:                    Pacific Cancer Medical Center, Inc, Anaheim, California, United States|Cancer Center of Kansas, Wichita, Kansas, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03348904

Study 90:
  NCT Number:                   NCT02754141
  Title:                        An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Malignant Solid Tumor
  Interventions:                Biological: BMS-986179|Biological: Nivolumab|Drug: rHuPH20
  Outcome Measures:             Number of adverse events (AE), serious adverse events (SAE), AEs leading to discontinuation, and deaths|BMS-986179 enzyme assays in pre- and on-treatment biopsies|BMS-986179 immunohistochemistry (IHC) in pre- and on-treatment biopsies|Objective response rate (ORR)|Duration of response (DOR)|Progression free survival rate (PFSR)|Maximum observed serum concentration (Cmax)|Time of maximum observed serum concentration (Tmax)|Area under the serum concentration-time curve from time zero to time of the last quantifiable concentration [AUC(0-T)]|Area under the serum concentration-time curve in 1 dosing interval [AUC(TAU)]|Apparent terminal half-life (T-HALF)|Area under the serum concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]|Effective elimination half-life (T-HALFeff)|Concentration at the end of the dosing interval (Ctau)|Trough observed serum concentration at the end of the dosing interval (Ctrough)|Total body clearance (CLT)|Volume of distribution at steady state (Vss)|Accumulation index (AI)|Apparent volume of distribution of terminal phase (Vz)|Degree of fluctuation or fluctuation index (DF)|Frequency of positive anti-drug antibody (ADA) to BMS-986179|Frequency of positive anti-drug antibody (ADA) to nivolumab
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   221
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA013-004|2016-000603-91
  Start Date:                   June 20, 2016
  Primary Completion Date:      March 11, 2019
  Completion Date:              May 21, 2020
  First Posted:                 April 28, 2016
  Results First Posted:         null
  Last Update Posted:           July 30, 2018
  Locations:                    Johns Hopkins University, Baltimore, Maryland, United States|Local Institution, Boston, Massachusetts, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Columbia University Medical Center (Cumc), New York, New York, United States|Local Institution, Pittsburgh, Pennsylvania, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Mary Crowley Medical Research Center, Dallas, Texas, United States|The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia|Scientia Clinical Research Limited, Randwick, New South Wales, Australia|Local Institution, Melbourne, Victoria, Australia|Local Institution, Ottawa, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Marseille Cedex 5, France|Local Institution, Toulouse Cedex 9, France|Local Institution, Villejuif Cedex, France|Local Institution, Freiburg, Germany|Klinikum rechts der Isar der Technischen Universitat Muenchen Klinik und Poliklinik fur Innere Mediz, Munich, Germany|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Amsterdam, Netherlands
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02754141

Study 91:
  NCT Number:                   NCT03383458
  Title:                        A Study of Nivolumab in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
  Acronym:                      CheckMate 9DX
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Hepatocellular Carcinoma|Liver Cancer
  Interventions:                Biological: Nivolumab|Other: Placebo
  Outcome Measures:             Recurrence-free Survival (RFS)|Overall Survival (OS)|Time to recurrence (TTR)
  Sponsor/Collaborators:        Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   530
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  Other IDs:                    CA209-9DX
  Start Date:                   December 18, 2017
  Primary Completion Date:      April 17, 2022
  Completion Date:              June 7, 2025
  First Posted:                 December 26, 2017
  Results First Posted:         null
  Last Update Posted:           November 20, 2018
  Locations:                    Pinnacle Research Group, Llc, Anniston, Alabama, United States|Mayo Clinic Hospital, Phoenix, Arizona, United States|USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|UCLA School Of Medicine, Los Angeles, California, United States|Stanford Cancer Center, Palo Alto, California, United States|California Pacific Medical Center Research Institute, San Francisco, California, United States|Sylvester Comprehensive Cancer Center/ UMHC, Miami, Florida, United States|H. Lee Moffit Cancer center and research institute, Tampa, Florida, United States|Winship Cancer Institute-Emory University, Atlanta, Georgia, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|University of Michigan, Ann Arbor, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Laura and Issac Perlmutter Cancer Center at NYU Langone - Belleview Hospital, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Providence Portland Medical Center, Portland, Oregon, United States|McGuire VA Medical Center, Richmond, Virginia, United States|Local Institution, Camperdown, New South Wales, Australia|Local Institution, Concord, New South Wales, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Perth, Western Australia, Australia|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Edegem, Belgium|Local Institution, Impact Migration, Belgium|Local Institution, Leuven, Belgium|Local Institution, Calgary, Alberta, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Bondy, France|Local Institution, Brest, France|Local Institution, Clermont-Ferrand, France|Local Institution, Clichy, France|Local Institution, Creteil Cedex, France|Local Institution, GRENOBLE Cedex 09, France|Local Institution, Lyon Cedex 4, France|Local Institution, Montpellier Cedex 5, France|Local Institution, Nice cedex 3, France|Local Institution, Paris, France|Local Institution, Poitiers, France|Local Institution, Reims Cedex, France|Local Institution, Rennes Cedex 9, France|Local Institution, Saint Etienne, France|Local Institution, Vandoeuvre-les-Nancy, France|Local Institution, Messina, ME, Italy|Local Institution, Cagliari, Italy|Local Institution, Firenze, Italy|Local Institution, Meldola, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Rome, Italy|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Kurume-shi, Fukuoka, Japan|Local Institution, Hiroshima-Shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Nishinomiya-shi, Hyogo, Japan|Local Institution, Kanazawa-shi, Ishikawa, Japan|Local Institution, Kawasaki-shi, Kanagawa, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Osaka-sayama, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Tokushima-shi, Tokushima, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Mitaka-shi, Tokyo, Japan|Local Institution, Musashino-shi, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Suwon-si, Gyeonggi-do, Korea, Republic of|Local Institution, Daegu, Korea, Republic of|Local Institution, Gyeonggi-do, Korea, Republic of|Local Institution, Gyeongsangnam-do, Korea, Republic of|Local Institution, Jeonnam, Korea, Republic of|Local Institution, Seongnam-si, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Brasov, Romania|Local Institution, Bucharest, Romania|Local Institution, Craiova, Romania|Local Institution, Timisoara, Romania|Local Institution, Arkhangelsk, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Barcelona, Spain|Local Institution, Cordoba, Spain|Local Institution, Donostia-San Sebastian, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Pamplona, Spain|Local Institution, Sabadell, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Local Institution, Zaragoza, Spain|Local Institution, Chiayi, Taiwan|Local Institution, Kaohsiung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Tainan, Taiwan|Local Institution, Tainan, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, Yunlin, Taiwan|Local Institution, London, United Kingdom|Local Institution, London, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Wirral, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03383458

Study 92:
  NCT Number:                   NCT02864251
  Title:                        A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Patients With EGFR Mutation, T790M Negative NSCLC Who Have Failed 1L EGFR TKI Therapy
  Acronym:                      CheckMate722
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Non-Small-Cell Lung Carcinoma
  Interventions:                Biological: Nivolumab|Biological: Ipilimumab|Drug: Pemetrexed|Drug: Cisplatin|Drug: Carboplatin
  Outcome Measures:             Progression free survival (PFS) in subjects with epidermal growth factor receptor (EGFR) mutation, T790M negative non-small cell lung carcinoma (NSCLC)|Overall survival (OS)|Objective response rate (ORR)|Duration of response (DOR)|Progression free survival (PFS) rate
  Sponsor/Collaborators:        Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   465
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-722
  Start Date:                   October 20, 2016
  Primary Completion Date:      September 30, 2019
  Completion Date:              December 31, 2023
  First Posted:                 August 11, 2016
  Results First Posted:         null
  Last Update Posted:           September 25, 2018
  Locations:                    Pacific Shores Medical Group, Long Beach, California, United States|Los Angeles Hematology Oncology Medical Group, Los Angeles, California, United States|UCLA Cancer Hematology Oncology, Los Angeles, California, United States|St Joseph Hospital, Orange, California, United States|Torrance Memorial Physican Network, Redondo Beach, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|University of Chicago, Chicago, Illinois, United States|Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|NYU Langone Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Texas Health Physicians Group, Fort Worth, Texas, United States|Baylor Scott and White Research Institute, Temple, Texas, United States|Tyler Hematology/Oncology PA, Tyler, Texas, United States|Huntsman Cancer Institute at The University of Utah, Salt Lake City, Utah, United States|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Chongqing, Chongqing, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Changsha, Hunan, China|Local Institution, Changchun, Jilin, China|Local Institution, Changchun, Jilin, China|Local Institution, Xi`an, Shan1xi, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Hanghzou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Shanghai, China|Local Institution, Marseille, France|Local Institution, Paris, France|Local Institution, Rennes, France|Local Institution, Toulouse, France|Local Institution, Hong Kong, Hong Kong|Local Institution, Hong Kong, Hong Kong|Local Institution, Hong Kong, Hong Kong|Local Institution, Hong Kong, Hong Kong|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Hirosaki-shi, Aomori, Japan|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Iizuka-shi, Fukuoka, Japan|Local Institution, Kurume-shi, Fukuoka, Japan|Local Institution, Fukushima-shi, Fukushima, Japan|Local Institution, Fukuyama, Hiroshima, Japan|Local Institution, Sapporo, Hokkaido, Japan|Local Institution, Himeji, Hyogo, Japan|Local Institution, Itami, Hyogo, Japan|Local Institution, Kobe City, Hyogo, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Yokohama-Shi, Kanagawa, Japan|Local Institution, Yokohama, Kanagawa, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Natori-shi, Miyagi, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Kiriyama-shi, Niigata, Japan|Local Institution, Hirakata-shi, Osaka, Japan|Local Institution, Kishiwada shi, Osaka, Japan|Local Institution, Osakasayama-shi, Osaka, Japan|Local Institution, Sakai-shi, Osaka, Japan|Local Institution, Hidaka, Saitama, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo, Tokyo, Japan|Local Institution, Koto, Tokyo, Japan|Local Institution, Ube, Yamaguchi, Japan|Local Institution, Chiba, Japan|Local Institution, Fukuoka, Japan|Local Institution, Niigata, Japan|Local Institution, Tokyo, Japan|Local Institution, Toyama, Japan|Local Institution, Wakayama, Japan|Local Institution, Cheogju-si, Korea, Republic of|Local Institution, Goyang, Korea, Republic of|Local Institution, Gyeonggi-do, Korea, Republic of|Local Institution, Inchoen, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Barcelona, Spain|Local Institution, L'Hospitalet de Llobregat, Spain|Local Institution, Madrid, Spain|Local Institution, Majadahonda, Spain|Local Institution, Malaga, Spain|Local Institution, Zaragoza, Spain|Local Institution, Chiayi, Taiwan|Local Institution, Kaohsiung City, Taiwan|Local Institution, Kaohsiung city, Taiwan|Local Institution, Kaohsiung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Tainan, Taiwan|Local Institution, Tainan, Taiwan|Local Institution, Taipei City, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02864251

Study 93:
  NCT Number:                   NCT03349710
  Title:                        Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Squamous Cell Carcinoma of the Head and Neck
  Interventions:                Biological: Nivolumab|Drug: Cetuximab|Drug: Cetuximab Placebo|Drug: Nivolumab Placebo|Drug: Cisplatin|Radiation: Radiotherapy
  Outcome Measures:             Event Free Survival (EFS)|Duration of loco-regional control (DLRC)|Overall Survival (OS)|European Organisation for the Research and Treatment of Cancer (EORTC)|Quality of Life Questionnaire-Core 30 (QLQ-C30)|European Organization for Research and Treatment of Cancer [EORTC] Quality of Life Head and Neck (QLQQH&N35)
  Sponsor/Collaborators:        Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   1046
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  Other IDs:                    CA209-9TM|2017-002676-87
  Start Date:                   December 15, 2017
  Primary Completion Date:      November 9, 2022
  Completion Date:              November 10, 2022
  First Posted:                 November 21, 2017
  Results First Posted:         null
  Last Update Posted:           October 23, 2018
  Locations:                    Pinnacle Research Group, Llc, Anniston, Alabama, United States|Cancer Treatment Centers of Phoneix, Goodyear, Arizona, United States|University of Arizona Cancer Center, Tucson, Arizona, United States|CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center, Bakersfield, California, United States|University of California San Diego (UCSD), La Jolla, California, United States|UCLA Health, Los Angeles, California, United States|Cancer Care - Torrance Memorial Physician Network, Redondo Beach, California, United States|Pacific Central Coast Health Centers - San Luis Obispo Oncology and Hematology Health Center, San Luis Obispo, California, United States|Cancer Center of Central Connecticut, Plainville, Connecticut, United States|Helen F. Graham Cancer Center, Newark, Delaware, United States|Orlando Health, Inc., Orlando, Florida, United States|Winship Cancer Insitute, Emory Crawford Long Hospital, Atlanta, Georgia, United States|CTCA Southeastern Region, Newnan, Georgia, United States|Lewis Hall Singletary Oncology Center at John D. Archbold Memorial Hospital, Thomasville, Georgia, United States|Northshore University HealthSystem, Evanston, Illinois, United States|Midwestern Regional medical Center, Zion, Illinois, United States|Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States|Medical Oncology And Hematology Associates Of Iowa, Des Moines, Iowa, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|Dana Farber Cancer Institute (DFCI), Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Forrest General Cancer Center, Hattiesburg, Mississippi, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Nebraska Cancer Specialists (Ncs) At Methodist Estabrook Cancer Center, Omaha, Nebraska, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Louis Stokes Cleveland VA Medical Center - Wade Park Campus Location, Cleveland, Ohio, United States|Eastern Regional Medical Center, Philadelphia, Pennsylvania, United States|Upmc- Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|St. Joseph Regional Cancer Center, Bryan, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|UT Health Science Center San Antonio, San Antonio, Texas, United States|Inova Health System, Falls Church, Virginia, United States|HHP Hematology & Oncology Bremerton, Bremerton, Washington, United States|Local Institution, Darlinghurst, New South Wales, Australia|Local Institution, Kogarah, New South Wales, Australia|Local Institution, Woolloongabba, Queensland, Australia|Local Institution, Moncton, New Brunswick, Canada|Local Institution, Grenoble, France|Local Institution, Marseille, France|Local Institution, Montpellier, France|Local Institution, Nice, France|Local Institution, Rouen Cedex 1, France|Local Institution, Firenze, Italy|Local Institution, Lucca, Italy|Local Institution, Meldola, Italy|Local Institution, Milan, Italy|Local Institution, Naples, Italy|Local Institution, Ravenna, Italy|Local Institution, Nagoya, Aichi, Japan|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Sapporo, Hokkaido, Japan|Local Institution, Akashi-shi, Hyogo, Japan|Local Institution, Kobe City, Hyogo, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Tsukuba-shi, Ibaraki, Japan|Local Institution, Kagoshima-shi, Kagoshima, Japan|Local Institution, Isehara, Kanagawa, Japan|Local Institution, Natori-shi, Miyagi, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Osaka-sayama-shi, Osaka, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Bunkyo-ku, Japan|Local Institution, Osaka, Japan|Local Institution, Cheongju-si, Korea, Republic of|Local Institution, Jeollanam-do, Korea, Republic of|Local Institution, Seongnam-si, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Bielsko-Biala, Poland|Local Institution, Gdynia, Poland|Local Institution, Moscow, Russian Federation|Local Institution, Yekaterinburg, Russian Federation|Local Institution, A Coruna, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Majadahonda, Spain|Local Institution, Valencia, Spain|Local Institution, Valencia, Spain|Local Institution, Valencia, Spain|Local Institution, Kaohsiung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Tainan, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, Ankara, Turkey|Local Institution, Istanbul, Turkey|Local Institution, Izmir, Turkey|Local Institution, Kocaeli, Turkey
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03349710

Study 94:
  NCT Number:                   NCT03336216
  Title:                        A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Advanced Pancreatic Cancer
  Interventions:                Biological: Cabiralizumab|Drug: Nab-paclitaxel|Drug: Onivyde|Biological: Nivolumab|Drug: Fluorouracil|Drug: Gemcitabine|Drug: Oxaliplatin|Drug: Leucovorin|Drug: Irinotecan Hydrochloride
  Outcome Measures:             Median progression free survival (mPFS)|Trough observed serum concentration (Ctrough)|Objective response rate (ORR)|Median duration of response (MDOR)|Overall survival rate (OSR)|Incidence of Adverse Events (AE)|Incidence of Serious Adverse Events (SAE)|Incidence of death|Incidence of laboratory abnormalities|Incidence of Adverse Events (AE) leading to discontinuation
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   160
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA025-006
  Start Date:                   December 15, 2017
  Primary Completion Date:      December 14, 2020
  Completion Date:              December 15, 2020
  First Posted:                 November 8, 2017
  Results First Posted:         null
  Last Update Posted:           October 3, 2018
  Locations:                    Local Institution, Phoenix, Arizona, United States|HonorHealth Research Institute, Scottsdale, Arizona, United States|HonorHealth, Scottsdale, Arizona, United States|Ucla Medical Center, Los Angeles, California, United States|University Of Colorado, Aurora, Colorado, United States|Johns Hopkins University, Baltimore, Maryland, United States|Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|Washington University, Saint Louis, Missouri, United States|Laura & Isaac Perlmutter Cancer Ctr at NYU Langone, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|UPMC, Pittsburgh, Pennsylvania, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Md Anderson, Houston, Texas, United States|Local Institution, Seattle, Washington, United States|Local Institution, Edmonton, Alberta, Canada|Local Institution, Kingston, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Heidelberg, Germany|Local Institution, Mannheim, Germany|Local Institution, Ulm, Germany|Local Institution, Wuerzburg, Germany|Local Institution, Padova, Italy|Local Institution, Rome, Italy|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Chur, Switzerland|Local Institution, Lausanne, Switzerland|Local Institution, Taipei, Taiwan|Local Institution, Glasgow, Strathclyde, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03336216

Study 95:
  NCT Number:                   NCT03040791
  Title:                        Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial)
  Acronym:                      ImmunoProst
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Prostate Cancer
  Interventions:                Drug: Nivolumab
  Outcome Measures:             PSA response rate|Time to PSA progression|PSA Response Rate at 6 and 12 months|Radiological progression-free survival (rPFS)|Time to Radiographic Progression|Progression free survival (PFS)|Overall survival
  Sponsor/Collaborators:        Hospital Moinhos de Vento|Bristol-Myers Squibb
  Gender:                       Male
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   29
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    64121317.4.1001.5330
  Start Date:                   June 1, 2018
  Primary Completion Date:      July 1, 2019
  Completion Date:              July 1, 2019
  First Posted:                 February 2, 2017
  Results First Posted:         null
  Last Update Posted:           July 31, 2018
  Locations:                    Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil|Instituto do Câncer do Estado de São Paulo, Sao Paulo, São Paulo, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03040791

Study 96:
  NCT Number:                   NCT03637543
  Title:                        Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Prostate Cancer
  Interventions:                Drug: Nivolumab
  Outcome Measures:             Disease Control|Maximal change in prostate specific antigen (PSA) during nivolumab treatment|Best PSA response during nivolumab treatment as an absolute change relative to baseline|Change in PSA doubling time (PSADT) at end-of-study relative to baseline|Time from enrollment to development of radiographic metastatic disease|Time from enrollment to initiation of androgen deprivation therapy (ADT)|Treatment-related adverse events as assessed by CTCAE v5.0
  Sponsor/Collaborators:        Beth Israel Deaconess Medical Center|Bristol-Myers Squibb|Dana-Farber Cancer Institute
  Gender:                       Male
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   34
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    18-249
  Start Date:                   September 30, 2018
  Primary Completion Date:      March 31, 2022
  Completion Date:              March 31, 2025
  First Posted:                 August 20, 2018
  Results First Posted:         null
  Last Update Posted:           August 22, 2018
  Locations:                    Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03637543

Study 97:
  NCT Number:                   NCT03414684
  Title:                        Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Breast Cancer
  Interventions:                Drug: Carboplatin|Drug: Nivolumab
  Outcome Measures:             Progression-free survival (PFS)|Overall Response Rate|Overall Survival|Clinical Benefit Rate|Duration of Response|Time to Objective Response|BRCA carriers|Incidence Rate of each Toxicity (safety and tolerability)
  Sponsor/Collaborators:        Dana-Farber Cancer Institute|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   132
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    17-512|CA209-9JX
  Start Date:                   January 30, 2018
  Primary Completion Date:      June 30, 2021
  Completion Date:              June 30, 2025
  First Posted:                 January 30, 2018
  Results First Posted:         null
  Last Update Posted:           October 2, 2018
  Locations:                    The Stamford Hospital, Stamford, Connecticut, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|St. Elizabeth's Medical Center, Boston, Massachusetts, United States|Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center, Milford, Massachusetts, United States|Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital, South Weymouth, Massachusetts, United States|Dana-Farber/New Hampshire Oncology-Hematology, Londonderry, New Hampshire, United States|Ohio State University, Columbus, Ohio, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03414684

Study 98:
  NCT Number:                   NCT03246958
  Title:                        Nivolumab Plus Ipilimumab in Thyroid Cancer
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Thyroid Cancer
  Interventions:                Drug: Nivolumab|Drug: Ipilimumab
  Outcome Measures:             Radiographic Response Rate|Progression Free Survival|Overall Survival|Tolerability
  Sponsor/Collaborators:        Dana-Farber Cancer Institute|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   54
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    17-255
  Start Date:                   September 20, 2017
  Primary Completion Date:      March 31, 2021
  Completion Date:              March 31, 2025
  First Posted:                 August 11, 2017
  Results First Posted:         null
  Last Update Posted:           August 24, 2018
  Locations:                    Dana Farber Cancer Institute, Boston, Massachusetts, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03246958

Study 99:
  NCT Number:                   NCT02829918
  Title:                        Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Biliary Tract Cancer|Biliary Tract Neoplasms
  Interventions:                Drug: Nivolumab
  Outcome Measures:             Overall Response Rate (ORR) After 4 Cycles of Treatment|Overall Survival (OS)|Progression Free Survival (PFS)
  Sponsor/Collaborators:        H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   52
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    MCC-18684
  Start Date:                   September 19, 2016
  Primary Completion Date:      October 31, 2019
  Completion Date:              October 31, 2020
  First Posted:                 July 12, 2016
  Results First Posted:         null
  Last Update Posted:           November 29, 2018
  Locations:                    City of Hope Cancer Center, Duarte, California, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory University Winship Cancer Institute, Atlanta, Georgia, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02829918

Study 100:
  NCT Number:                   NCT03532451
  Title:                        Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
  Acronym:                      PrE0807
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Bladder Cancer
  Interventions:                Drug: Nivolumab|Drug: Nivolumab/Lirilumab
  Outcome Measures:             Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE V5.0|Change in CD8+ Tumor-Infiltrating Lymphocytes (TIL) Density|Percent Change in CD8+ TIL Density|Number of Patients unable to undergo RC|Complete Response Rate|Recurrence-Free Survival (RFS)|Immunohistochemistry (IHC) Change|Peripheral Blood Mononuclear Cell (PBMC) T-Cell Subset Change
  Sponsor/Collaborators:        PrECOG, LLC.|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   43
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    PrE0807|CA209-9DF
  Start Date:                   November 2018
  Primary Completion Date:      December 2020
  Completion Date:              September 2022
  First Posted:                 May 22, 2018
  Results First Posted:         null
  Last Update Posted:           November 6, 2018
  Locations:                    University of TX Southwestern, Dallas, Texas, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03532451

Study 101:
  NCT Number:                   NCT03106610
  Title:                        Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy
  Acronym:                      
  Status:                       Terminated
  Study Results:                No Results Available
  Conditions:                   Bladder Cancer
  Interventions:                Drug: Nivolumab|Behavioral: Questionnaires
  Outcome Measures:             Safety of Nivolumab in Subjects Previously Treated with Intravesical Bacillus Calmette-Guerin (BCG) Immunotherapy assessed per NCI CTCAE version 4|Tolerability of Nivolumab in Subjects Previously Treated with Intravesical Bacillus Calmette-Guerin (BCG) Immunotherapy assessed using AUASS|Systemic Symptom Burden of Nivolumab in Subjects Previously Treated with Intravesical Bacillus Calmette-Guerin (BCG) Immunotherapy assessed using MDASI
  Sponsor/Collaborators:        M.D. Anderson Cancer Center|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   1
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    2016-0432|NCI-2017-00647
  Start Date:                   July 7, 2017
  Primary Completion Date:      May 16, 2018
  Completion Date:              May 16, 2018
  First Posted:                 April 10, 2017
  Results First Posted:         null
  Last Update Posted:           May 24, 2018
  Locations:                    University of Texas MD Anderson Cancer Center, Houston, Texas, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03106610

Study 102:
  NCT Number:                   NCT03712943
  Title:                        Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Colorectal Cancer|Metastatic Colorectal Cancer|Colon Cancer
  Interventions:                Drug: Regorafenib|Drug: Nivolumab
  Outcome Measures:             Maximum Tolerated Dose|Response Rate|Overall Survival (OS)|Frequency and Severity of Adverse Events
  Sponsor/Collaborators:        H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   28
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    MCC-19581
  Start Date:                   October 12, 2018
  Primary Completion Date:      October 2020
  Completion Date:              October 2022
  First Posted:                 October 19, 2018
  Results First Posted:         null
  Last Update Posted:           October 19, 2018
  Locations:                    H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03712943

Study 103:
  NCT Number:                   NCT03104439
  Title:                        Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Microsatellite Stable Colorectal Cancer|Pancreatic Cancer|MSI High Colorectal Cancer
  Interventions:                Drug: Nivolumab|Drug: Ipilimumab|Radiation: Radiation Therapy
  Outcome Measures:             Disease Control Rate|Median Progression free Survival|Median Overall Survival
  Sponsor/Collaborators:        Massachusetts General Hospital|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   80
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    17-021
  Start Date:                   May 10, 2017
  Primary Completion Date:      October 31, 2020
  Completion Date:              October 31, 2024
  First Posted:                 April 7, 2017
  Results First Posted:         null
  Last Update Posted:           October 12, 2018
  Locations:                    Massachusetts general Hospital, Boston, Massachusetts, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03104439

Study 104:
  NCT Number:                   NCT03061539
  Title:                        Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Prostate Cancer
  Interventions:                Drug: Nivolumab & Ipilimumab
  Outcome Measures:             Composite response rate|Overall survival|Radiological progression free survival|PSA progression free survival|Change in patient reported outcome measures (NCI's PRO-CTCAE)|Frequency and severity of adverse events
  Sponsor/Collaborators:        University College, London|Bristol-Myers Squibb
  Gender:                       Male
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   175
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-935
  Start Date:                   February 6, 2018
  Primary Completion Date:      April 2019
  Completion Date:              July 2024
  First Posted:                 February 23, 2017
  Results First Posted:         null
  Last Update Posted:           July 12, 2018
  Locations:                    University College London Hospital, London, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03061539

Study 105:
  NCT Number:                   NCT03171025
  Title:                        Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer
  Acronym:                      NEXT
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Bladder Cancer
  Interventions:                Drug: Nivolumab
  Outcome Measures:             Two-year rate of failure-free survival (FFS)|Rate of failure-free survival at two years in subjects with intact bladder (FFSIB).|Rate of acute and late grade 2 or higher treatment related Genitourinary, Gastrointestinal, hematologic and immune related adverse events.|Effect of treatment on Quality of Life|Cystoscopic Local Control|Rate of salvage cystectomy|Rate of distant failure free survival|Overall Survival
  Sponsor/Collaborators:        University of Utah|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   28
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    HCI100769
  Start Date:                   July 10, 2017
  Primary Completion Date:      June 2024
  Completion Date:              June 2024
  First Posted:                 May 31, 2017
  Results First Posted:         null
  Last Update Posted:           May 16, 2018
  Locations:                    Huntsman Cancer Institute, Salt Lake City, Utah, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03171025

Study 106:
  NCT Number:                   NCT02982954
  Title:                        A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer
  Acronym:                      CHECKMATE 920
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Renal Cell Carcinoma
  Interventions:                Drug: Nivolumab|Drug: Ipilimumab
  Outcome Measures:             Incidence of high grade immune-mediated adverse events (IMAEs)|Time to onset of all high grade IMAEs|Time to resolution of all high grade IMAEs|Percentage of patients who received immune modulating medication due to high grade IMAEs|Progression-free survival at time of initial progression (PFS 1) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria as assessed by the investigator|Objective response rate (ORR) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria as assessed by the investigator|Time to response (TTR) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria as assessed by the investigator|Duration of response (DOR) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria as assessed by the investigator
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 4
  Enrollment:                   200
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-920
  Start Date:                   December 7, 2016
  Primary Completion Date:      March 30, 2020
  Completion Date:              February 28, 2023
  First Posted:                 December 6, 2016
  Results First Posted:         null
  Last Update Posted:           July 18, 2018
  Locations:                    Northwest Alabama Cancer Center, Pc, Muscle Shoals, Alabama, United States|Alaska Urological Institute dba Alaska Clinical Research Center, Anchorage, Alaska, United States|Ironwood Cancer And Research Centers, Pc, Chandler, Arizona, United States|Highlands Oncology Group, P.A., Fayetteville, Arkansas, United States|eCare, Encinitas, California, United States|Pacific Shores Medical Group, Long Beach, California, United States|Los Angeles Cancer Network, Los Angeles, California, United States|UCLA Hematology Oncology, Los Angeles, California, United States|Torrance Health Association, Redondo Beach, California, United States|Kaiser Permanente Medical Group - Southern California, Riverside, California, United States|Sharp Memorial Hospital, San Diego, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|Central Coast Med Oncology, Santa Maria, California, United States|Florida Cancer Specialists S., Fort Myers, Florida, United States|University Of Miami/Sylvester Cancer Center, Miami, Florida, United States|UF Health Cancer Center at Orlando Health, Orlando, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Emory University - Winship Cancer Institute, Atlanta, Georgia, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Ft. Wayne Med Onco-Hema Inc, Fort Wayne, Indiana, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Minnesota Oncology Hematology, Minneapolis, Minnesota, United States|Southdale Cancer Clinic, Minneapolis, Minnesota, United States|Park Nicollet Clinic Cancer Center, Saint Louis Park, Minnesota, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Jackson Oncology Associates, Pllc, Jackson, Mississippi, United States|HCA Midwest Division, Kansas City, Missouri, United States|St. Francis Cancer Treatment Center, Grand Island, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|John Theurer Cancer Center, Hackensack, New Jersey, United States|University Of New Mexico, Albuquerque, New Mexico, United States|Montefiore Medical Center, Bronx, New York, United States|Maimonides Medical Center, Brooklyn, New York, United States|Broome Oncology, Johnson City, New York, United States|Laura & Isaac Perlmutter Cancer Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Southeastern Medical Oncology Center, Goldsboro, North Carolina, United States|Oklahoma Cancer Specialists and Research Institute, LLC, Tulsa, Oklahoma, United States|Va Medical Center Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States|Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina, United States|Hollings Cancer Center, Charleston, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Tennessee Oncology, PLLC, Chattanooga, Tennessee, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Oncology, Austin, Texas, United States|Texas Oncology, Dallas, Texas, United States|Texas Oncology-Fort Worth 12th Ave, Fort Worth, Texas, United States|Texas Oncology-Midland Allison Cancer Center, Midland, Texas, United States|Texas Oncology, San Antonio, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Inova Research Center, Fairfax, Virginia, United States|Bon Secours St Francis Hospital, Midlothian, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Medical Oncology Associates, Spokane, Washington, United States|Yakima Valley Memorial Hospital/North Star Lodge, Yakima, Washington, United States|University of Wisconsin Clinical Science Center, Madison, Wisconsin, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02982954

Study 107:
  NCT Number:                   NCT03298893
  Title:                        Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months
  Acronym:                      NiCOL
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Cervical Cancer|Locally Advanced Cervical Cancer
  Interventions:                Drug: Nivolumab Injection|Drug: Cisplatin|Radiation: radiotherapy
  Outcome Measures:             rate of occurrence of dose-limiting toxicity (DLT)|Objective Response Rate (ORR)|Progression Free Survival (PFS)|Disease Free Survival (DFS)|Incidence of Serious Adverse Events (SAEs) to assess the overall safety profile of the association of nivolumab and pelvic radio-chemotherapy|Incidence of Adverse Events (AEs) to assess the overall safety profile of the association of nivolumab and pelvic radio-chemotherapy|validation of molecular alterations detected by molecular analyses|ctDNA heterogeneity|tumor microenvironment description|tumor PD-L1 immunohistochemistry
  Sponsor/Collaborators:        Institut Curie|Bristol-Myers Squibb
  Gender:                       Female
  Age:                          18 Years to 99 Years   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   21
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    IC 2016-08
  Start Date:                   November 27, 2017
  Primary Completion Date:      April 2020
  Completion Date:              April 2020
  First Posted:                 October 2, 2017
  Results First Posted:         null
  Last Update Posted:           April 9, 2018
  Locations:                    Institut Curie, Paris, France|Hopital Européen Georges Pompidou, Paris, France|Institut Curie Hopital René Huguenin, Saint Cloud, France
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03298893

Study 108:
  NCT Number:                   NCT03172624
  Title:                        Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Salivary Gland Cancer
  Interventions:                Drug: Nivolumab|Drug: Ipilimumab
  Outcome Measures:             best overall response rate
  Sponsor/Collaborators:        Memorial Sloan Kettering Cancer Center|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   64
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    17-219
  Start Date:                   May 26, 2017
  Primary Completion Date:      May 2019
  Completion Date:              May 2019
  First Posted:                 June 1, 2017
  Results First Posted:         null
  Last Update Posted:           August 20, 2018
  Locations:                    Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memoral Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03172624

Study 109:
  NCT Number:                   NCT03026166
  Title:                        A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Small Cell Lung Cancer
  Interventions:                Drug: ipilimumab|Drug: nivolumab|Drug: rovalpituzumab tesirine
  Outcome Measures:             Number of participants with dose-limiting toxicities (DLT)|Clinical benefit rate (CBR)|Duration of response (DOR)|PFS status after 6 months from the initiation of study treatment|Objective Response Rate (ORR)|Progression-free survival (PFS)|Overall survival (OS)
  Sponsor/Collaborators:        AbbVie|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   42
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    M16-300|2016-003686-26
  Start Date:                   March 31, 2017
  Primary Completion Date:      July 3, 2019
  Completion Date:              July 3, 2019
  First Posted:                 January 20, 2017
  Results First Posted:         null
  Last Update Posted:           October 26, 2018
  Locations:                    Ucsd /Id# 161030, La Jolla, California, United States|Florida Hospital /ID# 161017, Orlando, Florida, United States|University Cancer & Blood Cent /ID# 161028, Athens, Georgia, United States|University of Chicago /ID# 161006, Chicago, Illinois, United States|The University of Kansas Clini /ID# 162915, Fairway, Kansas, United States|Washington University-School of Medicine /ID# 161011, Saint Louis, Missouri, United States|Rutgers Cancer Institute of NJ /ID# 161032, New Brunswick, New Jersey, United States|Memorial Sloan Kettering Cancer Center /ID# 161010, New York, New York, United States|Duke Univ Med Ctr /ID# 161009, Durham, North Carolina, United States|Oregon Health and Science University /ID# 161029, Portland, Oregon, United States|Medical University of South Carolina /ID# 161007, Charleston, South Carolina, United States|Tennessee Oncology, PLLC /ID# 161012, Nashville, Tennessee, United States|Vanderbilt University Med Ctr /ID# 162916, Nashville, Tennessee, United States|Virginia Cancer Institute /ID# 161025, Richmond, Virginia, United States|University of Wisconsin Clinic /ID# 161013, Madison, Wisconsin, United States|CHU de Besancon - Jean Minjoz /ID# 165173, Besancon, Doubs, France|Centre Oscar Lambret /ID# 165169, Lille, Hauts-de-France, France|Institut Gustave Roussy /ID# 165168, Villejuif, Val-de-Marne, France|Institut Sainte Catherine /ID# 165172, Avignon, France|CHRU de Brest - Hospital Morva /ID# 165170, Brest Cedex, France|Hopital La Timone /ID# 165171, Marseille, France|Universitaetsklinik Heidelberg /ID# 165184, Heidelberg, Baden-Wuerttemberg, Germany|KH Martha-Maria Halle Dolau /ID# 165180, Halle (Saale), Sachsen-Anhalt, Germany|Asklepios Fachkliniken M. Gaut /ID# 165183, Gauting, Germany|Lungen Clinic Grosshansdorf /ID# 165182, Grosshansdorf, Germany|Lungenfachklinik Immenhausen /ID# 165181, Immenhausen, Germany|Istituto Clinico Humanitas /ID# 165176, Rozzano, Milano, Italy|Centro di Riferimento Oncologi /ID# 165174, Aviano, Italy|Universitaria di Bologna Polic /ID# 165179, Bologna, Italy|A.O. Uni Policlinico Vittorio /ID# 165178, Catania, Italy|Istituto Europeo di Oncologia /ID# 165175, Milan, Italy|AO Univ di Modena /ID# 165177, Modena, Italy|Clinica Universitar de Navarra - Pamplona /ID# 165165, Pamplona, Navarra, Comunidad, Spain|Hosp Univ Quiron Dexues /ID# 165166, Barcelona, Spain|ICO l´Hosp- Hosp Duran Reynals /ID# 165167, Barcelona, Spain|Hospital Genl Gregorio Maranon /ID# 165162, Madrid, Spain|Hospital Universitario Fundaci /ID# 165164, Madrid, Spain|Hospital Universitario Madrid /ID# 165163, Madrid, Spain
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03026166

Study 110:
  NCT Number:                   NCT03670056
  Title:                        A Pilot Study of Combination Immunotherapy With Ipilimumab and Nivolumab in Patients With Recurrent Extensive Stage Small Cell Lung Cancer (SCLC) Who Have Previously Received Platinum-based Chemotherapy
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Small Cell Lung Cancer
  Interventions:                Drug: Combination immunotherapy with Ipilimumab and Nivolumab
  Outcome Measures:             Change in the ratio of Teff/Treg cells|Response rate|Duration of response|Progression-free survival
  Sponsor/Collaborators:        Yale University|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   40
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    2000023361|CA209-9YT
  Start Date:                   September 15, 2018
  Primary Completion Date:      September 30, 2020
  Completion Date:              September 30, 2022
  First Posted:                 September 13, 2018
  Results First Posted:         null
  Last Update Posted:           September 13, 2018
  Locations:                    Yale University, Yale Cancer Center, New Haven, Connecticut, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03670056

Study 111:
  NCT Number:                   NCT03544736
  Title:                        Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC)
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Esophageal Cancer
  Interventions:                Drug: Nivolumab|Radiation: Radiotherapy|Drug: Chemotherapy|Procedure: Surgery
  Outcome Measures:             Incidence of Treatment-Emergent Adverse Events|Response to treatment|Overall Survival|Progression Free Survival|Health Related Quality of Life (EQ-5D)|Health Related Quality of Life (EORTC QLQ-C30)|Health Related Quality of Life (EORTC QLQ-OG25)
  Sponsor/Collaborators:        Oslo University Hospital|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   54
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-9M9-01
  Start Date:                   April 26, 2018
  Primary Completion Date:      December 31, 2025
  Completion Date:              December 31, 2040
  First Posted:                 June 4, 2018
  Results First Posted:         null
  Last Update Posted:           June 4, 2018
  Locations:                    Oslo University Hospital, Oslo, Norway
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03544736

Study 112:
  NCT Number:                   NCT02866383
  Title:                        Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients
  Acronym:                      CheckPAC
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Metastatic Pancreatic Cancer|Metastatic Biliary Tract Cancer
  Interventions:                Drug: Nivolumab|Drug: Ipilimumab|Radiation: Radiotherapy
  Outcome Measures:             Clinical benefit rate (CBR)|Incidence of Treatment-Emergent Adverse Events [Safety]|CBR|Overall response rate (ORR) according to RECIST 1.1|Overall response rate (ORR) according to modified irRC|Progression free survival (PFS) per RECIST 1.1|Progression free survival (PFS) per modified irRC|Overall survival (OS) probability at 6 months|OS|Quality of Life
  Sponsor/Collaborators:        Herlev Hospital|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   160
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    GI 1616
  Start Date:                   November 2016
  Primary Completion Date:      November 2018
  Completion Date:              November 2019
  First Posted:                 August 15, 2016
  Results First Posted:         null
  Last Update Posted:           September 13, 2018
  Locations:                    Herlev & Gentofte Hospital, Herlev, Denmark
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02866383

Study 113:
  NCT Number:                   NCT03294304
  Title:                        BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Muscle Invasive Bladder Cancer
  Interventions:                Drug: Nivolumab|Drug: Cisplatin|Drug: Gemcitabine
  Outcome Measures:             Pathologic Response Rate (PaR) at time of radical cystectomy. PaR is defined as absence of residual MIBC at cystectomy in the surgical specimen (pathologic down-staging to ≤pT1pN0, which includes pT0, pT1,pTa and pTis)|Safety of Nivolumab with Gemcitabine/Cisplatin (cycle 1)|Safety of Nivolumab with Gemcitabine/Cisplatin (cycle 2)|Safety of Nivolumab with Gemcitabine/Cisplatin (cycle 3)|Safety of Nivolumab with Gemcitabine/Cisplatin (cycle 4)|Safety of Nivolumab with Gemcitabine/Cisplatin|Progression Free Survival (PFS)
  Sponsor/Collaborators:        Masonic Cancer Center, University of Minnesota|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   41
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    2017LS039
  Start Date:                   January 29, 2018
  Primary Completion Date:      November 1, 2019
  Completion Date:              November 1, 2021
  First Posted:                 September 27, 2017
  Results First Posted:         null
  Last Update Posted:           September 28, 2018
  Locations:                    Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Masonic Cancer Center - University of Minnesota, Minneapolis, Minnesota, United States|Huntsman Cancer Institute - University of Utah Health, Salt Lake City, Utah, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03294304

Study 114:
  NCT Number:                   NCT03043599
  Title:                        Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Small Cell Lung Cancer|Extensive-stage Small Cell Lung Cancer
  Interventions:                Radiation: Thoracic Radiation Therapy|Drug: Ipilimumab|Drug: Nivolumab
  Outcome Measures:             Phase I: Confirmation of Recommended Phase II Dose|Phase II: Progression Free Survival (PFS)|Overall Survival (OS)
  Sponsor/Collaborators:        H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   21
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    MCC-18914|CA209-840
  Start Date:                   February 13, 2017
  Primary Completion Date:      April 2021
  Completion Date:              April 2022
  First Posted:                 February 6, 2017
  Results First Posted:         null
  Last Update Posted:           October 3, 2018
  Locations:                    H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03043599

Study 115:
  NCT Number:                   NCT01658878
  Title:                        An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer
  Acronym:                      CheckMate040
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Hepatocellular Carcinoma
  Interventions:                Biological: Nivolumab|Drug: Sorafenib|Drug: Ipilimumab|Drug: Cabozantinib
  Outcome Measures:             Safety of nivolumab as evaluated by incidence of adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation, deaths and clinical laboratory test abnormalities|Tolerability of nivolumab as evaluated by incidence of adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation, deaths and clinical laboratory test abnormalities|Objective response rate (ORR) for Expansion phase of nivolumab|ORR for Nivolumab vs Sorafenib Cohort|Safety of nivolumab plus ipilimumab as evaluated by incidence of adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation, deaths and clinical laboratory test abnormalities|Tolerability of nivolumab plus ipilimumab as evaluated by incidence of adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation, deaths and clinical laboratory test abnormalities|ORR for Nivolumab plus Ipilimumab Combination Cohort|ORR for Child-Pugh B Cohort|Safety of nivolumab plus ipilimumab plus cabozantinib as evaluated by incidence of adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation, deaths and clinical laboratory test abnormalities|Tolerability of nivolumab plus ipilimumab plus cabozantinib as evaluated by incidence of adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation, deaths and clinical laboratory test abnormalities|ORR for Nivolumab plus Ipilimumab plus Cabozantinib Combination Cohort|Complete response (CR) Rate|Disease control rate (DCR)|Duration of response (DOR)|Time to response (TTR)|Time to progression (TTP)|TTP Rate|Progression free survival (PFS)|Overall survival (OS)|Overall survival rate (OSR)|PD-L1 expression|Maximum observed serum concentration (Cmax) of nivolumab|Time of maximum observed serum concentration (Tmax) of nivolumab|Area under the serum concentration time curve in the dosing interval AUC(TAU) of nivolumab|Serum concentration achieved at the end of dosing interval (trough concentration) (Ctrough) of nivolumab|Serum concentration achieved at the end of the infusion (Ceoinf) of nivolumab|Cmax at Cycle 3/ Cmax at Cycle 1 (AI_Cmax) of nivolumab|AUC(TAU) at Cycle 3/ AUC(TAU) at Cycle 1 (AI_AUC) of nivolumab|Effective T-Half of nivolumab
  Sponsor/Collaborators:        Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   620
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-040|2012-001514-42
  Start Date:                   September 26, 2012
  Primary Completion Date:      March 31, 2019
  Completion Date:              December 26, 2019
  First Posted:                 August 7, 2012
  Results First Posted:         null
  Last Update Posted:           November 6, 2018
  Locations:                    USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Georgetown University Medical Center Lombardi Cancer Center, Washington, District of Columbia, United States|Sacred Heart Medical Group, Pensacola, Florida, United States|Emory University, Atlanta, Georgia, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Univ Of Michigan, Ann Arbor, Michigan, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Saint Joseph's Regional Medical Center, Paterson, New Jersey, United States|Providence Portland Medical Center, Portland, Oregon, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|University Health Network - Princess Margaret Cancer Centre, Toronto, Ontario, Canada|CHUM, Montreal, Quebec, Canada|Local Institution, Angers, France|Local Institution, Creteil Cedex, France|Local Institution, Marseille Cedex 5, France|Local Institution, Marseille Cedex 9, France|Local Institution, Paris Cedex 13, France|Local Institution, Reims Cedex, France|Local Institution, Vandoeuvre les Nancy, France|Universitaetsklinikum Essen, Essen, Germany|Johann Wolfgang Goethe Universitaet, Frankfurt, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitaetsklinik Heidelberg, Heidelberg, Germany|Local Institution, Hong Kong, Hong Kong|Azienda Ospedaliera Di Bologna S. Orsola-Malpighi, Bologna, Italy|A.O.U. Careggi, Firenze, Italy|Istituto Romagnolo Per Lo Studio E La Cura Dei Tumori, Meldola (FC), Italy|Istituto Europeo Di Oncologia, Milano, Italy|Istituto Nazionale Tumori, Napoli, Italy|I.O.V. Istituto Oncologico Veneto Ircss, Padova, Italy|Istituto Clinico Humanitas, Rozzano, Italy|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Kurume-shi, Fukuoka, Japan|Local Institution, Yokohama, Kanagawa, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Osaka-sayama-shi, Osaka, Japan|Local Institution, Saga, Japan|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, San Juan, Puerto Rico|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Clinica Universitaria De Navarra, Pamplona, Spain|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Glasgow, Lanarkshire, United Kingdom|Local Institution, Wirral, Merseyside, United Kingdom|Local Institution, Birmingham, WEST Midlands, United Kingdom|Local Institution, London, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01658878

Study 116:
  NCT Number:                   NCT03355560
  Title:                        Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Head and Neck Cancer
  Interventions:                Drug: Nivolumab
  Outcome Measures:             Percentage of patients with Grade 3 and 4 adverse events of nivolumab|Percentage of patients any grade adverse events of nivolumab|Disease free survival
  Sponsor/Collaborators:        Trisha Wise-Draper|Bristol-Myers Squibb|University of Cincinnati
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   24
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    UCCI-HN-17-01|CA209-997
  Start Date:                   December 6, 2017
  Primary Completion Date:      May 2020
  Completion Date:              November 2020
  First Posted:                 November 28, 2017
  Results First Posted:         null
  Last Update Posted:           October 2, 2018
  Locations:                    UC Health, Cincinnati, Ohio, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03355560

Study 117:
  NCT Number:                   NCT02923934
  Title:                        A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Gastrointestinal Cancer|Neuroendocrine Tumours|Malignant Female Reproductive System Neoplasm
  Interventions:                Drug: Ipilimumab|Drug: Nivolumab
  Outcome Measures:             To determine the clinical efficacy of the combination treatment of ipilimumab with nivolumab in rare cancers.|To identify whether a common predictive biomarker or immune signature can be identified in responding patients that can occur irrespective of tumour type.
  Sponsor/Collaborators:        Olivia Newton-John Cancer Research Institute|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   120
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    ONJ2016-001
  Start Date:                   August 22, 2017
  Primary Completion Date:      August 2023
  Completion Date:              December 2023
  First Posted:                 October 5, 2016
  Results First Posted:         null
  Last Update Posted:           November 14, 2018
  Locations:                    Border Medical Oncology Unit, Albury, New South Wales, Australia|Blacktown Hospital, Sydney, New South Wales, Australia|Monash Health, Clayton, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02923934

Study 118:
  NCT Number:                   NCT02991196
  Title:                        Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer
  Acronym:                      
  Status:                       Terminated
  Study Results:                No Results Available
  Conditions:                   Colorectal Neoplasm
  Interventions:                Drug: DS-8273a + nivolumab
  Outcome Measures:             Dose Escalation Part: Number of Participants with Dose-Limiting Toxicities (DLT)|Dose Escalation and Dose Expansion Parts: Number of Participants with Clinically Significant Safety Parameters|Dose Escalation Part: Maximum Tolerated Dose (MTD)|Dose Expansion Part: Overall Objective Response Rate (per Response Evaluation Criteria in Solid Tumors [RECIST] Version 1.1)|Dose Expansion Part: Number of Participants in each Category of Best Overall Response (per Response Evaluation Criteria in Solid Tumors [RECIST] Version 1.1)|Dose Expansion Part: Disease Control Rate (DCR) for 6 Months|Dose Expansion Part: Number of Participants with Progression-Free Survival (PFS)|Dose Expansion Part: Time to Progression (TTP)|Dose Expansion Part: Duration of Response|Dose Escalation Part: Number of Participants with Immune-related Response (per Criteria Modified from RECIST Version 1.1 [irRECIST])|Plasma Concentrations of DS-8273a|Number of Participants with Primary Pharmacodynamic (PDy) Effects of the Combination Regimen on Myeloid-Derived Suppressor Cells (MDSCs) and their Subsets in Peripheral Blood
  Sponsor/Collaborators:        Daiichi Sankyo, Inc.|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   4
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science
  Other IDs:                    DS8273-A-U103|Protocol ID CA209-860
  Start Date:                   December 1, 2016
  Primary Completion Date:      September 22, 2017
  Completion Date:              September 22, 2017
  First Posted:                 December 13, 2016
  Results First Posted:         null
  Last Update Posted:           October 2, 2017
  Locations:                    Georgetown University Medical Center, Washington, D.C., District of Columbia, United States|South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan, United States|MD Anderson Cancer Center, Houston, Texas, United States|South Texas Accelerated Research Therapeutics, LLC (START), San Antonio, Texas, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02991196

Study 119:
  NCT Number:                   NCT03350126
  Title:                        Interest of iRECIST Evaluation for DCR for Evaluation of Patients With Deficient MMR and /or MSI Metastatic Colorectal Cancer Treated With Nivolumab and Ipilimumab
  Acronym:                      NIPICOL
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Metastatic Cancer Colorectal
  Interventions:                Drug: Ipilimumab 200 MG in 40 ML Injection|Drug: Nivolumab 10 MG/ML
  Outcome Measures:             Disease Control Rate (DCR)|Progression Free Survival (PFS)|Overall Response Rate (ORR)|Overall Survival (OS)|Toxicity according to NCI-CTCAE version 4.0 (National Cancer Institute Common Terminology Criteria for Adverse Events),
  Sponsor/Collaborators:        GERCOR - Multidisciplinary Oncology Cooperative Group|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   57
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    NIPICOL C17-01
  Start Date:                   December 4, 2017
  Primary Completion Date:      December 2018
  Completion Date:              December 2019
  First Posted:                 November 22, 2017
  Results First Posted:         null
  Last Update Posted:           January 23, 2018
  Locations:                    Institut Sainte Catherine, Avignon, France|CHRU Besançon, Besançon, France|Henri Mondor Hospital, Créteil, France|IHFB, Levallois-Perret, France|Centre Leon Berard, Lyon, France|CHU Nantes - Hôtel Dieu, Nantes, France|Hospital Saint Antoine, Paris, France|CHU Poitiers, Poitiers, France
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03350126

Study 120:
  NCT Number:                   NCT03316586
  Title:                        A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Breast Cancer
  Interventions:                Drug: Nivolumab|Drug: Cabozantinib
  Outcome Measures:             Overall Response Rate|Number of participants with adverse events|Clinical Benefit Rate|Progression Free Survival Rate|Overall Response Rate per Immune Criteria
  Sponsor/Collaborators:        Dana-Farber Cancer Institute|Bristol-Myers Squibb|Exelixis
  Gender:                       Female
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   35
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    17-324
  Start Date:                   November 30, 2017
  Primary Completion Date:      May 31, 2021
  Completion Date:              May 31, 2025
  First Posted:                 October 20, 2017
  Results First Posted:         null
  Last Update Posted:           August 28, 2018
  Locations:                    Dana-Farber Cancer Institute, Boston, Massachusetts, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03316586

Study 121:
  NCT Number:                   NCT02569242
  Title:                        Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Esophageal Cancer
  Interventions:                Drug: Nivolumab|Drug: Docetaxel/Paclitaxel
  Outcome Measures:             Overall survival|Progression-free survival|Objective response rate|Duration of response|Safety will be analyzed through the incidence of adverse events, serious adverse events|Safety will be analyzed through the incidence of laboratory abnormalities
  Sponsor/Collaborators:        Ono Pharmaceutical Co. Ltd|Bristol-Myers Squibb
  Gender:                       All
  Age:                          20 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   390
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    ONO-4538-24/CA209-473
  Start Date:                   December 2015
  Primary Completion Date:      September 2019
  Completion Date:              null
  First Posted:                 October 6, 2015
  Results First Posted:         null
  Last Update Posted:           September 25, 2017
  Locations:                    Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Georgetown University Med Ctr, Washington, D.C., District of Columbia, United States|Orlando Health, Inc, Orlando, Florida, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Duke Cancer Institute, Durham, North Carolina, United States|Vanderbilt-Ingram Cancer Ctr, Nashville, Tennessee, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|Odense University Hospital, Odense C, Denmark|RWTH Aachen University, Aachen, Germany|Charite Campus Virchow Klinikum, Berlin, Germany|University Hospital Heidelberg, Heidelberg, Germany|Universitatsklinikum Jena, Innere Medizin II, Jena, Germany|MVZ Mitte, Leipzig, Germany|University Of Mainz Medical Center, Mainz, Germany|Klinikum reechts der Isar, Technical University Munchen, Munich, Germany|HPG23, Bergamo, Italy|Fondazione Irccs Istituto Nazionale Tumori, Milan, Italy|Irccs Istituto Oncologico Veneto Iov, Padova, Italy|Aichi Clinical Site, Nagoya, Aichi, Japan|Aichi Clinical Site, Nagoya, Aichi, Japan|Aomori Clinical Site, Hirosaki, Aomori, Japan|Chiba Clinical Site, Kashiwa, Chiba, Japan|Ehime Clinical Site, Matsuyama, Ehime, Japan|Hokkaido Clinical Site, Sapporo, Hokkaido, Japan|Hokkaido Clinical Site, Sapporo, Hokkaido, Japan|Hyogo Clinical Site, Akashi, Hyogo, Japan|Hyogo Clinical Site, Kobe, Hyogo, Japan|Kanagawa Clinical Site, Isehara, Kanagawa, Japan|Kanagawa Clinical Site, Kawasaki, Kanagawa, Japan|Kanagawa Clinical Site, Yokohama, Kanagawa, Japan|Kanagawa Clinical Site, Yokohama, Kanagawa, Japan|Mie Clinical Site, Tsu, Mie, Japan|Miyagi Clinical Site, Sendai, Miyagi, Japan|Nagano Clinical Site, Saku, Nagano, Japan|Niigata Clinical Site, Nigatake, Niigata, Japan|Osaka Clinical Site, Osakasayama, Osaka, Japan|Osaka Clinical Site, Suita, Osaka, Japan|Osaka Clinical Site, Takatsuki, Osaka, Japan|Saitama Clinical Site, Hidaka, Saitama, Japan|Saitama Clinical Site, Kita-Adachi county, Saitama, Japan|Shizuoka Clinical Site, Suntou county, Shizuoka, Japan|Tochigi Clinical Site, Shimotsuke, Tochigi, Japan|Tokyo Clinical Site, Bunkyo-ku, Tokyo, Japan|Tokyo Clinical Site, Chuo-ku, Tokyo, Japan|Tokyo Clinical Site, Chuo-ku, Tokyo, Japan|Tokyo Clinical Site, Koto-ku, Tokyo, Japan|Tokyo Clinical Site, Meguro-ku, Tokyo, Japan|Tokyo Clinical Site, Minato-ku, Tokyo, Japan|Tokyo Clinical Site, Shinagawa-ku, Tokyo, Japan|Tokyo Clinical Site, Shinjuku-ku, Tokyo, Japan|Tokyo Clinical Site, Shinjuku-ku, Tokyo, Japan|Akita Clinical Site, Akita, Japan|Chiba Clinical Site, Chiba, Japan|Chiba Clinical Site, Chiba, Japan|Fukuoka Clinical Site, Fukuoka, Japan|Fukushima Clinical Site, Fukushima, Japan|Hiroshima Clinical Site, Hiroshima, Japan|Kagoshima Clinical Site, Kagoshima, Japan|Kumamoto Clinical Site, Kumamoto, Japan|Kyoto Clinical Site, Kyoto, Japan|Kyoto Clinical Site, Kyoto, Japan|Niigata Clinical Site, Niigata, Japan|Osaka Clinical Site, Osaka, Japan|Shizuoka Clinical Site, Shizuoka, Japan|Busan Clinical Site, Busan, Korea, Republic of|Daegu Clinical Site, Daegu, Korea, Republic of|Daegu Clinical Site, Daegu, Korea, Republic of|Daejeon Clinical Site, Daejeon, Korea, Republic of|Gyeonggi-do Clinical Site, Gyeonggi-do, Korea, Republic of|Hwasun-Gun Clinical Site, Hwasun-Gun, Korea, Republic of|Seoul Clinical Site, Seoul, Korea, Republic of|Seoul Clinical Site, Seoul, Korea, Republic of|Seoul Clinical Site, Seoul, Korea, Republic of|Seoul Clinical Site, Seoul, Korea, Republic of|Seoul Clinical Site, Seoul, Korea, Republic of|Ulsan Clinical Site, Ulsan, Korea, Republic of|Changhua Clinical Site, Changhua, Taiwan|Chiayi Clinical Site, Chiayi, Taiwan|Kaohsiung Clinical Site, Kaohsiung, Taiwan|Kaohsiung Clinical Site, Kaohsiung, Taiwan|Kaohsiung Clinical Site, Kaohsiung, Taiwan|Keelung Clinical Site, Keelung, Taiwan|Taichung Clinical Site, Taichung, Taiwan|Tainan Clinical Site, Tainan, Taiwan|Taipei Clinical Site, Taipei, Taiwan|Taipei Clinical Site, Taipei, Taiwan|Taoyuan Clinical Site, Taoyuan, Taiwan|Velindre Cancer Centre, Cardiff, Cardiganshire, United Kingdom|The Beatson West Of Scotland Cancer Centre, Glasgow, Lanarkshire, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02569242

Study 122:
  NCT Number:                   NCT03425331
  Title:                        Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Non-small Cell Lung Cancer
  Interventions:                Drug: Ipilimumab|Drug: Nivolumab
  Outcome Measures:             Best overall objective response rate|Progression-free survival (PFS)|Overall survival|Duration of response|Toxicity
  Sponsor/Collaborators:        Dana-Farber Cancer Institute|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   80
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    17-566
  Start Date:                   February 28, 2018
  Primary Completion Date:      August 28, 2021
  Completion Date:              August 28, 2025
  First Posted:                 February 7, 2018
  Results First Posted:         null
  Last Update Posted:           June 28, 2018
  Locations:                    Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03425331

Study 123:
  NCT Number:                   NCT02696993
  Title:                        Trial of Nivolumab With Radiation or Nivolumab and Ipilimumab With Radiation for the Treatment of Intracranial Metastases From Non-Small Cell Lung Cancer
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Metastatic Brain Cancer
  Interventions:                Drug: Nivolumab|Drug: Ipilimumab|Radiation: Stereotactic Radiosurgery (SRS)|Radiation: Whole Brain Radiation Therapy (WBRT)|Behavioral: Neurocognitive Exam
  Outcome Measures:             Recommended Phase 2 Dose (RP2D) of Nivolumab in Combination with Stereotactic Radiosurgery (SRS)|Recommended Phase 2 Dose (RP2D) of Nivolumab in Combination with Whole Brain Radiation Therapy (WBRT)|Recommended Phase 2 Dose (RP2D) of Nivolumab in Combination with Ipilimumab and Stereotactic Radiosurgery (SRS)|Recommended Phase 2 Dose (RP2D) of Nivolumab in Combination with Ipilimumab and Whole Brain Radiation Therapy (WBRT)|Intracranial Progression Free Survival|Neurocognitive Changes
  Sponsor/Collaborators:        M.D. Anderson Cancer Center|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   80
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    2015-0883|NCI-2016-00661
  Start Date:                   December 2016
  Primary Completion Date:      December 2020
  Completion Date:              December 2020
  First Posted:                 March 2, 2016
  Results First Posted:         null
  Last Update Posted:           May 31, 2018
  Locations:                    University of Texas MD Anderson Cancer Center, Houston, Texas, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02696993

Study 124:
  NCT Number:                   NCT03383302
  Title:                        SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects
  Acronym:                      STILE
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Non-small Cell Lung Cancer Stage II|Non-small Cell Lung Cancer Stage I
  Interventions:                Radiation: Stereotactic body radiotherapy|Drug: Nivolumab
  Outcome Measures:             Assessment of lung toxicity (pneumonitis) from treatment with Nivolumab after SBRT for early stage NSCLC|Adverse events (toxicity) assessment using CTCAE v.4|Number of doses of Nivolumab received by patients within 16 weeks of commencing adjuvant nivolumab after SBRT for early stage NSCLC|Disease relapse|Relapse at specified timepoints|Overall survival|Disease free survival|Health-related quality of life (HRQoL) using Patient Generated Subjective Global Assessment in patients treated with Nivolumab after SBRT for early stage NSCLC|Health-related quality of life (HRQoL) using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) in patients treated with Nivolumab after SBRT for early stage NSCLC|HRQoL using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) in patients treated with Nivolumab after SBRT for early stage NSCLC.
  Sponsor/Collaborators:        Royal Marsden NHS Foundation Trust|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   31
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CCR4644
  Start Date:                   January 2018
  Primary Completion Date:      June 2021
  Completion Date:              January 2022
  First Posted:                 December 26, 2017
  Results First Posted:         null
  Last Update Posted:           December 26, 2017
  Locations:                    
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03383302

Study 125:
  NCT Number:                   NCT02873962
  Title:                        A Phase II Study Of Nivolumab/ Bevacizumab
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Peritoneal Cancer|Ovarian Cancer|Fallopian Tube Cancer
  Interventions:                Drug: Bevacizumab|Drug: Nivolumab
  Outcome Measures:             Objective Response Rate|Progression Free|Best Overall Response Rate|Duration Of Response|The Association Of Baseline PD-L1 Expression With Anti-Tumor Activity
  Sponsor/Collaborators:        Dana-Farber Cancer Institute|Bristol-Myers Squibb
  Gender:                       Female
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   38
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    16-263
  Start Date:                   November 10, 2016
  Primary Completion Date:      February 2020
  Completion Date:              February 2024
  First Posted:                 August 22, 2016
  Results First Posted:         null
  Last Update Posted:           July 18, 2018
  Locations:                    Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02873962

Study 126:
  NCT Number:                   NCT03689699
  Title:                        Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Prostate Cancer|Adenocarcinoma of the Prostate
  Interventions:                Drug: Nivolumab|Drug: Degarelix|Drug: BMS-986253
  Outcome Measures:             Rate of PSA recurrence|Number of adverse events|Percentage change in PSA|Relapse-free survival (RFS)
  Sponsor/Collaborators:        Charles G. Drake|Bristol-Myers Squibb|Columbia University
  Gender:                       Male
  Age:                          18 Years to 99 Years   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   60
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    AAAR7949
  Start Date:                   October 2018
  Primary Completion Date:      January 2020
  Completion Date:              August 2022
  First Posted:                 September 28, 2018
  Results First Posted:         null
  Last Update Posted:           September 28, 2018
  Locations:                    Weill Cornell Medical Center, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Sidney Kimmel Cancer Center- Thomas Jefferson University, Philadelphia, Pennsylvania, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03689699

Study 127:
  NCT Number:                   NCT03006705
  Title:                        Study of Adjuvant ONO-4538 With Resected Gastric Cancer
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Gastric Cancer
  Interventions:                Drug: Nivolumab|Drug: Tegafur-gimeracil-oteracil potassium|Drug: Oxaliplatin|Drug: Capecitabine|Drug: Placebo
  Outcome Measures:             Relapse-free survival (RFS)|Overall survival (OS)|3-year OS rate|5-year OS rate|3-year RFS rate|5-year RFS rate|Safety will be analyzed through the incidence of adverse events, serious adverse events|Safety will be analyzed through the incidence of laboratory abnormalities
  Sponsor/Collaborators:        Ono Pharmaceutical Co. Ltd|Bristol-Myers Squibb
  Gender:                       All
  Age:                          20 Years to 80 Years   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   700
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  Other IDs:                    ONO-4538-38
  Start Date:                   January 2017
  Primary Completion Date:      June 2021
  Completion Date:              null
  First Posted:                 December 30, 2016
  Results First Posted:         null
  Last Update Posted:           October 2, 2018
  Locations:                    Anhui Province Clinical Site, Anhui Province, China|Beijing Clinical Site1, Beijing, China|Beijing Clinical Site2, Beijing, China|Cuangdong Province Clinical Site, Cuangdong Province, China|Guangdong Province Clinical Site1, Guangdong, China|Guangdong Province Clinical Site2, Guangdong, China|Henan Province Clinical Site1, Henan, China|Henan Province Clinical Site2, Henan, China|Jiangsu Province Clinical Site1, Jiangsu Province, China|Jiangsu Province Clinical Site3, Jiangsu Province, China|Jiangsu Province Clinical Site4, Jiangsu Province, China|Jiangsu Province Clinical Site5, Jiangsu Province, China|Jiangxi Province Clinical Site1, Jiangxi, China|Jiangxi Province Clinical Site2, Jiangxi, China|Jilin Province Clinical Site, Jilin, China|Shanghai Clinical Site1, Shanghai, China|Shanghai Clinical Site2, Shanghai, China|Shanxi Province Clinical Site, Shanxi, China|Tianjin Clinical Site1, Tianjin, China|Tianjin Clinical Site2, Tianjin, China|Zhejiang Province Clinical Site, Zhejiang, China|Zhengjiang Province Clinical Site, Zhengjiang Province, China|Aichi Clinical Site1, Nagoya, Aichi, Japan|Aichi Clinical Site2, Nagoya, Aichi, Japan|Chiba Clinical Site, Kamogawa, Chiba, Japan|Ehime Clinical Site, Matsuyama, Ehime, Japan|Ehime Clinicla Site, Matsuyama, Ehime, Japan|Gifu Clinical Site, Ōgaki, Gifu, Japan|Gunma Clinical Site, Ota, Gunma, Japan|Gunma Clinical Site, Takasaki, Gunma, Japan|Hiroshima Clinical Site, Fukuyama, Hiroshima, Japan|Hokkaido Clinical Site, Hakodate, Hokkaido, Japan|Hokkaido Clinical Site, Sapporo, Hokkaido, Japan|Hyogo Clinical Site, Akashi, Hyogo, Japan|Hyogo Clinical Site, Amagasaki, Hyogo, Japan|Hyogo Clinical Site, Nishinomiya, Hyogo, Japan|Iwate Clinical Site, Morioka, Iwate, Japan|Kanagawa Clinical Site, Sagamihara, Kanagawa, Japan|Kanagawa Clinical Site, Yokohama, Kanagawa, Japan|Miyagi Clinical Site, Osaki, Miyagi, Japan|Nagano Clinical Site, Saku, Nagano, Japan|Okayama Clinical Site, Kurashiki, Okayama, Japan|Osaka Clinical Site, Hirakata, Osaka, Japan|Osaka Clinical Site, Sakai, Osaka, Japan|Osaka Clinical Site, Suita, Osaka, Japan|Osaka Clinical Site, Takatsuki, Osaka, Japan|Osaka Clinical Site, Toyonaka, Osaka, Japan|Osaka Clinical Site, Ōsaka-sayama, Osaka, Japan|Saitama Clinical Site, Hidaka, Saitama, Japan|Saitama Clinical Site, Kitaadachi-gun, Saitama, Japan|Shizuoka Clinical Site, Sunto-gun, Shizuoka, Japan|Tochigi Clinical Site, Shimotsuke, Tochigi, Japan|Tokyo Clinical Site, Bunkyo-ku, Tokyo, Japan|Tokyo Clinical Site, Chuo-ku, Tokyo, Japan|Tokyo Clinical Site, Koto-ku, Tokyo, Japan|Tokyo Clinical Site, Shinjuku-ku, Tokyo, Japan|Chiba Clinical Site, Chiba, Japan|Fukuoka Clinical Site, Fukuoka, Japan|Gifu Clinical Site, Gifu, Japan|Hiroshima Clinical Site1, Hiroshima, Japan|Hiroshima Clinical Site2, Hiroshima, Japan|Hiroshima Clinical Site3, Hiroshima, Japan|Kochi Clinical Site, Kochi, Japan|Kumamoto Clinical Site, Kumamoto, Japan|Kyoto Clinical Site, Kyoto, Japan|Niigata Clinical Site, Niigata, Japan|Osaka Clinical Site1, Osaka, Japan|Osaka Clinical Site2, Osaka, Japan|Osaka Clinical Site3, Osaka, Japan|Osaka Clinical Site4, Osaka, Japan|Shizuoka Clinical Site, Shizuoka, Japan|Toyama Clinical Site, Toyama, Japan|Wakayama Clinical Site, Wakayama, Japan|Yamagata Clinical Site, Yamagata, Japan|Busan Clinical Site1, Busan, Korea, Republic of|Busan Clinical Site2, Busan, Korea, Republic of|Busan Clinical Site3, Busan, Korea, Republic of|Daegu Clinical Site1, Daegu, Korea, Republic of|Daegu Clinical Site2, Daegu, Korea, Republic of|Daegu Clinical Site3, Daegu, Korea, Republic of|Daejeon Clinical Site, Daejeon, Korea, Republic of|Gwangju Clinical Site, Gwangju, Korea, Republic of|Gyeonggi-do Clinical Site1, Gyeonggi-do, Korea, Republic of|Gyeonggi-do Clinical Site2, Gyeonggi-do, Korea, Republic of|Gyeonggi-do Clinical Site3, Gyeonggi-do, Korea, Republic of|Gyeonggi-do Clinical Site4, Gyeonggi-do, Korea, Republic of|Gyeonggi-do Clinical Site5, Gyeonggi-do, Korea, Republic of|Jeollabuk-do Clinical Site, Jeollabuk-do, Korea, Republic of|Seoul Clinical Site1, Seoul, Korea, Republic of|Seoul Clinical Site2, Seoul, Korea, Republic of|Seoul Clinical Site3, Seoul, Korea, Republic of|Seoul Clinical Site4, Seoul, Korea, Republic of|Seoul Clinical Site5, Seoul, Korea, Republic of|Seoul Clinical Site6, Seoul, Korea, Republic of|Seoul Clinical Site7, Seoul, Korea, Republic of|Kaohsiung Clinical Site2, Kaohsiung, Taiwan|Kaohsiung Clinical Site, Kaohsiung, Taiwan|New Taipei Clinical Site, New Taipei, Taiwan|Taichung Clinical Site, Taichung, Taiwan|Tainan Clinical Site2, Tainan, Taiwan|Tainan Clinical Site, Tainan, Taiwan|Taipei Clinical Site1, Taipei, Taiwan|Taipei Clinical Site2, Taipei, Taiwan
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03006705

Study 128:
  NCT Number:                   NCT03647839
  Title:                        Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer
  Acronym:                      MODULATE
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Colorectal Cancer Metastatic
  Interventions:                Drug: Nivolumab 10 MG/ML|Drug: BNC 105|Drug: BBI608
  Outcome Measures:             Objective response per iRECIST|Objective response per RECIST1.1|Progression free survival (PFS).|Adverse event assessed using CTCAE version 5.0|Overall survival
  Sponsor/Collaborators:        Australasian Gastro-Intestinal Trials Group
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   90
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209‐99U
  Start Date:                   September 6, 2018
  Primary Completion Date:      August 2022
  Completion Date:              August 2022
  First Posted:                 August 27, 2018
  Results First Posted:         null
  Last Update Posted:           October 29, 2018
  Locations:                    Border Cancer Hospital, Albury, New South Wales, Australia|Newcastle Private Hospital, Newcastle, New South Wales, Australia|Northern Cancer Institute, St Leonards, New South Wales, Australia|Sydney Adventist Hospital, Wahroonga, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Royal Brisbane Hospital, Herston, Queensland, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Ashford Cancer Centre Research, Kurralta Park, South Australia, Australia|Queen Elizabeth Hospital, Woodville South, South Australia, Australia|Ballarat Health Service, Ballarat, Victoria, Australia|Eastern Health, Box Hill, Victoria, Australia|Monash Health, Clayton, Victoria, Australia|Olivia Newton-John Cancer Wellness and Research Centre, Heidelberg, Victoria, Australia|Peninsula Health/Frankston Hospital, Mornington Peninsula, Victoria, Australia|Western Health, Saint Albans, Victoria, Australia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03647839

Study 129:
  NCT Number:                   NCT02329847
  Title:                        A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Hematologic Neoplasms
  Interventions:                Drug: Ibrutinib|Drug: Nivolumab
  Outcome Measures:             Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Overall Response Rate (ORR)|Duration of Stable Disease|Duration of response|Progression-Free Survival (PFS)|Overall survival|1-year Progression-Free Survival (PFS) Rate|Plasma and serum concentration of Ibrutinib and nivolumab
  Sponsor/Collaborators:        Janssen Research & Development, LLC|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   136
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CR106681|PCI-32765LYM1002|2014-005191-28
  Start Date:                   March 11, 2015
  Primary Completion Date:      July 15, 2019
  Completion Date:              July 31, 2020
  First Posted:                 January 1, 2015
  Results First Posted:         null
  Last Update Posted:           November 9, 2018
  Locations:                    New York, New York, United States|Bedford Park, Australia|Darlinghurst, Australia|Woolloongabba, Australia|Haifa, Israel|Jeursalem, Israel|Ramat Gan, Israel|Tel Aviv, Israel|Chorzow, Poland|Gdansk, Poland|Krakow, Poland|Wroclaw, Poland|Barcelona, Spain|Madrid, Spain|Salamanca, Spain|Ankara, Turkey|Istanbul, Turkey|İzmir, Turkey
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02329847

Study 130:
  NCT Number:                   NCT02828124
  Title:                        A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer
  Acronym:                      
  Status:                       Terminated
  Study Results:                No Results Available
  Conditions:                   Hepatocellular Carcinoma
  Interventions:                Biological: BMS-986183|Biological: Nivolumab
  Outcome Measures:             Incidence and Adverse Events (AEs) at its worst grade|Incidence of Serious Adverse Events (SAEs) at its worst grade|Incidence of AEs leading to discontinuations|Incidence of AEs leading to death|Frequency of laboratory test toxicity grade shifting from baseline|Best overall response (BOR)|Overall response rate (ORR)|Duration of response (DOR)|Progression free survival (PFS)|Changes in Fridericia-corrected QT interval (ΔQTcF)|Frequency of different subject immunogenicity status|Cmax (maximum observed serum and/or plasma concentration)|Tmax (time of maximum observed serum and/or plasma concentration)|AUC(0-t) (area under the concentration-time curve from time 0 to time t)|AUC(TAU) (area under the concentration-time curve in 1 dosing interval)|Ctau (concentration at the end of a dosing interval)|Ctrough (trough observed serum and/or plasma concentration, including predose concentrations and Ctau concentrations)|CLT (total body clearance calculated as dose divided by AUC(TAU)|Vss (apparent volume of distribution at steady-state)|Vz (volume of distribution of terminal phase)|AI_Cmax (accumulation index; ratio of Cmax at steady-state to Cmax after the first dose)|AI_Ctau (accumulation index; ratio of Ctau at steady-state to Ctau after the first dose)
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   25
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA015-003
  Start Date:                   August 23, 2016
  Primary Completion Date:      January 8, 2018
  Completion Date:              January 8, 2018
  First Posted:                 July 11, 2016
  Results First Posted:         null
  Last Update Posted:           October 24, 2018
  Locations:                    Local Institution, Ottawa, Ontario, Canada|Local Institution, Seoul, Korea, Republic of|Local Institution, Singapore, Singapore|Local Institution, Taipei, Taiwan
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02828124

Study 131:
  NCT Number:                   NCT03342352
  Title:                        Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)
  Acronym:                      
  Status:                       Withdrawn
  Study Results:                No Results Available
  Conditions:                   Head and Neck Cancer
  Interventions:                Drug: Nivolumab|Drug: Epacadostat|Drug: Placebo|Drug: Carboplatin|Drug: Cisplatin|Drug: Cetuximab|Drug: 5-Fluorouracil
  Outcome Measures:             Progression-free survival (PFS) with nivolumab plus epacadostat in combination with chemotherapy (Arm A) compared to the EXTREME regimen (Arm B)|Overall survival (OS) with nivolumab plus epacadostat in combination with chemotherapy (Arm A) compared to the EXTREME regimen (Arm B)|Objective response rate (ORR) with nivolumab plus epacadostat in combination with chemotherapy (Arm A) and the EXTREME regimen (Arm B)|Duration of response (DOR) with nivolumab plus epacadostat in combination with chemotherapy (Arm A) and the EXTREME regimen (Arm B)|ORR with nivolumab plus placebo in combination with chemotherapy (Arm C)|PFS with nivolumab plus placebo in combination with chemotherapy (Arm C)|DOR with nivolumab plus placebo in combination with chemotherapy (Arm C)|Time to meaningful symptomatic deterioration (TTSD) with nivolumab plus epacadostat in combination with chemotherapy (Arm A) compared to the EXTREME regimen (Arm B)
  Sponsor/Collaborators:        Incyte Corporation|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   0
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  Other IDs:                    CA2099NA/ECHO-310
  Start Date:                   December 15, 2017
  Primary Completion Date:      April 20, 2018
  Completion Date:              April 20, 2018
  First Posted:                 November 14, 2017
  Results First Posted:         null
  Last Update Posted:           May 23, 2018
  Locations:                    
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03342352

Study 132:
  NCT Number:                   NCT03143270
  Title:                        A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Liver Cancer
  Interventions:                Drug: Drug Eluting Bead Transarterial Chemoembolization|Drug: Nivolumab
  Outcome Measures:             Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
  Sponsor/Collaborators:        Memorial Sloan Kettering Cancer Center|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Early Phase 1
  Enrollment:                   14
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    17-087
  Start Date:                   April 28, 2017
  Primary Completion Date:      April 2019
  Completion Date:              April 2019
  First Posted:                 May 8, 2017
  Results First Posted:         null
  Last Update Posted:           September 11, 2018
  Locations:                    Mayo Clinic Cancer Center, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Abramson Cancer Center at University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03143270

Study 133:
  NCT Number:                   NCT03271047
  Title:                        Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   MSS|RAS-mutant Colorectal Cancer
  Interventions:                Drug: binimetinib|Drug: nivolumab|Drug: ipilimumab
  Outcome Measures:             (Phase 1b) Incidence of dose-limiting toxicities (DLTs) resulting from binimetinib in combination with nivolumab|(Phase 1b) Incidence of dose-limiting toxicities (DLTs) resulting from binimetinib in combination with nivolumab plus ipilimumab|(Phase 2) Objective Response Rate (ORR)|(Phase 1b) Objective Response Rate (ORR)|(Phase 1b and Phase 2) Duration of Response (DOR)|(Phase 1b and Phase 2) Rate of complete response (CR)|(Phase 1b and Phase 2) Incidence and severity of adverse events (AEs)|(Phase 1b and Phase 2) Sparse plasma concentrations for binimetinib
  Sponsor/Collaborators:        Array BioPharma|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   90
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    ARRAY-162-202
  Start Date:                   October 4, 2017
  Primary Completion Date:      June 2019
  Completion Date:              January 2020
  First Posted:                 September 1, 2017
  Results First Posted:         null
  Last Update Posted:           October 2, 2018
  Locations:                    Array BioPharma Investigative Site, Encinitas, California, United States|Array BioPharma Investigative Site, Laguna Hills, California, United States|Array BioPharma Investigative Site, Santa Monica, California, United States|Array BioPharma Investigative Site, Newark, Delaware, United States|Array BioPharma Investigative Sites (2), Port Saint Lucie, Florida, United States|Array BioPharma Investigative Site, Indianapolis, Indiana, United States|Array BioPharma Investigative Site, Saint Louis, Missouri, United States|Array BioPharma Investigative Sites (2), Philadelphia, Pennsylvania, United States|Array BioPharma Investigative Site, Chattanooga, Tennessee, United States|Array BioPharma Investigative Site, Nashville, Tennessee, United States|Array BioPharma Investigative Site, Houston, Texas, United States|Array BioPharma Investigative Site, Leuven, Belgium|Array BioPharma Investigative Site, Amsterdam, Noord-Holland, Netherlands|Array BioPharma Investigative Site, Amsterdam, Noord-Holland, Netherlands|Array BioPharma Investigative Site, Santander, Canabria, Spain|Array BioPharma Investigative Site, Madrid, Madrid, Communidad Delaware, Spain|Array BioPharma Investigative Site, Barcelona, Spain|Array BioPharma Investigative Site, Madrid, Spain|Array BioPharma Investigative Site, Madrid, Spain|Array BioPharma Investigative Sites (2), London, United Kingdom|Array BioPharma Investigative Site, Oxford, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03271047

Study 134:
  NCT Number:                   NCT03110978
  Title:                        Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I, Selected Stage IIa or Isolated Lung Parenchymal Recurrent Non-Small Cell Lung Cancer: I-SABR
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Malignant Neoplasms of Respiratory and Intrathoracic Organs|Non-small Cell Lung Cancer
  Interventions:                Radiation: Stereotactic Ablative Radiotherapy|Drug: Nivolumab
  Outcome Measures:             Event-Free Survival (EFS)|Overall Survival (OS)|Toxicity Related to SABR and Immunotherapy
  Sponsor/Collaborators:        M.D. Anderson Cancer Center|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   140
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    2016-0737|NCI-2018-01212
  Start Date:                   June 26, 2017
  Primary Completion Date:      June 2022
  Completion Date:              June 2022
  First Posted:                 April 12, 2017
  Results First Posted:         null
  Last Update Posted:           October 8, 2018
  Locations:                    University of Texas MD Anderson Cancer Center, Houston, Texas, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03110978

Study 135:
  NCT Number:                   NCT03158129
  Title:                        Study Of Induction Checkpoint Blockade For Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable For Surgical Resection
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Non-Small Cell Lung Cancer
  Interventions:                Drug: Nivolumab|Drug: Ipilimumab|Procedure: Thoracic Surgery
  Outcome Measures:             Major Pathologic Response (mPR)|Toxicity Assessed by the NCI CTCAE Version 4|Quantification of CD8+ TILs|Response Rates to Induction Treatment by RECIST version 1.1
  Sponsor/Collaborators:        M.D. Anderson Cancer Center|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   66
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    2016-0982|NCI-2018-01210
  Start Date:                   June 9, 2017
  Primary Completion Date:      June 2021
  Completion Date:              June 2022
  First Posted:                 May 17, 2017
  Results First Posted:         null
  Last Update Posted:           September 14, 2018
  Locations:                    University of Texas MD Anderson Cancer Center, Houston, Texas, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03158129

Study 136:
  NCT Number:                   NCT03256136
  Title:                        Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Lung Cancer
  Interventions:                Drug: Carboplatin|Drug: Nivolumab|Drug: pemetrexed|Drug: Ipilimumab
  Outcome Measures:             Objective Response Rate (ORR)|Disease Control Rate (DCR)|Progression Free Survival (PFS)|Overall Survival (OS)|Duration Of Response
  Sponsor/Collaborators:        Massachusetts General Hospital|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   100
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    17-011
  Start Date:                   November 22, 2017
  Primary Completion Date:      October 31, 2020
  Completion Date:              October 31, 2024
  First Posted:                 August 21, 2017
  Results First Posted:         null
  Last Update Posted:           June 12, 2018
  Locations:                    Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts general Hospital, Boston, Massachusetts, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03256136

Study 137:
  NCT Number:                   NCT03523572
  Title:                        Trastuzumab Deruxtecan (DS-8201a) With Nivolumab in Advanced Breast and Urothelial Cancer
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Breast Cancer|Urothelial Carcinoma
  Interventions:                Drug: Trastuzumab deruxtecan (DS-8201a)|Drug: Nivolumab
  Outcome Measures:             Number of participants with dose-limiting toxicity at each dose level|Part 2: Dose expansion - Objective response rate (ORR)|Duration of Response (DoR)|Disease Control Rate (DCR)|Progression Free Survival (PFS)|Time to Response based on central review|Overall Survival (OS)|ORR
  Sponsor/Collaborators:        Daiichi Sankyo, Inc.|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   99
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    DS8201-A-U105|2018-000371-32
  Start Date:                   June 20, 2018
  Primary Completion Date:      September 2020
  Completion Date:              September 2020
  First Posted:                 May 14, 2018
  Results First Posted:         null
  Last Update Posted:           November 27, 2018
  Locations:                    UCLA - Medical Center, Santa Monica, California, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Tennessee Oncology - Sara Cannon Research Institute, Nashville, Tennessee, United States|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03523572

Study 138:
  NCT Number:                   NCT03245892
  Title:                        A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab in Patients With Ovarian Cancer
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   High Grade Serous Ovarian|Fallopian Tube|Primary Peritoneal Cancer
  Interventions:                Drug: Carboplatin and Paclitaxel|Drug: Nivolumab|Procedure: cytoreductive surgery
  Outcome Measures:             number of patients with dose limiting toxicities
  Sponsor/Collaborators:        Memorial Sloan Kettering Cancer Center|Bristol-Myers Squibb
  Gender:                       Female
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   20
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    17-182
  Start Date:                   August 4, 2017
  Primary Completion Date:      August 2019
  Completion Date:              August 2019
  First Posted:                 August 10, 2017
  Results First Posted:         null
  Last Update Posted:           September 7, 2018
  Locations:                    Memorial Sloan Kettering Cancer Center, New York, New York, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03245892

Study 139:
  NCT Number:                   NCT02833233
  Title:                        A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Breast Cancer
  Interventions:                Procedure: Cryoablation|Drug: Ipilimumab|Drug: Nivolumab
  Outcome Measures:             Number of adverse events
  Sponsor/Collaborators:        Memorial Sloan Kettering Cancer Center|Bristol-Myers Squibb
  Gender:                       Female
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Not Applicable
  Enrollment:                   5
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    16-495
  Start Date:                   June 2016
  Primary Completion Date:      June 2019
  Completion Date:              June 2019
  First Posted:                 July 14, 2016
  Results First Posted:         null
  Last Update Posted:           July 3, 2018
  Locations:                    Memorial Sloan Kettering Cancer Center, New York, New York, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02833233

Study 140:
  NCT Number:                   NCT03161379
  Title:                        Phase 2 GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Pancreatic Cancer
  Interventions:                Drug: Cyclophosphamide|Drug: Nivolumab|Drug: GVAX Pancreas Vaccine|Radiation: Stereotactic Body Radiation (SBRT)
  Outcome Measures:             Pathologic complete response (pCR) rate at surgical resection.|Number of subjects who receive an R0 surgical resection.|Objective response rate (ORR)|Overall survival (OS)|Distant metastasis free survival (DMFS)|Number of drug related adverse events
  Sponsor/Collaborators:        Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years to 100 Years   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   50
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    J1756|IRB00130075
  Start Date:                   December 13, 2017
  Primary Completion Date:      September 2019
  Completion Date:              September 2019
  First Posted:                 May 19, 2017
  Results First Posted:         null
  Last Update Posted:           November 6, 2018
  Locations:                    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03161379

Study 141:
  NCT Number:                   NCT03532217
  Title:                        Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Metastatic Hormone-Sensitive Prostate Cancer
  Interventions:                Biological: PROSTVAC-V|Biological: PROSTVAC-F|Drug: Nivolumab|Drug: Ipilimumab|Biological: Neoantigen DNA vaccine|Device: TriGrid Delivery System|Procedure: Tumor biopsy|Procedure: Peripheral blood|Procedure: Fecal samples
  Outcome Measures:             Safety and tolerability of regimen as defined by incidence of adverse events|Immune response as measured by tetramers|Immune response as measured by genomic studies|Immune response as measured by flow cytometry|Safety and tolerability of regimen as defined by incidence of dose-limiting toxicities (DLTs)|Failure-free survival (FFS)|Milestone survival|Number of participants who have PSA responses at 30% reduction level|Number of participants who have PSA responses at 50% reduction level|Radiographic progression as determined by RECIST 1.1|Radiographic progression as determined by Prostate Cancer Working Group 3 (PCWG3)|Radiographic progression free survival (rPFS)|Comparison of the immune correlates on matched tumor tissue and peripheral blood
  Sponsor/Collaborators:        Washington University School of Medicine|Bristol-Myers Squibb
  Gender:                       Male
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   20
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    201808043|CA209-9MW
  Start Date:                   September 14, 2018
  Primary Completion Date:      October 14, 2021
  Completion Date:              September 14, 2023
  First Posted:                 May 22, 2018
  Results First Posted:         null
  Last Update Posted:           September 19, 2018
  Locations:                    National Cancer Institute (GU Malignancies Branch), Bethesda, Maryland, United States|Washington University School of Medicine, Saint Louis, Missouri, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03532217

Study 142:
  NCT Number:                   NCT03391869
  Title:                        Trial of Local Consolidation Therapy (LCT) After Nivolumab and Ipilimumab (LONESTAR)
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Malignant Neoplasms of Respiratory and Intrathoracic Organs|Non-small Cell Lung Cancer
  Interventions:                Drug: Ipilimumab|Drug: Nivolumab|Procedure: Local Consolidative Therapy (LCT)
  Outcome Measures:             Overall Survival (OS)|Overall Survival (OS) in Oligometastatic Patients|Progression-Free Survival (PFS)|Time to Appearance of New Metastases (TANM)|Progression of Target lesions Defined by RECIST 1.1 Criteria|Progression of Non-Target Lesions by RECIST 1.1 Criteria|Toxicity Evaluated Using CTCAE v4.0 Criteria|Quality of Life (QOL)
  Sponsor/Collaborators:        M.D. Anderson Cancer Center|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   270
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    2017-0311|NCI-2018-00825
  Start Date:                   December 29, 2017
  Primary Completion Date:      December 2022
  Completion Date:              December 2022
  First Posted:                 January 5, 2018
  Results First Posted:         null
  Last Update Posted:           November 26, 2018
  Locations:                    MD Anderson Cancer Center Memorial City, Houston, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|MD Anderson Cancer Center Katy, Houston, Texas, United States|MD Anderson Cancer Center Bay Area, Nassau Bay, Texas, United States|MD Anderson Cancer Center Sugar Land, Sugar Land, Texas, United States|MD Anderson Cancer Center The Woodlands, The Woodlands, Texas, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03391869

Study 143:
  NCT Number:                   NCT03335540
  Title:                        An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment
  Acronym:                      ADVISE
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Advanced Cancer
  Interventions:                Biological: Nivolumab|Biological: Relatlimab|Biological: Cabiralizumab|Biological: Ipilimumab|Biological: anti-GITR|Drug: IDO1 Inhibitor|Biological: Lirilumab|Radiation: Radiation Therapy
  Outcome Measures:             Number of participants with qualified tumor biopsy specimen at baseline|Percent of change from baseline in histopathologic features|Percent of change from baseline in biomarker expression patterns|Number of Adverse Events (AEs)|Number of Serious Adverse Events (SAEs)|Number of Laboratory Abnormalities
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   50
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA028-001
  Start Date:                   March 13, 2018
  Primary Completion Date:      January 30, 2020
  Completion Date:              January 31, 2022
  First Posted:                 November 7, 2017
  Results First Posted:         null
  Last Update Posted:           October 4, 2018
  Locations:                    The University of Chicago Medicine, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Local Institution, Baltimore, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03335540

Study 144:
  NCT Number:                   NCT03711058
  Title:                        Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor Along With Microsatellite Stable (MSS) Colon Cancer|Colon Cancer
  Interventions:                Drug: Copanlisib|Drug: Nivolumab
  Outcome Measures:             Determine maximum tolerated dose (MTD) of copanlisib with fixed dose nivolumab|6-month objective response rate (ORR) of patients treated with copanlisib and nivolumab|Disease control rate (DCR) status at 6 months.|Duration of response (DOR) status at 6 months.|Progression free survival (PFS) status at 6 months.|Overall survival (OS) status at 6 months.|Number of participants experiencing study drug-related toxicities
  Sponsor/Collaborators:        Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bayer|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years to 100 Years   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   54
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    J1887|IRB00175864|CA209-8LC
  Start Date:                   November 2018
  Primary Completion Date:      November 2020
  Completion Date:              November 2021
  First Posted:                 October 18, 2018
  Results First Posted:         null
  Last Update Posted:           October 18, 2018
  Locations:                    Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03711058

Study 145:
  NCT Number:                   NCT03554317
  Title:                        COMbination of Bipolar Androgen Therapy and Nivolumab
  Acronym:                      COMBAT-CRPC
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Castration-resistant Prostate Cancer|Metastatic Prostate Cancer|Prostate Cancer
  Interventions:                Drug: Testosterone cypionate|Drug: Nivolumab
  Outcome Measures:             Prostate Specific Antigen (PSA) response to Bipolar Androgen Therapy + Nivolumab|Safety of Bipolar Androgen Therapy + Nivolumab As Determined by the Number of CTCAEs ≥ grade 3|PSA Progression-Free Survival (PSA-PFS) to Bipolar Androgen Therapy + Nivolumab|Progression-Free Survival (PFS) to Bipolar Androgen Therapy + Nivolumab|Objective Response Rate (ORR) to Bipolar Androgen Therapy + Nivolumab|Durable Progression-Free Survival (Durable PFS) to Bipolar Androgen Therapy + Nivolumab|Median Overall Survival (OS) to Bipolar Androgen Therapy + Nivolumab
  Sponsor/Collaborators:        Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bristol-Myers Squibb
  Gender:                       Male
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   44
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    J1812|IRB00164973
  Start Date:                   September 5, 2018
  Primary Completion Date:      July 2020
  Completion Date:              July 2021
  First Posted:                 June 13, 2018
  Results First Posted:         null
  Last Update Posted:           November 7, 2018
  Locations:                    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03554317

Study 146:
  NCT Number:                   NCT03333616
  Title:                        Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Genitourinary Cancer|Adrenocortical Carcinoma|Non-urothelial Bladder|Non-urothelial Upper Tract|Penile Cancer|Non-adenocarcinoma Prostate Cancer|Refractory Germ-cell
  Interventions:                Drug: Ipilimumab|Drug: Nivolumab
  Outcome Measures:             Objective Response Rate|Objective Response Rate for all rare GU tumor types|Duration of Response|Immune related objective response rate|Progression-Free Survival for the total cohort and by tumor cohort|Overall Survival for all patients and by tumor cohort|Safety and tolerability according to Common Terminology Criteria for Adverse Events (CTCAE).
  Sponsor/Collaborators:        Dana-Farber Cancer Institute|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   57
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    17-423
  Start Date:                   December 28, 2017
  Primary Completion Date:      May 31, 2021
  Completion Date:              May 31, 2025
  First Posted:                 November 7, 2017
  Results First Posted:         null
  Last Update Posted:           September 21, 2018
  Locations:                    University of California, San Diego Moores Cancer Center, La Jolla, California, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|MD Anderson Cancer Center, Houston, Texas, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03333616

Study 147:
  NCT Number:                   NCT03487666
  Title:                        OXEL: Pilot Study of Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Triple Negative Breast Cancer
  Interventions:                Drug: Nivolumab|Drug: Capecitabine
  Outcome Measures:             Immune activation measured by changes in the peripheral immunoscore (PIS) at week 6|Immune activation measured by changes of PIS at week 12|Grade 3 and 4 toxicities according to the National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4.0 [NCI CTCAE v4.03]|Distant recurrence free survival (DRFS) and Overall Survival|Immune activation in the tumor by IHC|Immune activation in the tumor by flow cytometry|Immune activation in the tumor by ELISA|Intracellular cytokine staining and CD8+ T-cell clonal expansion|Circulating tumor DNA
  Sponsor/Collaborators:        Georgetown University|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   45
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    2017-1535
  Start Date:                   May 21, 2018
  Primary Completion Date:      December 2021
  Completion Date:              December 2022
  First Posted:                 April 4, 2018
  Results First Posted:         null
  Last Update Posted:           June 28, 2018
  Locations:                    MedStar Georgetown University Hospital, Washington, District of Columbia, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03487666

Study 148:
  NCT Number:                   NCT03044613
  Title:                        Nivolumab +/- Relatlimab Prior to Chemoradiation Plus Nivolumab +/- Relatlimab With II/III Gastro/Esophageal Cancer
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Gastric Cancer|Esophageal Cancer|GastroEsophageal Cancer
  Interventions:                Drug: Nivolumab|Drug: Relatlimab|Drug: Carboplatin|Drug: Paclitaxel|Radiation: Radiation
  Outcome Measures:             Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Feasibility is assessed through the proportion of eligible patients who proceed to surgery without substantial delay (more than 60 days) due to treatment-related reasons|Pathological Complete Response Rate|Approximate quantitation of infused nivolumab bound to PD-1 receptors on the surface of T cells in the peripheral blood and within the resected tumor and lymph node specimens|Changes in Expression of Selected Immune Markers|Overall Survival|Recurrence-Free Survival
  Sponsor/Collaborators:        Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   32
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    J1714|IRB00122689
  Start Date:                   July 11, 2017
  Primary Completion Date:      February 2019
  Completion Date:              February 2022
  First Posted:                 February 7, 2017
  Results First Posted:         null
  Last Update Posted:           October 5, 2018
  Locations:                    Johns Hopkins University, Baltimore, Maryland, United States|Alleghany Health Network, Pittsburgh, Pennsylvania, United States|Baylor University, Dallas, Texas, United States
  Study Documents:              "Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/13/NCT03044613/Prot_SAP_000.pdf
  URL:                          https://ClinicalTrials.gov/show/NCT03044613

Study 149:
  NCT Number:                   NCT03572478
  Title:                        Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Prostate Cancer|Endometrial Cancer
  Interventions:                Drug: Rucaparib|Drug: Nivolumab
  Outcome Measures:             Dose limiting toxicities (DLT) rate of the combination of rucaparib and nivolumab
  Sponsor/Collaborators:        University of Chicago|Bristol-Myers Squibb|Clovis Oncology
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   60
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    IRB18-0154
  Start Date:                   August 14, 2018
  Primary Completion Date:      October 14, 2020
  Completion Date:              November 2022
  First Posted:                 June 28, 2018
  Results First Posted:         null
  Last Update Posted:           August 16, 2018
  Locations:                    University of Chicago Medical Center, Chicago, Illinois, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03572478

Study 150:
  NCT Number:                   NCT03325816
  Title:                        Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Small Cell Lung Cancer|Small Cell Lung Cancer Extensive Stage
  Interventions:                Drug: Nivolumab|Radiation: 177Lu-DOTA0-Tyr3-Octreotate
  Outcome Measures:             Phase I - Recommended phase II dose (RP2D) of 177Lu-DOTA0-Tyr3-Octreotate|Phase II - Progression Free Survival|Safety profile of 177Lu-DOTA0-Tyr3-Octreotate in combination with nivolumab|Phase II - Overall survival|Phase II - Disease Control Rate|Phase II - Objective Response Rate|Phase II - Metabolic Response
  Sponsor/Collaborators:        Giuseppe Giaccone|Bristol-Myers Squibb|Advanced Accelerator Applications|Georgetown University
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   9
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    2017-1081
  Start Date:                   November 20, 2017
  Primary Completion Date:      December 2021
  Completion Date:              December 2022
  First Posted:                 October 30, 2017
  Results First Posted:         null
  Last Update Posted:           November 6, 2018
  Locations:                    Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03325816

Study 151:
  NCT Number:                   NCT02259621
  Title:                        Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC
  Acronym:                      NA_00092076
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Non-Small Cell Lung Cancer
  Interventions:                Drug: Nivolumab|Drug: Ipilimumab
  Outcome Measures:             Safety|Feasibility|Pathologic Reponse|Radiographic Response
  Sponsor/Collaborators:        Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   30
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    J1414|NA_00092076
  Start Date:                   September 2014
  Primary Completion Date:      January 2023
  Completion Date:              January 2023
  First Posted:                 October 8, 2014
  Results First Posted:         null
  Last Update Posted:           October 5, 2018
  Locations:                    Sibley Memorial Hospital, Washington, District of Columbia, United States|Johns Hopkins at Bayview Medical Center, Baltimore, Maryland, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Memorial Sloan Kettering, New York, New York, United States
  Study Documents:              "Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/21/NCT02259621/Prot_SAP_000.pdf
  URL:                          https://ClinicalTrials.gov/show/NCT02259621

Study 152:
  NCT Number:                   NCT03607890
  Title:                        Phase 2 Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy|MSI-H Tumors
  Interventions:                Drug: Nivolumab|Drug: Relatlimab
  Outcome Measures:             Objective response rate (ORR) using Response Evaluation Criteria in Solid Tumors (RECIST 1.1)|Number of participants experiencing study drug-related toxicities|Overall survival (OS) using RECIST 1.1|Progression free survival (PFS) using RECIST 1.1|Disease control rate (DCR) using RECIST 1.1|Best overall response (BOR) using RECIST 1.1|Duration of response (DOR) using RECIST 1.1|Duration of clinical benefit (DCB) using RECIST 1.1|Time to objective response (TTOR) using RECIST 1.1
  Sponsor/Collaborators:        Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years to 100 Years   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   21
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    J18102|IRB00173534
  Start Date:                   November 6, 2018
  Primary Completion Date:      October 2022
  Completion Date:              October 2022
  First Posted:                 July 31, 2018
  Results First Posted:         null
  Last Update Posted:           November 8, 2018
  Locations:                    Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03607890

Study 153:
  NCT Number:                   NCT03558087
  Title:                        Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Bladder Cancer
  Interventions:                Drug: Nivolumab|Drug: Gemcitabine|Drug: Cisplatin
  Outcome Measures:             Determine the clinical complete response rate (cT0 or cTa) with gemcitabine, cisplatin, plus nivolumab|Determine the ability of clinical complete response (cT0 or cTa) to predict benefit from treatment.|Assess Adverse Events|Bladder intact overall survival|Recurrence-free survival|Pathologic complete response rate in patients undergoing cystectomy|Determine the association between a prespecified panel of genomic biomarkers and benefit from treatment in patients achieving a clinical complete response.
  Sponsor/Collaborators:        Matthew Galsky|Bristol-Myers Squibb|Icahn School of Medicine at Mount Sinai|Hoosier Cancer Research Network
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   63
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    HCRN GU16-257
  Start Date:                   July 13, 2018
  Primary Completion Date:      June 2020
  Completion Date:              June 2022
  First Posted:                 June 15, 2018
  Results First Posted:         null
  Last Update Posted:           October 5, 2018
  Locations:                    Icahn School of Medicine: Tisch Cancer Institute at Mount Sinai Medical Center, New York, New York, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03558087

Study 154:
  NCT Number:                   NCT02768558
  Title:                        Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Non-Small Cell Lung Cancer
  Interventions:                Radiation: Thoracic RT|Drug: Cisplatin|Drug: Etoposide|Drug: Nivolumab|Other: Placebo
  Outcome Measures:             Overall Survival (OS)|Progression-Free Survival (PFS)
  Sponsor/Collaborators:        RTOG Foundation, Inc.|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   13
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  Other IDs:                    RTOG 3505|RF 3505|CA209-333
  Start Date:                   October 2016
  Primary Completion Date:      October 2022
  Completion Date:              October 2024
  First Posted:                 May 11, 2016
  Results First Posted:         null
  Last Update Posted:           November 22, 2017
  Locations:                    UC San Diego Moores Cancer Center, La Jolla, California, United States|Stanford University, Stanford, California, United States|University of Florida, Gainesville, Florida, United States|Mount Sinai Cancer Research Center, Miami Beach, Florida, United States|Nancy N. & J.C. Lewis Cancer & Research Pavilion at St. Joseph's/Candler Hospital, Savannah, Georgia, United States|University of Kentucky, Lexington, Kentucky, United States|Mercy Medical Cancer Center, Baltimore, Maryland, United States|Henry Ford Health System, Detroit, Michigan, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|Metro Health Medical Center, Cleveland, Ohio, United States|Reading Hospital/McGlinn Cancer Institute, West Reading, Pennsylvania, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|Virginia Mason, Seattle, Washington, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02768558

Study 155:
  NCT Number:                   NCT03470922
  Title:                        A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Melanoma
  Interventions:                Biological: Relatlimab|Biological: Nivolumab
  Outcome Measures:             Progression Free Survival (PFS)|PFS|Overall Survival (OS)|ORR|Duration of Response (DOR)|OS|Number of Adverse Events (AEs)|Number of Serious Adverse Events (SAEs)|Number of AEs Leading to Discontinuation|Number of Deaths|Number of Laboratory Abnormalities
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          12 Years and older   (Child, Adult, Older Adult)
  Phases:                       Phase 2|Phase 3
  Enrollment:                   700
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  Other IDs:                    CA224-047|2017-003583-12
  Start Date:                   April 10, 2018
  Primary Completion Date:      July 14, 2020
  Completion Date:              March 16, 2022
  First Posted:                 March 20, 2018
  Results First Posted:         null
  Last Update Posted:           November 20, 2018
  Locations:                    University of Arizona Cancer Center, Tucson, Arizona, United States|Local Institution, Los Angeles, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|Sansum Santa Barbara Medical Foundation Clinic, Santa Barbara, California, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Local Institution, Washington, District of Columbia, United States|Local Institution, Jacksonville, Florida, United States|Orlando Health, Inc, Orlando, Florida, United States|Moffitt Mckinley Outpatient Center, Tampa, Florida, United States|Northside Hospital, Atlanta, Georgia, United States|Local Institution, Chicago, Illinois, United States|Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States|H & J Weinberg Can Int @ Franklin Square, Baltimore, Maryland, United States|Local Institution, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Local Institution, New York, New York, United States|Carolinas Healthcare System, Charlotte, North Carolina, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Texas Oncology Sammons Cancer Center, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Instituto Alexander Fleming, Caba, Buenos Aires, Argentina|Hospital Britanico De Buenos Aires, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Hospital Italiano De Buenos Aires, Caba, Argentina|Melanoma Institute Australia, North Sydney, New South Wales, Australia|Local Institution, Waratah, New South Wales, Australia|Local Institution, Greenslopes, Queensland, Australia|Local Institution, Southport, Queensland, Australia|Local Institution, Bedford Park, South Australia, Australia|Local Institution, Murdoch, Western Australia, Australia|Med University Graz Dermatology, Graz, Austria|PMU Salzburg, Salzburg, Austria|Medizinische Universtaet Wien, Wien, Austria|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Gent, Belgium|Local Institution, Halifax, Nova Scotia, Canada|Local Institution, Ottawa, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|MUHC - Glen Site, Montreal, Quebec, Canada|Fundacion Arturo Lopez Perez, Santiago, Metropolitana, Chile|Local Institution, Bogota, Colombia|Local Institution, Medellin, Colombia|Local Institution, Aarhus, Denmark|Local Institution, Herlev, Denmark|Local Institution, Odense, Denmark|Local Institution, Helsinki, Finland|Local Institution, Oulu, Finland|Local Institution, Tampere, Finland|Local Institution, Turku, Finland|Chu D'Amiens - Hopital Nord, Amiens Cedex 1, France|Local Institution, Bordeaux Cedex, France|Local Institution, Lille, France|Local Institution, Marseille Cedex 5, France|Local Institution, Paris, France|Centre Hospitalier Lyon Sud, Pierre-Benite, France|Local Institution, Poitiers, France|Local Institution, Rennes Cedex, France|Elbe Klinikum Buxtehude, Buxtehude, Germany|Helios Klinikum Erfurt, Erfurt, Germany|Universitaetsklinik Essen, Essen, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitatsklinikum Heidelberg, Heidelberg, Germany|Universitaetsklinikum Des Saarlandes, Homburg / Saar, Germany|Universitaetsklinik Koeln, Koeln, Germany|University Of Lubeck, Lubeck, Germany|Universitaetsklinikum Mannheim, Mannheim, Germany|Klinikum rechts der Isar der Technischen Universitat Munchen, Munich, Germany|Klinikum Dorothea Christiane Erxleben Quedlinburg GmbH, Quedlinburg, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Germany|Univ. Klinikum Wuerzburg, Wuerzburg, Germany|Laiko General Hospital Of Athens, Athens, Greece|BioClinic Thessaloniki, Thessaloniki, Greece|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Ramat-gan, Israel|Local Institution, Bergamo, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Siena, Italy|Local Institution, Torino, Italy|Local Institution, Zapopan, Jalisco, Mexico|Local Institution, Monterrey, Nuevo LEON, Mexico|Local Institution, Merida, Yucatan, Mexico|Local Institution, Cancun, Quintana Roo, Mexico|Local Institution, Veracruz, Mexico|Local Institution, Dunedin, New Zealand|Local Institution, Hamilton, New Zealand|Local Institution, Tauranga, New Zealand|Local Institution, Oslo, Norway|Oddzial Onkologii Klinicznej i Doswiadczalnej, Poznan, Poland|Local Institution, Warszawa, Poland|Local Institution, Krasnodar, Russian Federation|Local Institution, Krasnoyarsk, Russian Federation|Comp. Hosp. Univ. A Coruna, A Coru?a, Spain|H. Univ. Vall dHebron, Barcelona, Spain|Hospital Clinic I Provincial, Barcelona, Spain|Hospital Universitario Ramon Y Cajal, Madrid, Spain|Onkologikoa Of San Sebastian, San Sabastian Gipuzkoa, Spain|Hosp Univ Virgen Macarena, Sevilla, Spain|Local Institution, Goteborg, Sweden|Local Institution, Lund, Sweden|Local Institution, Solna, Sweden|Local Institution, Uppsala, Sweden|Local Institution, Bristol, Avon, United Kingdom|Local Institution, Glasgow, Dumfries & Galloway, United Kingdom|Local Institution, Swansea, Glamorgan, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Inverness, Inverness-shire, United Kingdom|Local Institution, Oxford, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03470922

Study 156:
  NCT Number:                   NCT03203473
  Title:                        Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Renal Cancer
  Interventions:                Drug: Ipilimumab|Drug: Nivolumab
  Outcome Measures:             Number of subjects with persistent Partial Response (PR) or Complete Response (CR) at 1 year since nivolumab discontinuation (Arm A)|Number of subjects with Progressive Disease (PD) or Stable Disease (SD) that convert to PR or CR at 1 year upon the addition of ipilimumab to nivolumab (Arm B)|Progression Free Survival|Overall Survival|Salvage therapy-free interval|Immune related objective response rate (irORR)|Safety and tolerability according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.
  Sponsor/Collaborators:        Dana-Farber Cancer Institute|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   58
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    17-064
  Start Date:                   September 26, 2017
  Primary Completion Date:      November 30, 2020
  Completion Date:              November 30, 2024
  First Posted:                 June 29, 2017
  Results First Posted:         null
  Last Update Posted:           July 16, 2018
  Locations:                    University of California, San Diego Moores Cancer Center, La Jolla, California, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Lifespan Comprehensve Cancer Center, Providence, Rhode Island, United States|University of Utah, Huntsman Cancer Center, Salt Lake City, Utah, United States|Unviersity of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03203473

Study 157:
  NCT Number:                   NCT03651271
  Title:                        Treatment With Nivolumab and Ipilimumab or Nivolumab Alone According to the Percentage of Tumoral CD8 Cells in Advanced Metastatic Cancer
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Advanced Metastatic Cancer
  Interventions:                Biological: Nivolumab|Biological: Ipilimumab
  Outcome Measures:             Clinical benefit rate (CBR) of nivolumab with or without ipilimumab|Percentage of CD8 cells in on-treatment biopsies|Safety of nivolumab with or without ipilimumab measured by AEs based on CTCAE v5.0|Objective response rate (ORR) of nivolumab with or without ipilimumab in participants|The association of the percentage of CD8 cells in tumor samples with clinical outcomes
  Sponsor/Collaborators:        Parker Institute for Cancer Immunotherapy|Bristol-Myers Squibb|Cancer Research Institute, New York City
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   200
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    PICI0025
  Start Date:                   October 17, 2018
  Primary Completion Date:      September 14, 2020
  Completion Date:              September 14, 2022
  First Posted:                 August 29, 2018
  Results First Posted:         null
  Last Update Posted:           October 22, 2018
  Locations:                    M.D. Anderson Cancer Center, Houston, Texas, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03651271

Study 158:
  NCT Number:                   NCT03697564
  Title:                        Nivolumab + Cabiralizumab + Gemcitabine Versus Gemcitabine in Patients With Stage IV Pancreatic Cancer Achieving Disease Control in Response to First-line Chemotherapy (GemCaN Trial).
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Pancreatic Cancer Stage IV
  Interventions:                Drug: Gemcitabine|Drug: Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]|Drug: Cabiralizumab
  Outcome Measures:             Progression Free Survival (PFS)|Incidence of Treatment-Emergent Grade 2-5 Adverse Events assessed using NCI CTCAE v5.0 toxicity criteria|Overall Survival (OS)
  Sponsor/Collaborators:        Hitendra Patel|Stand Up To Cancer|Bristol-Myers Squibb|University of California, San Diego
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 4
  Enrollment:                   40
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    181395
  Start Date:                   October 2018
  Primary Completion Date:      October 2020
  Completion Date:              October 2020
  First Posted:                 October 5, 2018
  Results First Posted:         null
  Last Update Posted:           October 5, 2018
  Locations:                    UCSD Moores Cancer Center, La Jolla, California, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03697564

Study 159:
  NCT Number:                   NCT02499367
  Title:                        Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients
  Acronym:                      TONIC
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Breast Cancer
  Interventions:                Drug: Nivolumab|Radiation: Radiation therapy|Drug: Low dose doxorubicin|Drug: Cyclophosphamide|Drug: Cisplatin
  Outcome Measures:             Progression free survival|Overall response rate|Clinical benefit rate|Toxicity of all study regimens
  Sponsor/Collaborators:        The Netherlands Cancer Institute|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   84
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    N15TON
  Start Date:                   August 2015
  Primary Completion Date:      August 2019
  Completion Date:              August 2022
  First Posted:                 July 16, 2015
  Results First Posted:         null
  Last Update Posted:           September 14, 2017
  Locations:                    Antoni van Leeuwenhoek, Amsterdam, Netherlands
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02499367

Study 160:
  NCT Number:                   NCT03650894
  Title:                        Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Breast Neoplasm Female|Breast Cancer|Breast Carcinoma|Breast Tumor
  Interventions:                Drug: Nivolumab|Drug: Ipilimumab|Drug: Bicalutamide
  Outcome Measures:             iRECIST Clinical Benefit Rate (the number of patients with objective response or ongoing stable disease at week 24 using iRECIST guidelines)|RECIST Clinical Benefit Rate (the number of patients who have a response according to RECIST criteria at week 12)
  Sponsor/Collaborators:        Providence Health & Services|Bristol-Myers Squibb|Memorial Sloan Kettering Cancer Center
  Gender:                       Female
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   138
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-8H3
  Start Date:                   October 2018
  Primary Completion Date:      October 2022
  Completion Date:              October 2023
  First Posted:                 August 29, 2018
  Results First Posted:         null
  Last Update Posted:           August 29, 2018
  Locations:                    Providence Oncology & Hematology Care Clinic - Eastside, Portland, Oregon, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03650894

Study 161:
  NCT Number:                   NCT03121417
  Title:                        Nivolumab in Treating Patients With Advanced Metastatic Non-small Cell Lung Cancer
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Recurrent Non-Small Cell Lung Carcinoma|Stage IV Non-Small Cell Lung Cancer
  Interventions:                Biological: Nivolumab
  Outcome Measures:             Objective response rate (ORR)|Change in T cell population in the peripheral blood assessed by flow cytometry|Progression Free Survival (PFS)|Overall survival (OS)
  Sponsor/Collaborators:        Emory University|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   35
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    IRB00090380|NCI-2016-02017|Winship3286-16-CA209-461
  Start Date:                   July 21, 2017
  Primary Completion Date:      July 2020
  Completion Date:              July 2022
  First Posted:                 April 20, 2017
  Results First Posted:         null
  Last Update Posted:           August 17, 2018
  Locations:                    Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03121417

Study 162:
  NCT Number:                   NCT03563248
  Title:                        Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Pancreatic Cancer
  Interventions:                Drug: FOLFIRINOX|Drug: Losartan|Drug: Nivolumab|Radiation: SBRT|Procedure: Surgery
  Outcome Measures:             Proportion of participants with R0 resection|Progression-free survival|Overall survival|Pathologic complete response|Number of participants with treatment related serious adverse events
  Sponsor/Collaborators:        Massachusetts General Hospital|Bristol-Myers Squibb|Stand Up To Cancer
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   170
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    18-179
  Start Date:                   August 10, 2018
  Primary Completion Date:      December 31, 2021
  Completion Date:              December 31, 2025
  First Posted:                 June 20, 2018
  Results First Posted:         null
  Last Update Posted:           September 17, 2018
  Locations:                    Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03563248

Study 163:
  NCT Number:                   NCT03021993
  Title:                        Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Oral Cavity SCC
  Interventions:                Drug: Nivolumab
  Outcome Measures:             Objective response rate using pathological response|Level of Treg cells in peripheral blood using immunostaining|Level of activated T-cells in peripheral blood|Level of immune stimulatory cytokines in peripheral blood|Expression of Th1 responses in CD4+ cells from peripheral blood|Expression of Th2 responses in CD4+ cells from peripheral blood|Expression of CD8+ cells expressing granzyme B (ctolytic response) from peripheral blood
  Sponsor/Collaborators:        Medical University of South Carolina|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   19
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    102510
  Start Date:                   May 30, 2017
  Primary Completion Date:      April 2019
  Completion Date:              March 2020
  First Posted:                 January 16, 2017
  Results First Posted:         null
  Last Update Posted:           November 21, 2018
  Locations:                    Medical University of South Carolina, Charleston, South Carolina, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03021993

Study 164:
  NCT Number:                   NCT03406715
  Title:                        Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Small Cell Lung Cancer|Lung Cancer|Relapsed Small Cell Lung Cancer
  Interventions:                Drug: Nivolumab|Drug: Ipilimumab|Biological: Dendritic Cell based p53 Vaccine
  Outcome Measures:             Disease Control Rate (DCR)|Progression Free Survival (PFS)|Overall Survival (OS)|Overall Response Rate (ORR)|Immune Response (IR)
  Sponsor/Collaborators:        H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb|MultiVir, Inc.
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   41
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    MCC-19163|CA209-9KN|MVIR-Adp53DC-001
  Start Date:                   March 29, 2018
  Primary Completion Date:      April 2020
  Completion Date:              April 2021
  First Posted:                 January 23, 2018
  Results First Posted:         null
  Last Update Posted:           September 18, 2018
  Locations:                    H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03406715

Study 165:
  NCT Number:                   NCT01592370
  Title:                        An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Non-Hodgkin's Lymphoma|Hodgkin Lymphoma|Multiple Myeloma
  Interventions:                Biological: Nivolumab|Biological: Ipilimumab|Biological: Lirilumab|Biological: Daratumumab|Drug: Pomalidomide|Drug: Dexamethasone
  Outcome Measures:             Safety and tolerability of Nivolumab alone and in combination as measured by incidence of drug related adverse events (AEs), serious drug related AEs, dose-limiting toxicities, and laboratory test abnormalities|Maximum observed serum concentration (Cmax)|Serum concentration achieved at the end of dosing interval (trough concentration, all participants) [Cmin]|Time of maximum observed serum concentration (Tmax)|Area under the plasma concentration-time curve from time zero to the last time of the last quantifiable concentration [AUC(0-T)]|Area under the concentration-time curve in one dosing interval [AUC(TAU)]|Serum concentration achieved at the end of study drug infusion (Ceoinf)|Best Overall Response (BOR)|Objective Response Rate (ORR)|Duration of Objective Response|Progression Free Survival Rate (PFSR)|Modified Severity Weighted Assessment Tool (mSWAT) for patients with cutaneous T cell lymphoma|Immunogenicity as measured by the anti-drug antibody (ADA) status both at sample level and at patient level|Minimal Residual Disease (MRD) in patients with multiple myeloma receiving nivolumab in combination with daratumumab|PD-L1 expression
  Sponsor/Collaborators:        Bristol-Myers Squibb|Janssen, LP
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   375
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-039|2018-001030-17
  Start Date:                   June 27, 2012
  Primary Completion Date:      June 14, 2020
  Completion Date:              June 15, 2020
  First Posted:                 May 7, 2012
  Results First Posted:         null
  Last Update Posted:           November 20, 2018
  Locations:                    Local Institution, Little Rock, Arkansas, United States|Local Institution, Fresno, California, United States|Local Institution, Long Beach, California, United States|Division Of Hematology & Oncology Ctr. For Health Sciences, Los Angeles, California, United States|University of Colorado Denver, Aurora, Colorado, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Local Institution, Gainesville, Florida, United States|Local Institution, Miami, Florida, United States|Cancer Institute Of Florida, Orlando, Florida, United States|Local Institution, Tampa, Florida, United States|Local Institution, Atlanta, Georgia, United States|Local Institution, Skokie, Illinois, United States|Indiana University Melvin & Bren Simon Cancer Center, Indianapolis, Indiana, United States|Local Institution, Lafayette, Indiana, United States|University Of Kansas Medical Center, Kansas City, Kansas, United States|The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University Of Michigan Health System, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Local Institution, Saint Louis, Missouri, United States|Nebraska Cancer Specialists, Omaha, Nebraska, United States|John Theurer Cancer Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Local Institution, Cleveland, Ohio, United States|Local Institution, Columbus, Ohio, United States|Local Institution, Oklahoma City, Oklahoma, United States|OHSU Center for Hematologic Malignancies, Portland, Oregon, United States|Abramson Cancer Center, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Local Institution, Knoxville, Tennessee, United States|Local Institution, Murray, Utah, United States|Local Institution, Saint George, Utah, United States|Huntsman Cancer Institute At The Univ. Of Utah, Salt Lake City, Utah, United States|Local Institution, Salt Lake City, Utah, United States|Local Institution, Milwaukee, Wisconsin, United States|Local Institution, Impact Migration, Belgium|Local Institution, Sint-Niklaas, Belgium|Local Institution, Yvoir, Belgium|Local Institution, Nantes Cedex 1, France|Local Institution, Poitiers, France|Local Institution, Athens, Greece|Local Institution, Chorzow, Poland|Local Institution, Poznan, Poland|Local Institution, Warszawa, Poland|Local Institution, Wroclaw, Poland
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01592370

Study 166:
  NCT Number:                   NCT02423343
  Title:                        A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Solid Tumor|Non-Small Cell Lung Cancer Recurrent|Hepatocellular Carcinoma Recurrent
  Interventions:                Drug: Galunisertib|Drug: Nivolumab
  Outcome Measures:             Phase 1b: Maximum Tolerated Dose of Galunisertib in Combination with Nivolumab|Pharmacokinetics (PK): Minimum Concentration (Cmin) of Nivolumab|PK: Steady State Concentration of Galunisertib|Number of Participants with Anti-Nivolumab Antibodies When Administered in Combination with Galunisertib|Phase 2: Progression Free Survival (PFS)|Phase 2: Number of Participants who Achieve Best Overall Tumor Response of Complete Response or Partial Response: Objective Response Rate (ORR)|Phase 2: Duration of Response (DoR)|Phase 2: Time to Response|Phase 2: Overall Survival (OS)
  Sponsor/Collaborators:        Eli Lilly and Company|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   75
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    15702|H9H-MC-JBEF
  Start Date:                   October 9, 2015
  Primary Completion Date:      December 15, 2018
  Completion Date:              December 20, 2019
  First Posted:                 April 22, 2015
  Results First Posted:         null
  Last Update Posted:           November 20, 2018
  Locations:                    University of Alabama at Birmingham Medical Center, Birmingham, Alabama, United States|University of California - San Diego, La Jolla, California, United States|H Lee Moffitt Cancer Center, Tampa, Florida, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Institut Catala d'Oncologia, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Regional Universitario de Málaga, Malaga, Spain
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02423343

Study 167:
  NCT Number:                   NCT03416244
  Title:                        A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer
  Acronym:                      RAMONA
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Esophageal Cancer|Oesophageal Cancer|Oesophageal Cancer Metastatic|Esophageal Cancer Metastatic|Esophageal Cancers NOS|Oesophageal Cancer Nos|GastroEsophageal Cancer|Gastrooesophageal Cancer
  Interventions:                Drug: Nivolumab|Drug: Ipilimumab
  Outcome Measures:             Overall survival|Time to QoL deterioration|Progression free survival|Objective Response rate|Duration of response|Duration of treatment|Cumulative dose intensity|Quality of Life|Incidence of Treatment-Emergent Adverse Events
  Sponsor/Collaborators:        AIO-Studien-gGmbH|Bristol-Myers Squibb
  Gender:                       All
  Age:                          65 Years and older   (Older Adult)
  Phases:                       Phase 2
  Enrollment:                   75
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    AIO-STO-0117|2017-002056-86|CA209-9DD
  Start Date:                   February 21, 2018
  Primary Completion Date:      September 2019
  Completion Date:              January 2021
  First Posted:                 January 31, 2018
  Results First Posted:         null
  Last Update Posted:           March 23, 2018
  Locations:                    Universitätsmedizin Mannheim, Heidelberg University, II. Medizinische Klinik, Mannheim, Germany
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03416244

Study 168:
  NCT Number:                   NCT02919683
  Title:                        Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Head and Neck Cancer
  Interventions:                Drug: Nivolumab|Drug: Ipilimumab|Procedure: Standard of Care Surgery
  Outcome Measures:             Response rates to treatment|Pathological Response|Local failure Rate|Regional Failure Rate|Local Progression Free Survival|Regional Progression Free Survival|Disease Free Survival|Overall Survival|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
  Sponsor/Collaborators:        Dana-Farber Cancer Institute|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   40
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    16-284
  Start Date:                   November 2016
  Primary Completion Date:      April 2020
  Completion Date:              April 2024
  First Posted:                 September 29, 2016
  Results First Posted:         null
  Last Update Posted:           October 16, 2018
  Locations:                    Dana Farber Cancer Institute, Boston, Massachusetts, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02919683

Study 169:
  NCT Number:                   NCT02864316
  Title:                        Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure
  Acronym:                      
  Status:                       Terminated
  Study Results:                No Results Available
  Conditions:                   Solid Tumors Induced by Prior Radiation Exposure
  Interventions:                Drug: Nivolumab
  Outcome Measures:             Best Objective Response Rate|Percentage of patients progression-free at 24 weeks from the time of enrollment|Progression-free survival|Duration of response|Number of participants with treatment-related adverse event as accessed by CTCAE v4.0.|Overall survival
  Sponsor/Collaborators:        Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   6
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    J1695|IRB00105682
  Start Date:                   December 2016
  Primary Completion Date:      August 2018
  Completion Date:              September 2018
  First Posted:                 August 12, 2016
  Results First Posted:         null
  Last Update Posted:           October 2, 2018
  Locations:                    Sidney Kimmel Cancer Center @ Johns Hopkins, Baltimore, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02864316

Study 170:
  NCT Number:                   NCT02705105
  Title:                        Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Solid Tumor|Cancer|Carcinoma|Hepatocellular Carcinoma|HCC
  Interventions:                Biological: Mogamulizumab + Nivolumab
  Outcome Measures:             Maximum Tolerated Dose (MTD)|Number of subjects experiencing dose-limiting toxicity|Objective tumor response rate according to RECIST
  Sponsor/Collaborators:        Kyowa Kirin Pharmaceutical Development, Inc.|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   114
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    0761-014
  Start Date:                   December 2015
  Primary Completion Date:      October 2018
  Completion Date:              October 2018
  First Posted:                 March 10, 2016
  Results First Posted:         null
  Last Update Posted:           March 29, 2018
  Locations:                    Gilbert, Arizona, United States|Greenbrae, California, United States|Los Angeles, California, United States|Jacksonville, Florida, United States|Augusta, Georgia, United States|Chicago, Illinois, United States|Baltimore, Maryland, United States|Kalamazoo, Michigan, United States|Piscataway, New Jersey, United States|Albuquerque, New Mexico, United States|Goldsboro, North Carolina, United States|Columbus, Ohio, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Houston, Texas, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02705105

Study 171:
  NCT Number:                   NCT03285321
  Title:                        Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Non-small Cell Lung Cancer
  Interventions:                Drug: Nivolumab|Drug: Ipilimumab
  Outcome Measures:             Progression Free Survival (PFS)|Overall Survival (OS)|Time to Metastatic Disease|Assess Adverse Events
  Sponsor/Collaborators:        Greg Durm, MD|Bristol-Myers Squibb|Big Ten Cancer Research Consortium
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   108
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    BTCRC-LUN16-081
  Start Date:                   September 15, 2017
  Primary Completion Date:      September 30, 2021
  Completion Date:              September 30, 2022
  First Posted:                 September 18, 2017
  Results First Posted:         null
  Last Update Posted:           August 15, 2018
  Locations:                    University of Illinois Cancer Center, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Johns Hopkins Sidney Kimmel Comprehensive, Baltimore, Maryland, United States|Karmanos Cancer Center (Wayne State University), Detroit, Michigan, United States|Michigan State University, Lansing, Michigan, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03285321

Study 172:
  NCT Number:                   NCT03642067
  Title:                        Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Microsatellite Stable (MSS) Colorectal Adenocarcinomas|Colorectal Adenocarcinoma
  Interventions:                Drug: Nivolumab|Drug: Relatlimab
  Outcome Measures:             Objective response rate (ORR)|Number of participants experiencing study drug-related toxicities|Overall survival (OS)|Progression free survival (PFS)|Time to Progression (TTP)|Disease control rate (DCR)|Best overall response (BOR)|Duration of response (DOR)|Duration of clinical benefit (DCB)|Time to objective response (TTOR)
  Sponsor/Collaborators:        Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years to 100 Years   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   64
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    J18119|IRB00173537, CA224-068
  Start Date:                   November 2018
  Primary Completion Date:      October 2022
  Completion Date:              October 2022
  First Posted:                 August 22, 2018
  Results First Posted:         null
  Last Update Posted:           November 15, 2018
  Locations:                    Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03642067

Study 173:
  NCT Number:                   NCT03431948
  Title:                        Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer
  Acronym:                      C4-MOSART
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Cancer
  Interventions:                Drug: Nivolumab|Drug: Cabiralizumab|Drug: Urelumab|Radiation: Stereotactic Body Radiation Therapy
  Outcome Measures:             Recommended dose of SBRT given in combination with immunotherapy|Rates of Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or higher side effects|Rates of long term side effects|Response rate|Progression free survival rate|Overall survival rate|Local disease control of SBRT treated lesions
  Sponsor/Collaborators:        University of Chicago|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   60
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    IRB17-1317|CA025-002
  Start Date:                   March 15, 2018
  Primary Completion Date:      February 2020
  Completion Date:              February 2020
  First Posted:                 February 13, 2018
  Results First Posted:         null
  Last Update Posted:           June 7, 2018
  Locations:                    University of Chicago Medical Center, Chicago, Illinois, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03431948

Study 174:
  NCT Number:                   NCT03543189
  Title:                        Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Prostate Cancer|Prostate Disease
  Interventions:                Drug: Nivolumab|Radiation: Brachytherapy|Radiation: External Beam Radiation Therapy|Drug: Androgen Deprivation Therapy
  Outcome Measures:             Phase 1: Safety Run In - Rate of Dose Limiting Toxicity (CTCAE V5.0)|Phase II: Relapse Free Survival Rate|Time to PSA Nadir
  Sponsor/Collaborators:        H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb
  Gender:                       Male
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   34
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    MCC-19435|CA209-9MJ
  Start Date:                   September 26, 2018
  Primary Completion Date:      September 2020
  Completion Date:              September 2021
  First Posted:                 June 1, 2018
  Results First Posted:         null
  Last Update Posted:           October 24, 2018
  Locations:                    H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03543189

Study 175:
  NCT Number:                   NCT02393794
  Title:                        Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Triple-Negative Breast Cancer|Breast Cancer
  Interventions:                Drug: Romidepsin|Drug: Cisplatin|Drug: Nivolumab
  Outcome Measures:             Phase I: Recommended Phase II Dose of romidepsin in combination with cisplatin|Phase II: Objective response rate of treated subjects according to RECIST v1.1 criteria|Phase II: Clinical Benefit Rate at 16 weeks of study treatment for subjects treated at the recommended phase II dose of romidepsin plus cisplatin and nivolumab|Pharmacokinetics - romidepsin plasma concentration vs time profile when given with cisplatin and nivolumab|Pharmacokinetics - cisplatin plasma concentration vs time profile when given with romidepsin|Median Progression-Free Survival and Overall Survival
  Sponsor/Collaborators:        Priyanka Sharma|Celgene Corporation|Bristol-Myers Squibb|University of Kansas Medical Center
  Gender:                       Female
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   54
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    IIT-2014-CISRomiNivoTNBC|RM-CL-BRST-PI-002783|IIT-2014-PS-BRST-CISRomiTNBC
  Start Date:                   July 17, 2015
  Primary Completion Date:      July 2019
  Completion Date:              July 2020
  First Posted:                 March 19, 2015
  Results First Posted:         null
  Last Update Posted:           October 11, 2018
  Locations:                    University of Kansas Cancer Center - Clinical Research Center, Fairway, Kansas, United States|University of Kansas Cancer Center - West, Kansas City, Kansas, United States|University of Kansas Cancer Center - Overland Park, Overland Park, Kansas, United States|University of Kansas Cancer Center - Westwood, Westwood, Kansas, United States|University of Kansas Cancer Center - South, Kansas City, Missouri, United States|University of Kansas Cancer Center - North, Kansas City, Missouri, United States|University of Kansas Cancer Center - Lee's Summit, Lee's Summit, Missouri, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02393794

Study 176:
  NCT Number:                   NCT02526017
  Title:                        Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
  Acronym:                      FPA008-003
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Advanced Solid Tumors, Including But Not Limited to Lung Cancer|Head and Neck Cancer|Pancreatic Cancer|Ovarian Cancer|Renal Cell Carcinoma|Malignant Glioma
  Interventions:                Biological: FPA008|Biological: BMS-936558
  Outcome Measures:             Safety: Incidence of Grade 3 and Grade 4 Adverse Events (AEs) and clinical laboratory abnormalities defined as Dose Limiting Toxicities (Phase 1a)|Recommended dose (RD) of cabiralizumab with nivolumab (Phase 1a)|Safety: Incidence of AEs, Serious AEs (SAEs), clinical laboratory abnormalities, and ECG abnormalities (Phase 1a and 1b)|Safety: Incidence of treatment discontinuations, modifications, and interruptions due to adverse events (Phase 1b)|Efficacy: Objective response rate (ORR) defined as the total number of patients with confirmed responses of either complete response (CR) or partial response (PR) divided by the total number of patients evaluable for a response (Phase 1b)|Efficacy: Overall survival (OS) including median OS and one-year OS, duration of response (DOR), and progression free survival (PFS) (Phase 1b)|PK parameters of cabiralizumab : Area under the curve (AUC), clearance (CL), maximum observed concentration (Cmax), minimum observed concentration (Cmin), and volume of distribution at steady state (Vss). (Phase 1a and 1b)|Immunogenicity of cabiralizumab: Analysis of anti-FPA008 antibody level in serum (Phase 1a and 1b)|Immunogenicity of nivolumab: Analysis of anti-nivolumab antibody level in serum (Phase 1a and 1b)|PD biomarkers: Changes in macrophage and T-cell levels based on expression of CD68 and CD8 in tumor biopsy samples, changes in cytokine levels by multiplex analysis, and changes in whole blood monocyte subsets (Phase 1a and 1b)
  Sponsor/Collaborators:        Five Prime Therapeutics, Inc.|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   295
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    FPA008-003
  Start Date:                   September 2015
  Primary Completion Date:      March 2019
  Completion Date:              March 2020
  First Posted:                 August 18, 2015
  Results First Posted:         null
  Last Update Posted:           October 1, 2018
  Locations:                    Scottsdale Healthcare Hospitals DBA Honor Health, Scottsdale, Arizona, United States|Moores UC San Diego Cancer Center, La Jolla, California, United States|Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, United States|Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Center, Los Angeles, California, United States|UC Davis Comprehensive Cancer Center, Sacramento, California, United States|University of California, San Francisco, San Francisco, California, United States|Sarcoma Oncology Research Center, Santa Monica, California, United States|UCLA Hematology/Oncology- Santa Monica, Santa Monica, California, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory University Hospital, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Indiana University Health Hospital, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Norton Cancer Institute, Norton Healthcare Pavilion, Louisville, Kentucky, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Allina Health, Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan Kettering, New York, New York, United States|The Christ Hospital, Cincinnati, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh Cancer Institute, William M. Cooper Ambulatory Pavilion of the Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, United States|Henry-Joyce Cancer Clinic, Vanderbilt-Ingram Cancer Center,, Nashville, Tennessee, United States|Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Mischer Neuroscience Associates, The University of Texas Health Science Center at Houston, Houston, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Cancer Therapy & Research Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02526017

Study 177:
  NCT Number:                   NCT03347838
  Title:                        Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Bronchial Dysplasia|Tobacco Smoking|History of Non-Small Cell Lung Cancer|History of Head and Neck Cancer
  Interventions:                Drug: Nivolumab
  Outcome Measures:             Improvement in endobronchial histology|Incidence of immune-related adverse events (irAEs)|Additional endobronchial histology endpoints using the 2004 WHO classification scale for pre-invasive squamous lesions of the bronchus
  Sponsor/Collaborators:        University of Colorado, Denver|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years to 80 Years   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   42
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    17-1492.cc
  Start Date:                   December 2018
  Primary Completion Date:      July 2021
  Completion Date:              December 2021
  First Posted:                 November 20, 2017
  Results First Posted:         null
  Last Update Posted:           October 16, 2018
  Locations:                    University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States|Denver VA Hospital, Denver, Colorado, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03347838

Study 178:
  NCT Number:                   NCT03162731
  Title:                        Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage IVA-B Head and Neck Cancer
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Larynx|Lip, Oral Cavity and Pharynx
  Interventions:                Biological: Nivolumab|Biological: Ipilimumab|Radiation: Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy|Radiation: Volume Modulated Arc Therapy
  Outcome Measures:             Incidence of adverse events assessed using Common Terminology Criteria for Adverse Events version 4.03
  Sponsor/Collaborators:        Sidney Kimmel Cancer Center at Thomas Jefferson University|Bristol-Myers Squibb|Thomas Jefferson University
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Early Phase 1
  Enrollment:                   24
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    17P.082
  Start Date:                   May 11, 2017
  Primary Completion Date:      November 2021
  Completion Date:              January 2022
  First Posted:                 May 22, 2017
  Results First Posted:         null
  Last Update Posted:           October 9, 2018
  Locations:                    Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03162731

Study 179:
  NCT Number:                   NCT03026140
  Title:                        Nivolumab, Ipilimumab and COX2-inhibition in Early Stage Colon Cancer: an Unbiased Approach for Signals of Sensitivity
  Acronym:                      NICHE
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Colon Carcinoma
  Interventions:                Drug: Nivolumab|Drug: Ipilimumab|Drug: Celecoxib 200mg
  Outcome Measures:             Incidence of adverse events during the treatment and follow-up (safety)|Immune activating capacity of short-term pre-operative immunotherapy|Relapse free survival
  Sponsor/Collaborators:        The Netherlands Cancer Institute|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   60
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    N16NCI
  Start Date:                   March 29, 2017
  Primary Completion Date:      June 2019
  Completion Date:              January 2020
  First Posted:                 January 20, 2017
  Results First Posted:         null
  Last Update Posted:           August 2, 2018
  Locations:                    Antoni van Leeuwenhoek, Amsterdam, Netherlands|OLVG, Amsterdam, Netherlands
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03026140

Study 180:
  NCT Number:                   NCT03241745
  Title:                        A Study of Nivolumab in Selected Uterine Cancer Patients
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Uterine Cancer|Endometrial Carcinoma|Carcinosarcoma|Leiomyosarcoma|Undifferentiated Sarcoma|High Grade Endometrial Stromal Sarcoma|Clear Cell Carcinoma
  Interventions:                Drug: Nivolumab
  Outcome Measures:             Progression-Free Survival
  Sponsor/Collaborators:        Memorial Sloan Kettering Cancer Center|Bristol-Myers Squibb
  Gender:                       Female
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   40
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    17-180
  Start Date:                   August 3, 2017
  Primary Completion Date:      August 2020
  Completion Date:              August 2020
  First Posted:                 August 7, 2017
  Results First Posted:         null
  Last Update Posted:           November 28, 2018
  Locations:                    Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03241745

Study 181:
  NCT Number:                   NCT02451982
  Title:                        Neoadjuvant/Adjuvant GVAX Pancreas Vaccine (With CY) With or Without Nivolumab and Urelumab Trial for Surgically Resectable Pancreatic Cancer
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Pancreatic Cancer
  Interventions:                Drug: Cyclophosphamide|Biological: GVAX pancreatic cancer|Drug: Nivolumab|Drug: Urelumab
  Outcome Measures:             Median IL17A expression in vaccine-induced lymphoid aggregates found in surgically resected pancreatic tumors|Number of participants experiencing immune-related toxicities (IRAEs)|Overall Survival|Disease Free Survival
  Sponsor/Collaborators:        Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years to 100 Years   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   75
  Funded Bys:                   Other|NIH|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    J1568|IRB00050517|R01CA197296
  Start Date:                   February 2016
  Primary Completion Date:      June 2019
  Completion Date:              February 2020
  First Posted:                 May 22, 2015
  Results First Posted:         null
  Last Update Posted:           October 26, 2018
  Locations:                    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02451982

Study 182:
  NCT Number:                   NCT02426892
  Title:                        Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Solid Tumors
  Interventions:                Biological: ISA 101|Drug: Nivolumab
  Outcome Measures:             Overall Response Rate (ORR)
  Sponsor/Collaborators:        M.D. Anderson Cancer Center|ISA Pharmaceuticals B.V.|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   34
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    2014-1047|NCI-2015-01004
  Start Date:                   December 23, 2015
  Primary Completion Date:      December 2019
  Completion Date:              December 2019
  First Posted:                 April 27, 2015
  Results First Posted:         null
  Last Update Posted:           August 6, 2018
  Locations:                    University of Texas MD Anderson Cancer Center, Houston, Texas, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02426892

Study 183:
  NCT Number:                   NCT01998126
  Title:                        Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Non-small Cell Lung Cancer
  Interventions:                Drug: Ipilimumab|Drug: Erlotinib|Drug: Crizotinib|Drug: Nivolumab
  Outcome Measures:             toxicity of ipilimumab and erlotinib in EGFR mutated patients|toxicity of ipilimumab and crizotinib in ALK mutated patients|toxicity of nivolumab and erlotinib in EGFR mutated patients|toxicity of nivolumab and crizotinib in ALK mutated patients|Response rate|Progression Free Survival (PFS)|Overall Survival|immune function pre and post immune therapy
  Sponsor/Collaborators:        University of Utah|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   14
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    HCI66705
  Start Date:                   December 2, 2013
  Primary Completion Date:      May 9, 2017
  Completion Date:              March 29, 2018
  First Posted:                 November 28, 2013
  Results First Posted:         null
  Last Update Posted:           April 2, 2018
  Locations:                    Huntsman Cancer Institute, Salt Lake City, Utah, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01998126

Study 184:
  NCT Number:                   NCT03518320
  Title:                        Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Bladder Cancer TNM Staging Primary Tumor (T) T2|Bladder Cancer TNM Staging Primary Tumor (T) T2A|Bladder Cancer TNM Staging Primary Tumor (T) T2B|Bladder Cancer TNM Staging Primary Tumor (T) T3|Bladder Cancer TNM Staging Primary Tumor (T) T3A|Bladder Cancer TNM Staging Primary Tumor (T) T3B|Bladder Cancer TNM Staging Regional Lymph Node (N) N0|Bladder Cancer TNM Staging Regional Lymph Node (N) N1|Bladder Cancer TNM Staging Distant Metastasis (M) M0
  Interventions:                Drug: Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200|Drug: Nivolumab Injection [Opdivo]
  Outcome Measures:             Number of participants with incidence of treatment emergent adverse events (TEAEs) over 4 consecutive 21-day dosing cycles of TAR-200 in combination with Nivolumab as assessed by CTCAE V4.0.|Number of participants that do not require treatment discontinuation prior to the scheduled end date due to meeting any of the Subject Stopping Safety criteria or other drug or device related AE
  Sponsor/Collaborators:        Taris Biomedical LLC|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   25
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    TAR-200-104
  Start Date:                   November 2018
  Primary Completion Date:      June 2020
  Completion Date:              September 2020
  First Posted:                 May 8, 2018
  Results First Posted:         null
  Last Update Posted:           November 20, 2018
  Locations:                    DuPage Medical Group, Hinsdale, Illinois, United States|University of Rochester Medical Center, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|The University of Oklahoma Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03518320

Study 185:
  NCT Number:                   NCT03715946
  Title:                        Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Carcinoma, Squamous Cell of Head and Neck|Oropharynx Squamous Cell Carcinoma
  Interventions:                Drug: Nivolumab Injection|Radiation: Radiotherapy (RT)
  Outcome Measures:             Progression-free survival (PFS)|PEG tube dependence|Functional Assessment of Cancer Therapy - Head and Neck Cancer (FACT-H&N) Score|Locoregional control (LRC)|Distant disease recurrence|MD Anderson Symptom Inventory for head and neck cancer (MDASI-HN)|MD Anderson Dysphagia Inventory (MDADI)|Voice Handicap Index-10 (VHI-10)|Performance Status Scale (PSS-HN)|Modified Barium Swallow (MBS) rating|Overall Survival
  Sponsor/Collaborators:        Robert Ferris|Bristol-Myers Squibb|University of Pittsburgh
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   135
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    HCC 18-034
  Start Date:                   November 1, 2018
  Primary Completion Date:      August 31, 2020
  Completion Date:              August 31, 2021
  First Posted:                 October 23, 2018
  Results First Posted:         null
  Last Update Posted:           November 14, 2018
  Locations:                    UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03715946

Study 186:
  NCT Number:                   NCT03656627
  Title:                        Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Autoimmune Diseases|Non-small Cell Lung Cancer|Rheumatoid Arthritis|Psoriasis|Giant Cell Arteritis|Polymyalgia Rheumatica|Systemic Lupus Erythematosus|Crohn Disease|Multiple Sclerosis|Ulcerative Colitis
  Interventions:                Drug: Nivolumab
  Outcome Measures:             Dose-Limiting Toxicity (DLT)|Overall Response Rate|Progression-Free Survival|Overall Survival
  Sponsor/Collaborators:        Alliance Foundation Trials, LLC.|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   72
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    AFT-42
  Start Date:                   October 31, 2018
  Primary Completion Date:      October 31, 2022
  Completion Date:              October 31, 2022
  First Posted:                 September 3, 2018
  Results First Posted:         null
  Last Update Posted:           October 23, 2018
  Locations:                    
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03656627

Study 187:
  NCT Number:                   NCT02967133
  Title:                        A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Non-Small-Cell Lung Cancer Metastatic|Non-Small Cell Carcinoma of Lung, TNM Stage 4|Nonsmall Cell Lung Cancer|Non Small Cell Lung Cancer Recurrent
  Interventions:                Drug: Nivolumab|Drug: nab-paclitaxel
  Outcome Measures:             Progression-Free Survival
  Sponsor/Collaborators:        Alliance Foundation Trials, LLC.|Celgene Corporation|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   200
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    AFT-31
  Start Date:                   December 2016
  Primary Completion Date:      December 2020
  Completion Date:              December 2020
  First Posted:                 November 18, 2016
  Results First Posted:         null
  Last Update Posted:           March 20, 2018
  Locations:                    Mount Siani Medical Center, Miami, Florida, United States|St. Elizabeth's Healthcare, Edgewood, Kentucky, United States|Metro Minnesota community oncology research consortium, Saint Louis Park, Minnesota, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Englewood hospital and medical center, Englewood, New Jersey, United States|Rapid City Regional Hospital/Regional Cancer Care Institute, Rapid City, South Dakota, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02967133

Study 188:
  NCT Number:                   NCT03366766
  Title:                        Nivolumab, Cisplatin, and Pemetrexed Disodium or Gemcitabine Hydrochloride in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Non-Squamous Non-Small Cell Lung Carcinoma|Stage I Non-Small Cell Lung Cancer|Stage IA Non-Small Cell Lung Carcinoma|Stage IB Non-Small Cell Lung Carcinoma|Stage II Non-Small Cell Lung Cancer|Stage IIA Non-Small Cell Lung Carcinoma|Stage IIB Non-Small Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer
  Interventions:                Biological: Nivolumab|Drug: Cisplatin|Drug: Pemetrexed Disodium|Drug: Gemcitabine Hydrochloride
  Outcome Measures:             Major pathologic response (mpCR) defined as < 10% viable tumor|Incidence of adverse events according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03|Progression free survival|Overall survival|Overall clinical response
  Sponsor/Collaborators:        Sidney Kimmel Cancer Center at Thomas Jefferson University|Bristol-Myers Squibb|Thomas Jefferson University
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   34
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    17P.556
  Start Date:                   December 20, 2017
  Primary Completion Date:      July 2021
  Completion Date:              July 2022
  First Posted:                 December 8, 2017
  Results First Posted:         null
  Last Update Posted:           March 5, 2018
  Locations:                    Abington Hospital - Jefferson Health, Abington, Pennsylvania, United States|Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03366766

Study 189:
  NCT Number:                   NCT02327078
  Title:                        A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   B-cell Malignancies|Colorectal Cancer (CRC)|Head and Neck Cancer|Lung Cancer|Lymphoma|Melanoma|Ovarian Cancer|Glioblastoma
  Interventions:                Drug: Nivolumab (Phase 1)|Drug: Epacadostat (Phase 1)|Drug: Chemotherapy (Phase 1)|Drug: Nivolumab (Phase 2)|Drug: Epacadostat (Phase 2)
  Outcome Measures:             Phase 1, Part 1: Safety and tolerability of epacadostat and nivolumab assessed by number of subjects with dose limiting toxicities (DLTs)|Phase 1, Part 2: Safety and tolerability of epacadostat administered in combination with nivolumab and chemotherapy regimen assessed by number of subjects with DLTs|Phase 1, Part 1 and 2: Safety assessed by the frequency of adverse events, serious adverse events, and deaths|Phase 2: Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 for subjects with solid tumors and per Cheson criteria for subjects with DLBCL|Phase 2: Progression free survival (PFS)|Phase 2: Overall survival (OS)|Phase 1, Part 1: ORR per RECIST v1.1 and mRECIST for subjects with solid tumors; per Cheson and mCheson criteria for subjects with B-cell NHL; and per RANO and mRANO criteria for subjects with GBM|Phase 1, Part 2: ORR per RECIST v1.1 and modified RECIST for subjects with advanced or metastatic SCCHN and advanced or metastatic NSCLC|Phase 1, Part 2: Duration of response (DOR) for subjects with advanced or metastatic SCCHN and advanced or metastatic NSCLC|Phase 1, Part 2: PFS for subjects with advanced or metastatic SCCHN and advanced or metastatic NSCLC|Phase 2: Duration of response (DOR)|Phase 2: Duration of disease control, defined as CR, PR, and stable disease (SD)|Phase 2: Safety and tolerability measured by the frequency of adverse events (AEs), serious adverse events (SAEs), and deaths
  Sponsor/Collaborators:        Incyte Corporation|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   309
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    INCB 24360-204 / ECHO-204
  Start Date:                   November 2014
  Primary Completion Date:      April 2020
  Completion Date:              October 2020
  First Posted:                 December 30, 2014
  Results First Posted:         null
  Last Update Posted:           May 11, 2018
  Locations:                    UAB Comprehensive Cancer Center, Birmingham, Alabama, United States|The Angeles Clinic and Research Institute, Los Angeles, California, United States|USC Norris Cancer Center, Los Angeles, California, United States|UCSF - University of California San Francisco, San Francisco, California, United States|University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States|The University of Kansas Clinical Research Center, Fairway, Kansas, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Lahey Hospital & Medical Center, Burlington, Massachusetts, United States|NYU Cancer Center, New York, New York, United States|Columbia University, Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest Medical Center Boulevard, Winston-Salem, North Carolina, United States|Sanford Research, Fargo, North Dakota, United States|University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States|Sanford Research, North Sioux City, South Dakota, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Oncology Research, Austin, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|The Christie NHS Foundation Trust, Manchester, United Kingdom|Oxford University Hospitals NHS Trust, Oxford, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02327078

Study 190:
  NCT Number:                   NCT02983045
  Title:                        A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) or in Combination With Nivolumab and Anti-CTLA4 Antibody (Ipilimumab) in Patients With Select Advanced or Metastatic Solid Tumors
  Acronym:                      PIVOT-02
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Melanoma|Renal Cell Carcinoma|Non Small Cell Lung Cancer|Urothelial Carcinoma|Triple Negative Breast Cancer
  Interventions:                Drug: Combination of NKTR-214 + nivolumab|Drug: Combination of NKTR-214 + nivolumab + ipilimumab
  Outcome Measures:             Safety of NKTR-214 in combination with nivolumab as evaluated by incidence of drug-related Adverse Events (AEs), Serious Adverse Events (SAEs), and adverse events leading to discontinuation, deaths, and clinical laboratory test abnormalities|Safety of NKTR-214 in combination with nivolumab and ipilmumab as evaluated by incidence of drug-related AEs, SAEs, and adverse events leading to discontinuation, deaths, and clinical laboratory test abnormalities|Tolerability of NKTR-214 in combination with nivolumab as evaluated by incidence of Dose Limiting Toxicities (DLTs), drug-related AEs, SAEs, adverse events leading to discontinuation, deaths and clinical laboratory test abnormalities|Tolerability of NKTR-214 in combination with nivolumab and ipilmumab as evaluated by incidence of Dose Limiting Toxicities (DLTs), drug-related AEs, SAEs, adverse events leading to discontinuation, deaths and clinical laboratory test abnormalities|Efficacy of NKTR-214 in combination with nivolumab as assessed by the Objective Response Rate (ORR) based on RECIST 1.1|Efficacy of NKTR-214 in combination with nivolumab and ipilmumab as assessed by the Objective Response Rate (ORR) based on RECIST 1.1|Overall Survival (OS)|Progression-Free Survival (PFS)
  Sponsor/Collaborators:        Nektar Therapeutics|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   480
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    16-214-02
  Start Date:                   October 2016
  Primary Completion Date:      June 2020
  Completion Date:              June 2021
  First Posted:                 December 6, 2016
  Results First Posted:         null
  Last Update Posted:           October 22, 2018
  Locations:                    Local Institution - La Jolla, La Jolla, California, United States|Local Institution - Los Angeles, Los Angeles, California, United States|Local Institution- Palo Alto, Stanford, California, United States|Local Institution - Aurora, Aurora, Colorado, United States|Local Institution - New Haven, New Haven, Connecticut, United States|Local Institution - Gainesville, Gainesville, Florida, United States|Local Institution - Tampa, Tampa, Florida, United States|Local Institution - Atlanta, Atlanta, Georgia, United States|Local Institution - Maywood, Maywood, Illinois, United States|Local Institution - Indianapolis, Indianapolis, Indiana, United States|Local Institution - Kansas City, Kansas City, Kansas, United States|Local Institution - Boston, Boston, Massachusetts, United States|Local Institution - Detroit, Detroit, Michigan, United States|Local Institution - St. Louis, Saint Louis, Missouri, United States|Local Institution - Buffalo, Buffalo, New York, United States|Local Institution - New York 1, New York, New York, United States|Local Institution - New York 2, New York, New York, United States|Local Institution - Cleveland, Cleveland, Ohio, United States|Local Institution - Portland, Portland, Oregon, United States|Local Institution - Nashville, Nashville, Tennessee, United States|Local Institution - Houston, Houston, Texas, United States|Local Institution - Fairfax ISC, Fairfax, Virginia, United States|Local Institution - Fairfax VCS, Fairfax, Virginia, United States|Local Institution - Seattle, Seattle, Washington, United States|Local Institution - Edegem, Edegem, Belgium|Local Institution - Kortrijk, Kortrijk, Belgium|Local Institution - Leuven, Leuven, Belgium|Local Institution - Liège, Liège, Belgium|Local Institution - Wilrijk, Wilrijk, Belgium|Local Institution - Vancouver, Vancouver, British Columbia, Canada|Local Institution - Toronto SBH, Toronto, Ontario, Canada|Local Institution - Toronto PMH, Toronto, Ontario, Canada|Local Institution - Montreal, Montréal, Quebec, Canada|Local Institution - Montréal, Montréal, Quebec, Canada|Local Institution - Marseille LPC, Marseille, Brouches-duRhone, France|Local Institution - Saint-Herblain, Saint-Herblain, Loire-Atlantique, France|Local Institution - Lyon, Lyon, France|Local Institution - Marseille HN, Marseille Cedex 20, France|Local Institution - Villejuif Cedex, Villejuif, France|Local Institution - Milano FIIN, Milano, Italy|Local Institution - Milano 2, Milano, Italy|Local Institution - Napoli, Napoli, Italy|Local Institution - Roma, Roma, Italy|Local Institution - Siena, Siena, Italy|Local Institution - Buriasco (Turin), Turin, Italy|Local Institution - Brzozów, Brzozów, Poland|Local Institution - Gdynia, Gdynia, Poland|Local Institution - Kraków, Kraków, Poland|Local Institution - Otwock, Otwock, Poland|Local Institution - Poznań WCPT, Poznań, Poland|Local Institution - Poznań MPS, Poznań, Poland|Local Institution - Lodz, Łódź, Poland|Local Institution - Barcelona HQB, Barcelona, Spain|Local Institution - Barcelona HCB, Barcelona, Spain|Local Institution - Madrid HURCPO, Madrid, Spain|Local Institution - Madrid HU12, Madrid, Spain|Local Institution - Madrid CIOCC, Madrid, Spain|Local Institution - Pamplona, Pamplona, Spain|Local Institution - Sevilla, Sevilla, Spain|Local Institution - London, London, United Kingdom|Local Institution - Northwood, Northwood, United Kingdom|Local Institution - Withington, Withington, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02983045

Study 191:
  NCT Number:                   NCT02892734
  Title:                        Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   HER2/Neu Negative|Recurrent Inflammatory Breast Carcinoma|Stage IV Breast Cancer|Stage IV Inflammatory Breast Carcinoma
  Interventions:                Biological: Ipilimumab|Other: Laboratory Biomarker Analysis|Biological: Nivolumab
  Outcome Measures:             Progression Free Survival (PFS)|Overall Response Rate (ORR)|Clinical Benefit Rate (CBR)|Overall survival|Incidence of Adverse Events
  Sponsor/Collaborators:        Northwestern University|Bristol-Myers Squibb|National Cancer Institute (NCI)
  Gender:                       Female
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   29
  Funded Bys:                   Other|Industry|NIH
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    NU 16B07|STU00203191|P30CA060553|NCI-2016-01038
  Start Date:                   September 5, 2017
  Primary Completion Date:      April 2019
  Completion Date:              September 2020
  First Posted:                 September 8, 2016
  Results First Posted:         null
  Last Update Posted:           September 11, 2017
  Locations:                    Northwestern University, Chicago, Illinois, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02892734

Study 192:
  NCT Number:                   NCT03451331
  Title:                        Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Metastatic Urothelial Cancer
  Interventions:                Drug: Nivolumab|Drug: Gemcitabine|Drug: Carboplatin|Drug: Oxaliplatin
  Outcome Measures:             Objective Response Rate (ORR)|Assess Safety|Duration of Response|Progression-Free Survival (PFS)|Overall Survival (OS)
  Sponsor/Collaborators:        Matthew Galsky|Bristol-Myers Squibb|Hoosier Cancer Research Network
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   44
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    HCRN GU16-287
  Start Date:                   May 10, 2018
  Primary Completion Date:      May 1, 2020
  Completion Date:              December 1, 2020
  First Posted:                 March 1, 2018
  Results First Posted:         null
  Last Update Posted:           November 5, 2018
  Locations:                    Icahn School of Medicine: Tisch Cancer Institute at Mount Sinai Medical Center, New York, New York, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03451331

Study 193:
  NCT Number:                   NCT03421652
  Title:                        Nivolumab and Radiation Therapy in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemotherapy
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Stage II Bladder Urothelial Carcinoma AJCC v6 and v7|Stage III Bladder Urothelial Carcinoma AJCC v6 and v7|Stage IV Bladder Urothelial Carcinoma AJCC v7
  Interventions:                Drug: Nivolumab|Radiation: Radiation
  Outcome Measures:             Progression-free survival (PFS)|Incidence of adverse events graded per Common Terminology Criteria for Adverse Events version 4.0.|Overall response rate (ORR)|Metastasis-free survival (MFS)|Overall survival (OS)|Quality of life (QOL) and bladder functioning questionnaires assessment|PD-1 and PDL-1 expression analysis using immunohistochemistry (IHC)|Th1/Th2 cytokine ratio analysis
  Sponsor/Collaborators:        Barbara Ann Karmanos Cancer Institute|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   34
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    2016-195
  Start Date:                   April 24, 2018
  Primary Completion Date:      January 2020
  Completion Date:              January 2020
  First Posted:                 February 5, 2018
  Results First Posted:         null
  Last Update Posted:           May 15, 2018
  Locations:                    Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03421652

Study 194:
  NCT Number:                   NCT02978404
  Title:                        Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Clear-Cell Metastatic Renal Cell Carcinoma|Non Small Cell Lung Cancer Metastatic|Brain Metastases, Adult
  Interventions:                Drug: Nivolumab|Radiation: Radiosurgery
  Outcome Measures:             Intracranial progression-free survival|Treated brain lesions control rate|Overall survival after receiving Nivolumab.|Maximum response rate of distant non-irradiated disease|Progression-free survival|Correlation between tumor PD-L1 expression and clinical outcomes|Patient quality of life|Neurocognitive function, as measured by the HVLT-R|Neurocognitive function, as measured by TMT|Neurocognitive function, as measured by COWA|Acute and late toxicity of SRS + Nivolumab|Imaging indicators of response
  Sponsor/Collaborators:        Centre hospitalier de l'Université de Montréal (CHUM)|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   60
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    16.206|OZM-080
  Start Date:                   June 2, 2017
  Primary Completion Date:      June 2020
  Completion Date:              June 2020
  First Posted:                 December 1, 2016
  Results First Posted:         null
  Last Update Posted:           August 28, 2018
  Locations:                    Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada|McGill University Health Centre, Montreal, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02978404

Study 195:
  NCT Number:                   NCT03123783
  Title:                        CD40 Agonistic Antibody APX005M in Combination With Nivolumab
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Cancer|Non Small Cell Lung Cancer Metastatic|Metastatic Melanoma|Neoplasm of Lung|Melanoma
  Interventions:                Drug: APX005M|Drug: Nivolumab
  Outcome Measures:             Incidence of dose limiting toxicities|Incidence of adverse events|Objective response rate|Blood concentrations of APX005M
  Sponsor/Collaborators:        Apexigen, Inc.|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   100
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    APX005M-002
  Start Date:                   July 10, 2017
  Primary Completion Date:      May 2019
  Completion Date:              December 2019
  First Posted:                 April 21, 2017
  Results First Posted:         null
  Last Update Posted:           November 7, 2018
  Locations:                    University of Arizona Cancer Center, Tucson, Arizona, United States|City of Hope, Duarte, California, United States|Yale University, New Haven, Connecticut, United States|Hem-Onc Associates of the Treasure Coast, Port Saint Lucie, Florida, United States|University Cancer & Blood Center, Athens, Georgia, United States|Nebraska Cancer Specialists, Omaha, Nebraska, United States|Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Tennessee Oncology, Nashville, Tennessee, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03123783

Study 196:
  NCT Number:                   NCT03048500
  Title:                        Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Recurrent Non-Small Cell Lung Carcinoma|Stage III Non-Small Cell Lung Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer
  Interventions:                Other: Laboratory Biomarker Analysis|Drug: Metformin Hydrochloride|Biological: Nivolumab
  Outcome Measures:             Objective Response Rate (ORR)|Depth of Response|Duration of Response|Persistence of Response|Disease Control Rate (DCR)|Progression-Free Survival (PFS)|Overall Survival (OS)|ORR|Incidence of Adverse Events
  Sponsor/Collaborators:        Northwestern University|Bristol-Myers Squibb|National Cancer Institute (NCI)
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   51
  Funded Bys:                   Other|Industry|NIH
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    NU 16L04|STU00204354|P30CA060553|NCI-2017-00060
  Start Date:                   June 6, 2017
  Primary Completion Date:      August 2020
  Completion Date:              February 2021
  First Posted:                 February 9, 2017
  Results First Posted:         null
  Last Update Posted:           October 2, 2018
  Locations:                    Northwestern University, Chicago, Illinois, United States|Northwestern University- Lake Forest Hospital, Lake Forest, Illinois, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03048500

Study 197:
  NCT Number:                   NCT03583086
  Title:                        Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Thymic Carcinoma|Non-small Cell Lung Cancer|Refractory Thoracic Tumors
  Interventions:                Drug: VEGFR/PDGFR Dual Kinase Inhibitor X-82|Biological: Nivolumab
  Outcome Measures:             Phase II recommended combination dose per Common Terminology Criteria for Adverse Events (CTCAE) criteria version 4.03|Phase II best response per Response Evaluation Criteria in Solid Tumors (RECIST)|Phase II best response|Progression-free survival|Overall survival|Objective response rate as related to PD-L1 status measured as < 1%, 1-49%, and > 50%.|Disease control rate
  Sponsor/Collaborators:        Vanderbilt-Ingram Cancer Center|Bristol-Myers Squibb|Xcovery Holdings, INC
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   140
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    VICC THO 1802|CA209-982
  Start Date:                   July 10, 2018
  Primary Completion Date:      July 2023
  Completion Date:              July 2024
  First Posted:                 July 11, 2018
  Results First Posted:         null
  Last Update Posted:           August 16, 2018
  Locations:                    Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03583086

Study 198:
  NCT Number:                   NCT03639714
  Title:                        A Study of a Personalized Neoantigen Cancer Vaccine
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Non Small Cell Lung Cancer|Colorectal Cancer|Gastroesophageal Adenocarcinoma|Urothelial Carcinoma
  Interventions:                Biological: GRT-C901|Biological: GRT-R902|Biological: nivolumab|Biological: ipilimumab
  Outcome Measures:             Incidence of adverse events (AEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs)|Objective Response Rate (ORR) in Phase 2 using RECIST v1.1|Identify the recommended Phase 2 dose (RP2D) of GRT-C901 and GRT-R902|Measure the immune response to neoantigens encoded by GRT-C901 and GRT-R902|Objective Response Rate (ORR) in Phase 1 using RECIST v1.1|Duration of response (DOR) using RECIST v1.1|Clinical benefit rate (using RECIST v1.1)|Progression-free survival (PFS)|Overall survival (OS)|Percentage of patients for whom vaccine is successfully manufactured and timeframe for vaccine manufacturing
  Sponsor/Collaborators:        Gritstone Oncology, Inc.|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   214
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    GO-004
  Start Date:                   October 2018
  Primary Completion Date:      July 2022
  Completion Date:              March 2023
  First Posted:                 August 21, 2018
  Results First Posted:         null
  Last Update Posted:           October 23, 2018
  Locations:                    
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03639714

Study 199:
  NCT Number:                   NCT03190265
  Title:                        Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Pancreatic Cancer
  Interventions:                Drug: Cyclophosphamide|Drug: Nivolumab|Drug: Ipilimumab|Drug: GVAX Pancreas Vaccine|Drug: CRS-207
  Outcome Measures:             Objective response rate (ORR) using Response Evaluation Criteria for Solid Tumors (RECIST 1.1)|Number of participants experiencing study drug-related toxicities|Overall survival (OS)|Progression free survival (PFS)|Duration of response (DOR)|Time to progression (TTP)|Tumor marker kinetics (CA19-9)
  Sponsor/Collaborators:        Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Aduro Biotech, Inc.|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years to 100 Years   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   63
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    J1790|IRB00137389
  Start Date:                   December 5, 2017
  Primary Completion Date:      October 2019
  Completion Date:              October 2019
  First Posted:                 June 16, 2017
  Results First Posted:         null
  Last Update Posted:           April 18, 2018
  Locations:                    Johns Hopkins SKCCC, Baltimore, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03190265

Study 200:
  NCT Number:                   NCT03721757
  Title:                        CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer
  Acronym:                      NICO
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Squamous Cell Carcinoma of the Oral Cavity
  Interventions:                Biological: Nivolumab, Surgery, Radiotherapy|Biological: Nivolumab, Surgery, Chemoradiotherapy
  Outcome Measures:             Disease free survival|Recruitment Rate|Overall survival|Surgical complications - Infection rate|Surgical complications - length of hospital admission|Surgical complications - free flap failure|Surgical complications - perioperative (30-day mortality)|Assessment of adverse events|The change of Quality of Life: EORTC QLQ-C30 v3|The change of symptom
  Sponsor/Collaborators:        The Clatterbridge Cancer Centre NHS Foundation Trust|University of Liverpool|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   120
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    C0947|2017-005015-13|ISRCTN17428671|CA209-891
  Start Date:                   November 2018
  Primary Completion Date:      May 2021
  Completion Date:              November 2021
  First Posted:                 October 26, 2018
  Results First Posted:         null
  Last Update Posted:           October 26, 2018
  Locations:                    
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03721757

Study 201:
  NCT Number:                   NCT03117049
  Title:                        Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Non-Small Cell Lung Cancer
  Interventions:                Drug: ONO-4538|Drug: Carboplatin|Drug: Paclitaxel|Drug: Bevacizumab|Drug: Placebo
  Outcome Measures:             Progression Free Survival (PFS) as assessed by the Independent Radiology Review Committee (IRRC)|Overall survival (OS)|PFS (as assessed by the study site's investigator)|Objective response rate (ORR [as assessed by the IRRC and study site's investigator])|Disease control rate (DCR [as assessed by the IRRC and study site's investigator])|Duration of response (DOR [as assessed by the IRRC])|Time to response (TTR [as assessed by the IRRC])|Best overall response (BOR [as assessed by the IRRC and study site's investigator])|Maximum percentage of change in the sum of diameters of target lesions (as assessed by the IRRC)|Safety will be analyzed through the incidence of adverse events, serious adverse events|Patient reported outcome (PRO)
  Sponsor/Collaborators:        Ono Pharmaceutical Co. Ltd|Bristol-Myers Squibb
  Gender:                       All
  Age:                          20 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   530
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  Other IDs:                    ONO-4538-52
  Start Date:                   June 13, 2017
  Primary Completion Date:      April 2020
  Completion Date:              July 2022
  First Posted:                 April 17, 2017
  Results First Posted:         null
  Last Update Posted:           October 2, 2018
  Locations:                    Aichi Clinical Site2, Nagoya, Aichi, Japan|Aichi Clinical Site3, Nagoya, Aichi, Japan|Aichi Clinical Site4, Nagoya, Aichi, Japan|Aichi Clinical Site, Nagoya, Aichi, Japan|Aichi Clinical Site, Toyoake, Aichi, Japan|Aomori Clinical Site2, Hirosaki, Aomori, Japan|Aomori Clinical Site, Hirosaki, Aomori, Japan|Chiba Clinical Site, Yachiyo, Chiba, Japan|Ehime Clinical Site, Matsuyama, Ehime, Japan|Fukuoka Clinical Site, Iizuka, Fukuoka, Japan|Fukuoka Clinical Site, Kitakyushu, Fukuoka, Japan|Fukuoka Clinical Site, Koga, Fukuoka, Japan|Fukuoka Clinical Site, Kurume, Fukuoka, Japan|Fukushima Clinical Site, Kōriyama, Fukushima, Japan|Gunma Clinical Site, Ota, Gunma, Japan|Gunma Clinical Site, Shibukawa, Gunma, Japan|Hokkaido Clinical Site, Asahikawa, Hokkaido, Japan|Hokkaido Clinical Site2, Sapporo, Hokkaido, Japan|Hokkaido Clinical Site, Sapporo, Hokkaido, Japan|Hyogo Clinical Site, Akashi, Hyogo, Japan|Hyogo Clinical Site, Amagasaki, Hyogo, Japan|Hyogo Clinical Site, Himeji, Hyogo, Japan|Hyogo Clinical Site, Itami, Hyogo, Japan|Hyogo Clinical Site, Kobe, Hyogo, Japan|Hyogo Clinical Site, Nishinomiya, Hyogo, Japan|Ibaraki Clinical Site, Higashiibaraki, Ibaraki, Japan|Ibaraki Clinical Site, Kasama, Ibaraki, Japan|Ibaraki Clinical Site, Tsuchiura, Ibaraki, Japan|Ishikawa Clinical Site2, Kanazawa, Ishikawa, Japan|Ishikawa Clinical Site3, Kanazawa, Ishikawa, Japan|Ishikawa Clinical Site, Kanazawa, Ishikawa, Japan|Iwate Clinical Site, Morioka, Iwate, Japan|Kanagawa Clinical Site, Isehara, Kanagawa, Japan|Kanagawa Clinical Site2, Kawasaki, Kanagawa, Japan|Kanagawa Clinical Site, Kawasaki, Kanagawa, Japan|Kanagawa Clinical Site, Sagamihara, Kanagawa, Japan|Kanagawa Clinical Site2, Yokohama, Kanagawa, Japan|Kanagawa Clinical Site3, Yokohama, Kanagawa, Japan|Kanagawa Clinical Site, Yokohama, Kanagawa, Japan|Kumamoto Clinical Site, Koshi, Kumamoto, Japan|Kyoto Clinical Site, Jōyō, Kyoto, Japan|Mie Clinical Site, Tsu, Mie, Japan|Miyagi Clinical Site, Natori, Miyagi, Japan|Miyagi Clinical Site, Sendai, Miyagi, Japan|Nagano Clinical Site, Matsumoto, Nagano, Japan|Nagasaki Clinical Site, Ōmura, Nagasaki, Japan|Nara Clinical Site, Ikoma, Nara, Japan|Niigata Clinical Site, Nagaoka, Niigata, Japan|Oita Clinical Site, Beppu, Oita, Japan|Oita Clinical Site, Yufu, Oita, Japan|Osaka Clinical Site2, Osaka, Osaka Clinical Site, Japan|Osaka Clinical Site, Habikino, Osaka, Japan|Osaka Clinical Site, Hirakata, Osaka, Japan|Osaka Clinical Site, Kishiwada, Osaka, Japan|Osaka Clinical Site, Osakasayama, Osaka, Japan|Osaka Clinical Site, Sakai, Osaka, Japan|Osaka Clinical Site, Toyonaka, Osaka, Japan|Saga Clinical Site, Ureshino, Saga, Japan|Saitama Clinical Site, Hidaka, Saitama, Japan|Saitama Clinical Site, Kitaadachi-gun, Saitama, Japan|Shimane Clinical Site, Izumo, Shimane, Japan|Shizuoka Clinical Site, Hamamatsu, Shizuoka, Japan|Shizuoka Clinical Site, Sunto-gun, Shizuoka, Japan|Tokyo Clinical Site2, Bunkyo-ku, Tokyo, Japan|Tokyo Clinical Site, Bunkyo-ku, Tokyo, Japan|Tokyo Clinical Site2, Bunkyō-Ku, Tokyo, Japan|Tokyo Clinical Site2, Chuo-ku, Tokyo, Japan|Tokyo Clinical Site, Chuo-ku, Tokyo, Japan|Tokyo Clinical Site, Fuchū, Tokyo, Japan|Tokyo Clinical Site, Itabashi-ku, Tokyo, Japan|Tokyo Clinical Site, Kiyose, Tokyo, Japan|Tokyo Clinical Site, Koto-ku, Tokyo, Japan|Tokyo Clinical Site, Meguro, Tokyo, Japan|Tokyo Clinical Site, Minato-ku, Tokyo, Japan|Tokyo Clinical Site, Mitaka-shi, Tokyo, Japan|Tokyo Clinical Site, Shibuya, Tokyo, Japan|Tokyo Clinical Site2, Shinjuku-Ku, Tokyo, Japan|Tokyo Clinical Site3, Shinjuku-Ku, Tokyo, Japan|Tokyo Clinical Site, Shinjuku-ku, Tokyo, Japan|Tokyo Clinical Site, Tachikawa, Tokyo, Japan|Tottori Clinical Site, Yonago, Tottori, Japan|Yamaguchi Clinical Site, Iwakuni, Yamaguchi, Japan|Chiba Clinical Site2, Chiba, Japan|Chiba Clinical Site, Chiba, Japan|Fukui Clinical Site, Fukui, Japan|Fukuoka Clinical Site2, Fukuoka, Japan|Fukuoka Clinical Site3, Fukuoka, Japan|Fukuoka Clinical Site4, Fukuoka, Japan|Fukuoka Clinical Site, Fukuoka, Japan|Gifu Clinical Site2, Gifu, Japan|Gifu Clinical Site, Gifu, Japan|Hiroshima Clinical Site2, Hiroshima, Japan|Hiroshima Clinical Site, Hiroshima, Japan|Kochi Clinical Site, Kochi, Japan|Kumamoto Clinical Site, Kumamoto, Japan|Kyoto Clinical Site, Kyoto, Japan|Nagasaki Clinical Site, Nagasaki, Japan|Niigata Clinical Site2, Niigata, Japan|Niigata Clinical Site, Niigata, Japan|Okayama Clinical Site2, Okayama, Japan|Okayama Clinical Site, Okayama, Japan|Osaka Clinical Site3, Osaka, Japan|Osaka Clinical Site, Osaka, Japan|Tokushima Clinical Site, Tokushima, Japan|Toyama Clinical Site2, Toyama, Japan|Toyama Clinical Site, Toyama, Japan|Wakayama Clinical Site, Wakayama, Japan|Yamaguchi Clinical Site, Yamaguchi, Japan|Chungcheongbuk-do Clinical Site, Cheongju-si, Chungcheongbuk-do, Korea, Republic of|Gangwon-Do Clinical Site, Wŏnju, Gangwon-Do, Korea, Republic of|Gyeonggi-do Clinical Site2, Seongnam-si, Gyeonggi-do, Korea, Republic of|Gyeonggi-do Clinical Site, Seongnam-si, Gyeonggi-do, Korea, Republic of|Gyeonggi-do Clinical Site, Suwon, Gyeonggi-do, Korea, Republic of|Gyeongsangnam-do Clinical Site, Jinju-si, Gyeongsangnam-do, Korea, Republic of|Busan Clinical Site, Busan, Korea, Republic of|Daegu Clinical Site, Daegu, Korea, Republic of|Incheon Clinical Site, Incheon, Korea, Republic of|Seoul Clinical Site2, Seoul, Korea, Republic of|Seoul Clinical Site3, Seoul, Korea, Republic of|Seoul Clinical Site4, Seoul, Korea, Republic of|Seoul Clinical Site5, Seoul, Korea, Republic of|Seoul Clinical Site6, Seoul, Korea, Republic of|Seoul Clinical Site, Seoul, Korea, Republic of|Changhua Clinical Site, Changhua, Taiwan|Chiayi Clinical Site, Chiayi City, Taiwan|Kaohsiung Clinical Site2, Kaohsiung, Taiwan|Kaohsiung Clinical Site3, Kaohsiung, Taiwan|Kaohsiung Clinical Site, Kaohsiung, Taiwan|Taichung Clinical Site, Taichung, Taiwan|Tainan Clinical Site, Tainan, Taiwan|Taipei Clinical Site2, Taipei, Taiwan|Taipei Clinical Site, Taipei, Taiwan|Taoyuan Clinical Site, Taoyuan, Taiwan
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03117049

Study 202:
  NCT Number:                   NCT03600350
  Title:                        pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Prostate Cancer
  Interventions:                Biological: pTVG-HP|Drug: Nivolumab|Drug: GM-CSF
  Outcome Measures:             Percentage of subjects within acceptable toxicity boundaries|Prostate-Specific Antigen (PSA) Complete Response (CR) Rate|Metastasis-free Survival Rate|Median Radiographic Progression-free Survival|PSA Doubling Time|PSA Response Rate (</= 50% of baseline)|Number of participants requiring GM-CSF as an adjuvant after week 4
  Sponsor/Collaborators:        University of Wisconsin, Madison|National Cancer Institute (NCI)|Bristol-Myers Squibb|Madison Vaccines Inc. (MVI)
  Gender:                       Male
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   41
  Funded Bys:                   Other|NIH|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    UW18008|2018-0418|P30CA014520
  Start Date:                   September 10, 2018
  Primary Completion Date:      October 31, 2020
  Completion Date:              October 31, 2022
  First Posted:                 July 25, 2018
  Results First Posted:         null
  Last Update Posted:           September 18, 2018
  Locations:                    University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03600350

Study 203:
  NCT Number:                   NCT02335918
  Title:                        A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Ovarian Carcinoma-Enrollment Completed|Colorectal Cancer (CRC)-Enrollment Completed|Renal Cell Carcinoma (RCC) (Phase ll Only)|Glioblastoma (GBM) (Phase ll Only)-Enrollment Completed
  Interventions:                Drug: Combination of varlilumab and nivolumab
  Outcome Measures:             Phase I: Number of participants with treatment-related adverse events as determined by CTCAE v4.0, dose-limiting toxicities, and laboratory abnormalities.|Phase II: Preliminary antitumor activity of the combination of varlilumab and nivolumab as measured by objective response rate (ORR) in patients with CRC, ovarian cancer, RCC and SCCHN and Overall Survival-12 months in GBM.
  Sponsor/Collaborators:        Celldex Therapeutics|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   175
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CDX1127-02
  Start Date:                   January 2015
  Primary Completion Date:      December 2018
  Completion Date:              December 2018
  First Posted:                 January 12, 2015
  Results First Posted:         null
  Last Update Posted:           November 29, 2018
  Locations:                    University of Arizona Cancer Center, Tucson, Arizona, United States|The Stanford Center for Clinical and Translational Education and Research, Palo Alto, California, United States|UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|University of Colorado Medical Center, Aurora, Colorado, United States|Smilow Cancer Hospital at Yale University Cancer Center, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|Northwest Georgia Oncology Centers PC, Marietta, Georgia, United States|Parkview Research Center, Fort Wayne, Indiana, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Laura and Isaac Perlmutter Cancer Center, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Providence Health & Services, Portland, Oregon, United States|Inova Schar Cancer Institute Research, Fairfax, Virginia, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02335918

Study 204:
  NCT Number:                   NCT03219775
  Title:                        Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma
  Acronym:                      TITAN-TCC
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Transitional Cell Carcinoma|Advanced Cancer|Metastatic Cancer
  Interventions:                Biological: Nivolumab/Ipilimumab
  Outcome Measures:             Objective Response Rate (ORR)|Remission Rates (RR)|Time to Immunotherapy Resistance (TIR)|Time to Response (TTR)|Duration of Response (DOR)|Progression free survival (PFS)|Overall survival (OS)|Safety - Incidence of adverse events, serious adverse events, deaths and laboratory abnormalities|EORTC QLQ-C30|EQ-5D|EQ-5D VAS
  Sponsor/Collaborators:        AIO-Studien-gGmbH|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   250
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    0416-ASG
  Start Date:                   July 6, 2017
  Primary Completion Date:      December 2020
  Completion Date:              December 2020
  First Posted:                 July 18, 2017
  Results First Posted:         null
  Last Update Posted:           April 27, 2018
  Locations:                    Univ. Klinik für Innere Medizin, Graz, Austria|Ordensklinikum Linz - KH Barmherzige Schwestern, Linz, Austria|Universitätsklinikum Salzburg, Salzburg, Austria|Landesklinikum Wiener Neustadt, Wiener Neustadt, Austria|KH der Barmherzigen Brüder Wien, Wien, Austria|Universitätsklinikum Jena und Poliklinik für Urologie, Jena, Thüringen, Germany|Uniklinik der RWTH Aachen, Aachen, Germany|Klinikum Bayreuth, Bayreuth, Germany|Charite Universitätsklinikum Campus Benjamin Franklin, Berlin, Germany|Vivantes Klinikum Neukölln, Berlin, Germany|ATURO, Berlin, Germany|Uniklinik C.-G.-Dresden, Dresden, Germany|Urologicum Duisburg, Duisburg, Germany|Universitätsklinikum Düsseldorf, Düsseldorf, Germany|Helios Klinikum Erfurt, Erfurt, Germany|Universitätsklinikum Erlangen, Erlangen, Germany|Chirurgische Universitätsklinik Freiburg, Freiburg, Germany|Überörtliche Gemeinschaftspraxis für Urologie GbR, Fürth, Germany|Greifswald Universitätsklinikum, Greifswald, Germany|Universitätsklinikum Heidelberg Chirurgische Klinik Klinik für Urologie, Heidelberg, Germany|Marien Hospital, Herne, Germany|Studienzentrum Bayenthal, Köln, Germany|Universitätsklinikum Magdeburg, Magdeburg, Germany|UKGM Marburg, Marburg an der Lahn, Germany|Klinikum der Universität München - Großhadern, München, Germany|Universitätsklinikum Münster, Münster, Germany|Universtätsmedizin Rostock, Rostock, Germany|Universitätsklinikum Ulm, Ulm, Germany|Kliniken Nordoberpfalz AG, Klinikum Weiden, Weiden, Germany|Urologie Praxis am Wasserturm, Würselen, Germany
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03219775

Study 205:
  NCT Number:                   NCT02726581
  Title:                        An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma
  Acronym:                      CheckMate 602
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Multiple Myeloma
  Interventions:                Biological: Nivolumab|Biological: Elotuzumab|Drug: Pomalidomide|Drug: Dexamethasone
  Outcome Measures:             Progression free survival (PFS) by Independent Review Committee (IRC)|Time to objective response (TTR)|Duration of objective response (DOR)|Investigator-assessed PFS|Investigator-assessed ORR|Objective response rate (ORR) by IRC|Overall Survival (OS)
  Sponsor/Collaborators:        Bristol-Myers Squibb|AbbVie
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   348
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-602|2015-005699-21
  Start Date:                   April 21, 2016
  Primary Completion Date:      March 15, 2020
  Completion Date:              December 8, 2022
  First Posted:                 April 1, 2016
  Results First Posted:         null
  Last Update Posted:           November 6, 2018
  Locations:                    Uab Comprehensive Cancer Center, Birmingham, Alabama, United States|Southern Cancer Center Pc, Mobile, Alabama, United States|Highland Oncology Group, Fayetteville, Arkansas, United States|CBCC Global Research, Inc., Bakersfield, California, United States|Compassionate Cancer Res Grp, Corona, California, United States|Compassionate Cancer Res Grp, Fountain Valley, California, United States|Scripps Health Dba Scripps Clinical Research Services, La Jolla, California, United States|UC San Diego Moores Cancer Ctr, La Jolla, California, United States|Los Angeles Hematology/Oncology Medical Group, Los Angeles, California, United States|Ronald Reagan Ucla Medical Center, Los Angeles, California, United States|Torrance Health Association, Redondo Beach, California, United States|Compassionate Cancer Res Grp, Riverside, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|Central Coast Med Oncology, Santa Maria, California, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Poudre Valley Health Care, Fort Collins, Colorado, United States|St. Mary's Hospital Med Ctr, Grand Junction, Colorado, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|University Cancer Institute, Boynton Beach, Florida, United States|Florida Cancer Specialists S., Fort Myers, Florida, United States|Memorial Cancer Institute, Hollywood, Florida, United States|Cancer Specialists of North FL, Jacksonville, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Florida Cancer Specialists, Tallahassee, Florida, United States|Florida Cancer Specialists, West Palm Beach, Florida, United States|University Cancer Blood Ctr, Athens, Georgia, United States|Piedmont Cancer Institute, PC, Atlanta, Georgia, United States|Winship Cancer Institute., Atlanta, Georgia, United States|Augusta University, Augusta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Ft. Wayne Med Onco-Hema Inc, Fort Wayne, Indiana, United States|Indiana University Cancer Ctr, Indianapolis, Indiana, United States|St. Agnes Healthcare, Inc., Baltimore, Maryland, United States|Regional Cancer Care Associates, LLC, Bethesda, Maryland, United States|Department Of Medicine Division Of Hematology/Oncology, Worcester, Massachusetts, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|St. Louis Cancer Care, Llp, Bridgeton, Missouri, United States|HCA Midwest Division, Kansas City, Missouri, United States|Washington University, Saint Louis, Missouri, United States|Mercy Medical Research Institute, Springfield, Missouri, United States|Southeast Nebraska Cancer Center, Lincoln, Nebraska, United States|Local Institution, Flemington, New Jersey, United States|John Theurer Cancer Center, Hackensack, New Jersey, United States|Local Institution, New Brunswick, New Jersey, United States|The Valley Hospital, Paramus, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Broome Oncology, Johnson City, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Mid Ohio Oncology Hematology, Columbus, Ohio, United States|University Of Oklahoma, Oklahoma City, Oklahoma, United States|Providence Portland Med Ctr, Portland, Oregon, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Donald Guthrie Foundation, Sayre, Pennsylvania, United States|Greenville Health System, Greenville, South Carolina, United States|The West Clinic, Germantown, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Baylor Research Institute, Dallas, Texas, United States|Millennium Oncology, Houston, Texas, United States|CTRC at UTHSC San Antonio, San Antonio, Texas, United States|Scott And White Memorial Hosp, Temple, Texas, United States|Northern Utah Associates, Ogden, Utah, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Emily Couric Clinical Cancer Center, Charlottesville, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Va Puget Sound Health Care System, Seattle, Washington, United States|Elisabethinen Hospital Dept of Medicine, Linz, Austria|Universitaetsklinik Salzburg, Salzburg, Austria|Akh, Vienna, Austria|Klinikum Wels-Grieskirchen Gmbh, Wels, Austria|Wilhelminenspital, Wien, Austria|Local Institution, Edmonton, Alberta, Canada|Local Institution, Vancouver, British Columbia, Canada|Local Institution, Toronto, Ontario, Canada|Centre Hospitalier De L'Universite De Montreal, Montreal, Quebec, Canada|MUHC - Glen Site, Montreal, Quebec, Canada|CIUSSS du Nord-de-l'ile-de-Montreal - Hopital du Sacre-Coeur de Montreal, Montreal, Quebec, Canada|CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski, Rimouski, Quebec, Canada|Local Institution, Quebec, Canada|Interni hematologicka a onkologicka klinika, Brno, Czechia|Klinika hematoonkologie, Ostrava-Poruba, Czechia|I. interni klinika - klinika hematologie 1. LF UK a VFN v Praze, Praha 2, Czechia|Local Institution, Aarhus, Denmark|Local Institution, Odense, Denmark|Charite Universitatsmedizin Berlin, Berlin, Germany|Universitaetsklinikum Carl Gustav Carus, Dresden, Germany|Uniklinikum Duesseldorf, Duesseldorf, Germany|Universitaetsklink Schleswig-Holstein, Kiel, Germany|Klinikum Der Johannes Gutenberg Universitaet Mainz, Mainz, Germany|University Hopistal ULM Dept of Internal Medizin, Ulm, Germany|Alexandra General Hospital Of Athens, Athens, Greece|Local Institution, Beer Sheva, Israel|Local Institution, Jerusalem, Israel|Local Institution, Petah Tikva, Israel|Local Institution, Ramat-gan, Israel|Local Institution, Tel Aviv, Israel|Azienda Ospedaliero Universitaria Ospedali Riuniti Di Ancona, Ancona, Italy|ASST Papa Giovanni XXIII, Bergamo, Italy|A. O. U. Di Bologna, Policlinico S. Orsola Malpighi, Bologna, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola (FC), Italy|Azienda Ospedaliera S. Maria, Terni, Italy|Azienda Ospedaliera Citta' Della Salute E Della Scienza Di Torino, Torino, Italy|Local Institution, Oslo, Norway|Local Institution, Stavanger, Norway|Local Institution, Lisboa, Portugal|Local Institution, Porto, Portugal|Auxilio Mutuo Cancer Center, San Juan, Puerto Rico|Local Institution, Pozuelo De Alarcon, Madrid, Spain|Local Institution, Badalona-Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Pamplona, Spain|Local Institution, Salamanca, Spain|Local Institution, Stockholm, Sweden|Hopitaux Universitaires de Geneve, Geneve, Switzerland
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02726581

Study 206:
  NCT Number:                   NCT02105636
  Title:                        Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                Has Results
  Conditions:                   Squamous Cell Carcinoma of the Head and Neck
  Interventions:                Drug: Nivolumab|Drug: Cetuximab|Drug: Methotrexate|Drug: Docetaxel
  Outcome Measures:             Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint|Overall Survival (OS) Rate in All Randomized Participants at Primary Endpoint|Progression-Free Survival (PFS)|Objective Response Rate (ORR)
  Sponsor/Collaborators:        Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   506
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-141|2013-003622-86
  Start Date:                   May 1, 2014
  Primary Completion Date:      November 6, 2015
  Completion Date:              October 27, 2020
  First Posted:                 April 7, 2014
  Results First Posted:         January 11, 2017
  Last Update Posted:           August 2, 2018
  Locations:                    Stanford University Medical Center, Stanford, California, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|University Of Chicago, Chicago, Illinois, United States|Crescent City Research Consortium, LLC, Metairie, Louisiana, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University Of Michigan, Ann Arbor, Michigan, United States|Dumc, Durham, North Carolina, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|Vanderbilt Cancer Clinic, Nashville, Tennessee, United States|Univ Of Tx. Md Anderson, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Medical College Of Wisconsin, Milwaukee, Wisconsin, United States|COIBA, Berazategui, Buenos Aires, Argentina|Centro Para La Atencion Integral Del Paciente Oncologico, San Miguel De Tucuman, Tucuman, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Sao Paulo, Brazil|British Columbia Cancer Agency-Vancouver Ctr, Vancouver, British Columbia, Canada|London Regional Cancer Program, London, Ontario, Canada|Local Institution, Lyon Cedex 08, France|Local Institution, Nice Cedex 2, France|Local Institution, Villejuif Cedex, France|Local Institution, Berlin, Germany|Universitaetsklinikum Bonn, Bonn, Germany|Universitaetsklinikum Essen, Essen, Germany|Uniklinikum Hamburg-Eppendorf, Hamburg, Germany|Med Hochschule Hannover, Hannover, Germany|Klinikum Der Universitaet, Wuerzburg, Germany|Local Institution, Hong Kong, Hong Kong|Ist.Scient. Romagnolo Per Lo Studio E Cura Tumori, Meldola, FC, Italy|Local Institution, Milano, MI, Italy|Local Institution, Torino, TO, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Nagoya, Aichi, Japan|Local Institution, Kashiwa, Chiba, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Takatsuki, Osaka, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Akashi, Hyogo, Japan|Local Institution, Tokyo, Japan|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Amsterdam, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Leiden, Netherlands|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Valencia, Spain|Universitatsspital Zurich, Zuerich, Switzerland|Local Institution, Tainan, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Wirral, Merseyside, United Kingdom|Local Institution, Surrey, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02105636

Study 207:
  NCT Number:                   NCT02612779
  Title:                        A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Multiple Myeloma
  Interventions:                Drug: Elotuzumab|Drug: Pomalidomide|Drug: Dexamethasone|Drug: Nivolumab
  Outcome Measures:             EPd cohort: Progression Free Survival (PFS)|EN Cohort: Objective Response Rate (ORR)|EPd Cohort: Objective Response Rate (ORR)|EPd Cohort: Overall Survival Rate (OS)|EN Cohort: Progression Free Survival (PFS)
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   95
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA204-142
  Start Date:                   December 18, 2015
  Primary Completion Date:      October 27, 2019
  Completion Date:              January 15, 2020
  First Posted:                 November 24, 2015
  Results First Posted:         null
  Last Update Posted:           February 1, 2018
  Locations:                    Southern Cancer Center, Mobile, Alabama, United States|Sansum Clinic - USOR, Santa Barbara, California, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Rocky Mountain Cancer Centers (Williams) - USOR, Denver, Colorado, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|Local Institution, Saint Petersburg, Florida, United States|SCRI Florida Cancer Specialists East, Saint Petersburg, Florida, United States|Local Institution, Atlanta, Georgia, United States|Illinois Cancer Care, Peoria, Illinois, United States|Local Institution, Indianapolis, Indiana, United States|Regional Cancer Care Associates LLC, Bethesda, Maryland, United States|Bay Hematology Oncology, Easton, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|Barbara Ann Karmanos Cancer Center, Detroit, Michigan, United States|Washington University, Saint Louis, Missouri, United States|Greenville Health System, Greenville, South Carolina, United States|Local Institution, Germantown, Tennessee, United States|SCRI Tennessee Oncology Nashville, Nashville, Tennessee, United States|Texas Oncology (Loop) - USOR, Arlington, Texas, United States|Virginia Cancer Specialists (Leesburg) - USOR, Leesburg, Virginia, United States|Swedish Medical Center, Seattle, Washington, United States|Cancer Care Northwest, Spokane, Washington, United States|Aurora Health Care, Burlington, Wisconsin, United States|Avera Health Care, Warszawa, Poland
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02612779

Study 208:
  NCT Number:                   NCT03071406
  Title:                        Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Merkel Cell Carcinoma|Skin Cancer
  Interventions:                Drug: Nivolumab|Drug: Ipilimumab|Radiation: Stereotactic Body Radiation Therapy (SBRT)
  Outcome Measures:             Overall Response Rate|Progression Free Survival (PFS)|Overall Survival (OS)
  Sponsor/Collaborators:        H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   50
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    MCC-18786|CA209-737
  Start Date:                   March 3, 2017
  Primary Completion Date:      July 2023
  Completion Date:              July 2023
  First Posted:                 March 6, 2017
  Results First Posted:         null
  Last Update Posted:           August 1, 2018
  Locations:                    H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03071406

Study 209:
  NCT Number:                   NCT02763761
  Title:                        An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
  Acronym:                      
  Status:                       Withdrawn
  Study Results:                No Results Available
  Conditions:                   Renal Cell Carcinoma|Melanoma|Lung Cancer
  Interventions:                Drug: Infliximab + Prednisone|Drug: Methylprednisolone + Prednisone
  Outcome Measures:             Improvement in management of immune related grade 3 and 4 diarrhea as measured by proportion of responders to less than or equal to grade 1|Improvement in management of persistent grade 2 diarrhea as measured by proportion of responders to less than or equal to grade 1|Number of days to improvement to less than grade 1 diarrhea|Quality of life as measured by European Quality of Life-5 Dimensions Questionnaire (EQ-5D)|Number of hospitalizations|Duration of hospitalizations|Number of patients with adverse events (AEs)|Number of patients with AEs related to steroid use|Number of patients with Gastrointestinal (GI) specific AEs
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   0
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-601
  Start Date:                   August 16, 2016
  Primary Completion Date:      March 31, 2017
  Completion Date:              March 31, 2017
  First Posted:                 May 5, 2016
  Results First Posted:         null
  Last Update Posted:           October 8, 2018
  Locations:                    University of California Los Angeles, Los Angeles, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|University of Louisville, Louisville, Kentucky, United States|University of Michigan, Ann Arbor, Michigan, United States|Atlantic Health System, Morristown, New Jersey, United States|Local Institution, Albuquerque, New Mexico, United States|NYU Langone Medical Center, New York, New York, United States|Huntsman Cancer Institute at The University of Utah, Salt Lake City, Utah, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02763761

Study 210:
  NCT Number:                   NCT02845323
  Title:                        Neoadjuvant Nivolumab With and Without Urelumab in Patients With Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma of the Bladder
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Urothelial Carcinoma|Bladder Cancer
  Interventions:                Drug: Nivolumab in combination with Urelumab|Drug: Nivolumab monotherapy
  Outcome Measures:             Immune response to treatment with Nivolumab and Urelumab compared to Nivolumab monotherapy measured by tumor infiltrating CD8+ T cell density at cystectomy|To evaluate the number of participants with treatment-related adverse events as assessed by CTCAE v 4.0|Proportion of patients achieving pathologic response (<pT2N0) with Nivolumab and Urelumab and the use of Urelumab alone|Prognostic value of tumor biopsy PD-1 and PD-L1 expression and change in expression for pathologic tumor response as defined by cystectomy pathologic staging <pT2 N0 in patients treated with Nivolumab|Change in expression for pathologic tumor response as defined by cystectomy pathologic staging <pT2 N0 in patients treated with Nivolumab|Prognostic value of tumor bx 4-1BB (CD137)& 4-1BB ligand (CD137L) expression|Change in expression, assessed by (IHC) analysis, for tumor response, defined by cystectomy staging < pT2N0, in cisplatin-ineligible MIBC pts tx w/Urelumab.|Prognostic value of tumor biopsy 4-1BB expression|Change in expression, assessed by (IHC) analysis, for pathologic CR response, defined by cystectomy staging pT0N0, in cisplatin-ineligible MIBC pts tx w/ Urelumab.|Proportion of patients achieving pathologic complete response with neoadjuvant Nivolumab and Urelumab (Arm A) and Nivolumab monotherapy (Arm B).
  Sponsor/Collaborators:        Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   44
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    J1682|IRB00103062
  Start Date:                   September 2016
  Primary Completion Date:      September 2019
  Completion Date:              January 2020
  First Posted:                 July 27, 2016
  Results First Posted:         null
  Last Update Posted:           October 17, 2018
  Locations:                    Johns Hopkins Hospital, Baltimore, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02845323

Study 211:
  NCT Number:                   NCT03317327
  Title:                        REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors
  Acronym:                      REPORT
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Head and Neck Squamous Cell Carcinoma
  Interventions:                Drug: Nivolumab|Radiation: Radiotherapy (RT)
  Outcome Measures:             Incidence, nature, and severity of adverse events graded according to Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.|Progression-free survival (PFS)|Objective response rate (ORR)|Overall survival (OS)|Duration of response (DOR)|Durable response rate (DRR)
  Sponsor/Collaborators:        Oslo University Hospital|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   20
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-686_REPORT
  Start Date:                   September 9, 2017
  Primary Completion Date:      November 2, 2023
  Completion Date:              November 2, 2040
  First Posted:                 October 23, 2017
  Results First Posted:         null
  Last Update Posted:           November 14, 2018
  Locations:                    Oslo University Hospital, Oslo, Norway
  Study Documents:              "Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/27/NCT03317327/Prot_SAP_000.pdf
  URL:                          https://ClinicalTrials.gov/show/NCT03317327

Study 212:
  NCT Number:                   NCT03726281
  Title:                        Nivolumab in Platinum Recurrent or Refractory Metastatic Germ Cell Tumors
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Germ Cell Tumors
  Interventions:                Drug: Nivolumab
  Outcome Measures:             Clinical Benefit Rate (CBR, %)|CR + marker-negative PR (%)|CR + PR with stable or declining tumor markers (αFP and HCG)|Time to response|Duration of clinical response|Progression Free Survival (PFS)|Overall Survival (OS)
  Sponsor/Collaborators:        Hospital Beatriz Ângelo|Universidade Nova de Lisboa|Bristol-Myers Squibb|Instituto de Patologia e Imunologia Molecular da Universidade do Porto
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   30
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    HBA_001
  Start Date:                   October 1, 2018
  Primary Completion Date:      October 1, 2020
  Completion Date:              December 1, 2022
  First Posted:                 October 31, 2018
  Results First Posted:         null
  Last Update Posted:           November 2, 2018
  Locations:                    Hospital Beatriz Ângelo, Loures, Portugal
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03726281

Study 213:
  NCT Number:                   NCT03262779
  Title:                        Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Carcinoma, Non-Small-Cell Lung
  Interventions:                Biological: combination nivolumab and ipilimumab
  Outcome Measures:             Objective response rate using RECIST v1.1 to nivolumab and ipilimumab when administered in combination to patients with pre-treated advanced NSCLC who have experienced primary resistance to anti-PD-1 axis therapy as their last line of systemic therapy.|Progression-free survival with nivolumab and ipilimumab when administered in combination to patients with pre- treated advanced NSCLC who have experienced primary resistance to anti-PD-1 axis therapy as their last line of systemic therapy|Overall survival (OS) with nivolumab and ipilimumab when administered in combination to patients with pre- treated advanced NSCLC who have experienced PRIMARY resistance to anti-PD-1 axis therapy as their last line of systemic therapy.|Objective response rate using irRC to nivolumab and ipilimumab when administered in combination to patients with pre-treated advanced NSCLC who have experienced primary resistance to anti-PD-1 axis therapy as their last line of systemic therapy.|Objective response rate in in advanced non-small cell lung cancer (NSCLC) with ACQUIRED resistance to anti-programmed death (PD)-1 axis therapy as their last line of systemic therapy.|Progression free survival by RECIST v1.1 with nivolumab and ipilimumab in patients with pre-treated advanced NSCLC who have experienced acquired resistance to anti-PD-1 axis therapy as their last line of systemic therapy.|Overall survival with nivolumab and ipilimumab in patients with pre-treated advanced NSCLC who have experienced ACQUIRED resistance to anti-PD-1 axis therapy as their last line of systemic therapy.|Safety of nivolumab and ipilimumab when administered in combination in patients with pre-treated advanced NSCLC who have experienced PRIMARY or ACQUIRED resistance to anti-PD-1 axis therapy as their last line of systemic therapy.|Feasibility of sequential biopsies (performed or not performed) in patients with pre-treated advanced NSCLC who have experienced PRIMARY or ACQUIRED resistance to anti-PD-1 axis therapy as their last line of systemic therapy,
  Sponsor/Collaborators:        Yale University|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   50
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    2000020343
  Start Date:                   July 20, 2017
  Primary Completion Date:      November 1, 2019
  Completion Date:              November 1, 2020
  First Posted:                 August 25, 2017
  Results First Posted:         null
  Last Update Posted:           May 30, 2018
  Locations:                    Yale Cancer Center, New Haven, Connecticut, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03262779

Study 214:
  NCT Number:                   NCT03502330
  Title:                        APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Advanced Melanoma|Non-small Cell Lung Cancer|Renal Cell Carcinoma
  Interventions:                Drug: APX005M|Drug: Cabiralizumab|Drug: Nivolumab
  Outcome Measures:             Safety and Tolerability measured by assessing serious adverse events (SAEs)and adverse events (AEs)|Safety and Tolerability measured by Eastern Cooperative Oncology Group(ECOG) performance status|Efficacy measured by objective response rate (ORR)
  Sponsor/Collaborators:        Yale University|Bristol-Myers Squibb|Apexigen, Inc.
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   120
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    2000021757
  Start Date:                   June 9, 2018
  Primary Completion Date:      May 2022
  Completion Date:              October 2024
  First Posted:                 April 18, 2018
  Results First Posted:         null
  Last Update Posted:           June 19, 2018
  Locations:                    Yale Cancer Center, New Haven, Connecticut, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03502330

Study 215:
  NCT Number:                   NCT03529890
  Title:                        Radio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the Bladder
  Acronym:                      RACE IT
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Urinary Bladder Cancer
  Interventions:                Drug: Nivolumab|Radiation: Radiation therapy of the pelvis|Procedure: Radical cystectomy with standardized pelvic lymphadenectomy
  Outcome Measures:             Rate of patients with completed Treatment|Acute toxicity of preoperative radio-immunotherapy|Rate of immune related toxicities|Late toxicity|Disease free survival|Cancer specific survival|Overall survival|radiological Overall Response rate|ypT0 rate|surgical margin Status
  Sponsor/Collaborators:        Technische Universität München|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   33
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    AB 65/18|CA209-9WT
  Start Date:                   November 2018
  Primary Completion Date:      February 2022
  Completion Date:              August 2022
  First Posted:                 May 18, 2018
  Results First Posted:         null
  Last Update Posted:           May 18, 2018
  Locations:                    Department of Radiation Oncology, Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt, Germany|Department of Urology, Klinikum rechts der Isar der Technischen Universität München, München, Germany|Department of Urology, Universitätsklinikum Würzburg, Würzburg, Germany
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03529890

Study 216:
  NCT Number:                   NCT03083691
  Title:                        BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer
  Acronym:                      
  Status:                       Enrolling by invitation
  Study Results:                No Results Available
  Conditions:                   Carcinoma, Non-Small-Cell Lung|Carcinoma, Small Cell Lung
  Interventions:                Drug: Nivolumab, Ipilimumab
  Outcome Measures:             Cohort 1: ORR after addition of ipilimumab to nivolumab treatment.|Cohort 2: ORR of the combination therapy nivolumab and ipilimumab.|Overall survival of nivolumab monotherapy/nivolumab + ipilimumab combination therapy|Progression-free survival of nivolumab monotherapy/nivolumab + ipilimumab combination therapy|Duration of response of nivolumab monotherapy/nivolumab + ipilimumab combination therapy|Incidence, severity and grading of adverse events (AEs) during nivolumab monotherapy/ nivolumab + ipilimumab combination therapy|Incidence, severity and grading of serious adverse events (SAEs) during nivolumab monotherapy/ nivolumab + ipilimumab combination therapy
  Sponsor/Collaborators:        Lung Cancer Group Cologne|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   106
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    Uni-Koeln-2785|2016-003334-25
  Start Date:                   April 5, 2017
  Primary Completion Date:      March 2019
  Completion Date:              August 2020
  First Posted:                 March 20, 2017
  Results First Posted:         null
  Last Update Posted:           May 12, 2017
  Locations:                    University Hospital of Cologne, Cologne, NRW, Germany
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03083691

Study 217:
  NCT Number:                   NCT02434081
  Title:                        NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma
  Acronym:                      NICOLAS
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Non-small Cell Lung Cancer Stage III
  Interventions:                Drug: Nivolumab
  Outcome Measures:             Grade ≥3 pneumonitis (CTCAE v4.0) from the end of radiotherapy|1-year progression-free survival by RECIST v1.1 (PFS)|Time to first pneumonitis of grade ≥3 (TFP3)|Objective response|Time to treatment failure (TTF).|Overall Survival (OS)|Adverse events graded according to CTCAE V4.0 (Toxicity)
  Sponsor/Collaborators:        European Thoracic Oncology Platform|Bristol-Myers Squibb|Frontier Science Foundation, Hellas
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   94
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    ETOP 6-14 NICOLAS|2014-005097-11|SNCTP000001672
  Start Date:                   November 2015
  Primary Completion Date:      August 2020
  Completion Date:              August 2020
  First Posted:                 May 5, 2015
  Results First Posted:         null
  Last Update Posted:           August 7, 2018
  Locations:                    University Hospital Leuven, Leuven, Belgium|Thoracic Oncology Centre Munich, Munich, Germany|VUMC, Amsterdam, Netherlands|MAASTRO Clinic, Maastricht, Netherlands|Vall d'Hebron University Hospital, Barcelona, Spain|Catalan Institute of Oncology, Barcelona, Spain|Hospital Virgen de la Salud, Toledo, Spain|HFR Fribourg- Hôpital cantonal, Fribourg, Switzerland|Kantonsspital Winterthur, Winterthur, Switzerland|Hirslanden Klinik Zürich, Zurich, Switzerland|University Hospital Zürich, Zürich, Switzerland
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02434081

Study 218:
  NCT Number:                   NCT03353675
  Title:                        A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   NSCLC
  Interventions:                Biological: TG4010|Drug: Chemotherapy|Drug: Nivolumab
  Outcome Measures:             Objective Response Rate (ORR)|Progression Free Survival (PFS)|Disease Control Rate (DCR)|Overall Survival (OS)|Duration of overall Response (DoR)|Evaluation of Safety profile
  Sponsor/Collaborators:        Transgene|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   39
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    TG4010.24
  Start Date:                   January 16, 2018
  Primary Completion Date:      September 2019
  Completion Date:              September 2020
  First Posted:                 November 27, 2017
  Results First Posted:         null
  Last Update Posted:           September 24, 2018
  Locations:                    Charlotte, Charlotte, North Carolina, United States|Nashville, Nashville, Tennessee, United States|Libramont, Libramont, Belgium|Herlev, Herlev, Denmark|Créteil, Créteil, France|Mulhouse, Mulhouse, France|Rennes, Rennes, France|Strasbourg, Strasbourg, France|Budapest, Budapest, Hungary|Szekesfehervar, Szekesfehervar, Hungary
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03353675

Study 219:
  NCT Number:                   NCT03508570
  Title:                        Nivolumab With or Without Ipilimumab in Treating Participants With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Malignant Peritoneal Neoplasm|Malignant Retroperitoneal Neoplasm|Peritoneal Carcinomatosis|Recurrent Cervical Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Recurrent Uterine Corpus Carcinoma|Stage IV Cervical Cancer AJCC v8|Stage IV Fallopian Tube Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Primary Peritoneal Cancer AJCC v8|Stage IV Uterine Corpus Cancer AJCC v8|Stage IVA Cervical Cancer AJCC v8|Stage IVA Fallopian Tube Cancer AJCC v8|Stage IVA Ovarian Cancer AJCC v8|Stage IVA Primary Peritoneal Cancer AJCC v8|Stage IVA Uterine Corpus Cancer AJCC v8|Stage IVB Cervical Cancer AJCC v8|Stage IVB Fallopian Tube Cancer AJCC v8|Stage IVB Ovarian Cancer AJCC v8|Stage IVB Primary Peritoneal Cancer AJCC v8|Stage IVB Uterine Corpus Cancer AJCC v8
  Interventions:                Biological: Ipilimumab|Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Other: Pharmacokinetic Study
  Outcome Measures:             Maximum tolerated dose (MTD)/recommended phase II dose (RP2D) of intraperitoneal (i.p.) nivolumab in combination with ipilimumab|PK Parameters|Clinical Benefit Rate
  Sponsor/Collaborators:        M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   48
  Funded Bys:                   Other|NIH|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    2017-0264|NCI-2018-00282|P30CA016672
  Start Date:                   September 21, 2018
  Primary Completion Date:      January 2020
  Completion Date:              January 2020
  First Posted:                 April 25, 2018
  Results First Posted:         null
  Last Update Posted:           September 25, 2018
  Locations:                    University of Texas MD Anderson Cancer Center, Houston, Texas, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03508570

Study 220:
  NCT Number:                   NCT02897765
  Title:                        A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Urinary Bladder Cancer|Bladder Tumors|Transitional Cell Carcinoma of the Bladder|Malignant Melanoma|Melanoma|Skin Cancer|Carcinoma, Non-Small-Cell Lung|Lung Cancer
  Interventions:                Biological: NEO-PV-01|Biological: Nivolumab|Other: Adjuvant
  Outcome Measures:             Rate of adverse events including SAEs and AEs leading to treatment discontinuation|Rate of adverse events including SAEs and AEs leading to changes in safety laboratory evaluations|Rate of adverse events including SAEs and AEs leading to physical examination findings|Rate of adverse events including SAEs and AEs leading to vital signs findings|Rate of adverse events including SAEs and AEs leading to changes in ECOG status|Objective response rate (ORR)|Duration of response (DOR)|Clinical benefit rate (CBR)|Response conversion rate (RCR)|Progression-free survival (PFS)|Overall survival (OS)
  Sponsor/Collaborators:        Neon Therapeutics, Inc.|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   55
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    NT-001
  Start Date:                   October 2016
  Primary Completion Date:      December 2018
  Completion Date:              December 2020
  First Posted:                 September 13, 2016
  Results First Posted:         null
  Last Update Posted:           September 6, 2018
  Locations:                    City of Hope, Duarte, California, United States|UCLA Medical Center, Los Angeles, California, United States|University of California San Francisco, San Francisco, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Center, Boston, Massachusetts, United States|Washington University in St. Louis, Saint Louis, Missouri, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|MD Anderson Cancer Center, Houston, Texas, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02897765

Study 221:
  NCT Number:                   NCT02350764
  Title:                        Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Advanced Stage Non-small Cell Lung Cancer
  Interventions:                Drug: nivolumab|Drug: pilimumab
  Outcome Measures:             Best overall response rate (confirmed partial + complete response) will be assessed as part of this study. Tumor response will be assessed using RECIST 1.1)
  Sponsor/Collaborators:        Memorial Sloan Kettering Cancer Center|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   35
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    14-137
  Start Date:                   January 2015
  Primary Completion Date:      January 2019
  Completion Date:              January 2019
  First Posted:                 January 30, 2015
  Results First Posted:         null
  Last Update Posted:           January 30, 2018
  Locations:                    Memorial Sloan Kettering Cancer Center, New York, New York, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02350764

Study 222:
  NCT Number:                   NCT03146650
  Title:                        Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Major Salivary Gland Carcinoma|Minor Salivary Gland Carcinoma|Recurrent Salivary Gland Carcinoma|Stage IV Major Salivary Gland Carcinoma|Stage IVA Major Salivary Gland Carcinoma|Stage IVB Major Salivary Gland Carcinoma|Stage IVC Major Salivary Gland Carcinoma
  Interventions:                Biological: Ipilimumab|Other: Laboratory Biomarker Analysis|Biological: Nivolumab
  Outcome Measures:             Median PFS (median Progression-Free Survival)|PFS at 6 months|PFS at 12 months|Response Rate (RR)|Disease Control Rate (DCR)|Overall Survival (OS)|PFS (RECIST 1.1 criteria)|Overall Response Rate (ORR)|DCR (irRECIST)|PFS (irRECIST criteria)|OS (irRECIST)|Incidence of Adverse Events
  Sponsor/Collaborators:        Northwestern University|Bristol-Myers Squibb|National Cancer Institute (NCI)
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   63
  Funded Bys:                   Other|Industry|NIH
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    NU 16N03|STU00204579|P30CA060553|NCI-2017-00406
  Start Date:                   May 19, 2017
  Primary Completion Date:      July 2021
  Completion Date:              June 2022
  First Posted:                 May 10, 2017
  Results First Posted:         null
  Last Update Posted:           August 14, 2018
  Locations:                    Northwestern University, Chicago, Illinois, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03146650

Study 223:
  NCT Number:                   NCT03547999
  Title:                        A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Metastatic Colorectal Cancer
  Interventions:                Drug: mFOLFOX6|Biological: MVA-BN-CV301|Biological: FPV-CV301|Drug: Nivolumab
  Outcome Measures:             Overall Survival (OS)|Recurrence free survival (RFS)|Evaluate Overall Response Rate (ORR)|Evaluate the proportion of patients amenable to complete resection/ablation|Evaluate the perioperative surgical outcomes|Pathologic Complete Response|Progression Free Survival (PFS)
  Sponsor/Collaborators:        Darren Carpizo, MD|Bavarian Nordic|Hoosier Cancer Research Network|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   78
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    HCRN GI16-288
  Start Date:                   June 26, 2018
  Primary Completion Date:      June 2019
  Completion Date:              June 2023
  First Posted:                 June 6, 2018
  Results First Posted:         null
  Last Update Posted:           October 31, 2018
  Locations:                    Rutgers Cacner Institute of New Jersey, New Brunswick, New Jersey, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03547999

Study 224:
  NCT Number:                   NCT02823990
  Title:                        TG4010 and Nivolumab in Patients With Lung Cancer
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Recurrent Non-Small Cell Lung Carcinoma|Stage I Non-Small Cell Lung Cancer|Stage II Non-Small Cell Lung Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer
  Interventions:                Biological: TG4010|Biological: Nivolumab
  Outcome Measures:             ORR defined as the proportion of patients whose best overall response (BOR) is either complete response (CR) or partial response (PR) according to RECIST 1.1|Disease control rate defined as the proportion of patients whose BOR is either CR, PR or SD, assessed by RECIST 1.1|Duration of response (DOR) defined as patients whose best overall response is CR or PR (confirmed response)|Incidence of adverse events reported per CTCAE v4.0|Overall survival (OS) defined by RECIST 1.1|Progression free survival (PFS) defined by RECIST 1.1|Stable disease (SD) rate defined as the proportion of patients whose BOR is SD, assessed by RECIST 1.1
  Sponsor/Collaborators:        Karen Kelly|National Cancer Institute (NCI)|Transgene|Bristol-Myers Squibb|University of California, Davis
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   33
  Funded Bys:                   Other|NIH|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    885316|UCDCC#263|P30CA093373|NCI-2016-00960
  Start Date:                   December 2016
  Primary Completion Date:      February 2019
  Completion Date:              February 2019
  First Posted:                 July 6, 2016
  Results First Posted:         null
  Last Update Posted:           October 9, 2018
  Locations:                    City of Hope Comprehensive Cancer Center, Duarte, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|University of California San Diego, San Diego, California, United States|UCSF Medical Center-Mount Zion, San Francisco, California, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02823990

Study 225:
  NCT Number:                   NCT03012581
  Title:                        Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types
  Acronym:                      AcSé
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Carcinoma, Renal Cell|Head and Neck Neoplasm|Skin Neoplasms|Microsatellite Instability|Penile Neoplasms
  Interventions:                Drug: Nivolumab
  Outcome Measures:             Objective response rate|Progression-free survival|Overall survival|Best response|Response duration|Time to response|Frequency and severity of adverse events|Objective response rate in subgroups of subjects with high versus low expression (cutoff set at the median for the population measured) of different immune markers (PD-L1, CD4+, FOXP3+, Fas-L, OX40, VEGF, CD31; CD34)|Progression-free survival in subgroups of subjects with high versus low expression (cutoff set at the median for the population measured) of different immune markers (PD-L1, CD4+, FOXP3+, Fas-L, OX40, VEGF, CD31; CD34)|Overall survival in subgroups of subjects with high versus low expression (cutoff set at the median for the population measured) of different immune markers (PD-L1, CD4+, FOXP3+, Fas-L, OX40, VEGF, CD31; CD34)
  Sponsor/Collaborators:        UNICANCER|National Cancer Institute, France|Ligue contre le cancer, France|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   300
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    UC0105/1611|2016-002257-37
  Start Date:                   June 16, 2017
  Primary Completion Date:      January 2023
  Completion Date:              December 2023
  First Posted:                 January 6, 2017
  Results First Posted:         null
  Last Update Posted:           May 21, 2018
  Locations:                    Gustave Roussy Cancer Campus, Villejuif, France
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03012581

Study 226:
  NCT Number:                   NCT02636036
  Title:                        Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors
  Acronym:                      SPICE
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Colorectal Cancer|Bladder Carcinoma|Squamous Cell Carcinoma of the Head and Neck|Salivary Gland Cancer
  Interventions:                Biological: enadenotucirev|Biological: nivolumab
  Outcome Measures:             Maximum Tolerated and/or Maximum Feasible Dose|to assess the blood levels of enadenotucirev following combination treatment|To examine the anti-tumor activity of combination treatment with enadenotucirev and nivolumab
  Sponsor/Collaborators:        PsiOxus Therapeutics Ltd|Bristol-Myers Squibb|Syneos Health
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   40
  Funded Bys:                   Industry|Other
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    ColoAd1-1003
  Start Date:                   January 2016
  Primary Completion Date:      October 2019
  Completion Date:              March 2020
  First Posted:                 December 21, 2015
  Results First Posted:         null
  Last Update Posted:           September 20, 2018
  Locations:                    University of Arizona Cancer Center, 1515 North Campbell Ave., Tucson, Arizona, United States|City of Hope Comprehensive Cancer Center, 1500 E Duarte Str., Duarte, California, United States|UCLA Medical Center, 10945 Le Conte Ave, Ste. 3360, Santa Monica, California, United States|Horizon Oncology Research, 1345 Unity Place, Suite 345, Lafayette, Indiana, United States|Henry Ford Hospital, 2799 West Grand Blvd., Detroit, Michigan, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02636036

Study 227:
  NCT Number:                   NCT03575234
  Title:                        Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma|Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
  Interventions:                Drug: Cyclophosphamide|Biological: IRX-2|Biological: Nivolumab|Procedure: Surgery
  Outcome Measures:             Incidence of adverse events (AEs) described using Common Terminology Criteria for Adverse Events 4.03|Change in tumor size determined by central radiology review by radiologists blinded to the treatment regimen
  Sponsor/Collaborators:        Emory University|Bristol-Myers Squibb|IRX Therapeutics
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   30
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    IRB00102105|NCI-2018-00411|Winship4300-18
  Start Date:                   July 1, 2019
  Primary Completion Date:      January 31, 2025
  Completion Date:              January 31, 2025
  First Posted:                 July 2, 2018
  Results First Posted:         null
  Last Update Posted:           July 2, 2018
  Locations:                    Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03575234

Study 228:
  NCT Number:                   NCT03527108
  Title:                        Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Non Small Cell Lung Cancer
  Interventions:                Drug: Nivolumab, ramucirumab|Drug: Nivolumab
  Outcome Measures:             Number of patients with progression free survival (PFS) at 6 months in IO naive patients.treated with nivolumab and ramucirumab combination therapy vs the nivolumab monotherapy|Disease control rate (DCR) in IO experienced patients.treated with nivolumab and ramucirumab combination therapy|Overall Response Rate (ORR) in IO naive patients treated with nivolumab and ramucirumab combination therapy|Overall Response Rate in IO naive patients treated with nivolumab monotherapy|Number of patients with treatment related toxicities in IO naive patients treated with nivolumab and ramucirumab combination therapy|Number of patients with treatment related toxicities in IO naive patients treated with nivolumab monotherapy|Overall survival in IO naive patients treated with nivolumab and ramucirumab combination.|Overall survival in IO naive patients treated with nivolumab monotherapy|Number of patients with PFS at 6 months in IO experienced patients treated with nivolumab and ramucirumab combination therapy .|ORR in IO experienced patients treated with nivolumab and ramucirumab combination therapy .|Number of patients with treatment related toxicities in IO experienced patients treated with nivolumab and ramucirumab combination therapy .|Overall survival in IO experienced patients treated with nivolumab and ramucirumab combination therapy .
  Sponsor/Collaborators:        Fox Chase Cancer Center|Bristol-Myers Squibb|Eli Lilly and Company
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   117
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    18-1026|TH-125
  Start Date:                   December 1, 2018
  Primary Completion Date:      April 1, 2020
  Completion Date:              April 1, 2023
  First Posted:                 May 16, 2018
  Results First Posted:         null
  Last Update Posted:           August 1, 2018
  Locations:                    Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03527108

Study 229:
  NCT Number:                   NCT03572582
  Title:                        Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma
  Acronym:                      IMMUTACE
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Carcinoma, Hepatocellular|Hepatic Carcinoma|Hepatocellular Cancer
  Interventions:                Drug: Nivolumab|Drug: TACE
  Outcome Measures:             Objective Response Rate (ORR)|Progression Free Survival (PFS)|Time to Progression (TTP)|Overall survival (OS)|Duration of Response (OR)|Objective Response Rate according to RECIST 1.1|Time to Failure of Strategy (TTFS)|Quality of Life (QoL)|Incidence of Treatment Emergent Adverse Events as assessed by NCI CTCAE V4.03 (Safety and Tolerability)
  Sponsor/Collaborators:        AIO-Studien-gGmbH|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   49
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    AIO-HEP-0217|2017‐003553‐42|CA209-9KK
  Start Date:                   June 14, 2018
  Primary Completion Date:      December 2021
  Completion Date:              September 2022
  First Posted:                 June 28, 2018
  Results First Posted:         null
  Last Update Posted:           June 28, 2018
  Locations:                    Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie & Endokrinologie, Hannover, Germany
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03572582

Study 230:
  NCT Number:                   NCT03585465
  Title:                        Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors or Lymphoma
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Childhood Solid Tumor|Childhood Lymphoma
  Interventions:                Drug: Vinblastine|Drug: Cyclophosphamide|Drug: Capecitabine|Drug: Nivolumab
  Outcome Measures:             Dose Limiting Toxicities according to the NCI-CTCAE V5|Progression-free survival according appropriate criteria (RANO, WHO, INRC, RECIST v1.1, or standard criteria for lymphoma).|Adverse events according to the NCI-CTCAE V5.|Tumor response in terms of complete/partial response or stable/progressive disease (using RANO, WHO, INRC, RECIST v1.1, or standard criteria for lymphoma) and overall survival|Dose-intensity for each drug (ratio between the computed dose-intensity, and the protocol dose-intensity)
  Sponsor/Collaborators:        Centre Oscar Lambret|Anticancer Fund, Belgium|Bristol-Myers Squibb
  Gender:                       All
  Age:                          4 Years to 18 Years   (Child, Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   102
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    Metro-PD1-1708
  Start Date:                   September 2018
  Primary Completion Date:      January 2024
  Completion Date:              July 2027
  First Posted:                 July 13, 2018
  Results First Posted:         null
  Last Update Posted:           July 13, 2018
  Locations:                    
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03585465

Study 231:
  NCT Number:                   NCT03222076
  Title:                        Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable and Potentially Resectable Hepatocellular Carcinoma (HCC) (CA209-956)
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Malignant Neoplasms of Digestive Organs|Hepatocellular Carcinoma
  Interventions:                Drug: Nivolumab|Drug: Ipilimumab
  Outcome Measures:             Safety of Nivolumab Alone or Nivolumab plus Ipilimumab in Participants with Hepatocellular Carcinoma (HCC) Determined by Adverse Events|Objective Response Rate (ORR)|Progression-free survival (PFS)|Conversion Rate to Surgery for Potentially Resectable Participants.
  Sponsor/Collaborators:        M.D. Anderson Cancer Center|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   45
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    2017-0097|NCI-2018-01106
  Start Date:                   September 28, 2017
  Primary Completion Date:      September 2022
  Completion Date:              September 2022
  First Posted:                 July 19, 2017
  Results First Posted:         null
  Last Update Posted:           November 5, 2018
  Locations:                    University of Texas MD Anderson Cancer Center, Houston, Texas, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03222076

Study 232:
  NCT Number:                   NCT03461952
  Title:                        Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)
  Acronym:                      NIMBLe
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Advanced Solid Tumors
  Interventions:                Drug: Nivolumab|Drug: Ipilimumab
  Outcome Measures:             Objective Response Rate by RECIST 1.1|Efficacy as measured by objective response rate|Duration of response|Number and severity of adverse events using CTCAE 5.0|Correlation between POLE or POLD1 mutations in tumor and POLE or POLD1 mutations in blood|To evaluate response by iRECIST
  Sponsor/Collaborators:        Canadian Cancer Trials Group|Cancer Research Institute, New York City|Bristol-Myers Squibb|Personal Genome Diagnostics
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   100
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    I235|0001
  Start Date:                   August 28, 2018
  Primary Completion Date:      May 2021
  Completion Date:              July 2022
  First Posted:                 March 12, 2018
  Results First Posted:         null
  Last Update Posted:           November 14, 2018
  Locations:                    Tom Baker Cancer Centre, Calgary, Alberta, Canada
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03461952

Study 233:
  NCT Number:                   NCT03576963
  Title:                        Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Colorectal Adenocarcinoma|CpG Island Methylator Phenotype|Metastatic Microsatellite Stable Colorectal Carcinoma|Refractory Colorectal Carcinoma|Stage IV Colorectal Cancer AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8
  Interventions:                Drug: Guadecitabine|Biological: Nivolumab
  Outcome Measures:             Maximum tolerated dose (MTD) of guadecitabine when given in combination with nivolumab|Recommended phase 2 dose (RP2D) of guadecitabine when given in combination with nivolumab|Incidence and severity of adverse events
  Sponsor/Collaborators:        University of Southern California|National Cancer Institute (NCI)|Bristol-Myers Squibb|Astex Pharmaceuticals
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   45
  Funded Bys:                   Other|NIH|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    3C-18-5|NCI-2018-01072|P30CA014089
  Start Date:                   October 22, 2018
  Primary Completion Date:      October 22, 2020
  Completion Date:              October 22, 2021
  First Posted:                 July 4, 2018
  Results First Posted:         null
  Last Update Posted:           August 24, 2018
  Locations:                    USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03576963

Study 234:
  NCT Number:                   NCT03283046
  Title:                        Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma
  Acronym:                      
  Status:                       Withdrawn
  Study Results:                No Results Available
  Conditions:                   Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic|Multiple Myeloma
  Interventions:                Drug: Nivolumab|Drug: Lenalidomide|Drug: Dexamethasone|Drug: Ipilimumab
  Outcome Measures:             Maximum Tolerated Dose (MTD) of Nivolumab and Ipilimumab with Dexamethasone and Lenalidomide (NILd) in Participants with Newly Diagnosed Multiple Myeloma|Adverse Events (AE) of Nivolumab and Ipilimumab with Dexamethasone and Lenalidomide (NILd) in Participants with Newly Diagnosed Multiple Myeloma|Rate of Response of Nivolumab and Ipilimumab with Dexamethasone and Lenalidomide (NILd) in Participants with Newly Diagnosed Multiple Myeloma|Progression Free Survival (PFS) of Nivolumab and Ipilimumab with Dexamethasone and Lenalidomide (NILd) in Participants with Newly Diagnosed Multiple Myeloma|Overall Survival of Nivolumab and Ipilimumab with Dexamethasone and Lenalidomide (NILd) in Participants with Newly Diagnosed Multiple Myeloma|Duration of Response (DOR) of Nivolumab and Ipilimumab with Dexamethasone and Lenalidomide (NILd) in Participants with Newly Diagnosed Multiple Myeloma|Clinical Benefit Rate (CBR) of Nivolumab and Ipilimumab with Dexamethasone and Lenalidomide (NILd) in Participants with Newly Diagnosed Multiple Myeloma
  Sponsor/Collaborators:        M.D. Anderson Cancer Center|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   0
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    2016-0482
  Start Date:                   October 2017
  Primary Completion Date:      October 2020
  Completion Date:              October 2020
  First Posted:                 September 14, 2017
  Results First Posted:         null
  Last Update Posted:           September 20, 2017
  Locations:                    
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03283046

Study 235:
  NCT Number:                   NCT03409198
  Title:                        Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer
  Acronym:                      ICON
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Breast Cancer|Luminal B
  Interventions:                Drug: Ipilimumab|Drug: Nivolumab|Drug: Pegylated liposomal doxorubicin|Drug: Cyclophosphamide
  Outcome Measures:             Toxicity: CTCAE v4.0|Progression-free survival (PFS)|Duration of Response (DR)|Overall Survival (OS)|Duration of Response (DR) in cross-over arm|Overall Suvival (OS) in cross-over arm|Toxicity, cross-over arm, CTCAE v4.0|Objective tumor Response Rate (ORR)|Durable tumor Response Rate (DRR)|Objective tumor Response Rate (ORR) in cross-over arm|Durable tumor Response Rate (DRR) in cross-over arm|Clinical Benefit Rate (CBR)|Clinical Benefit Rate (CBR) in cross-over arm|PD-L1 expression|Chalder Fatigue Questionnaire (FQ)|Pain intensity|EORTC QLQ-C15-PAL
  Sponsor/Collaborators:        Oslo University Hospital|Bristol-Myers Squibb|Helse Stavanger HF|Helse Sor-Ost|Sorlandet Hospital HF
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   75
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    ICON CA209-9FN
  Start Date:                   January 21, 2018
  Primary Completion Date:      January 1, 2022
  Completion Date:              January 1, 2025
  First Posted:                 January 24, 2018
  Results First Posted:         null
  Last Update Posted:           August 20, 2018
  Locations:                    Soerlandet Hospital HF Kristiansand, Kristiansand, Norway|Oslo University Hospital, Oslo, Norway|Stavanger University Hospital, Stavanger, Norway
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03409198

Study 236:
  NCT Number:                   NCT02553642
  Title:                        Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Bladder Cancer|Melanoma
  Interventions:                Drug: Nivolumab|Drug: Nivolumab plus Ipilimumab
  Outcome Measures:             response rate|PD-L1 expression
  Sponsor/Collaborators:        Memorial Sloan Kettering Cancer Center|UConn Health|Bristol-Myers Squibb|Adaptive Biotechnologies|MedGenome
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   70
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    15-126
  Start Date:                   September 14, 2015
  Primary Completion Date:      September 2019
  Completion Date:              September 2019
  First Posted:                 September 17, 2015
  Results First Posted:         null
  Last Update Posted:           August 16, 2018
  Locations:                    University of Connecticut Health Center, Farmington, Connecticut, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02553642

Study 237:
  NCT Number:                   NCT03465592
  Title:                        Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Sarcoma|Solid Tumor, Adult|Solid Tumor, Childhood
  Interventions:                Drug: Nivolumab
  Outcome Measures:             Adverse events attributed to Nivolumab for patients enrolled in this study|Overall survival
  Sponsor/Collaborators:        Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bristol-Myers Squibb
  Gender:                       All
  Age:                          12 Months to 40 Years   (Child, Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   39
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    J17124|IRB00143746
  Start Date:                   May 1, 2018
  Primary Completion Date:      March 2022
  Completion Date:              March 2022
  First Posted:                 March 14, 2018
  Results First Posted:         null
  Last Update Posted:           September 6, 2018
  Locations:                    Johns Hopkins Hospital, Baltimore, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03465592

Study 238:
  NCT Number:                   NCT02764593
  Title:                        Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Head and Neck Squamous Cell Carcinoma (HNSCC)
  Interventions:                Drug: Nivolumab|Drug: Cisplatin|Drug: Cetuximab|Radiation: IMRT
  Outcome Measures:             Dose Limiting Toxicity (DLT)
  Sponsor/Collaborators:        RTOG Foundation, Inc.|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   40
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    RTOG 3504|RF 3504|CA209-410
  Start Date:                   June 2016
  Primary Completion Date:      March 2019
  Completion Date:              March 2021
  First Posted:                 May 6, 2016
  Results First Posted:         null
  Last Update Posted:           August 21, 2018
  Locations:                    Stanford Cancer Institute, Palo Alto, California, United States|University of Florida Cancer Center at Orlando Health, Orlando, Florida, United States|Emory University/Winship Cancer Institute, Atlanta, Georgia, United States|University of Louisville, Louisville, Kentucky, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|UPMC - Shadyside Hospital, Pittsburgh, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02764593

Study 239:
  NCT Number:                   NCT03521570
  Title:                        Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Recurrent Head and Neck Squamous Cell Carcinoma
  Interventions:                Radiation: IMRT|Biological: Nivolumab
  Outcome Measures:             1 year progression-free survival (PFS)|1 year overall survival (OS)|Pattern of failure|Incidence of acute adverse events|Incidence of late adverse events|Quality of life (QOL)
  Sponsor/Collaborators:        Emory University|Bristol-Myers Squibb|The Cleveland Clinic|Medical College of Wisconsin
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   51
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    IRB00100923|NCI-2018-00064|Winship4221-17
  Start Date:                   June 28, 2018
  Primary Completion Date:      December 31, 2020
  Completion Date:              December 31, 2020
  First Posted:                 May 10, 2018
  Results First Posted:         null
  Last Update Posted:           July 13, 2018
  Locations:                    Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03521570

Study 240:
  NCT Number:                   NCT02529072
  Title:                        Nivolumab With DC Vaccines for Recurrent Brain Tumors
  Acronym:                      AVERT
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Malignant Glioma|Astrocytoma|Glioblastoma
  Interventions:                Drug: nivolumab|Biological: DC
  Outcome Measures:             The safety of administering DC vaccines with nivolumab, as measured by the percentage of patients who experience unacceptable toxicity during combination treatment|Survival of subjects treated with any protocol treatment (i.e. nivolumab or DC vaccines).|Progression Free Survival (PFS) of subjects treated with any protocol treatment (i.e. nivolumab or DC vaccines).
  Sponsor/Collaborators:        Gary Archer Ph.D.|Bristol-Myers Squibb|Duke Cancer Institute|Duke University
  Gender:                       All
  Age:                          18 Years to 80 Years   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   7
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    Pro00065241
  Start Date:                   January 2016
  Primary Completion Date:      September 15, 2017
  Completion Date:              December 2019
  First Posted:                 August 19, 2015
  Results First Posted:         null
  Last Update Posted:           November 8, 2018
  Locations:                    Duke University Medical Center, Durham, North Carolina, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02529072

Study 241:
  NCT Number:                   NCT03442569
  Title:                        PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Colon Cancer
  Interventions:                Drug: Panitumumab|Drug: Nivolumab|Drug: Ipilimumab
  Outcome Measures:             Overall Response Rate|Overall Response Rate per irRECIST|Length of Progression Free Survival|Length of Overall Survival|Duration of Response|Toxicity of Treatment
  Sponsor/Collaborators:        UNC Lineberger Comprehensive Cancer Center|Amgen|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years to 120 Years   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   56
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    LCCC1632
  Start Date:                   March 9, 2018
  Primary Completion Date:      December 14, 2020
  Completion Date:              December 14, 2023
  First Posted:                 February 22, 2018
  Results First Posted:         null
  Last Update Posted:           November 9, 2018
  Locations:                    Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03442569

Study 242:
  NCT Number:                   NCT03527264
  Title:                        BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Cervical Cancer
  Interventions:                Drug: Nivolumab induction|Drug: Cisplatin|Radiation: Radiation|Drug: Nivolumab with chemoradiation|Drug: Nivolumab maintenance
  Outcome Measures:             Feasibility of the incorporation of nivolumab with weekly cisplatin and extended field (EFRT) or whole pelvic radiation therapy (WPRT) in women with cervical cancer.|Feasibility of the regimen through assessment of acute toxicities.|Progression free survival
  Sponsor/Collaborators:        Don Dizon|Rhode Island Hospital|The Miriam Hospital|Women and Infants Hospital of Rhode Island|Bristol-Myers Squibb|Brown University
  Gender:                       Female
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   24
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    BrUOG 355
  Start Date:                   July 2018
  Primary Completion Date:      December 2020
  Completion Date:              December 2023
  First Posted:                 May 17, 2018
  Results First Posted:         null
  Last Update Posted:           May 17, 2018
  Locations:                    Rhode Island Hospital, Providence, Rhode Island, United States|Women and Infants Hospital, Providence, Rhode Island, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03527264

Study 243:
  NCT Number:                   NCT03409848
  Title:                        Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma
  Acronym:                      INTEGA
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Gastric Cancer|Esophageal Cancer|Adenocarcinoma Gastric|HER2 Positive Gastric Cancer|Metastatic Gastric Cancer|GastroEsophageal Cancer
  Interventions:                Drug: Nivolumab|Drug: Ipilimumab
  Outcome Measures:             Overall Survival|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Progression Free Survival|Response Rate|Health related Quality of Life|Translational research tumor block|Translational research blood - immunoprofiling|Translational research blood - circulating Tumor cells (CTC)|Translational research blood - circulating Tumor DNA (ctDNA)|Central Imaging Review - ORR|Central Imaging Review - PFS
  Sponsor/Collaborators:        AIO-Studien-gGmbH|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   97
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    AIO-STO-0217|2017-000624-10|CA209-99R
  Start Date:                   March 1, 2018
  Primary Completion Date:      October 2021
  Completion Date:              January 2022
  First Posted:                 January 24, 2018
  Results First Posted:         null
  Last Update Posted:           March 23, 2018
  Locations:                    Universitätsklinikum Hamburg-Eppendorf Hubertus Wald Tumorzentrum - UCCH II. Medizinische Klinik und Poliklinik (Onkologie, Hämatologie, KMT mit Sektion Pneumologie), Hamburg, Germany
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03409848

Study 244:
  NCT Number:                   NCT03507699
  Title:                        Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Colorectal Neoplasms Malignant|Liver Metastases
  Interventions:                Radiation: Liver radiation therapy|Drug: Nivolumab Injection [Opdivo]|Drug: Ipilimumab Injection [Yervoy]|Drug: CMP-001
  Outcome Measures:             Number of participants with serious dose-limiting treatment-related adverse events as assessed by CTCAE v5.0|Response rate as assessed by RECIST v1.1|Progression free survival
  Sponsor/Collaborators:        Sheba Medical Center|Checkmate Pharmaceuticals|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   19
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    4465-17-SMC|CA209-991
  Start Date:                   July 1, 2018
  Primary Completion Date:      May 31, 2020
  Completion Date:              May 31, 2021
  First Posted:                 April 25, 2018
  Results First Posted:         null
  Last Update Posted:           April 25, 2018
  Locations:                    Sheba Medical Center, Ramat Gan, Israel
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03507699

Study 245:
  NCT Number:                   NCT03044626
  Title:                        Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC
  Acronym:                      FORCE
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Carcinoma，Non-Small-Cell Lung|Metastatic Lung Cancer|Nonsmall Cell Lung Cancer|Lung Adenocarcinoma Metastatic|Large Cell Lung Carcinoma Metastatic
  Interventions:                Drug: Radiotherapy|Drug: Nivolumab
  Outcome Measures:             objective response rate (ORR) according to RECIST 1.1 criteria|progression free survival (PFS)|PFS using assessment according to irRECIST|ORR using assessment according to irRECIST|Overall Survival (OS)|Adverse Events|Assesment of Quality of life
  Sponsor/Collaborators:        AIO-Studien-gGmbH|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   130
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    AIO-YMO/TRK-0415|2015-005741-31|CA209-430
  Start Date:                   February 10, 2017
  Primary Completion Date:      August 2019
  Completion Date:              November 2021
  First Posted:                 February 7, 2017
  Results First Posted:         null
  Last Update Posted:           July 30, 2018
  Locations:                    Evangelische Lungenklinik Berlin, Berlin, Germany|DRK Kliniken Berlin Mitte, Berlin, Germany|Klinikum Chemnitz, Chemnitz, Germany|Universitätsklinikum Carl-Gustav-Carus, Dresden, Germany|Klinikum Esslingen GmbH, Esslingen, Germany|Krankenhaus Nordwest, Frankfurt / Main, Germany|LungenClinic Grosshansdorf, Großhansdorf, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany|Universitätsklinikum des Saarlandes, Homburg/Saar, Germany|Klinikverbund Kempten-Oberallgäu, Immenstadt, Germany|Kliniken der Stadt Köln Krankenhaus Merheim, Köln, Germany|Ev. Diakonissenkrankenhaus, Leipzig, Germany|Klinik Löwenstein, Löwenstein, Germany|Universitätsklinikum Mannheim, Mannheim, Germany|Asklepios Fachkliniken München-Gauting, München-Gauting, Germany|Klinikum Nürnberg, Nürnberg, Germany|Universitätsklinikum Tübingen, Tübingen, Germany|Universitätsklinikum Ulm, Ulm, Germany
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03044626

Study 246:
  NCT Number:                   NCT03250273
  Title:                        A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Cancer|Cholangiocarcinoma|Pancreatic Cancer|Metastatic Pancreatic Cancer
  Interventions:                Drug: Entinostat|Drug: Nivolumab
  Outcome Measures:             a. Objective response rate (ORR) using Response Evaluation Criteria for Solid Tumors (RECIST 1.1)|Number of participants experiencing study drug-related toxicities|Progression free survival (PFS) status at 6, 12 and 24 months.|Overall survival (OS)|OS at 6 months, at 1, 2 and 3 years|Duration of response (DOR)
  Sponsor/Collaborators:        Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Syndax Pharmaceuticals|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years to 100 Years   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   54
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    J1798|IRB00142149
  Start Date:                   November 6, 2017
  Primary Completion Date:      November 2020
  Completion Date:              November 2020
  First Posted:                 August 15, 2017
  Results First Posted:         null
  Last Update Posted:           October 18, 2018
  Locations:                    Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03250273

Study 247:
  NCT Number:                   NCT03342911
  Title:                        Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Name Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma|Stage II Oropharyngeal Squamous Cell Carcinoma|Stage III Hypopharyngeal Squamous Cell Carcinoma|Stage III Laryngeal Squamous Cell Carcinoma|Stage III Oral Cavity Squamous Cell Carcinoma|Stage III Oropharyngeal Squamous Cell Carcinoma|Stage IV Hypopharyngeal Squamous Cell Carcinoma|Stage IV Laryngeal Squamous Cell Carcinoma|Stage IV Oral Cavity Squamous Cell Carcinoma|Stage IV Oropharyngeal Squamous Cell Carcinoma|Stage IVA Hypopharyngeal Squamous Cell Carcinoma|Stage IVA Laryngeal Squamous Cell Carcinoma|Stage IVA Oral Cavity Squamous Cell Carcinoma|Stage IVA Oropharyngeal Squamous Cell Carcinoma|Stage IVB Hypopharyngeal Squamous Cell Carcinoma|Stage IVB Laryngeal Squamous Cell Carcinoma|Stage IVB Oral Cavity Squamous Cell Carcinoma|Stage IVB Oropharyngeal Squamous Cell Carcinoma|Stage IVC Hypopharyngeal Squamous Cell Carcinoma|Stage IVC Laryngeal Squamous Cell Carcinoma|Stage IVC Oral Cavity Squamous Cell Carcinoma|Stage IVC Oropharyngeal Squamous Cell Carcinoma
  Interventions:                Drug: Paclitaxel|Drug: Carboplatin|Biological: Nivolumab
  Outcome Measures:             Pathologic complete response rate|Major pathologic response defined as 10% or less residual viable tumor
  Sponsor/Collaborators:        Sidney Kimmel Cancer Center at Thomas Jefferson University|Bristol-Myers Squibb|Thomas Jefferson University
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   37
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    17P.513
  Start Date:                   November 13, 2017
  Primary Completion Date:      June 2020
  Completion Date:              June 2021
  First Posted:                 November 17, 2017
  Results First Posted:         null
  Last Update Posted:           February 21, 2018
  Locations:                    Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03342911

Study 248:
  NCT Number:                   NCT03061188
  Title:                        Nivolumab and Veliparib in Treating Patients With Recurrent or Refractory Stage IV Solid Tumors That Cannot Be Removed by Surgery or Lymphoma With or Without Alterations in DNA Repair Genes
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Advanced Solid Neoplasm|Aggressive Non-Hodgkin Lymphoma|Recurrent Solid Neoplasm|Refractory Mantle Cell Lymphoma|T-Cell Non-Hodgkin Lymphoma|Unresectable Solid Neoplasm
  Interventions:                Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Other: Pharmacological Study|Drug: Veliparib
  Outcome Measures:             Maximum Tolerated Dose (MTD)|Incidence of Adverse Events|ORR|Clinical Benefit Rate (CBR)|Progression Free Survival (PFS)|immune-related PFS (irPFS)|Overall Survival (OS)|Proportion of patients alive and progression free
  Sponsor/Collaborators:        Northwestern University|Bristol-Myers Squibb|AbbVie|National Cancer Institute (NCI)
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   50
  Funded Bys:                   Other|Industry|NIH
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    NU 16MH03|STU00204250|P30CA060553|NCI-2016-02018
  Start Date:                   May 23, 2017
  Primary Completion Date:      September 2020
  Completion Date:              January 2021
  First Posted:                 February 23, 2017
  Results First Posted:         null
  Last Update Posted:           January 24, 2018
  Locations:                    Northwestern University, Chicago, Illinois, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03061188

Study 249:
  NCT Number:                   NCT03041181
  Title:                        Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Non-Squamous Non-Small Cell Lung Cancer (NSCLC)|Adenocarcinoma of the Lung|Lung Cancer|Squamous Cell Lung Cancer
  Interventions:                Drug: Docetaxel|Drug: Nivolumab|Drug: Gemcitabine|Drug: Pemetrexed
  Outcome Measures:             Progression free survival (PFS), as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.|Overall Response rate (ORR) for subjects on each treatment arm, as defined by RECIST 1.1 and immune-related response criteria (irRECIST)|Clinical benefit rate (CBR) for subjects on each treatment arm, as defined by RECIST 1.1 and irRECIST|Progression free survival (PFS), as defined by irRECIST|Assess adverse events
  Sponsor/Collaborators:        Nasser Hanna, M.D.|Hoosier Cancer Research Network|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   62
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    HCRN LUN15-233
  Start Date:                   January 27, 2017
  Primary Completion Date:      March 2019
  Completion Date:              September 2020
  First Posted:                 February 2, 2017
  Results First Posted:         null
  Last Update Posted:           August 8, 2018
  Locations:                    St. Vincent Anderson Regional Hospital, Anderson, Indiana, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|IU Health Central Indiana Cancer Center, Indianapolis, Indiana, United States|Community Regional Cancer Care, Indianapolis, Indiana, United States|IU Health Ball Memorial Hospital Cancer Center, Muncie, Indiana, United States|Community Healthcare System, Munster, Indiana, United States|HealthPartners Institute, Minneapolis, Minnesota, United States|University of Texas Medical Branch at Galveston, Galveston, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03041181

Study 250:
  NCT Number:                   NCT03522246
  Title:                        A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
  Acronym:                      ATHENA
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Epithelial Ovarian Cancer|Primary Peritoneal|Fallopian Tube Cancer|Newly Diagnosed|FIGO Stage III-IV|Partial Response|Complete Response
  Interventions:                Drug: Rucaparib|Drug: Nivolumab|Drug: Placebo Oral Tablet|Drug: Placebo IV Infusion
  Outcome Measures:             Investigator assessed Progression-free survival (PFS)|Blinded independent central review (BICR) PFS|Overall Survival (OS)|Objective response rate (ORR)|Duration of response (DOR)|Number of participants with treatment-emergent Adverse Events (AEs) as assessed by CTCAE v4 (or higher) as a measure of safety and tolerability|Number of participants with serious AEs as a measure of safety and tolerability|Number of participants with laboratory abnormalities as a measure of safety and tolerability
  Sponsor/Collaborators:        Clovis Oncology, Inc.|Bristol-Myers Squibb|Gynecologic Oncology Group|European Network of Gynaecological Oncological Trial Groups (ENGOT)|Foundation Medicine
  Gender:                       Female
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   1012
  Funded Bys:                   Industry|Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  Other IDs:                    CO-338-087/GOG-3020/ENGOT-ov45
  Start Date:                   May 14, 2018
  Primary Completion Date:      December 30, 2024
  Completion Date:              December 30, 2030
  First Posted:                 May 11, 2018
  Results First Posted:         null
  Last Update Posted:           November 8, 2018
  Locations:                    Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States|The University of Arizona Cancer Center, Tucson, Arizona, United States|Rocky Mountain Cancer Centers, Lakewood, Colorado, United States|Augusta University, Augusta, Georgia, United States|Dr. Sudarshan K. Sharma, Ltd - Gynecologic Oncology, Hinsdale, Illinois, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, United States|Women's Cancer Center of Nevada, Las Vegas, Nevada, United States|Women's Cancer Care Associates, Albany, New York, United States|Broome Oncology, LLC, Johnson City, New York, United States|Oncology Hematology Care, Inc, Cincinnati, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Oklahoma Cancer Specialists and Research Institute, Tulsa, Oklahoma, United States|Willamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States|Northwest Cancer Specialists, P.C., Portland, Oregon, United States|Avera Gynecologic Oncology, Sioux Falls, South Dakota, United States|Texas Oncology - Austin Central, Austin, Texas, United States|Texas Oncology - Bedford, Bedford, Texas, United States|Texas Oncology - Dallas Presbyterian Hospital, Dallas, Texas, United States|Texas Oncology - Fort Worth, Fort Worth, Texas, United States|Texas Oncology - San Antonio Medical Center, San Antonio, Texas, United States|Texas Oncology - The Woodlands, Gynecologic Oncology, The Woodlands, Texas, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Border Medical Oncology, Albury, AU, Australia|Newcastle Private Hospital, New Lambton Heights, New South Wales, Australia|Northern Cancer Institute St Leonards, Saint Leonards, New South Wales, Australia|Prince of Wales Hospital, Sydney, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03522246

Study 251:
  NCT Number:                   NCT03121677
  Title:                        Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Follicular Lymphoma
  Interventions:                Biological: Personalized tumor vaccine|Drug: Poly ICLC|Biological: Nivolumab|Procedure: Peripheral blood draws|Procedure: Leukapheresis|Biological: Rituximab|Procedure: Biopsy
  Outcome Measures:             Feasibility and safety of vaccine in combination with nivolumab +/1 anti-CD20 monoclonal antibody therapy as measured by the number of participants whose personal vaccines can be manufactured and delivered without unacceptable toxicity|Overall response rate (ORR)|Complete response (CR) rate|Duration of response|Progression-free survival (PFS)|Overall survival (OS)|Partial response (PR) rate
  Sponsor/Collaborators:        Washington University School of Medicine|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   20
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    201804151
  Start Date:                   October 16, 2018
  Primary Completion Date:      July 31, 2022
  Completion Date:              January 31, 2028
  First Posted:                 April 20, 2017
  Results First Posted:         null
  Last Update Posted:           November 14, 2018
  Locations:                    Washington University School of Medicine, Saint Louis, Missouri, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03121677

Study 252:
  NCT Number:                   NCT03215810
  Title:                        Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Non-Small Cell Lung Cancer|Metastatic Non-small Cell Lung Cancer|Squamous Cell Carcinoma|Advanced NSCLC|Adenosquamous Carcinoma|Adenocarcinomas
  Interventions:                Procedure: Tumor-infiltrating Lymphocytes (TIL)|Drug: Nivolumab|Drug: Cyclophosphamide|Drug: Fludarabine|Other: Tumor-infiltrating Lymphocyte Therapy|Drug: Interleukin-2 (IL2)
  Outcome Measures:             Rate of Dose Limiting Toxicity (DLT)|Objective Response Rate (ORR)
  Sponsor/Collaborators:        H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb|Prometheus Inc.|Stand Up To Cancer|Iovance Biotherapeutics, Inc.
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   18
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    MCC-19122|CA209-9JA
  Start Date:                   October 11, 2017
  Primary Completion Date:      March 2020
  Completion Date:              March 2021
  First Posted:                 July 12, 2017
  Results First Posted:         null
  Last Update Posted:           September 3, 2018
  Locations:                    University of Florida Health Cancer Center., Gainesville, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03215810

Study 253:
  NCT Number:                   NCT02046733
  Title:                        Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease
  Acronym:                      STIMULI
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Limited Stage Small Cell Lung Cancer|Small Cell Lung Cancer
  Interventions:                Drug: Ipilimumab|Drug: Nivolumab
  Outcome Measures:             Overall survival|Progression-free survival determined by RECIST 1.1|Objective response|Time to treatment failure|Toxicity
  Sponsor/Collaborators:        European Thoracic Oncology Platform|Intergroupe Francophone de Cancerologie Thoracique|Ludwig Center for Cancer Research of Lausanne|Frontier Science Foundation, Hellas|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   260
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    ETOP/IFCT 4-12|2013-002609-78|CA184-310|SNCTP000000166
  Start Date:                   July 28, 2014
  Primary Completion Date:      October 2019
  Completion Date:              January 2022
  First Posted:                 January 28, 2014
  Results First Posted:         null
  Last Update Posted:           February 20, 2018
  Locations:                    University Hospital Gasthuisberg, KU Leuven, Leuven, Belgium|Avignon - Institut Sainte-Catherine, Avignon, France|Caen - Centre François Baclesse, Caen, France|CHU, Caen, France|Percy/Armées, Clamart, France|Clermont-Ferrand, Clermont-Ferrand, France|Créteil - CHI, Creteil, France|CHU, Grenoble, France|Centre Hospitalier Général, Le Mans, France|Hôpital Louis Pradel, Lyon, France|Lyon - Sud, Lyon, France|AP-HM, Marseille, France|Centre Hospitalier Universitaire de Montpellier, Montpellier, France|CH, Mulhouse, France|CRLCC, Nantes, France|Nice - CRLCC, Nice, France|Orléans - CH, Orléans, France|Paris - Bichat, Paris, France|Paris - Saint-Louis, Paris, France|Paris - Tenon, Paris, France|CHU, Rennes, France|Nouvel Hôpital Civil, Strasbourg, France|Suresnes, Suresnes, France|CHI, Toulon, France|CHU, Toulouse, France|CHU, Tours, France|Institut Gustave Roussy, Villejuif, France|Klinikum Esslingen, Esslingen, Germany|LungenClinic Grosshansdorf GmbH, Grosshansdorf, Germany|Klinikum München-Bogenhausen, München, Germany|Thoracic Oncology Centre Munich, München, Germany|Pius-Hospital Oldenburg, Oldenburg, Germany|Krankenhaus der Barmherzigen Brüder, Trier, Germany|Universitätsklinikum Tübingen, Tübingen, Germany|VUMC, Amsterdam, Netherlands|Maastro Clinic, Maastricht, Netherlands|Hospital General Universitario Alicante, Alicante, Spain|Hospital Universitario Cruces, Barakaldo, Spain|Hospital De La Santa Creu I Sant Pau, Barcelona, Spain|Clinico San Carlos, Madrid, Spain|Hospital Puerta de Hierro, Madrid, Spain|Hospital Universitario 12 Octubre, Madrid, Spain|Hospital Universitario Fundacion Jimenez Díaz, Madrid, Spain|Hospital Universitario Central De Asturias, Oviedo, Spain|Hospital Virgen De La Salud, Toledo, Spain|Hospital Clínico Universitario De Valencia, Valencia, Spain|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|University Hospital Zürich, Zürich, Switzerland|St James' University Hospital, Leeds, United Kingdom|Royal Marsden, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02046733

Study 254:
  NCT Number:                   NCT03542461
  Title:                        Early Switch Maintenance vs Delayed Second-line Nivolumab in Advanced Stage Squamous Non-small Cell Lung Cancer (NSCLC) Patients (EDEN Trial)
  Acronym:                      EDEN
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Squamous Non-small Cell Lung Cancer
  Interventions:                Drug: Nivolumab 10 MG/ML Intravenous Solution|Other: Best Supportive Care
  Outcome Measures:             Overall survival (OS)|Progression-Free Survival (PFS)|Progression-Free Survival from induction (PFSind)|Time to Treatment Failure (TTF)|Overall Survival from Induction (OSind)
  Sponsor/Collaborators:        Gruppo Oncologico Italiano di Ricerca Clinica|Mipharm S.p.A.|Bioikos Ambiente Srl|Istituto Toscano Tumori|Temas srl|Bristol Myers Squibb Srl Italia
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   388
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    GOIRC-04-2016
  Start Date:                   September 25, 2017
  Primary Completion Date:      September 30, 2022
  Completion Date:              September 30, 2022
  First Posted:                 May 31, 2018
  Results First Posted:         null
  Last Update Posted:           July 2, 2018
  Locations:                    UOC Oncologia - Azienda USL di Imola - Ospedale Santa Maria della Scaletta, Imola, Bologna, Italy|Oncologia Medica - IRST - IRCCS di Meldola, Meldola, Forlì, Italy|AUSL 12 Viareggio, Ospedale Versilia, Lido di Camaiore (LU) - Oncologia Medica, Lido Di Camaiore, Lucca, Italy|UO Medicina Oncologica - Ospedale di Carpi (MO) - Azienda USL di Modena, Carpi, Modena, Italy|UOC di Oncologia Medica - Presidio Santa Croce Azienda Ospedaliera - Ospedale Riuniti Marche NORD, Fano, Pesaro-Urbino, Italy|UOC di Oncologia Medica - ASST Valle Olona - Presidio Ospedaliero di Saronno, Saronno, Varese, Italy|UOC Oncologia Medica - Azienda ULSS21 di Legnago VR, Legnago, Verona, Italy|Oncologia Medica - Ospedale Sacro Cuore - Don Calabria, Negrar, Verona, Italy|SC Oncologia - ASO "SS Antonio e Biagio e Cesare Arrigo", Alessandria, Italy|U.O.C. di Oncologia Medica - Istituto Tumori "Giovanni Paolo II" I.R.C.C.S. Ospedale Oncologico di Bari, Bari, Italy|Humanitas Gavazzeni - Cliniche Gavazzeni spa - Sezione Oncologia Pneumologica ed Urologica, Bergamo, Italy|UO Oncologia Medica - A.S.S.T. Papa Giovanni XXIII di Bergamo, Bergamo, Italy|UO di Oncologia Medica - Azienda Ospedaliero-Universitaria S. Orsola Malpighi, Bologna, Italy|UOC di Oncologia - Azienda USL di Bologna, Ospedale Bellaria, Bologna, Italy|Divisione di Oncologia Medica - Ospedale di Bolzano, Bolzano, Italy|UOC Oncologia Medica - PO A.Perino ASL di Brindisi, Brindisi, Italy|Azienda Ospedaliero - Universitaria "Policlinico - Vittorio Emanuele" - P.O. "G. Rodolico" - Oncologia Medica, Catania, Italy|SC di Oncologia - Istituti Ospitalieri di Cremona, Cremona, Italy|Dipartimento di Oncologia Medica - Azienda Ospedaliera S.Croce e Carle Cuneo - Ospedale Carle, Cuneo, Italy|UO di Oncologia Ematologia - Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy|S.C. Oncologia Medica 1 - Azienda Ospedaliero Universitaria Careggi, Firenze, Italy|UOS Tumori Polmonari - IRCCS AOU San Martino -IST- Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy|Azienda USL Toscana nord ovest - Ospedale San Luca di Lucca - Dipartimento Oncologico, Lucca, Italy|Azienda Ospedaliero-Universitaria di Modena - Policlinico - Dipartimento di Scienze Mediche e Chirurgiche, Materno Infantili e dell'adulto, Modena, Italy|SC di Oncologia Medica - A.O. San Gerardo, Monza, Italy|S. C. di Oncologia Medica - AORN "Antonio Cardarelli", Napoli, Italy|U.O.C Pneumologia ad Indirizzo Oncologico - AORN Ospedali dei Colli Monaldi, Napoli, Italy|IOV Istituto Oncologico Veneto - UOC di Oncologia Medica 2, Padova, Italy|UOC di Oncologia Medica - Azienda Ospedaliero Universitaria di Parma, Parma, Italy|S.C. di Oncologia Medica - Ospedale S.Maria della Misericordia, Perugia, Italy|AUSL - Piacenza - Ospedale "Guglielmo da Saliceto"-Dip.Oncologia e Ematologia- UO di Oncologia Medica Azienda, Piacenza, Italy|Azienda Ospedaliera Universitaria Pisana - Dipartimento Medico in Oncologia, Pisa, Italy|Struttura Complessa di Oncologia - IRCCS - Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|AUSL della Romagna - Ambito di Rimini - Ospedale Infermi di Rimini - UO di Oncologia, Rimini, Italy|Pneumologia ad Indirizzo Oncologico 1 - A.O. San Camillo Forlanini, Roma, Italy|Università la Sapienza - Policlinico Umberto I - Dipartimento di scienze radiologiche, oncologiche e anatomo-patologiche - UOC Oncologia B, Roma, Italy|UO Oncologia Medica - ASL N.1 di Sassari - Ospedale Civile di Sassari, Sassari, Italy|U.O. Oncologia Medica - Ospedale Santa Chiara, Trento, Italy|Reparto di Oncologia - Azienda Sanitaria Universitaria Integrata di Udine - Presidio Ospedaliero Santa Maria della Misericordia, Udine, Italy|U.S.O. GIVOP (Gruppo Interdisciplinare Veronese Oncologia Polmonare) Oncologia - Azienda Ospedaliera Integrata Verona, Verona, Italy
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03542461

Study 255:
  NCT Number:                   NCT03502746
  Title:                        Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Mesothelioma, Malignant
  Interventions:                Drug: Nivolumab|Drug: Ramucirumab
  Outcome Measures:             Response Rate|Adverse event assessment|Progression-free survival|Overall survival
  Sponsor/Collaborators:        Arkadiusz Z. Dudek, MD|HealthPartners Institute Regions Cancer Care Center|Eli Lilly and Company|Bristol-Myers Squibb|Hoosier Cancer Research Network
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   35
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    HCRN-LUN15-299
  Start Date:                   June 26, 2018
  Primary Completion Date:      June 2020
  Completion Date:              June 2021
  First Posted:                 April 19, 2018
  Results First Posted:         null
  Last Update Posted:           November 5, 2018
  Locations:                    Moffitt Cancer Center, Tampa, Florida, United States|HealthPartners Institute Regions Cancer Care Center, Minneapolis, Minnesota, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03502746

Study 256:
  NCT Number:                   NCT03138161
  Title:                        SAINT:Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Advanced Soft Tissue Sarcoma|Metastatic Soft Tissue Sarcoma
  Interventions:                Drug: Trabectedin|Drug: Ipilimumab|Drug: Nivolumab
  Outcome Measures:             Maximum tolerated dose|Objective response rate (ORR), disease control rate (DCR)|Progression free survival (PFS), 6 month PFS rate|Overall survival (OS), 6 month OS rate
  Sponsor/Collaborators:        Sarcoma Oncology Research Center, LLC|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   45
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    SOC-1702
  Start Date:                   April 13, 2017
  Primary Completion Date:      June 30, 2020
  Completion Date:              August 31, 2020
  First Posted:                 May 3, 2017
  Results First Posted:         null
  Last Update Posted:           September 6, 2018
  Locations:                    Sarcoma Oncology Research Center, Santa Monica, California, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03138161

Study 257:
  NCT Number:                   NCT03695250
  Title:                        BMS-986205 and Nivolumab as First Line Therapy in Treating Patients With Liver Cancer
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Metastatic Hepatocellular Carcinoma|Stage III Hepatocellular Carcinoma AJCC v8|Stage IIIA Hepatocellular Carcinoma AJCC v8|Stage IIIB Hepatocellular Carcinoma AJCC v8|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IVA Hepatocellular Carcinoma AJCC v8|Stage IVB Hepatocellular Carcinoma AJCC v8|Unresectable Hepatocellular Carcinoma
  Interventions:                Drug: IDO1 Inhibitor BMS-986205|Biological: Nivolumab
  Outcome Measures:             Incidence of adverse events (AE)|Objective response rate (ORR)|Disease control rate (DCR)|Progression-free survival (PFS)|Duration of response (DOR)|Overall survival (OS)
  Sponsor/Collaborators:        Edward Kim|National Cancer Institute (NCI)|Bristol-Myers Squibb|University of California, Davis
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   23
  Funded Bys:                   Other|NIH|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    1229924|NCI-2018-02009|UCDCC#276|P30CA093373
  Start Date:                   December 1, 2018
  Primary Completion Date:      December 1, 2021
  Completion Date:              June 1, 2022
  First Posted:                 October 4, 2018
  Results First Posted:         null
  Last Update Posted:           October 4, 2018
  Locations:                    University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03695250

Study 258:
  NCT Number:                   NCT02837029
  Title:                        Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Stage IIIA Hepatocellular Carcinoma|Stage IIIB Hepatocellular Carcinoma|Stage IIIC Hepatocellular Carcinoma|Stage IVA Hepatocellular Carcinoma|Stage IVB Hepatocellular Carcinoma
  Interventions:                Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Radiation: Yttrium Y 90 Glass Microspheres
  Outcome Measures:             Maximum Tolerated Dose (MTD)|Objective Response Rate (ORR)|Incidence of Adverse Events|Progression Free Survival (PFS)|Disease Control Rate (DCR)
  Sponsor/Collaborators:        Northwestern University|Bristol-Myers Squibb|National Cancer Institute (NCI)
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   35
  Funded Bys:                   Other|Industry|NIH
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    NU 16I01|STU00203003|P30CA060553|NCI-2016-01001
  Start Date:                   July 2016
  Primary Completion Date:      July 2019
  Completion Date:              July 2020
  First Posted:                 July 19, 2016
  Results First Posted:         null
  Last Update Posted:           June 19, 2018
  Locations:                    Northwestern University, Chicago, Illinois, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02837029

Study 259:
  NCT Number:                   NCT03439891
  Title:                        Sorafenib and Nivolumab as First-Line Therapy in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Stage III Hepatocellular Carcinoma AJCC v8|Stage IIIA Hepatocellular Carcinoma AJCC v8|Stage IIIB Hepatocellular Carcinoma AJCC v7|Stage IIIC Hepatocellular Carcinoma AJCC v7|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IVA Hepatocellular Carcinoma AJCC v8|Stage IVB Hepatocellular Carcinoma AJCC v8
  Interventions:                Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Drug: Sorafenib
  Outcome Measures:             Maximum tolerated dose (MTD) (Part 1)|Overall response rate (ORR) assessed using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Part 2)|Duration of response (DOR)|Incidence of adverse classified using NCI CTCAE version 4.03|ORR assessed by RECIST 1.1 for overall study|Overall survival (OS)|Progression-free survival (PFS)|Rate of immune-related adverse event (irAE) for combination
  Sponsor/Collaborators:        University of California, San Francisco|Bayer|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   40
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    174523|NCI-2018-00051|17-23590|P30CA082103
  Start Date:                   February 21, 2018
  Primary Completion Date:      May 29, 2020
  Completion Date:              December 31, 2020
  First Posted:                 February 20, 2018
  Results First Posted:         null
  Last Update Posted:           March 7, 2018
  Locations:                    University of California, San Francisco, San Francisco, California, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03439891

Study 260:
  NCT Number:                   NCT03404960
  Title:                        Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy
  Acronym:                      Parpvax
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Pancreatic Adenocarcinoma
  Interventions:                Drug: Niraparib + Nivolumab|Drug: Niraparib + Ipilimumab
  Outcome Measures:             Progression-free survival|Proportion of tumors with homologous recombination deficits (HRD), in patients with stability or response to platinum therapy|Objective response rate (ORR) in those with measurable disease|Duration of response (DOR)|Overall survival (OS)|Safety and tolerability of this combination. Number of participants with treatment-related adverse events as assessed by CTCAE version 4.03|Correlation of HRDs with response to treatment with niraparib plus immune checkpoint blockade|Immune activation prior to treatment|Immune activation prior during treatment
  Sponsor/Collaborators:        University of Pennsylvania|Bristol-Myers Squibb|Tesaro, Inc.
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   84
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    828516
  Start Date:                   January 31, 2018
  Primary Completion Date:      January 2021
  Completion Date:              June 2021
  First Posted:                 January 19, 2018
  Results First Posted:         null
  Last Update Posted:           February 21, 2018
  Locations:                    University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03404960

Study 261:
  NCT Number:                   NCT03136627
  Title:                        Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Carcinoma, Renal Cell
  Interventions:                Drug: Tivozanib|Drug: Nivolumab
  Outcome Measures:             Maximum Tolerated Dose (MTD) of tivozanib administered orally in combination with Nivolumab in subjects with advanced renal cell carcinoma.|Disease status will be summarized by cycle and dose group, including changes from baseline.
  Sponsor/Collaborators:        AVEO Pharmaceuticals, Inc.|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   28
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    AV-951-16-119
  Start Date:                   March 22, 2017
  Primary Completion Date:      December 21, 2017
  Completion Date:              December 2018
  First Posted:                 May 2, 2017
  Results First Posted:         null
  Last Update Posted:           June 26, 2018
  Locations:                    Bordeaux Hospital University Center (CHU), Bordeaux, France|Center Léon Bérard, Lyon, France|Institut Paoli-Calmettes, Marseille, France|Centre Paul Strauss, Strasbourg, France|Institut Gustave Roussy, Villejuif, France
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03136627

Study 262:
  NCT Number:                   NCT03014804
  Title:                        Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Giant Cell Glioblastoma|Gliosarcoma|Oligodendroglioma|Recurrent Glioblastoma|Small Cell Glioblastoma
  Interventions:                Biological: autologous dendritic cells pulsed with tumor lysate antigen Vaccine|Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Other: Quality-of-Life Assessment|Other: Questionnaire Administration
  Outcome Measures:             Incidence of adverse events assessed by National Cancer Institute's Common Terminology Criteria for Adverse Events version 4.03|Overall Survival (OS)|Overall Survival rate|Progression Free Survival (PFS)|Quality of Life (QoL)|Number of participants with complete response (CR)|Number of participants with partial response (PR)|Number of participants with stable disease (SD)|Number of participants with progressive disease (PD)|Objective response rate (ORR) defined as the percentage of participants with CR + PR|Response/Stable Disease Rate (RSDR) defined as the percentage of participants demonstrating CR+PR+SD
  Sponsor/Collaborators:        Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)|Northwest Biotherapeutics|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years to 75 Years   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   30
  Funded Bys:                   Other|NIH|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    16-001706|NCI-2016-01587|P30CA016042
  Start Date:                   January 1, 2019
  Primary Completion Date:      January 1, 2020
  Completion Date:              January 1, 2022
  First Posted:                 January 9, 2017
  Results First Posted:         null
  Last Update Posted:           October 24, 2018
  Locations:                    UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03014804

Study 263:
  NCT Number:                   NCT02626962
  Title:                        Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma
  Acronym:                      GEM1402
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Uveal Melanoma
  Interventions:                Drug: ipilimumab|Drug: Nivolumab
  Outcome Measures:             Overall Survival at 12 months|Overall survival at 24 months.|Progression Free Survival (PFS)|Global PFS according to RECIST 1.1 criteria.|Objective Response Rate (ORR)|Disease Control Rate|Duration of response
  Sponsor/Collaborators:        Grupo Español Multidisciplinar de Melanoma|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years to 99 Years   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   48
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    GEM-1402|2015-004429-15
  Start Date:                   April 2016
  Primary Completion Date:      February 2020
  Completion Date:              February 2020
  First Posted:                 December 10, 2015
  Results First Posted:         null
  Last Update Posted:           November 27, 2018
  Locations:                    Hospital Son Espases, Palma De Mallorca, Baleares, Spain|ICO Hospitalet, L'Hospitalet de Llobregat, Spain|H. Insular de Canarias, Las Palmas de Gran Canaria, Spain|Hospital La Paz, Madrid, Spain|H. U. Virgen de la Victoria, Malaga, Spain|Clínica Universidad de Navarra, Pamplona, Spain|H. U. Clínico de Santiago, Santiago, Spain|H.U. Virgen Macarena, Sevilla, Spain|Hospital General Universitario de Valencia, Valencia, Spain|H. C. U. de Valladolid, Valladolid, Spain
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02626962

Study 264:
  NCT Number:                   NCT02658981
  Title:                        Anti-LAG-3 or Urelumab Alone and in Combination With Nivolumab in Treating Patients With Recurrent Glioblastoma
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Glioblastoma|Gliosarcoma|Recurrent Brain Neoplasm
  Interventions:                Biological: Anti-LAG-3 Monoclonal Antibody BMS 986016|Biological: Anti-PD-1|Other: Pharmacological Study|Other: Laboratory Biomarker Analysis|Biological: Anti-CD137
  Outcome Measures:             Maximum tolerated dose (MTD) of anti-LAG-3 monoclonal antibody BMS-986016 as monotherapy as determined by frequency of toxicity|Maximum tolerated dose (MTD) of anti-CD137 as monotherapy as determined by frequency of toxicity|MTD of Anti-LAG-3 + Anti-PD-1 as determined by frequency of toxicity|MTD of Anti-CD137 + Anti-PD-1 as determined by frequency of toxicity|Overall Survival|Progression-free survival rate|Overall Response, assessed by RANO and iRANO|Overall Response to anti-LAG-3 monoclonal antibody BMS-98601, assessed by RANO and iRANO|Overall Response to anti-CD137 as monotherapy, assessed by RANO and iRANO|Overall Response to Anti-LAG-3 + Anti-PD-1, assessed by RANO and iRANO
  Sponsor/Collaborators:        Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   100
  Funded Bys:                   Other|NIH|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    ABTC 1501|IRB00095527|UM1CA137443
  Start Date:                   August 2016
  Primary Completion Date:      August 2019
  Completion Date:              December 2020
  First Posted:                 January 20, 2016
  Results First Posted:         null
  Last Update Posted:           October 11, 2018
  Locations:                    UAB Comprehensive Cancer Center, Birmingham, Alabama, United States|Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Abrams Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02658981

Study 265:
  NCT Number:                   NCT03238365
  Title:                        Window of Opportunity Trial of Nivolumab and Tadalafil in Patients With Squamous Cell Carcinoma of the Head and Neck
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Lip, Oral Cavity and Pharynx|Larynx
  Interventions:                Biological: Nivolumab|Drug: Tadalafil|Procedure: Therapeutic Conventional Surgery
  Outcome Measures:             Change in immune cell polarization (Th1/Th2; M1/M2) in peripheral blood and tumor specimens using multiplex cytokine analysis|Prevalence of intratumoral immune cell populations
  Sponsor/Collaborators:        Sidney Kimmel Cancer Center at Thomas Jefferson University|Bristol-Myers Squibb|Thomas Jefferson University
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Early Phase 1
  Enrollment:                   50
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    17P.210
  Start Date:                   August 10, 2017
  Primary Completion Date:      December 16, 2019
  Completion Date:              December 16, 2020
  First Posted:                 August 3, 2017
  Results First Posted:         null
  Last Update Posted:           March 27, 2018
  Locations:                    Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Vanderbilt University, Nashville, Tennessee, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03238365

Study 266:
  NCT Number:                   NCT02011945
  Title:                        A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Chronic Myeloid Leukemia
  Interventions:                Drug: Dasatinib|Drug: Nivolumab
  Outcome Measures:             Safety and Tolerability for the combination of Dasatinib and Nivolumab|Major Molecular Response (MMR) and Molecular Response (MR) rates|Time to, and duration of, MMR and MR
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   69
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA180-373|2013-002156-33
  Start Date:                   February 7, 2014
  Primary Completion Date:      August 8, 2019
  Completion Date:              August 9, 2019
  First Posted:                 December 16, 2013
  Results First Posted:         null
  Last Update Posted:           August 31, 2018
  Locations:                    Winship Cancer Institute, Atlanta, Georgia, United States|Dana Faber Cancer Institute, Boston, Massachusetts, United States|Ut Southwestern Medical Center At Dallas, Dallas, Texas, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|Froedtert Hospital & Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Local Institution, St Leonards, New South Wales, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Parkville, Victoria, Australia|QEII Health Sciences Centre-VG Site, Halifax, Nova Scotia, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada|Local Institution, Bordeaux, France|Campus Virchow Klinikum Der Charite, Berlin, Germany|Universitaetsklinikum Bonn, Bonn, Germany|Universitaetsklinikum Carl Gustav Carus, Dresden, Germany|Universitaetsklinik Frankfurt, Frankfurt am Main, Germany|Local Institution, Napoli, Italy|Local Institution, Orbassano, Italy|Local Institution, Roma, Italy|Local Institution, Madrid, Spain|Local Institution, Valencia, Spain
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02011945

Study 267:
  NCT Number:                   NCT02899299
  Title:                        Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients
  Acronym:                      CheckMate743
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Mesothelioma
  Interventions:                Biological: Nivolumab|Biological: Ipilimumab|Drug: Pemetrexed|Drug: Cisplatin|Drug: Carboplatin
  Outcome Measures:             Overall Survival (OS)|Progression Free Survival (PFS)|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Composite correlation of PD-L1 expression level and efficacy
  Sponsor/Collaborators:        Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   600
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-743|2016-001859-43
  Start Date:                   October 25, 2016
  Primary Completion Date:      October 4, 2020
  Completion Date:              September 28, 2021
  First Posted:                 September 14, 2016
  Results First Posted:         null
  Last Update Posted:           November 20, 2018
  Locations:                    Ucsf, San Francisco, California, United States|Yale University, New Haven, Connecticut, United States|H. Lee Moffitt Cancer Center & Research Inst, Inc, Tampa, Florida, United States|University Of Chicago, Chicago, Illinois, United States|Univ Of Maryland Greenbaum Cancer Center, Baltimore, Maryland, United States|Barbara Ann Karmanos Cancer Center, Detroit, Michigan, United States|Cancer & Hematology Centers Of Western Michigan, Grand Rapids, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Allegheny Cancer Center, Jefferson Hills, Pennsylvania, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|West Virginia University, Morgantown, West Virginia, United States|Concord Repatriation General Hospital, Sydney, New South Wales, Australia|Local Institution, Birtinya, Queensland, Australia|Monash Medical Centre Clayton, Clayton, Victoria, Australia|Cabrini Hospital, Malvern, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Brussels, Belgium|Local Institution, Edegem, Belgium|Local Institution, Liege, Belgium|Local Institution, Sint-Niklaas, Belgium|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Centro Internacional de Estudios Clinicos, Recoleta, Santiago DE Chile, Chile|Local Institution, Beijing, Beijing, China|Local Institution, Haerbin, Heilongjiang, China|Local Institution, Changchun, Jilin, China|Local Institution, Shenyang, Liaoning, China|Local Institution, Hanghzou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Kunming, China|Local Institution, Shanghai, China|Administradora Del Country S.A. - Clinica Del Country, Bogota, Colombia|Hospital Universitario San Ignacio, Bogota, Colombia|Local Institution, Caen, France|Local Institution, Creteil, France|Local Institution, La Tronche, France|Local Institution, Lille Cedex, France|Local Institution, Marseille Cedex 20, France|Local Institution, Paris, France|Local Institution, Saint Herblain, France|Local Institution, Strasbourg Cedex, France|Local Institution, Toulon Cedex, France|Local Institution, Toulouse Cedex 9, France|Local Institution, Coswig, Germany|Local Institution, Essen, Germany|Local Institution, Gottingen, Germany|Local Institution, Grosshansdorf, Germany|Local Institution, Hamburg, Germany|Local Institution, Heidelberg, Germany|Local Institution, Homburg an d. Saar, Germany|Local Institution, Immenhausen, Germany|Local Institution, Koeln, Germany|Local Institution, Moers, Germany|Sotiria General Hospital, Athens, Greece|Interbalkan European Medical Center, Thessaloniki, Greece|Centro Di Riferimento Oncologico, Aviano, Italy|Istituto Tumori Giovanni Paolo II, Bari, Italy|Aou Policlinico V. Emanuele Di Catania, Catania, Italy|Ospedale Policlinico San Martino, Genova, Italy|Aorn Dei Colli, Napoli, Italy|Ospedale S. Maria Delle Croci, Ravenna, Italy|Istituto Clinico Humanitas, Rozzano, Italy|Azienda Ospedaliera Universitaria Senese, Siena, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Fukuyama-shi, Hiroshima, Japan|Local Institution, Hiroshima-Shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Amagasaki-shi, Hyogo, Japan|Local Institution, Nishinomiya-shi, Hyogo, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Natori-shi, Miyagi, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Ube-shi, Yamaguchi, Japan|Local Institution, Osakasayama-city, Japan|Local Institution, Df, Distrito Federal, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Medica Sur, Mexico, Distrito Federal, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Centro Estatal de Cancerologia, Chihuahua, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Bytom, Poland|Local Institution, Krakow, Poland|Local Institution, Warszawa, Poland|Local Institution, Bucharest, Romania|Local Institution, Bucuresti, Romania|Local Institution, Craiova, Romania|Local Institution, Romania, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, St.petersburg, Russian Federation|Local Institution, Johannesburg, Gauteng, South Africa|Local Institution, Parktown, Johannesburg, Gauteng, South Africa|Local Institution, Pretoria, Gauteng, South Africa|Local Institution, Cape Town, Western CAPE, South Africa|Local Institution, Bern, Switzerland|Local Institution, Lausanne, Switzerland|Local Institution, Zurich, Switzerland|Local Institution, Diyarbak?r, Turkey|Local Institution, Istanbul, Turkey|Local Institution, Seyhan, Turkey|Local Institution, Truro, Cornwall, United Kingdom|Edinburgh Cancer Centre, Edinburgh, Midlothian, United Kingdom|Local Institution, Leicester, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Southampton, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02899299

Study 268:
  NCT Number:                   NCT03430791
  Title:                        Trial of Combination TTF(Optune), Nivolumab Plus/Minus Ipilimumab for Bevacizumab-naïve, Recurrent Glioblastoma
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Recurrent Glioblastoma
  Interventions:                Drug: Nivolumab 240 mg IV|Drug: Nivolumab 3 mg/kg|Drug: Ipilimumab 1 mg/kg|Device: NovoTTF200A (Optune)
  Outcome Measures:             Objective response rate according to modified iRANO criteria
  Sponsor/Collaborators:        Baptist Health South Florida|Bristol-Myers Squibb|NovoCure Ltd.
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   60
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    2017-ODI-002
  Start Date:                   November 5, 2018
  Primary Completion Date:      August 2020
  Completion Date:              August 2021
  First Posted:                 February 13, 2018
  Results First Posted:         null
  Last Update Posted:           November 15, 2018
  Locations:                    Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03430791

Study 269:
  NCT Number:                   NCT03227432
  Title:                        An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma
  Acronym:                      
  Status:                       Withdrawn
  Study Results:                No Results Available
  Conditions:                   Multiple Myeloma
  Interventions:                Drug: Dexamethasone|Drug: Pomalidomide|Drug: Elotuzumab|Drug: Nivolumab
  Outcome Measures:             Response Rate|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|The Rate of Clinical Benefit Response (CBR)|Time to Response|Duration of Response|Progression Free Survival|Overall Survival|Time to Treatment Failure
  Sponsor/Collaborators:        Dana-Farber Cancer Institute|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   0
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    16-645
  Start Date:                   December 2018
  Primary Completion Date:      December 31, 2021
  Completion Date:              December 31, 2024
  First Posted:                 July 24, 2017
  Results First Posted:         null
  Last Update Posted:           August 14, 2018
  Locations:                    Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03227432

Study 270:
  NCT Number:                   NCT03341936
  Title:                        Adjuvant Nivolumab and Lirilumab in Patients With Relapsed, Resectable Squamous Cell Carcinoma of the Head and Neck
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Squamous Cell Carcinoma of the Head and Neck
  Interventions:                Drug: Nivolumab|Drug: Lirilumab
  Outcome Measures:             Disease-free survival|Best overall Response Rate|Overall Survival Rate
  Sponsor/Collaborators:        Dana-Farber Cancer Institute|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   58
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    17-411
  Start Date:                   March 15, 2018
  Primary Completion Date:      June 30, 2021
  Completion Date:              June 30, 2025
  First Posted:                 November 14, 2017
  Results First Posted:         null
  Last Update Posted:           March 29, 2018
  Locations:                    Dana-Farber Cancer Institute, Boston, Massachusetts, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03341936

Study 271:
  NCT Number:                   NCT02460068
  Title:                        A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis
  Acronym:                      NIBIT-M2
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Brain Metastases
  Interventions:                Drug: Fotemustine|Drug: Fotemustine and Ipilimumab|Drug: Ipilimumab and nivolumab
  Outcome Measures:             Overall Survival (OS)|safety (adverse events)|m-WHO and immune-related Disease Control Rate (DCR) in and outside the brain|Immune-related Progression-free Survival (irPFS)|m-WHO Progression-free Survival (irPFS)|Objective Response Rate (ORR)|Immune-related Objective Response Rate (irORR)|Time to Response (TTR)|Immune-related Time to Response (irTTR)|Duration of Response (DoR)|Immune-related Duration of Response (irDoR)|Brain progression-free survival (Brain-PFS)
  Sponsor/Collaborators:        Italian Network for Tumor Biotherapy Foundation|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   168
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    NIBIT-M2
  Start Date:                   December 2012
  Primary Completion Date:      January 2018
  Completion Date:              January 2020
  First Posted:                 June 2, 2015
  Results First Posted:         null
  Last Update Posted:           June 2, 2015
  Locations:                    Medical Oncology, Cancer Institute "Giovanni Paolo II", Bari, Italy|Medical Oncology, Pope Giovanni XXIII Hospital, Bergamo, Italy|National Institute for Cancer Research, Genoa, Italy|Immunotherapy and Somatic Cell Therapy Unit, Scientific Institute of Romagna, Meldola, Italy|Surgical Oncology, National Cancer Institute, Milan, Italy|European Institute of Oncology, Milan, Italy|Medical Oncology and Innovative Therapy, National Cancer Institute, Naples, Italy|esophageal and melanoma oncology, Istituto Oncologico Veneto, Padua, Italy|Medical Oncology, National Cancer Institute "Regina Elena", Rome, Italy|Medical Oncology and Immunotherapy Unit, University Hospital of Siena, Siena, Italy|S C Dermatology, A.O.U. City of Health and Science of Turin, Turin, Italy
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02460068

Study 272:
  NCT Number:                   NCT01668784
  Title:                        Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                Has Results
  Conditions:                   Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma
  Interventions:                Biological: Nivolumab|Drug: Everolimus
  Outcome Measures:             Overall Survival (OS) at Primary Endpoint|Investigator-assessed Objective Response Rate (ORR) at Primary Endpoint|Investigator-assessed Duration of Objective Response at Primary Endpoint|Investigator-assessed Time to Objective Response at Primary Endpoint|Investigator-assessed Time of Progression-free Survival (PFS) at Primary Endpoint|Overall Survival (OS) by Programmed Death-Ligand 1 (PD-L1) Expression Level at Primary Endpoint|Number of Participants With Serious Adverse Events, Death, Discontinuation Due to Adverse Events at Primary Endpoint|Percentage of Participants With Disease-related Symptom Progression (DRSP) at Primary Endpoint|Number of Participants Meeting Marked Laboratory Abnormality Criteria in Specific Liver and Thyroid Tests at Primary Endpoint|Number of Participants With Abnormal Hematology and Serum Chemistry Laboratory Parameters by Worse CTC Grade - SI Units
  Sponsor/Collaborators:        Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   1068
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-025|2011‐005132‐26
  Start Date:                   September 27, 2012
  Primary Completion Date:      May 6, 2015
  Completion Date:              September 28, 2018
  First Posted:                 August 20, 2012
  Results First Posted:         April 29, 2016
  Last Update Posted:           January 24, 2018
  Locations:                    Highland Oncology Group, Fayetteville, Arkansas, United States|UCSD Moores Cancer Center, La Jolla, California, United States|University Of Southern California, Los Angeles, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Ucsf Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Stanford Cancer Institute, Stanford, California, United States|University Of Colorado, Aurora, Colorado, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Winship Cancer Institute., Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Loyola University Chicago, Maywood, Illinois, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|University Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University Of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|The Ohio State University, Columbus, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|St Francis Hospital, Greenville, South Carolina, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|CTRC at UTHSC San Antonio, San Antonio, Texas, United States|Virginia Cancer Institute, Richmond, Virginia, United States|University Of Washington, Seattle, Washington, United States|COIBA, Berazategui, Buenos Aires, Argentina|Local Institution, Capital Federal, Buenos Aires, Argentina|Centro Para La Atencion Integral Del Paciente Oncologico, San Miguel De Tucuman, Tucuman, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Local Institution, Westmead, New South Wales, Australia|Local Institution, Woodville South, South Australia, Australia|Local Institution, Box Hill, Victoria, Australia|Local Institution, Clayton, Victoria, Australia|Local Institution, Melbourne, Australia|Local Institution, Linz, Austria|Local Institution, Vienna, Austria|Local Institution, Wien, Austria|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Gent, Belgium|Local Institution, Leuven, Belgium|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|Centre D'Oncologie Dr-Leon-Richard, Moncton, New Brunswick, Canada|QEII Health Sciences Centre, Halfax, Nova Scotia, Canada|Lakeridge Health Oshawa-Durham Regional Cancer Centre, Oshawa, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Chum, Hopital Notre-Dame, Montreal, Quebec, Canada|Smbd Jewish General Hospital, Montreal, Quebec, Canada|Local Institution, Hradec Kralove, Czechia|Local Institution, Olomouc, Czechia|Local Institution, Prague 5, Czechia|Local Institution, Aarhus C, Denmark|Local Institution, Herlev, Denmark|Local Institution, Odense, Denmark|Local Institution, Helsinki, Finland|Local Institution, Bordeaux, France|Local Institution, Lyon Cedex, France|Local Institution, Marseille Cedex 9, France|Local Institution, Paris, France|Local Institution, Poitiers, France|Local Institution, Saint Herblain Cedex, France|Local Institution, Toulouse Cedex 9, France|Local Institution, Vandoeuvre Les Nancy, France|Local Institution, Villejuif Cedex, France|Local Institution, Aachen, Germany|Local Institution, Dresden, Germany|Local Institution, Erlangen, Germany|Local Institution, Essen, Germany|Local Institution, Hannover, Germany|Local Institution, Heidelberg, Germany|Local Institution, Munich, Germany|Local Institution, Tuebingen, Germany|Local Institution, Athens, Greece|Local Institution, Thessaloniki, Greece|Local Institution, Tallaght, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Haifa, Israel|Local Institution, Petah Tikva, Israel|Local Institution, Ramat-gan, Israel|Local Institution, Tel Aviv, Israel|Local Institution, Arezzo, Italy|Local Institution, Meldola (fc), Italy|Local Institution, Milano, Italy|Local Institution, Rimini, Italy|Local Institution, Roma, Italy|Local Institution, Roma, Italy|Local Institution, Rozzano, Italy|Local Institution, Siena, Italy|Local Institution, Terni, Italy|Local Institution, Akita-shi, Akita, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Higashi-ku, Fukuoka, Japan|Local Institution, Sapporo-shi, Hokai-do, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Morioka-shi, Iwate, Japan|Local Institution, Yokohama, Kangawa, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Osaka-sayama-shi, Osaka, Japan|Local Institution, Suita, Osaka, Japan|Local Institution, Hamamatsu-shi, Shizuoka, Japan|Local Institution, Tokushima-shi, Tokushima, Japan|Local Institution, Yamagata-shi, Yamagata, Japan|Local Institution, Kobe-city, Hyogo, Japan|Local Institution, Tokyo, Japan|Local Institution, Tokyo, Japan|Local Institution, Tokyo, Japan|Local Institution, Tokyo, Japan|Local Institution, Tokyo, Japan|Local Institution, Tokyo, Japan|Local Institution, Bergen, Norway|Local Institution, Lorenskog, Norway|Local Institution, Gdansk, Poland|Local Institution, Lodz, Poland|Local Institution, Poznan, Poland|Local Institution, Rybnik, Poland|Local Institution, Warszawa, Poland|Local Institution, Wroclaw, Poland|Local Institution, Bucharest, Romania|Local Institution, Craiova, Romania|Local Institution, Iasi, Romania|Local Institution, Timisoara, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, Hospitalet De Llobregat, Barcelona, Spain|Local Institution, Pamplona, Navarra, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Gothenberg, Sweden|Local Institution, Solna, Sweden|Local Institution, Cambridge, Cambridgeshire, United Kingdom|Local Institution, Swansea, Carmarthenshire, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01668784

Study 273:
  NCT Number:                   NCT02939300
  Title:                        Ipilimumab and Nivolumab in Leptomeningeal Metastases
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Leptomeningeal Carcinomatosis
  Interventions:                Drug: Nivolumab|Drug: Ipilimumab
  Outcome Measures:             Overall Survival Rate|Intracranial Response Rate|Extracranial Response Rate|Leptomeningeal Disease Response Rate|Time To The First Occurrence Of Extracranial Disease Progression, Or Death From Any Cause|Time To The First Occurrence Of Intracranial Disease Progression, Or Death From Any Cause|Toxicity by CTCAE Criteria
  Sponsor/Collaborators:        Massachusetts General Hospital|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   18
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    16-136
  Start Date:                   January 2017
  Primary Completion Date:      January 2020
  Completion Date:              January 2024
  First Posted:                 October 20, 2016
  Results First Posted:         null
  Last Update Posted:           September 18, 2018
  Locations:                    Massachusetts general Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02939300

Study 274:
  NCT Number:                   NCT01585194
  Title:                        Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Melanoma|Uveal Melanoma
  Interventions:                Drug: Nivolumab|Drug: Ipilimumab
  Outcome Measures:             Overall Response Rate|Progression-Free Survival
  Sponsor/Collaborators:        M.D. Anderson Cancer Center|Bristol-Myers Squibb|National Cancer Institute (NCI)
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   67
  Funded Bys:                   Other|Industry|NIH
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    2011-0919|NCI-2012-00665|1R21CA208609-01
  Start Date:                   November 29, 2012
  Primary Completion Date:      November 2019
  Completion Date:              November 2019
  First Posted:                 April 25, 2012
  Results First Posted:         null
  Last Update Posted:           November 5, 2018
  Locations:                    University of Texas MD Anderson Cancer Center, Houston, Texas, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01585194

Study 275:
  NCT Number:                   NCT03436862
  Title:                        Nivolumab as Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Hodgkin Lymphoma at Risk of Relapse or Progression
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Hodgkin Lymphoma
  Interventions:                Drug: Nivolumab
  Outcome Measures:             The incidence of treatment-emergent adverse events (AEs) and serious adverse events (SAEs) as a measure of safety|12 month progression-free survival (PFS)
  Sponsor/Collaborators:        SCRI Development Innovations, LLC|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   40
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    SCRI BMT 24
  Start Date:                   May 23, 2018
  Primary Completion Date:      September 2021
  Completion Date:              September 2023
  First Posted:                 February 19, 2018
  Results First Posted:         null
  Last Update Posted:           July 16, 2018
  Locations:                    Colorado Blood Cancer Institute, Denver, Colorado, United States|Tennessee Oncology, Nashville, Tennessee, United States|St. David's South Austin Medical Center, Austin, Texas, United States|Texas Transplant Institute, San Antonio, Texas, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03436862

Study 276:
  NCT Number:                   NCT03387761
  Title:                        Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy
  Acronym:                      NABUCCO
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Urothelial Carcinoma
  Interventions:                Drug: Ipilimumab|Drug: Nivolumab
  Outcome Measures:             Number of patients that have surgical resection <12 weeks after study start|Efficacy of immunotherapy, assessed by by the percentage of pathological complete response rate (pCR) at cystectomy|Differences in immune infiltrates in responders vs nonresponders|T-cell (dys)functionality as measured by comparing the transcriptome of tumor-specific T cells in intra-patient pre- and post therapy tissue|Explore whether radiomics-based predictive models can be established for immunotherapy responders vs non-responders
  Sponsor/Collaborators:        The Netherlands Cancer Institute|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   24
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    N17NAB
  Start Date:                   January 15, 2018
  Primary Completion Date:      June 1, 2020
  Completion Date:              December 1, 2020
  First Posted:                 January 2, 2018
  Results First Posted:         null
  Last Update Posted:           November 14, 2018
  Locations:                    Antoni van Leeuwenhoek ziekenhuis, Amsterdam, NH, Netherlands
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03387761

Study 277:
  NCT Number:                   NCT03267498
  Title:                        Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Nasopharyngeal Carcinoma
  Interventions:                Drug: Nivolumab|Drug: Cisplatin|Radiation: Radiation Therapy
  Outcome Measures:             Feasibility of treatment completion: Rate of completion of all adjuvant immunotherapy, in comparison to the rate of completion of a standard adjuvant cisplatin-based platform.|Overall response rate (ORR)|Number and frequency of Adverse Events (AEs)|Locoregional Control (LRC) Rate|Distant Metastasis (DM) Rate|Overall survival rate (OSR)|Rate of Epstein-Barr Virus (EBV) DNA clearance|Quality of life|Acute and late toxicity rates according to CTCAE version 5, including immune-related AEs
  Sponsor/Collaborators:        University of California, San Francisco|National University Cancer Institute, Singapore|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   40
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    162010|NCI-2017-02291
  Start Date:                   December 12, 2017
  Primary Completion Date:      October 15, 2019
  Completion Date:              October 15, 2020
  First Posted:                 August 30, 2017
  Results First Posted:         null
  Last Update Posted:           May 21, 2018
  Locations:                    Helen Diller Family Comprehensive Center, UCSF, San Francisco, California, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03267498

Study 278:
  NCT Number:                   NCT03316274
  Title:                        Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Kaposi Sarcoma|HIV/AIDS|Immunosuppression
  Interventions:                Drug: Intra-lesional injection of nivolumab
  Outcome Measures:             Safety and tolerability as assessed by Common Terminology Criteria for Adverse Events version 4 (CTCAE v. 4)|The changes in frequency of circulating activated T cells in the skin KS lesions as determined by immunohistochemistry and flow cytometry|The changes in number of circulating activated T cells in the skin KS lesions as determined by immunohistochemistry and flow cytometry|The changes in frequency of circulating activated T cells in the peripheral blood as determined by flow cytometry|The changes in number of circulating activated T cells in the peripheral blood as determined by flow cytometry|The changes in PD-1 expression as determined by immunohistochemistry in lesions|The changes in PD-L1 expression as determined by immunohistochemistry in lesions
  Sponsor/Collaborators:        University of California, San Francisco|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Early Phase 1
  Enrollment:                   12
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CC17872
  Start Date:                   April 15, 2018
  Primary Completion Date:      December 2018
  Completion Date:              June 2019
  First Posted:                 October 20, 2017
  Results First Posted:         null
  Last Update Posted:           May 2, 2018
  Locations:                    Zuckerberg San Francisco General Hospital, San Francisco, California, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03316274

Study 279:
  NCT Number:                   NCT03620123
  Title:                        A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck
  Acronym:                      OPTIM
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|Carcinoma, Squamous Cell of Head and Neck
  Interventions:                Drug: Nivolumab and Ipilimumab|Drug: Docetaxel
  Outcome Measures:             objective response rate in all randomized subjects|overall survival [OS]|Progression-free survival [PFS]|Best overall response [BOR]|Duration of Response [DOR]|Health related quality of life|Health related quality of life: EORTC QLQ-H&N35|Health related quality of life: EQ-5D-5L|Toxicity/Safety according to CTC-AE-criteria
  Sponsor/Collaborators:        AIO-Studien-gGmbH|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   280
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    AIO-KHT-0117|2017-003349-14|CA209-998
  Start Date:                   July 16, 2018
  Primary Completion Date:      July 2022
  Completion Date:              July 2023
  First Posted:                 August 8, 2018
  Results First Posted:         null
  Last Update Posted:           August 8, 2018
  Locations:                    Medical School Hannover (MHH) Dept. of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover, Germany
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03620123

Study 280:
  NCT Number:                   NCT02857426
  Title:                        A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)
  Acronym:                      CheckMate 647
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Lymphoma
  Interventions:                Drug: Nivolumab
  Outcome Measures:             Objective response rate (ORR)|Progression-free survival (PFS)|Duration of response (DOR)|Overall survival (OS)
  Sponsor/Collaborators:        Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   65
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-647|2016-000894-19
  Start Date:                   October 18, 2016
  Primary Completion Date:      June 9, 2019
  Completion Date:              December 6, 2019
  First Posted:                 August 5, 2016
  Results First Posted:         null
  Last Update Posted:           October 23, 2018
  Locations:                    University of Alabama at Birmingham, Birmingham, Alabama, United States|City Of Hope Medical Center, Duarte, California, United States|UCSF Medical Center, San Francisco, California, United States|Yale Cancer Center, New Haven, Connecticut, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|H. Lee Moffitt Cancer Center & Research Inst, Inc, Tampa, Florida, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Columbia University, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Hospital Of The University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University Of Pittsburgh Medical Center Cancer Center, Pittsburgh, Pennsylvania, United States|Baylor Research Institute, Dallas, Texas, United States|Swedish Medical Center, Seattle, Washington, United States|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Paulo, Brazil|BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|CHU de Quebec, Quebec, Canada|Local Institution, Praha 2, Czechia|Local Institution, Bordeaux, France|Local Institution, Caen, France|Local Institution, La Tronche, France|Local Institution, Lille Cedex, France|Local Institution, Nancy, France|Local Institution, Paris cedex 13, France|Centre Hospitalier Lyon Sud - UPCO, Pierre Benite, France|Local Institution, Rennes Cedex 9, France|Local Institution, St. Cloud, France|Local Institution, Tours Cedex 9, France|Local Institution, Heidelberg, Germany|Klinikum Stuttgart, Stuttgart, Germany|Local Institution, Hong Kong, Hong Kong|I. sz. Belgyogyaszati Klinika SE, Budapest, Hungary|Belgyogyaszati Onkologia OOI, Budapest, Hungary|II. sz. Belgyogyaszati Klinika DEKK, Debrecen, Hungary|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Petah Tikva, Israel|Local Institution, Tel Aviv, Israel|Irccs Ospedale S. Raffaele, Milano, Italy|Fondazione Policlinico Universitario A. Gemelli, Roma, Italy|Istituto Clinico Humanitas, Rozzano (milano), Italy|Local Institution, Nagoya, Aichi, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Hidaka-shi, Saitama, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Kotoku, Tokyo, Japan|Local Institution, Mitaka-shi, Tokyo, Japan|Local Institution, Yamagata, Japan|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Bellinzona, Switzerland
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02857426

Study 281:
  NCT Number:                   NCT02596035
  Title:                        An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma
  Acronym:                      CheckMate 374
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Renal Cell Carcinoma
  Interventions:                Drug: Nivolumab
  Outcome Measures:             Incidence of high grade (Grade 3-4 and Grade 5) IMAEs in subjects with advanced or metastatic renal cell carcinoma (RCC) who are treated with nivolumab monotherapy|Median time to onset of high grade (Grade 3-4) IMAEs|Median time to resolution of high grade (Grade 3-4) IMAEs|Percentage of subjects who receive immune modulating medication for the immune-mediated event|Percentage of subjects who receive hormonal replacement therapy for the immune-mediated event|Percentage of subjects who receive ≥ 40 mg prednisone equivalents for the immune-mediated event|Total duration of all immune modulating medications given for the immune-mediated event
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 4
  Enrollment:                   197
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other
  Other IDs:                    CA209-374|2015-003286-28
  Start Date:                   November 30, 2015
  Primary Completion Date:      May 1, 2018
  Completion Date:              December 1, 2021
  First Posted:                 November 4, 2015
  Results First Posted:         null
  Last Update Posted:           November 1, 2018
  Locations:                    Arizona Oncology Associates, Phoenix, Arizona, United States|St. Jude Hospital Yorba Linda, Fullerton, California, United States|Cancer Care Associates Medical Group, Inc., Los Angeles, California, United States|Comprehensive Blood And Cancer Center, Los Angeles, California, United States|Local Institution, Los Angeles, California, United States|Central Coast Med Oncology, Santa Maria, California, United States|University Of Colorado, Aurora, Colorado, United States|St. Mary's Hospital Regional Cancer Center, Grand Junction, Colorado, United States|Rocky Mountain Cancer Centers, Lakewood, Colorado, United States|Florida Cancer Specialists S., Fort Myers, Florida, United States|Baptist Health Medical Group Oncology, Miami, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Palm Beach Cancer Institute, West Palm Beach, Florida, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Ft. Wayne Med Onco-Hema Inc, Fort Wayne, Indiana, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Center For Cancer And Blood Disorders, Bethesda, Maryland, United States|HCA Midwest Division, Kansas City, Missouri, United States|Southeast Nebraska Hematology & Oncology Consultants, P.C., Lincoln, Nebraska, United States|Urology Cancer Center Laboratory, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Local Institution, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Broome Oncology, Johnson City, New York, United States|Weill Cornell Medical College, New York, New York, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Oklahoma Cancer Specialists and Research Institute, LLC, Tulsa, Oklahoma, United States|Northwest Cancer Specialists - East DBA Compass Oncology - East, Portland, Oregon, United States|Local Institution, Springfield, Oregon, United States|Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina, United States|Tennessee Oncology, PLLC, Chattanooga, Tennessee, United States|The West Clinic, Germantown, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Local Institution, Dallas, Texas, United States|Blue Ridge Cancer Care, DFW Airport, Texas, United States|Cancer Centers of South Texas, DFW Airport, Texas, United States|Nebraska Methodist Hospital, DFW Airport, Texas, United States|Sansum Santa Barbara Medical Foundation Clinic, DFW Airport, Texas, United States|Texas Cancer Center - Sherman, DFW Airport, Texas, United States|The Center For Cancer And Blood Disorders, Fort Worth, Texas, United States|Texas Oncology, P.A., Fort Worth, Texas, United States|Texas Oncology, Houston, Texas, United States|Texas Oncology, Paris, Texas, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|University Of Washington, Seattle, Washington, United States|Local Institution, Spokane, Washington, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02596035

Study 282:
  NCT Number:                   NCT03635983
  Title:                        A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Melanoma
  Interventions:                Biological: NKTR-214|Biological: Nivolumab
  Outcome Measures:             Overall response rate (ORR) by Blinded Independent Central Review (BICR)|Progression-free survival (PFS) by BICR|Overall survival (OS)|Clinical benefit rate (CBR)|Duration of response (DoR)|Duration of overall complete response (DoCR)|Time to response (TTR)|ORR by investigator and in biomarker population|PFS by investigator and in biomarker population|OS in biomarker population|Incidence of participants with non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) leading to discontinuation|Incidence of treatment-related AEs|Incidence of treatment-related SAEs|Incidence of laboratory abnormalities
  Sponsor/Collaborators:        Bristol-Myers Squibb|Nektar Therapeutics
  Gender:                       All
  Age:                          12 Years and older   (Child, Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   764
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA045-001|2018-001423-40|17-214-08
  Start Date:                   September 14, 2018
  Primary Completion Date:      August 15, 2023
  Completion Date:              March 15, 2025
  First Posted:                 August 17, 2018
  Results First Posted:         null
  Last Update Posted:           November 20, 2018
  Locations:                    Local Institution, La Jolla, California, United States|Local Institution, Los Angeles, California, United States|Local Institution, Palo Alto, California, United States|Local Institution, Aurora, Colorado, United States|Local Institution, New Haven, Connecticut, United States|Local Institution, Miami Beach, Florida, United States|Local Institution, Tampa, Florida, United States|Local Institution, Atlanta, Georgia, United States|Local Institution, Louisville, Kentucky, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Minneapolis, Minnesota, United States|Local Institution, Saint Louis, Missouri, United States|The Cancer Center At Hackensack University Medical Center, Hackensack, New Jersey, United States|Local Institution, Buffalo, New York, United States|Local Institution, New York, New York, United States|Local Institution, Cleveland, Ohio, United States|Local Institution, Cleveland, Ohio, United States|Portland Providence Medical Center, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|St. Luke's Hospital & Health Network, Easton, Pennsylvania, United States|Local Institution, Philadelphia, Pennsylvania, United States|Local Institution, Houston, Texas, United States|Local Institution, Fairfax, Virginia, United States|Local Institution, Autonoma, Buenos Aires, Argentina|Local Institution, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Local Institution, Caba, Argentina|Local Institution, Caba, Argentina|Local Institution, North Sydney, New South Wales, Australia|Local Institution, Cairns, Queensland, Australia|Local Institution, Greenslopes, Queensland, Australia|Local Institution, Woolloongabba, Queensland, Australia|Local Institution, Melbourne, Victoria, Australia|Local Institution, Melbourne, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Bruxelles, Belgium|Local Institution, Hasselt, Belgium|Local Institution, Leuven, Belgium|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Edmonton, Alberta, Canada|Local Institution, Abbotsford, British Columbia, Canada|Local Institution, St. John's, Newfoundland and Labrador, Canada|Local Institution, Hamilton, Ontario, Canada|Local Institution, Kitchener, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Quebec, Canada|Local Institution, Brno, Czechia|Local Institution, Hradec Kralove, Czechia|Local Institution, Praha 10, Czechia|Local Institution, Praha 2, Czechia|Local Institution, Wilton, Cork, Ireland|Local Institution, Dublin 7, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Beer Sheva, Israel|Local Institution, Jerusalem, Israel|Local Institution, Ramat-gan, Israel|Local Institution, Bari, Italy|Local Institution, Genova, Italy|Local Institution, Medola, Italy|Local Institution, Milan, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Siena, Italy|Local Institution, Amsterdam, Netherlands|Local Institution, Amsterdam, Netherlands|Local Institution, Leiden, Netherlands|Local Institution, Nijmegen, Netherlands|Local Institution, Christchurch, New Zealand|Local Institution, Wellington, New Zealand|Local Institution, Lublin, Poland|Local Institution, Warszawa, Poland|Local Institution, Wroclaw, Poland|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Cordoba, Spain|Local Institution, Jaen, Spain|Local Institution, Madrid, Spain|Local Institution, Santiago Compostela, Spain|Local Institution, Valencia, Spain|Local Institution, London, Greater London, United Kingdom|Local Institution, Edinburgh, Midlothian, United Kingdom|Local Institution, Belfast, United Kingdom|Local Institution, Cambridge, United Kingdom|Local Institution, Cottingham, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Southampton, United Kingdom|Local Institution, Sutton., United Kingdom|Local Institution, Tauton, United Kingdom|Local Institution, Wirral, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03635983

Study 283:
  NCT Number:                   NCT02320058
  Title:                        An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself
  Acronym:                      CheckMate204
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Melanoma
  Interventions:                Drug: Ipilimumab|Drug: Nivolumab
  Outcome Measures:             Intracranial Clinical Benefit Rate (CBR)|Extracranial Clinical Benefit Rate|Overall Survival (OS)|Number of adverse events (AEs)|Number of serious adverse events (SAEs)|Number AEs leading to death|Number of clinically significant abnormalities in general laboratory tests in combination with Ipilimumab and Nivolumab|Objective response rate (ORR)|Progression free survival (PFS)
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   119
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-204
  Start Date:                   January 5, 2015
  Primary Completion Date:      November 3, 2022
  Completion Date:              November 4, 2022
  First Posted:                 December 19, 2014
  Results First Posted:         null
  Last Update Posted:           May 22, 2018
  Locations:                    City of Hope, Duarte, California, United States|Angeles Clinic and Research Institute, Los Angeles, California, United States|UCLA Medical Hematology and Oncology, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|The California Pacific Medical Research Institute, San Francisco, California, United States|UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Washington Cancer Inst at MedStar Washington Hospital Ctr, Washington, District of Columbia, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Mount Sinai Medical Center, Aventura, Florida, United States|H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Loyola University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Weinberg Cancer Institute At Franklin Square, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Faber Cancer Institute, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|NYU Langone Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Case School of Medicineuniversity Hospitals of Cleveland, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|St Luke's Health Network, Easton, Pennsylvania, United States|Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute at The University of Utah, Salt Lake City, Utah, United States|Inova Melanoma and Skin Cancer Center, Fairfax, Virginia, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02320058

Study 284:
  NCT Number:                   NCT01927419
  Title:                        Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma
  Acronym:                      CheckMate 069
  Status:                       Active, not recruiting
  Study Results:                Has Results
  Conditions:                   Unresectable Melanoma|Metastatic Melanoma
  Interventions:                Drug: Nivolumab|Drug: Ipilimumab|Drug: Placebo
  Outcome Measures:             Percentage of Participants With Investigator-assessed Objective Response in the Randomized, BRAF Wild-type Population|Percentage of Participants With Investigator-assessed Objective Response in the Randomized Population|Investigator-assessed Progression-free Survival (PFS) in All Populations|Percentage of BRAF Mutation-positive Participants With Investigator-assessed Objective Response|Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Overall Quality of Life (QOL) Score
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   179
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  Other IDs:                    CA209-069|2013-002018-11
  Start Date:                   August 21, 2013
  Primary Completion Date:      July 24, 2014
  Completion Date:              February 6, 2019
  First Posted:                 August 22, 2013
  Results First Posted:         February 8, 2016
  Last Update Posted:           April 9, 2018
  Locations:                    San Francisco Oncology Associates, San Francisco, California, United States|Orlando Health Inc, Orlando, Florida, United States|University Of Louisville Medical Center, Inc., Dba, Louisville, Kentucky, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Comprehensive Cancer Centers Of Nevada, Las Vegas, Nevada, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|University Of New Mexico Cancer Center, Albuquerque, New Mexico, United States|NYU Clinical Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|The Christ Hospital, Cincinnati, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|St. Luke's Hospital, Easton, Pennsylvania, United States|GHS Cancer Institute, Greenville, South Carolina, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|University Of Wisconsin Paul P Carbone Comprehensive Ca Ctr, Madison, Wisconsin, United States|Local Institution, Toulouse, France|Local Institution, Villejuif, France
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01927419

Study 285:
  NCT Number:                   NCT01783938
  Title:                        Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                Has Results
  Conditions:                   Advanced or Metastatic Melanoma
  Interventions:                Biological: Nivolumab|Biological: Ipilimumab
  Outcome Measures:             Percentage of Participants With Treatment-related Grade 3-5 Adverse Events (AEs) During the Induction Periods|Investigator-assessed Response Rate at Week 25|Investigator-assessed Duration of Response (DOR)|Investigator-assessed Rate of Progression
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   177
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-064
  Start Date:                   April 17, 2013
  Primary Completion Date:      April 3, 2015
  Completion Date:              October 18, 2019
  First Posted:                 February 5, 2013
  Results First Posted:         April 11, 2016
  Last Update Posted:           August 2, 2018
  Locations:                    H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Indiana University Health Melvin And Bren Simon Cancer Center, Indianapolis, Indiana, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|University Of Virginia Health System, Charlottesville, Virginia, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01783938

Study 286:
  NCT Number:                   NCT02652455
  Title:                        Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Melanoma (Skin)|Skin Cancer
  Interventions:                Drug: Nivolumab|Procedure: Surgery to Remove Tumor for Growth of TIL|Drug: CD137|Drug: Cyclophosphamide|Drug: Fludarabine|Biological: TIL Infusion|Drug: Interleukin-2
  Outcome Measures:             Occurrence of Study Related Adverse Events
  Sponsor/Collaborators:        H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb|Prometheus Inc.|Iovance Biotherapeutics, Inc.
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Early Phase 1
  Enrollment:                   11
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    MCC-18377
  Start Date:                   March 2, 2016
  Primary Completion Date:      August 2019
  Completion Date:              August 2020
  First Posted:                 January 11, 2016
  Results First Posted:         null
  Last Update Posted:           August 2, 2018
  Locations:                    H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02652455

Study 287:
  NCT Number:                   NCT03068455
  Title:                        An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma
  Acronym:                      CheckMate 915
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Melanoma
  Interventions:                Biological: nivolumab|Biological: ipilimumab
  Outcome Measures:             Recurrence-free survival (RFS)|Overall Survival (OS)|PD-L1 expression
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          12 Years and older   (Child, Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   2000
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  Other IDs:                    CA209-915|2016-003729-41
  Start Date:                   April 7, 2017
  Primary Completion Date:      November 8, 2020
  Completion Date:              February 17, 2023
  First Posted:                 March 1, 2017
  Results First Posted:         null
  Last Update Posted:           October 9, 2018
  Locations:                    University of Arizona Cancer Center, Tucson, Arizona, United States|The Angeles Clinic & Research Institute, Los Angeles, California, United States|California Pacific Medical Center, San Francisco, California, United States|University Of Colorado, Aurora, Colorado, United States|Georgetown University Med Ctr, Washington, District of Columbia, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|UF Health Cancer Center at Orlando Health, Orlando, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|University Of Chicago, Chicago, Illinois, United States|Oncology Specialists, S.C., Park Ridge, Illinois, United States|Mass General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University Of Michigan Health System, Ann Arbor, Michigan, United States|Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|NYU Langone Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Carolinas Med Ctr, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Providence Cancer Center Oncology And Hematology Care, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|St. Luke's University Health Network, Bethlehem, Pennsylvania, United States|Local Institution, Nashville, Tennessee, United States|Texas Oncology Sammons Cancer Center, Dallas, Texas, United States|Md Anderson Can Cnt, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|University Of Virginia Health System, Charlottesville, Virginia, United States|Inova Melanoma and Skin Cancer Center, Fairfax, Virginia, United States|University Of Washington Cancer Care Alliance, Seattle, Washington, United States|Local Institution, North Sydney, New South Wales, Australia|Local Institution, Waratah, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Greenslopes, Queensland, Australia|Local Institution, Southport, Queensland, Australia|Local Institution, Woolloongabba, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Box Hill, Victoria, Australia|Local Institution, Melbourne, Victoria, Australia|Local Institution, Melbourne, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Subiaco, Western Australia, Australia|Local Institution, Graz, Austria|Local Institution, Wien, Austria|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Gent, Belgium|Local Institution, Liege, Belgium|Local Institution, Salvador, Bahia, Brazil|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Florianopolis, Santa Catarina, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Jose do Rio Preto, SAO Paulo, Brazil|Local Institution, Rio De Janeiro, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Edmonton, Alberta, Canada|Local Institution, Vancouver, British Columbia, Canada|Local Institution, Ottawa, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|CHU de Quebec - Universite Laval, Quebec, Canada|Klinika komplexni onkologicke pece, Brno, Czechia|Klinika onkologie a radioterapie, Hradec Kralove, Czechia|Dermatovenerologicka klinika 3. LF UK a FNKV, Praha 10, Czechia|Dermatovenerologicka klinika VFN a 1. LF UK, Praha 2, Czechia|Centre Hospitalier Universitaire Dijon Bocage, Dijon, France|Hopital Claude Huriez, LILLE Cedex, France|Hopital De La Timone, Marseille Cedex 5, France|Chu Nantes, Nantes, France|Hopital Saint Louis, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite Cedex, France|Institut Claudius Regaud, Toulouse Cedex 9, France|Institut Gustave Roussy, Villejuif, France|Local Institution, Berlin, Germany|Local Institution, Buxtehude, Germany|Local Institution, Essen, Germany|Local Institution, Gera, Germany|Local Institution, Hannover, Germany|Local Institution, Heidelberg, Germany|Local Institution, Luebeck, Germany|Local Institution, Muenchen, Germany|Local Institution, Tuebingen, Germany|Local Institution, Athens, Greece|Metropolitan Hospital, Athens, Greece|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Tel Hashomer, Israel|Local Institution, Bergamo, Italy|Ospedale Policlinico San Martino, Genova, Italy|IRCCS Istituto Nazionale Tumori Milano, Milano, Italy|Istituto Nazionale Tumori Fondazione Pascale, Napoli, Italy|Istituto Oncologico Veneto IOV, Padova, Italy|Azienda Ospedaliera Universitaria Senese, Siena, Italy|Local Institution, Tauranga, BAY OF Plenty, New Zealand|Local Institution, Christchurch, New Zealand|Local Institution, Dunedin, New Zealand|Klinika Nowotworow Ukladowych i Uogolnionych, Krakow, Poland|Klinika Nowotworow Tkanek Miekkich, Kosci i Czerniakow, Warszawa, Poland|Institute Of Oncology "Prof.Dr.Alexandru Trestioreanu" Bucha, Bucharest, Romania|Sf. Nectarie Oncology Center, Craiova, Romania|Local Institution, Krasnodar, Russian Federation|Local Institution, Krasnoyarsk, Russian Federation|Local Institution, Moscow, Russian Federation|Hospital Universitari Germans Trias I Pujol, Badalona-barcelona, Spain|H. Univ. Vall dHebron, Barcelona, Spain|Hospital Clinic I Provincial, Barcelona, Spain|Hospital Gral. Univ. Gregorio Maranon, Madrid, Spain|Hospital Regional Universitario De Malaga, Malaga, Spain|Hosp Univ Virgen Macarena, Sevilla, Spain|Hospital Universitario Y Politecnico La Fe, Valencia, Spain|Local Institution, Lausanne, Switzerland|Local Institution, Zurich, Switzerland|The Beatson West Of Scotland Cancer Centre, Glasgow, Dumfries & Galloway, United Kingdom|Local Institution, Oxford, Oxfordshire, United Kingdom|The Royal Marsden Hospital, London, United Kingdom|Christie Hospital Nhs Trust, Manchester, United Kingdom|Royal Marsden Hospital - Surrey, Sutton., United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03068455

Study 288:
  NCT Number:                   NCT02905266
  Title:                        A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Melanoma
  Interventions:                Biological: Nivolumab|Biological: Ipilimumab
  Outcome Measures:             Incidence of adverse events in anaphylactic reaction SMQ (Standardized Medical Dictionary for Regulatory Activities Queries)|Incidence of events within the hypersensitivity/infusion reaction select Adverse Events (AEs)category|Incidence of grade 3-5 AEs|Objective Response Rate (ORR)|Progression Free Survival (PFS)|Pharmacokinetics (PK) as measured using serum concentration-time data.
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   139
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-742|2016-001941-26
  Start Date:                   October 27, 2016
  Primary Completion Date:      October 23, 2017
  Completion Date:              November 17, 2020
  First Posted:                 September 19, 2016
  Results First Posted:         null
  Last Update Posted:           December 13, 2017
  Locations:                    Local Institution, North Sydney, New South Wales, Australia|Local Institution, Greenslopes, Queensland, Australia|Cabrini Hospital, Malvern, Victoria, Australia|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 5, France|Local Institution, Nantes Cedex 1, France|Local Institution, Paris Cedex 14, France|Local Institution, Paris, France|Local Institution, Tours, France|Istituto Nazionale Per La Ricerca Sul Cancro - Oncologia Med, Genova, Italy|Istituto Scientifico Romagnolo Per Lo Studio E Cura Tumori, Meldola (FC), Italy|Istituto Europeo Di Oncologia, Milan, Italy|Azienda Ospedaliera Citta della Salute e della Scienza, Torino, Italy|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02905266

Study 289:
  NCT Number:                   NCT02599402
  Title:                        Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma
  Acronym:                      CheckMate 401
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Melanoma
  Interventions:                Drug: Nivolumab|Drug: Ipilimumab
  Outcome Measures:             Rate and frequency for high-grade (CTCAE v4.0 Grade 3-5) treatment-related, select adverse events in study subjects|Incidence of all high-grade (Grades 3-5), select adverse events|Median time to onset (Grades 3-4) of select adverse events|Median time to resolution (Grades 3-4) of select adverse events|Resolution of an Adverse Event (AE)|Overall survival time from first dosing date to the date of death.|Safety will be measured by the incidence of all AEs, treatment-related AEs, serious AEs, deaths, laboratory abnormalities, and select AEs|Tolerability will be measured by the incidence of all AEs, treatment-related AEs, serious AEs, deaths, laboratory abnormalities, and select AEs|ORR|Investigator-assessed Progression free survival (PFS)
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   615
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-401|2015-001274-17
  Start Date:                   December 8, 2015
  Primary Completion Date:      December 19, 2021
  Completion Date:              December 20, 2021
  First Posted:                 November 6, 2015
  Results First Posted:         null
  Last Update Posted:           August 1, 2018
  Locations:                    Local Institution, Garran, Australian Capital Territory, Australia|Local Institution, Coffs Harbour, New South Wales, Australia|Local Institution, Gateshead, New South Wales, Australia|Local Institution, North Sydney, New South Wales, Australia|Local Institution, Tiwi, Northern Territory, Australia|Local Institution, Brisbane, Queensland, Australia|Local Institution, Cairns, Queensland, Australia|Local Institution, Greenslopes, Queensland, Australia|Local Institution, Southport, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Bedford Park, South Australia, Australia|Local Institution, Hobart, Tasmania, Australia|Local Institution, Box Hill, Victoria, Australia|Local Institution, Melbourne, Victoria, Australia|Local Institution, Melbourne, Victoria, Australia|Local Institution, Murdoch, Western Australia, Australia|Local Institution, Perth, Western Australia, Australia|Local Institution, Camperdown, Australia|Local Institution, Nedlands, Australia|Local Institution, Graz, Austria|Local Institution, Innsbruck, Austria|Local Institution, Salzburg, Austria|Local Institution, Vienna, Austria|Local Institution, Brussel, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Helsinki, Finland|Local Institution, Oulu, Finland|Local Institution, Tampere, Finland|Local Institution, Turku, Finland|Local Institution, Angers, France|Local Institution, Bordeaux, France|Local Institution, Boulogne Billancourt, France|Local Institution, Cedex, France|Local Institution, Clermont-Ferrand, France|Local Institution, Dijon, France|Local Institution, Le Mans, France|Local Institution, Lille, France|Local Institution, Marseille, France|Local Institution, Montpellier, France|Local Institution, Nantes, France|Local Institution, Nice, France|Local Institution, Paris, France|Local Institution, Pierre Benite Cedex, France|Local Institution, Rennes, France|Local Institution, Rouen, France|Local Institution, TOULOUSE Cedex 9, France|Local Institution, Vandoeuvre les Nancy, France|Local Institution, Villejuif, France|Local Institution, Berlin, Germany|Local Institution, Dresden, Germany|Local Institution, Erfurt, Germany|Local Institution, Erlangen, Germany|Local Institution, Frankfurt, Germany|Local Institution, Freiburg im Breisgau, Germany|Local Institution, Gottingen, Germany|Local Institution, Hannover, Germany|Local Institution, Leipzig, Germany|Local Institution, Ludwigshafen, Germany|Local Institution, Luebeck, Germany|Local Institution, Mainz, Germany|Local Institution, Mannheim, Germany|Local Institution, Regensburg, Germany|Local Institution, Schwerin, Germany|Local Institution, Stade, Germany|Local Institution, Cork, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Bari, Italy|Local Institution, Bergamo, Italy|Local Institution, Genova, Italy|Local Institution, Meldola, Italy|Local Institution, Milano, Italy|Local Institution, Milan, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Pisa, Italy|Local Institution, Roma, Italy|Local Institution, Roma, Italy|Local Institution, Siena, Italy|Local Institution, Terni, Italy|Local Institution, Torino, Italy|Local Institution, Oslo, Norway|Local Institution, Stavanger, Norway|Local Institution, Eskilstuna, Sweden|Local Institution, Gavle, Sweden|Local Institution, Karlskrona, Sweden|Local Institution, Karlstad, Sweden|Local Institution, Linkoping, Sweden|Local Institution, Solna, Sweden|Local Institution, Sundsvall, Sweden|Local Institution, Vaxjo, Sweden|Local Institution, Basel, Switzerland|Local Institution, Lausanne, Switzerland|Local Institution, Sheffield, Yorkshire, United Kingdom|Local Institution, Cambridge, United Kingdom|Local Institution, Cottingham, United Kingdom|Local Institution, Glasgow, United Kingdom|Local Institution, Headington, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Newcastle Upon Tyne, United Kingdom|Mount Vernon Cancer Centre, Northwood, United Kingdom|Local Institution, Nottingham, United Kingdom|Local Institution, Preston, United Kingdom|Local Institution, Southampton, United Kingdom|Local Institution, Sutton., United Kingdom|Local Institution, Swansea, United Kingdom|Local Institution, Truro, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02599402

Study 290:
  NCT Number:                   NCT02903381
  Title:                        A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma
  Acronym:                      
  Status:                       Suspended
  Study Results:                No Results Available
  Conditions:                   Smoldering Multiple Myeloma
  Interventions:                Drug: Nivolumab|Drug: Lenalidomide|Drug: Dexamethasone
  Outcome Measures:             2 Year Progression Free Rate|Objective Response Rate|Time to Progression Rate|Duration of Response Rate|Progression Free Survival (PFS) Rate|Overall Survival Rate|Progression Free Survival Rate-Without cyclophosphamide|Number of Participants with Adverse Events
  Sponsor/Collaborators:        Dana-Farber Cancer Institute|Bristol-Myers Squibb|Multiple Myeloma Research Consortium
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   41
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    16-242|CA209-607
  Start Date:                   October 2016
  Primary Completion Date:      June 2020
  Completion Date:              February 2024
  First Posted:                 September 16, 2016
  Results First Posted:         null
  Last Update Posted:           December 22, 2017
  Locations:                    Dana Farber Cancer Institute, Boston, Massachusetts, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02903381

Study 291:
  NCT Number:                   NCT02156804
  Title:                        A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Melanoma
  Interventions:                Drug: Nivolumab (BMS-936558)
  Outcome Measures:             Rate and frequency for high-grade (CTCAE v4.0 Grade 3 or higher) treatment-related, select adverse events in subjects with melanoma|Rate and frequency of AEs regardless of causality|Rate and frequency of treatment-related AEs|Rate and frequency of any AEs of special interest (AEOSI), such as pulmonary, gastrointestinal, cuteaneous, renal, hepatic, pancreatic, endocrine, infusion-related, or hypersensitivity|Incidence of all high-grade (Grade 3 and higher) select adverse events|Median time to onset (Grades 3-4) of select adverse events|Median time to resolution (Grades 3-4) of select adverse events|Time to overall survival (OS)|Investigator assessed objective response rate (ORR)
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   1215
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-172|2014-001286-28
  Start Date:                   October 7, 2014
  Primary Completion Date:      January 30, 2019
  Completion Date:              January 30, 2019
  First Posted:                 June 5, 2014
  Results First Posted:         null
  Last Update Posted:           July 13, 2018
  Locations:                    Local Institution, Graz, Austria|Local Institution, Innsbruck, Austria|Local Institution, Salzburg, Austria|Local Institution, St. Polten, Austria|Local Institution, Wien, Austria|Local Institution, Wien, Austria|Universitair Ziekenhuis Brussel, Brussels, Belgium|Institut Jules Bordet, Bruxelles, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|Local Institution, Edegem, Belgium|Local Institution, Gent, Belgium|Local Institution, Hasselt, Belgium|Az Groeninge, Kortrijk, Belgium|Local Institution, Leuven, Belgium|Chu De Liege, Liege, Belgium|Local Institution, Brno, Czechia|Local Institution, Hradec Kralove, Czechia|Local Institution, Praha 10, Czechia|Local Institution, Praha 2, Czechia|Local Institution, Helsinki, Finland|Local Institution, Jyvaskyla, Finland|Local Institution, Oulu, Finland|Local Institution, Tampere, Finland|Local Institution, Luebeck, Schleswig-holstein, Germany|Local Institution, Augsburg, Germany|Local Institution, Bochum, Germany|Local Institution, Buxtehude, Germany|Local Institution, Chemnitz, Germany|Local Institution, Dessau, Germany|Local Institution, Dresden, Germany|Local Institution, Erfurt, Germany|Local Institution, Erlangen, Germany|Local Institution, Essen, Germany|Local Institution, Frankfurt Am Main, Germany|Local Institution, Freiburg, Germany|Local Institution, Gera, Germany|Local Institution, Giessen, Germany|Local Institution, Goettingen, Germany|Local Institution, Hamburg, Germany|Local Institution, Hannover, Germany|Local Institution, Heidelberg, Germany|Local Institution, Heilbronn, Germany|Local Institution, Jena, Germany|Local Institution, Kassel, Germany|Local Institution, Kiel, Germany|Local Institution, Koln, Germany|Local Institution, Leipzig, Germany|Local Institution, Ludwigshafen, Germany|Local Institution, Magdeburg, Germany|Local Institution, Mainz, Germany|Local Institution, Marburg, Germany|Local Institution, Minden, Germany|Local Institution, Muenster, Germany|Local Institution, Munchen, Germany|Local Institution, Munich, Germany|Local Institution, Munster, Germany|Local Institution, Nuernberg, Germany|Local Institution, Quedlinburg, Germany|Local Institution, Recklinghausen, Germany|Local Institution, Regensburg, Germany|Local Institution, Schwerin, Germany|Local Institution, Traunstein, Germany|Local Institution, Tubingen, Germany|Local Institution, Wurzbug, Germany|Local Institution, Heraklion, Creta, Greece|Local Institution, Athens, Greece|Local Institution, Athens, Greece|Local Institution, Thessaloniki, Greece|Local Institution, Thessaloniki, Greece|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Debrecen, Hungary|Local Institution, Pecs, Hungary|Local Institution, Szegedi, Hungary|Local Institution, Szombathely, Hungary|Local Institution, Wilton, Cork, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Waterford, Ireland|Local Institution, Bari, Italy|Local Institution, Bergamo, Italy|Local Institution, Genova, Italy|Local Institution, Meldola (FC), Italy|Local Institution, Milano, Italy|Local Institution, Milano, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Palermo, Italy|Local Institution, Roma, Italy|Local Institution, Roma, Italy|Local Institution, Siena, Italy|Local Institution, Terni, Italy|Local Institution, Torino, Italy|Local Institution, Luxembourg, Luxembourg|Local Institution, Amsterdam, Netherlands|Local Institution, Amsterdam, Netherlands|Local Institution, Breda, Netherlands|Local Institution, Enschede, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Leeuwarden, Netherlands|Local Institution, Leiden, Netherlands|Local Institution, Maastrict, Netherlands|Local Institution, Nijmegen, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Sittard-Geleen, Netherlands|Local Institution, Utrecht, Netherlands|Local Institution, Veldhoven, Netherlands|Local Institution, Zwolle, Netherlands|Local Institution, Alesund, Norway|Local Institution, Bergen, Norway|Local Institution, Oslo, Norway|Local Institution, Bydgoszcz, Poland|Local Institution, Gdansk, Poland|Local Institution, Lodz, Poland|Local Institution, Warszawa, Poland|Local Institution, Coimbra, Portugal|Local Institution, Lisboa, Portugal|Local Institution, Porto, Portugal|Local Institution, Bucharest, Romania|Local Institution, Romania, Romania|Local Institution, Moscow, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Albacete, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Bilbao, Spain|Local Institution, Granada, Spain|Local Institution, Las Palmas de Gran Canaria, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Hospital De Madrid, Norte Sanchinarro, Madrid, Spain|Local Institution, Malaga, Spain|Local Institution, Oviedo, Spain|Local Institution, Palma de Mallorca, Spain|Local Institution, Salamanca, Spain|Local Institution, San Sebastian, Spain|Comp. H. U. De Santiago, Santiago de Compostela, Spain|Local Institution, Sevilla, Spain|Local Institution, Toledo, Spain|Local Institution, Valencia, Spain|Local Institution, Valencia, Spain|Local Institution, Lund, Sweden|Local Institution, Uppsala, Sweden|Local Institution, Aarau, Switzerland|Local Institution, Basel, Switzerland|Local Institution, Bellinzona, Switzerland|Local Institution, Bern, Switzerland|Local Institution, Chur, Switzerland|Local Institution, Zurich, Switzerland|Local Institution, Bristol, Avon, United Kingdom|Local Institution, Northwood, Middlesex, United Kingdom|Local Institution, Birmingham, United Kingdom|Local Institution, Cambridge, United Kingdom|Local Institution, Cottingham, United Kingdom|Local Institution, Essex, United Kingdom|Local Institution, Glasgow, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Newcastle Upon Tyne, United Kingdom|Local Institution, Oxford, United Kingdom|Local Institution, Southampton, United Kingdom|Local Institution, Surrey, United Kingdom|Local Institution, Swansea, United Kingdom|Local Institution, Truro, United Kingdom|Local Institution, Wirral, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02156804

Study 292:
  NCT Number:                   NCT03029780
  Title:                        An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma
  Acronym:                      CheckMate 800
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Renal Cell Carcinoma
  Interventions:                Biological: Opdivo|Biological: Yervoy
  Outcome Measures:             Incidence of adverse events (AEs) in anaphylactic reaction SMQ (Standardized Medical Dictionary for Regulatory Activities Queries)|Incidence of AEs in anaphylactic reaction SMQ (Standardized Medical Dictionary for Regulatory Activities Queries)|Incidence of grade 3-5 AEs|Nivolumab as measured using serum concentration- time data|Ipilimumab as measured using serum concentration- time data|Anti-nivolumab antibody|Anti-ipilimumab antibody|Maximum observed serum concentration (Cmax)|Objective Response Rate (ORR)|Progression Free Survival (PFS)
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   118
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-800
  Start Date:                   February 9, 2017
  Primary Completion Date:      November 27, 2017
  Completion Date:              February 21, 2021
  First Posted:                 January 24, 2017
  Results First Posted:         null
  Last Update Posted:           April 30, 2018
  Locations:                    Cancer Specialists of North FL, Jacksonville, Florida, United States|University Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Local Institution, Pittsburgh, Pennsylvania, United States|Local Institution, Waratah, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Herston, Queensland, Australia|Local Institution, Elizabeth Vale, South Australia, Australia|Local Institution, Malvern, Victoria, Australia|Fundacion Arturo Lopez Perez, Santiago, Metropolitana, Chile|Centro Internacional de Estudios Clinicos, Recoleta, Santiago DE Chile, Chile
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03029780

Study 293:
  NCT Number:                   NCT01844505
  Title:                        Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                Has Results
  Conditions:                   Unresectable or Metastatic Melanoma
  Interventions:                Biological: Nivolumab|Biological: Ipilimumab|Biological: Placebo for Nivolumab|Biological: Placebo for Ipilimumab
  Outcome Measures:             Progression Free Survival (PFS)|Overall Survival (OS)|Rate of Overall Survival|Rate of Progression-Free Survival|Objective Response Rate (ORR) Per Investigator Assessment|Progression-Free Survival Based on PD-L1 Expression Level|Overall Survival Based on PD-L1 Expression Level|Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Global Health Status|Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Social Functioning|Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Cognitive Functioning|Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Emotional Functioning|Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Role Functioning|Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Physical Functioning
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   1296
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  Other IDs:                    CA209-067|2012-005371-13
  Start Date:                   May 23, 2013
  Primary Completion Date:      August 1, 2016
  Completion Date:              March 31, 2019
  First Posted:                 May 1, 2013
  Results First Posted:         September 26, 2017
  Last Update Posted:           March 16, 2018
  Locations:                    Banner-MD Anderson Cancer Center, Gilbert, Arizona, United States|University Of Arizona Cancer Center, Tucson, Arizona, United States|UC San Diego Moores Cancer Ctr, La Jolla, California, United States|The Angeles Clinic And Research Institute., Los Angeles, California, United States|University Of California - Los Angeles, Los Angeles, California, United States|Comprehensive Cancer Center At Desert Regional Medical Ctr, Palm Springs, California, United States|Desert Hematology Oncology Medical Group, Rancho Mirage, California, United States|California Pacific Medical Center Research Institute, San Francisco, California, United States|Ucsf Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|University Of Colorado Cancer Center, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Medstar Washington Hospital Center, Washington, District of Columbia, United States|Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States|Orlando Health, Inc, Orlando, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Maine Center For Cancer Medicine, Scarborough, Maine, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Lutherville, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconness Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University Of Michigan Health System, Ann Arbor, Michigan, United States|Allina Health, Minneapolis, Minnesota, United States|University Of Mississippi Medical Center, Jackson, Mississippi, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Comprehensive Cancer Centers Of Nevada, Las Vegas, Nevada, United States|Atlantic Melanoma Center, Morristown, New Jersey, United States|University Of New Mexico Cancer Center, Albuquerque, New Mexico, United States|New York Oncology Hematology, Pc, Clifton Park, New York, United States|NYU Clinical Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Duke Cancer Institute, Durham, North Carolina, United States|University Hospitals, Cleveland, Ohio, United States|Providence Cancer Center Oncology and Hematology Care- Eastside, Portland, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|St. Luke's Cancer Center - Anderson Campus, Easton, Pennsylvania, United States|Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Greenville Health System, Greenville, South Carolina, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Texas Oncology, Dallas, Texas, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|University of Washington, Seattle, Washington, United States|Local Institution, Camperdown, New South Wales, Australia|Local Institution, Coffs Harbour, New South Wales, Australia|Local Institution, Gateshead, New South Wales, Australia|Local Institution, North Sydney, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Greenslopes, Queensland, Australia|Local Institution, Southport, Queensland, Australia|Local Institution, Woolloongabba, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Kurralta Park, South Australia, Australia|Local Institution, Box Hill, Victoria, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Melbourne, Australia|Local Institution, Salzburg, Austria|Local Institution, Wien, Austria|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Edegem, Belgium|Local Institution, Gent, Belgium|Local Institution, Leuven, Belgium|Cross Cancer Institute, Edmonton, Alberta, Canada|BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|London Regional Cancer Program, London, Ontario, Canada|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|CHUM, Montreal, Quebec, Canada|CHU de Quebec, Quebec, Canada|Local Institution, Brno, Czechia|Local Institution, Hradec Kralove, Czechia|Local Institution, Praha 2, Czechia|Local Institution, Praha 8, Czechia|Aarhus University Hospital, Aarhus C, Denmark|Herlev University Hospital, Herlev, Denmark|Odense University Hospital, Odense, Denmark|Local Institution, Helsinki, Finland|Local Institution, Tampere, Finland|Local Institution, Boulogne Billancourt, France|Local Institution, Marseille Cedex 5, France|Local Institution, Nantes Cedex, France|Local Institution, Paris Cedex 10, France|Local Institution, Pierre Benite, France|Local Institution, Rennes, France|Local Institution, Villejuif, France|Local Institution, Buxtehude, Germany|Local Institution, Erfurt, Germany|Local Institution, Erlangen, Germany|Local Institution, Essen, Germany|Local Institution, Hannover, Germany|Local Institution, Heidelberg, Germany|Local Institution, Kiel, Germany|Local Institution, Leipzig, Germany|Local Institution, Munich, Germany|Local Institution, Tubingen, Germany|Local Institution, Cork, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Jerusalem, Israel|Local Institution, Tel Hashomer, Israel|Local Institution, Bergamo, Italy|Local Institution, Genova, Italy|Local Institution, Meldola (FC), Italy|Local Institution, Milano, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Roma, Italy|Local Institution, Siena, Italy|Local Institution, Amsterdam, Netherlands|Local Institution, Leiden, Netherlands|Local Institution, Nijmegen, Netherlands|Local Institution, Auckland, New Zealand|Local Institution, Oslo, Norway|Local Institution, Bydgoszcz, Poland|Local Institution, Gdansk, Poland|Local Institution, Krakow, Poland|Local Institution, Lodz, Poland|Local Institution, Warsaw, Poland|Local Institution, Badalona-Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Malaga, Spain|Local Institution, Pamplona-Navarra, Spain|Local Institution, Gothenberg, Sweden|Local Institution, Stockholm, Sweden|Local Institution, Geneva, Switzerland|Local Institution, Lausanne, Switzerland|Local Institution, St. Gallen, Switzerland|Local Institution, Zürich, Switzerland|Local Institution, Cambridge, Cambridgeshire, United Kingdom|Local Institution, Swansea, Carmarthenshire, United Kingdom|Local Institution, Glasgow, Dumfries & Galloway, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Northwood, Middlesex, United Kingdom|Local Institution, Nottingham, Nottinghamshire, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01844505

Study 294:
  NCT Number:                   NCT02231749
  Title:                        Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                Has Results
  Conditions:                   Advanced Renal Cell Carcinoma|Metastatic Renal Cell Carcinoma
  Interventions:                Biological: Nivolumab|Biological: Ipilimumab|Drug: Sunitinib
  Outcome Measures:             Investigator-assessed Objective Response Rate(ORR) in Intermediate/Poor Risk Participants Per IRRC Using RECIST v1.1|Overall Survival (OS) in Intermediate/Poor-Risk Participants With Previously Untreated Metastatic Renal Cell Carcinoma (mRCC)|Progression-Free Survival (PFS) in Intermediate/Poor-Risk Participants With Previously Untreated Metastatic Renal Cell Carcinoma (mRCC)|Investigator-assessed Objective Response Rate(ORR) in Any Risk Participants Per IRRC Using RECIST v1.1|Overall Survival (OS) in Any Risk Participants With Previously Untreated Metastatic Renal Cell Carcinoma (mRCC)|Progression-Free Survival (PFS) in Any Risk Participants With Previously Untreated Metastatic Renal Cell Carcinoma (mRCC)
  Sponsor/Collaborators:        Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   1390
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-214|2014-001750-42
  Start Date:                   October 13, 2014
  Primary Completion Date:      June 26, 2017
  Completion Date:              September 30, 2019
  First Posted:                 September 4, 2014
  Results First Posted:         October 16, 2018
  Last Update Posted:           October 16, 2018
  Locations:                    City Of Hope, Duarte, California, United States|UCSD Moores Cancer Center, La Jolla, California, United States|Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Stanford Cancer Center, Stanford, California, United States|Smilow Cancer Hospital. At Yale New Haven, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute., Atlanta, Georgia, United States|Indiana University Health Melvin And Bren Simon Cancer Center, Indianapolis, Indiana, United States|University Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States|University Of Kansas Cancer Center, Fairway, Kansas, United States|Uof Md,Greenebaum Cancer Ctr., Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Beth Isr. Deacon. Med Cnt, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University Of Michigan Health System, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Cancer Institute Cancer Services, Pittsburgh, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|Erlanger Oncology & Hematology - Univ. of TN, Chattanooga, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Texas Oncology, P.A., Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|COIBA, Berazategui, Buenos Aires, Argentina|Local Institution, Capital Federal, Buenos Aires, Argentina|Hospital Italiano De Buenos Aires, Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina|Centro Medico San Roque, San Miguel de Tucuman, Tucuman, Argentina|Centro Para La Atencion Integral Del Paciente Oncologico, San Miguel De Tucuman, Tucuman, Argentina|Instituto Medico Especialazado Alexander Fleming, Caba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Local Institution, Kogarah, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Herston, Queensland, Australia|Local Institution, Southport, Queensland, Australia|Local Institution, Box Hill, Victoria, Australia|Local Institution, Clayton, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Elizabeth Vale, Australia|Local Institution, Murdoch, Australia|Local Institution, Linz, Austria|Local Institution, Vienna, Austria|Local Institution, Wels, Austria|Local Institution, Gent, Belgium|Local Institution, Leuven, Belgium|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Calgary, Alberta, Canada|Local Institution, Edmonton, Alberta, Canada|Local Institution, Vancouver, British Columbia, Canada|Local Institution, Moncton, New Brunswick, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Centro De Cancer, Pontificia Universidad Catolica, Santiago, Metropolitana, Chile|Fundacion Arturo Lopez Perez, Santiago, Metropolitana, Chile|Centro Internacional de Estudios Clinicos, Recoleta, Santiago DE Chile, Chile|Instituto Oncologico, Vina del Mar, Chile|Local Institution, Bogota, Colombia|Hospital Pablo Tobon Uribe, Medellin, Colombia|Instituto de Cancerologia SA, Medellin, Colombia|Local Institution, Brno, Czechia|Local Institution, Hradec Kralove, Czechia|Local Institution, Liberec, Czechia|Local Institution, Olomouc, Czechia|Aarhus University Hospital, Aarhus C, Denmark|Herlev University Hospital, Herlev, Denmark|Local Institution, Odense, Denmark|Helsinki University Hospital, Helsinki, Finland|Tampere University Hospital, Tampere, Finland|Local Institution, Besancon, France|Local Institution, Bordeaux, France|Local Institution, La Roche sur Yon, France|Local Institution, Marseille Cedex 9, France|Local Institution, Paris, France|Local Institution, Saint Herblain, France|Local Institution, Strasbourg, France|Local Institution, Toulouse Cedex 9, France|Local Institution, Villejuif, France|Local Institution, Aachen, Germany|Local Institution, Erlangen, Germany|Local Institution, Frankfurt, Germany|Local Institution, Hamburg, Germany|Local Institution, Hannover, Germany|Local Institution, Heidelberg, Germany|Local Institution, Homburg, Germany|Local Institution, Jena, Germany|Local Institution, Magdeburg, Germany|Local Institution, Muenchen, Germany|Local Institution, Muenster, Germany|Local Institution, Ulm, Germany|Local Institution, Budapest, Hungary|Local Institution, Debrecen, Hungary|Local Institution, Gyula, Hungary|Local Institution, Pecs, Hungary|Local Institution, Wilton, Cork, Ireland|Local Institution, Dublin 7, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Beer Jacob, Israel|Local Institution, Haifa, Israel|Local Institution, Kfar Saba, Israel|Local Institution, Petach Tikva, Israel|Local Institution, Ramat-gan, Israel|Ospedal S. Donato Usl 8, Arezzo, Italy|Ist.Scient. Romagnolo Per Lo Studio E Cura Tumori, Meldola (fc), Italy|Local Institution, Milano, Italy|Azienda Ospedaliera Di Rilievo Nazionale A. Cardarelli, Napoli, Italy|Istituto Oncologico Veneto IOV, Padova, Italy|Local Institution, Pavia, Italy|Local Institution, Roma, Italy|Local Institution, Akita-shi, Akita, Japan|Local Institution, Hirosaki-shi, Aomori, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Sapporo-shi, Hokai-do, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Tsukuba-shi, Ibaraki, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Hamamatsu-shi, Shizuoka, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Koto-ku, Tokyo, Japan|Local Institution, Shinjuku-Ku, Tokyo, Japan|Local Institution, Yamagata-shi, Yamagata, Japan|Local Institution, Tokyo, Japan|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Mexico D.f., Distrito Federal, Mexico|Local Institution, Monterrey, Nuevo LEON, Mexico|Local Institution, Santiago de Queretaro, Queretaro, Mexico|Local Institution, Oaxaca, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Nijmegen, Netherlands|Local Institution, Krakow, Poland|Local Institution, Olsztyn, Poland|Local Institution, Poznan, Poland|Local Institution, Wroclaw, Poland|Hospital De La Santa Creu I Sant Pau, Barcelona, Spain|H. Univ. Vall dHebron, Barcelona, Spain|Hospital Ramon Y Cajal, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hosp Univer 12 De Octubre, Madrid, Spain|Hospital General De Asturias, Oviedo, Spain|Hospital General Universitario Virgen Del Rocio, Sevilla, Spain|Karolinska University Hospital, Solna, Sweden|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, Ankara, Turkey|Local Institution, Antalya, Turkey|Local Institution, Istanbul, Turkey|Local Institution, London, Greater London, United Kingdom|Local Institution, Glasgow, Lanarkshire, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Northwood, United Kingdom|Local Institution, Swansea, United Kingdom
  Study Documents:              "Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02231749/SAP_000.pdf|"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02231749/Prot_001.pdf
  URL:                          https://ClinicalTrials.gov/show/NCT02231749

Study 295:
  NCT Number:                   NCT03138512
  Title:                        A Study Comparing the Combination of Nivolumab and Ipilimumab Versus Placebo in Participants With Localized Renal Cell Carcinoma
  Acronym:                      CheckMate 914
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Renal Cell Carcinoma
  Interventions:                Biological: Nivolumab|Biological: Ipilimumab|Drug: Placebo
  Outcome Measures:             Disease-free survival (DFS)|Overall Survival (OS)|Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   800
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  Other IDs:                    CA209-914|2016-004502-34
  Start Date:                   July 5, 2017
  Primary Completion Date:      September 5, 2022
  Completion Date:              July 7, 2023
  First Posted:                 May 3, 2017
  Results First Posted:         null
  Last Update Posted:           November 20, 2018
  Locations:                    Alabama Oncology, Birmingham, Alabama, United States|Highland Oncology Group, Fayetteville, Arkansas, United States|California Pacific Medical Center Research Institute, San Francisco, California, United States|Local Institution, New Haven, Connecticut, United States|University Cancer Blood Ctr, Athens, Georgia, United States|Local Institution, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Local Institution, Evansville, Indiana, United States|Washington University, Saint Louis, Missouri, United States|Meridan Health System-Jersey Shore Medical Center, Neptune, New Jersey, United States|Local Institution, Albany, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Ohio State University, Columbus, Ohio, United States|Providence Newburg Medical Center, Portland, Oregon, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Bon Secours-St Francis Hosp, Greenville, South Carolina, United States|Erlanger Oncology & Hematology - Univ. of TN, Chattanooga, Tennessee, United States|Inova Schar Cancer Institute, Fairfax, Virginia, United States|Local Institution, Seattle, Washington, United States|Local Institution, Ciudad Autonoma Beunos Aires, Buenos Aires, Argentina|Hospital Privado De Comunidad, Mar Del Plata, Buenos Aires, Argentina|Instituto Medico Rio Cuarto S.A., Rio Cuarto, Cordoba, Argentina|Hospital Italiano De Buenos Aires, Caba, Argentina|Local Institution, Caba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Clinica Privada Universitaria Reina Fabiola, Cordoba, Argentina|Centro Polivalente de Asistencia e Investigacion Clinica CER San Juan, San Juan, Argentina|Centro Medico San Roque, Tucuman, Argentina|Local Institution, Randwick, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|ICON Cancer Center, Chermside, Queensland, Australia|Local Institution, Malvern, Victoria, Australia|St John of God Murdoch Hospital, Perth, Western Australia, Australia|Lyell McEwin Hospital, Elizabeth Vale, Australia|Krankenhaus Der Barmherzigen Schwestern, Linz, Austria|Local Institution, Wien, Austria|Local Institution, Bruxelles, Belgium|Local Institution, Gent, Belgium|Local Institution, Hasselt, Belgium|Local Institution, Liege, Belgium|Local Institution, Brasilia, Distrito Federal, Brazil|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Vancouver, British Columbia, Canada|Local Institution, Saint John, New Brunswick, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Rimouski, Quebec, Canada|Local Institution, Oshawa, Canada|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Fuzhou, Fujian, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Wuhan, Hubei, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanchang, Jiangxi, China|Local Institution, Changchun, Jilin, China|Local Institution, Yantai, Shandong, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Tianjin, Tianjin, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Guangzhou, China|Local Institution, Hangzhou, China|Local Institution, Shanghai, China|Local Institution, Shanghai, China|Local Institution, Xi?an, China|Klinika onkologie a radioterapie, Hradec Kralove, Czechia|Onkologicka klinika, Olomouc, Czechia|Local Institution, Besancon, France|Local Institution, La Roche sur Yon, France|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 9, France|Local Institution, Strasbourg, France|Local Institution, Tours Cedex, France|Local Institution, Vandoeuvre Les Nancy, France|Local Institution, Villejuif, France|Universitaetsklinikum Aachen, Aachen, Germany|Universitaetsklinikum Essen, Essen, Germany|Asklepios Klinik Altona, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitaetsklinikum Jena, Jena, Germany|Klinikum Grosshadern, Munich, Germany|Klinikum Nuernberg Nord, Urologische Klinik, Nuernberg, Germany|Universitaetsklinikum Rostock, Rostock, Germany|Univ. Klinikum Wuerzburg, Wuerzburg, Germany|Local Institution, Arezzo, Italy|A.O. Istituti Ospitalieri Di Cremona, Cremona, Italy|Azienda Ospedaliera Di Rilievo Nazionale A. Cardarelli, Napoli, Italy|Azienda Ospedaliera Di Parma, Parma, Italy|Fondazione Policlinico Universitario A. Gemelli, Roma, Italy|Policlinico G. Rossi, Verona, Italy|Local Institution, Toyoake Shi, Aichi, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Hiroshima-Shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Morioka-shi, Iwate, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Nagasaki-shi, Nagasaki, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Osaka-sayama, Osaka, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Tokushima-shi, Tokushima, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Shinjuku-Ku, Tokyo, Japan|Local Institution, Yamagata-shi, Yamagata, Japan|Local Institution, Ube, Yamaguchi, Japan|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Tlalpan, Distrito Federal, Mexico|Local Institution, Zapopan, Jalisco, Mexico|Local Institution, Monterrey, Nuevo LEON, Mexico|Local Institution, Monterrey, Nuevo LEON, Mexico|Local Institution, Mazatlan, Sinaloa, Mexico|Local Institution, Chihuahua, Mexico|Local Institution, San Luis Potosi, Mexico|Local Institution, San Luis Potosi, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Zwolle, Netherlands|Local Institution, Biala Podlaska, Poland|Ambulatorium Chemioterapii, Bydgoszcz, Poland|Local Institution, Lublin, Poland|Local Institution, Warsaw, Poland|Oddzial Onkologii Klinicznej, Wroclaw, Poland|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Nizhniy Novgorod, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Hospital San Pedro De Alcantara, Caceres, Spain|H. Lucus Augusti, Lugo, Spain|Local Institution, Madrid, Spain|Hospital Parc Tauli, Sabadell, Spain|Hospital General Universitario Virgen Del Rocio, Sevilla, Spain|Local Institution, Sevilla, Spain|Local Institution, Glasgow, Dumfries & Galloway, United Kingdom|Local Institution, Swansea, Glamorgan, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Preston, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03138512

Study 296:
  NCT Number:                   NCT01621490
  Title:                        PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma
  Acronym:                      PD-1
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Advanced Melanoma|Metastatic Melanoma
  Interventions:                Biological: Nivolumab|Drug: Ipilimumab
  Outcome Measures:             Immunomodulatory effects of Nivolumab and Nivolumab in combination with Ipilimumab as measured by changes from baseline in activated and memory T cells, interferon, interferon inducible factors, and CD4 and CD8 T cell infiltration|Safety and tolerability of Nivolumab, Ipilimumab and Nivolumab in combination with Ipilimumab as measured by the incidence of adverse events (AEs), serious AEs, death, and changes in vital signs|Safety and tolerability of Nivolumab, Ipilimumab and Nivolumab in combination with Ipilimumab as measured by laboratory test abnormalities|Antitumor Activity of Nivolumab and Nivolumab in combination with Ipilimumab as measured by the objective response rate (ORR), duration of response, and progression free survival (PFS)|Immunogenicity of Nivolumab and Nivolumab in combination with Ipilimumab as measured by the frequency of baseline positive subjects and the frequency of ADA positive subjects|Association between Programmed cell death ligand 1 (PD-L1) and clinical efficacy will be measured by PDL1 expression levels clinical activity (ORR, PFS)
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   237
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science
  Other IDs:                    CA209-038|2012-001840-23
  Start Date:                   September 27, 2012
  Primary Completion Date:      September 12, 2017
  Completion Date:              December 2, 2018
  First Posted:                 June 18, 2012
  Results First Posted:         null
  Last Update Posted:           August 1, 2018
  Locations:                    Ucla, Los Angeles, California, United States|University Of Chicago, Chicago, Illinois, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Lutherville, Maryland, United States|Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Providence Portland Medical Center, Portland, Oregon, United States|Vanderbilt-Ingram Cancer Ctr, Nashville, Tennessee, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|University Of Virginia, Charlottesville, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Local Institution, Amsterdam, Netherlands|Local Institution, Pamplona, Spain
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01621490

Study 297:
  NCT Number:                   NCT02374242
  Title:                        Anti‐PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases
  Acronym:                      ABC
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Melanoma|Brain Metastases
  Interventions:                Drug: Nivolumab|Drug: Ipilimumab
  Outcome Measures:             Intracranial response rate|Extracranial response rate|Overall response rate|Progression free survival in intracranial disease|Progression free survival in extracranial disease|Overall progression free survival|Overall survival|Safety and tolerability of nivolumab and nivolumab + ipilimumab (verse events by type, frequency and severity using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.)|Patient rated quality of life|Clinical response using immune related response criteria (irRC)|Tissue and blood biomarkers of response and progression|FET‐PET response in the brain at 6 and 12 weeks on therapy (Proportion of patients with a lower standardised uptake value from baseline in intracranial metastases, following at least ONE dose of study treatment)
  Sponsor/Collaborators:        Melanoma Institute Australia|Australia and New Zealand Melanoma Trials Group|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   76
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209‐170|ACTRN12614001315606|ANZMTG 01.14
  Start Date:                   November 4, 2014
  Primary Completion Date:      September 4, 2017
  Completion Date:              December 2022
  First Posted:                 February 27, 2015
  Results First Posted:         null
  Last Update Posted:           April 11, 2018
  Locations:                    Melanoma Institute Australia, North Sydney, New South Wales, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02374242

Study 298:
  NCT Number:                   NCT02576509
  Title:                        An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Hepatocellular Carcinoma
  Interventions:                Drug: Nivolumab|Drug: Sorafenib
  Outcome Measures:             Overall Survival (OS)|Progression-Free Survival (PFS)|Programmed death (PD)-L1 expression|Overall Response Rate (ORR)
  Sponsor/Collaborators:        Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   726
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-459
  Start Date:                   November 25, 2015
  Primary Completion Date:      June 9, 2019
  Completion Date:              July 14, 2020
  First Posted:                 October 15, 2015
  Results First Posted:         null
  Last Update Posted:           November 6, 2018
  Locations:                    University Of Alabama At Birmingham, Birmingham, Alabama, United States|Ucla-Division Of Hematology/Oncology, Los Angeles, California, United States|Pacific Hematology Oncology Associates, San Francisco, California, United States|University Of California San Francisco, San Francisco, California, United States|University Of Chicago, Chicago, Illinois, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Icahn School Of Medicine At Mount Sinai, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|UT Southwestern Medical Center, Dallas, Texas, United States|The University Of Texas Health Science Center, San Antonio, Texas, United States|Scott & White Memorial Hospital And Clinic, Temple, Texas, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|University Of Wisconsin, Madison, Wisconsin, United States|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Monash Medical Centre Clayton, Clayton, Victoria, Australia|Austin Hospital, Heidelberg, Victoria, Australia|The Alfred Hospital, Prahran, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Universitaetsklinikum Graz, Graz, Austria|AKH Wien, Wien, Austria|Local Institution, Bruxelles, Belgium|Local Institution, Leuven, Belgium|Local Institution, Liege, Belgium|Tom Baker Cancer Centre, Calgary, Alberta, Canada|British Columbia Cancer Agency-Vancouver Ctr, Vancouver, British Columbia, Canada|CHU de Quebec - Universite Laval, Quebec, Canada|Local Institution, Hefei, Anhui, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Fuzhou, Fujian, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Nanning, Guangxi, China|Local Institution, Harbin, Heilongjiang, China|Local Institution, Changsha, Hunan, China|Local Institution, Changzhou, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Chang Chun, Jilin, China|Local Institution, Changchun, Jilin, China|Local Institution, Dalian, Liaoning, China|Local Institution, Xi'an, Shan3xi, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Tianjin, Tianjin, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Klinika komplexni onkologicke pece, Brno, Czechia|Klinika onkologie a radioterapie, Hradec Kralove, Czechia|Onkologicka klinika, Olomouc, Czechia|Local Institution, La Tronche, France|Local Institution, Lille Cedex, France|Local Institution, Lyon, France|Local Institution, Montpellier Cedex, France|Local Institution, Paris Cedex 13, France|Local Institution, Pessac, France|Local Institution, Rennes Cedex, France|Local Institution, Toulouse Cedex 9, France|Charite Campus Virchow Klinikum, Berlin, Germany|Kliniken Essen-Mitte/Huyssens-Stift, Essen, Germany|Klinikum Der Johann Wolfgang Goethe-Universitat, Frankfurt, Germany|Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universitaetsklinikum Leipzig, Leipzig, Germany|Johannes -Gutenberg Universitat, Mainz, Germany|Klinikum Grosshadern, Munich, Germany|Universitaetsklinikum Regensburg, Regensburg, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Germany|Local Institution, Hong Kong, Hong Kong|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Petah-tikva, Israel|Local Institution, Tel Aviv, Israel|Ospedale G.Rummo, Benevento, Italy|Azienda Ospedaliera Papa Giovanni Xxiii, Bergamo, Italy|Istituto Nazionale Per Lo Studio E La Cura, Milano, Italy|Local Institution, Orbassano, Italy|AOUS - Policlinico S.Maria Alle Scotte, Siena, Italy|Local Institution, Chiba City, Chiba, Japan|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Kurume-shi, Fukuoka, Japan|Local Institution, Ogaki-shi, Gifu, Japan|Local Institution, Hiroshima-Shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kanazawa-shi, Ishikawa, Japan|Local Institution, Kawasaki-shi, Kanagawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Osaka-Sayama-Shi, Osaka, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Saga-shi, Saga, Japan|Local Institution, Chiyoda-ku, Tokyo, Japan|Local Institution, Mitaka-shi, Tokyo, Japan|Local Institution, Musashino-shi, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Daegu, Korea, Republic of|Local Institution, Gyeonggi-do, Korea, Republic of|Local Institution, Hwasun-gun, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Uniwersyteckie Centrum Kliniczne Klinika Onkologii I Radiote, Gdansk, Poland|Klinika Gastroenterologii Onkologicznej, Warszawa, Poland|Oddzial Onkologii, Wroclaw, Poland|Local Institution, Moscow, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Alicante, Spain|Local Institution, Majadahonda - Madrid, Spain|Local Institution, Pamplona, Spain|Local Institution, Santiago Compostela, Spain|Local Institution, Goteborg, Sweden|Local Institution, Stockholm, Sweden|Universitaetsspital Basel, Basel, Switzerland|Inselspital Bern, Bern, Switzerland|Local Institution, Kaohsiung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Tainan, Taiwan|Local Institution, Tainan, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Glasgow, Lanarkshire, United Kingdom|Local Institution, Wirral, Merseyside, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02576509

Study 299:
  NCT Number:                   NCT01354431
  Title:                        BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                Has Results
  Conditions:                   Renal Cell Carcinoma
  Interventions:                Biological: nivolumab
  Outcome Measures:             Median Progression Free Survival (PFS) at Primary Endpoint - Randomized Population|Objective Response Rate (ORR) at Primary Endpoint- Randomized Population|Number of Participants With Best Overall Response at Primary Endpoint - Randomized Population|Median Overall Survival in Months at Interim Data Cut-off - Randomized Population|Median Progression Free Survival (PFS) in Months at Interim Data Cut-off - Randomized Population
  Sponsor/Collaborators:        Bristol-Myers Squibb|Ono Pharma USA Inc
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   198
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  Other IDs:                    CA209-010
  Start Date:                   May 17, 2011
  Primary Completion Date:      May 15, 2013
  Completion Date:              July 1, 2019
  First Posted:                 May 16, 2011
  Results First Posted:         October 20, 2015
  Last Update Posted:           September 25, 2018
  Locations:                    UCSD Moores Cancer Center, La Jolla, California, United States|Ucla, Los Angeles, California, United States|Samuel Oschin Comprehensive Cancer Inst., Los Angeles, California, United States|Stanford Cancer Center, Stanford, California, United States|University Of Colorado, Aurora, Colorado, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Northwestern University Feinberg School Of Medicine, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Indiana University Health Melvin And Bren Simon Cancer Center, Indianapolis, Indiana, United States|University Of Kansas Medical Center, Kansas City, Kansas, United States|University Of Maryland, Baltimore, Maryland, United States|The Bunting-Blaustein Cancer Research Building, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Ctr., Boston, Massachusetts, United States|University Of Michigan Medical Center, Ann Arbor, Michigan, United States|Wayne State University, Detroit, Michigan, United States|Masonic Cancer Ctr, University Of Minnesota, Minneapolis, Minnesota, United States|North Mississippi Hematology And Oncology Associates, Ltd, Tupelo, Mississippi, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|St. Luke'S Roosevelt Hospital Center, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Blumenthal Cancer Center, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Ctr, Nashville, Tennessee, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Wheaton Franciscan Health Care, Wauwatosa, Wisconsin, United States|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Centre D'Oncologie Dr-Leon-Richard, Moncton, New Brunswick, Canada|Local Institution, Halifax, Nova Scotia, Canada|London Regional Cancer Program, London, Ontario, Canada|Centre Hospitalier Universitaire De Montreal-Notre-Dame Hosp, Montreal, Quebec, Canada|Local Institution, Helsinki, Finland|Local Institution, Siena, Italy
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01354431

Study 300:
  NCT Number:                   NCT02017717
  Title:                        A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients
  Acronym:                      CheckMate 143
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Recurrent Glioblastoma
  Interventions:                Biological: Nivolumab|Biological: Bevacizumab|Biological: Ipilimumab
  Outcome Measures:             Cohorts 1,1b, 1c and 1d : Safety and tolerability based on drug related events leading to permanent discontinuation prior to completing 4 doses|Cohort 2: Overall Survival (OS)|Cohort 2: Overall Survival rate (OS)|Cohort 2: Progression Free Survival (PFS)|Cohort 2: Objective Response Rate(ORR)
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          Child, Adult, Older Adult
  Phases:                       Phase 3
  Enrollment:                   626
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-143|2013-003738-34
  Start Date:                   January 27, 2014
  Primary Completion Date:      January 10, 2017
  Completion Date:              October 26, 2018
  First Posted:                 December 23, 2013
  Results First Posted:         null
  Last Update Posted:           March 16, 2018
  Locations:                    University of Alabama at Birmingham, Birmingham, Alabama, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|UCLA Neuro-Oncology Program, Los Angeles, California, United States|The Regents of the University of California, San Francisco, San Francisco, California, United States|Anschutz Cancer Pavilion, Aurora, Colorado, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Johns Hopkins University School Of Medicine, Baltimore, Maryland, United States|Beth Israel Deaconess Med Ctr, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Preston Robert Tisch Brain Tumor Center at Duke University, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University Of Texas Md Anderson Cancer Ctr, Houston, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Swedish Neuroscience Institute, Seattle, Washington, United States|Local Institution, Liverpool, New South Wales, Australia|Local Institution, East Bentleigh, Victoria, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Aarhus University Hospital, Aarhus C, Denmark|Odense University Hospital, Odense C, Denmark|Local Institution, Bron cedex, France|Local Institution, Marseille Cedex 5, France|Local Institution, Paris cedex 13, France|Local Institution, Paris, France|Universitaetsklinikum Bonn, Bonn, Germany|Klinikum Der J. W. Goethe-Universitaet Frankfurt/Main, Frankfurt Am Main, Germany|Local Institution, Heidelberg, Germany|Universitaetsklinikum Muenster, Muenster, Germany|Local Institution, Bologna, Italy|Local Institution, Milano, Italy|Local Institution, Siena, Italy|Local Institution, Torino, Italy|Local Institution, Amsterdam, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Gdansk, Poland|Local Institution, Warszawa, Poland|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Pamplona, Spain|Centre hospitalier universitaire Vaudois (CHUV), Lausanne, Switzerland|UniversitaetsSpital Zurich, Zuerich, Switzerland|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Wirral, Merseyside, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02017717

Study 301:
  NCT Number:                   NCT02388906
  Title:                        Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238)
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Melanoma
  Interventions:                Drug: Ipilimumab|Drug: Nivolumab|Other: Placebo matching Ipilimumab|Other: Placebo matching Nivolumab
  Outcome Measures:             Recurrence -free-survival|Overall survival
  Sponsor/Collaborators:        Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd
  Gender:                       All
  Age:                          15 Years and older   (Child, Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   800
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  Other IDs:                    CA209-238|2014-002351-26
  Start Date:                   March 12, 2015
  Primary Completion Date:      November 29, 2018
  Completion Date:              November 26, 2019
  First Posted:                 March 17, 2015
  Results First Posted:         null
  Last Update Posted:           July 3, 2018
  Locations:                    University Of Arkansas For Medical Sciences, Little Rock, Arkansas, United States|UC San Diego Moores Cancer Ctr, La Jolla, California, United States|The Angeles Clinic & Research Institute, Los Angeles, California, United States|California Pacific Medical Center Research Institute, San Francisco, California, United States|Ucsf-Comprehensive Cancer Center, San Francisco, California, United States|University Of Colorado Cancer Center, Aurora, Colorado, United States|Medstar Washington Hospital Center, Washington, District of Columbia, United States|Baptist Cancer Institute, Jacksonville, Florida, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|Orlando Health, Inc, Orlando, Florida, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Winship Cancer Institute., Atlanta, Georgia, United States|University of Chicago, Chicago, Illinois, United States|Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University Of Michigan Health System, Ann Arbor, Michigan, United States|Allina Health, Fridley, Minnesota, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|The Cancer Center At Hackensack University Medical Center, Hackensack, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Nyu Clinical Cancer Institute, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Carolinas Healthcare System / Carolinas Medical Center, Charlotte, North Carolina, United States|Duke Cancer Center, Durham, North Carolina, United States|The Ohio State University, Columbus, Ohio, United States|Providence Cancer Center Oncology And Hematology Care, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|St. Luke's Cancer Center - Anderson Campus, Easton, Pennsylvania, United States|Medical University of South Carolina Hollings Cancer Center, Charleston, South Carolina, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Texas Oncology Sammons Cancer Center, Dallas, Texas, United States|University Of Virginia Health System, Charlottesville, Virginia, United States|University Of Washington Cancer Care Alliance, Seattle, Washington, United States|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, San Miguel de Tucuman, Tucuman, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Gateshead, New South Wales, Australia|Local Institution, North Sydney, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Greenslopes, Queensland, Australia|Local Institution, Southport, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Prahran, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Camperdown, Australia|Local Institution, Graz, Austria|Local Institution, Salzburg, Austria|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Gent, Belgium|Local Institution, Leuven, Belgium|Cross Cancer Institute, Edmonton, Alberta, Canada|BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Mcgill University Dept Of Oncology, Montreal, Quebec, Canada|CHU de Quebec - Universite Laval, Quebec, Canada|Local Institution, Hradec Kralove, Czechia|Local Institution, Ostrava-Poruba, Czechia|Local Institution, Praha 10, Czechia|Local Institution, Praha 2, Czechia|Local Institution, Helsinki, Finland|Local Institution, Tampere, Finland|Local Institution, Lille, France|Local Institution, Marseille Cedex 5, France|Local Institution, Nantes Cedex 1, France|Local Institution, Paris, France|Local Institution, Pierre Benite, France|Local Institution, Toulouse Cedex 9, France|Local Institution, Athens, Greece|Local Institution, Neo Faliro, Greece|Local Institution, Budapest, Hungary|Local Institution, Dublin 7, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Bergamo, Italy|Local Institution, Genova, Italy|Local Institution, Meldola (FC), Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Roma, Italy|Local Institution, Siena, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Tsukuba-shi, Ibaraki, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Matsumoto-shi, Nagano, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Chuo-shi, Yamanashi, Japan|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Amsterdam, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Nijmegen, Netherlands|Local Institution, Veldhoven, Netherlands|Local Institution, Bergen, Norway|Local Institution, Oslo, Norway|Local Institution, Gdansk, Poland|Local Institution, Krakow, Poland|Local Institution, Warszawa, Poland|Local Institution, Craiova, Romania|Local Institution, Romania, Romania|Local Institution, Johannesburg, Gauteng, South Africa|Local Institution, Pretoria, Gauteng, South Africa|Local Institution, Saxonwold, Johannesburg, Gauteng, South Africa|Local Institution, Cape Town, Western CAPE, South Africa|Local Institution, Cape Town, Western CAPE, South Africa|Hospital Clinic I Provincial, Barcelona, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hosp Univ Virgen Macarena, Sevilla, Spain|Hospital General Univ De Valencia, Valencia, Spain|Local Institution, Gothenberg, Sweden|Local Institution, Lund, Sweden|Local Institution, Zurich, Switzerland|Local Institution, Kaohsiung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, Bristol, Avon, United Kingdom|Local Institution, Swansea, Carmarthenshire, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Northwood, Middlesex, United Kingdom|Local Institution, Oxford, Oxfordshire, United Kingdom|Local Institution, Newcastle Upon Tyne, Tyne and Wear, United Kingdom|Local Institution, Leicester, United Kingdom|Local Institution, Surrey, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02388906

Study 302:
  NCT Number:                   NCT02714218
  Title:                        A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Melanoma
  Interventions:                Biological: Nivolumab 3 mg/kg IV|Biological: Ipilimumab 1 mg/kg IV|Biological: Nivolumab 1 mg/kg IV|Biological: Ipilimumab 3 mg/kg IV|Biological: Nivolumab 6 mg/kg IV
  Outcome Measures:             Incidence of drug-related Grade 3 - 5 Adverse Events (AEs)|Objective I Response Rate (ORR)|Overall survival (OS)|Mean changes from baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) global health status/quality of life (Qol) composite scale|Progression Free Survival (PFS) in all treated subjects
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   483
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  Other IDs:                    CA209-511
  Start Date:                   March 24, 2016
  Primary Completion Date:      April 20, 2017
  Completion Date:              April 15, 2022
  First Posted:                 March 21, 2016
  Results First Posted:         null
  Last Update Posted:           April 27, 2018
  Locations:                    University Of Colorado Cancer Center, Aurora, Colorado, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Allina Health, Fridley, Minnesota, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|University Of Virginia Health System, Charlottesville, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Local Institution, North Sydney, New South Wales, Australia|Local Institution, Waratah, New South Wales, Australia|Local Institution, Greenslopes, Queensland, Australia|Local Institution, Melbourne, Victoria, Australia|Cross Cancer Institute, Edmonton, Alberta, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|CHU de Quebec - Universite Laval, Quebec, Canada|Local Institution, Aarhus, Denmark|Local Institution, Herlev, Denmark|Local Institution, Odense, Denmark|Hopital Saint Andre, Bordeaux, France|Chru De Lille, Lille, France|Hopital De La Timone, Marseille Cedex 5, France|Hopital Hotel Dieu, Nantes Cedex, France|Hopital Saint Louis, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite, France|Institut Claudius Regaud, Toulouse Cedex 9, France|Institut Gustave Roussy, Villejuif, France|Universitaetsklinikum Essen, Essen, Germany|Universitaetsklinikum Heidelberg, Heidelberg, Germany|Ludwig-Maximilians-Universitaet, Muenchen, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Germany|Local Institution, Ramat Gan, Israel|Local Institution, Bergamo, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Siena, Italy|Local Institution, Taormina, Italy|Netherland Cancer Institute, Amsterdam, Netherlands|Local Institution, Amsterdam, Netherlands|University Medical Center Groningen (Umcg), Groningen, Netherlands|Uniwersyteckie Centrum Kliniczne Klinika Onkologii I Radiote, Gdansk, Poland|Klinika Nowotworow Ukladowych i Uogolnionych, Krakow, Poland|Klinika Nowotworow Tkanek Miekkich, Kosci i Czerniakow, Warszawa, Poland|Local Institution, Moscow, Russian Federation|Local Institution, Badalona-barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, San Sabastian Gipuzkoa, Spain|Local Institution, Valencia, Spain|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Oxford, Oxfordshire, United Kingdom|Local Institution, Guildford, Surrey, United Kingdom|Local Institution, London, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02714218

Study 303:
  NCT Number:                   NCT01721772
  Title:                        Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma
  Acronym:                      CheckMate 066
  Status:                       Active, not recruiting
  Study Results:                Has Results
  Conditions:                   Melanoma
  Interventions:                Biological: BMS-936558 (Nivolumab)|Biological: Placebo matching BMS-936558 (Nivolumab)|Drug: Dacarbazine|Drug: Placebo matching Dacarbazine
  Outcome Measures:             Overall Survival (OS)|Overall Survival (OS) Rate|Progression-free Survival (PFS)|Progression-free Survival (PFS) Rate|Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST)|Overall Survival by Programmed Cell Death Ligand 1 (PD-L1) Expression Level|Change From Baseline in Health-related Quality of Life (HRQoL) Scores
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   583
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  Other IDs:                    CA209-066|2012‐003718‐16
  Start Date:                   January 17, 2013
  Primary Completion Date:      June 24, 2014
  Completion Date:              February 23, 2019
  First Posted:                 November 6, 2012
  Results First Posted:         February 25, 2016
  Last Update Posted:           August 8, 2018
  Locations:                    Fundacion Cidea, Capital Federal, Buenos Aires, Argentina|Instituto Medico Especialazado Alexander Fleming, Buenos Aires, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Local Institution, Camperdown, New South Wales, Australia|Local Institution, Coffs Harbour, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Greenslopes, Queensland, Australia|Local Institution, Southport, Queensland, Australia|Local Institution, Woolloongabba, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Malvern, Victoria, Australia|Local Institution, North Sydney, Australia|Tom Baker Cancer Centre, Calgary, Alberta, Canada|BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|Qe Ii Health Science Centre, Halfax, Nova Scotia, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Mcgill University, Dept. Oncology, City, Quebec, Canada|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Vi?a Del Mar, Valparaiso, Chile|Local Institution, Santiago, Chile|Aarhus Universitetshospital, Aarhus, Denmark|Herlev Hospital, Herlev, Denmark|Odense University Hospital, Odense, Denmark|Helsinki University Hospital, Helsinki, Finland|Local Institution, Bordeaux, France|Local Institution, Grenoble, France|Local Institution, Lille, France|Local Institution, Montpellier, France|Local Institution, Paris, France|Local Institution, Villejuif, France|Local Institution, Wuerzburg, Bayern, Germany|Local Institution, Essen, Germany|Local Institution, Gera, Germany|Local Institution, Goettingen, Germany|Local Institution, Heidelberg, Germany|Local Institution, Kiel, Germany|Local Institution, Koeln, Germany|Local Institution, Magdeburg, Germany|Local Institution, Mainz, Germany|Local Institution, Nuernberg, Germany|Local Institution, Recklinghausen, Germany|Local Institution, Tubingen, Germany|Local Institution, Athens, Greece|Local Institution, Neo Faliro, Greece|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Tel Hashomer, Israel|Local Institution, Bari, Italy|Local Institution, Bergamo, Italy|Local Institution, Genova, Italy|Local Institution, Meldola (fc), Italy|Local Institution, Milano, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Roma, Italy|Local Institution, Siena, Italy|Local Institution, Tlalpan, Distrito Federal, Mexico|Local Institution, Leon, Guanajato, Guanajuato, Mexico|Local Institution, Morelia, Michoacan, Mexico|Local Institution, Mexico City, Mexico|Local Institution, Oslo, Norway|Local Institution, Gdansk, Poland|Local Institution, Lodz, Poland|Local Institution, Warszawa, Poland|Local Institution, San Sebastian, Guipuzcoa, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Local Institution, Gothenberg, Sweden|Local Institution, Lund, Sweden|Local Institution, Umea, Sweden
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01721772

Study 304:
  NCT Number:                   NCT02038946
  Title:                        Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                Has Results
  Conditions:                   Lymphoma
  Interventions:                Drug: Nivolumab
  Outcome Measures:             Overall Response Rate (ORR) as Determined by IRRC|Duration of Response (DOR) Based on IRRC Assessments|Complete Remission Rate (CRR) Based on IRRC Assessment|Partial Remission (PR) Rate Based on IRRC Assessment|Progression Free Survival (PFS) Based on IRRC Assessment|Overall Response Rate (ORR) Based on Investigator Assessments
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   116
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-140|2013-003645-42
  Start Date:                   March 6, 2014
  Primary Completion Date:      May 17, 2017
  Completion Date:              April 8, 2019
  First Posted:                 January 17, 2014
  Results First Posted:         June 12, 2018
  Last Update Posted:           November 14, 2018
  Locations:                    Mayo Clinic Arizona, Phoenix, Arizona, United States|Division Of Hematology & Oncology Ctr. For Health Sciences, Los Angeles, California, United States|Winship Cancer Institute., Atlanta, Georgia, United States|Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Weill Cornell Medical College, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Local Institution, Woodville, South Australia, Australia|Local Institution, Parkville, Victoria, Australia|Local Institution, B-leuven, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Gent, Belgium|Jewish General Hospital, Montreal, Quebec, Canada|CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski, Rimouski, Quebec, Canada|Local Institution, Creteil, France|Local Institution, Montpellier Cedex 05, France|Local Institution, Pierre Benite Cedex, France|Local Institution, Rennes, France|Universitaetsklinikum Essen, Essen, Germany|Universitaetsklinikum Des Saarlandes, Homburg, Germany|Local Institution, Regensburg, Germany|Universitaetsklinikum Ulm, Ulm, Germany|Local Institution, Bergamo, Italy|Local Institution, Bologna, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Roma, Italy|Local Institution, Oslo, Norway|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Hospital Duran I Reynals, Hospitalet Llobregat- Barcelona, Spain|Local Institution, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Local Institution, Salamanca, Spain|Local Institution, Gothenberg, Sweden|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Withington, Manchester, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom
  Study Documents:              "Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02038946/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02038946/SAP_001.pdf
  URL:                          https://ClinicalTrials.gov/show/NCT02038946

Study 305:
  NCT Number:                   NCT02038933
  Title:                        Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                Has Results
  Conditions:                   Lymphoma. Non-Hodgkin
  Interventions:                Drug: Nivolumab
  Outcome Measures:             Objective Response Rate (ORR) Per Independent Radiologic Review Committee (IRRC) Assessment|Duration of Response (DOR)|Complete Remission Rate|Duration of Complete Remission|Rate of Partial Remission|Duration of Partial Remission|Progression Free Survival|Objective Response Rate (ORR) Per Investigator Assessment
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   161
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-139|2013-003621-28
  Start Date:                   February 10, 2014
  Primary Completion Date:      April 8, 2016
  Completion Date:              April 1, 2019
  First Posted:                 January 17, 2014
  Results First Posted:         May 30, 2017
  Last Update Posted:           October 24, 2018
  Locations:                    Mayo Clinic Arizona, Phoenix, Arizona, United States|Division Of Hematology & Oncology Ctr. For Health Sciences, Los Angeles, California, United States|Winship Cancer Center, Atlanta, Georgia, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Columbia University Medical Center (Cumc), New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Local Institution, Waratah, New South Wales, Australia|Local Institution, Woodville, South Australia, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, B-leuven, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Gent, Belgium|Local Institution, Montreal, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Creteil, France|Local Institution, Montpellier Cedex 05, France|Local Institution, Pierre Benite Cedex, France|Local Institution, Rennes, France|Local Institution, Erlangen, Germany|Local Institution, Essen, Germany|Local Institution, Homburg, Germany|Local Institution, Ulm, Germany|Local Institution, Bergamo, Italy|Local Institution, Bologna, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Roma, Italy|Local Institution, Amsterdam, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Utrecht, Netherlands|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Hospitalet Llobregat- Barcelona, Spain|Local Institution, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Local Institution, Salamanca, Spain|Local Institution, Gothenberg, Sweden|Local Institution, Lund, Sweden|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Withington, Manchester, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02038933

Study 306:
  NCT Number:                   NCT01024231
  Title:                        Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Malignant Melanoma
  Interventions:                Drug: BMS-936558 (MDX1106-04)|Drug: Ipilimumab
  Outcome Measures:             Safety assessments will be based on adverse event reports and the results of clinical laboratory tests, immune safety tests, physical examinations, vital sign measurements, ECOG performance status, and ECG evaluations|Pharmacokinetic peak and trough concentration of each study drug when given in combination together or in a sequenced regimen|Blood samples to test immunogenicity|Tumor response evaluations
  Sponsor/Collaborators:        Bristol-Myers Squibb|Medarex|Ono Pharma USA Inc
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   136
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-004|(MDX1106-04)
  Start Date:                   December 14, 2009
  Primary Completion Date:      April 7, 2019
  Completion Date:              December 30, 2019
  First Posted:                 December 2, 2009
  Results First Posted:         null
  Last Update Posted:           December 13, 2017
  Locations:                    Yale University School Of Medicine, New Haven, Connecticut, United States|Medstar Georgetown-Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Hillman Cancer Research Pavilion, Pittsburgh, Pennsylvania, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01024231

Study 307:
  NCT Number:                   NCT03141177
  Title:                        A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
  Acronym:                      CheckMate 9ER
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Renal Cell Carcinoma
  Interventions:                Biological: Nivolumab|Drug: Cabozantinib|Drug: Sunitinib|Biological: Ipilimumab
  Outcome Measures:             Progression Free Survival (PFS) per blinded independent central review (BICR)|Overall Survival (OS)|Objective Response Rate (ORR)|Incidence of adverse events (AEs)|Incidence of Serious Adverse Events (SAEs)
  Sponsor/Collaborators:        Bristol-Myers Squibb|Exelixis|Ono Pharmaceutical Co. Ltd
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   630
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-9ER|2017-000759-20
  Start Date:                   July 11, 2017
  Primary Completion Date:      September 22, 2019
  Completion Date:              April 22, 2023
  First Posted:                 May 4, 2017
  Results First Posted:         null
  Last Update Posted:           November 20, 2018
  Locations:                    Southern Cancer Center, Inc., Daphne, Alabama, United States|Cancer Treatment Centers of America-Western, Goodyear, Arizona, United States|University of Arizona Cancer Center, Tucson, Arizona, United States|CBCC Global Research, Inc., Bakersfield, California, United States|Local Institution, Los Angeles, California, United States|UCLA Hematology Oncology, Los Angeles, California, United States|Cancer Care Associates Medical Group, Inc., Redondo Beach, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|Central Coast Med Oncology, Santa Maria, California, United States|University Of Colorado Cancer Center, Aurora, Colorado, United States|University Cancer Blood Ctr, Athens, Georgia, United States|Southeastern Regional Medical Center - CTCA, Newnan, Georgia, United States|Rush University Med Ctr, Chicago, Illinois, United States|Midwestern Regional Medical Center, Zion, Illinois, United States|Ft. Wayne Med Onco-Hema Inc, Fort Wayne, Indiana, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|University Of Michigan, Ann Arbor, Michigan, United States|HCA Midwest Division, Kansas City, Missouri, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Local Institution, Buffalo, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Local Institution, Cincinnati, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Texas Oncology, Austin, Texas, United States|Baylor Sammons Cancer Center, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Local Institution, Midland, Texas, United States|Local Institution, Plano, Texas, United States|Texas Cancer Center - Sherman, Sherman, Texas, United States|Local Institution, Salt Lake City, Utah, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Local Institution, Seattle, Washington, United States|Hospital Italiano De Buenos Aires, Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina|Local Institution, Córdoba, Cordoba, Argentina|Clinica Viedma S.A., Viedma, RIO Negro, Argentina|Centro Medico San Roque, San Miguel De Tucuman, Tucuman, Argentina|Centro De Diagnostico Urologico S.R.L., Buenos Aires, Argentina|Local Institution, Caba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Clinica Privada Universitaria Reina Fabiola, Cordoba, Argentina|The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia|Macquarie University, North Ryde, New South Wales, Australia|Local Institution, Sydney, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Local Institution, South Brisbane, Queensland, Australia|Tasman Oncology Research Pty Ltd, Southport, Queensland, Australia|Cabrini Hospital, Malvern, Victoria, Australia|Affinity Clinical Research Services Pty Ltd, Doubleview, Western Australia, Australia|Local Institution, Elizabeth Vale, Australia|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Rio De Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Centro Internacional de Estudios Clinicos, Recoleta, Santiago DE Chile, Chile|Klinika onkologie a radioterapie, Hradec Kralove, Czechia|Onkologicka klinika, Olomouc, Czechia|Local Institution, Bordeaux, France|Local Institution, Caen, France|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 9, France|Local Institution, Montpellier Cedex, France|Local Institution, Nantes, France|Local Institution, Paris, France|Local Institution, Strasbourg Cedex, France|Local Institution, Toulouse, France|Local Institution, Villejuif, France|Universitaetsklinikum Aachen, Aachen, Germany|Universitaetsklinikum Bonn, Bonn, Germany|Klinik Essen-Mitte, Essen, Germany|Universitaetsklinikum Jena, Jena, Germany|Klinikum Rechts Der Isar Der Tum, Muenchen, Germany|Klinikum Nuernberg Nord, Urologische Klinik, Nuernberg, Germany|Uniklinik Tuebingen, Tuebingen, Germany|Alexandra General Hospital, Athens, Greece|Local Institution, Thessaloniki, Greece|Local Institution, Haifa, Israel|Local Institution, Kfar Saba, Israel|Local Institution, Petah Tikva, Israel|Local Institution, Ramat Gan, Israel|Ospedale S. Donato - Usl 8, Arezzo, Italy|Ospedale San Raffaele, Milano, Italy|Azienda Ospedaliera Di Rilievo Nazionale A. Cardarelli, Napoli, Italy|I.O.V. Istituto Oncologico Veneto Ircss, Padova, Italy|IRCCS Istituti Clinici Scientifici Maugeri, Pavia, Italy|Local Institution, Pavia, Italy|Local Institution, Akita-shi, Akita, Japan|Local Institution, Hirosaki-shi, Aomori, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Sapporo, Hokkaido, Japan|Local Institution, Kobe, Hyogo, Japan|Local Institution, Morioka-shi, Iwate, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Yokohama, Kanagawa, Japan|Local Institution, Nagasaki-shi, Nagasaki, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Osakasayama-shi, Osaka, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Hidaka-shi, Saitama, Japan|Local Institution, Tokushima-shi, Tokushima, Japan|Local Institution, Arakawa-ku, Tokyo, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Minato-ku, Tokyo, Japan|Local Institution, Shinjuku-Ku, Tokyo, Japan|Local Institution, Yamagata-shi, Yamagata, Japan|Local Institution, Fukuoka, Japan|Comite Mexicano para la Prevenion de la Osteoporosis A.C., Ciudad de Mexico, Distrito Federal, Mexico|Instituto Nacional De Ciencias Medicas Y Nutricion S.Z., Mexico, Distrito Federal, Mexico|Local Institution, Tlalpan, Distrito Federal, Mexico|Investigacion Biomedica para el desarrollo de Farmacos, S.A. de C.V., Zapopan, Jalisco, Mexico|Local Institution, Monterrey, Nuevo LEON, Mexico|Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, Nuevo LEON, Mexico|Merida Investigacion Clincia, Merida, Yucatan, Mexico|Local Institution, Monterrey, NL, Mexico|Hospital Medica Tec 100, Queretaro, Mexico|WSS w Bialej Podlaskiej, Biala Podlaska, Poland|Ambulatorium Chemioterapii, Bydgoszcz, Poland|Wojewodzkie Centrum Onkologii, Gdansk, Poland|Prof. Dr. Ion Chiricuta Institute Of Oncology Day Care Depar, Cluj-napoca, Romania|Sf. Nectarie Oncology Center, Craiova, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Nizhniy Novgorod, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Local Institution, A Coru?a, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Santander, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Local Institution, Ankara, Turkey|Local Institution, Ankara, Turkey|Local Institution, Ankara, Turkey|Local Institution, Antalya, Turkey|Local Institution, Denizli, Turkey|Local Institution, Edirne, Turkey|Local Institution, Istanbul, Turkey|Local Institution, London, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Newcastle Upon Tyne, United Kingdom|Local Institution, Truro, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03141177

Study 308:
  NCT Number:                   NCT01472081
  Title:                        Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Renal Cell Carcinoma|Clear-cell Metastatic Renal Cell Carcinoma
  Interventions:                Biological: Nivolumab|Biological: Pazopanib|Drug: Sunitinib|Biological: Ipilimumab
  Outcome Measures:             Safety and tolerability of Nivolumab plus Sunitinib, Pazopanib, or Ipilimumab measured by incidence of Adverse event (AE)|Safety and tolerability of Nivolumab plus Sunitinib, Pazopanib, or Ipilimumab measured by incidence of Serious adverse event (SAE)|Safety and tolerability of Nivolumab plus Sunitinib, Pazopanib, or Ipilimumab measured by incidence of lab abnormality|Antitumor activity of Nivolumab plus Sunitinib, Pazopanib, or Ipilimumab measured by Objective Response Rate (ORR)|Antitumor activity of Nivolumab plus Sunitinib, Pazopanib, or Ipilimumab measured by duration of response according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1
  Sponsor/Collaborators:        Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   175
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-016
  Start Date:                   January 2012
  Primary Completion Date:      February 2016
  Completion Date:              June 2018
  First Posted:                 November 16, 2011
  Results First Posted:         null
  Last Update Posted:           April 19, 2017
  Locations:                    City Of Hope, Duarte, California, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Tennessee Oncology, Pllc, Nashville, Tennessee, United States|The University Of Texas Md Anderson Cancer Center, Houston, Texas, United States|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|Bc Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|Princess Margaret Hospital-Uhn, Toronto, Ontario, Canada
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01472081

Study 309:
  NCT Number:                   NCT03380130
  Title:                        A Study of the Safety and Antitumoral Efficacy of Nivolumab After SIRT for the Treatment of Patients With HCC
  Acronym:                      NASIR-HCC
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Hepatocellular Carcinoma
  Interventions:                Drug: Nivolumab|Device: SIR-Spheres
  Outcome Measures:             Rate and type of adverse events, liver decompensation, and transient and permanent drug discontinuations due to toxicity.|Response rate|Disease control rate|Duration of response|Time to progression|Progression-free survival|Overall survival|Pattern of progression according to RECIST 1.1 criteria.
  Sponsor/Collaborators:        Clinica Universidad de Navarra, Universidad de Navarra|Sirtex Medical|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   40
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    NASIR-HCC/CA209-992
  Start Date:                   September 11, 2017
  Primary Completion Date:      October 1, 2019
  Completion Date:              October 1, 2019
  First Posted:                 December 20, 2017
  Results First Posted:         null
  Last Update Posted:           April 13, 2018
  Locations:                    Hospital Universitario de Cruces, Baracaldo, Spain|Hospital Clinic, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Clinica Universidad de Navarra, Pamplona, Spain|Hospital Universitario Donostia, San Sebastián, Spain|Hospital Universitario Lozano Blesa, Zaragoza, Spain
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03380130

Study 310:
  NCT Number:                   NCT03355976
  Title:                        BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma|Extra Renal Origin|Clear Cell Adenocarcinoma
  Interventions:                Drug: Nivolumab|Drug: Ipilimumab
  Outcome Measures:             Proportion of patients who have objective tumor response (complete or partial) by modified RECIST 1.1 in patients with clear cell carcinomas treated with nivolumab or the combination of nivolumab and ipilimumab|Compare median PFS for patients treated with nivolumab (Arm 1) and the combination of nivolumab and ipilimumab (Arm 2)
  Sponsor/Collaborators:        Don Dizon|Bristol-Myers Squibb|Rhode Island Hospital|The Miriam Hospital|Brown University
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   62
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    BrUOG 354
  Start Date:                   April 30, 2018
  Primary Completion Date:      February 2020
  Completion Date:              February 2022
  First Posted:                 November 29, 2017
  Results First Posted:         null
  Last Update Posted:           July 26, 2018
  Locations:                    Rhode Island Hospital, Providence, Rhode Island, United States|The Miriam Hospital, Providence, Rhode Island, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03355976

Study 311:
  NCT Number:                   NCT03149120
  Title:                        Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas
  Acronym:                      
  Status:                       Withdrawn
  Study Results:                No Results Available
  Conditions:                   Soft Tissue Sarcomas
  Interventions:                Biological: Nivolumab|Drug: Pazopanib
  Outcome Measures:             Progression-free survival (PFS) at 6 months for nivolumab alone or nivolumab in combination with pazopanib|Measure of Tolerability|Overall Response Rate|Median Progression Free Overall Survival (OS)
  Sponsor/Collaborators:        New York University School of Medicine|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years to 100 Years   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   0
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    16-02078
  Start Date:                   August 2017
  Primary Completion Date:      August 17, 2017
  Completion Date:              June 2022
  First Posted:                 May 11, 2017
  Results First Posted:         null
  Last Update Posted:           August 22, 2017
  Locations:                    New York University School of Medicine, New York, New York, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03149120

Study 312:
  NCT Number:                   NCT02581631
  Title:                        An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas
  Acronym:                      CheckMate 436
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Non-Hodgkin's Disease
  Interventions:                Biological: Nivolumab|Drug: Brentuximab Vedotin
  Outcome Measures:             Safety of combination of nivolumab and brentuximab vedotin based on incidence of deaths, adverse events (AE), serious adverse events (SAE), AE leading to discontinuation, AE leading to dose delay, drug-related adverse events|Tolerability of combination of nivolumab and brentuximab vedotin based on incidence of deaths, AE, SAE, adverse events leading to discontinuation, adverse events leading to dose delay, drug-related adverse events|Overall Response Rate (ORR)|Overall duration of response (DOR)|Complete response rate (CRR)|Duration of complete response|Progression-Free Survival (PFS)|Overall Survival (OS)
  Sponsor/Collaborators:        Bristol-Myers Squibb|Seattle Genetics, Inc.
  Gender:                       All
  Age:                          15 Years and older   (Child, Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   146
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-436|2015-003286-28
  Start Date:                   December 18, 2015
  Primary Completion Date:      June 9, 2019
  Completion Date:              February 13, 2020
  First Posted:                 October 21, 2015
  Results First Posted:         null
  Last Update Posted:           September 25, 2018
  Locations:                    University of Alabama At Birmingham, Birmingham, Alabama, United States|University Of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute., Atlanta, Georgia, United States|University Of Chicago, Chicago, Illinois, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Local Institution, Hackensack, New Jersey, United States|Icahn School Of Medicine At Mount Sinai, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University Of Rochester, Rochester, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Providence Portland Medical Center, Portland, Oregon, United States|Bon Secours-St Francis Hosp, Greenville, South Carolina, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Local Institution, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite Cedex, France|Local Institution, Bergamo, Italy|Local Institution, Bologna, Italy|Local Institution, Rozzano (milano), Italy|Hospital Duran I Reynals, Hospitalet de Llobregat - Barcelona, Spain|Churchill Hospital, Oxford, Oxfordshire, United Kingdom|Royal Marsden Hospital, Sutton, Surrey, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02581631

Study 313:
  NCT Number:                   NCT03138499
  Title:                        A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,
  Acronym:                      CheckMate 812
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Hodgkin's Disease
  Interventions:                Biological: Nivolumab|Biological: Brentuximab vedotin
  Outcome Measures:             Progression Free Survival (PFS)|Complete Response Rate (CRR)|Objective Response Rate (ORR)|Duration of response (DOR)|Duration of complete response (DOCR)|Overall Survival (OS)
  Sponsor/Collaborators:        Bristol-Myers Squibb|Seattle Genetics, Inc.|Ono Pharmaceutical Co. Ltd
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   340
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-812|2017-000847-41
  Start Date:                   May 16, 2017
  Primary Completion Date:      November 29, 2020
  Completion Date:              July 27, 2023
  First Posted:                 May 3, 2017
  Results First Posted:         null
  Last Update Posted:           November 20, 2018
  Locations:                    Dr. Moh'd Khushman MD, Office of, Mobile, Alabama, United States|University Of Arkansas For Medical Sciences, Little Rock, Arkansas, United States|City of Hope National Medical Center, Duarte, California, United States|University of California San Diego (UCSD), La Jolla, California, United States|Pacific Shores Medical Group, Long Beach, California, United States|University of Califomia, Los Angeles, Los Angeles, California, United States|Local Institution, Palo Alto, California, United States|UC Davis Comprehensive Cancer Center, Sacramento, California, United States|Hartford Healthcare Cancer Institute at The Hospital of Central Connecticut, Plainville, Connecticut, United States|Georgetown University Hospital, Washington, District of Columbia, United States|Miami Cancer Institute, Baptist Health South Florida, Miami, Florida, United States|Orlando Health, Inc, Orlando, Florida, United States|H. Lee Moffit Cancer center and research institute, Tampa, Florida, United States|Parkview Cancer Center, Fort Wayne, Indiana, United States|University of Kansas Hospital, Westwood, Kansas, United States|Louisville Oncology, Louisville, Kentucky, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Dana Farber Cancer Institute (DFCI), Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Local Institution, Rochester, Minnesota, United States|Mercy Clinic Oncology and Hematology - Joplin, Joplin, Missouri, United States|Mercy Medical Research Institute, Springfield, Missouri, United States|Memorial Sloan-Kettering Cancer Center (MSKCC) - Basking Ridge, Basking Ridge, New Jersey, United States|John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center Monmouth, Middletown, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Local Institution, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Local Institution, Rochester, New York, United States|Memorial Sloan Kettering Cancer Center Rockville Centre, Rockville Centre, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|East Carolina University Brody School of Medicine(ECU), Greenville, North Carolina, United States|Local Institution, Raleigh, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Local Institution, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Bon Secours Saint Francis Cancer Center, Greenville, South Carolina, United States|Greenville Health System Cancer Institute, Spartanburg, South Carolina, United States|Center For Biomedical Research, Knoxville, Tennessee, United States|UT Medical Center Cancer Institute, Knoxville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Local Institution, San Antonio, Texas, United States|Local Institution, Charlottesville, Virginia, United States|Vista Oncology - East Olympia, Olympia, Washington, United States|Swedish Cancer Institute, Seattle, Washington, United States|Local Institution, Albury, New South Wales, Australia|Local Institution, Randwick, New South Wales, Australia|Local Institution, Brisbane, Queensland, Australia|Local Institution, Woolloongabba, Queensland, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Prague 2, Czechia|Local Institution, Debrecen, Hungary|Local Institution, Milano, Italy|Local Institution, Reggio Emilia, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Nagoya, Aichi, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Isehara, Kanagawa, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Osakasayaha, Osaka, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Koto-ku, Tokyo, Japan|Local Institution, San Juan, Puerto Rico|Local Institution, Ankara, Turkey|Local Institution, Samsun, Turkey
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03138499

Study 314:
  NCT Number:                   NCT02181738
  Title:                        Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)
  Acronym:                      CheckMate 205
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Hodgkin Disease
  Interventions:                Drug: Nivolumab|Drug: Doxorubicin|Drug: Vinblastine|Drug: Dacarbazine
  Outcome Measures:             Independent radiologic review committee (IRRC) assessed objective response rate (ORR)|proportion of subjects who experienced at least one treatment-related Grade 3 5 AEs (per NCI CTCAE version 4.0 criteria, any PT term) with an onset date after or on the first dose date and no later than 30 days after the last study dose date|Duration of response (DOR)|Complete remission (CR) rate|CR duration|Partial remission (PR) rate|PR duration|Investigator-assessed ORR|Investigator-assessed DOR|Treatment discontinuation rate, defined by the number of subjects who were treated with fewer than 12 doses|Treatment discontinuation rate of nivolumab monotherapy|Treatment discontinuation rate of the Nivolumab-AVD combination therapy|Treatment discontinuation rate of the combination therapy|Incidence of treatment related grade 3-5 AEs during the monotherapy phase|Incidence of treatment related grade 3-5 AEs during the combination phase
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   338
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-205|2014-001509-42
  Start Date:                   July 19, 2014
  Primary Completion Date:      August 31, 2017
  Completion Date:              October 1, 2020
  First Posted:                 July 4, 2014
  Results First Posted:         null
  Last Update Posted:           January 23, 2018
  Locations:                    Cedars Sinai Medical Center, Los Angeles, California, United States|Division Of Hematology & Oncology Ctr. For Health Sciences, Los Angeles, California, United States|Winship Cancer Center, Atlanta, Georgia, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|The Cancer Center At Hackensack University Medical Center, Hackensack, New Jersey, United States|Weill Cornell Med Coll/Ny Pres, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Md Anderson Can Cnt, Houston, Texas, United States|Universitaetsklinikum Innsbruck, Innsbruck, Austria|Department Fuer Haematologie, Wien, Austria|Local Institution, B-leuven, Belgium|Local Institution, Gent, Belgium|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Praha 2, Czechia|Local Institution, Berlin, Germany|Asklepios Klinik St. Georg, Hamburg, Germany|Universitaetsklinik Koeln, Koeln, Germany|University Hopistal ULM Dept of Internal Medizin, Ulm, Germany|Local Institution, Bologna, Italy|Local Institution, Napoli, Italy|Istituto Clinico Humanitas, Rozzano (milano), Italy|Local Institution, Amsterdam, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Utrecht, Netherlands|Hospital Costa Del Sol, Marbella, Malaga, Spain|Hospital Duran I Reynals, Hospitalet Llobregat- Barcelona, Spain|Hosp. Univ. Puerta De Hierro, Majadahonda - Madrid, Spain|Singleton Hospital, Swansea, Carmarthenshire, United Kingdom|The Christie NHS Foundation Trust, Withington, Manchester, United Kingdom|Churchill Hospital, Oxford, Oxfordshire, United Kingdom|The Royal Marsden Hospital, Sutton, Surrey, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02181738

Study 315:
  NCT Number:                   NCT02927769
  Title:                        A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
  Acronym:                      CheckMate 744
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Hodgkin Disease
  Interventions:                Biological: Nivolumab|Biological: brentuximab vedotin|Biological: bendamustine
  Outcome Measures:             Event Free Survival (EFS)|Complete Metabolic Response (CMR) rate prior to HDCT/ASCT|Complete Metabolic Response (CMR) rate at any time prior to radiation therapy|Overall Response Rate (ORR) after 4 cycles of nivolumab + brentuximab vedotin treatment|Progression Free Survival Rate (PFSR)|Duration of Response (DOR)|Incidence of serious and non-serious adverse events of nivolumab (BMS-936558) and brentuximab when given in combination.|Incidence of clinically significant abnormalities in general laboratory tests of nivolumab (BMS-936558) and brentuximab when given in combination.|Incidence of clinically significant vital sign measurements of nivolumab (BMS-936558) and brentuximab when given in combination.
  Sponsor/Collaborators:        Bristol-Myers Squibb|Seattle Genetics, Inc.
  Gender:                       All
  Age:                          5 Years to 30 Years   (Child, Adult)
  Phases:                       Phase 2
  Enrollment:                   80
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-744|2016-002347-41
  Start Date:                   March 27, 2017
  Primary Completion Date:      March 28, 2021
  Completion Date:              March 27, 2022
  First Posted:                 October 7, 2016
  Results First Posted:         null
  Last Update Posted:           November 20, 2018
  Locations:                    Children'S Hospital Of Alabama, Birmingham, Alabama, United States|Phoenix Children'S Hospital, Phoenix, Arizona, United States|Loma Linda University Cancer Center, Loma Linda, California, United States|Local Institution, Los Angeles, California, United States|Southern California Permanente Medical Group, Los Angeles, California, United States|Valley Children's Hospital, Madera, California, United States|Children'S Hospital & Research Center At Oakland, Oakland, California, United States|Local Institution, Orange, California, United States|Local Institution, Palo Alto, California, United States|Local Institution, San Francisco, California, United States|Childrens Hospital of Colorado, Aurora, Colorado, United States|Local Institution, Hartford, Connecticut, United States|Smilow Cancer Hospital At Yale New Haven Hospital, New Haven, Connecticut, United States|Nemours / A. I. duPont Hospital for Children, Wilmington, Delaware, United States|Children'S National Medical Center, Washington, District of Columbia, United States|Nemours Children'S Clinic, Jacksonville, Florida, United States|All Children'S Hospital, Saint Petersburg, Florida, United States|Children's Healthcare Of Atlanta, Atlanta, Georgia, United States|Local Institution, Chicago, Illinois, United States|Indiana University - Riley Children'S Hospital, Indianapolis, Indiana, United States|University Of Iowa, Iowa City, Iowa, United States|Local Institution, Louisville, Kentucky, United States|John Hopkins University, Baltimore, Maryland, United States|Dana Farber Cancer Institute., Boston, Massachusetts, United States|Local Institution, Ann Arbor, Michigan, United States|Local Institution, Detroit, Michigan, United States|Local Institution, Grand Rapids, Michigan, United States|Local Institution, Minneapolis, Minnesota, United States|University Of Mississippi Medical Center, Jackson, Mississippi, United States|Children'S Mercy Hospital And Clinics, Kansas City, Missouri, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Local Institution, New Hyde Park, New York, United States|Local Institution, New York, New York, United States|Local Institution, New York, New York, United States|Local Institution, Valhalla, New York, United States|UNC Lineberger Cancer Center, Chapel Hill, North Carolina, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Cincinnati Children'S Hospital Medical Center, Cincinnati, Ohio, United States|Nationwide Children'S Hospital, Columbus, Ohio, United States|Local Institution, Oklahoma City, Oklahoma, United States|Local Institution, Portland, Oregon, United States|Penn State Hershey Children'S Hospital, Hershey, Pennsylvania, United States|Childrens Hospital Of Philadelphia, Philadelphia, Pennsylvania, United States|Local Institution, Pittsburgh, Pennsylvania, United States|Vanderbilt University, Nashville, Tennessee, United States|Dell Children'S Medical Center Of Central Texas, Austin, Texas, United States|The University Of Texas, Dallas, Texas, United States|Local Institution, Fort Worth, Texas, United States|Baylor College Of Medicine, Houston, Texas, United States|Primary Children's Hospital, Salt Lake City, Utah, United States|Local Institution, Fairfax, Virginia, United States|Children'S Hosp-Kings Daughter, Norfolk, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Seattle Childrens Hospital, Seattle, Washington, United States|Children'S Hospital Of Wisconsin, Milwaukee, Wisconsin, United States|Local Institution, Calgary, Alberta, Canada|Local Institution, Toronto, Ontario, Canada|The Montreal Children's Hospital of the MUHC, Montreal, Quebec, Canada|Klinika detske hematologie a onkologie, Praha 5, Czechia|Local Institution, Lille cedex, France|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 5, France|Local Institution, Nantes, France|Local Institution, Paris Cedex 12, France|Hopital Robert Debre, Paris, France|Local Institution, Toulouse cedex 9, France|Local Institution, Vandoeuvre les Nancy, France|Local Institution, Villejuif Cedex, France|Campus Virchow Klinikum Der Charite, Berlin, Germany|Uniklinikum Giessen und Marburg, Giessen, Germany|Mhh Kinderklinik, Hannover, Germany|Dr. von Haunersches Kinderspital, Muenchen, Germany|Local Institution, Dublin, Ireland|Cro-Aviano, Aviano (PN), Italy|Policlinico S. Orsola Malpighi, Bologna, Italy|Irccs Istituto G. Gaslini, Genova, Italy|Fondazione Monza e Brianza per il Bambino e la sua Mamma MBBM, Monza (mb), Italy|Ao Santobono - Pausilipon, Napoli, Italy|AOU Policlinico Umberto I, Roma, Italy|Local Institution, Rotterdam, Netherlands|Local Institution, Utrecht, Netherlands|Local Institution, Gdansk, Poland|Local Institution, Krakow, Poland|Local Institution, Poznan, Poland|Local Institution, Warszawa, Poland|Local Institution, Esplugues de Llobregat, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Local Institution, London, Greater London, United Kingdom|Local Institution, Leeds, North Yorkshire, United Kingdom|Local Institution, Leeds, WEST Yorkshire, United Kingdom|Local Institution, Leeds, Yorkshire, United Kingdom|Local Institution, Birmingham, United Kingdom|Local Institution, Glasgow, United Kingdom|Local Institution, Glasgow, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Nottingham, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02927769

Study 316:
  NCT Number:                   NCT03370276
  Title:                        Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Squamous Cell Carcinoma of the Oropharynx|Squamous Cell Carcinoma of the Larynx|Squamous Cell Carcinoma of the Oral Cavity|Squamous Cell Carcinoma of the Hypopharynx|Squamous Cell Carcinoma of the Paranasal Sinus|Head and Neck Squamous Cell Carcinoma|Squamous Cell Cancer|Head and Neck Carcinoma
  Interventions:                Drug: Nivolumab|Drug: Cetuximab
  Outcome Measures:             Phase I: Recommended Phase 2 Dose (RP2D)|Phase II: Overall Survival (OS) Rate|Overall Response Rate (ORR)|Progression Free Survival (PFS)|Occurrence of Study Treatment Related Adverse Events
  Sponsor/Collaborators:        H. Lee Moffitt Cancer Center and Research Institute|James and Esther King Biomedical Research Program|Eli Lilly and Company|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   52
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    MCC-19178
  Start Date:                   December 6, 2017
  Primary Completion Date:      December 2021
  Completion Date:              December 2022
  First Posted:                 December 12, 2017
  Results First Posted:         null
  Last Update Posted:           September 12, 2018
  Locations:                    H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory University School of Medicine, Atlanta, Georgia, United States|The Ohio State University, Columbus, Ohio, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03370276

Study 317:
  NCT Number:                   NCT01358721
  Title:                        Phase I Biomarker Study (BMS-936558)
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Renal Cell Carcinoma
  Interventions:                Drug: BMS-936558 (Anti-PD-1)
  Outcome Measures:             Immunomodulatory activity as measured by the functional and phenotypic characterization of peripheral immune cells, modulation/changes in soluble factors, and the characterization of tumor immune infiltrates and the expression of tumor markers|Safety and tolerability of BMS-936558 as measured by the incidence and severity of adverse events|Progression free survival in the BMS-936558 arms|The tumor response rate in the BMS-936558 arms as assessed by the Investigator assessment of best overall response|Overall response rate for BMS-936558 as assessed by the number of subjects which demonstrate an objective response divided by the total number of treated subjects with measurable disease at baseline|Disease control rate for BMS-936558 as measured by the number of subjects with an objective response + the number of subjects with stable disease divided by the total number of treated subjects with measurable disease at baseline|Duration of objective response for BMS-936558 as measured by the time when the criteria for an objective response are first met until the date of documented disease progression or death|Duration of stable disease for BMS-936558 as measured in subjects whose best overall response is stable disease as the time from baseline until the date of documented disease progression or death|Immunogenicity of BMS-936558 as measured by the detection of human antibodies against BMS-936558
  Sponsor/Collaborators:        Bristol-Myers Squibb|Ono Pharma USA Inc
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   119
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science
  Other IDs:                    CA209-009|2011-005379-18
  Start Date:                   August 11, 2011
  Primary Completion Date:      December 1, 2014
  Completion Date:              November 16, 2018
  First Posted:                 May 24, 2011
  Results First Posted:         null
  Last Update Posted:           January 23, 2018
  Locations:                    Ucsf Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|University Of Chicago Medical Center, Chicago, Illinois, United States|The Bunting-Blaustein Cancer Research Building, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Dana Farber Cancer Inst, Boston, Massachusetts, United States|Duke University Medical Center, Durham, North Carolina, United States|Providence Portland Med Ctr, Portland, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Upmc Cancer Pavilion, Pittsburgh, Pennsylvania, United States|University Of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States|Local Institution, Villejuif Cedex, France|Local Institution, Pamplona, Spain
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01358721

Study 318:
  NCT Number:                   NCT03177239
  Title:                        Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)
  Acronym:                      UNISoN
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Renal Cell Carcinoma|Papillary Renal Cell Carcinoma Type 1|Papillary Renal Cell Carcinoma Type 2|Chromophobe Renal Cell Carcinoma|Sarcomatoid Renal Cell Carcinoma|Xp11 Translocation Carcinoma
  Interventions:                Drug: Nivolumab|Drug: Ipilimumab
  Outcome Measures:             The objective tumour response rate, as assessed by RECIST1.1|Duration of objective tumour response, as assessed by RECIST1.1|Progression-free survival (PFS), as assessed by RECIST1.1|Immune-related tumour response rate, as assessed by irRECIST.|Immune-related disease control rate (irDCR6), as assessed by irRECIST.|The number of patients alive at the end of the study, as assessed by date of death.|The number of patients with adverse events, particularly immune-related adverse events, that are related to study drug, as assessed and graded according to CTCAE v4.03.|The number of participants with permanent discontinuation of treatment or delays due to toxicity, as assessed and graded according to CTCAE v4.03.
  Sponsor/Collaborators:        Australian and New Zealand Urogenital and Prostate Cancer Trials Group|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   85
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    ANZUP 1602
  Start Date:                   October 19, 2017
  Primary Completion Date:      December 2021
  Completion Date:              December 2022
  First Posted:                 June 6, 2017
  Results First Posted:         null
  Last Update Posted:           June 29, 2018
  Locations:                    Border Medical Oncology, Albury, New South Wales, Australia|Campbelltown Hospital, Campbelltown, New South Wales, Australia|Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia|St Vincents Hospital, Darlinghurst, New South Wales, Australia|Northern Cancer Institute, French Forest, New South Wales, Australia|St. George Hospital, Kogarah, New South Wales, Australia|Calvary Mater Newcastle, Newcastle, New South Wales, Australia|Port Macquarie Base Hospital, Port Macquarie, New South Wales, Australia|Prince of Wales Hospital, Randwick, New South Wales, Australia|Tamworth Hospital - North West Cancer Centre, Tamworth, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Royal Brisbane & Women's Hospital, Brisbane, Queensland, Australia|Flinders Medical Centre, Adelaide, South Australia, Australia|Ashford Cancer Centre, Adelaide, South Australia, Australia|Ballarat Oncology & Haematology Services, Ballarat, Victoria, Australia|Box Hill Hospital - Eastern Health, Box Hill, Victoria, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03177239

Study 319:
  NCT Number:                   NCT01721746
  Title:                        A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                Has Results
  Conditions:                   Unresectable or Metastatic Melanoma
  Interventions:                Biological: BMS-936558|Drug: Dacarbazine|Drug: Carboplatin|Drug: Paclitaxel
  Outcome Measures:             Objective Response Rate (ORR)|Median Overall Survival (OS) at Primary Endpoint|Median Months of Progression-free Survival (PFS) Per Independent Radiology Review Committee (IRC/IRRC)|Objective Response Rate (ORR) by Baseline PD-L1 Expression|Median Overall Survival (OS) Time in Months by Baseline PD-L1 Expression|Mean Change From Baseline in Health-related Quality of Life (HRQoL) Global Health Status Scores
  Sponsor/Collaborators:        Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   631
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-037|2012-001828-35
  Start Date:                   December 13, 2012
  Primary Completion Date:      February 16, 2016
  Completion Date:              March 6, 2019
  First Posted:                 November 6, 2012
  Results First Posted:         March 22, 2017
  Last Update Posted:           September 26, 2017
  Locations:                    Mayo Clinic, Scottsdale, Arizona, United States|UCSD Moores Cancer Center, La Jolla, California, United States|The Angeles Clinic & Research Institute, Los Angeles, California, United States|University Of California - Los Angeles, Los Angeles, California, United States|San Francisco Oncology Associates, San Francisco, California, United States|Ucsf Comprehensive Cancer Center, San Francisco, California, United States|University Of Colorado, Aurora, Colorado, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|Orlando Health, Inc, Orlando, Florida, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University Of Michigan Health System, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Allina Health, Minneapolis, Minnesota, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|NYU Clinical Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals, Cleveland, Ohio, United States|Providence Oncology And Hematology, Portland, Oregon, United States|Network Office of Research and Innovation, Allentown, Pennsylvania, United States|St. Luke'S Health System, Easton, Pennsylvania, United States|Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Local Institution, Innsbruck, Austria|Local Institution, Wien, Austria|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Edegem, Belgium|Local Institution, Leuven, Belgium|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Cross Cancer Institute, Edmonton, Alberta, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Chum-Hopital Notre-Dame, Montreal, Quebec, Canada|Sir Mortimer B Davis - Jewish General Hospital, Montreal, Quebec, Canada|Aarhus Universitetshospital, Aarhus, Denmark|Herlev Hospital, Herlev, Denmark|Odense University Hospital, Odense, Denmark|Local Institution, Clermont Ferrand, France|Local Institution, Lille Cedex, France|Local Institution, Marseille, France|Local Institution, Nantes Cedex 1, France|Local Institution, Nice, France|Local Institution, Paris, France|Local Institution, Pierre Benite, France|Local Institution, Villejuif, France|Local Institution, Wuerzburg, Bayern, Germany|Local Institution, Buxtehude, Germany|Local Institution, Dresden, Germany|Local Institution, Essen, Germany|Local Institution, Frankfurt am Main, Germany|Local Institution, Hannover, Germany|Local Institution, Heidelberg, Germany|Local Institution, Kiel, Germany|Local Institution, Luebeck, Germany|Local Institution, Magdeburg, Germany|Local Institution, Munich, Germany|Local Institution, Tubingen, Germany|Local Institution, Jerusalem, Israel|Local Institution, Ramat Gan, Israel|Local Institution, Bari, Italy|Local Institution, Bergamo, Italy|Local Institution, Genova, Italy|Local Institution, Milano, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Roma, Italy|Local Institution, Siena, Italy|Local Institution, Amsterdam, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Maastricht, Netherlands|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Pamplona, Spain|Local Institution, Valencia, Spain|Local Institution, Lausanne, Switzerland|Local Institution, Zurich, Switzerland|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Oxford, Oxfordshire, United Kingdom|Local Institution, London, Surrey, United Kingdom|Local Institution, Newcastle Upon Tyne, Tyne and Wear, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01721746

Study 320:
  NCT Number:                   NCT03496662
  Title:                        BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Pancreatic Ductal Adenocarcinoma
  Interventions:                Drug: BMS-813160|Drug: Nivolumab|Drug: Gemcitabine|Drug: Nab-paclitaxel|Procedure: Biopsy|Procedure: Peripheral blood
  Outcome Measures:             (Part A only) Safety of the combination of BMS-813160 plus nivolumab plus gemcitabine plus nab-paclitaxel as measured by frequency, type, and severity of adverse events|(Part B only) Objective response rate|(Part B only) Percentage of patients who disease becomes resectable after treatment|(Part B only) Progression-free survival (PFS)|(Part B only) Overall survival (OS)
  Sponsor/Collaborators:        Washington University School of Medicine|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   53
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    201806007
  Start Date:                   August 31, 2018
  Primary Completion Date:      January 31, 2026
  Completion Date:              January 31, 2026
  First Posted:                 April 12, 2018
  Results First Posted:         null
  Last Update Posted:           September 13, 2018
  Locations:                    Washington University School of Medicine, Saint Louis, Missouri, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03496662

Study 321:
  NCT Number:                   NCT03333746
  Title:                        Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma
  Interventions:                Other: Laboratory Biomarker Analysis|Drug: Lenalidomide|Biological: Nivolumab|Other: Pharmacological Study
  Outcome Measures:             ORR (Overall Response Rate)|Overall survival (OS)|Progression free survival (PFS)|Time to progression (TTP)
  Sponsor/Collaborators:        Yvonne Efebera|National Cancer Institute (NCI)|American Cancer Society, Inc.|Bristol-Myers Squibb|Ohio State University Comprehensive Cancer Center
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   18
  Funded Bys:                   Other|NIH|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    OSU-17160|NCI-2017-01653|P30CA016058
  Start Date:                   March 21, 2018
  Primary Completion Date:      December 31, 2020
  Completion Date:              December 31, 2020
  First Posted:                 November 7, 2017
  Results First Posted:         null
  Last Update Posted:           July 18, 2018
  Locations:                    Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03333746

Study 322:
  NCT Number:                   NCT03274258
  Title:                        Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Renal Medullary Carcinoma|Other Disorders of Kidney and Ureter
  Interventions:                Drug: Nivolumab|Drug: Ipilimumab
  Outcome Measures:             Overall Response Rate (ORR) of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma|Progression-Free Survival (PFS) of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma|Safety of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma by CTCAE v4.03
  Sponsor/Collaborators:        M.D. Anderson Cancer Center|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   35
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    2017-0201|NCI-2018-01066
  Start Date:                   December 13, 2017
  Primary Completion Date:      July 2020
  Completion Date:              July 2020
  First Posted:                 September 6, 2017
  Results First Posted:         null
  Last Update Posted:           September 14, 2018
  Locations:                    University of Texas MD Anderson Cancer Center, Houston, Texas, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03274258

Study 323:
  NCT Number:                   NCT03729245
  Title:                        A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Renal Cell Carcinoma|Metastatic Renal Cell Carcinoma
  Interventions:                Biological: NKTR-214|Drug: Sunitinib|Biological: Nivolumab|Drug: Cabozantinib
  Outcome Measures:             Overall response rate (ORR) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Blinded Independent Central Review (BICR)|Overall survival (OS)|Progression-free survival (PFS) by BICR|Incidence of treatment-related Adverse Events (AEs)|ORR using RECIST 1.1 by investigator and in biomarker population|PFS by investigator and in biomarker population|OS in biomarker population|Changes in cancer-related symptoms and quality-of-life in patients using the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy (NCCN/FACT) Symptom Index for Kidney Cancer (FKSI-19)
  Sponsor/Collaborators:        Nektar Therapeutics|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   600
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    17-214-09|CA045002
  Start Date:                   December 2018
  Primary Completion Date:      December 2021
  Completion Date:              June 2024
  First Posted:                 November 2, 2018
  Results First Posted:         null
  Last Update Posted:           November 2, 2018
  Locations:                    Investigator Site - Whittier, Whittier, California, United States|Investigator Site - Houston, Houston, Texas, United States|Investigator Site - Leesburg, Leesburg, Virginia, United States|Investigator Site - Kurralta Park, Kurralta Park, South Australia, Australia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03729245

Study 324:
  NCT Number:                   NCT03493932
  Title:                        Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Glioblastoma
  Interventions:                Drug: Nivolumab|Drug: BMS-986016
  Outcome Measures:             The primary outcome measure is the proportion of patients that have a rise in interferon gamma levels within the tumor microenvironment of 4 pg/ml or higher before the first dose of Nivolumab as compared to after the first dose, the safety of th...|1)change in IFNg in body 2)response of immune environment of brain tumor tissue to Nivolumab 3)To evaluate clinical response of pts 4)the difference in survival between responders and non-responders 5)differences in the immune cells and secreted...
  Sponsor/Collaborators:        National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   15
  Funded Bys:                   NIH
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other
  Other IDs:                    180077|18-N-0077
  Start Date:                   September 24, 2018
  Primary Completion Date:      June 1, 2021
  Completion Date:              June 1, 2021
  First Posted:                 April 11, 2018
  Results First Posted:         null
  Last Update Posted:           October 26, 2018
  Locations:                    National Institutes of Health Clinical Center, Bethesda, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03493932

Study 325:
  NCT Number:                   NCT03023527
  Title:                        Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma
  Acronym:                      
  Status:                       Terminated
  Study Results:                No Results Available
  Conditions:                   Multiple Myeloma
  Interventions:                Drug: Nivolumab|Drug: Pomalidomide|Drug: Dexamethasone|Drug: Elotuzumab
  Outcome Measures:             Safety of Nivolumab: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
  Sponsor/Collaborators:        PETHEMA Foundation|Celgene|Bristol-Myers Squibb|Adknoma Health Research, S.L.
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   6
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    GEM-NIVOPOMDEX
  Start Date:                   January 2017
  Primary Completion Date:      January 2018
  Completion Date:              January 2018
  First Posted:                 January 18, 2017
  Results First Posted:         null
  Last Update Posted:           May 23, 2018
  Locations:                    ICO Badalona, Badalona, Spain|Hospital Clinic, Barcelona, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital Universitario de Canarias, Las Palmas de Gran Canaria, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Universitario 12 de octubre, Madrid, Spain|Hospital Morales Messeguer, Murcia, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Son Llatzer, Palma de Mallorca, Spain|Clinica Universidad de Navarra, Pamplona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Complejo Hospitalario Regional Virgen del Rocío, Sevilla, Spain
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03023527

Study 326:
  NCT Number:                   NCT02846376
  Title:                        Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant
  Acronym:                      CPIT-002
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Acute Myeloid Leukemia and Myelodysplastic Syndrome
  Interventions:                Drug: Nivolumab|Drug: Ipilimumab
  Outcome Measures:             Safety: The occurrence of at least one treatment-related limiting toxicity defined as a ≥ grade 4 non-hematologic toxicity as specified by the CTCAE 4.0.|Toxicities: Common Terminology Criteria for Adverse Events (CTCAE) will be used for the assessment and grading of all toxicities experienced by patients enrolled into this study.|Assessment of blood immune reconstitution by sequencing to determine diversity and highest frequency clonal specificities|Tumor site immune phenotyping|Assessment of complete response (CR) rate|Assessment of blood phenotype|Assessment of blood TCR repertoire via TCR Immunoseq Assay Profiling|Assess tumor site TCR repertoire using Poisson regression analysis with generalized estimating equations (GEE)|Assess tumor site PD-L1/2 expression|Efficacy as assessed by progression free survival (PFS)
  Sponsor/Collaborators:        Hackensack Meridian Health
  Gender:                       All
  Age:                          18 Years to 70 Years   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   21
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    Pro2016-0526
  Start Date:                   October 2018
  Primary Completion Date:      July 2019
  Completion Date:              July 2023
  First Posted:                 July 27, 2016
  Results First Posted:         null
  Last Update Posted:           October 2, 2018
  Locations:                    John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02846376

Study 327:
  NCT Number:                   NCT02532231
  Title:                        Nivolumab in Acute Myeloid Leukemia (AML) in Remission at High Risk for Relapse
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Leukemia|Acute Myeloid Leukemia
  Interventions:                Drug: Nivolumab
  Outcome Measures:             Recurrence-Free Survival (RFS)
  Sponsor/Collaborators:        M.D. Anderson Cancer Center|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   30
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    2015-0213|NCI-2015-01522
  Start Date:                   October 2015
  Primary Completion Date:      October 2019
  Completion Date:              October 2020
  First Posted:                 August 25, 2015
  Results First Posted:         null
  Last Update Posted:           March 26, 2018
  Locations:                    University of Texas MD Anderson Cancer Center, Houston, Texas, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02532231

Study 328:
  NCT Number:                   NCT02575222
  Title:                        Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Clear Cell Renal Cell Carcinoma
  Interventions:                Drug: Nivolumab
  Outcome Measures:             Safety as assessed by number of participants experiencing adverse events|Objective Tumor Response Rate (by RECIST)|Objective Tumor Response Rate (by irRC)|Quality of Life as assessed by the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI) -15 questionnaire|Metastasis-Free Survival|Overall Survival
  Sponsor/Collaborators:        Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   30
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    J15179|IRB00068726
  Start Date:                   February 2016
  Primary Completion Date:      December 2018
  Completion Date:              December 2019
  First Posted:                 October 14, 2015
  Results First Posted:         null
  Last Update Posted:           September 19, 2018
  Locations:                    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02575222

Study 329:
  NCT Number:                   NCT02304458
  Title:                        Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Metastatic Melanoma|Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Recurrent Hodgkin Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Rhabdomyosarcoma|Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Refractory Hodgkin Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Melanoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Rhabdomyosarcoma|Stage III Cutaneous Melanoma AJCC v7|Stage IIIA Cutaneous Melanoma AJCC v7|Stage IIIB Cutaneous Melanoma AJCC v7|Stage IIIC Cutaneous Melanoma AJCC v7|Stage IV Cutaneous Melanoma AJCC v6 and v7
  Interventions:                Biological: Ipilimumab|Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Other: Pharmacological Study
  Outcome Measures:             Maximum tolerated dose of nivolumab (Phase I)|Response rate of nivolumab, defined as either complete response, partial response, stable disease, or progressive disease, according to the Response Evaluation Criteria in Solid Tumors (Part B)|Response rate of nivolumab in expanded cohorts of patients with neuroblastoma, osteosarcoma, rhabdomyosarcoma, Ewing sarcoma, Hodgkin lymphoma, and non-Hodgkin lymphoma (Part B)|Recommended phase 2 dose of nivolumab plus ipilimumab (Part C)|Response rate of nivolumab combined with ipilimumab, defined as either complete response, partial response, stable disease, or progressive disease, according to the Response Evaluation Criteria in Solid Tumors (Part D)|Response rate of nivolumab combined with ipilimumab in expanded cohorts of patients with neuroblastoma, osteosarcoma, rhabdomyosarcomas, Ewing sarcoma, Hodgkin lymphoma, and non-Hodgkin lymphoma (Part D)|Response rate assessed according to Response Evaluation Criteria in Solid Tumors (Part E)
  Sponsor/Collaborators:        National Cancer Institute (NCI)
  Gender:                       All
  Age:                          12 Months to 30 Years   (Child, Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   484
  Funded Bys:                   NIH
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    NCI-2014-01222|ADVL1412|UM1CA097452
  Start Date:                   February 2, 2015
  Primary Completion Date:      October 31, 2020
  Completion Date:              null
  First Posted:                 December 2, 2014
  Results First Posted:         null
  Last Update Posted:           November 26, 2018
  Locations:                    Children's Hospital of Alabama, Birmingham, Alabama, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Children's Hospital of Orange County, Orange, California, United States|Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States|UCSF Medical Center-Mission Bay, San Francisco, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Columbia University/Herbert Irving Cancer Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|Hospital for Sick Children, Toronto, Ontario, Canada
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02304458

Study 330:
  NCT Number:                   NCT03299946
  Title:                        Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Locally Advanced Hepatocellular Carcinoma
  Interventions:                Drug: Cabozantinib|Drug: Nivolumab
  Outcome Measures:             Number of adverse events in participants of neoadjuvant cabozantinib plus nivolumab.|Number of patients who complete pre-op treatment and proceed to surgery.|Percentage of participants who obtain R0 resection.|Percentage of participants who obtain a pathologic complete response (CR).|Percentage of participants who obtain a major pathologic responses (MPR)|Objective response rate (ORR)|Median Overall Survival (OS)|Disease free survival (DFS)
  Sponsor/Collaborators:        Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Exelixis|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years to 100 Years   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   15
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    J17136|IRB00149350
  Start Date:                   January 24, 2018
  Primary Completion Date:      March 2022
  Completion Date:              March 2022
  First Posted:                 October 3, 2017
  Results First Posted:         null
  Last Update Posted:           November 7, 2018
  Locations:                    Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03299946

Study 331:
  NCT Number:                   NCT02497508
  Title:                        Nivolumab in Patients With Recurrent Malignant Mesothelioma
  Acronym:                      NivoMes
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Malignant Pleural Mesothelioma
  Interventions:                Drug: nivolumab
  Outcome Measures:             DCR|PFS|OS|TTP|ORR|Safety and tolerability (The incidence of (serious) adverse events)
  Sponsor/Collaborators:        The Netherlands Cancer Institute|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   33
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    N14MPN
  Start Date:                   July 2015
  Primary Completion Date:      July 2017
  Completion Date:              July 2017
  First Posted:                 July 14, 2015
  Results First Posted:         null
  Last Update Posted:           September 14, 2017
  Locations:                    
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02497508

Study 332:
  NCT Number:                   NCT03048474
  Title:                        Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma
  Acronym:                      INITIATE
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Malignant Pleural Mesothelioma
  Interventions:                Drug: nivolumab and ipilimumab
  Outcome Measures:             Disease Controle Rate (DCR) at 12 weeks|Safety: the incidence of adverse events, serious adverse events, deaths and laboratory abnormalities.|Disease Controle Rate (DCR) at 6 months|Progression Free Survival (PFS)|Overall Survival (OS)|Overall Response Rate (ORR)
  Sponsor/Collaborators:        The Netherlands Cancer Institute|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   36
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    N16INM
  Start Date:                   September 2016
  Primary Completion Date:      December 2017
  Completion Date:              December 2019
  First Posted:                 February 9, 2017
  Results First Posted:         null
  Last Update Posted:           November 1, 2018
  Locations:                    Netherlands Cancer Institute-Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, North-Holland, Netherlands
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03048474

Study 333:
  NCT Number:                   NCT03590210
  Title:                        Combined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue Sarcomas
  Acronym:                      NiTraSarc
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Metastatic Adult Soft Tissue Sarcoma
  Interventions:                Drug: Trabectedin|Drug: Nivolumab
  Outcome Measures:             progression free survival rate at 6 months - PFSR6|safety, as measured by: - Incidence of adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation, and deaths - Incidence of clinical laboratory test abnormalities|overall response rate (ORR)|overall survival (OS)|progression-free survival (PFS)|duration of disease stabilization (DoDS)|PDL-1 expression
  Sponsor/Collaborators:        University Medicine Greifswald|IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest|PharmaMar|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   74
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    GISG-15
  Start Date:                   June 8, 2018
  Primary Completion Date:      December 2019
  Completion Date:              July 2021
  First Posted:                 July 18, 2018
  Results First Posted:         null
  Last Update Posted:           July 20, 2018
  Locations:                    Helios Klinikum Bad Saarow, Klinik für Hämatologie, Onkologie und Palliativmedizin, Sarkomzentrum Berlin-Brandenburg, Bad Saarow, Germany|Helios Klinikum Berlin Buch, Klinik für interdisziplinäre Onkologie, Sarkomzentrum Berlin-Brandenburg, Berlin, Germany|Universitätsmedizin Greifswald, Klinik und Poliklinik für Innere Medizin C, Hämatologie und Onkologie, Greifswald, Germany
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03590210

Study 334:
  NCT Number:                   NCT02599649
  Title:                        Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Leukemia
  Interventions:                Drug: Lirilumab|Drug: Nivolumab|Drug: Azacitidine
  Outcome Measures:             Overall Response Rate (ORR)
  Sponsor/Collaborators:        M.D. Anderson Cancer Center|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   12
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    2014-0934|NCI-2015-02120
  Start Date:                   March 21, 2016
  Primary Completion Date:      March 2025
  Completion Date:              March 2026
  First Posted:                 November 6, 2015
  Results First Posted:         null
  Last Update Posted:           February 23, 2018
  Locations:                    University of Texas MD Anderson Cancer Center, Houston, Texas, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02599649

Study 335:
  NCT Number:                   NCT03214250
  Title:                        Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Metastatic Pancreatic Adenocarcinoma
  Interventions:                Drug: APX005M|Drug: Nivolumab|Drug: Nab-Paclitaxel|Drug: Gemcitabine
  Outcome Measures:             Number and percentage of subjects with adverse events (AEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs)|Overall survival (OS) defined as the time from initiation of study therapy to date of death due to any cause or date of most recent subject contact.|Objective response rate (ORR) as determined by RECIST criteria|Duration of response (DOR) defined as time from first documentation of response (complete response [CR] or partial response [PR]) to first documentation of progressive disease|Disease control rate (DCR) is defined as the proportion of subjects who achieve a CR or PR or SD|Progression free survival (PFS) defined as the time from initiation of study therapy to date of first documented progression of disease, date of death due to any cause or date of most recent subject contact which documented progression free status
  Sponsor/Collaborators:        Parker Institute for Cancer Immunotherapy|Bristol-Myers Squibb|Apexigen, Inc.|Cancer Research Institute, New York City
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   105
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    PICI0002|UPCC 11217
  Start Date:                   July 21, 2017
  Primary Completion Date:      July 1, 2022
  Completion Date:              September 1, 2022
  First Posted:                 July 11, 2017
  Results First Posted:         null
  Last Update Posted:           August 13, 2018
  Locations:                    University of California, Los Angeles, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States|M.D. Anderson Cancer Center, Houston, Texas, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03214250

Study 336:
  NCT Number:                   NCT03628209
  Title:                        Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Osteosarcoma|Osteosarcoma in Children|Osteosarcoma Recurrent|Sarcoma
  Interventions:                Drug: Nivolumab|Drug: Azacitidine|Procedure: Post Treatment Surgery
  Outcome Measures:             Phase I: Recommended Phase II Dose (RP2D)|Phase II: Rate of Continued Complete Remission (CR)|Percentage of Participants with Event Free Survival (EFS)|Overall Survival (OS) Rate
  Sponsor/Collaborators:        H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb
  Gender:                       All
  Age:                          up to 39 Years   (Child, Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   51
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    MCC-19487|CA209-9WW
  Start Date:                   January 2019
  Primary Completion Date:      January 2021
  Completion Date:              January 2022
  First Posted:                 August 14, 2018
  Results First Posted:         null
  Last Update Posted:           November 6, 2018
  Locations:                    Phoenix Children's Hospital, Phoenix, Arizona, United States|Children's Hospital of Los Angeles, USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|Alfred I DuPont Hospital for Children, Wilmington, Delaware, United States|Shand's Hospital for Children at the University of Florida, Gainesville, Florida, United States|Nemours Children's Hospital, Jacksonville, Florida, United States|Holtz Children's Hospital at the University of Miami, Miami, Florida, United States|Nemours Children's Clinic, Orlando, Florida, United States|Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Coordinating Center, Tampa, Florida, United States|University of Kentucky, Markey Cancer Center, Lexington, Kentucky, United States|Johns Hopkins University, Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Montefiore Medical Center, Albert Einstein Cancer Center, Bronx, New York, United States|University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Carolina Medical Center, Levine Cancer Institute, Charlotte, North Carolina, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Primary Children's Hospital, Huntsman Cancer Institute, Salt Lake City, Utah, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03628209

Study 337:
  NCT Number:                   NCT03337919
  Title:                        ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma
  Acronym:                      ANIMATE
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Hodgkin Lymphoma
  Interventions:                Drug: Nivolumab
  Outcome Measures:             Overall response rate (ORR) by PET-CT scan following 4-8 cycles of nivolumab|Progression-free survival|Overall survival|Proportion of patients progressing to stem cell transplant|Adverse events [Safety and toxicity of nivolumab]|Transplant-related mortality|Transplant-related morbidity
  Sponsor/Collaborators:        University College, London|Bristol-Myers Squibb
  Gender:                       All
  Age:                          16 Years and older   (Child, Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   120
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    UCL/15/0515|CA-209-445
  Start Date:                   November 2018
  Primary Completion Date:      May 2022
  Completion Date:              May 2025
  First Posted:                 November 9, 2017
  Results First Posted:         null
  Last Update Posted:           October 24, 2018
  Locations:                    
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03337919

Study 338:
  NCT Number:                   NCT02917772
  Title:                        Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma
  Acronym:                      TITAN-RCC
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Carcinoma, Renal Cell|Clear-cell Metastatic Renal Cell Carcinoma
  Interventions:                Biological: Nivolumab/Ipilimumab
  Outcome Measures:             Objective Response Rate (ORR)|General considerations: RR, TTR, DoR, PFS, TIR (Time to Immunotherapy Resistance), OS|Remission Rates during TITAN treatment: RR1, RR2, RR2SD, RR3|Time to Immunotherapy Resistance: TIR|Time-to-Response: TTR|Duration of Response: DOR|Overall survival:OS|Safety: Adverse events assessment|Safety: Frequency of abnormal laboratory parameters|Patient reported outcomes|Exploratory objectives: Immune monitoring
  Sponsor/Collaborators:        AIO-Studien-gGmbH|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   200
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    0216-ASG
  Start Date:                   October 2016
  Primary Completion Date:      October 2018
  Completion Date:              July 2021
  First Posted:                 September 28, 2016
  Results First Posted:         null
  Last Update Posted:           July 16, 2018
  Locations:                    Ordensklinikum Linz Barmherzige Schwestern, Linz, Austria|AKH Wien Universitätsklinik für Innere Medizin I, Wien, Austria|ZNA Middelheim, Antwerpen, Belgium|CHR Verviers, Verviers, Belgium|Fakultní nemocnice Hradec Králové, Hradec Králové, Czechia|Fakultní nemocnice Olomouc, Olomouc, Czechia|FN Motol, Praha, Czechia|Všeobecné fakultní nemocnice, Praha, Czechia|CHD Vendée, La Roche-Sur-Yon, France|Centre Hôpitalier Lyon Sud, Lyon, France|Hôpitaux Universitaires de Strasbourg Hôpital Civil, Strasbourg, France|Institut Claudius Regaud, Toulouse, France|Institut Gustave Roussy, Villejuif, France|Universitätsklinikum Jena und Poliklinik für Urologie, Jena, Thüringen, Germany|Charité Universitätsmedizin Berlin, Berlin, Germany|Universitätsklinikum Carl Gustav Carus, Dresden, Germany|Universitätsklinikum Düsseldorf, Düsseldorf, Germany|Universitätsklinikum, Düsseldorf, Germany|Universität des Saarlandes Medizinische Fakultät, Homburg/Saar, Germany|Azienda USL8 Arezzo U.O.C. Oncologia Medica, Arezzo, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy|IRCCS Fondazione Policlinico San Matteo, Pavia, Italy|Azienda Ospedaliera San Camillo Forlanini, Roma, Italy|Policlinico Universitario A. Gemelli, Roma, Italy|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Complejo Hospitalario de Navarra, Pamplona, Spain|Hospital Universitario Marques de Valdecilla, Santander, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Broomfield Hospital, Chelmsford, United Kingdom|Charing Cross Hospital, London, United Kingdom|Kent Oncology Centre, Maidstone, United Kingdom|Royal Preston Hospital, Preston, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02917772

Study 339:
  NCT Number:                   NCT03557359
  Title:                        Nivolumab for Recurrent or Progressive IDH Mutant Gliomas
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Gliomas
  Interventions:                Drug: Nivolumab
  Outcome Measures:             Overall Response Rate|Duration of Response|Progression-Free Survival (PFS)|Overall Survival (OS)
  Sponsor/Collaborators:        Columbia University|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   37
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    AAAR6354
  Start Date:                   June 12, 2018
  Primary Completion Date:      June 2020
  Completion Date:              June 2021
  First Posted:                 June 15, 2018
  Results First Posted:         null
  Last Update Posted:           October 5, 2018
  Locations:                    Miami Cancer Center, Miami, Florida, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Columbia University Medical Center, New York, New York, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03557359

Study 340:
  NCT Number:                   NCT03692325
  Title:                        Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Leukoplakia, Oral
  Interventions:                Drug: Nivolumab
  Outcome Measures:             Best Overall Response Rate|Quality of Life (QOL)|Evaluate safety and toxicity (Adverse Events and Serious Adverse Events)|Evaluate the time to the next surgery for a head and neck malignancy|Estimate Cancer Free Survival (CFS) from the time of study registration|Estimate Overall Survival (OS) from the time of study registration|Characterize distinct tumor and circulating immunophentoypes (biomarkers in biopsy and blood samples)
  Sponsor/Collaborators:        Dana-Farber Cancer Institute|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   33
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  Other IDs:                    18-387
  Start Date:                   October 31, 2018
  Primary Completion Date:      June 30, 2021
  Completion Date:              June 30, 2024
  First Posted:                 October 2, 2018
  Results First Posted:         null
  Last Update Posted:           October 2, 2018
  Locations:                    Dana Farber Cancer Institute, Boston, Massachusetts, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03692325

Study 341:
  NCT Number:                   NCT03013335
  Title:                        Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen
  Acronym:                      NIVOREN
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Metastatic Renal Cell Carcinoma
  Interventions:                Drug: Nivolumab
  Outcome Measures:             Incidence for high-grade (Grade3-4-5) adverse reactions of interest|Assessment of Overall Survival (OS) by Follow-up continued|Number of patients with a Best Overall Response (BOR) by RECIST v1.1|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Percentage of patients who received immune modulating concomitant medication|Percentage of patients who received hormonal replacement therapy|Median time to resolution of adverse reactions of interest|Assessment of quality of life by questionnaire FACT-G|Assessment of quality of life by questionnaire FKSI-19|Assessment of quality of life by questionnaire EQ-5D
  Sponsor/Collaborators:        UNICANCER|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   450
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    UC 0160/1506 GETUG-AFU 26
  Start Date:                   January 2016
  Primary Completion Date:      January 2023
  Completion Date:              January 2023
  First Posted:                 January 6, 2017
  Results First Posted:         null
  Last Update Posted:           January 6, 2017
  Locations:                    Centre Francois Baclesse, Caen, France|Centre Georges-Francois Leclerc, Dijon, France|Centre Leon Berard, Lyon, France|Institut Paoli-Calmettes, Marseille, France|Centre Antoine Lacassagne, Nice, France|Institut de Cancerologie de Lorraine, Vandoeuvre Les Nancy, France|Gustave Roussy Cancer Campus Grand Paris, Villejuif, France
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03013335

Study 342:
  NCT Number:                   NCT02925234
  Title:                        The Drug Rediscovery Protocol (DRUP Trial)
  Acronym:                      DRUP
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Cancer|Tumors|Neoplasm|Neoplasia
  Interventions:                Drug: Panitumumab|Drug: Olaparib|Drug: Dabrafenib|Drug: Nilotinib|Drug: Trametinib|Drug: Erlotinib|Drug: Trastuzumab and Pertuzumab (combination treatment)|Drug: Vemurafenib and Cobimetinib (combination treatment)|Drug: Vismodegib|Drug: Regorafenib|Drug: Nivolumab
  Outcome Measures:             Percentage of patients that are treated based on their molecular tumor profile|Objective tumor response|Stable disease|Treatment-related grade≥3 and serious adverse events|Progression-free survival|Overall survival|Duration of treatment on study (time on drug)
  Sponsor/Collaborators:        The Netherlands Cancer Institute|Amgen|AstraZeneca|Bayer|Bristol-Myers Squibb|Novartis|Roche Pharma AG
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   400
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    M15DRU
  Start Date:                   August 2016
  Primary Completion Date:      August 2019
  Completion Date:              December 2019
  First Posted:                 October 5, 2016
  Results First Posted:         null
  Last Update Posted:           October 5, 2016
  Locations:                    Meander Medical Center, Amersfoort, Utrecht, Netherlands|Netherlands Cancer Institute, Amsterdam, Netherlands|AZVU, Amsterdam, Netherlands|Amphia Hospital, Breda, Netherlands|Maxima Medisch Centrum, Eindhoven, Netherlands|Orbis Concern, Geleen, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Maastricht University Medical Center, Maastricht, Netherlands|Radboud umc, NIjmegen, Netherlands|St. Fransicus Gasthuis, Rotterdam, Netherlands|Erasmus MC, Rotterdam, Netherlands|St. Elisabeth, Tilburg, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02925234

Study 343:
  NCT Number:                   NCT03630640
  Title:                        Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation
  Acronym:                      NIVOLEP
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Hepatocellular Carcinoma
  Interventions:                Drug: Nivolumab Injection [Opdivo]
  Outcome Measures:             Local recurrence-free survival during a 2-years follow-up after Nivolumab neoadjuvant/adjuvant therapy and EP procedure|Changes of tumorous and non-tumorous perfusion parameters observed with CUS and MRI after one months of neoadjuvant treatments|Per nodule rates of early response|Incidences of intra segmental/ extra segmental distant recurrence|Assessment of overall survival|Assessment of tolerance of the immunotherapy treatment:|Compliance to neoadjuvant treatments|Compliance to adjuvant treatments|Frequency of SAEs|Frequency of discontinuations treatment due to AEs
  Sponsor/Collaborators:        Assistance Publique - Hôpitaux de Paris|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years to 99 Years   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   50
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    P171001J
  Start Date:                   October 11, 2018
  Primary Completion Date:      September 30, 2020
  Completion Date:              September 30, 2020
  First Posted:                 August 15, 2018
  Results First Posted:         null
  Last Update Posted:           November 14, 2018
  Locations:                    Hôpital Jean Verdier, Bondy, France
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03630640

Study 344:
  NCT Number:                   NCT03528408
  Title:                        Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Melanoma
  Interventions:                Drug: Nivolumab|Drug: Ipilimumab
  Outcome Measures:             3 year Relapse Free Survival (RFS)|Median RFS|Overall Survival (OS)|3 year OS|Assess Adverse Events
  Sponsor/Collaborators:        Suthee Rapisuwon|Bristol-Myers Squibb|Hoosier Cancer Research Network
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   50
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    HCRN-MEL17-309
  Start Date:                   July 26, 2018
  Primary Completion Date:      July 2020
  Completion Date:              June 2023
  First Posted:                 May 17, 2018
  Results First Posted:         null
  Last Update Posted:           September 21, 2018
  Locations:                    Georgetown University, Washington, District of Columbia, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03528408

Study 345:
  NCT Number:                   NCT02572167
  Title:                        A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Hodgkin Lymphoma
  Interventions:                Drug: brentuximab vedotin|Drug: nivolumab
  Outcome Measures:             Incidence of adverse events|Complete response rate|Objective response rate|Duration of complete response|Duration of objective response|Progression-free survival post-autologous stem cell transplant
  Sponsor/Collaborators:        Seattle Genetics, Inc.|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   93
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    SGN35-025
  Start Date:                   October 2015
  Primary Completion Date:      March 1, 2018
  Completion Date:              October 2020
  First Posted:                 October 8, 2015
  Results First Posted:         null
  Last Update Posted:           March 14, 2018
  Locations:                    City of Hope National Medical Center, Duarte, California, United States|Stanford Cancer Center, Stanford, California, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Karmanos Cancer Institute / Wayne State University, Detroit, Michigan, United States|Mayo Clinic Minnesota, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center - Commack, Commack, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|James Cancer Hospital / Ohio State University, Columbus, Ohio, United States|Charles A. Sammons Cancer Center / Baylor University Medical Center, Dallas, Texas, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02572167

Study 346:
  NCT Number:                   NCT03405155
  Title:                        Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Melanoma (Skin)
  Interventions:                Biological: Nivolumab
  Outcome Measures:             Recurrence-free survival|Median duration of overall survival|Median duration of distant metastases-free survival|Incidence of adverse events
  Sponsor/Collaborators:        Sidney Kimmel Cancer Center at Thomas Jefferson University|Bristol-Myers Squibb|Thomas Jefferson University
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   73
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    17P.641
  Start Date:                   January 17, 2018
  Primary Completion Date:      October 11, 2022
  Completion Date:              October 2023
  First Posted:                 January 19, 2018
  Results First Posted:         null
  Last Update Posted:           May 16, 2018
  Locations:                    Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03405155

Study 347:
  NCT Number:                   NCT03743766
  Title:                        Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Melanoma
  Interventions:                Drug: Relatlimab|Drug: Nivolumab|Drug: Relatlimab + Nivolumab
  Outcome Measures:             Change in LAG3 Expression|Change in PD1 expression|Change in Tumor Size|Overall Response Rate (ORR)|Clinical Benefit Rate|Duration of Response|Progression-free Survival (PFS)|Overall Survival (OS)|LAG3 Expression|PD-1 Expression|Change in CD4+ tumor infiltrating lymphocytes|Change in CD8+ tumor infiltrating lymphocytes|Change in granzyme B serum levels|Change in cell effector/memory status|Change in activation and maturation of dendritic cells|Change in T cell count|Change in soluble LAG3 levels|Soluble LAG3 levels|Change in Regulatory T cell (Treg) marker level|Regulatory T cell (Treg) marker levels
  Sponsor/Collaborators:        John Kirkwood|Bristol-Myers Squibb|University of Pittsburgh
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   42
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    18-071
  Start Date:                   November 2018
  Primary Completion Date:      October 2020
  Completion Date:              October 2022
  First Posted:                 November 16, 2018
  Results First Posted:         null
  Last Update Posted:           November 16, 2018
  Locations:                    UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03743766

Study 348:
  NCT Number:                   NCT03382886
  Title:                        Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma
  Acronym:                      NUANCE
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Hepatocellular Carcinoma
  Interventions:                Drug: Nivolumab|Drug: Bevacizumab
  Outcome Measures:             Adverse Events that occur|Determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D)|Progression Free Survival (PFS)|Overall Survival
  Sponsor/Collaborators:        University of Utah|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   12
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    HCI103945
  Start Date:                   April 11, 2018
  Primary Completion Date:      March 2023
  Completion Date:              March 2023
  First Posted:                 December 26, 2017
  Results First Posted:         null
  Last Update Posted:           November 14, 2018
  Locations:                    Huntsman Cancer Institute, Salt Lake City, Utah, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03382886

Study 349:
  NCT Number:                   NCT03605719
  Title:                        Dexamethasone, Carfilzomib, & Nivolumab With Reovirus for Relapsed/Refractory Multiple Myeloma
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Recurrent Plasma Cell Myeloma
  Interventions:                Drug: Carfilzomib|Drug: Dexamethasone|Biological: Nivolumab|Biological: Wild-type Reovirus
  Outcome Measures:             Dose-limiting toxicity (DLT) of 4-drug regimen evaluated according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)|Maximum tolerated dose (MTD) of 4-drug regimen|DLT of 3-drug regimen evaluated according to NCI CTCAE version 5.0|Time to progression|Progression-free survival|Overall survival
  Sponsor/Collaborators:        Emory University|Bristol-Myers Squibb|Oncolytics Biotech|University of Utah|City of Hope Medical Center|Phylogeny
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   62
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    IRB00104234|NCI-2018-01217|Winship4398-18
  Start Date:                   October 24, 2018
  Primary Completion Date:      October 31, 2021
  Completion Date:              October 31, 2024
  First Posted:                 July 30, 2018
  Results First Posted:         null
  Last Update Posted:           November 5, 2018
  Locations:                    Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03605719

Study 350:
  NCT Number:                   NCT02970981
  Title:                        Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Melanoma
  Interventions:                Biological: Nivolumab|Biological: Ipilimumab
  Outcome Measures:             Safety (adverse events) of the protocol therapy|Immune Response Assessment|Time to relapse
  Sponsor/Collaborators:        New York University School of Medicine|Bristol-Myers Squibb
  Gender:                       All
  Age:                          16 Years and older   (Child, Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   16
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    16-00098
  Start Date:                   November 29, 2016
  Primary Completion Date:      November 2018
  Completion Date:              November 2020
  First Posted:                 November 22, 2016
  Results First Posted:         null
  Last Update Posted:           December 18, 2017
  Locations:                    Laura and Isaac Perlmutter Cancer Center, New York, New York, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02970981

Study 351:
  NCT Number:                   NCT03374839
  Title:                        Combined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma Patients
  Acronym:                      Nivo-TIL
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Melanoma
  Interventions:                Drug: TIL + IL-2 + Nivolumab
  Outcome Measures:             Incidence of Treatment (adoptive T cell therapy associated to intravenous injections of Nivolumab) - Emergent Adverse Events|Efficacy of adoptive T cell therapy associated to intravenous injections of Nivolumab|Duration of the clinical response|Progression-free survival|Overall survival|Specific immune monitoring n°1: Evaluate the fraction of TIL specific to Melan-A and MELOE-1|Specific immune monitoring n°2: Evaluate the proportion of regulatory T cells|Specific immune monitoring n°3: Analyse the expression of tumor antigens|Specific immune monitoring n°4: Analyse the expression of immunosuppressive cytokines|Specific immune monitoring n°5: Analyse the expression of indoleamine 2,3-dioxygenase (IDO)|Specific immune monitoring n°6: Analyse the expression of FoxP3|Specific immune monitoring n°7: Analyse the expression of regulatory molecules|Specific immune monitoring n°8: Analyse the mutations of BRAF|Specific immune monitoring n°9: Analyse the mutations of Neuroblastoma Ras viral oncogene homolog (NRAS)|Specific immune monitoring n°10: Analyse the mutations of proto-oncogene ckit (cKit)|Specific immune monitoring n°11: Determine the percentage of reactive T cells in the expanded cells|Specific immune monitoring n°12: Determine the phenotype of the expanded T cells|Specific immune monitoring n°13: Test TIL reactivity
  Sponsor/Collaborators:        Nantes University Hospital|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years to 75 Years   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   11
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    RC15_0247
  Start Date:                   February 12, 2018
  Primary Completion Date:      March 12, 2021
  Completion Date:              March 12, 2021
  First Posted:                 December 15, 2017
  Results First Posted:         null
  Last Update Posted:           February 20, 2018
  Locations:                    Nantes University Hospital, Nantes, France
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03374839

Study 352:
  NCT Number:                   NCT02731729
  Title:                        Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Melanoma
  Interventions:                Drug: ipilimumab|Drug: nivolumab
  Outcome Measures:             objective response as defined by RECIST v1.1 criteria
  Sponsor/Collaborators:        Parker Institute for Cancer Immunotherapy|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   70
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    PICI0001|16-043
  Start Date:                   April 2016
  Primary Completion Date:      August 2018
  Completion Date:              January 1, 2021
  First Posted:                 April 7, 2016
  Results First Posted:         null
  Last Update Posted:           July 9, 2018
  Locations:                    University of California, Los Angeles, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02731729

Study 353:
  NCT Number:                   NCT02754726
  Title:                        Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Untreated Metastatic Pancreatic Ductal Adenocarcinoma
  Interventions:                Drug: Nivolumab|Drug: Albumin-bound paclitaxel|Drug: Paricalcitol|Drug: Cisplatin|Drug: Gemcitabine
  Outcome Measures:             Complete response rate|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
  Sponsor/Collaborators:        HonorHealth Research Institute|Translational Genomics Research Institute|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   10
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    NAPPCG-EB 2015-001
  Start Date:                   April 2016
  Primary Completion Date:      July 2019
  Completion Date:              July 2020
  First Posted:                 April 28, 2016
  Results First Posted:         null
  Last Update Posted:           October 10, 2018
  Locations:                    HonorHealth Research Institute, Scottsdale, Arizona, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02754726

Study 354:
  NCT Number:                   NCT03149159
  Title:                        Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab
  Acronym:                      
  Status:                       Withdrawn
  Study Results:                No Results Available
  Conditions:                   Clear Cell Renal Cell Carcinoma|Metastatic Renal Cell Carcinoma
  Interventions:                Drug: Nivolumab|Drug: Ipilimumab|Radiation: Steriotactic radiation therapy
  Outcome Measures:             Number of patients with a partial or complete response|Progression free survival (PFS)
  Sponsor/Collaborators:        Medical University of South Carolina|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   0
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    102576|CA209-927
  Start Date:                   April 1, 2018
  Primary Completion Date:      April 1, 2018
  Completion Date:              April 1, 2018
  First Posted:                 May 11, 2017
  Results First Posted:         null
  Last Update Posted:           June 18, 2018
  Locations:                    Medical University of South Carolina, Charleston, South Carolina, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03149159

Study 355:
  NCT Number:                   NCT03682276
  Title:                        Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma
  Acronym:                      PRIME-HCC
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Hepatocellular Carcinoma
  Interventions:                Biological: Ipilimumab|Biological: Nivolumab
  Outcome Measures:             Delay to surgery|Incidence of treatment-emergent adverse events [Safety and Tolerability]|Objective response rate|Pathologic response rate
  Sponsor/Collaborators:        Imperial College London|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   32
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    C/36/2017|2018-000987-27|CA209-9LC
  Start Date:                   December 1, 2018
  Primary Completion Date:      December 1, 2020
  Completion Date:              September 1, 2022
  First Posted:                 September 24, 2018
  Results First Posted:         null
  Last Update Posted:           September 24, 2018
  Locations:                    Imperial College Healthcare NHS Trust, London, Greater London, United Kingdom
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03682276

Study 356:
  NCT Number:                   NCT03219671
  Title:                        Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS)
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Classic Kaposi Sarcoma
  Interventions:                Drug: Nivolumab|Drug: Ipilimumab
  Outcome Measures:             ORR|PFS rate|Safety - Incidence of Treatment-Emergent Adverse Events according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events, Version 4.0 (CTCAE v4)|Tolerability - treatment related adverse events (AEs) that caused study drug interruption and discontinuation
  Sponsor/Collaborators:        Alona Zer|Bristol-Myers Squibb|Rabin Medical Center
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   20
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-937|0095-17-RMC
  Start Date:                   December 1, 2017
  Primary Completion Date:      September 1, 2020
  Completion Date:              September 1, 2022
  First Posted:                 July 17, 2017
  Results First Posted:         null
  Last Update Posted:           September 29, 2017
  Locations:                    
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03219671

Study 357:
  NCT Number:                   NCT03739619
  Title:                        Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma|Classical Hodgkin Lymphoma|Hodgkin Lymphoma
  Interventions:                Drug: Bendamustine|Drug: Gemcitabine|Biological: Nivolumab
  Outcome Measures:             Maximum tolerable dose (Phase I)|Complete response (CR) rate (Phase II)|Overall response rate (Phase II)|Duration of response (Phase II)|Progression free survival (PFS) (Phase II)|Overall survival (OS) (Phase II)
  Sponsor/Collaborators:        Emory University|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   54
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    IRB00104033|NCI-2018-02221|Winship4388-18
  Start Date:                   November 1, 2019
  Primary Completion Date:      November 30, 2023
  Completion Date:              November 30, 2023
  First Posted:                 November 14, 2018
  Results First Posted:         null
  Last Update Posted:           November 14, 2018
  Locations:                    Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03739619

Study 358:
  NCT Number:                   NCT02736123
  Title:                        Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone
  Acronym:                      
  Status:                       Withdrawn
  Study Results:                No Results Available
  Conditions:                   Melanoma
  Interventions:                Drug: Nivolumab - Arm A|Drug: Nivolumab + Ipilimumab - Arm B
  Outcome Measures:             Assess the pathologic complete response rate (absence of viable tumor on histologic assessment)|Evaluate preoperative clinical/radiologic response rate|Assess progression free survival|Assess overall survival|Assess biomarkers CD8 T cell, PD-L1 and IDO expression by immunohistochemistry|Assess safety and adverse events
  Sponsor/Collaborators:        University of Pittsburgh|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   0
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    15-113
  Start Date:                   October 2016
  Primary Completion Date:      February 9, 2017
  Completion Date:              February 9, 2017
  First Posted:                 April 13, 2016
  Results First Posted:         null
  Last Update Posted:           September 20, 2017
  Locations:                    UPMC Cancer Center Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02736123

Study 359:
  NCT Number:                   NCT02959554
  Title:                        Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control
  Acronym:                      NIVOSWITCH
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Metastatic Renal Cell Carcinoma
  Interventions:                Drug: Nivolumab|Drug: Sunitinib|Drug: Pazopanib
  Outcome Measures:             Overall survival (OS)|Best overall response rate|Progression free survival (PFS)|Quality of Life|Safety - Absolute and relative frequencies of emergent adverse events according to CTCAE 4.03
  Sponsor/Collaborators:        AIO-Studien-gGmbH|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   244
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    AIO-NZK-0116ass.|CA209-443
  Start Date:                   December 2016
  Primary Completion Date:      September 2020
  Completion Date:              December 2021
  First Posted:                 November 9, 2016
  Results First Posted:         null
  Last Update Posted:           October 25, 2018
  Locations:                    Medizinische Universität Wien - Universitätsklinik für Innere Medizin I, Klinische Abteilung für Onkologie, Wien, Austria|Universitätsklinikum Essen (AöR) - Klinik und Poliklinik für Urologie / Kinderurologie und Uroonkologie, Essen, Germany
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02959554

Study 360:
  NCT Number:                   NCT03724968
  Title:                        Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Metastatic Melanoma|Advanced Melanoma|Metastatic Melanoma Stratified by MHC-II Expression
  Interventions:                Drug: Nivolumab|Drug: Relatlimab|Drug: Ipilimumab
  Outcome Measures:             Change in activated GZMB+ CD8+T-cell density intratumorally, of two immunotherapy regimens|Response rate|Median progression free survival|Median overall survival|Number of participants with treatment-related adverse events as assessed by CTCAE version 5.0
  Sponsor/Collaborators:        Elizabeth Davis|Bristol-Myers Squibb|Vanderbilt-Ingram Cancer Center
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   36
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    VICC MEL 18114|NCI-2018-02469
  Start Date:                   November 2018
  Primary Completion Date:      November 2022
  Completion Date:              November 2023
  First Posted:                 October 30, 2018
  Results First Posted:         null
  Last Update Posted:           October 30, 2018
  Locations:                    Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03724968

Study 361:
  NCT Number:                   NCT03015896
  Title:                        Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Grade 3a Follicular Lymphoma|Recurrent Burkitt Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Lymphoplasmacytic Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Waldenstrom Macroglobulinemia|Refractory Burkitt Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Lymphoplasmacytic Lymphoma|Refractory Mantle Cell Lymphoma
  Interventions:                Other: Laboratory Biomarker Analysis|Drug: Lenalidomide|Biological: Nivolumab
  Outcome Measures:             Incidence of adverse events summarized by NCI CTCAE version 4|Maximum tolerated dose (MTD) defined as the dose level at which no more than one of 6 patients experiences a dose-limiting toxicity summarized by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4|Complete response rate (CR) in patients|Overall Response Rate (ORR)|Overall Survival (OS)|Progression free survival (PFS)
  Sponsor/Collaborators:        Kami Maddocks|Bristol-Myers Squibb|Ohio State University Comprehensive Cancer Center
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   102
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    OSU-16167|NCI-2016-01966
  Start Date:                   February 14, 2017
  Primary Completion Date:      April 30, 2020
  Completion Date:              April 30, 2020
  First Posted:                 January 10, 2017
  Results First Posted:         null
  Last Update Posted:           September 12, 2018
  Locations:                    Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03015896

Study 362:
  NCT Number:                   NCT02196961
  Title:                        Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies Versus Observation
  Acronym:                      ADMEC-O
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Merkel Cell Carcinoma
  Interventions:                Drug: Ipilimumab|Drug: Nivolumab
  Outcome Measures:             Disease-free survival (DFS) at 12 months|Number of adverse events|Overall survival rate at 12 months|DFS rate at 12 months
  Sponsor/Collaborators:        Prof. Dr. med. Dirk Schadendorf|Bristol-Myers Squibb|University Hospital, Essen
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   177
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA184-205
  Start Date:                   June 2014
  Primary Completion Date:      March 2021
  Completion Date:              March 2021
  First Posted:                 July 22, 2014
  Results First Posted:         null
  Last Update Posted:           August 29, 2017
  Locations:                    University Hospital Essen, Dermatology, Essen, NRW, Germany|Charité Universitätsmedizin Berlin, Berlin, Germany|Elbeklinikum Buxtehude, Buxtehude, Germany|University Hospital Dresden, Dermatology, Dresden, Germany|SRH Wald-Klinikum Gera, Gera, Germany|Hannover Medical School, Hannover, Germany|National Centre for Tumour Diseases (NCT), Heidelberg, Germany|University Hospital Schleswig-Holstein, Kiel, Kiel, Germany|University Hospital München (LMU), Munich, Germany|Specialist clinic in Hornheide, Münster, Germany|University Hospital Tübingen, Tübingen, Germany
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02196961

Study 363:
  NCT Number:                   NCT03707457
  Title:                        Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Glioblastoma|Glioblastoma Multiforme
  Interventions:                Drug: Nivolumab|Drug: Anti-GITR Monoclonal Antibody MK-4166|Drug: IDO1 inhibitor INCB024360|Drug: Ipilimumab
  Outcome Measures:             Proportion of subjects with dose limiting toxicities evaluated according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
  Sponsor/Collaborators:        Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   30
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    J17154
  Start Date:                   November 2018
  Primary Completion Date:      November 2021
  Completion Date:              November 2023
  First Posted:                 October 16, 2018
  Results First Posted:         null
  Last Update Posted:           October 16, 2018
  Locations:                    
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03707457

Study 364:
  NCT Number:                   NCT03638375
  Title:                        TIL and Anti-PD1 in Metastatic Melanoma
  Acronym:                      ACTME
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Toxicity, Drug|Adverse Drug Event|Effects of Immunotherapy
  Interventions:                Drug: Nivolumab & Tumor Infiltrating Lymphocytes with/without Interferon-Alpha
  Outcome Measures:             Incidence of treatment-related serious adverse events as assessed by CTCAE 4.0 criteria|Evaluation of disease control rate according to RECIST 1.1 criteria|Evaluation of disease control rate according to immune RECIST response criteria|To study the potential working mechanisms of the different treatment compounds. Therefore, blood will be drawn to analyse changes in circulating immune cells and their function during treatment.|To establish a possible prognostic biomarker profile in patients tumor material, blood, serum and TILs used for infusion|To characterize the infusion product|To analyse potential correlations between the clinical response and hypothesis related immune parameters|To analyse the overall survival following treatment
  Sponsor/Collaborators:        Leiden University Medical Center|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   34
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    NL64805.000.18
  Start Date:                   July 31, 2018
  Primary Completion Date:      May 9, 2022
  Completion Date:              May 9, 2023
  First Posted:                 August 20, 2018
  Results First Posted:         null
  Last Update Posted:           August 20, 2018
  Locations:                    Leiden University Medical Center, Leiden, Netherlands
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03638375

Study 365:
  NCT Number:                   NCT02357732
  Title:                        Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib
  Acronym:                      
  Status:                       Withdrawn
  Study Results:                No Results Available
  Conditions:                   Metastatic Melanoma
  Interventions:                Drug: Nivolumab|Drug: Trametinib|Drug: Dabrafenib
  Outcome Measures:             To determine the Maximally Tolerated Dose and/or Recommended Phase II Dose (RP2D) of nivolumab in combination with dabrafenib and/or trametinib in patients with BRAF- or NRAS-mutated metastatic melanoma|Antitumor Effects and Immune Related Response
  Sponsor/Collaborators:        University of Pittsburgh|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   0
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    14-115
  Start Date:                   August 2015
  Primary Completion Date:      August 2015
  Completion Date:              August 2015
  First Posted:                 February 6, 2015
  Results First Posted:         null
  Last Update Posted:           December 11, 2015
  Locations:                    
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02357732

Study 366:
  NCT Number:                   NCT03340129
  Title:                        Anti-PD 1 Brain Collaboration + Radiotherapy: The ABC-X Study
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Melanoma Stage Iv
  Interventions:                Drug: Ipilimumab|Drug: Nivolumab|Radiation: Stereotactic Radiotherapy|Radiation: Whole Brain Radiotherapy
  Outcome Measures:             Intracranial response to immunotherapy|Intracranial progression free survival for patients receiving the addition of radiotherapy|Best extracranial response rate|Overall response rate|Overall progression free survival|Overall survival|Change in neurocognitive function scores|Neurological adverse events requiring an intervention|Description of impaired neurological function and neurological adverse events|Time to neurological deterioration|Duration of neurological deterioration|Patient rated quality of life|Proxy rated quality of life|Functional performance status|Adverse events|Tissue and blood biomarkers of response, progression and neurotoxicity
  Sponsor/Collaborators:        Melanoma Institute Australia|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years to 120 Years   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   155
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    MIA2017/CT
  Start Date:                   February 2019
  Primary Completion Date:      August 2020
  Completion Date:              August 2023
  First Posted:                 November 13, 2017
  Results First Posted:         null
  Last Update Posted:           November 2, 2018
  Locations:                    Westmead Hospital, Sydney, New South Wales, Australia|Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03340129

Study 367:
  NCT Number:                   NCT02437279
  Title:                        Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients
  Acronym:                      OpACIN
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Stage III Skin Melanoma
  Interventions:                Procedure: Surgery of the tumor|Drug: Infusion with ipilimumab 3 mg/kg q3wks|Drug: Infusion with nivolumab 1 mg/kg q3wks
  Outcome Measures:             The alteration in magnitude of the neo-antigen specific T cell response in the time interval pre- to post-adjuvant therapy in peripheral blood|Safety as measured by SUSARs.|The alteration in breadth of the neo-antigen specific T cell response in the time interval pre- to post-adjuvant therapy in peripheral blood|Feasibility as measured adherence to the timelines in the study protocol.|Recurrence Free Survival, as determined according to RECIST 1.1 criteria.|Rate of adverse events and late adverse events|Type of adverse events and late adverse events
  Sponsor/Collaborators:        The Netherlands Cancer Institute|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   20
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    N14OPC|CA209-278|NL51280.031.14
  Start Date:                   August 12, 2015
  Primary Completion Date:      December 2017
  Completion Date:              April 2018
  First Posted:                 May 7, 2015
  Results First Posted:         null
  Last Update Posted:           July 18, 2017
  Locations:                    Netherlands Cancer Institute, Amsterdam, NH, Netherlands
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02437279

Study 368:
  NCT Number:                   NCT03305445
  Title:                        Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Relapsed Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma
  Interventions:                Drug: Ipilimumab|Drug: Nivolumab
  Outcome Measures:             Dose Limiting Toxicities (DLTs)|Completion Remission (CR) Rate|Progression Free Survival (PFS)|Overall Survival (OS)|IgVH level|Delayed CR|Overall Response Rate (ORR)
  Sponsor/Collaborators:        Icahn School of Medicine at Mount Sinai|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   13
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    GCO 17-2164
  Start Date:                   May 14, 2018
  Primary Completion Date:      February 1, 2020
  Completion Date:              April 1, 2020
  First Posted:                 October 10, 2017
  Results First Posted:         null
  Last Update Posted:           May 24, 2018
  Locations:                    Icahn School of Medicine at Mount Sinai, New York, New York, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03305445

Study 369:
  NCT Number:                   NCT02420912
  Title:                        Nivolumab With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Leukemia|Chronic Lymphocytic Leukemia
  Interventions:                Drug: Nivolumab|Drug: Ibrutinib
  Outcome Measures:             Cohort 1 and 3: Response Rate of Nivolumab in Combination with Ibrutinib|Cohort 2: Conversion Rate of Nivolumab in Combination with Ibrutinib
  Sponsor/Collaborators:        M.D. Anderson Cancer Center|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   72
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    2014-0931|NCI-2015-00844
  Start Date:                   June 2015
  Primary Completion Date:      June 2021
  Completion Date:              June 2021
  First Posted:                 April 20, 2015
  Results First Posted:         null
  Last Update Posted:           January 17, 2018
  Locations:                    University of Texas MD Anderson Cancer Center, Houston, Texas, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02420912

Study 370:
  NCT Number:                   NCT02659540
  Title:                        A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Melanoma
  Interventions:                Drug: Ipilimumab|Drug: Nivolumab|Radiation: Radiotherapy
  Outcome Measures:             Assessment of Safety according to to the National Cancer Institute Common Terminology Criteria for Adverse Events.|Overall response rate at weeks 12 and 18.|Disease control rate at weeks 12 and 18.|Progression-Free Survival|Overall Survival|Duration of Response
  Sponsor/Collaborators:        Ludwig Institute for Cancer Research|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   20
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    LUD2015-006
  Start Date:                   October 13, 2016
  Primary Completion Date:      December 2018
  Completion Date:              December 2021
  First Posted:                 January 20, 2016
  Results First Posted:         null
  Last Update Posted:           September 13, 2018
  Locations:                    Research Facility, Palo Alto, California, United States|Research Facility, New York, New York, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02659540

Study 371:
  NCT Number:                   NCT02977052
  Title:                        Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab
  Acronym:                      OpACIN-neo
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Malignant Melanoma Stage III
  Interventions:                Drug: Ipilimumab|Drug: Nivolumab|Procedure: Surgery|Procedure: Blood for PBMCs|Procedure: Biopsies
  Outcome Measures:             Safety as measured by the frequency of grade 3/4 immune-related adverse events, using CTCAE 4.03|Response rate according to RECIST 1.1|Pathological response according to central pathological revision, according to pathological response criteria|Pathologic response rate according to central revision of the marked index lymph node|RFS at 24 months in patients achieving pCR or pnCR in their marked index lymph node and did not undergo CLND. RFS will be calculated from date of resection of the marked lymph node.|RFS at 24 months in patients with pNR and being subsequently treated with adjuvant nivolumab+optional radiotherapy (or dabrafenib/trametinib if BRAFV600E pos. and treatment is approved). RFS will be calculated from day of resection of marked lymph node.|Recurrence Free Survival|Description of late adverse events using CTCAE 4.03|Description of associations of mutational load, RNA tumor signatures, and tumor educated platelet signatures with tumor immune infiltrates and response|Response rate according to RECIST 1.1 at week 6|RFS at 2, 3 and 5 years
  Sponsor/Collaborators:        The Netherlands Cancer Institute|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   110
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    M16OPN|2016-001984-35|CA209-701
  Start Date:                   November 2016
  Primary Completion Date:      June 2020
  Completion Date:              June 2022
  First Posted:                 November 30, 2016
  Results First Posted:         null
  Last Update Posted:           November 6, 2018
  Locations:                    Melanoma Institute Australia, Sydney, New South Wales, Australia|Medical University of Vienna, Vienna, Austria|Netherlands Cancer Institute, Amsterdam, NH, Netherlands|Karolinska Institutet, Stockholm, Sweden
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02977052

Study 372:
  NCT Number:                   NCT03307616
  Title:                        Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Systemic Connective Tissue Disorders
  Interventions:                Drug: Nivolumab|Drug: Ipilimumab|Radiation: Radiation Therapy
  Outcome Measures:             Pathologic Response|Immunologic Response|Change in Immune Infiltrate in Response to Neoadjuvant Nivolumab Monotherapy and Neoadjuvant Nivolumab and Ipilimumab Combination Therapy|Objective Response Rate (ORR) of Nivolumab Monotherapy and Nivolumab and Ipilimumab Combination Therapy|Recurrence-Free Survival (RFS)|Overall Survival (OS)|Safety of Nivolumab Monotherapy and Combination Ipilimumab and Nivolumab in the Neoadjuvant Setting and Peri-Operatively
  Sponsor/Collaborators:        M.D. Anderson Cancer Center|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   40
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    2017-0143|NCI-2018-01031
  Start Date:                   October 4, 2017
  Primary Completion Date:      October 2021
  Completion Date:              October 2021
  First Posted:                 October 12, 2017
  Results First Posted:         null
  Last Update Posted:           October 12, 2018
  Locations:                    University of Texas MD Anderson Cancer Center, Houston, Texas, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03307616

Study 373:
  NCT Number:                   NCT03245021
  Title:                        Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A
  Acronym:                      1stFLOR
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Follicular Lymphoma
  Interventions:                Drug: Opdivo
  Outcome Measures:             To evaluate the feasibility and safety of combination nivolumab and rituximab as determined by the proportion of toxicity grade 3 or higher per CTCAE v4.0 occurring on induction treatment (ie first 16 weeks of therapy)|Overall toxicity|Response rate|Complete response rate|Time to treatment failure|Progression free survival|Overall survival
  Sponsor/Collaborators:        Dr. Eliza Hawkes|Bristol-Myers Squibb|Austin Health
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   39
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CA209-676
  Start Date:                   September 7, 2017
  Primary Completion Date:      June 2022
  Completion Date:              June 2024
  First Posted:                 August 10, 2017
  Results First Posted:         null
  Last Update Posted:           September 11, 2017
  Locations:                    Ballarat Health, Ballarat, Victoria, Australia|Eastern Health, Box Hill, Victoria, Australia|Monash Health, Clayton, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|St Vincent's Hospital, Melbourne, Victoria, Australia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03245021

Study 374:
  NCT Number:                   NCT03259425
  Title:                        Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Melanoma
  Interventions:                Drug: Nivolumab|Drug: HF10
  Outcome Measures:             Pathological Response after 12 weeks|Recurrence-free survival|Overall Survival|Complete Surgical Resecetion|Rate of adverse events for patients while taking nivolumab and HF10
  Sponsor/Collaborators:        University of Utah|Bristol-Myers Squibb|Takara Bio Inc.
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   20
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    HCI102346
  Start Date:                   December 21, 2017
  Primary Completion Date:      October 2022
  Completion Date:              October 2022
  First Posted:                 August 23, 2017
  Results First Posted:         null
  Last Update Posted:           September 13, 2018
  Locations:                    Huntsman Cancer Institute, Salt Lake City, Utah, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03259425

Study 375:
  NCT Number:                   NCT03117309
  Title:                        Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Advanced Renal Cell Carcinoma
  Interventions:                Drug: Nivolumab 240 mg|Drug: Ipilimumab 1mg/kg|Drug: Nivolumab 3mg/kg|Drug: Nivolumab 360mg
  Outcome Measures:             Progression Free Survival (PFS) rate|Objective Response Rate (CR/PR)|Response Rate|Clinical Activity (Complete Response (CR), Partial Response (PR) and Stable Disease (SD)|Progression Free Survival (PFS) at one year|Toxicity by calculating the frequency and percentage of adverse event terms (CTCAE v4)
  Sponsor/Collaborators:        Michael B. Atkins, MD|Bristol-Myers Squibb|Hoosier Cancer Research Network
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   120
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    HCRN GU16-260
  Start Date:                   April 24, 2017
  Primary Completion Date:      February 2020
  Completion Date:              February 2021
  First Posted:                 April 17, 2017
  Results First Posted:         null
  Last Update Posted:           November 5, 2018
  Locations:                    Georgetown University, Washington, District of Columbia, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Northwestern University Feinberg Schooll Of Medicine, Chicago, Illinois, United States|University of Illinois Cancer Center, Chicago, Illinois, United States|Beth Isreal Deaconess Medical Center, Boston, Massachusetts, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Columbia University, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Univeristy of Pennsylvania, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03117309

Study 376:
  NCT Number:                   NCT03241186
  Title:                        Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Mucosal Melanoma
  Interventions:                Drug: Ipilimumab|Drug: Nivolumab
  Outcome Measures:             Assess Recurrence-free survival time (RFS)|Assess the Adverse Events|Overall Survival (OS)
  Sponsor/Collaborators:        Robert R. McWilliams, MD|Bristol-Myers Squibb|Hoosier Cancer Research Network
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   36
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    MEL16-252
  Start Date:                   September 12, 2017
  Primary Completion Date:      April 2019
  Completion Date:              April 2021
  First Posted:                 August 7, 2017
  Results First Posted:         null
  Last Update Posted:           July 13, 2018
  Locations:                    University of Iowa Hospital and Clinics, Iowa City, Iowa, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Nebraska Cancer Specialists, Omaha, Nebraska, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03241186

Study 377:
  NCT Number:                   NCT02983006
  Title:                        Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Melanoma
  Interventions:                Biological: DS-8273a|Biological: Nivolumab
  Outcome Measures:             Safety (adverse events) of the protocol therapy|Anti-tumor activity of the protocol therapy
  Sponsor/Collaborators:        New York University School of Medicine|Bristol-Myers Squibb|Daiichi Sankyo, Inc.
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   36
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    15-00906
  Start Date:                   October 2016
  Primary Completion Date:      October 2019
  Completion Date:              December 2019
  First Posted:                 December 6, 2016
  Results First Posted:         null
  Last Update Posted:           November 8, 2018
  Locations:                    Laura and Isaac Perlmutter Cancer Center, New York, New York, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02983006

Study 378:
  NCT Number:                   NCT03681561
  Title:                        Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Hodgkin Lymphoma
  Interventions:                Drug: Ruxolitinib|Drug: Nivolumab
  Outcome Measures:             Maximum Tolerated Dose|Overall Response Rate|Progression Free Survival|Duration of Response|Overall Survival|Frequency and Severity of Adverse Events as assessed by CTCAE v4.0
  Sponsor/Collaborators:        Veronika Bachanova|Incyte Corporation|Bristol-Myers Squibb|Big Ten Cancer Research Consortium
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   20
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    BTCRC-HEM15-027
  Start Date:                   September 13, 2018
  Primary Completion Date:      September 2020
  Completion Date:              March 2024
  First Posted:                 September 24, 2018
  Results First Posted:         null
  Last Update Posted:           September 24, 2018
  Locations:                    University of Minnesota, Minneapolis, Minnesota, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03681561

Study 379:
  NCT Number:                   NCT03692338
  Title:                        INTENSE: A Study of a Supervised or Semi-Supervised Exercise InterveNtion or Usual Care With Functional Capacity and Quality of Life Evaluations in Subjects Receiving Ipilimumab and Nivolumab for Advanced or Metastatic Renal Cell Carcinoma
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Metastatic Renal Cell Carcinoma
  Interventions:                Behavioral: Exercise
  Outcome Measures:             Change in Cardiopulmonary function,|Patient-reported fatigue as measured by the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale|Patient-reported activity as measured by the Godin Leisure Time Exercise Questionnaire|Patient-reported symptoms as measured by the Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 (FKSI-19)|Patient health outcome as measured by the EQ-5D health questionnaire
  Sponsor/Collaborators:        Duke University|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Not Applicable
  Enrollment:                   30
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care
  Other IDs:                    Pro00082941
  Start Date:                   November 19, 2018
  Primary Completion Date:      August 31, 2020
  Completion Date:              August 31, 2020
  First Posted:                 October 2, 2018
  Results First Posted:         null
  Last Update Posted:           November 26, 2018
  Locations:                    Duke University Medical Center, Durham, North Carolina, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03692338

Study 380:
  NCT Number:                   NCT02464657
  Title:                        Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Leukemia|Acute Myeloid Leukemia|Myelodysplastic Syndrome
  Interventions:                Drug: Nivolumab|Drug: Idarubicin|Drug: Cytarabine|Drug: Solu-medrol|Drug: Dexamethasone
  Outcome Measures:             Maximum Tolerated Dose (MTD) of Nivolumab|Event-Free Survival (EFS)
  Sponsor/Collaborators:        M.D. Anderson Cancer Center|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   75
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    2014-0907|NCI-2015-01258
  Start Date:                   July 2015
  Primary Completion Date:      July 2019
  Completion Date:              July 2019
  First Posted:                 June 8, 2015
  Results First Posted:         null
  Last Update Posted:           May 30, 2018
  Locations:                    University of Texas MD Anderson Cancer Center, Houston, Texas, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02464657

Study 381:
  NCT Number:                   NCT02243371
  Title:                        GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Previously Treated Metastatic Adenocarcinoma of the Pancreas
  Interventions:                Biological: CRS-207|Biological: GVAX|Drug: nivolumab|Drug: CY
  Outcome Measures:             Overall survival (OS) in metastatic pancreatic cancer patients treated with cyclophosphamide (CY)/nivolumab/GVAX pancreas vaccine followed by nivolumab/CRS-207 (Arm A) versus patients treated with CY/GVAX pancreas vaccine followed by CRS-207 (Arm B)|Number of patients experiencing treatment-related toxicities|Progression-free survival (PFS) by RECIST 1.1 in metastatic pancreatic cancer patients treated with CY/GVAX/CRS-207/nivolumab (Arm A) versus patients treated with CY/GVAX/CRS-207 (Arm B)|Immune-related progression-free survival (irPFS) by IRRC in metastatic pancreatic cancer patients treated with CY/GVAX/CRS-207/nivolumab (Arm A) versus patients treated with CY/GVAX/CRS-207 (Arm B)|Time to progression (TTP) by RECIST 1.1 and IRRC in metastatic pancreatic cancer patients treated with CY/GVAX/CRS-207/nivolumab (Arm A) versus patients treated with CY/GVAX/CRS-207 (Arm B)|Response rate measured by RECIST 1.1 in metastatic pancreatic cancer patients treated with CY/GVAX/CRS-207/nivolumab (Arm A) versus patients treated with CY/GVAX/CRS-207 (Arm B)|Tumor marker kinetics (CA 19-9) in metastatic pancreatic cancer patients treated with CY/GVAX/CRS-207/nivolumab (Arm A) versus patients treated with CY/GVAX/CRS-207 (Arm B)
  Sponsor/Collaborators:        Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bristol-Myers Squibb|Stand Up To Cancer|Aduro Biotech, Inc.|American Association for Cancer Research
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   96
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    J14113|ADU-CL-06|IRB00043936
  Start Date:                   December 2014
  Primary Completion Date:      January 2019
  Completion Date:              January 2019
  First Posted:                 September 17, 2014
  Results First Posted:         null
  Last Update Posted:           July 23, 2018
  Locations:                    University of California, San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Providence Portland Medical Center, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02243371

Study 382:
  NCT Number:                   NCT02530463
  Title:                        Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS)
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Leukemia|Myelodysplastic Syndrome
  Interventions:                Drug: Nivolumab|Drug: Ipilimumab|Drug: 5-azacitidine
  Outcome Measures:             Overall Response Rate (ORR) in MDS Participants with Hypomethylating Agent Failure|Overall Response Rate (ORR) in MDS Participants Who Have Not Received Hypomethylating Agents
  Sponsor/Collaborators:        M.D. Anderson Cancer Center|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   120
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    2014-0930|NCI-2015-01494
  Start Date:                   September 8, 2015
  Primary Completion Date:      September 2021
  Completion Date:              September 2022
  First Posted:                 August 21, 2015
  Results First Posted:         null
  Last Update Posted:           April 30, 2018
  Locations:                    University of Texas MD Anderson Cancer Center, Houston, Texas, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02530463

Study 383:
  NCT Number:                   NCT03704714
  Title:                        Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Aggressive Non-Hodgkin Lymphoma|B-Cell Non-Hodgkin Lymphoma|CD20 Positive|Diffuse Large B-Cell Lymphoma Unclassifiable|Intravascular Large B-Cell Lymphoma|Primary Mediastinal (Thymic) Large B-Cell Lymphoma|T-Cell/Histiocyte-Rich Large B-Cell Lymphoma|Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
  Interventions:                Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Biological: Nivolumab|Drug: Prednisone|Other: Quality-of-Life Assessment|Biological: Rituximab|Drug: Vincristine Sulfate
  Outcome Measures:             Maximum tolerated dose (MTD) for the combination treatment of nivolumab and R-CHOP|Progression Free Survival (PFS)|Overall response rate (ORR)|Overall survival (OS) rate|Event-free survival (EFS)|Overall response rates as defined by the RECIL and LYRIC criteria|Frailty/Geriatric Assessments|Incidence of Adverse Events|Quality of life Assessment
  Sponsor/Collaborators:        Northwestern University|Bristol-Myers Squibb (BMS)|National Cancer Institute (NCI)
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   30
  Funded Bys:                   Other|NIH
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    NU 17H08|STU00207793|P30CA060553|NCI-2018-01666
  Start Date:                   November 8, 2018
  Primary Completion Date:      May 11, 2021
  Completion Date:              June 11, 2022
  First Posted:                 October 15, 2018
  Results First Posted:         null
  Last Update Posted:           October 15, 2018
  Locations:                    Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03704714

Study 384:
  NCT Number:                   NCT02693535
  Title:                        TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
  Acronym:                      TAPUR
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Lymphoma, Non-Hodgkin|Multiple Myeloma|Advanced Solid Tumors
  Interventions:                Drug: Axitinib|Drug: Bosutinib|Drug: Crizotinib|Drug: Palbociclib|Drug: Sunitinib|Drug: Temsirolimus|Drug: Trastuzumab and Pertuzumab|Drug: Vemurafenib and Cobimetinib|Drug: Cetuximab|Drug: Dasatinib|Drug: Regorafenib|Drug: Olaparib|Drug: Pembrolizumab|Drug: Nivolumab and Ipilimumab
  Outcome Measures:             Objective Response Rate defined as % of participants in a cohort with complete or partial response or with stable disease according to standard response criteria|Overall survival (OS)
  Sponsor/Collaborators:        American Society of Clinical Oncology|AstraZeneca|Bayer|Bristol-Myers Squibb|Eli Lilly and Company|Genentech, Inc.|Merck Sharp & Dohme Corp.|Pfizer
  Gender:                       All
  Age:                          12 Years and older   (Child, Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   1440
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    Pro00014171
  Start Date:                   March 2016
  Primary Completion Date:      March 2019
  Completion Date:              null
  First Posted:                 February 26, 2016
  Results First Posted:         null
  Last Update Posted:           September 11, 2018
  Locations:                    University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States|Cancer Treatment Centers of America-Phoenix, Phoenix, Arizona, United States|The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, California, United States|Sutter Cancer Research Consortium, San Francisco, California, United States|University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Cancer Treatment Centers of America - Atlanta, Atlanta, Georgia, United States|Emory University Winship Cancer Institute, Atlanta, Georgia, United States|Cancer Treatment Centers of America-Chicago, Chicago, Illinois, United States|University of Michigan, Ann Arbor, Michigan, United States|Cancer Research Consortium of West Michigan, Grand Rapids, Michigan, United States|Michigan Cancer Research Consortium, Traverse City, Michigan, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Carolina's HealthCare System's Levine Cancer Institute, Charlotte, North Carolina, United States|Sanford Health- Bismarck, Bismarck, North Dakota, United States|Sanford Health- Fargo, Fargo, North Dakota, United States|Cancer Treatment Centers of America-Tulsa, Tulsa, Oklahoma, United States|Providence Health & Services, Portland, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Cancer Treatment Centers of America-Philadelphia, Philadelphia, Pennsylvania, United States|Sanford Cancer Center Oncology Clinic and Pharmacy, Sioux Falls, South Dakota, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Intermountain Healthcare, Salt Lake City, Utah, United States|Inova Schar Cancer Institute, Fairfax, Virginia, United States|Swedish Cancer Institute, Seattle, Washington, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02693535

Study 385:
  NCT Number:                   NCT03558750
  Title:                        Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Recurrent Central Nervous System Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Refractory Central Nervous System Lymphoma|Refractory Diffuse Large B-Cell Lymphoma
  Interventions:                Biological: Nivolumab|Biological: Rituximab|Drug: Lenalidomide
  Outcome Measures:             Dose limiting toxicity (DLT) (Phase I)|Overall response rate (complete response, partial response, or stable disease) (Phase II)|Time to progression (complete response, partial response, or stable disease)|Progression free survival|Overall survival|Incidence of adverse events per national Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.03|Difference in overall response rate between those with and without programmed cell death ligand 1 (PD-L1) protein expression in tumor (subgroup analysis)|Difference in overall response rate between those with and without MYD88 mutation in tumor (subgroup analysis)
  Sponsor/Collaborators:        Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)|Bristol-Myers Squibb
  Gender:                       All
  Age:                          19 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   48
  Funded Bys:                   Other|NIH|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    VICC PCL 1758|NCI-2018-01092
  Start Date:                   June 14, 2018
  Primary Completion Date:      May 31, 2022
  Completion Date:              May 31, 2023
  First Posted:                 June 15, 2018
  Results First Posted:         null
  Last Update Posted:           June 18, 2018
  Locations:                    Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03558750

Study 386:
  NCT Number:                   NCT03552380
  Title:                        Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Renal Cell Carcinoma
  Interventions:                Drug: Entinostat|Drug: Nivolumab|Drug: Ipilimumab
  Outcome Measures:             Establish the recommended Phase II dose (RP2D)|Objective Response Rate (ORR) via RECIST 1.1|Assess Adverse Events|ORR via irRC|Progression Free Survival (PFS) via RECIST 1.1|Progression Free Survival (PFS) via irRC|Overall Survival (OS)
  Sponsor/Collaborators:        Roberto Pili|Bristol-Myers Squibb|Syndax Pharmaceuticals|Indiana University School of Medicine|Hoosier Cancer Research Network
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   53
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    HCRN GU17-326
  Start Date:                   August 31, 2018
  Primary Completion Date:      August 2019
  Completion Date:              August 2020
  First Posted:                 June 11, 2018
  Results First Posted:         null
  Last Update Posted:           September 10, 2018
  Locations:                    Indiana Univeristy Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03552380

Study 387:
  NCT Number:                   NCT03749018
  Title:                        Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Aggressive Non-Hodgkin Lymphoma|Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma|Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma|Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma|Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements|High Grade B-Cell Lymphoma, Not Otherwise Specified|Indolent Non-Hodgkin Lymphoma|Mediastinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma|Transformed Non-Hodgkin Lymphoma
  Interventions:                Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Drug: Etoposide|Biological: Nivolumab|Drug: Prednisone|Biological: Rituximab|Drug: Vincristine Sulfate
  Outcome Measures:             Progression-free survival (PFS)|Objective response rate|Duration of response defined for all patients who have achieved an objective response (CR or PR)|Incidence of adverse events per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
  Sponsor/Collaborators:        Kami Maddocks|National Cancer Institute (NCI)|Bristol-Myers Squibb|Ohio State University Comprehensive Cancer Center
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   30
  Funded Bys:                   Other|NIH|Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    OSU-18281|NCI-2018-02699|P30CA016058
  Start Date:                   January 1, 2019
  Primary Completion Date:      December 31, 2021
  Completion Date:              December 31, 2021
  First Posted:                 November 21, 2018
  Results First Posted:         null
  Last Update Posted:           November 21, 2018
  Locations:                    Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03749018

Study 388:
  NCT Number:                   NCT03297606
  Title:                        Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
  Acronym:                      CAPTUR
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Lymphoma, Non-Hodgkin|Multiple Myeloma|Advanced Solid Tumors
  Interventions:                Drug: Olaparib|Drug: Dasatinib|Drug: Nivolumab plus Ipilimumab|Drug: Axitinib|Drug: Bosutinib|Drug: Crizotinib|Drug: Palbociclib|Drug: Sunitinib|Drug: Temsirolimus|Drug: Erlotinib|Drug: Trastuzumab plus Pertuzumab|Drug: Vemurafenib plus Cobimetinib|Drug: Vismodegib
  Outcome Measures:             Objective response rate defined as the number of patients with complete response or partial response|Number and severity of adverse events|Progression-free survival confirmed by disease-appropriate objective criteria
  Sponsor/Collaborators:        Canadian Cancer Trials Group|AstraZeneca|Bristol-Myers Squibb|Hoffmann-La Roche|Pfizer
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   720
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    PM1|ESR‐17‐12831|CA209‐9DL|ML39800|WI233446
  Start Date:                   October 6, 2017
  Primary Completion Date:      September 2021
  Completion Date:              September 2021
  First Posted:                 September 29, 2017
  Results First Posted:         null
  Last Update Posted:           August 22, 2018
  Locations:                    BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada|London Regional Cancer Program, London, Ontario, Canada|Ottawa Hospital Research Institute, Ottawa, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|The Jewish General Hospital, Montreal, Quebec, Canada
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03297606

Study 389:
  NCT Number:                   NCT03366272
  Title:                        Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients
  Acronym:                      NIVEAU
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Lymphoma, Non-Hodgkin
  Interventions:                Drug: Nivolumab|Drug: Rituximab|Drug: Gemcitabine|Device: Oxaliplatin
  Outcome Measures:             PFS|CR rate|PR rate|ORR rate|Duration of response|Primary Progression rate|Treatment related deaths rate|Relapse rate|EFS|OS|Toxicities: rates and grades of adverse events|Protocol adherence according to number of given chemotherapy cycles|Protocol adherence according to duration of given chemotherapy cycles|Protocol adherence according to cumulative dose of immunochemotherapy given|Protocol adherence according to relative dose of immunochemotherapy given|QoL|Biological Parameters according to PD-L1 expression alterations|Biological Parameters according to PD-1 expression|Biological Parameters according to cell of origin|Biological Parameters according to 9p24.1 alterations
  Sponsor/Collaborators:        University Hospital, Saarland|Bristol-Myers Squibb|Lymphoma Study Association|University of Leipzig
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2|Phase 3
  Enrollment:                   388
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    DSHNHL 2015-1
  Start Date:                   December 5, 2017
  Primary Completion Date:      November 2022
  Completion Date:              November 2024
  First Posted:                 December 8, 2017
  Results First Posted:         null
  Last Update Posted:           October 18, 2018
  Locations:                    INSTITUT JULES BORDET -Hematology, Brüssel, Belgium|UNIVERSITE CATHOLIQUE DE LOUVAIN SAINT-LUC - Hematology, Brüssel, Belgium|UNIVERSITAIR ZIEKENHUIS GENT - Hematology, Gent, Belgium|CHU DE LIEGE - Hematology, Liège, Belgium|UNIVERSITE CATHOLIQUE DE LOUVAIN MONT GODINNE - Hematology, Yvoir, Belgium|CHU Côte de Nacre - Service Hématologie Clinique, Caen, France|Hôpital Henri Mondor - Unité "Hémopathies Lymphoïdes" - HDJ 11è, Créteil Cedex, France|CHU Dijon - Hôpital d'Enfants - Hématologie Clinique, Dijon, France|CHU de Grenoble - Hôpital Albert Michallon - Hématologie Clinique, Grenoble, France|CH Départemental Vendée - Onco-Hématologie, La Roche-sur-Yon, France|CHRU de Lille - Hôpital Claude Hurriez, Lille, France|Institut Paoli Calmettes - Hématologie, Marseille, France|CHU de Montpellier - Hématologie Clinique, Montpellier, France|CHU de Nantes - Hôtel Dieu - Hématologie, Nantes, France|Hôpital Saint Louis - Onco-Hématologie, Paris cedex 20, France|Hôpital Necker - Hématologie Clinique, Paris, France|CHU de Bordeaux - Hôpital Haut Lévêque - Centre François Magendie, Pessac, France|CHU Lyon Sud - Hématologie, Pierre-Bénite, France|Hôpital Pontchaillou - Hématologie, Rennes, France|Centre Henri Becquerel - Hématologie, Rouen, France|Hôpitaux Universitaires de Strasbourg - Hôpital de Hautepierre, Strasbourg, France|IUCT Oncopole - Hématologie, Toulouse, France|CHU Nancy - Hôpital de Brabois - Service d'Hématologie et Médecine Interne, Vandoeuvre-les-Nancy, France|Charité - Universitätsklinikum Berlin, Med. Klinik m. S. Hämatologie, Berlin, Germany|Vivantes Klinikum am Urban, Klinik für Innere, Hämatologie und Onkologie, Berlin, Germany|Klinikum Chemnitz, Innere Medizin III, Chemnitz, Germany|BAG Freiberg-Richter, Jacobasch, Wolf, Illmer, Dresden, Germany|Gemeinschaftspraxis Dres. Mohm, Prange-Krex, Dresden, Germany|St. Antonius-Hospital Eschweiler, Klinik für Hämatologie, Eschweiler, Germany|Universitätsklinikum Essen, Klinik für Hämatologie, Essen, Germany|Universitätsmedizin Göttingen, Klinik für Hämatologie, Göttingen, Germany|Universitätsklinikum Haale (Saale), Klinik für Innere Medizin IV, Haale, Germany|Med. Hochschule Hannover, Klinik für Hämatologie, Hannover, Germany|Medizinische Hochschule Hannover, Klinik für Hämatologie, Hannover, Germany|Universitätsklinikum des Saarlandes, Innere Med. I, Homburg, Germany|Westpfalz-Klinikum, Klinik für Innere Medizin I, Kaiserslautern, Germany|St. Vincentius Kliniken Karlsruhe, Med. Klinik Abt. 2, Karlsruhe, Germany|Klinikum der Universität zu Köln, Klinik I für Innere Medizin, Köln, Germany|Uni Gießen und Marburg, Klinik für Hämatologie, Marburg, Germany|Stauferklinikum Schwäbisch Gmünd, Zentrum für Innere Medizin, Mutlangen, Germany|Klinikum der Universität München, Med. Klinik und Poliklinik III, München, Germany|Universitätsklinikum Münster, Münster, Germany|Universitätsklinikum Regensburg, Klinik für Innere Medizin III, Regensburg, Germany|Universitätsmedizin Rostock, Klinik für Hämatologie, Rostock, Germany|Klinikum Stuttgart, Klinik für Hämatologie, Stuttgart, Germany|Klinikum Mutterhaus der Borromäerinnen, Med. Abteilung I, Trier, Germany|Krankenhaus der Barmherzigen Brüder, I. Med. Abteilung, Trier, Germany|Universitätsklinikum Tübingen, Innere Medizin II, Tübingen, Germany|Uniklinikum Ulm, Klinik für Innere Medizin III, Ulm, Germany|Schwarzwald-Baar Klinikum, Innere Medizin II, Villingen-Schwenningen, Germany|The Chaim Sheba Medical Center - Division of Hematology and Bone-Marrow Transplantation, Ramat Gan, Israel|Instituto Português Oncologia - Hematology, Lisboa, Portugal
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03366272

Study 390:
  NCT Number:                   NCT03033914
  Title:                        A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Hodgkin Lymphoma
  Interventions:                Drug: doxorubicin|Drug: Bleomycin|Drug: vinblastine|Drug: dacarbazine|Drug: Nivolumab
  Outcome Measures:             number of patients who have dose limiting toxicity|Phase II- progression free survival
  Sponsor/Collaborators:        Memorial Sloan Kettering Cancer Center|Bristol-Myers Squibb|Barbara Ann Karmanos Cancer Institute|British Columbia Cancer Agency
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   26
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    16-1536|CA209-447
  Start Date:                   January 25, 2017
  Primary Completion Date:      January 2020
  Completion Date:              January 2020
  First Posted:                 January 27, 2017
  Results First Posted:         null
  Last Update Posted:           November 20, 2018
  Locations:                    Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03033914

Study 391:
  NCT Number:                   NCT01176474
  Title:                        Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Melanoma (Skin)
  Interventions:                Biological: NY-ESO-1 157-165 (165V)|Drug: Nivolumab|Biological: gp100:280-288 (288V)|Drug: Montanide ISA 51 vegetable grade (VG)|Drug: Ipilimumab|Procedure: Apheresis Procedure
  Outcome Measures:             Time to Relapse|Overall Survival (OS)
  Sponsor/Collaborators:        H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI)|Medarex|Bristol-Myers Squibb
  Gender:                       All
  Age:                          16 Years and older   (Child, Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   73
  Funded Bys:                   Other|NIH|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    MCC-15651|NCI-8316
  Start Date:                   July 28, 2010
  Primary Completion Date:      October 2019
  Completion Date:              October 2020
  First Posted:                 August 6, 2010
  Results First Posted:         null
  Last Update Posted:           July 12, 2018
  Locations:                    H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01176474

Study 392:
  NCT Number:                   NCT03161756
  Title:                        Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma
  Acronym:                      CHARLI
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Melanoma Stage Iv|Melanoma Stage Iii|Melanoma
  Interventions:                Drug: Denosumab|Drug: Nivolumab|Drug: Ipilimumab
  Outcome Measures:             Median Progression-Free Survival|Occurrence of Grade 3 and 4 Selected Immune-related Adverse Events (irAEs) of interest|Rate of Grade 3 and 4 irAEs|Best Overall Response According to RECIST 1.1|Progression-Free Survival|Overall Survival|Toxicity Profiles of the Checkpoint-Denosumab Combinations|Occurrence of Treatment Discontinuation Due to Toxicity
  Sponsor/Collaborators:        Australia and New Zealand Melanoma Trials Group|Peter MacCallum Cancer Centre, Australia|Amgen|Bristol-Myers Squibb
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   72
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    ANZMTG 01.15
  Start Date:                   December 7, 2017
  Primary Completion Date:      June 2021
  Completion Date:              June 2023
  First Posted:                 May 22, 2017
  Results First Posted:         null
  Last Update Posted:           September 26, 2018
  Locations:                    Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03161756

Study 393:
  NCT Number:                   NCT01716806
  Title:                        A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL)
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Hodgkin Disease
  Interventions:                Drug: brentuximab vedotin|Drug: bendamustine|Drug: dacarbazine|Drug: nivolumab
  Outcome Measures:             Objective response rate|Incidence of adverse events|Incidence of laboratory abnormalities|Complete remission rate (CR)|Duration of response|Progression-free survival|B symptom resolution rate|Blood concentrations of brentuximab vedotin and metabolites|Incidence of brentuximab vedotin antitherapeutic antibodies (ATA)|Blood concentrations of nivolumab and metabolites|Incidence of nivolumab antitherapeutic antibodies (ATA)
  Sponsor/Collaborators:        Seattle Genetics, Inc.|Bristol-Myers Squibb
  Gender:                       All
  Age:                          60 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   100
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    SGN35-015
  Start Date:                   October 2012
  Primary Completion Date:      July 2019
  Completion Date:              July 2021
  First Posted:                 October 30, 2012
  Results First Posted:         null
  Last Update Posted:           November 1, 2018
  Locations:                    University of Alabama at Birmingham, Birmingham, Alabama, United States|Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States|Providence St Joseph Medical Center, Burbank, California, United States|City of Hope National Medical Center, Duarte, California, United States|Rocky Mountain Cancer Centers - Aurora, Aurora, Colorado, United States|Georgia Cancer Specialists / Northside Hospital Cancer Institute, Sandy Springs, Georgia, United States|Illinois Cancer Specialists / Advocate Lutheran General Hospital, Niles, Illinois, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Minnesota Oncology Hematology P.A., Minneapolis, Minnesota, United States|Nebraska Cancer Specialists, Omaha, Nebraska, United States|New York Oncology Hematology, P.C., Albany, New York, United States|James P. Wilmot Cancer Center / University of Rochester Medical Center, Rochester, New York, United States|Willamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States|Northwest Cancer Specialists, P.C., Tualatin, Oregon, United States|Greenville Health System Cancer Institute, Greenville, South Carolina, United States|Texas Oncology - Bedford, Bedford, Texas, United States|Texas Oncology - Fort Worth 12th Avenue, Fort Worth, Texas, United States|Texas Oncology - Longview, Longview, Texas, United States|Texas Oncology - Seton Williamson, Round Rock, Texas, United States|Oncology and Hematology Assoc of SW VA DBA Blue Ridge Cancer Care, Blacksburg, Virginia, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Virginia Commonwealth University Medical Center, Richmond, Virginia, United States|Swedish Cancer Institute, Seattle, Washington, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01716806

Study 394:
  NCT Number:                   NCT01176461
  Title:                        Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Melanoma (Skin)
  Interventions:                Biological: MART-1|Biological: NY-ESO-1|Biological: gp100:209-217(210M)|Biological: gp100:280-288(288V)|Drug: Montanide ISA 51 VG|Biological: BMS-936558
  Outcome Measures:             Best Overall Response Rate (BORR)|Time to Response|Duration of Response
  Sponsor/Collaborators:        H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI)|Bristol-Myers Squibb|Medarex
  Gender:                       All
  Age:                          16 Years and older   (Child, Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   127
  Funded Bys:                   Other|NIH|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    MCC-15400|NCI-P-7997|CA209-006/007|10-15526-99-01
  Start Date:                   August 4, 2010
  Primary Completion Date:      December 12, 2016
  Completion Date:              December 2019
  First Posted:                 August 6, 2010
  Results First Posted:         null
  Last Update Posted:           July 12, 2018
  Locations:                    H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01176461

